American Society of Clinical Oncology 47th Annual ... - ABCSG

American Society of Clinical Oncology47th Annual MeetingMeeting ProgramNote: Sessions in which Special Awards are presentedare shaded in gray

Friday, June 3, 2011FRIDAY1:00 PM - 2:15 PMEDUCATION SESSIONSCustomized Cancer Treatment: A Systems Biology Approach to DrugSelectionLocation: E354bCME credit: 1.25Track(s): Developmental Therapeutics, Cancer Genetics, Clinical TrialsJohn Mendelsohn, MD—ChairUniversity of Texas M. D. Anderson Cancer CenterCustomized Cancer Medicine: Are We Ready for What It Will Take?Jeffrey M. Trent, PhDTGenLarge-scale, Multidimensional Genomics Data: Making Sense for PatientsAndrea Califano, PhDColumbia UniversityCancer’s Complexity: Are We Looking at the Wrong Levels to Develop Effective Interventions?Endometrial Cancer: Present State and Future PromiseLocation: E354aCME credit: 1.25Track(s): Gynecologic CancerDon S. Dizon, MD—ChairWarren Alpert Medical School of Brown UniversityOptions in the Treatment of Relapsed Endometrial Cancer: Beyond First-line TherapyKaren H. Lu, MDUniversity of Texas M. D. Anderson Cancer CenterMolecular Characterization of Endometrial Cancer: Going beyond HistologyDavid Scott Miller, MDUniversity of Texas Southwestern Medical CenterIncorporation of Adjuvant Chemotherapy into Endometrial Cancer TreatmentNeoadjuvant Therapy in Operable Breast Cancer: Who, What, When, Why, andHow?Location: Hall D1CME credit: 1.25Track(s): Breast CancerLuca Gianni, MD—ChairFondazione IRCCS Istituto Nazionale dei TumoriNeoadjuvant Assumptions and Application to Chemotherapy, Endocrine Therapy, and BiologicTherapy-based RegimensDavid W. Ollila, MDUniversity of North Carolina at Chapel HillSurgical Implications of the Neoadjuvant Approach: Facilitating Research Biopsies, BreastConservation in Previously T3–4 Tumors, and Axillary Staging—Before or After?Thomas A. Buchholz, MDUniversity of Texas M. D. Anderson Cancer CenterRadiation in the Setting of Marked Cytoreduction: Do We Radiate a Cleared Nodal Basin orBreast?58

Friday, June 3, 2011Pediatric Bone Sarcomas: Converging Progress on the Biologic and ClinicalFronts?Location: S504CME credit: 1.25Track(s): Pediatric Oncology, SarcomaStephen L. Lessnick, MD, PhD—ChairHuntsman Cancer InstituteRecent Progress in Understanding the Biology of Bone TumorsFRIDAYHolcombe E. Grier, MDDana-Farber Cancer InstituteAdvances in the Treatment of Ewing’s SarcomaNeyssa Marina, MDStanford University School of MedicineUpdate on the Management of Children, Adolescents, and Young Adults with OsteosarcomaRadiation Therapy Updates for Primary Brain Tumors: Clinical Role for ProtonTherapy, Stereotactic Radiosurgery, and Hypofractionated SchedulesLocation: S100bcCME credit: 1.25Track(s): Central Nervous System TumorsJohn H. Suh, MD—ChairCleveland ClinicRadiosurgery Applications for Primary Brain TumorsEugen Hug, MDPaul Scherrer InstitutProton Therapy for Primary Brain Tumors: When to ReferEric L. Chang, MDUniversity of Texas M. D. Anderson Cancer CenterAbbreviated Course of Radiation Therapy in Older Patients with GlioblastomaSurvivorship Care: Whose Job Is It?Location: S406CME credit: 1.25Track(s): Patient and Survivor Care, Health Services ResearchJulia Howe Rowland, PhD—ChairNational Cancer Institute/National Institutes of HealthOverview of This Emerging Challenge in Survivors’ CarePaul Han, MD, MA, MPHMaine Medical Center Research InstitutePresentation of Data from the National Cancer Institute– and American Cancer Society–fundedStudy: Survey of Physician Attitudes Regarding Care of Cancer SurvivorsJames Ross Waisman, MDBreastlink Medical Group Inc.How to Implement Survivorship Care in Practice59

Friday, June 3, 2011FRIDAYThe Identification and Treatment of the “High Risk” Patient with Non-HodgkinLymphoma and MyelomaLocation: Arie Crown TheaterCME credit: 1.25Track(s): Lymphoma and Plasma Cell DisordersFrancine M. Foss, MD—ChairYale Cancer CenterHigh-risk Peripheral T-cell LymphomaMichael Pfreundschuh, MDSaarland University HospitalHigh-risk B-cell Non-Hodgkin LymphomaRafael Fonseca, MDMayo ClinicHigh-risk Myeloma60

Friday, June 3, 20111:00 PM - 2:15 PMMEET THE PROFESSOR SESSIONImplementing a Quality Research Program in a Community Setting(M05)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Clinical Trials, Practice Management and Information Technology, ProfessionalDevelopmentFRIDAYPatrick J. Flynn, MDMetro Minnesota Community Clinical Oncology ProjectPractical Aspects of Clinical Trial Implementation in the Community SettingLidia Schapira, MDMassachusetts General HospitalTalking to Patients about Clinical Trials61

Friday, June 3, 2011FRIDAY1:00 PM - 3:15 PMEXTENDED EDUCATION SESSIONSHow to Participate in Clinical Research across BordersLocation: S100aCME credit: 2.25Track(s): Clinical Trials, InternationalEduardo L. Cazap, MD—ChairLatin American-Caribbean Society of Medical OncologyMartine J. Piccart-Gebhart, MD, PhDJules Bordet InstituteThe BIG Experience: Challenges and OpportunitiesEdward Lloyd Trimble, MDNational Cancer InstitutePromoting Independent Research at the U.S. National Cancer InstituteJean-Yves Blay, MD, PhDCentre Léon BérardHow to Participate in European Organisation for Research and Treatment of Cancer TrialsHenry Leonidas Gomez, MDInstituto Nacional de Enfermedades NeoplasicasLeading Clinical Research in Low-resource ScenariosRole of Nutrition, Supplements, and Integrative Medicine in Cancer Prevention,Treatment, and SurvivorshipLocation: E353CME credit: 2.25Track(s): Cancer Prevention/Epidemiology, General Oncology, Patient and Survivor CareCharles L. Loprinzi, MD—ChairMayo ClinicNutrition Recommendations for Patients with Far-advanced DiseaseHeather Greenlee, ND, PhDColumbia UniversityLifestyle Modification and Dietary Supplements in Cancer Prevention: What Is the Role?Kimberly Robien, PhD, RDUniversity of MinnesotaApproaches to Nutrition Interventions during Cancer TreatmentWendy Demark-Wahnefried, PhD, RDUniversity of Alabama at BirminghamNutrition and Physical Activity Recommendations for Cancer Survivorship: What Do We TellOur Patients and Their Families after Treatment?Lorenzo Cohen, PhDUniversity of Texas M. D. Anderson Cancer CenterImproving Patient Outcomes: The Role of Integrative Medicine in Cancer Care62

Friday, June 3, 20111:00 PM - 3:30 PMEXTENDED EDUCATION SESSIONSGrant Writing Workshop I: Basic Grant WritingLocation: S106CME credit: 2.5Track(s): Professional Development, Clinical TrialsFRIDAYCharles M. Rudin, MD, PhD—ChairThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins UniversityDeveloping Hypothesis and Stating AimsLei Ming, PhDNational Cancer InstituteNational Cancer Institute Training and Career Development GrantsKathleen A. Cooney, MDUniversity of Michigan Medical School, University of Michigan Comprehensive Cancer CenterConquer Cancer Foundation of ASCO (formerly The ASCO Cancer Foundation) GrantsProgramSusan Blaney, MDTexas Children’s Cancer CenterChoosing a Mentor and Obtaining Letters of SupportHeidi Nelson, MDMayo ClinicTips for Grant Writing in the New National Institutes of Health FormatDonna S. Neuberg, ScDDana-Farber Cancer InstituteStatistical ConsiderationsMary L. Disis, MDUniversity of WashingtonGrant Writing PearlsOn the Shoulders of Giants: Historical Perspectives on Biomarkers andColorectal CarcinomaLocation: E350CME credit: 2.5Track(s): Professional Development, Gastrointestinal (Colorectal) CancerJill Gilbert, MD—ChairVanderbilt UniversityRobert J. Mayer, MDDana-Farber Cancer InstituteHistory of Systemic Treatment for Colorectal CancerS. Gail Eckhardt, MDUniversity of Colorado School of Medicine, Anschutz Medical CampusHistory of the Development of Novel Agents and Integration of Biomarkers in Colorectal CancerKatherine Elizabeth Reeder-Hayes, MDUniversity of North Carolina HospitalCase Study: Colorectal CarcinomaJae Hong Park, MDMemorial Sloan-Kettering Cancer CenterCase Study: Colorectal Carcinoma63

Friday, June 3, 2011FRIDAY1:00 PM - 4:00 PMEXTENDED EDUCATION SESSIONMaintenance of Certification and Lifelong Learning Workshop(MOC)—Ticketed SessionLocation: E451bTrack(s): Professional DevelopmentAlexandria T. Phan, MD—ChairUniversity of Texas M. D. Anderson Cancer CenterABIM 2010 Update in Medical OncologyGregory A. Masters, MDThomas Jefferson University Medical School and Medical Oncology Hematology ConsultantsABIM 2010 Update in Medical OncologyAnne Moore, MDWeill Cornell Medical CollegeABIM 2010 Update in Medical Oncology64

Friday, June 3, 20112:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONCentral Nervous System TumorsDisplay Time: 2:00 PM - 6:00 PMDisplay Location: S102Discussion Time: 5:00 PM - 6:00 PMDiscussion Location: S100aCME credit: 1Track(s): Central Nervous System TumorsFRIDAYMark R. Gilbert, MD—Co-ChairUniversity of Texas M. D. Anderson Cancer CenterJohn L. Villano, MD—Co-ChairUniversity of IllinoisDiscussion5:00 PM Martin Kelly Nicholas, MD, PhD (Abstracts #2012–2017)The University of ChicagoDiscussion5:30 PM Jeffrey J. Raizer, MD (Abstracts #2025–2030)Northwestern University Feinberg School of MedicineDiscussion5:45 PM David M. Peereboom, MD (Abstracts #2031–2036)Cleveland ClinicBrd. 1 A population-based study of glioblastoma multiforme (GBM) in the newStupp paradigm: Have we improved outcome? (Abstract #2012)Z. Lwin, D. MacFadden, A. AL-Zahrani, E. Atenafu, B. Miller, C. Menard,N. Laperriere, W. P. MasonBrd. 2 Improved survival time trends for glioblastoma using the SEER 17population-based registries. (Abstract #2013)M. Koshy, J. L. Villano, T. A. Dolecek, A. Howard, S. Chmura,R. R. Weichselbaum, B. J. McCarthyBrd. 3 Real-life survival in unselected adult glioblastoma patients: A populationbasedstudy. (Abstract #2014)M. Preusser, A. Woehrer, N. Zielonke, H. Heinzl, C. Auer, T. Waldhoer,K. Roessler, C. Marosi, J. A. HainfellnerBrd. 4 Effects of surgery with BCNU wafer placement on neurocognitive function inpatients with one to three brain metastases. (Abstract #2015)M. G. Ewend, C. A. Meyers, E. Silva, M. Booth-Jones, S. Jain, S. BremBrd. 5 Clinical utility of neurocognitive function (NCF), quality of life (QOL), andsymptom assessment as prognostic factors for survival and measures oftreatment effects on RTOG 0525. (Abstract #2016)T. S. Armstrong, J. S. Wefel, M. Wang, M. Won, A. Bottomley, T. R. Mendoza,C. Coens, M. Werner-Wasik, D. Brachman, A. K. Choucair, M. R. GilbertBrd. 6 Variation over time and interdependence between disease progression anddeath among patients with glioblastoma (GBM) on RTOG 0525. (Abstract#2017)M. Wang, J. Dignam, M. Won, W. J. Curran Jr., M. P. Mehta, M. R. GilbertBrd. 7 Outcome of grade 3 and 4 cytopenia in newly diagnosed glioblastomamultiforme (GBM) patients treated with temozolomide (TMZ). (Abstract#2018)B. E. Sanchez, J. Munoz, H. Y. Ali, J. M. Anderson, P. Kuriakose65

Friday, June 3, 2011FRIDAYBrd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16Brd. 17Brd. 18Single nucleotide polymorphisms (SNPs) and circulating endothelial cells(CECs) as outcome predictors in patients (pts) with recurrent glioblastoma(rGBM) treated with bevacizumab (BEV) and sorafenib (SOR). (Abstract#2019)S. Anderson, J. M. Lafky, X. W. Carrero, T. K. Kimlinger, T. M. Halling, S. Kumar,P. J. Flynn, H. M. Gross, K. A. Jaeckle, J. C. Buckner, E. GalanisDetection of IDH1 mutations in a series of 91 oligodendrogliomas:Comparison of immunohistochemistry, DNA sequencing, and allele-specificPCR. (Abstract #2020)D. Loussouarn, A. Le Loupp, J. Frenel, F. Leclair, A. Von Deimling, M. Aumont,S. Martin, M. Campone, M. G. DenisThe role of the development of hypertension or proteinuria in predictingoutcome with the use of bevacizumab for patients with glioblastomamultiforme (GBM). (Abstract #2021)C. S. Nangia, D. Wang, L. Scarpace, L. Schultz, A. Khanshour, T. MikkelsenClinical use of personalized molecular biomarkers in patients withglioblastoma. (Abstract #2022)M. Holdhoff, J. O. Blakeley, C. Carson, C. H. Ferrigno, L. Blair,A. S. Balmanoukian, P. Burger, S. A. Grossman, L. A. Diaz Jr.Triple-negative, low-grade gliomas: A highly aggressive tumor with dismalprognosis. (Abstract #2023)P. Metellus, B. Coulibaly, C. Colin, A. Maues de Paula, A. Barlier, A. Loundou,S. Fuentes, H. Dufour, M. Barrie, O. L. Chinot, L. Ouafik, D. Figarella-BrangerThe role of amide proton transfer imaging in detecting active malignantglioma. (Abstract #2024)J. O. Blakeley, X. Ye, M. Lim, H. Zhu, L. Blair, A. Quinones-Hinojosa, C. Eberhart,P. Barker, J. Laterra, P. C. van Zijl, J. ZhouMethotrexate (MTX) rechallenge for recurrent primary CNS lymphoma(PCNSL). (Abstract #2025)E. Pentsova, L. M. DeAngelis, A. M. OmuroImpact of meningeal dissemination (MD) on outcome in primary CNSlymphoma in the G-PCNSL-SG1 trial. (Abstract #2026)A. Korfel, L. Fischer, P. Martus, R. Moehle, H. A. Klasen, M. Rauch, A. Roeth,B. Hertenstein, T. Fischer, H. Mergenthaler, T. Hundsberger, M. Leithäuser,T. Birnbaum, A. Florschütz, K. Jahnke, U. Herrlinger, M. Weller, E. ThielPhase II trial of bevacizumab with fotemustine in recurrent glioblastoma:Final results of a multicenter study of AINO (Italian Association of Neurooncology).(Abstract #2027)R. Soffietti, E. Trevisan, R. Ruda, L. Bertero, C. Bosa, M. Fabrini, I. LolliPhase II study of bevacizumab (BEV), temozolomide (TMZ), andhypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosedglioblastoma (GBM). (Abstract #2028)A. M. Omuro, K. Beal, S. Karimi, D. Correa, T. A. Chan, L. M. DeAngelis,I. T. Gavrilovic, C. Nolan, A. Hormigo, A. B. Lassman, T. J. Kaley, I. K. Mellinghoff,C. Grommes, K. Panageas, A. S. Reiner, R. Barradas, L. E. Abrey, P. H. GutinRandomized multicenter phase II trial of irinotecan and bevacizumab asneoadjuvant and adjuvant to temozolomide-based chemoradiation versuschemoradiation for unresectable glioblastoma: Interim results of theTEMAVIR study from the ANOCEF group. (Abstract #2029^)B. Chauffert, L. Feuvret, F. Bonnetain, L. Taillandier, H. Taillia, D. Frappaz,R. Schott, J. Honnorat, M. Fabbro, I. Tennevet, F. Ghiringhelli, J. S. Guillamo,X. Durando, D. Castera, M. Frenay, C. Campello, R. Guillevin, J. Skrzypski,T. S. Dabakuyo, O. L. Chinot, Association des Neuro-Oncologues d’ExpressionFrancaise66

Friday, June 3, 2011Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25Bevacizumab (BV) continuation following BV progression: Meta-analysis offive consecutive recurrent glioblastoma (GBM) trials. (Abstract #2030)D. A. Reardon, J. J. Vredenburgh, A. Desjardins, K. Peters, A. D. Coan,J. E. Herndon, H. S. FriedmanPhase II study of erlotinib with concurrent whole-brain radiation therapy forpatients with brain metastases from non-small cell lung cancer. (Abstract#2031)J. Welsh, A. Amini, E. S. Kim, P. Allen, J. Y. Chang, L. L. Garland, J. Holt,D. Erdman, R. Komaki, B. SteaPhase I study of vorinostat in combination with temozolomide in patientswith malignant gliomas. (Abstract #2032)P. Y. Wen, V. K. Puduvalli, J. G. Kuhn, J. M. Reid, K. Lamborn, T. F. Cloughesy,S. M. Chang, J. Drappatz, W. A. Yung, M. R. Gilbert, H. Robins, F. S. Lieberman,A. B. Lassman, R. M. McGovern, S. Desideri, X. Ye, M. M. Ames,I. J. Espinoza-Delgado, S. A. Grossman, M. PradosNCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients withrecurrent glioblastoma: A North Central Cancer Treatment Group study.(Abstract #2033)K. A. Jaeckle, D. Schiff, S. K. Anderson, E. Galanis, P. J. Stella, P. J. Flynn,J. N. Sarkaria, B. W. Scheithauer, B. J. Erickson, J. C. Buckner, NCCTGTEMOBIC: An ANOCEF phase II study of BCNU and temozolomide (TMZ)combination prior to radiotherapy (RT) in anaplasic oligodendroglial gliomas(AOG). (Abstract #2034)O. L. Chinot, K. Hoang-Xuan, M. Fabbro, L. Taillandier, J. Honnorat, M. Barrie,M. Sanson, C. Kerr, P. Beauchesne, S. Cartalat-Carel, D. Autran, A. Loundou,R. Guillevin, K. Mokhtari, D. Figarella-Branger, J. Delattre, Association desNeuro-Oncologues d’Expression FrancaiseOpen-label, dose-confirmation study of interstitial 131 I-chTNT-1/b mab for thetreatment of glioblastoma multiforme (GBM) at first relapse: Interim results.(Abstract #2035)W. R. Shapiro, D. Gupta, A. K. Mahapatra, S. Gopal, K. Judy, S. J. Patel, J. ShanA phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), andradiation (RT) for newly diagnosed high-grade gliomas. (Abstract #2036)S. A. Jeyapalan, M. Goldmann, J. Donahue, H. Elinzano, D. L. Evans,B. M. O’Connor, M. A. Puthawala, A. Oyelese, D. Cielo, M. Blitstein, M. Dargush,A. Santaniello, M. Constantinou, T. Dipetrillo, H. Safran, Brown UniversityOncology GroupFRIDAY67

Friday, June 3, 2011FRIDAY2:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONGynecologic CancerDisplay Time: 2:00 PM - 6:00 PMDisplay Location: E450aDiscussion Time: 5:00 PM - 6:00 PMDiscussion Location: E354bCME credit: 1Track(s): Gynecologic CancerDaniela Matei, MD—Co-ChairIndiana University Simon Cancer CenterSeiko Diane Yamada, MD—Co-ChairThe University of ChicagoDiscussion5:00 PM Paul J. Goodfellow, PhD (Abstracts #5012–5016)Washington University School of MedicineDiscussion5:15 PM David R. Spriggs, MD (Abstracts #5017–5024)Memorial Sloan-Kettering Cancer CenterDiscussion5:30 PM Beth Karlan, MD (Abstracts #5025–5031)Cedars-Sinai Medical CenterDiscussion5:45 PM Patricia J. Eifel, MD (Abstracts #5032–5036)University of Texas M. D. Anderson Cancer CenterBrd. 1 A phase II study of everolimus and letrozole in patients with recurrentendometrial carcinoma. (Abstract #5012)B. M. Slomovitz, J. Brown, T. A. Johnston, D. Mura, C. Levenback, J. Wolf,K. R. Adler, K. H. Lu, R. L. ColemanBrd. 2 Phase II study of oral ridaforolimus in patients with metastatic and/or locallyadvanced recurrent endometrial cancer: NCIC CTG IND 192. (Abstract #5013)H. Mackay, S. Welch, M. S. Tsao, J. J. Biagi, L. Elit, P. Ghatage, L. Martin,K. S. Tonkin, S. Ellard, S. K. Lau, L. McIntosh, E. A. Eisenhauer, A. M. OzaBrd. 3 Hormone therapy plus temsirolimus for endometrial carcinoma (EC):Gynecologic Oncology Group trial #248. (Abstract #5014)G. F. Fleming, V. L. Filiaci, P. Hanjani, J. J. Burke II, S. A. Davidson,K. K. Leslie, R. J. Zaino, Gynecologic Oncology GroupBrd. 4 A phase II trial of temsirolimus and bevacizumab in patients withendometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cellcancer: Ovarian cancer (OC) subset—A study of the Princess Margaret,Mayo, Southeast phase II and California Cancer (CCCP) N01 ConsortiaNCI#8233. (Abstract #5015)R. Morgan, A. M. Oza, R. Qin, K. M. Laumann, H. Mackay, E. L. Strevel, S. Welch,D. Sullivan, R. M. Wenham, H. X. Chen, L. A. Doyle, D. R. Gandara, C. ErlichmanBrd. 5 The search continues: Looking for predictive biomarkers for response mTORinhibition in endometrial cancer. (Abstract #5016)L. A. Meyer, B. M. Slomovitz, B. Djordjevic, J. M. Galbincea, T. A. Johnston,M. Munsell, J. K. Burzawa, M. Huang, R. Broaddus, D. A. Iglesias, R. L. Coleman,D. M. Gershenson, T. W. Burke, J. Wolf, K. H. LuBrd. 6 Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005,NSC# 724770) in patients with recurrent ovarian, primary peritoneal, andfallopian tube cancer. (Abstract #5017)R. L. Coleman, L. R. Duska, P. T. Ramirez, S. C. Modesitt, K. M. Schmeler, R. Iyer,M. Garcia, A. Sood68

Friday, June 3, 2011Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16Brd. 17Brd. 18Brd. 19The role of bevacizumab incombination with pegylated liposomaldoxorubicin in patients with platinum-resistant recurrent or refractoryovarian cancers. (Abstract #5018)H. Kouta, K. Kudoh, M. Takano, R. Kikuchi, T. Kita, T. Goto, K. Furuya, Y. KikuchiA phase II study of intermittent sorafenib with bevacizumab in patients withbevacizumab-naive epithelial ovarian cancer (EOC). (Abstract #5019)E. C. Kohn, J. Lee, C. M. Annunziata, L. M. Minasian, J. Zujewski, S. A. Prindiville,H. L. Kotz, J. Squires, N. D. Houston, H. X. Chen, J. J. WrightA phase II trial of weekly nab-paclitaxel with GM-CSF aschemoimmunotherapy for platinum-resistant epithelial ovarian cancer.(Abstract #5020)R. E. Swensen, J. Childs, D. Higgins, T. Gooley, B. A. Goff, P. A. Fintak,B. Buening, M. L. DisisA phase II study of ENMD-2076 in platinum-resistant ovarian cancer.(Abstract #5021)U. Matulonis, W. P. Tew, D. Matei, K. Behbakht, G. F. Fleming, A. M. OzaPhase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer(OC). (Abstract #5022)G. Scambia, D. Lorusso, G. Amadio, N. Trivellizzi, A. Pietragalla, R. De Vincenzo,V. Salutari, M. Di Stefano, G. Mangili, S. Montoli, G. Citterio, A. Lambiase,C. BordignonIndependent radiologic review of GOG218, a phase III trial of bevacizumab(BEV) in the primary treatment of advanced epithelial ovarian (EOC), primaryperitoneal (PPC), or fallopian tube cancer (FTC). (Abstract #5023)R. A. Burger, M. F. Brady, J. Rhee, M. A. Sovak, H. Nguyen, M. A. BookmanA single-center experience of EMA/CO chemotherapy for high-riskgestational trophoblastic neoplasia: Induction low-dose cisplatin andetoposide chemotherapy. (Abstract #5024)C. Alifrangis, R. Agarwal, D. Short, P. Savage, M. SecklSequence-specific effects on DNA and cell damage with the PARP inhibitorolaparib (AZD2281) and carboplatin. (Abstract #5025)J. L. Hays, G. Kim, J. Mariani, R. F. Murphy, M. Angelos, A. McCollum, J. Lu,B. C. Widemann, J. Lee, E. C. KohnGerm-line BRCA mutations in high-grade ovarian cancer: A case for routineBRCA mutation screening after a diagnosis of invasive ovarian cancer.(Abstract #5026)K. Alsop, S. Fereday, C. Meldrum, A. deFazio, P. Webb, M. J. Birrer,M. Friedlander, S. B. Fox, D. Bowtell, G. Mitchell, The Australian Ovarian CancerStudy (AOCS) GroupLoss of heterozygosity (LOH) as a measure of whole-genome instability inovarian cancer correlates with clinical outcomes. (Abstract #5027)G. Korpanty, K. Timms, V. Abkevich, M. Carey, A. Gutin, Y. Li, J. Li, M. Markman,R. Broaddus, J. S. Lanchbury, K. H. Lu, G. B. Mills, B. HennessyA phase I trial of the PARP inhibitor olaparib (AZD2281) in combination withthe antiangiogenic cediranib (AZD2171) in recurrent ovarian or triplenegativebreast cancer. (Abstract #5028)J. Liu, G. F. Fleming, S. M. Tolaney, M. J. Birrer, R. T. Penson, S. T. Berlin,C. Whalen, K. Tyburski, K. Matijevich, E. Kasparian, M. Roche, H. Lee,E. P. Winer, S. P. Ivy, U. MatulonisEffect of WBC BRCA1 promoter methylation on ovarian cancer risk. (Abstract#5029)P. Lonning, M. Bjornslett, S. Knappskog, L. Vatten, P. Romundstad, U. Axcrona,D. G. Evans, A. Howell, A. Dørum , R. ChrisantharAssociations between MDM2 SNP309 and SNP285C haplotypes and ovariancancer risk in BRCA1 mutation carriers. (Abstract #5030)M. Bjørnslett, S. Knappskog, P. Lonning, A. DørumFRIDAY69

Friday, June 3, 2011FRIDAYBrd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25A multivariate longitudinal algorithm for early detection of ovarian cancerusing multiple biomarkers. (Abstract #5031)Z. Zhang, S. J. Skates, L. J. Sokoll, Z. Lu, C. H. Clarke, M. A. Hernandez, K. H. Lu,R. C. BastA phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiationtherapy (RT) for women with locally advanced cervical cancer (CXCA): AGOG study. (Abstract #5032)K. N. Moore, M. Sill, D. S. Miller, P. Disilvestro, K. De Geest, P. G. Rose,H. R. Cardenes, R. S. Mannel, J. H. Farley, R. J. Schilder, P. M. FracassoINCA-GYN001: Erlotinib added to cisplatin and definitive radiotherapy inuntreated patients with locally advanced squamous cell cervicalcarcinoma—Final report of a phase II trial. (Abstract #5033)A. N. Rodrigues, I. A. Small, C. C. Carmo, G. M. Moralez, F. Erlich, R. Grazziotin,M. H. Lewer, C. C. Camisao, F. V. Alves, C. G. FerreiraPhase II trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locallyadvanced cervical and vaginal cancer. (Abstract #5034)C. Kunos, S. E. Waggoner, K. M. Zanotti, R. DeBernardo, N. Fusco, A. Heugel,J. Knazek, R. Adams, T. Radivoyevitch, A. DowlatiUtility of preoperative ferumoxtran-10 enhanced MRI to evaluateretroperitoneal lymph node metastasis in advanced cervical cancer: Resultsof ACRIN 6671/GOG 0233. (Abstract #5035)M. Atri, Z. Zhang, H. Marques, J. Gorelick, M. Harisinghani, A. Sohaib, D. Koh,S. Raman, M. S. Gee, H. Choi, L. M. Landrum, R. S. Mannel, L. T. Chuang,J. Q. Yu, C. K. McCourt, M. Gold, ACRIN/GOGEstimation of expectedness: How reliable are the predictions for the outcomeof standard therapy in randomized phase III studies (RP3) in epithelialovarian cancer (EOC)? (Abstract #5036)V. Castonguay, I. Diaz-Padilla, L. Wang, A. M. Oza70

Friday, June 3, 20112:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONHead and Neck CancerDisplay Time: 2:00 PM - 6:00 PMDisplay Location: S403Discussion Time: 5:00 PM - 6:00 PMDiscussion Location: S406CME credit: 1Track(s): Head and Neck CancerFRIDAYQuynh-Thu Le, MD—Co-ChairStanford University Medical CenterBarbara A. Murphy, MD—Co-ChairVanderbilt Medical CenterDiscussion5:00 PM Quynh-Thu Le, MD (Abstracts #5507–5515^)Stanford University Medical CenterDiscussion5:15 PM Bonnie S. Glisson, MD (Abstracts #5516–5520)University of Texas M. D. Anderson Cancer CenterDiscussion5:30 PM Barbara A. Murphy, MD (Abstracts #5521–5526)Vanderbilt Medical CenterDiscussion5:45 PM Lisa F. Licitra, MD (Abstracts #5527–5529)Fondazione IRCCS Istituto Nazionale dei TumoriBrd. 1 Genetic sequence variants (GSV) in relation to acute and late toxicities inhead and neck cancer (HNC) patients treated with radiation therapy (RT).(Abstract #5507)F. Meyer, I. Bairati, W. Xu, A. Azad, G. LiuBrd. 2 Interference of amphiregulin and EGFRvIII expression with outcome ofpatients with squamous cell carcinoma of the head and neck (SCCHN)receiving cetuximab-docetaxel treatment. (Abstract #5508)I. Tinhofer, K. F. Klinghammer, W. Weichert, M. Knoedler, A. Stenzinger,T. C. Gauler, V. Budach, U. KeilholzBrd. 3 MDM2 309 single nucleotide polymorphisms (SNP) and clinical outcome inpatients with advanced squamous cell carcinoma of head and neck (SCCHN).(Abstract #5509)M. Gasco, D. Vivenza, M. Monteverde, L. Lattanzio, I. Colantonio, G. Natoli,E. Miraglio, A. Comino, N. Syed, T. Crook, M. C. Merlano, C. Lo NigroBrd. 4 Updated clinical and biomarker results from a phase I study of vandetanibwith radiation therapy (RT) with or without cisplatin in locally advanced headand neck squamous cell carcinoma (HNSCC). (Abstract #5510)V. Papadimitrakopoulou, J. Heymach, S. J. Frank, J. Myers, H. Lin, H. T. Tran,C. Chen, F. R. Hirsch, P. B. Langmuir, J. R. Vasselli, S. M. Lippman, D. RabenBrd. 5 Correlation of circulating tumor cells in SCCNH patients to cancerreoccurrence using a negative enrichment technology. (Abstract #5511)K. Jatana, P. Balasubramanian, J. C. Lang, T. N. Teknos, D. E. Schuller,J. J. ChalmersBrd. 6 Predictive value of human papillomavirus (HPV) 16 in situ hybridization (ISH)and p16 immunohistochemistry (IHC) for HPV oncogene expression inparaffin-embedded oropharynx squamous cell carcinoma (OPSCC).(Abstract #5512)M. L. Gillison, R. Jordan, M. Lingen, B. Perez-Ordonez, X. He, R. Pickard,A. Inman, M. Koluder, B. Jiang, P. Wakely, W. Xiao71

Friday, June 3, 2011FRIDAYBrd. 7 H-RAS and PIK3CA mutations and response to cetuximab in head and necksquamous cell carcinoma (HNSCC). (Abstract #5513)T. Rampias, A. Giagini, K. Florou, P. Gouveris, E. Vaja, N. Haralambakis,P. Katsaounis, D. G. Pectasides, T. Economopoulos, A. PsyrriBrd. 8 Molecular prognostic prediction by support vector machine integratedapproach for local advanced nasopharyngeal carcinoma. (Abstract #5514)X. Wan, X. Wu, X. Fan, H. Cai, M. Chen, J. Xu, M. Hong, Q. LiuBrd. 9 Exosomal-miRNA profiles as diagnostic and prognostic biomarkers in headand neck squamous cell carcinoma (HNSCC). (Abstract #5515^)G. Rabinowits, C. G. Taylor, G. H. Kloecker, A. Patel, M. B. Hall, D. D. TaylorBrd. 10 Phase II study of chemoradiation plus bevacizumab (BV) forlocally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminaryclinical results of RTOG 0615. (Abstract #5516)N. Y. Lee, Q. Zhang, A. S. Garden, J. J. Kim, D. G. Pfister, J. Mechalakos, K. Hu,Q. Le, B. S. Glisson, A. T. Chan, K. AngBrd. 11 Phase II study of gefitinib adaptive dose escalation to skin toxicity inrecurrent and/or metastatic squamous cell carcinoma of the head and neck.(Abstract #5517)C. A. Perez, H. Song, L. E. Raez, M. Agulnik, T. A. Grushko, A. Dekker,K. Stenson, E. A. Blair, O. I. Olopade, T. Y. Seiwert, E. E. Vokes, E. E. CohenBrd. 12 Phase I trial of bevacizumab combined with concurrent chemoradiation forsquamous cell carcinoma of the head and neck: Preliminary outcome results.(Abstract #5518)P. M. Harari, D. Khuntia, A. M. Traynor, T. Hoang, D. T. Yang, G. K. Hartig,T. M. McCulloch, R. Jeraj, M. J. Nyflot, P. A. Wiederholt, L. R. GentryBrd. 13 A randomized phase II trial of cetuximab-based induction chemotherapyfollowed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionatedradiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation withconcomitant boost (CetuxPX) in patients with locoregionally advanced headand neck cancer (HNC). (Abstract #5519)T. Y. Seiwert, D. J. Haraf, E. E. Cohen, E. A. Blair, K. Stenson, J. K. Salama,M. Kocherginsky, V. M. Villaflor, M. Witt, R. Williams, A. Dekker, E. E. VokesBrd. 14 Randomized trial of a short course of erlotinib 150 to 300 mg daily prior tosurgery for squamous cell carcinomas of the head and neck (SCCHN) incurrent, former, and never smokers: Objective responses and clinicaloutcomes. (Abstract #5520)W. N. William Jr., R. S. Weber, J. Lee, J. Myers, L. E. Ginsberg, A. K. El-Naggar,E. M. Sturgis, A. L. Sabichi, M. S. Kies, E. Y. Hanna, A. C. Hessel, C. Lu, S. Y. Lai,R. Ayuste, S. M. Lippman, E. S. KimBrd. 15 A randomized phase III trial of magic mouthwash and sucralfate versusbenzydamine hydrochloride for prophylaxis of radiation-induced oralmucositis in head and neck cancer. (Abstract #5521)J. S. Kuk, S. Parpia, S. M. Sagar, T. Tsakiridis, D. Kim, D. I. Hodson, C. Zywine,J. R. WrightBrd. 16 Neurocognitive function (NCF) in patients (pts) treated withchemo/bioradiotherapy (C/B-RT) for head and neck cancers (HNC). (Abstract#5522)A. R. Abdul Razak, L. L. Siu, A. Chan, G. R. Pond, K. M. Tirona, E. X. Chen,A. J. Hope, J. Ringash, B. O’Sullivan, J. N. Waldron, K. Chan, H. K. Gan,L. J. BernsteinBrd. 17 Patient-reported fatigue in head and neck cancer survivors. (Abstract #5523)G. B. Gunn, T. R. Mendoza, A. S. Garden, X. S. Wang, W. H. Morrison, S. J. Frank,E. Y. Hanna, C. Lu, B. M. Beadle, K. Ang, C. S. Cleeland, D. I. Rosenthal72

Friday, June 3, 2011Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Phase III trial of low-level laser therapy to prevent induced oral mucositis inhead and neck cancer patients submitted to concurrent chemoradiation.(Abstract #LBA5524)H. S. Antunes, D. Herchenhorn, C. M. Araujo, E. Cabral, E. M. D. S. Ferreira,I. A. Small, M. P. Rampini, N. Teich, P. C. Rodrigues, T. G. P. D. Silva, L. F. Dias,C. G. M. FerreiraThe utility of using area under the curve to analyze symptom burden duringradiation/chemoradiation for head and neck cancer. (Abstract #5525)T. R. Mendoza, G. B. Gunn, C. D. Fuller, X. S. Wang, D. I. Rosenthal,C. S. CleelandToxicity in combined modality treatment of HNSCC: Cisplatin versuscetuximab. (Abstract #5526)A. Chew, J. Hay, J. J. Laskin, J. Wu, C. HoCorrelation of HPV status and hypoxic imaging using [18F]-misonidazole(FMISO) PET in head and neck squamous cell carcinoma (HNSCC). (Abstract#5527)M. E. Trinkaus, R. J. Hicks, R. J. Young, L. J. Peters, B. J. Solomon, M. Bressel,J. Corry, R. Fisher, D. Binns, G. A. McArthur, D. RischinHuman papillomavirus (HPV)–related head and neck squamous cellcarcinoma (HNSCC) and outcome after treatment with epidermal growthfactor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versusconventional chemotherapy (CT) plus RT. (Abstract #5528)B. Pajares, J. Trigo Perez, M. D. Toledo, M. Alvarez, L. Perez-Villa,C. Gonzalez-Hermoso, A. Rueda, J. A. Medina, B. Jimenez, J. Jerez, L. Perez,E. AlbaHuman papillomavirus (HPV) and rising oropharyngeal cancer incidence andsurvival in the United States. (Abstract #5529)A. Chaturvedi, E. Engels, R. Pfeiffer, B. Y. Hernandez, W. Xiao, E. Kim, B. Jiang,M. Goodman, M. Sibug-Saber, W. Cozen, L. Liu, C. Lynch, N. Wentzensen,R. Jordan, S. Altekruse, W. F. Anderson, P. Rosenberg, M. L. GillisonFRIDAY73

Friday, June 3, 2011FRIDAY2:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONLeukemia, Myelodysplasia, and TransplantationDisplay Time: 2:00 PM - 6:00 PMDisplay Location: E450bDiscussion Time: 5:00 PM - 6:00 PMDiscussion Location: Arie Crown TheaterCME credit: 1Track(s): Leukemia, Myelodysplasia, and TransplantationJane Liesveld, MD—Co-ChairUniversity of Rochester Medical CenterHarry Paul Erba, MD, PhD—Co-ChairUniversity of Michigan Medical CenterDiscussion5:00 PM Olatoyosi Odenike, MD (Abstracts #6509–6515)The University of ChicagoDiscussion5:15 PM Farhad Ravandi, MD (Abstracts #6516–6522)University of Texas M. D. Anderson Cancer CenterDiscussion5:30 PM Joseph P. Uberti, MD (Abstracts #6523–6528)Karmanos Cancer Institute, Wayne State UniversityDiscussion5:45 PM Guido Marcucci, MD (Abstracts #6529–6533)The Ohio State University Comprehensive Cancer CenterBrd. 1 Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phasechronic myeloid leukemia (CP CML) in the BELA trial: Eighteen-monthfollow-up. (Abstract #6509)C. Gambacorti-Passerini, J. E. Cortes, D. Kim, H. Kantarjian, N. Khattry,J. H. Lipton, C. Powell, P. Harris, A. M. Countouriotis, T. H. BrummendorfBrd. 2 Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia inchronic phase (CML-CP): Two-year follow-up from DASISION. (Abstract#6510)H. Kantarjian, N. P. Shah, J. E. Cortes, M. Baccarani, M. Bradley-Garelik, C. Zhu,A. HochhausBrd. 3 Comparison of nilotinib and imatinib in patients (pts) with newly diagnosedchronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-monthfollow-up. (Abstract #6511)R. A. Larson, D. Kim, G. Rosti, L. Stenke, R. Pasquini, A. Hoenekopp,R. E. Blakesley, N. J. Gallagher, A. Hochhaus, T. P. Hughes, G. Saglio,H. KantarjianBrd. 4 Five-year follow-up of patients with imatinib-resistant or -intolerant chronicphasechronic myeloid leukemia (CML-CP) receiving dasatinib. (Abstract#6512)N. P. Shah, J. E. Cortes, C. A. Schiffer, F. Guilhot, T. H. Brummendorf, A. C. Chen,D. Healey, A. Lambert, G. SaglioBrd. 5 A survey of current practices in the management of chronic myeloidleukemia (CML). (Abstract #6513)M. J. Mauro, J. E. Cortes, R. A. Larson, P. M. Herout, V. K. Bollu, A. Niyazov,H. KantarjianBrd. 6 Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment ofmyelofibrosis. (Abstract #6514)A. D. Pardanani, D. Caramazza, G. George, T. L. Lasho, W. J. Hogan,M. R. Litzow, K. Begna, C. A. Hanson, R. F. McClure, L. M. Bavisotto,G. Smith, M. Kowalski, S. Sirhan, A. W. Roberts, V. Gupta, J. Gotlib, A. Tefferi74

Friday, June 3, 2011Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16Brd. 17Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patientswith myelofibrosis. (Abstract #6515)H. J. Deeg, O. Odenike, B. L. Scott, Z. Estrov, J. E. Cortes, D. A. Thomas,H. J. Zhu, H. Kantarjian, S. VerstovsekPhase I trial of the targeted alpha-particle nano-generator actinium-225( 225 Ac-lintuzumab; anti-CD33; HuM195) in acute myeloid leukemia (AML).(Abstract #6516)J. G. Jurcic, T. L. Rosenblat, M. R. McDevitt, N. Pandit-Taskar, J. A. Carrasquillo,S. M. Chanel, C. Ryan, M. G. Frattini, D. Cicic, S. M. Larson, D. A. ScheinbergInterim results of OPAL, a study of tosedostat in elderly relapsed/refractoryAML. (Abstract #6517)E. J. Feldman, K. W. Yee, D. Rizzieri, A. S. Advani, A. Charman, A. Richardson,M. J. Toal, J. E. CortesPonatinib in patients with acute myeloid leukemia (AML): Preliminaryfindings from a phase I study in hematologic malignancies. (Abstract #6518)M. Talpaz, N. P. Shah, M. W. Deininger, M. J. Mauro, I. W. Flinn, S. Lustgarten,W. Lindmark, J. M. Gozgit, T. Clackson, C. D. Turner, F. G. Haluska, H. Kantarjian,J. E. CortesCPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newlydiagnosed AML patients age 60–75: Safety and efficacy in secondary AML(sAML). (Abstract #6519)J. E. Lancet, J. E. Cortes, T. Kovacsovics, D. Hogge, J. E. Kolitz, M. S. Tallman,M. Chiarella, A. C. Louie, E. J. FeldmanA phase III, open-label, randomized comparison of AS1413 (amonafideL-malate) plus cytarabine with daunorubicin plus cytarabine in secondaryacute myeloid leukemia (ACCEDE). (Abstract #6520)R. M. Stone, S. L. Allen, A. Pigneux, R. K. Stuart, M. Wetzler, D. Rizzieri,H. P. Erba, L. E. Damon, J. Jang, M. S. Tallman, K. Warzocha, T. Masszi,M. A. Sekeres, E. Miklos, H. Horst, D. L. Selleslag, S. R. Solomon, P. Venugopal,A. S. Lundberg, B. L. PowellA phase I and pharmacodynamic (PD) study of the histone deacetylase(HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloidmalignancies. (Abstract #6521)O. Odenike, L. A. Godley, J. Madzo, T. Karrison, M. Green, A. S. Artz,R. J. Mattison, K. W. Yee, M. Bennett, N. Fulton, G. Koval, G. Malnassy,R. A. Larson, M. J. Ratain, W. StockEarly lenalidomide (LEN) dose intensity and durable RBC-transfusionindependence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplasticsyndromes (MDS) and del5q. (Abstract #6522)A. F. List, A. Giagounidis, J. T. Backstrom, T. Fu, P. FenauxRelapse incidence and leukemia-free survival (LFS) in patients (pts) olderthan age 60 with AM undergoing stem cell transplantation: A report of theEast German Study Group Hematology and Oncology (OSHO). (Abstract#6523)D. Niederwieser, G. Maschmeyer, T. Fischer, L. Uharek, R. Kortmann,U. Hegenbart, P. Dreger, M. Herold, H. G. Sayer, H. Wolf, U. Kreibich, D. Hähling,C. Junghanss, N. Grobe, R. Krahl, T. Lange, H. Al-Ali, W. Pönisch, C. Nehring,G. DoelkenA randomized, phase III trial comparing BuCy and BuFlu as a myeloablativeconditioning regimen. (Abstract #6524)S. Kim, J. Lee, Y. Joo, H. Kim, H. Ryoo, M. Kim, G. Lee, W. Lee, J. Park, S. Bae,M. Hyun, D. Kim, Y. Min, Cooperative Study Group A for Hematology (COSAH)Reduced intensity conditioning with combined haploidentical and cord bloodtransplantation results in rapid engrafment and durable remissions.(Abstract #6525)K. Van Besien, H. Liu, E. S. Rich, L. A. Godley, O. Odenike, L. Joseph, J. P. Kline,V. H. Nguyen, J. M. Cunningham, R. A. Larson, W. Stock, A. Wickrema, A. S. ArtzFRIDAY75

Friday, June 3, 2011FRIDAYBrd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25Mechanism of thymic renewal after infusion of suicide gene-modified donorT cells after hematopoietic stem cell transplantation (HSCT) in adult patients.(Abstract #6526)C. Bordignon, L. Vago, G. Oliveira, M. Noviello, C. Soldati, D. Ghio, I. Brigida,A. Aiuti, M. Lupo-Stanghellini, J. Peccatori, A. Lambiase, A. Bondanza,A. Del Maschio, F. Ciceri, C. BoniniVincristine sulfate liposomes injection (VSLI) “bridging” to potentiallycurative hematopoietic stem cell transplantation (HSCT) in adults withPhiladelphia chromosome–negative (Ph-) acute lymphoblastic leukemia(ALL). (Abstract #6527)G. J. Schiller, S. E. Coutre, M. L. Larson, D. Ben Yehuda, P. Venugopal,S. Goldberg, G. L. Messerschmidt, J. Silverman, S. R. Deitcher, H. KantarjianA phase Ib clinical trial of Ad-ISF35-transduced autologous cells incombination with fludarabine, cyclophosphamide, rituximab (FCR) forpatients with fludarabine-refractory and/or del(17p)/p53-defective chroniclymphocytic leukemia (CLL). (Abstract #6528)J. E. Castro, L. S. Schwartzberg, J. Pinilla-Ibarz, T. J. Kipps, M. J. CantwellHigh-throughput mutation analysis in acute myeloid leukemia (AML).(Abstract #6529)J. Dunlap, C. L. Corless, W. H. Fleming, R. Braziel, N. Leeborg, K. Gatter,M. Loriaux, K. Kelemen, T. Kovacsovics, G. FanAssociation of IDH1 mutations in normal karyotype acute myeloid leukemiasamples with higher HIF-1 and VEGF-A expression. (Abstract #6530)M. Smonskey, P. Starostik, G. Deeb, K. Demock, R. Vargas, D. Lal, S. N. Sait,M. Wetzler, E. S. WangPRDM16 (1p36) translocations define a distinct entity of myeloidmalignancies with poor prognosis but may also occur in lymphoidmalignancies. (Abstract #6531)F. P. Duhoux, G. Ameye, K. Bahloula, M. Mozziconacci, S. Laibe, I. Wlodarska,L. Michaux, P. Talmant, S. Richebourg, E. Lippert, F. Speleman, C. Herens,S. Struski, S. Raynaud, N. Nadal, M. Lafage, N. Auger, J. Libouton, J. Demoulin,H. A. Poirel, Groupe Francophone de Cytogenetique Hematologique (GFCH) andBelgian Cytogenetic Group for Hematology and Oncology (BCG-HO)The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL). (Abstract #6532)I. Iacobucci, A. Ferrari, A. Lonetti, C. Papayannidis, F. Paoloni, M. Abbenante,V. Guadagnuolo, E. Ottaviani, F. Cattina, A. Vitale, S. Paolini, S. Soverini, S. Parisi,M. Vignetti, M. Baccarani, G. MartinelliNovel jumping translocations (JT) associated with genetic instability andaggressive disease in chronic lymphocytic leukemia (CLL). (Abstract #6533)C. Miller, F. Racke, G. Lozanski, A. McFaddin, J. C. Byrd, N. A. Heerema76

Friday, June 3, 20112:45 PM - 4:00 PMEDUCATION SESSIONSAcute Myeloid Leukemia: Update on Therapy and Molecular BasisLocation: Arie Crown TheaterCME credit: 1.25Track(s): Leukemia, Myelodysplasia, and Transplantation, Geriatric OncologyFRIDAYMartin S. Tallman, MD—ChairMemorial Sloan-Kettering Cancer CenterTherapy of the Elderly Patient with Acute Myeloid LeukemiaSami N. Malek, MDUniversity of Michigan Comprehensive Cancer CenterUpdate on the Molecular Biology of Acute Myeloid Leukemia: Clinical ImplicationsAlan Burnett, MDUniversity of Wales College of MedicineTherapy of Acute Myeloid Leukemia in Patients Younger Than Age 55Challenges in HER2-positive Breast CancerLocation: Hall D1CME credit: 1.25Track(s): Breast CancerMark D. Pegram, MD—ChairUniversity of Miami Sylvester Comprehensive Cancer CenterOverview and Discussion of HER2 Biology: De Novo and Acquired Resistance to TargetingGiuseppe Viale, MDEuropean Institute of OncologyControversies in Testing for HER2Eric P. Winer, MDDana-Farber Cancer InstituteTherapeutic Implications of HER2 Targeting in Very Small Clinical Low-risk Tumors and HER2Targeting after ProgressionTargeting ALK in Pediatric MalignanciesLocation: S504CME credit: 1.25Track(s): Pediatric Oncology, Lymphoma and Plasma Cell DisordersStephan Morris, MD—ChairSt. Jude Children’s Research HospitalThe Role of ALK Signaling in Anaplastic Large Cell LymphomaYael P. Mosse, MDThe Children’s Hospital of Philadelphia“Driver” ALK Mutations in NeuroblastomaPasi A. Janne, MD, PhDDana-Farber Cancer InstituteDeveloping Drugs That Taget ALK and Other Genomic Aberrations77

Friday, June 3, 2011FRIDAYWhen Adults Are Diagnosed with Children’s SarcomasLocation: S406CME credit: 1.25Track(s): Sarcoma, Pediatric OncologyKaren H. Albritton, MD—ChairCooks Children’s Medical CenterThe Unique Issues of the Adolescent and Young Adult (AYA) with SarcomaDavid Parham, MDUniversity of Oklahoma Health Sciences CenterPathologic Differences between Adult and Pediatric SarcomasRobert G. Maki, MD, PhDMount Sinai School of MedicineThe Management of the Adult with Children’s Sarcoma78

Friday, June 3, 20112:45 PM - 4:00 PMMEET THE PROFESSOR SESSIONSetting Up a Cancer Genetics Program (M02)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Cancer Genetics, Cancer Prevention/EpidemiologyFRIDAYJeffrey N. Weitzel, MDCity of HopeThe Academic PerspectiveTherese M. Mulvey, MDSouthcoast Hospitals GroupCommunity Practice Perspective79

Friday, June 3, 2011FRIDAY3:00 PM - 4:30 PMCLINICAL SCIENCE SYMPOSIUMPersonalized MedicineLocation: E354bCME credit: 1.5Track(s): Developmental TherapeuticsJames L. Gulley, MD, PhD—ChairNational Cancer Institute3:00 PM Personalized medicine in a phase I clinical trials program: The University ofTexas M. D. Anderson Cancer Center Initiative. (Abstract #CRA2500)A. M. Tsimberidou, N. G. Iskander, D. S. Hong, J. J. Wheler, S. Fu, S. A. Piha-Paul,A. Naing, G. S. Falchook, F. Janku, R. Luthra, S. Wen, R. KurzrockDiscussion3:15 PM Paula M. Fracasso, MD, PhD (Abstract #CRA2500)University of Virginia3:30 PM Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).(Abstract #2501)D. R. Camidge, Y. Bang, E. L. Kwak, A. T. Shaw, A. J. Iafrate, R. G. Maki,B. J. Solomon, S. I. Ou, R. Salgia, K. D. Wilner, D. B. Costa, G. Shapiro,P. LoRusso, P. Stephenson, Y. Tang, K. Ruffner, J. W. ClarkDiscussion3:45 PM Nasser H. Hanna, MD (Abstract #2501)Indiana University4:00 PM The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTORand RAS/MEK/ERK pathways in first-in-human phase I study: The STARTCenter experience. (Abstract #2502)T. Shimizu, A. W. Tolcher, K. P. Papadopoulos, M. Beeram, D. W. Rasco,L. S. Smith, S. Gunn, L. Smetzer, T. A. Mays, B. Kaiser, C. Alvarez,G. L. Mangold, A. PatnaikDiscussion4:15 PM James L. Gulley, MD, PhD (Abstract #2502)National Cancer Institute80

Friday, June 3, 20113:30 PM - 4:45 PMSPECIAL SESSIONASCO/Society of Nuclear Medicine (SNM) Joint Session: Molecular Imaging inCancer Clinical TrialsLocation: S100aCME credit: 1.25Track(s): Clinical Trials, Special SessionFRIDAYGeorge W. Sledge Jr., MD—Co-ChairIndiana University Simon Cancer CenterIntroduction and OverviewDavid A. Mankoff, MD, PhD—Co-ChairUniversity of WashingtonThe Imaging PerspectiveAnthony Frank Shields, MD, PhDKarmanos Cancer Institute/Wayne State UniversityThe Medical Oncology Perspective81

Friday, June 3, 2011FRIDAY3:30 PM - 6:00 PMEXTENDED EDUCATION SESSIONCareer Choices: Options in Academia, Private Practice, Industry, andGovernmentLocation: S404Track(s): Professional DevelopmentJohn E. Pippen, MD—ChairBaylor Sammons Cancer Center and Texas Oncology/US OncologyHybrid: Academia and Private PracticeMartine J. Piccart-Gebhart, MD, PhDJules Bordet InstituteAcademiaJohanna C. Bendell, MDSarah Cannon Research InstitutePrivate PracticeBarbara L. McAneny, MDNew Mexico Oncology Hematology ConsultantsHybrid: Public Policy and Private PracticeSandra J. Horning, MDGenentech Inc.IndustryRichard Pazdur, MDU.S. Food and Drug AdministrationGovernment82

Friday, June 3, 20113:45 PM - 6:00 PMEXTENDED EDUCATION SESSIONSAn Update on Biomarkers for the Early Detection of Cancer, Prediction ofPrognosis, and as Surrogate Endpoints for Cancer Prevention TrialsLocation: E354aCME credit: 2.25Track(s): Cancer Prevention/Epidemiology, Cancer GeneticsFRIDAYDean E. Brenner, MD—ChairUniversity of Michigan Medical CenterOverview and Fundamental Concepts of Biomarker Development and ValidationCarol J. Fabian, MDUniversity of Kansas Medical CenterBiomarkers as Surrogate Endpoints for Cancer Prevention Trials: Where Are We?Sanford D. Markowitz, MD, PhDCase Western Reserve UniversityBiomarkers for the Early Detection of Colon CancerHarvey I. Pass, MDNew York University School of MedicineEarly Detection and Prognostic Biomarkers for Lung CancerIan Thompson, MDUniversity of Texas Health Science Center at San AntonioProstate Cancer and Prostate-specific antigen: Our “Perfect Biomarker”—Fact or Fantasy?Robert C. Bast, MDUniversity of Texas M. D. Anderson Cancer CenterOvarian Cancer: CA-125 as a Prototype for an Early-diagnosis Biomarker—Do We HaveReasonable Expectations?Biologic, Clinical, and Psychosocial Correlates at the Interface of Aging andCancer: Report from the National Institute on Aging (NIA)/National CancerInstitute (NCI) Conference on Geriatric Oncology Research to Improve ClinicalCareLocation: S100bcCME credit: 2.25Track(s): Geriatric OncologyWilliam Dale, MD, PhD—ChairThe University of Chicago Medical CenterPsychosocial Factors at the Interface of Cancer and AgingArti Hurria, MDCity of HopeImproving Geriatric Oncology Clinical Care through ResearchHarvey Jay Cohen, MDDuke University Medical CenterBiologic Factors at the Interface of Cancer and AgingSupriya Gupta Mohile, MD, MSUniversity of Rochester Medical CenterClinical Factors at the Interface of Cancer and Aging83

Friday, June 3, 2011FRIDAYSecond Malignant Neoplasms: Epidemiology, Genetics, and Risk PredictionLocation: E353CME credit: 2.25Track(s): Cancer Prevention/Epidemiology, Cancer Genetics, Patient and Survivor CareLois B. Travis, MD, ScD—ChairUniversity of Rochester School of Medicine and DentistryEpidemiology of Second Malignant Neoplasms: An OverviewSophie D. Fossa, MDOslo University Hospital, The Norwegian Radium HospitalSecond Malignant Neoplasms in Survivors of Testicular CancerM. Eileen Dolan, PhDThe University of ChicagoGenomics and Late Effects of Treatment: Cisplatin as a ParadigmMargaret R. Spitz, MDUniversity of Texas M. D. Anderson Cancer CenterRisk Prediction Models for Second Cancers: Synopsis of Ongoing Research and GeneticPredictorsAndrea K. Ng, MD, MPHBrigham and Women’s Hospital and Harvard Medical SchoolScreening for Second Cancers: Evidence-based Recommendations to DateScott Michael Lippman, MDUniversity of Texas M. D. Anderson Cancer CenterChemoprevention and Interventional Strategies in Second Cancers: A Review of EvidencebasedRecommendations84

Friday, June 3, 20114:00 PM - 6:00 PMEXTENDED EDUCATION SESSIONGrant Writing Workshop II: Improving Your Grant Writing Skills (Mock StudySection and Small Group Discussions)Location: S106CME credit: 2Track(s): Professional Development, Clinical TrialsFRIDAYBruce E. Johnson, MD—ChairDana-Farber Cancer InstituteEric Jay Small, MDUniversity of California, San FranciscoSmall Group Roundtable DiscussantAlex A. Adjei, MD, PhDRoswell Park Cancer InstituteSmall Group Roundtable DiscussantFabrice Andre, MD, PhDInstitut Gustave-RoussySmall Group Roundtable DiscussantDawn L. Hershman, MD, MSColumbia University Medical CenterSmall Group Roundtable DiscussantJ. Jack Lee, PhD, DDSUniversity of Texas M. D. Anderson Cancer CenterSmall Group Roundtable DiscussantWells A. Messersmith, MDUniversity of Colorado Cancer CenterSmall Group Roundtable DiscussantGary K. Schwartz, MDMemorial Sloan-Kettering Cancer CenterSmall Group Roundtable DiscussantLillian L. Siu, MDPrincess Margaret HospitalSmall Group Roundtable Discussant85

Friday, June 3, 2011FRIDAY4:30 PM - 5:45 PMEDUCATION SESSIONSCancer Predisposition in Children, Adolescents, and Young AdultsLocation: S504CME credit: 1.25Track(s): Pediatric Oncology, Cancer GeneticsDavid Malkin, MD—ChairThe Hospital for Sick Children, University of TorontoFamilial Cancer Syndromes: Moving past p53Stephen J. Chanock, MDNational Cancer InstituteCancer Susceptibility: Methods for Identifying the Key MutationsKenan Onel, MD, PhDThe University of Chicago Medical CenterGenetic Predisposition to Secondary Cancers in Survivors of Pediatric CancerUpdates in Triple-negative Breast CancerLocation: Hall D1CME credit: 1.25Track(s): Breast Cancer, General Oncology, Tumor BiologyLisa A. Carey, MD—ChairUniversity of North Carolina at Chapel HillClinical and Molecular Biology of Triple-negative Breast CancerWilliam Foulkes, PhDMcGill UniversityTriple-negative Disease: Basal-like and BRCAness Findings and Implications of EpidemiologicRisk Factor StudiesAndrew Nicholas James Tutt, PhD, MBChBGuy’s Hospital Breakthrough Breast Cancer Research Unit, Guy’s HospitalPARP Inhibitors and DNA Damage Repair as a Therapeutic Target86

Friday, June 3, 20114:30 PM - 5:45 PMMEET THE PROFESSOR SESSIONCancer Epidemiology for the Clinical Oncologist: When Should We HaveConfidence in Studies and What Should We Tell Our Patients and Colleagues?(M03)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Cancer Prevention/EpidemiologyFRIDAYChristine B. Ambrosone, PhDRoswell Park Cancer Institute87

Friday, June 3, 2011FRIDAY4:45 PM - 6:00 PMCLINICAL PROBLEMS IN ONCOLOGY SESSIONLiver-directed Therapy in Colorectal Cancer: What Are the Options and WhenShould They Be Used? (C01)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Gastrointestinal (Colorectal) CancerAlan Paul Venook, MD—ChairUniversity of California, San FranciscoUnder- and Overutilization of Liver-focused Treatments: The Medical Oncologist Perspective ofWhen to Use and When Not to UseKenneth Tanabe, MDMassachusetts General Hospital Cancer CenterWhich Patients Should Undergo Hepatic Metastasectomy and Which Should Not?Stephen Barnett Solomon, MDMemorial Sloan-Kettering Cancer CenterRadiofrequency Ablation, Cryoablation, Stereotactic Radiosurgery, External Beam Radiation:Lots of Choices, but Which to Use?88

Saturday, June 4, 20117:30 AM - 8:15 AMEDUCATION SESSIONHow to Navigate the Annual Meeting (Fellows and Junior Faculty Only)Location: S501Track(s): Professional DevelopmentJohn E. Pippen, MD—ChairBaylor Sammons Cancer Center and Texas Oncology/US OncologyClifford Hudis, MDMemorial Sloan-Kettering Cancer CenterSATURDAY89

Saturday, June 4, 20118:00 AM - 9:15 AMEDUCATION SESSIONSASCO/Children’s Oncology Group (COG) Joint Session: Designing Trials toTest Novel Treatment Strategies for “Go” or “No Go” DecisionsLocation: S504CME credit: 1.25Track(s): Pediatric Oncology, Clinical Trials, Special SessionMark J. Ratain, MD—ChairThe University of ChicagoDesigning Early-phase Studies with “Go” versus “No Go” RulesSATURDAYFrank M. Balis, MDThe Children’s Hospital of PhiladelphiaEarly-phase Pediatric Studies: Identifying Valid EndpointsSusan Blaney, MDTexas Children’s Cancer CenterChallenges of Conducting Early-phase Studies in PediatricsBiomarkers in Genitourinary Cancers: Relevance to Clinical PracticeLocation: Hall D2CME credit: 1.25Track(s): Genitourinary Cancer, Clinical Trials, Tumor BiologyNancy Ann Dawson, MD—ChairGeorgetown University Hospital Lombardi Comprehensive Cancer CenterCirculating Tumor Cells in Prostate CancerMark Garzotto, MDPortland Veterans Affairs Medical CenterProstate-specific Antigen Kinetics in Biochemically Recurrent Prostate Cancer(Castration-naive or -resistant): Does It Guide Management?Kimryn Rathmell, MD, PhDUniversity of North Carolina at Chapel HillRenal Cell Cancer Biomarkers: Relevance to Clinical PracticeContemporary Topics in Ovarian Cancer ManagementLocation: E354aCME credit: 1.25Track(s): Gynecologic Cancer, Cancer Genetics, General OncologyGottfried E. Konecny, MD—ChairUniversity of California, Los AngelesMolecular Characterization of Ovarian Cancer: Where Are We Headed?Deborah Kay Armstrong, MDThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins UniversityDoctor, I’m Confused: What Is the Best Treatment for My Advanced Ovarian Cancer?Martin Eric Gore, PhDRoyal Marsden HospitalBevacizumab Incorporation into Ovarian Cancer Treatment: Practical Considerations90

Etiology and Treatment of HPV-related Oropharyngeal CancerLocation: E354bCME credit: 1.25Track(s): Head and Neck CancerAndy Trotti, MD—ChairH. Lee Moffitt Cancer Center and Research InstituteCurrent Therapy and Modifications in HPV-related Oropharyngeal CancerSara Pai, MD, PhDThe Johns Hopkins University School of MedicineBiology and Immune Therapy of HPV-related Oropharyngeal CancerSaturday, June 4, 2011Maura L. Gillison, MD, PhDThe Ohio State UniversityEpidemiology and Etiology of HPV-related Oropharyngeal CancerIdentification of Molecular Signatures for Classification, Response, Outcomes,and Novel TargetsLocation: S406CME credit: 1.25Track(s): SarcomaSATURDAYPaul S. Meltzer, MD, PhD—ChairNational Cancer InstituteIdentification of Novel Targets through Genomics, Proteomics, and MetabolomicsMatt Van De Rijn, MD, PhDStanford UniversityMolecular Signatures for Classification, Response, and OutcomesGeorge D. Demetri, MDDana-Farber Cancer InstituteMolecular Translation: Bench to Bedside in SarcomasPARP Inhibitors, DNA Repair, and Beyond: Theory Meets Reality in the ClinicLocation: S100aCME credit: 1.25Track(s): Tumor Biology, Developmental TherapeuticsMichael B. Kastan, MD, PhD—ChairSt. Jude Children’s Research HospitalDNA Damage Response: Opportunities for Therapeutic TargetingElizabeth R. Plummer, MD, DPhilNorthern Centre for Cancer CareDevelopment of PARP Inhibitors and Potential Roles in Chemotherapy PotentiationJudy Ellen Garber, MD, MPHDana-Farber Cancer InstituteClinical Development of PARP Inhibitors: Current Status91

Saturday, June 4, 2011Running an Oncology Practice in 2011: Finance, Resourcing, and AncillaryOpportunitiesLocation: E353CME credit: 1.25Track(s): Practice Management and Information TechnologyDee Anna Smith—ChairSarah Cannon Research InstituteHow to Understand the Financial Position of Your Practice: Financial Statements 101Jeffrey Patton, MDTennessee OncologyHow Do You Assess and Implement Ancillary Services That Will Enhance Your Practice?SATURDAYJohn Emmett Hennessy, CMPEKansas City Cancer CenterHow Do You Manage the Resources in Your Office and How Does Technology Enable EfficientFormulary Management and Related Reimbursement Issues?92

Saturday, June 4, 20118:00 AM - 9:15 AMMEET THE PROFESSOR SESSIONMechanisms of Metastasis (M04)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Breast CancerLarry Norton, MDMemorial Sloan-Kettering Cancer CenterSATURDAY8:00 AM - 9:15 AMCLINICAL PROBLEMS IN ONCOLOGY SESSIONHow to Manage Challenging Cases of Urothelial Cancer (C02)—TicketedSessionLocation: E451bCME credit: 1.25Track(s): Genitourinary Cancer, Geriatric OncologyJoaquim Bellmunt, MD, PhD—ChairUniversity Hospital del Mar-IMIMTreatment Options for a Patient with Locally Advanced but Unresectable Bladder Cancer andfor a Patient with Muscle-invasive but with Mixed Histology or Predominantly NontransitionalCellTheresa M. Koppie, MDUniversity of California, DavisPalliative Surgery in Patients with Advanced Bladder Cancer and Management of Upper TractTumorsDaniel Peter Petrylak, MDColumbia University College of Physicians and SurgeonsSystemic Therapy for Select Patient Subsets: Renal Dysfunction, Impaired Performance Status,Frail Elderly, or Platinum-refractory Disease93

Saturday, June 4, 20118:00 AM - 9:30 AMCLINICAL SCIENCE SYMPOSIUMEmerging Novel Targets for Lung CancerLocation: Hall D1CME credit: 1.5Track(s): Lung CancerSATURDAYGeorge R. Simon, MD—Co-ChairMedical University of South CarolinaNeeta Somaiah, MD—Co-ChairFox Chase Cancer Center8:00 AM An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) asmonotherapy in patients with advanced non-small cell lung cancer (NSCLC).(Abstract #7500)K. Wong, M. Koczywas, J. W. Goldman, E. H. Paschold, L. Horn, J. M. Lufkin,R. K. Blackman, F. Teofilovici, G. Shapiro, M. A. SocinskiDiscussion8:15 AM Suresh S. Ramalingam, MD (Abstract #7500)Winship Cancer Institute of Emory UniversityHeat Shock Protein Inhibitors: Shock and Awe?8:30 AM Open-label, randomized multicenter phase II clinical trial of a toll-likereceptor-2 (TLR2) agonist mycobacterium w (Cadi-05) in combination withpaclitaxel plus cisplatin versus paclitaxel plus cisplatin in advanced nonsmallcell lung cancer (NSCLC). (Abstract #7501)C. P. Belani, D. Desai, B. M. Khamar, for the Cadi-05 Investigators Study GroupDiscussion8:45 AM Raffit Hassan, MD (Abstract #7501)National Cancer InstituteChemoimmunotherapy: A Light in the Darkness?9:00 AM Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP)with or without the vascular disrupting agent vadimezan (ASA404) inadvanced non-small cell lung cancer (NSCLC). (Abstract #7502)P. Lara, J. Douillard, K. Nakagawa, J. Von Pawel, M. J. McKeage, I. Albert,G. Losonczy, M. Reck, D. S. Heo, X. Fan, A. Fandi, G. ScagliottiDiscussion9:15 AM Jean-Charles Soria, MD, PhD (Abstract #7502)Institut Gustave-RoussyVascular Disrupting Agents: Is There a Future?94

Saturday, June 4, 20118:00 AM - 9:30 AMCLINICAL SCIENCE SYMPOSIUMPatient and Survivor Care and Health Services Research Session:Survivorship—Care Plans, Quality of Care, and Barriers to CareLocation: S100bcCME credit: 1.5Track(s): Patient and Survivor Care, Health Services ResearchWendy Demark-Wahnefried, PhD, RD—Co-ChairUniversity of Alabama at BirminghamLynne I. Wagner, PhD—Co-ChairNorthwestern University8:00 AM Quality of care for comorbid conditions during the transition to survivorship.(Abstract #9004)C. F. Snyder, K. D. Frick, R. J. Herbert, A. L. Blackford, B. A. Neville,A. C. Wolff, M. A. Carducci, C. Earle8:15 AM Results of a multicenter randomized trial to evaluate a survivorship care planfor breast cancer survivors. (Abstract #9005)E. Grunfeld, M. N. Levine, J. A. Julian, G. R. Pond, E. Maunsell, A. Folkes,S. F. Dent, A. Joy, L. F. Paszat, K. I. Pritchard, G. A. Porter, D. Rayson,A. Robidoux, S. Smith, J. Sussman, L. Provencher, J. Wiernikowski, J. J. Sisler,FUPII Trial Investigators, Ontario Clinical Oncology GroupDiscussion8:30 AM Lynne I. Wagner, PhD (Abstract #CRA9006)Northwestern University8:45 AM Barriers in providing breast and colorectal cancer survivorship care:Perceptions of U.S. primary care physicians (PCPs) and medical oncologists(MOs). (Abstract #CRA9006)K. S. Virgo, C. C. Lerro, C. N. Klabunde, C. Earle, P. A. Ganz9:00 AM Long-term consequences of treatment on paid work after diagnosis of breastcancer. (Abstract #9007)R. Jagsi, S. T. Hawley, P. Abrahamse, J. J. Griggs, A. S. Hamilton, S. J. KatzDiscussion9:15 AM Wendy Demark-Wahnefried, PhD, RD (Abstract #9007)University of Texas M. D. Anderson Cancer CenterSATURDAY95

Saturday, June 4, 20118:00 AM - 11:00 AMSPECIAL SESSIONDesigning Clinical Trials for Older Patients: Nuts and BoltsLocation: S106CME credit: 3Track(s): Geriatric Oncology, Clinical Trials, Professional DevelopmentHarvey Jay Cohen, MD—Co-ChairDuke University Medical CenterSATURDAYHyman Bernard Muss, MD—Co-ChairUniversity of North Carolina Lineberger Comprehensive Cancer CenterMartine Extermann, MDH. Lee Moffitt Cancer Center & Research InstituteDefining Eligibility Criteria: Healthy, Vulnerable, FrailLazzaro Repetto, MD, PhDIstituto Nazionale Riposo E Cura Per AnzianiClinical Trial RecruitmentHeidi D. Klepin, MD, MSWake Forest UniversityAcute Myeloid Leukemia: Bringing Theory to PracticeWilliam Thomas Barry, PhDDuke University Medical CenterNovel Design of Clinical Trials for Vulnerable Patients96

Saturday, June 4, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONCentral Nervous System TumorsLocation: Hall ATrack(s): Central Nervous System TumorsBrd. 1A Objective responses to chemotherapy in recurrent glioma: A prospectiveanalysis from the German Glioma Network. (Abstract #2037)O. Baehr, B. Hentschel, E. Hattingen, S. Nussbaum, H. Berger, M. Tatagiba,J. Tonn, O. Schnell, M. Simon, T. Reithmeier, D. Krex, T. Pietsch, G. Reifenberger,O. Heese, M. Weller, J. Steinbach, M. Loeffler, German Glioma NetworkBrd. 1B Phase II study of dose-intense temozolomide in recurrent glioblastoma.(Abstract #2038)S. Hammond, A. D. Norden, G. J. Lesser, J. Drappatz, C. E. Fadul, T. Batchelor,E. C. Quant, R. Beroukhim, A. Muzikansky, A. S. Ciampa, L. M. Doherty,D. C. LaFrankie, S. Ruland, C. A. Bochacki, K. Griffin, M. Gerard, C. Sceppa,M. R. Rosenfeld, P. Y. WenBrd. 1C Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) forrecurrent primary CNS lymphoma (PCNSL): North American Brain TumorConsortium (NABTC) study 05-01. (Abstract #2039)L. Nayak, L. E. Abrey, J. Drappatz, M. R. Gilbert, D. A. Reardon, K. Lamborn,P. Y. Wen, M. Prados, L. M. DeAngelis, A. M. OmuroBrd. 1D Phase II study of monthly pasireotide LAR (SOM230C) for recurrent orprogressive meningioma. (Abstract #2040)A. D. Norden, S. Hammond, J. Drappatz, S. Phuphanich, D. A. Reardon, E. Wong,S. R. Plotkin, G. J. Lesser, J. J. Raizer, T. Batchelor, E. C. Quant, R. Beroukhim,T. J. Kaley, A. Muzikansky, A. S. Ciampa, L. M. Doherty, K. H. Smith, M. Gerard,C. Sceppa, P. Y. WenBrd. 1E AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM)and primary breast cancer (pBC) with eventual BM and association withoutcome. (Abstract #2041)B. Adamo, A. M. Deal, C. Livasy, E. Burrows, K. Fritchie, K. L. Blackwell,E. P. Hamilton, J. Geradts, L. Thorne, A. Ugolkov, C. R. Miller, M. G. Ewend,L. A. Carey, C. M. Perou, V. L. Cryns, C. K. AndersBrd. 1F Glioma-associated antigens associated with prolonged survival in a phase Istudy of ICT-107 for patients with newly diagnosed glioblastoma. (Abstract#2042)S. Phuphanich, C. J. Wheeler, J. Rudnick, M. Mazer, M. Nuno, X. Fan, J. Bender,E. S. Hawkins, K. L. Black, J. YuBrd. 1G Phase I study of aflibercept (VEGF Trap) and temozolomide in newlydiagnosed, high-grade glioma. (Abstract #2043)J. F. De Groot, T. Cloughesy, F. S. Lieberman, S. M. Chang, A. M. Omuro,J. Drappatz, T. Batchelor, L. M. DeAngelis, M. R. Gilbert, W. A. Yung, J. D. Fisher,X. Ye, K. Lamborn, A. P. Chen, S. A. Grossman, M. Prados, P. Y. WenBrd. 2A Circulating endothelial cells and progenitors in recurrent high-grade gliomastreated with bevacizumab and irinotecan. (Abstract #2044)M. Eoli, A. Calleri, L. Cuppini, E. Anghileri, S. Pellegatta, E. Prodi, M. Bruzzone,F. Bertolini, G. FinocchiaroBrd. 2B Effect of standard therapy on lymphocyte subsets and cytokines in newlydiagnosed high-grade gliomas (HGG). (Abstract #2045)A. S. Balmanoukian, S. A. Grossman, C. Thoburn, F. Kos, M. Holdhoff, A. HessBrd. 2C A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grademeningioma. (Abstract #2046)S. A. Grimm, M. C. Chamberlain, J. Chandler, K. Muro, L. Rice, K. McCarthy,A. Rademaker, I. B. Helenowski, S. K. Johnston, M. M. Mrugala, J. J. RaizerSATURDAY97

Saturday, June 4, 2011SATURDAYBrd. 2D Vascular hemodynamic profiles of vestibular schwannomas andglioblastoma using MRI. (Abstract #2047)S. R. Plotkin, D. Jennings, K. Mouridsen, K. E. Emblem, A. G. SorensenBrd. 2E FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET followinghypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV),and temozolomide (TMZ) for glioblastoma (GBM). (Abstract #2048)C. Grommes, S. Karimi, K. Beal, T. A. Chan, L. E. Abrey, P. H. Gutin, A. M. OmuroBrd. 2F CD44 as a prognostic and predictive marker for GBM. (Abstract #2049)B. D. Vaillant, K. Bhat, E. P. Sulman, V. Balasubramaniyan, S. Wang, K. D. Aldape,H. ColmanBrd. 2G A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma(HGG). (Abstract #2050)J. Drappatz, J. J. Raizer, D. Schiff, A. S. Chi, T. Batchelor, S. M. Snodgrass,E. C. Quant, A. D. Norden, R. Beroukhim, S. A. Grimm, L. M. Doherty,A. S. Ciampa, D. C. LaFrankie, S. Ruland, M. Gerard, S. Hammond, P. Y. WenBrd. 3A Concurrent temozolomide and radiation as the initial treatment for anaplasticglioma. (Abstract #2051)C. Tham, S. See, S. Tan, W. Ng, K. H. Lim, J. Thomas, E. ChuaBrd. 3B Randomized phase II study of neoadjuvant bevacizumab and irinotecanversus bevacizumab and temozolomide followed by concomitantchemoradiotherapy in newly diagnosed primary glioblastoma multiforme.(Abstract #2052)K. F. Hofland, S. Hansen, M. Sorensen, H. P. Schultz, A. Muhic, S. Engelholm,A. Ask, C. Kristiansen, C. Thomsen, H. Skovgaard Poulsen, U. N. LassenBrd. 3C Prognostic factors in patients with WHO grade 3 gliomas: The ClevelandClinic experience. (Abstract #2053)N. Hashemi-Sadraei, H. S. Bawa, A. Satra, G. Rahmathulla, M. Patel, G. Stevens,T. M. Tekautz, L. A. Rybicki, D. M. Peereboom, J. H. Suh, R. Weil,M. A. Vogelbaum, G. Barnett, M. S. AhluwaliaBrd. 3D Phase l study of sorafenib in combination with radiation therapy andtemozolomide for the first-line treatment of patients with high-grade glioma.(Abstract #2054)A. F. Hottinger, A. Ben Aissa, A. Bodmer, D. Squiban, N. Dunkel, N. Maradan,M. I. Vargas, D. C. Weber, E. Brendel, P. DietrichBrd. 3E Upfront bevacizumab with temozolomide or with temozolomide andirinotecan for unresectable or multifocal glioblastoma. (Abstract #2055)E. Lou, D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan,S. G. Turner, A. L. Sumrall, L. Bailey, H. S. Friedman, J. J. VredenburghBrd. 3F Phase II clinical trial of bortezomib and bevacizumab combination inrecurrent glioblastoma. (Abstract #2056)D. A. Bota, Z. Eroglu, D. A. Reardon, B. D. Fu, J. Norfleet, A. Desjardins,M. E. Linskey, K. Peters, H. S. Friedman, J. J. VredenburghBrd. 3G Temozolomide-based chemoradiation in naive pure and mixed anaplasticastrocytoma: Long-term results of a phase II study. (Abstract #2057)S. Chiesa, G. Chiloiro, S. Manfrida, A. Mangiola, G. R. D’Agostino, G. Mantini,A. Albanese, P. De Bonis, C. Anile, M. BalducciBrd. 3H Prognostic factors in newly diagnosed glioblastoma: Have we missedgender? (Abstract #2058)E. Franceschi, A. Tosoni, S. Bartolini, L. Scopece, L. Lombardo, R. Poggi,V. Mazzocchi, L. La Torre, M. Ermani, A. A. BrandesBrd. 4A Current status of a phase III trial of nimotuzumab (ti-EGF-R) in newlydiagnosed glioblastoma. (Abstract #2059)F. Bach, M. Westphal, OSAG-101 Study Group98

Saturday, June 4, 2011Brd. 4B Efficacy of nitrosourea-based chemotherapy in recurrent malignant gliomaaccording to time to adjuvant temozolomide failure: A pooled analysis.(Abstract #2060)A. Paccapelo, I. Lolli, S. Scoccianti, B. Detti, G. Silvano, M. Fabrini, F. Perrone,G. Savio, S. CascinuBrd. 4C Use of exosome analysis to reveal glioma-specific genetic changes in patientserum. (Abstract #2061)B. Carter, F. Hochberg, X. Breakefield, L. Balaj, S. Sivaraman, W. Curry,S. N. Kalkanis, L. Loguidice, L. M. Russo, M. Noerhelm, J. SkogBrd. 4D Neurotoxicity of intra-CSF liposomal cytarabine in the treatment ofleptomeningeal metastases. (Abstract #2062)M. C. Chamberlain, S. K. JohnstonBrd. 4E Glioblastoma in the elderly: Treatment planning, toxicity, and efficacy in anambulatory practice. (Abstract #2063)W. P. Mason, Z. Lwin, D. MacFadden, A. AL-Zahrani, N. Laperriere, C. Menard,B. Millar, A. Sahgal, C. Massey, L. E. CoateBrd. 4F A phase I trial of laromustine (VNP40101M) and temozolomide for patientswith malignant gliomas in first relapse or progression. (Abstract #2064)J. J. Raizer, L. Rice, A. Rademaker, J. Chandler, K. Muro, R. M. Levy, S. A. GrimmBrd. 4G A mathematical model of diffuse low-grade gliomas treated with PCVchemotherapy. (Abstract #2065)F. Ducray, M. Peyre, D. Ricard, B. Cajavec-Bernard, E. Grenier, M. Tod, V. Calvez,D. Frappaz, M. Sunyach, A. Vasiljevic, J. Pallud, S. Cartalat-Carel, J. Honnorat,B. RibbaBrd. 4H Glioblastoma in the elderly: The Cleveland Clinic experience (1992–2010).(Abstract #2066)H. S. Bawa, N. Hashemi-Sadraei, J. H. Suh, G. Stevens, G. Rahmathulla,S. T. Chao, T. M. Tekautz, P. Elson, D. M. Peereboom, L. Angelov, R. Weil,M. A. Vogelbaum, G. Barnett, M. S. AhluwaliaBrd. 5A The effect of surgery in determining pseudoprogression and predictingoutcome in adults with glioblastoma. (Abstract #2067)I. Melguizo, K. R. Hess, D. Blas-Boria, J. Bruner, N. Guha-Thakurta, V. K. PuduvalliBrd. 5B Survival after recurrence of medulloblastoma in the contemporary era.(Abstract #2068)C. Koschmann, K. L. Schmidt, J. R. Geyer, S. LearyBrd. 5C Preliminary results from a multicenter, phase II, randomized, noncomparativeclinical trial of radiation and temozolomide with or without vandetanib innewly diagnosed glioblastoma (GBM). (Abstract #2069)E. C. Quant, T. Batchelor, A. B. Lassman, D. Schiff, T. J. Kaley, E. Wong,T. Mikkelsen, J. Drappatz, A. D. Norden, R. Beroukhim, S. E. Weiss,B. M. Alexander, C. Sceppa, M. Gerard, S. D. Hallisey, C. A. Bochacki,K. H. Smith, A. Muzikansky, P. Y. WenBrd. 5D A pharmacokinetic (PK) study of AC480 administered twice daily in patientswith surgically resectable, recurrent malignant glioma (MG) not on enzymeinducingantiepileptic drug (EIAED). (Abstract #2070)A. Desjardins, D. A. Reardon, J. J. Vredenburgh, K. Peters, M. Trikha, J. James,M. Gardner, A. Brickhouse, J. E. Herndon, H. S. FriedmanBrd. 5E Novel use of MR spectroscopy in detecting CSF lactate for diagnosis ofneoplastic meningitis. (Abstract #2071)C. L. Weston, O. Zalatimo, J. Sheehan, R. Harbaugh, D. A. Bota, A. Shedden,M. J. GlantzBrd. 5F Clinical improvement and rapid radiographic regression induced by a METinhibitor in a patient with MET-amplified glioblastoma. (Abstract #2072)A. S. Chi, E. L. Kwak, J. W. Clark, D. L. Wang, D. N. Louis, A. J. Iafrate,T. BatchelorSATURDAY99

Saturday, June 4, 2011SATURDAYBrd. 5GBrd. 5HBrd. 6ABrd. 6BBrd. 6CConcurrent, 3-times daily ultrafractionated radiation therapy andtemozolomide for newly inoperable glioblastoma: TEMOFRAC—A phase IItrial. (Abstract #2073)P. D. Beauchesnes, G. Faure, G. Noel, T. Schmitt, L. Martin, L. Taillandier,C. D. CarninEfficacy of radiation therapy on epileptic seizures of grade 2 and 3 gliomas:A retrospective study. (Abstract #2074)R. Ruda, E. Trevisan, U. Magliola, C. Mantovani, U. Ricardi, R. SoffiettiValue of CA 15–3 detection in cerebrospinal fluid (CSF) of breast cancerleptomeningeal metastases. (Abstract #2075)S. Salingue, M. Girot, I. Rodrigues, S. Taillibert, N. Kotecki, F. Zairi, M. Baranzelli,M. Faivre-Pierret, P. Devos, J. Bonneterre, F. Dubois, E. Le RhunPrognostic relevance of promoter methylation-associated loss of ID4expression in glioblastoma multiforme. (Abstract #2076)M. Martini, T. Cenci, N. Montano, V. Cesarini, R. Pallini, L. LaroccaStereotactic volumetric resection, intracavitary carmustine wafers, andradiation therapy for brain metastases: The Moffitt Cancer Centerexperience. (Abstract #2077)S. Brem, R. Sampath, D. Yu, A. Staller, M. Obadia, M. G. EwendBrd. 6D IDH mutation status impact on in vivo hypoxia biomarkers expression: Newinsights from a clinical, nuclear imaging, and immunohistochemical study in34 patients with glioma. (Abstract #2078)P. Metellus, C. Colin, D. Taieb, E. Guedj, I. Nanni-Metellus, B. Coulibaly,C. Colavolpe, S. Fuentes, H. Dufour, M. Barrie, O. L. Chinot, L. Ouafik,D. Figarella-BrangerBrd. 6E Is cerebrospinal fluid cytology a useful test? (Abstract #2079)C. M. Zoccoli, O. Zalatimo, M. J. GlantzBrd. 6F Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: Aphase II study. (Abstract #2080)F. Zustovich, L. Landi, G. Lombardi, L. Galli, C. Porta, D. Amoroso, A. Fontana,M. Andreuccetti, C. Galli, A. Falcone, V. ZagonelBrd. 6G Feasibility pilot of attenuated maintenance chemotherapy for adolescentsand adults with newly diagnosed localized medulloblastoma and otherprimitive neuroectodermal tumors. (Abstract #2081)J. N. Dagri, A. Evans, J. Torkildson, J. Portnow, L. S. Ashby, B. Zakotnik,R. J. Brown, G. Dhall, J. L. FinlayBrd. 6H Safety results from a prospective study of concurrent radiosurgery andbevacizumab for recurrent malignant glioma. (Abstract #2082)K. C. Cuneo, A. R. Cabrera, J. H. Sampson, K. J. Allen, J. J. Vredenburgh,K. Peters, Z. Chang, J. E. Herndon, A. Desjardins, D. A. Reardon, J. KirkpatrickBrd. 7A Chemotherapy plus concomitant low-dose fractionated radiotherapy assecond-line treatment for recurrent or progressive glioblastoma aftertemozolomide-based chemoradiation: A pilot study. (Abstract #2083)G. R. D’Agostino, B. Diletto, S. Manfrida, A. Mangiola, S. Chiesa, L. De Filippo,V. Frascino, F. Miccichè, C. Anile, M. BalducciBrd. 7B Use of Tegwondo, a near-continuous temozolomide regimen, in high- andlow-grade gliomas. (Abstract #2084)H. M. Strik, H. C. Bock, C. MarosiBrd. 7C Baseline and long-term cognition and neuroimaging in patients with primaryCNS lymphoma (PCNSL) treated with enhanced chemotherapy (CHT)delivery. (Abstract #2085)N. D. Doolittle, M. A. Lubow, D. F. Kraemer, E. Dosa, N. A. Hedrick, R. Tyson,C. Lacy, L. M. Maron, R. W. Butler, E. A. Neuwelt100

Saturday, June 4, 2011Brd. 7D Bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM):Results of a retrospective cohort study of the OMIT Bretagne and Pays de laLoire. (Abstract #2086)F. Grude, M. Campone, J. Frenel, P. Soulie, E. Vauleon, Y. Hadjarab, G. Ganem,F. Denis, J. Egreteau, A. Lortholary, M. Porneuf, H. Simon, P. DAM Hieu, V. Klein,B. Dominique, P. Deguiral, H. Desclos, P. Menei, S. TraoréBrd. 7E Functional and survival effect of bevacizumab and irinotecan administered atrecurrence in a cohort of patients with GBM. (Abstract #2087)E. Tabouret, M. Barrie, C. Boucard, M. Matta, D. Autran, A. Loundou, O. L. ChinotBrd. 7F Phase II study of verubulin (MPC-6827) for the treatment of subjects withrecurrent glioblastoma naive to treatment with bevacizumab. (Abstract#2088)L. J. Kim, M. C. Chamberlain, J. Zhu, J. J. Raizer, S. A. Grimm, S. Phuphanich,C. E. Fadul, S. Rosenfeld, A. H. Balch, C. C. Pope, M. Brulotte, A. A. Beelen,L. D. RechtBrd. 7G Prospective follow-up of 96 patients with breast cancer with leptomeningealmetastasis recruited from 2007 to 2010. (Abstract #2089)E. Le Rhun, N. Kotecki, F. Zairi, I. Rodrigues, A. Mailliez, M. Baranzelli,M. Faivre-Pierret, P. Devos, J. Cazin, J. Bonneterre, F. DuboisBrd. 8A Radiographic pattern of progression of recurrent GBM treated withbevacizumab with or without irinotecan. (Abstract #2091)P. Dory-Lautrec, E. Tabouret, M. Barrie, C. Boucard, M. Matta, D. Autran,N. Girard, O. L. ChinotBrd. 8B Clinical outcome of concomitant chemoradiotherapy followed by adjuvanttemozolomide (TMZ) therapy for high-grade gliomas (HGG) in Colombia(RedLANO registry). (Abstract #2092)L. D. Ortiz, A. F. Cardona, C. E. Fadul, A. Londono, H. A. Becerra,E. Jimenez-Hakim, C. J. Yepes, H. Carranza, R. E. Bruges Maya, C. J. Castro,C. A. VargasBrd. 8C Prognostic factors in elderly patients with grade 3 gliomas. (Abstract #2093)A. Satra, N. Hashemi-Sadraei, H. S. Bawa, D. M. Peereboom, G. Stevens,L. A. Rybicki, J. H. Suh, M. A. Vogelbaum, R. Weil, G. Barnett, M. S. AhluwaliaBrd. 8D Photodynamic therapy (PDT) in the multidisciplinary treatment of braintumors: A feasibility study. (Abstract #2094)M. S. Gonzalez, V. Vanaclocha, I. Azinovic, J. Rebollo, R. Cañon, E. Calvo,A. BrugarolasBrd. 8E The role of plasma GFAP as a biomarker for glioblastoma. (Abstract #2095)H. Husain, W. Savage, A. Everett, X. Ye, C. Blair, K. E. Romans, C. Bettegowda,P. Burger, S. A. Grossman, M. HoldhoffBrd. 8G O(6)-methylguanine DNA-methyltransferase (MGMT) in glioblastoma:Analysis on first and following surgeries. (Abstract #2097)F. Bertolini, C. Baraldi, E. Zunarelli, A. Valentini, R. Depenni, A. Falasca,F. Bertoni, F. Cavalleri, A. Chiari, A. Fontana, P. F. Conte, G. Pinna,Gruppo Neuro-Oncologico Modena (GNO-MO)Brd. 8H Bevacizumab, temozolomide, and radiation therapy followed bybevacizumab, temozolomide, and oral topotecan for newly diagnosedglioblastoma multiforme (GBM). (Abstract #2098)J. J. Vredenburgh, A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick,A. D. Coan, L. Bailey, D. Janney, C. Lu, H. S. FriedmanBrd. 9A A review of how antineoplastic treatments impact the sexuality, fertility, andsexual function of adult patients with brain cancer: Implications for real-timetreatment planning. (Abstract #2099)E. M. Dunbar, S. Savona, N. Ferree, P. A. PumphreySATURDAY101

Saturday, June 4, 2011Brd. 9BBrd. 9CTreatment of patients with advanced neurofibromatosis type 2 (NF2) withnovel molecularly targeted therapies. (Abstract #2100)V. Subbiah, J. M. Slopis, D. S. Hong, L. S. Angelo, I. E. McCutcheon, R. KurzrockA comparative study of pediatric CNS tumor activity as assessed by [18F]-FDG PET imaging and proton magnetic resonance spectroscopic imaging.(Abstract #2101)S. J. Hipp, E. A. Steffen-Smith, P. Herscovitch, N. J. Patronas, J. M. Solomon,R. Bent, S. M. Steinberg, K. E. WarrenSATURDAY102

Saturday, June 4, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONGastrointestinal (Colorectal) CancerLocation: Hall ATrack(s): Gastrointestinal (Colorectal) CancerBrd. 10A The biology of early-onset colorectal cancer: An examination of tumormarkers, pathology, and survival in a large cohort of patients. (Abstract#3537)S. A. Khan, M. Morris, K. Idrees, M. Gimbel, S. Rosenberg, Z. Zeng, J. Shia,M. P. La Quaglia, P. PatyBrd. 10B Colorectal cancer cases with de novo germ-line mutations in MLH1, MSH2,and MSH6 from the Colon Cancer Family Registry. (Abstract #3538)A. Win, M. A. Jenkins, D. D. Buchanan, J. P. Young, S. N. Thibodeau,J. L. Hopper, N. M. LindorBrd. 10C Incidence and characteristics of BRAF V600E mutation in colorectal cancer(CRC) with mismatch repair (MMR) protein defect due to loss of MLH1: Aprospective evaluation of 104 consecutive patients. (Abstract #3539)S. A. Mahesh, E. Hanna, M. Khan, P. Ravichandran, F. SlezakBrd. 10D The effect of screening on stage of disease and tumor characteristics inpatients with operable colorectal cancer. (Abstract #3540)M. J. Proctor, E. Chrighton, C. H. Richards, D. C. Mcmillan, P. G. HorganBrd. 10E Quality of life (QOL) for patients treated with FOLFOX with or withoutcetuximab (Cmab) following complete resection of colorectal cancer (CRC):Results from North Central Cancer Treatment Group (NCCTG) phase III trialN0147. (Abstract #3541)M. R. Mahoney, J. A. Sloan, J. M. Hubbard, H. Liu, A. F. Shields, E. Chan,R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. G. Nair, D. J. Sargent, S. R. AlbertsBrd. 10F The final results of the SWOG S9304 phase III intergroup trial’spharmacogenetic analysis: Association of polymorphisms with survival andtoxicity in stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU)and pelvic radiation (RT). (Abstract #3542)P. M. Wilson, P. O. Bohanes, C. J. Rankin, J. K. Benedetti, C. M. Ulrich,S. R. Smalley, K. W. Makar, W. Zhang, T. Winder, Y. Ning, A. Gerger,L. Benhaim, R. El-Khoueiry, M. J. Labonte, C. D. Blanke, H. LenzBrd. 10G Accuracy of endorectal ultrasonography in evaluation of response tochemoradiation in locally advanced rectal cancer. (Abstract #3543)B. Farnault, L. Moureau-Zabotto, C. de Chaisemartin, M. Giovannini, G. Monges,J. Delpero, P. Viens, M. ResbeutBrd. 10H Neoadjuvant chemoradiotherapy and multivisceral resection for primarylocally advanced adherent colon cancer. (Abstract #3544)M. Cukier, H. Soliman, A. Smith, S. WongBrd. 11A Neoadjuvant treatment response and outcomes in locally advanced rectalcancer: Establishing oncologic benchmarks. (Abstract #3545)G. J. Chang, I. Park, Y. You, C. Hu, S. R. Hamilton, C. Eng, B. W. Feig, P. Das,S. Krishnan, C. H. Crane, S. T. Nguyen, M. A. Rodriguez-Bigas, J. M. SkibberBrd. 11B Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) inpatients with K-ras-unmutated, locally advanced rectal cancer (LARC): Arandomized multicenter phase II trial (SAKK 41/07). (Abstract #3546)D. Helbling, G. Bodoky, O. Gautschi, H. Sun, F. Bosman, B. Gloor, R. Burkhard,R. C. Winterhalder, A. Madlung, D. Rauch, P. Saletti, L. A. Widmer, M. M. Borner,D. Baertschi, P. Yan, D. KoeberleBrd. 11C Factors influencing histopathology-assessed TME quality after low anteriorrectal resection: Results of a prospective multicenter observational trial.(Abstract #3547)B. Garlipp, H. Ptok, U. Schmidt, P. Stuebs, F. Meyer, I. Gastinger, H. LippertSATURDAY103

Saturday, June 4, 2011SATURDAYBrd. 11D Morbidity and mortality results from a prospective randomized trialcomparing mesorectal excision with or without lateral lymph node dissectionfor clinical stage II and III lower rectal cancer: Japan Clinical Oncology Groupstudy JCOG0212. (Abstract #3548)S. Fujita, S. Saito, Y. Moriya, J. Mizusawa, K. Nakamura, N. Saito, Y. Kinugasa,Y. Kanemitsu, M. Ohue, S. Fujii, Y. Akazai, M. Shiozawa, T. Yamaguchi,H. Bandou, T. Aoki, K. Murata, K. Shirouzu, N. Takiguchi, Y. Saida, ColorectalCancer Study Group of Japan Clinical Oncology GroupBrd. 11E Prospective analysis of KRAS, BRAF, and PIK3CA mutational status andEGFR copy number in patients (pts) with locally advanced rectal cancer: Atranslational substudy of a clinical trial (SAKK 41/07) evaluating the effect ofneoadjuvant chemoradiation (CRT) with or without panitumumab. (Abstract#3549)D. Koeberle, S. Bougel, J. Benhattar, F. Bosman, O. Gautschi, H. Sun, G. Bodoky,R. von Moos, D. Helbling, for the Swiss Group for Clinical Cancer Research(SAKK)Brd. 11F Mortality risk after preoperative versus postoperative chemotherapy andradiotherapy in lymph node–positive rectal cancer. (Abstract #3550)T. E. Seery, A. Ziogas, B. S. Lin, C. G. Pan, M. J. Stamos, J. A. ZellBrd. 11G Results of a nationwide Japanese study on lateral pelvic lymph nodemetastasis in low rectal cancer: Is it regional or distant disease? (Abstract#3551)T. Akiyoshi, T. Watanabe, S. Miyata, K. Kotake, T. Muto, K. SugiharaBrd. 11H Three-year outcomes of GCR-3: A phase II randomized trial comparingconventional preoperative chemoradiation (CRT) followed by surgery andpostoperative adjuvant chemotherapy (CT) with induction CT followed byCRT and surgery in locally advanced rectal cancer. (Abstract #3552)C. Fernandez-Martos, C. Pericay, A. Salud, B. Massuti, V. Alonso, M. Safont,R. Vera, M. P. Escudero, J. Maurel, J. AparicioBrd. 11H Three-year outcomes of GCR-3: A phase II randomized trial comparingconventional preoperative chemoradiation (CRT) followed by surgery andpostoperative adjuvant chemotherapy (CT) with induction CT followed byCRT and surgery in locally advanced rectal cancer. (Abstract #3552)C. Fernandez-Martos, C. Pericay, A. Salud, B. Massuti, V. Alonso, M. Safont,R. Vera, M. P. Escudero, J. Maurel, J. AparicioBrd. 12A Oncologic and functional hazards of obesity among patients with locallyadvanced rectal cancer. (Abstract #3553)I. Park, C. Hu, M. A. Rodriguez-Bigas, Y. You, J. M. Skibber, C. Eng, R. A. Wolff,P. Das, C. H. Crane, G. J. ChangBrd. 12B Adherence to NCCN treatment guidelines for rectal cancer: Analysis ofnational practice patterns. (Abstract #3554)R. Chagpar, J. N. Cormier, B. W. Feig, G. J. Chang, Y. You, Y. Chiang,M. A. Rodriguez-Bigas, J. M. Skibber, Y. XingBrd. 12C Comparison of outcomes of intensity-modulated radiotherapy and 3-Dconformal radiotherapy for anal squamous cell carcinoma using a propensityscore analysis. (Abstract #3555)D. A. Rothenstein, T. Dasgupta, J. F. Chou, Z. Zhang, J. L. Wright, L. K. Temple,L. Saltz, K. A. GoodmanBrd. 12D Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer(CC): A pooled analysis of 16,425 patients from the ACCENT database.(Abstract #3556)Q. Shi, J. M. Hubbard, G. A. Yothers, T. Andre, L. Saltz, G. Francini, B. M. Bot,C. Twelves, M. E. Buyse, A. Grothey, D. J. Sargent, for the ACCENT CollaborativeGroup104

Saturday, June 4, 2011Brd. 12E Survival rates among patients vaccinated following resection of colorectalcancer metastases in a phase II randomized study compared withcontemporary controls. (Abstract #3557)M. Morse, D. Niedzwiecki, J. Marshall, C. R. Garrett, D. Z. Chang, M. Aklilu,T. S. Crocenzi, D. J. Cole, S. Dessureault, A. Hobeika, T. Osada, B. M. Clary,S. D. Hsu, G. Devi, A. Bulusu, R. Annechiarico, V. Chadaram, T. M. Clay,H. K. LyerlyBrd. 12F Independent validation of a prognostic classifier (Predictor-C) in a set of 292patients with colorectal cancer of UICC stage II. (Abstract #3558)H. Adams, T. Mayr, B. Hinzmann, A. RosenthalBrd. 12G External validation of a tumor derived 5-gene prognostic signature(OncoDefender-CRC) for recurrence (R) of stages I/II colorectal cancer (CRC).(Abstract #3559)P. F. Lenehan, L. A. Boardman, D. W. Fry, E. R. Heyman, J. Ohrnberger,W. P. WorzelBrd. 12H Microsatellite instability to predict the efficacy of adjuvant chemotherapy forstage II colon cancer. (Abstract #3560)J. Kim, H. Kim, Y. Hong, J. Lee, M. Ryu, H. Chang, S. Jang, M. Kim, C. Yu, T. KimBrd. 13A Initial safety report of ACTS-CC trial (TRICC0706): A randomized phase IIItrial of UFT/LV versus S-1 as adjuvant therapy for stage III colon cancer.(Abstract #3561)A. Takagane, H. Takiuchi, K. Ikejiri, I. Mochizuki, H. Mochizuki, K. Kotake,S. Kameoka, K. Takahashi, T. Watanabe, M. Watanabe, N. Boku, N. Tomita,Y. Matsubara, K. SugiharaBrd. 13B Updated results of the FIRIS study: A phase II/III trial of5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) assecond-line chemotherapy for metastatic colorectal cancer (mCRC).(Abstract #3562)H. Baba, K. Muro, H. Yasui, Y. Shimada, A. Tsuji, S. Sameshima, T. Satoh,T. Denda, K. Ina, K. SugiharaBrd. 13C Carcinoma of unknown primary site (CUP): Outcomes in patients with acolorectal molecular profile treated with site-specific chemotherapy.(Abstract #3563)F. A. Greco, W. J. Lennington, D. R. Spigel, G. R. Varadhachary, J. D. HainsworthBrd. 13D Role of surgical resection among chemotherapy-treated patients withcolorectal cancer with stage IV disease: A survival analysis. (Abstract #3564)B. S. Lin, A. Ziogas, T. E. Seery, M. J. Stamos, J. A. ZellBrd. 13E A randomized two-arm phase III study to investigate bevacizumab incombination with capecitabine plus oxaliplatin (CAPOX) versus CAPOXalone in post radical resection of patients with liver metastases of colorectalcancer. (Abstract #3565)E. E. Voest, N. Snoeren, S. B. Schouten, A. M. Bergman, E. van Werkhoven,O. J. Loosveld, T. M. van Gulik, J. M. Smit, A. Cats, E. Boven, E. Hesselink,A. Rijken, M. Tol, O. Dalesio, H. M. Verheul, R. A. Tollenaar, J. van der Sijp,I. Borel Rinkes, R. van HillegersbergBrd. 13F Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, arandomized controlled trial in advanced colorectal cancer (aCRC). (Abstract#3566)G. W. Middleton, S. J. Gwyther, S. R. Brown, T. S. Maughan, C. Olivier,S. Richman, N. R. Maisey, M. Hill, S. Gollins, S. Myint, S. Slater, J. Wagstaff,J. A. Bridgewater, R. Glynne-Jones, G. Hemmings, H. Marshall, D. Blake, V. Napp,P. Quirke, M. T. Seymour, UK NCRI Colorectal Clinical Studies GroupBrd. 13G Randomized phase III study of panitumumab (pmab) with FOLFOX4compared with FOLFOX4 alone as first-line treatment (tx) for metastaticcolorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group(ECOG) performance status (PS). (Abstract #3567^)S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel, Y. Humblet,D. Cunningham, F. Xu, K. Krishnan, J. DouillardSATURDAY105

Saturday, June 4, 2011SATURDAYBrd. 13HBrd. 14ABrd. 14BBrd. 14CBrd. 14DBrd. 14EBrd. 14FBrd. 14GBrd. 14HBrd. 15ABrd. 15BFOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT)with or without an anti-EGFR monoclonal antibody for locally advanced,operable colon cancer: Planned interim report. (Abstract #3568)D. Morton, L. Magill, K. Handley, G. Brown, D. R. Ferry, Z. b. Gray, P. Quirke,M. T. Seymour, B. Warren, R. G. Gray, on behalf of the FOxTROT CollaborativeGroupInitial change in tumor size as an imaging surrogate of outcomes in patientswith metastatic colorectal cancer (mCRC) treated with first-line irinotecanand 5-FU combination chemotherapy. (Abstract #3569)C. Suzuki, L. Blomqvist, A. Sundin, P. Bystrom, A. Berglund, H. Jacobsson,P. Nygren, B. GlimeliusCan patients be cured after cytoreductive surgery plus intraperitonealchemotherapy for colorectal peritoneal carcinomatosis? (Abstract #3570)D. Goéré, D. Tzanis, V. G. Gava, L. Maggiori Jr., F. Dumont, M. Ducreux, D. EliasTreatment of colorectal peritoneal carcinomatosis with systemicchemotherapy: A pooled analysis of NCCTG’s phase III trials N9741 andN9841. (Abstract #3571)J. Franko, Q. Shi, C. D. Goldman, B. A. Pockaj, G. D. Nelson, R. M. Goldberg,H. C. Pitot, A. Grothey, S. R. Alberts, D. J. SargentEarly tumor shrinkage and long-term outcome in metastatic colorectalcancer (mCRC): Assessment of predictive utility across treatment arms inthe CRYSTAL and OPUS studies. (Abstract #3572)H. Piessevaux, E. Van Cutsem, C. Bokemeyer, M. Schlichting, S. Heeger,S. TejparPhase II study of panitumumab with irinotecan for patients with KRASwild-type metastatic colorectal cancer (MCRC) refractory to standardchemotherapy: A GERCOR study. (Abstract #3573)B. Chibaudel, C. Tournigand, M. Mabro, M. Bennamoun, P. Artru, S. Nguyen,J. Bachet, N. Aissat, H. Blons, P. Laurent-Puig, A. De Gramont, T. Andre,GERCOREvaluation of panitumumab (pmab) plus fluorouracil, leucovorin, andirinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) withmetastatic colorectal cancer (mCRC): A subgroup analysis of study 181.(Abstract #3574^)M. Peeters, T. J. Price, A. H. Strickland, T. E. Ciuleanu, W. Scheithauer,S. O’Reilly, M. M. Keane, D. R. Spigel, Y. Tian, K. KrishnanFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-linetreatment for patients with metastatic colorectal cancer (mCRC): Analysis ofpatients with KRAS mutated tumors in the randomized German AIO studyKRK-0306. (Abstract #3575)S. Stintzing, J. Neumann, A. Jung, L. Fischer von Weikersthal, T. Decker,U. Vehling-Kaiser, E. Jaeger, T. Heintges, C. Stoll, D. P. Modest, T. Kirchner,W. Scheithauer, V. HeinemannEfficacy of chemotherapy plus cetuximab according to metastatic site inKRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTALand OPUS studies. (Abstract #3576)C. Kohne, C. Bokemeyer, S. Heeger, U. Sartorius, P. Rougier, E. Van CutsemA multicenter, multinational retrospective analysis of mitomycin C (MMC) inrefractory metastatic colorectal cancer (mCRC). (Abstract #3577)R. Ferrarotto, K. K. Machado, M. P. Mak, V. A. Vieira, T. K. Takahashi,D. Saragiotto, S. Kopetz, M. J. Overman, P. HoffPhase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab inthe front-line treatment of patients with metastatic colorectal cancer (mCRC)and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504trial): Final results. (Abstract #3578)E. Mitry, O. Bouche, J. Seitz, P. Etienne, J. Legoux, T. Aparicio, G. Breysacher,C. Lecaille, T. Lecomte, J. Jouve, FFCD106

Saturday, June 4, 2011Brd. 15C Bevacizumab plus capecitabine as maintenance treatment after initialtreatment with bevacizumab plus XELOX in previously untreated metastaticcolorectal cancer: Updated findings from a randomized, multicenter phase IIItrial. (Abstract #3579)S. Yalcin, R. Uslu, F. Dane, U. Yilmaz, N. Zengin, E. Buyukunal, S. Buyukberber,C. Camci, O. Sencan, S. KilickapBrd. 15D Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 asfirst-line therapy in patients (pts) with KRAS wild-type (wt) metastaticcolorectal cancer (mCRC). (Abstract #3580)T. Ciuleanu, V. Nikolic, E. Shmueli, D. Vrbanec, S. Plate, Z. M. Krmpotic, M. Dank,G. Purkalne, T. Brodowicz, C. ZielinskiBrd. 15E Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan(IRI) or with FOLFIRI bevacizumab (BV) in previously treated patients (Pts)with metastatic colorectal cancer (mCRC). (Abstract #3581)A. D. Baron, C. L. O’Bryant, Y. Choi, A. Ashkenazi, S. Royer-Joo, C. C. PorteraBrd. 15F Phase I results of the randomized, placebo controlled, phase I/II study of thenovel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C)in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer(mCRC) who have received front-line systemic therapy. (Abstract #3582)A. Bessudo, J. C. Bendell, N. Gabrail, M. V. Kopp, L. Mueller, L. L. Hart,V. I. Vladimirov, A. U. Pande, I. Gorbatchevsky, C. EngBrd. 15G Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination withbevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectalcancer (CRC): AIO KRK 0205. (Abstract #3583)G. von Wichert, T. Hoehler, C. C. Schimanski, M. H. Moehler, R. Hofheinz,S. Kanzler, A. Hinke, T. Seufferlein, J. Siebler, A. Hochhaus, D. Arnold, M. Hallek,U. T. Hacker, Arbeitsgemeinschaft Internistische Onkologie (AIO)Brd. 15H A fixed-sequence, open-label study to determine the activity of SCH 717454(robatumumab) as assessed by positron emission tomography in patientswith relapsed or recurrent colorectal cancer. (Abstract #3584)E. H. Lin, H. Lenz, M. N. Saleh, S. Badarinath, J. A. Knost, M. J. MacKenzie,B. N. Polite, P. Kavan, E. X. Chen, L. P. Leichman, K. Pathiraja, B. D. LuBrd. 16A Phase I study of regorafenib sequentially administered with either FOLFOXor FOLFIRI in patients with first-/second-line colorectal cancer. (Abstract#3585)B. Schultheis, G. Folprecht, J. Kuhlmann, R. Ehrenberg, U. T. Hacker, C. Kohne,M. Kornacker, O. Boix, T. Lin, J. Krauss, R. Fischer, S. Hamann, D. Strumberg,K. B. MrossBrd. 16B Phase I study of dasatinib in combination with capecitabine, oxaliplatin, andbevacizumab followed by an expanded cohort in previously untreatedmetastatic colorectal cancer. (Abstract #3586)J. H. Strickler, A. L. Cohn, C. Arrowood, S. Haley, M. Morse, H. Uronis,G. C. Blobe, S. D. Hsu, Y. Zafar, H. HurwitzBrd. 16C Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C)in second-line metastatic colorectal cancer (mCRC): Hoosier OncologyGroup GI05–102—Final report. (Abstract #3587)S. Shahda, M. Yu, J. Picus, J. A. Bufill, W. A. Harb, M. Burns, A. J. Spittler,J. Flynn, Y. Zeng, G. H. Vance, J. Wu, C. R. Currie, P. J. Loehrer, E. G. ChioreanBrd. 16D The relationship between the development of rash and clinical and healthrelatedquality of life outcomes by KRAS mutation status in patients withcolorectal cancer treated with cetuximab in NCIC CTG CO.17. (Abstract#3588)C. J. O’Callaghan, D. Tu, C. S. Karapetis, H. Au, M. J. Moore, N. C. Tebbutt,M. G. Trudeau, T. J. Price, D. Yip, D. J. JonkerSATURDAY107

Saturday, June 4, 2011SATURDAYBrd. 16EBrd. 16FBrd. 16GBrd. 16HBrd. 17ABrd. 17BBrd. 17CBrd. 17DBrd. 17EBrd. 17FBrd. 17GCorrelation of capecitabine-induced skin toxicity with treatment efficacy inpatients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial.(Abstract #3589)V. Heinemann, L. Fischer von Weikersthal, U. Vehling-Kaiser, M. Stauch, H. Hass,H. F. Dietzfelbinger, D. V. Oruzio, S. Klein, K. Zellmann, T. Decker, M. Schulze,W. Abenhardt, G. Puchtler, H. W. Kappauf, J. Mittermueller, C. Haberl,C. A. Giessen, N. Moosmann, S. StintzingAssociation of baseline CEA, VEGF, and soluble VEGF receptor 2 withtreatment outcomes in two randomized phase III trials of cediranib inmetastatic colorectal cancer (mCRC). (Abstract #3590^)H. Schmoll, P. M. Hoff, J. D. Robertson, L. Pike, S. Morgan, D. Wilson,J. M. JürgensmeierAxitinib inhibition of [ 18 F] fluorothymidine (FLT) uptake in patients (pts) withcolorectal cancer (CRC): Implications for cytotoxic chemotherapycombinations. (Abstract #3591)C. Hoh, J. R. Infante, H. A. Burris III, J. C. Tarazi, S. Kim, B. Rosbrook, T. R. ReidAngiogenesis gene polymorphisms and clinical outcome of metastaticcolorectal cancer treated with first-line bevacizumab and oxaliplatin-basedchemotherapy. (Abstract #3592)A. Gerger, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, T. Winder, M. J. Labonte,P. M. Wilson, L. Benhaim, R. El-Khoueiry, G. Absenger, A. B. El-Khoueiry, S. Iqbal,H. LenzSerial FDG-PET/CT for early outcome prediction in patients with metastaticcolorectal cancer undergoing chemotherapy. (Abstract #3593)A. Hendlisz, V. Golfinopoulos, C. Garcia, P. Emonts, A. Covas, L. Ameye,M. Paesmans, A. Deleporte, G. Machiels, E. Toussaint, B. Vanderlinden,A. Awada, M. Piccart, P. FlamenEvaluation of the association between tagging polymorphisms of the MACC1locus and overall survival in patients with colorectal cancer. (Abstract #3594)A. Lang, S. Geller-Rhomberg, T. Winder, B. L. Hartmann, K. Gasser, B. Kohler,I. Grizelj, N. Stark, P. Tschann, H. Drexel, A. MuendleinCpG island methylator phenotype and KRAS mutation status as prognosticmarkers in patients with resected colorectal cancer. (Abstract #3595)D. H. Koo, Y. Hong, K. Kim, J. Lee, H. Chang, Y. Kang, C. Yu, J. Kim, M. Kim,S. Jang, T. KimThe prognostic influence and interrelationships of CD8 T-cell infiltration inmalignant colorectal tumors. (Abstract #3596)C. H. Richards, A. Powell, S. Platt, C. S. Roxburgh, D. C. Mcmillan, P. G. HorganStandardization of EGFR FISH in colorectal cancer: Results of aninternational, interlaboratory reproducibility ring study. (Abstract #3597)A. Sartore-Bianchi, S. Fieuws, S. Veronese, M. Moroni, N. Personeni, M. Frattini,V. Torri, F. Cappuzzo, S. Vander Borght, V. Martin, M. Skokan, A. Santoro,M. Gambacorta, S. Tejpar, M. Varella-Garcia, S. SienaDetermination of genomic profile to predict clinical response to FOLFOX plusbevacizumab in metastatic colorectal cancer. (Abstract #3598)T. J. George, H. Liu, L. V. Duckworth, J. E. Sullivan, J. Dong, C. Liu, L. H. Dang,K. Slentz-Kesler, C. J. AllegraCell-free DNA, KRAS, and BRAF mutations in plasma from patients withmetastatic colorectal cancer treated with third-line cetuximab and irinotecan.(Abstract #3599)N. Pallisgaard, K. G. Spindler, I. S. Vogelius, A. K. Jakobsen108

Saturday, June 4, 2011Brd. 17HBrd. 18ABrd. 18BBrd. 18CBrd. 18DBrd. 18EBrd. 18FBrd. 18GBrd. 18HBrd. 19AThe predictive value of single nucleotide polymorphisms in the vascularendothelial growth factor system in patients with metastatic colorectalcancer treated with bevacizumab plus chemotherapy as first-line treatment:Results of the phase III ACT trial NCT00598156 translational study. (Abstract#3600)T. Hansen, R. D. Christensen, R. F. Andersen, K. G. Spindler, A. Johnsson,A. K. JakobsenThe influence of hypomagnesemia (hMg) on overall survival (OS) in a phaseIII randomized study of cetuximab (CET) plus best supportive care (BSC)versus BSC: NCIC CTG/AGITG CO.17. (Abstract #3601)M. M. Vickers, C. S. Karapetis, D. Tu, C. J. O’Callaghan, T. J. Price, N. C. Tebbutt,G. Van Hazel, J. D. Shapiro, N. Pavlakis, P. Gibbs, J. Blondal, U. J. Yu Min Lee,J. M. Meharchand, R. L. Burkes, S. H. Rubin, J. Simes, J. R. Zalcberg,M. J. Moore, L. Zhu, D. J. JonkerEarly change in tumor size from waterfall plot analysis and RECIST responseas predictor of overall survival (OS) in advanced, chemotherapy-refractorycolorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study. (Abstract #3602)G. A. Van Hazel, D. Tu, N. C. Tebbutt, D. J. Jonker, T. J. Price, C. O’Callaghan,J. R. Zalcberg, M. Taylor, A. H. Strickland, A. T. Tomiak, D. Yip, J. Simes,S. K. Yadav, M. Links, M. J. Burnell, M. Jefford, C. S. KarapetisThe role of KRAS, BRAF, and PI3K mutations as markers of resistance tocetuximab in metastatic colorectal cancer. (Abstract #3603)A. Passardi, P. Ulivi, M. Valgiusti, E. Scarpi, R. Moscati, E. Chiadini, P. Rosetti,L. Saragoni, L. Capelli, A. Casadei Gardini, A. Ragazzini, M. Monti, S. Calpona,W. Zoli, C. Milandri, L. FrassinetiPrediction of tumor recurrence in stage II colon cancer through geneticvariants in formyl peptide receptor 2 (FPR2). (Abstract #3604)R. D. Ladner, W. Zhang, M. J. Labonte, D. Yang, Y. Ning, A. Gerger,P. O. Bohanes, T. Winder, A. B. El-Khoueiry, S. Iqbal, N. Petasis, H. LenzClinicopathological features of patients with colorectal cancer among KRASwild-type p.G13D and other mutations: Results from a multicenter, crosssectionalstudy by the Japan Study Group of KRAS Mutation in ColorectalCancer. (Abstract #3605)H. Uetake, T. Watanabe, T. Yoshino, K. Yamazaki, M. Ishiguro, K. Sugihara,Y. OhashiSafety, pharmacokinetics (PK), and cost-effectiveness of upfront genotypingof DPYD in fluoropyrimidine therapy. (Abstract #3606)M. J. Deenen, A. Cats, M. K. Sechterberger, J. L. Severens, P. H. Smits,R. Bakker, C. M. Mandigers, M. Soesan, J. H. Beijnen, J. H. SchellensInfluence of KRAS and BRAF mutational status and rash on disease-freesurvival (DFS) in patients with resected stage III colon cancer receivingcetuximab (Cmab): Results from NCCTG N0147. (Abstract #3607)S. R. Alberts, S. N. Thibodeau, D. J. Sargent, M. R. Mahoney, F. Sinicrope,A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg,J. T. Quesenberry, T. C. Smyrk, A. Grothey, S. G. NairCpG island methylation in PTEN, MGMT, and E/H cadherin promoters,mutations of K-ras and B-raf may indicate how progression in the colorectaladenocarcinoma sequence occurs. (Abstract #3608)B. Metzger, M. Dicato, G. MahonGenome-wide association study (GWAS) of the efficacy of capecitabine,oxaliplatin, and bevacizumab in metastatic colorectal cancer in the CAIRO2trial of the Dutch Colorectal Cancer Group (DCCG). (Abstract #3609)H. Guchelaar, J. Pander, S. Bohringer, T. van der Straaten, Y. Ariyurek,J. Houwing-Duistermaat, H. Gelderblom, C. J. PuntSATURDAY109

Saturday, June 4, 2011SATURDAYBrd. 19BBrd. 19CBrd. 19DBrd. 19EBrd. 19FBrd. 19GBrd. 19HBrd. 20ABrd. 20BBrd. 20CBrd. 20DBrd. 20EBrd. 20FA specific miRNA signature correlates with complete pathological responseto neoadjuvant chemoradiotherapy in locally advanced rectal cancer.(Abstract #3610)G. Della Vittoria Scarpati, C. Carlomagno, S. Marchini, P. Ubezio, F. Falcetta,M. D’Incalci, S. De Placido, F. Sabbatino, C. Fusciello, S. PepeClinical and prognostic relevance of methylation of circulating HLTF andHPP1 tumor DNA and CEA in serum of patients with colorectal carcinoma(CRC). (Abstract #3611)F. T. Kolligs, A. B. Philipp, D. Nagel, F. Spelsberg, A. Herbst, P. StieberCancer stem cell gene variants associated with colon cancer recurrence.(Abstract #3612)L. Benhaim, A. Gerger, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, T. Winder,M. J. Labonte, P. M. Wilson, R. El-Khoueiry, A. B. El-Khoueiry, S. Iqbal, H. LenzUse of KRAS mutation status to predict clinical outcomes in patients withmetastatic colorectal cancer (mCRC) treated with the VEGF signalinginhibitor cediranib. (Abstract #3613^)J. M. Jürgensmeier, P. M. Hoff, L. Pike, J. D. Robertson, S. Morgan, G. McWalter,D. Wilson, J. SmithEffects of a neurokinin-1 receptor (NK-1R) antagonist on colon cancerthrough suppression of colon tumor–initiating cells. (Abstract #3614)C. Polytarchou, J. M. Bugni, S. Dry, C. Pothoulakis, D. IliopoulosEffect of body mass index (BMI) and body surface area (BSA) on outcomes inearly-stage colon cancer (CC). (Abstract #3615)S. Alipour, R. Woods, H. J. Lim, S. Gill, H. F. Kennecke, C. Speers, C. J. Brown,W. Y. CheungComparison of innovative estimation of efficacy to standard using theACCENT database. (Abstract #3616)J. W. Chapman, C. O’Callaghan, N. Hu, K. Ding, G. A. Yothers, P. J. Catalano,Q. Shi, R. G. Gray, M. J. O’Connell, D. J. Sargent, for the ACCENT collaborativegroupEvaluating the relationship between progression-free survival (PFS) andoverall survival (OS) in clinical trials of patients (pts) with metastaticcolorectal cancer (mCRC). (Abstract #3617)R. Sidhu, A. Rong, S. DahlbergSurvival advantage associated with metformin usage in patients withcolorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM).(Abstract #3618)H. M. Hassabo, M. Hassan, B. George, S. Wen, V. Baladandayuthapani,S. Kopetz, D. R. Fogelman, B. K. Kee, C. Eng, C. R. GarrettPredictive and prognostic value of gender in early-stage colon cancer: Apooled analysis of 33,345 patients from the ACCENT database. (Abstract#3619)W. Y. Cheung, Q. Shi, M. O’Connell, J. Cassidy, C. D. Blanke, D. J. Kerr,E. Van Cutsem, S. R. Alberts, G. A. Yothers, D. J. Sargent, for the ACCENTCollaborative GroupEffect of VTE on mortality in patients with stage III colon cancer. (Abstract#3620)C. D. Mullins, K. A. Bikov, D. L. McNally, N. C. Onwudiwe, M. R. Dalal, N. HannaOutcome and dose intensity (DI) in the elderly subgroup of the AGITG MAXphase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) infirst-line metastatic colorectal cancer (CRC). (Abstract #3621)T. J. Price, D. Zannino, K. Wilson, J. Simes, G. A. Van Hazel, B. A. Robinson,A. Broad, V. Ganju, S. P. Ackland, N. C. TebbuttShort-term outcomes after colorectal cancer among the oldest old patients:A cross-national comparative study. (Abstract #3622)A. Syse, J. P. Bynum, H. G. Welch, S. Tretli, S. S. Soneji110

Saturday, June 4, 2011Brd. 20GBrd. 20HBrd. 21ABrd. 21BBrd. 21CBrd. 21DBrd. 21EBrd. 21FBrd. 21GBrd. 21HBrd. 22ABrd. 22BAllergic reactions (ARs) induced by FOLFOX4 treatment in colorectal cancer:A comparative analysis between Asian and Western patients (pts). (Abstract#3623)K. Sugihara, A. Ohtsu, Y. Shimada, N. Mizunuma, P. Lee, A. De Gramont,R. M. Goldberg, M. L. Rothenberg, T. Andre, S. BrienzaCetuximab (CET)-related hypersensitivity reactions (HSRs): An analysis oftiming, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial.(Abstract #3624)E. Elimova, C. J. O’Callaghan, D. Tu, C. S. Karapetis, T. J. Price, L. Zhu,J. R. Zalcberg, J. Simes, D. J. JonkerEffectiveness of first- or second-line bevacizumab (BV) treatment (tx) inelderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, anobservational cohort study (OCS). (Abstract #3625)M. Kozloff, T. S. Bekaii-Saab, J. C. Bendell, A. L. Cohn, H. Hurwitz, N. Roach,H. Tezcan, S. Fish, E. D. Flick, Y. Mun, D. Dalal, A. GrotheyThe effect of tumor response on quality of life (QoL) in patients with KRASwild-type metastatic colorectal cancer (mCRC): Analysis from the CRYSTALstudy. (Abstract #3626)I. Griebsch, I. Lang, U. Sartorius, E. Van CutsemEffect of dose modification on the efficacy of capecitabine: Data from sixrandomized, phase III trials in patients with colorectal or breast cancer.(Abstract #3627)J. Cassidy, J. O’Shaughnessy, H. Schmoll, C. Twelves, T. H. Cartwright,A. Buzdar, E. McKenna, F. Gilberg, N. Scotto, D. G. HallerAn analysis of the effect of stage at diagnosis of bowel cancer on survival:Findings from the South Australian Clinical Registry (SACR) for metastaticcolorectal cancer (mCRC). (Abstract #3628)K. Jain, T. J. Price, C. Beeke, R. Padbury, G. P. Young, D. Roder, A. R. Townsend,S. Bishnoi, C. S. KarapetisSurgical treatment of colorectal cancer in the advanced elderly: Doesoutcome justify treatment? (Abstract #3629)J. D. Cull, S. Kukreja, T. J. HiekenPreoperative chemoradiation (CRT) with concurrent capecitabine (Cap),oxaliplatin (Ox), and bevacizumab (Bev) in patients with locally advancedrectal cancer (RC): Effects on pathological complete response (pCR) andsurgical complications. (Abstract #3630)T. Hoehler, K. Dellas, D. Riesenbeck, T. Reese, F. Wuerschmidt, C. Roedel,W. Wagner, H. Zuehlke, M. Richter, J. DunstColorectal cancer in African American and Caucasian patients: Acomparison of an urban, university hospital with the National CancerInstitute SEER database. (Abstract #3631)E. P. Mitchell, A. Topham, R. Singla, S. Maron, J. Schoenfeld, F. Guiles,S. Goldstein, P. R. Anne, G. Isenberg, P. J. Maxwell IV, J. PalazzoCould baseline health-related quality of life (QoL) improve prognostication ofoverall survival in metastatic colorectal cancer? Results from GERCOROPTIMOX 1 study. (Abstract #3632)M. Diouf, F. Bonnetain, B. Chibaudel, C. Tournigand, L. Teixeira, H. Marijon,N. Perez-Staub, A. De GramontApplication of adaptive study designs: Phase II and III results from thecediranib (CED) HORIZON (HZ) II and III studies. (Abstract #3633^)D. Wilson, P. M. Hoff, H. Schmoll, J. D. Robertson, A. StoneThe relationship between quality of life (QoL) and tumor response in patients(pts) with metastatic colorectal cancer (mCRC) receiving panitumumab(pmab) plus FOLFIRI as first-line therapy: An analysis of study 314. (Abstract#3634)M. Karthaus, J. Thaler, R. Hofheinz, L. Mineur, H. Letocha, R. Greil, E. Fernebro,E. Gamelin, A. Baños, C. KohneSATURDAY111

Saturday, June 4, 2011Brd. 22CBrd. 22DLet-7a microRNA levels in KRAS-mutated colorectal carcinomas determinesurvival differences in patients treated with anti-EGFR. (Abstract #3635)E. Canestrari, A. Ruzzo, B. Vincenzi, N. Galluccio, G. Perrone, F. Andreoni,P. Lorenzini, E. Rulli, S. d’Emidio, V. Catalano, F. Loupakis, R. Bisonni, I. Floriani,M. De Nictolis, D. Santini, L. Salvatore, G. Tonini, A. Falcone,M. Magnani, F. GrazianomiR128 and LET-7 microRNAs as potential biomarkers for selection ofpatients with metastatic colorectal cancer candidate tocetuximab/panitumumab therapy. (Abstract #3636)L. Landi, F. Biagioni, V. Ludovini, A. Sacconi, A. Destro, G. Blandino, M. Roncalli,L. Crinò, F. CappuzzoSATURDAY112

Saturday, June 4, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONGastrointestinal (Noncolorectal) CancerLocation: Hall ATrack(s): Gastrointestinal (Noncolorectal) CancerBrd. 23A Gemcitabine plus oxaliplatin (GemOx) in advanced hepatocellular carcinoma(HCC): A multicenter study of over 200 patients. (Abstract #4033)N. Williet, A. Zaanan, M. Hebbar, V. Boige, L. Fartoux, T. Mansourbakht,O. Dubreuil, O. Rosmorduc, F. Bonnetain, J. TaïebBrd. 23B Phase II trial of concurrent chemoradiotherapy consisting of two courseswith S-1 and cisplatin for locally advanced esophageal cancer. (Abstract#4034)H. Iwase, M. Shimada, T. Tsuzuki, N. Ryuge, H. GotoBrd. 23C Clinical significance of tumor markers as prognostic factors in patients withmetastatic gastric cancer receiving first-line chemotherapy. (Abstract #4035)J. Jo, M. Ryu, D. Koo, B. Ryoo, H. Kim, J. Lee, H. Chang, T. Kim, K. Choi, G. Lee,H. Jung, K. Kim, J. Yook, S. Oh, B. Kim, J. Kim, Y. KangBrd. 23D Effect of neoadjuvant chemotherapy on survival in patients with gastricsignet ring cell adenocarcinoma: A multicentric comparative study. (Abstract#4036)C. Mariette, M. Messager, J. H. Lefevre, V. Pichot, A. Souadka, T. Thibot,D. Brachet, N. Carrere, M. Fernandez, J. Guiramand, B. Tsilividis, R. Flamein,K. Kraft, J. Balon, F. Borie, A. Glaise, X. d’Journo, F. Peschaud, F. Vandois,G. Piessen, FRENCHBrd. 23E Prediction of response and prognosis by a score including onlypretherapeutic parameters in 410 neoadjuvant treated gastric cancerpatients. (Abstract #4037)S. Lorenzen, S. Blank, K. Becker, R. Langer, F. Lordick, D. Jaeger, J. R. Siewert,K. OttBrd. 23FBrd. 23GBrd. 23HBrd. 24AC-MET gene copy number variation (CNV) analysis by quantitative PCR(qPCR) assay in Caucasian patients with gastric cancer (GC). (Abstract#4038)N. Galluccio, A. Ruzzo, E. Canestrari, P. Lorenzini, S. d’Emidio, V. Sisti,V. Catalano, F. Andreoni, C. Zingaretti, M. De Nictolis, C. Ligorio, F. Cappuzzo,M. Magnani, F. GrazianoMulticenter phase II trial to investigate safety and efficacy of an adjuvanttherapy with gemcitabine and cetuximab in patients with R0 or R1 resectedpancreatic cancer. (Abstract #4039)H. Fensterer, C. Schade-Brittinger, H. Mueller, B. Schupfner, J. Fass, U. Lindig,U. Settmacher, M. P. Ebert, M. Kornmann, R. Hofheinz, E. Endlicher, C. Brendel,P. J. Barth, D. K. Bartsch, T. M. Gress, Arbeitsgemeinschaft InternistischeOnkologie (AIO)The final analysis of a multicenter randomized controlled trial of gemcitabine(G) alone versus gemcitabine and S-1 combination therapy (GS) in patientswith unresectable advanced pancreatic cancer (PC): GEMSAP study.(Abstract #4040)H. Isayama, Y. Nakai, T. Sasaki, N. Sasahira, K. Hirano, T. Tsujino, M. Tada,M. Omata, K. Koike, GEMSAP study groupEffect of baseline (BL) biomarkers on overall survival (OS) in metastaticpancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG479) or placebo (P) in combination with gemcitabine (G). (Abstract #4041)I. McCaffery, Y. Tudor, H. Deng, R. Tang, S. Badola, H. L. Kindler, C. S. Fuchs,E. Loh, S. D. Patterson, L. Chen, J. L. GansertSATURDAY113

Saturday, June 4, 2011SATURDAYBrd. 24BBrd. 24CBrd. 24EBrd. 24FBrd. 24GBrd. 24HBrd. 25ABrd. 25BBrd. 25CBrd. 26ABrd. 26BAdjuvant treatments in pancreatic cancer: Preliminary data of a pooledanalysis. (Abstract #4042)F. Drudi, D. Tassinari, C. Castellani, F. Carloni, C. Santelmo, E. Tamburini,M. Fantini, M. Papi, L. Gianni, A. RavaioliPhase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellularcarcinoma (HCC). (Abstract #4043)G. K. Abou-Alfa, B. Gansukh, J. F. Chou, J. Shia, M. Capanu, M. Kalin, H. X. Chen,N. J. Zojwalla, S. Katz, D. L. Reidy, D. P. Kelsen, L. SaltzScreening for pancreatic cancer in a high-risk cohort: A 7-year experience.(Abstract #4045)W. Al-Sukhni, A. Borgida, H. Rothenmund, S. Holter, S. Wilson, M. J. Moore,S. Narod, K. Jhaveri, M. A. Haider, S. GallingerClinicopathologic features and treatment outcomes of patients (pts) withHER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) andgastroesophageal junction (GEJ). (Abstract #4046)B. E. Phillips, R. R. Tubbs, T. W. Rice, L. A. Rybicki, T. Plesec, C. P. Rodriguez,G. M. Videtic, J. P. Saxton, D. I. Ives, D. J. AdelsteinMolecular markers of the EGFR pathway in erlotinib-treated patients withadvanced pancreatic cancer (APC): Translational analyses of a randomized,cross-over AIO phase III trial. (Abstract #4047)S. H. Boeck, A. Jung, R. P. Laubender, J. Neumann, R. Egg, C. Goritschan,U. Vehling-Kaiser, C. Winkelmann, L. Fischer von Weikersthal, M. R. Clemens,T. C. Gauler, A. Marten, S. Klein, G. Kojouharoff, M. Barner, M. Geissler,T. F. Greten, U. Mansmann, T. Kirchner, V. HeinemannLenalidomide for advanced hepatocellular cancer (HCC) in patientsprogressing on or intolerant to sorafenib. (Abstract #4048)H. Safran, K. Charpentier, A. Kaubisch, G. Dubel, G. Soares,K. E. Faricy-Anderson, T. J. Miner, Y. Eng, I. Ribizzi-Akhtar, A. M. Plette,N. J. Espat, D. Berz, A. Schumacher, D. Luppe, P. Bakalarski, P. Wingate,J. Victor, K. Rosati, D. IsdaleExposure-response (E-R) analysis to facilitate phase III (P3) dose selectionfor ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treatmetastatic pancreatic cancer (mPC). (Abstract #4049)J. Lu, H. Deng, R. Tang, C. Hsu, H. L. Kindler, C. S. Fuchs, J. L. Gansert, S. Bray,S. S. Suzuki, E. Loh, M. ZhuAdjuvant therapy in the treatment of biliary tract cancer (BTC): A systematicreview and meta-analysis. (Abstract #4050)A. M. Horgan, E. Amir, T. Walter, J. J. KnoxAn evaluation of cytoreductive surgery plus hyperthermic intraperitonealchemotherapy on patients with peritoneal carcinomatosis: Final results of aphase II prospective and randomized clinical trial. (Abstract #4051)Y. Li, X. Yang, G. Yang, Y. Zhou, Y. YonrmuraComprehensive analysis of potential predictive biomarkers for insulin-likegrowth factor type 1 receptor (IGF-1R) targeted therapy in pancreatic cancer.(Abstract #4052)R. T. Shroff, M. M. Javle, D. Li, R. A. Wolff, D. J. Mauro, G. Naumov, M. Nebozhyn,T. Zhang, Y. Li, S. SathyanarayananPerioperative chemotherapy with docetaxel, cisplatin, and capecitabine(DCX) in gastroesophageal adenocarcinoma: A phase II study of theArbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4053)P. C. Thuss-Patience, R. Hofheinz, D. Arnold, A. Florschütz, S. Daum,A. Kretzschmar, L. Mantovani-Löffler, D. Bichev, B. Gahn, G. Schumacher,M. Kneba114

Saturday, June 4, 2011Brd. 26CBrd. 27ABrd. 27BBrd. 27CBrd. 28ABrd. 28BBrd. 28CBrd. 29ABrd. 29BBrd. 29CBrd. 30ABrd. 30BImproved survival in patients with hepatocellular carcinoma over 30 years inJapan: Analysis of nationwide prospective registry of 148,161 patients.(Abstract #4054)M. Kudo, N. Izumi, N. Kokudo, M. Sakamoto, Y. Matsuyama, T. Ichida,O. Nakashima, O. Matsui, Y. Ku, M. Makuuchi, for the Liver Cancer Study Group ofJapanPrognostic significance of post-treatment standardized uptake value (pSUV)of positron emission tomography (PET) to predict overall survival (OS) andrelapse-free survival (RFS) in patients with esophageal or gastroesophagealcancer treated with definitive chemoradiotherapy. (Abstract #4055)A. Suzuki, L. Xiao, Y. Hayashi, J. Welsh, S. H. Lin, D. Maru, W. L. Hofstetter,R. J. Mehran, J. H. Lee, M. S. Bhutani, H. A. Macapinlac, Z. X. Liao, J. A. AjaniBevacizumab (Bev) plus chemotherapy for advanced gastroesophagealadenocarcinoma (GC): Combined U.S. experience. (Abstract #4056)E. C. Smyth, P. C. Enzinger, J. Li, M. Vincitore, J. Lacy, B. F. El-Rayes, P. L. Kunz,J. M. Ford, E. Robinson, D. P. Kelsen, M. A. ShahA phase II study of neoadjuvant combination chemotherapy with docetaxel,cisplatin, and S-1 for locally advanced gastric cancer. (Abstract #4057)H. Ohnuma, Y. Sato, T. Takayama, T. Sagawa, M. Hirakawa, K. Harada,T. Nobuoka, K. Hirata, Y. Takahashi, S. Katsuki, S. Takahashi, M. Hirayama,M. Takahashi, M. Maeda, T. Sato, K. Miyanishi, M. Kobune, R. Takimoto, J. KatoQuantitation of circulating methylated RASSF1A in prognostication andmonitoring of treatment response in unresectable hepatocellular carcinoma(HCC). (Abstract #4058)S. L. Chan, A. K. Chan, E. P. Hui, S. Yu, L. Leung, H. H. Loong, B. Ma, T. Mok,A. T. Chan, W. YeoPrognostic factors in Japanese patients with advanced gastric cancer usingthe data from JCOG9912 study. (Abstract #4059)D. Takahari, A. Takashima, J. Mizusawa, Y. Yamada, T. Yoshino, K. Yamazaki,W. Koizumi, Y. Suzuki, N. Boku, A. OhtsuFinal results of feasibility study of neoadjuvant chemotherapy withdocetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II/III esophagealsquamous cell carcinoma. (Abstract #4060)H. Hara, H. Daiko, K. Kato, H. Igaki, S. Kadowaki, Y. Tanaka, Y. Hamamoto,H. Matsushita, M. Nagase, Y. Hosoya, M. TaharaPrognostic microRNAs in patients operated for pancreatic cancer. (Abstract#4061)N. A. Schultz, K. K. Andersen, A. Roslind, H. Willenbrock, M. Wøjdemann,J. S. JohansenAn evaluation of microRNA signature and response of patients with gastriccancer to cisplatin and fluorouracil. (Abstract #4062)H. K. Kim, C. H. Kim, J. Kim, I. J. Choi, D. J. Munroe, J. E. GreenEffect of metformin on survival of diabetic patients with pancreaticadenocarcinoma. (Abstract #4063)N. Sadeghi, J. L. Abbruzzese, S. J. Yeung, M. Hassan, D. LiPreliminary results of a randomized phase II study: Treatment of Chinesepatients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 orthe reverse sequence. (Abstract #4064)F. Bi, Q. Li, C. Zhou, J. Yu, X. Cai, M. Qiu, J. Liu, C. Yi, D. Luo, F. Xu, The WesternCooperative Gastrointestinal Oncology Group of ChinaPhase II single-arm, single institution trial of neoadjuvant gemcitabine andoxaliplatin treatment (NT) in patients (pts) with resectable pancreasadenocarcinoma (PC). (Abstract #4065)E. M. O’Reilly, W. R. Jarnagin, M. F. Brennan, C. Winston, L. H. Tang, M. Capanu,M. Schattner, L. Y. Chen, R. P. DeMatteo, C. J. DiMaio, M. I. D’Angelica,R. C. Kurtz, D. S. Klimstra, M. A. Lowery, D. G. Coit, D. L. Reidy, P. J. AllenSATURDAY115

Saturday, June 4, 2011SATURDAYBrd. 30CBrd. 31ABrd. 31BBrd. 31CBrd. 31DBrd. 31EBrd. 31FBrd. 31GBrd. 31HBrd. 32ABrd. 32BCorrelation of HER2 and PTEN status with clinical outcome in esophageal(E), gastric (G), and gastroesophageal junction (GEJ) adenocarcinomas(ACs). (Abstract #4066)K. Linos, C. E. Sheehan, J. S. RossA new prognostic classification scheme with treatment guidelines for Asianpatients with hepatocellular carcinoma (HCC): The Hong Kong CombinedLiver Cancer (HKCLC) classification. (Abstract #4067)Y. Tang, T. Yao, C. C. Yau, S. Fan, R. PoonQuality of lymphadenectomy for esophageal cancer in the United States: Ananalysis of the SEER database. (Abstract #4068)B. M. Stiles, A. Nasar, F. Mirza, J. L. Port, P. C. Lee, S. Paul, N. K. AltorkiA multinational phase II study of PEP02 (liposome irinotecan) for patientswith gemcitabine-refractory metastatic pancreatic cancer. (Abstract #4069)A. H. Ko, M. A. Tempero, Y. Shan, W. Su, Y. Lin, E. Dito, A. Ong, Y. Wang, G. Yeh,L. ChenDefining two prognostic groups of metastatic gastric cancer: FLOT3 trial ofthe Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4070)S. Al-Batran, R. Hofheinz, N. Homann, G. Illerhaus, U. M. Martens,J. Stoehlmacher-Williams, H. Schmalenberg, K. B. Luley, N. Prasnikar, M. Egger,S. Probst, J. T. Hartmann, M. H. Moehler, D. Arnold, W. Fischbach, C. Pauligk,S. P. Moenig, P. Piso, E. JaegerCA19-9 for the prediction of efficacy of chemotherapy in patients withadvanced pancreas cancer: A pooled analysis of six prospective trials.(Abstract #4071)T. M. Bauer, T. S. Bekaii-Saab, X. Li, M. A. Villalona-Calero, P. A. Philip,A. F. Shields, M. M. Zalupski, N. Hammad, B. F. El-RayesChemoradiation with FOLFOX plus cetuximab in locally advanced cardia oresophageal cancer: Final results of a GERCOR phase II trial (ERaFOX).(Abstract #4072)L. Dahan, B. Chibaudel, F. Di Fiore, P. Artru, L. Mineur, M. Galais, O. Dupuis,V. Blondin, S. Abdiche, M. Attia, A. De Gramont, G. Lledo, GERCORPrognostic values of microRNAs in phase III clinical trial gastric cancerpatients treated with S-1/oxaliplatin or doxifluridine/oxaliplatin. (Abstract#4073)J. Jiang, C. Wu, X. Zheng, Q. Zhou, X. Zhang, X. Xu, B. Lu, J. JuPhase I study of everolimus in combination with sorafenib in patients withadvanced hepatocellular carcinoma (HCC). (Abstract #4074)R. S. Finn, R. Poon, T. Yau, H. Klumpen, L. Chen, Y. Kang, T. Kim,C. Gomez-Martin, C. Rodriguez-Lope, T. Kunz, T. Paquet, K. Asubonteng,R. E. Winkler, O. Anak, D. B. Sellami, J. BruixEverolimus plus octreotide LAR versus placebo plus octreotide LAR inpatients with advanced neuroendocrine tumors: Analysis by primary tumorsite from RADIANT-2. (Abstract #4075)E. M. Wolin, N. Fazio, S. Saletan, R. E. Winkler, A. Panneerselvam, L. KvolsUse of MTHFR A1298C polymorphism to predict response in a phase IIinternational clinical trial of patients with advanced gastric (GC) orgastroesophageal junction (GEJ) adenocarcinoma treated with first-linelapatinib plus capecitabine. (Abstract #4076)M. J. Labonte, D. Yang, W. Zhang, P. M. Wilson, A. Gerger, P. O. Bohanes,Y. Ning, L. Benhaim, R. El-Khoueiry, Y. M. Nagarwala, A. M. Kemner,M. J. Pishvaian, R. K. Hsieh, O. Gladkov, S. Urba, S. Y. Rha, D. Sakaeva, S. Iqbal,A. B. El-Khoueiry, H. Lenz116

Saturday, June 4, 2011Brd. 32CBrd. 32DBrd. 32EBrd. 32FBrd. 32GBrd. 32HBrd. 33ABrd. 33BBrd. 33CBrd. 33DBrd. 33EA randomized, double-blind, multicenter phase II AIO trial with gemcitabineplus sorafenib versus gemcitabine plus placebo in patients withchemotherapy-naive advanced or metastatic biliary tract cancer: First safetyand efficacy data. (Abstract #4077)M. H. Moehler, C. C. Schimanski, S. Kanzler, M. A. Woerns, U. Denzer,F. T. Kolligs, M. P. Ebert, A. Distelrath, M. Geissler, S. Zeuzem, F. Lammert,A. W. Lohse, M. M. Dollinger, U. Lindig, E. M. Duerr, N. Lubomierski,S. Zimmermann, M. Kabisch, S. Schadmann-Fischer, P. R. Galle, German AIOEverolimus plus octreotide LAR versus placebo plus octreotide LAR inpatients with advanced neuroendocrine tumors (NET): Effect of priorsomatostatin analog therapy on progression-free survival in the RADIANT-2trial. (Abstract #4078)L. B. Anthony, M. Peeters, J. D. Hainsworth, E. Baudin, D. Hoersch, J. Klimovsky,K. Grouss, V. Jehl, M. E. Pavel, J. C. YaoCirculating protein and cellular biomarkers of sunitinib in patients withadvanced neuroendocrine tumors. (Abstract #4079)A. J. Zurita, J. Heymach, M. Khajavi, L. Tye, X. Huang, M. Kulke, H. Lenz,N. J. Meropol, W. Carley, S. E. DePrimo, C. S. HarmonThe role of cytoreductive surgery in patients with carcinomatosis fromhigh-grade appendix cancer in the era of modern systemic chemotherapy.(Abstract #4080)H. M. El Halabi, P. Ledakis, V. Gushchin, J. Francis, N. Athas, R. Macdonald,K. Studeman, A. SardiFinal toxicity results of a phase I dose-escalation trial of tremelimumab(CP-675206) in combination with gemcitabine in chemotherapy-naivepatients (pts) with metastatic pancreatic cancer. (Abstract #4081)M. Aglietta, C. Barone, M. B. Sawyer, M. J. Moore, W. H. Miller Jr., C. Bagalà,D. A. Ferraro, F. Colombi, C. Cagnazzo, L. Gioeni, K. D. Fly, B. Huang, F. LeoneEfficacy and safety of single-agent sunitinib in treating patients withadvanced hepatocelluar carcinoma after sorafenib failure: A prospective,open-label, phase II study. (Abstract #4082)T. Yau, R. C. Leung, H. Wong, J. Chiu, P. Chan, R. Pang, S. Fan, R. PoonThe use of single-agent sorafenib in the treatment of patients with advancedhepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis.(Abstract #4083)J. Chiu, Y. Tang, T. Yao, A. Wong, H. Wong, R. C. Leung, P. Chan, T. Cheung,R. Poon, S. Fan, C. C. YauHER2 status as an independent prognostic marker in patients with advancedgastric cancer receiving adjuvant chemotherapy after curative gastrectomy.(Abstract #4084)Y. Park, M. Ryu, H. Park, H. Kim, B. Ryoo, J. Yook, B. Kim, S. Jang, Y. KangA phase I study of GC33, a recombinant humanized antibody againstglypican-3, in patients with advanced hepatocellular carcinoma (HCC).(Abstract #4085)A. X. Zhu, P. J. Gold, A. B. El-Khoueiry, T. A. Abrams, H. Morikawa, T. Ohtomo,P. A. PhilipC-reactive protein as a biomarker to predict outcomes after livertransplantation for hepatocellular carcinoma. (Abstract #4086)H. An, J. Jang, M. Lee, S. Bae, J. Choi, S. Yoon, Y. You, D. Kim, E. Jeon, K. Park,S. ChunCombination of exposure-response and case-control analyses in regulatorydecision making. (Abstract #4087)J. Yang, Y. Wang, H. Zhao, C. Garnett, J. Gobburu, W. Pierce, G. Schechter,J. Summers, P. Keegan, B. Booth, N. RahmanSATURDAY117

Saturday, June 4, 2011SATURDAYBrd. 33FBrd. 33GBrd. 33HBrd. 34ABrd. 34BBrd. 34CBrd. 34DBrd. 34EBrd. 34FBrd. 34GBrd. 34HFluoropyrimidine/platinum-based first-line chemotherapy in metastaticesophageal squamous cell carcinoma: Prognostic factor analysis in 239patients. (Abstract #4088)H. Jung, J. Lee, H. Ahn, S. Park, Y. Park, Y. ImClinical/pathologic features and survival of patients with fibrolamellarhepatocellularcarcinoma (FLL-HCC): Data from the Fibrolamellar-Hepatocellular (FLL-HCC) Consortium. (Abstract #4089)C. Ang, A. P. Venook, M. A. Choti, R. P. DeMatteo, R. K. Kelley, D. Cosgrove,J. P. McGuire, M. S. Torbenson, T. M. Pawlik, W. R. Jarnagin, M. I. D’Angelica,Y. Fong, J. F. Chou, E. M. O’Reilly, D. S. Klimstra, A. C. Griffin, G. P. Vallarapu,M. Capanu, D. P. Kelsen, G. K. Abou-AlfaThe association between body mass index and baseline clinical stage ofesophageal carcinoma. (Abstract #4090)Y. Hayashi, A. M. Correa, W. L. Hofstetter, A. A. Vaporciyan, D. C. Rice,G. L. Walsh, R. J. Mehran, A. Suzuki, J. H. Lee, M. S. Bhutani, S. H. Lin, J. Welsh,D. Maru, S. Swisher, J. A. AjaniAdjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC):Results of a phase II trial. (Abstract #4091)J. J. Knox, R. Wong, G. E. Darling, J. Lister, M. Guindi, G. Liu, W. Xu, J. J. Kim,D. J. Jonker, J. Wells, W. Kendal, H. Mackay, A. Visbal, R. E. Dinniwell, A. Pierre,R. Feld, S. Sundaresan, A. Bayley, Y. Shargall, A. M. HorganSafety results from a randomized trial of perioperative epirubicin, cisplatinplus capecitabine (ECX) with or without bevacizumab (B) in patients (pts)with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma.(Abstract #4092)A. F. Okines, R. E. Langley, L. C. Thompson, S. P. Stenning, L. Stevenson,S. Falk, M. T. Seymour, F. Y. Coxon, G. W. Middleton, D. Smith, L. Evans,S. Slater, J. S. Waters, D. Ford, M. Hall, T. Iveson, R. D. Petty, C. Plummer,W. Allum, D. Cunningham, The National Cancer Research Institute (NCRI) UpperGastrointestinal Cancers Clinical Studies GroupUtility of routine endoscopy in the follow-up of resected gastric carcinoma.(Abstract #4093)M. Satolli, W. Evangelista, C. Mecca, R. Napoletano, A. Giacobino, A. Novarino,F. Brusa, J. Fiore, L. Pomba, M. Garino, G. Fronda, L. CiuffredaPhase II trial of postoperative adjuvant gemcitabine and cisplatinchemotherapy followed by chemoradiation with gemcitabine in patients withresected pancreatic cancer. (Abstract #4094)J. Kwon, E. Chie, J. Kim, S. Im, D. Oh, Y. Kim, S. Han, K. Lee, J. Jang, T. Kim,H. S. Han, S. Kim, Y. Yoon, Y. Bang, S. HaProgression-free survival as surrogate endpoint of overall survival inpatients with advanced/recurrent gastric cancer: Individual patient dataanalysis on 4,102 patients from 20 randomized trials. (Abstract #4095)K. Shitara, T. Burzykowski, on behalf of GASTRIC projectMature long-term outcome using a continuous 50-Gy shrinking fieldchemoradiation schedule for squamous cell carcinoma of the anus. (Abstract#4096)R. Cooper, K. Spindler, R. Prestwich, P. Byrnes, D. Sebag-MontefioreArray-based comparative genomic hybridization analysis to identifyprognostic markers for resected pancreatic cancer. (Abstract #4097)J. Lee, I. Petrini, J. Hwang, E. Giovannetti, J. Voortman, Y. Wang, S. M. Steinberg,N. Funel, P. S. Meltzer, G. GiacconeCetuximab plus radiochemotherapy in locally advanced anal cancer: Interimresults of the French multicenter phase II trial ACCORD16. (Abstract #4098)E. Deutsch, C. Lemanski, E. Paris, A. Delarochefordiere, I. Martel-Lafay, E. Rio,L. Miglianico, Y. Becouarn, J. Pignon, J. Berille, P. Ezra, D. Azria118

Saturday, June 4, 2011Brd. 35ABrd. 35BBrd. 35CBrd. 35DBrd. 35EBrd. 35FBrd. 35GBrd. 35HBrd. 36ABrd. 36BBrd. 36CBrd. 36DBrd. 36EImpact of prior procedures on overall survival following radioembolization inpatients with unresectable hepatocellular carcinoma (HCC). (Abstract #4099)G. M. Ettorre, B. Sangro, R. Cianni, D. Gasparini, R. Golfieri, S. Ezzidin,F. T. Kolligs, F. Izzo, on behalf of European Network for Radioembolization usingY90 microspheres (ENRY)Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction(GEJ) cancer: Response and protracted stable disease observed inadenocarcinoma. (Abstract #4100)D. Ilson, Y. Y. Janjigian, M. A. Shah, D. P. Kelsen, L. H. Tang, J. Campbell,L. Fuqua, M. CapanuMarker driven systemic treatment of inoperable cholangiocarcinomas:Panitumumab and combination chemotherapy in KRAS wild-type tumors.(Abstract #4101)L. H. Jensen, J. Lindebjerg, J. Ploen, T. Hansen, A. K. JakobsenPancreatic cancer and diabetes mellitus: A retrospective cohort study.(Abstract #4102)A. Yacoub, E. Siegel, I. MakhoulImpact of prior chemotherapy on progression-free survival in patients (pts)with advanced pancreatic neuroendocrine tumors (pNET): Results from theRADIANT-3 trial. (Abstract #4103)R. F. Pommier, E. M. Wolin, A. Panneerselvam, S. Saletan, R. E. Winkler,E. Van CutsemEpidemiology, treatment outcome, and survival of primary gallbladdercancer in the United States: A period prevalence SEER database study1973–2007. (Abstract #4104)A. M. Hossain, R. F. Khozouz, R. N. RahmanClinical factors and outcomes in HPV-associated anal canal cancer.(Abstract #4105)J. Nair, Y. Hu, W. M. Mendenhall, C. Liu, C. G. Morris, R. Zlotecki, J. Kirwan,L. H. Dang, S. Tan, E. Huang, C. J. Allegra, T. J. GeorgeOxaliplatin, 5-FU, and leucovorin (FOLFOX) in advanced biliary tract cancer.(Abstract #4106)S. Lee, K. Kim, H. Kim, S. Kim, S. Bae, C. Kim, N. Lee, K. Lee, S. Park, J. Won,J. Moon, D. Hong, H. ParkTACE plus sorafenib for the treatment of hepatocellular carcinoma: Finalresults of the multicenter SOCRATES trial. (Abstract #4107)A. Erhardt, F. T. Kolligs, M. M. Dollinger, E. Schott, H. Wege IV, M. Bitzer, C. Gog,J. Raedle, M. Schuchmann, C. Walter, D. Blondin, C. Ohmann, D. HaeussingerFOLFIRI followed by radiochemotherapy and surgery in locally advancedgastric cancer: FFCD 0308 phase II trial. (Abstract #4108)P. Michel, G. Breysacher, F. Desseigne, L. Dahan, C. Petorin, D. Moussata,J. Grenier, S. Nguyen, F. Viret, N. Carrere, C. Mariette, C. Garnier Tixidre,K. Bouhier Leporrier, M. Galais, F. Fein, I. Iwanicki-Caron, E. Maillard, B. Dousset,F. Mornex, L. BedenneMeta-analyses of 22 randomized trials assessing the influence ofchemotherapy in advanced/recurrent gastric cancer. (Abstract #4109)H. Bleiberg, D. J. Sargent, GASTRICDose-ranging study of tesetaxel, a novel oral taxane, administered assecond-line therapy at a flat dose to patients with advanced gastric cancer.(Abstract #4110)J. S. Baker, A. Qureshi, L. Itri, W. Sun, M. F. Mulcahy, J. A. AjaniOutcomes following sequential trials of stereotactic body radiotherapy(SBRT) for hepatocellular carcinoma (HCC). (Abstract #4111)A. Bujold, C. Massey, J. J. Kim, J. D. Brierley, R. Wong, C. Cho, Z. Kassam,R. E. Dinniwell, J. Ringash, B. Cummings, J. J. Knox, M. Sherman, L. A. DawsonSATURDAY119

Saturday, June 4, 2011SATURDAYBrd. 36FBrd. 36GBrd. 36HBrd. 37ABrd. 37BBrd. 37CBrd. 37DBrd. 37EBrd. 37FBrd. 37GAssociation of the expression of the glioma-associated oncogene homolog(GLI) 1 with nuclear expression of NF-B and unfavorable overall survival ofpatients with pancreatic cancer. (Abstract #4112)S. Yang, S. H. Kuo, C. Hsu, J. Lee, Y. Tien, A. ChengSorafenib and bevacizumab combination targeted therapy in advancedneuroendocrine tumor: A phase II study of the Spanish NeuroendocrineTumor Group (GETNE0801). (Abstract #4113)D. E. Castellano, J. Capdevila, R. Salazar, J. Sastre, V. Alonso, M. Llanos,R. Garcia-Carbonero, A. Abad, I. Sevilla, I. Duran, Spanish Neuroendocrine TumorGroup (GETNE)The safety of IPI-926, a novel hedgehog pathway inhibitor, in combinationwith gemcitabine in patients (pts) with metastatic pancreatic cancer.(Abstract #4114)J. Stephenson, D. A. Richards, B. M. Wolpin, C. R. Becerra, J. T. Hamm,W. A. Messersmith, S. Devens, J. Cushing, J. Goddard, T. Schmalbach,C. S. FuchsPhase II randomized trial on dose-escalated sorafenib (S) versus bestsupportive care (BSC) in patients with advanced hepatocellular carcinoma(HCC) with disease progression on prior S treatment. (Abstract #4115)T. Pressiani, L. Rimassa, C. Boni, R. Labianca, S. Fagiuoli, A. Ardizzoni, P. Foa,E. Cortesi, C. Porta, F. Artioli, L. Latini, C. Carnaghi, R. Lutman, G. Torzilli,M. Tommasini, R. Ceriani, G. Covini, L. Giordano, N. Locopo, A. SantoroPhase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-linetherapy in hepatocellular cancer (HCC): North Central Cancer TreatmentGroup trial N0745. (Abstract #4116)J. M. Hubbard, S. R. Alberts, W. S. Loui, M. R. Mahoney, L. R. Roberts,T. C. Smyrk, Z. Gatalica, S. Kumar, S. R. Dakhil, P. J. Flynn, J. M. Lafky,M. J. Bury, NCCTGInfluence of tumor infiltrating Foxp3 regulatory T cells on prognosis inresectable gastric cancer. (Abstract #4117)J. Kwon, M. Cho, E. Nam, J. Jo, S. LeeS100A2 as a prognostic marker in patients receiving adjuvant therapy forpancreatic cancer (PC): A secondary analysis of RTOG 9704. (Abstract#4118)M. A. Tempero, K. A. Winter, G. E. Kim, S. Kakar, T. S. Hyun, W. Regine,R. B. Mowat, K. Charpentier, W. Small Jr., C. Guha, D. K. Chang, A. V. Biankin,RTOGSurvival analysis by pooling risk factors in AVAGAST: First-line capecitabineand cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) withadvanced gastric cancer (AGC). (Abstract #4119)Y. Kang, A. Ohtsu, E. Van Cutsem, L. Roman, J. Nunes, C. Li, D. Otero, F. Rivera,G. Aprile, P. R. Pimentel Alvarez, M. H. Moehler, J. Wu, B. Langer, M. A. ShahUpdated results of a phase I study of pasireotide (SOM230) in combinationwith everolimus (RAD001) in patients (pts) with advanced neuroendocrinetumors (NET). (Abstract #4120)J. A. Chan, D. P. Ryan, C. S. Fuchs, A. X. Zhu, T. A. Abrams, B. M. Wolpin,P. Malinowski, E. Regan, M. KulkePolymorphisms in EGF a61G, GSTP1 Ile105Val, and MTHFR A1298C topredict response and survival in a phase II study for patients with metastaticor unresectable gastric (G) or gastroesophageal junction (GEJ) cancertreated with capecitabine, oxaliplatin (XELOX), and cetuximab. (Abstract#4121)S. Iqbal, M. J. Labonte, D. Yang, W. Zhang, P. O. Bohanes, Y. Ning, L. Benhaim,R. El-Khoueiry, P. M. Wilson, A. Gerger, A. B. El-Khoueiry, H. Lenz120

Saturday, June 4, 2011Brd. 37HBrd. 38ABrd. 38BBrd. 38CBrd. 38EBrd. 38FBrd. 38GBrd. 38HBrd. 39ABrd. 39BClinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II studyof telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) asfirst-line treatment in patients (pts) with advanced gastric orgastroesophageal junction (GEJ) cancer. (Abstract #4122)M. Alsina, A. H. Ko, M. Garcia De Paredes, F. Rivera, L. S. Schwartzberg,A. Fattaey, L. A. Kunkel, J. Tabernero, J. A. AjaniPatients with carcinoma of unknown primary with isolated carcinomatosis onpresentation: Clinicopathologic features and survival data. (Abstract #4123)H. R. Carlson, S. Karanth, M. A. Zarzour, R. Lenzi, M. N. Raber,G. R. VaradhacharyA phase I study of two different schedules of nab-paclitaxel (nab-P) withascending doses of vandetanib (V) with expansion in patients (Pts) withpancreatic cancer (PC). (Abstract #4124)A. B. El-Khoueiry, S. Iqbal, H. Lenz, B. J. Gitlitz, D. Yang, S. Cole, V. Duddalwar,A. GarciaBILCAP: A randomized clinical trial evaluating adjuvant chemotherapy withcapecitabine compared to expectant treatment alone following curativesurgery for biliary tract cancer. (Abstract #4125)J. A. Bridgewater, C. Stubbs, J. N. Primrose, National Cancer Research Institute(UK) Upper Gastrointestinal Studies GroupA randomized phase II study of gemcitabine (G) plus the cardiac glycosidehuachansu (H) in the treatment of patients with locally advanced (LAPC) ormetastatic pancreatic cancer (MPC). (Abstract #4127)Z. Meng, L. Liu, Y. Shen, P. Yang, L. Cohen, Y. Huo, Q. Zhao, C. S. Ng,D. Z. Chang, C. R. GarrettInactivation of BRCA2 cooperates with Trp53 R172H to induce invasivepancreatic ductal adenocarcinomas in mice: A mouse model of familialpancreatic cancer. (Abstract #4128)G. Feldmann, C. Karikari, M. dal Molin, S. Duringer, P. Volkmann, D. K. Bartsch,S. Bisht, J. Koorstra, P. Brossart, A. Maitra, V. FendrichPrevention of Barrett’s esophagus (BE) and esophageal adenocarcinoma(EAC) in the levrat rat model of EAC by treatment with a smoothened (SMO)inhibitor. (Abstract #4129)M. K. Gibson, A. H. Zaidi, J. M. Davison, B. Hough, A. F. Sanz, T. Foxwell,T. Hoppo, Y. Komatsu, K. S. Nason, C. Rotoloni, U. Malhotra, A. Atasoy,C. Smith, J. D. Luketich, B. A. Jobe, Pittsburgh Esophageal Neoplasia GroupIdentification of a small and lethal subgroup of esophagogastricadenocarcinoma with evidence of responsiveness to crizotinib by METamplification. (Abstract #4130)J. K. Lennerz, E. L. Kwak, M. Michael, S. B. Fox, A. Ackerman, K. Bergethon,G. Y. Lauwers, J. G. Christensen, K. D. Wilner, D. A. Haber, R. Salgia, Y. Bang,J. W. Clark, B. J. Solomon, A. J. IafrateREAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin,and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) inadvanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, andmolecular analysis from phase II. (Abstract #4131)I. Chau, A. F. Okines, D. Gonzalez de Castro, C. Saffery, Y. Barbachano,A. Wotherspoon, L. Puckey, S. Hulkki Wilson, F. Y. Coxon, G. W. Middleton,D. R. Ferry, T. D. Crosby, S. Madhusudan, J. Wadsley, J. S. Waters, M. Hall,D. Swinson, A. Robinson, D. Smith, D. Cunningham, UK National CancerResearch Institute Upper Gastrointestinal Cancer Clinical Studies GroupFOLFIRI regimen as second-/third-line chemotherapy in patients withadvanced pancreatic adenocarcinoma refractory to gemcitabine andplatinum-salts: A retrospective series of 70 patients. (Abstract #4132)C. Neuzillet, O. Hentic, B. Rousseau, V. Rebours, L. Bengrine-Lefèvre,F. Bonnetain, E. Raymond, P. Ruszniewski, C. Louvet, P. HammelSATURDAY121

Saturday, June 4, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONSATURDAYHealth Services ResearchLocation: Hall ATrack(s): Health Services ResearchBrd. 40A Comparative analysis of lung cancer in a public hospital versus privatehospitals in New York. (Abstract #6037)V. Gotlieb, V. Verma, J. Fogel, A. Multz, R. J. GrallaBrd. 40B The development of a value-based pricing index for new drugs in metastaticcolorectal cancer. (Abstract #6038)G. Dranitsaris, I. Truter, M. LubbeBrd. 40C The influence of self-reported conflicts of interest on the conclusions ofeditorial authors of phase III cancer trials. (Abstract #6039)M. C. Miranda, A. T. Lera, A. Ueda, B. Briones, T. Lerner, A. Del Giglio,R. P. RiechelmannBrd. 40D Perceptions of caregivers on the participation of cancer patients into clinicaltrials. (Abstract #6040)A. T. Lera, M. C. Miranda, P. Santi, G. Brito, P. Prestes, M. Oliveira, A. Del Giglio,R. P. RiechelmannBrd. 40E Factors influencing patient preferences for outpatient treatment of febrileneutropenia. (Abstract #6041)N. Lathia, P. K. Isogai, C. De Angelis, S. Walker, M. C. Cheung, N. MittmannBrd. 40F Analysis of dermatologist density and melanoma mortality. (Abstract #6042)S. Aneja, J. S. BordeauxBrd. 40G Changes in Medicaid reimbursements for cancer screening: Keeping pacewith inflation? (Abstract #6043)M. T. Halpern, S. G. Haber, F. K. Tangka, D. H. Howard, L. C. Richardson,S. A. Sabatino, S. SujhaBrd. 40H Preferences of patients with metastatic breast cancer. (Abstract #6044)M. Smith, C. B. White, E. Railey, A. M. Storniolo, G. W. Sledge Jr.Brd. 41A A predictive model to identify cancer patients at risk for in-hospital mortalitybased on admission criteria. (Abstract #6045)K. Ramchandran, J. Shega, M. Schumacher, A. Rademaker, b. Weitner,E. Szmuilowicz, S. A. WeitzmanBrd. 41B Discordance between conclusions in the abstract and conclusions stated inthe body of the article: An analysis of randomized controlled trials (RCTs) oflung cancer. (Abstract #6046)A. K. Altwairgi, C. Booth, W. Hopman, T. D. BaetzBrd. 41C Assessing 2-month clinical prognosis in patients with solid tumors: Firstresults of PRONOPALL study. (Abstract #6047)H. P. Bourgeois, S. Traoré, P. Solal-Celigny, O. Dupuis, P. Maillart, O. Capitain,R. Delva, P. Soulie, M. Marcq, E. Boucher, G. Ganem, E. Bourbouloux, J. Baudon,M. Kaassis, M. Zinger, C. Lafond, V. Berger, P. Mussault, P. Ingrand, F. GrudeBrd. 41D Factors associated with histologic versus cytologic diagnosis of lungcancer. (Abstract #6048)C. S. Lathan, A. Cronin, J. C. WeeksBrd. 41E Randomized controlled trials (RCTs) in the era of molecular oncology:Methodology, biomarkers, and endpoints. (Abstract #6049)A. Kay, J. Higgins, A. G. Day, R. M. Meyer, C. M. BoothBrd. 41F Socioeconomic position, stage of lung cancer, and time between referral anddiagnosis in Denmark, 2001–2008. (Abstract #6050)S. O. Dalton, B. L. Frederiksen, E. Jakobsen, M. Steding-Jessen, K. Oesterlind,J. Schuz, M. Osler, C. Johansen122

Saturday, June 4, 2011Brd. 41G Are breast cancer quality metrics being met? (Abstract #6051)A. Murphy, G. Rauscher, D. Dupuy, R. Alvarez, T. Macarol, E. Knightly, D. Ansell,P. Grabler, P. A. Robinson, E. A. MarcusBrd. 41H Implementation of a prospective screening tool for breast cancer clinical trialeligibility at an NCI-designated cancer center. (Abstract #6052)K. H. Lethert, S. K. Cheng, D. J. Nauman, D. M. Dilts, A. Sandler, S. Y. ChuiBrd. 42A Predictive markers of utilization of chemotherapy in patients with advancedcolorectal cancer (CRC): A population-based study. (Abstract #6053)S. Ahmed, T. Zhu, R. Lee-Ying, C. Ubhi, V. Kundapur, R. Alvi, K. HaiderBrd. 42B Assessing two meta-analysis (MA) methods: Individual patient data-based(IPD) versus literature-based abstracted data (AD) in 10 MA including 37,002patients (pts)—Are there differences of concern? (Abstract #6054)E. Bria, R. J. Gralla, H. Raftopoulos, I. Sperduti, M. Milella, F. Cognetti,D. GiannarelliBrd. 42C Defining indicators for measuring the quality of systemic cancer therapyusing administrative data. (Abstract #6055)M. K. Krzyzanowska, C. M. Booth, K. K. Chan, K. Enright, M. E. TrudeauBrd. 42D Attrition bias: Does the benefit of targeted agents (TA) increase the more wesearch for a selection biomarker? Meta-regression analysis of randomizedclinical trials (RCTs) in advanced non-small cell lung and colorectal cancer(NSCLC/CRC). (Abstract #6056)D. Giannarelli, M. Milella, F. Loupakis, F. Cuppone, V. Vaccaro, I. Sperduti,P. Carlini, A. Falcone, F. Cognetti, E. BriaBrd. 42E SBRT for early NSCLC: Markov model insight for optimal patient selection.(Abstract #6057)A. V. Louie, G. Rodrigues, M. Hannouf, D. Palma, G. Zaric, S. SenanBrd. 42F Pathways of care for adolescents with cancer in France. (Abstract #6058)E. Desandes, S. Bonnay, C. Berger, L. Brugieres, F. Isfan, V. Laurence, L. Mignot,D. Olive-Sommelet, I. Tron, J. Clavel, B. LacourBrd. 42G Screening for hepatitis B virus (HBV) prior to chemotherapy: Acost-effectiveness analysis. (Abstract #6059)U. Zurawska, L. K. Hicks, G. Woo, C. M. Bell, M. Krahn, K. K. Chan, J. J. FeldBrd. 42H The cost-effectiveness of bevacizumab in combination with paclitaxel infirst-line treatment of patients with metastatic breast cancer. (Abstract #6060)A. J. Montero, S. Gluck, G. D. Lopes Jr.Brd. 43A Prognostic significance of QOL deterioration during early lung cancersurvivorship: Secondary analysis of RTOG 0212 and 0214. (Abstract #6061)V. Gondi, R. Paulus, D. Bruner, C. A. Meyers, E. Gore, A. H. Wolfson,M. Werner-Wasik, H. Choy, B. Movsas, Radiation Therapy Oncology Group(RTOG)Brd. 43B Smaller, faster trials: The right way to assess new targeted agents? Asimulation study. (Abstract #6062)M. Le Deley, K. V. Ballman, D. J. SargentBrd. 43C Utilization and clinical practice impact of an interactive tool for guidingchoice of systemic adjuvant treatment (adj TX) for patients with early breastcancer (EBC). (Abstract #6063)P. Ravdin, S. Martino, M. D. Pegram, N. J. Robert, S. M. Swain, D. Janssen,A. Bowser, J. A. Mortimer, R. W. CarlsonBrd. 43D Clinical practice guidelines (CPGs) for adjuvant chemotherapy (aCT) incolorectal cancer: A population-based analysis of adherence and nonreceipt.(Abstract #6064)D. Rayson, R. Urquhart, E. Grunfeld, M. Cox, C. Kendell, M. Jorgensen, B. Colwell,G. A. PorterBrd. 43E Understanding patients’ attitudes toward communication about the cost ofcancer care. (Abstract #6065)A. J. Bullock, E. W. Hofstatter, M. Yushak, M. K. BussSATURDAY123

Saturday, June 4, 2011SATURDAYBrd. 43FBrd. 43GBrd. 43HBrd. 44ABrd. 44BBrd. 44CBrd. 44DBrd. 44EBrd. 44FBrd. 44GBrd. 44HBrd. 45ABrd. 45BBrd. 45CBrd. 45DBrd. 45EAre African American men adequately represented in prostate cancerrandomized controlled trials? A systematic review. (Abstract #6066)S. Galeb, T. Reljic, B. Djulbegovic, C. Gwede, N. B. Kumar, A. KumarCosts and utilization of oncology health care services at the end of life.(Abstract #6067)B. Chastek, C. R. Harley, J. D. Kallich, L. N. Newcomer, C. J. Paoli, A. TeitelbaumWillingness to pay to prevent chemotherapy-induced nausea and vomiting.(Abstract #6068)P. Miller, S. Balu, D. Buchner, M. Walker, E. J. Stepanski, L. S. SchwartzbergMeta analysis of behavioral interventions to reduce cancer pain. (Abstract#6069)S. S. Gorin, H. Badr, P. B. Jacobsen, E. Janke, H. S. Jim, P. KrebsAnalysis of minority-based community clinical oncology program (MBCCOP)accrual activity. (Abstract #6070)E. H. Williams, W. J. McCaskill-Stevens, T. E. LadSurgical treatment of colon cancer in patients older than age 80. (Abstract#6071)H. B. Neuman, E. S. O’Connor, J. Weiss, N. K. LoConte, D. Y. Greenblatt,M. SmithCancer in the adolescent and young adult (AYA) population in the UnitedStates: Current statistics and projections. (Abstract #6072)R. S. Go, J. D. GundrumA review of medical malpractice claims related to clinical genetic testing.(Abstract #6073)R. A. Lindor, G. E. MarchantASCO Quality Oncology Practice Initiative (QOPI) quality measures forsmoking cessation and survival in metastatic NSCLC. (Abstract #6074)I. T. Lennes, J. S. Temel, J. A. Greer, J. O. Jacobson, E. R. Park,V. A. Jackson, E. R. Gallagher, H. Bemis, W. F. PirlA clinical trial with culturally tailored video to increase participation ofAfrican Americans in cancer clinical trials. (Abstract #6075)D. R. Banda, M. Mete, R. Kapoor, S. M. SwainQuantifying the personal financial impact of a career choice in academichematology/oncology (AHO). (Abstract #6076)M. Palmeri, E. Stansfield, A. Stansfield, A. D. Fuld, J. M. Pipas, B. A. Arrick,E. Wadsworth, T. H. DavisComparison of beliefs of lung cancer providers and minority patients.(Abstract #6077)C. B. Smith, N. Bickell, E. Halm, A. R. Berman, C. A. Powell, J. Salazar-Schicchi,J. E. Nelson, J. P. WisniveskyImpact of early prostate cancer diagnosis in the United States. (Abstract#6078)Y. Zhang, B. K. Hollenbeck, J. E. Montie, J. T. WeiPredictors of successful breast-conserving surgery (BCS) in patients withductal carcinoma in situ (DCIS). (Abstract #6079)J. J. Griggs, M. E. Sorbero, G. M. Ahrendt, L. M. Schiffhauer, A. Stark, A. W. DickAccelerated partial-breast irradiation using brachytherapy (APBIb) for breastcancer: Predictors of use and guideline concordance. (Abstract #6080)J. A. Hattangadi, N. Taback, B. A. Neville, J. R. Harris, R. S. PungliaCost-effectiveness of intraoperative radiation therapy for breastconservation. (Abstract #6081)M. Alvarado, E. Ozanne, A. Mohan, L. Esserman124

Saturday, June 4, 2011Brd. 45F Cost effectiveness of a survivorship care plan for breast cancer survivors.(Abstract #6082)D. Coyle, E. Grunfeld, K. Coyle, J. A. Julian, G. R. Pond, A. Folkes, M. N. Levine,FUPII Trial Investigators, Ontario Clinical Oncology GroupBrd. 45G Clinical outcome of advanced colorectal cancer patients pre and postbevacizumab therapy using the SEER database. (Abstract #6083)M. Choi, G. Dyson, P. A. Philip, A. F. ShieldsBrd. 45H How often are opioids prescribed for cancer patients reporting pain? Resultsof a population-based analysis. (Abstract #6084)L. C. Barbera, H. Seow, A. Husain, D. Howell, C. Atzema, C. Earle, Y. Liu,J. Sussman, R. Sutradhar, D. J. DudgeonBrd. 46A Validation of a claims-based predicted performance status measure inSEER-Medicare. (Abstract #6085)F. Hendrick, I. H. Zuckerman, N. B. Pandya, X. Ke, M. J. Edelman, A. J. DavidoffBrd. 46B The cost-effectiveness of primary prophylaxis with granulocyte colonystimulatingfactor in docetaxel-containing adjuvant chemotherapy in earlybreast cancer: The impact of risk of febrile neutropenia and its mortality.(Abstract #6086)K. K. Chan, M. E. Trudeau, A. Eisen, J. L. Verreault, C. A. Freedman, S. DentBrd. 46C Correlates of poor surgical margins following initial surgery for ductalcarcinoma in situ and receipt of additional surgery. (Abstract #6087)M. E. Sorbero, J. J. Griggs, G. M. Ahrendt, L. M. Schiffhauer, A. Stark, A. W. DickBrd. 46D A year in the life of oncology health services research. (Abstract #6088)M. Brundage, C. F. Snyder, B. H. BassBrd. 46E Changing prognosis of glioblastoma multiforme (GBM) in the 21st century:The influence of age and regional income. (Abstract #6089)M. V. Mishra, A. Dicker, M. Werner-Wasik, D. W. Andrews, X. Shen,T. N. Showalter, J. Glass, Z. Symon, Y. R. LawrenceBrd. 46F Reporting of cancer clinical trial adverse drug events: A RADAR report.(Abstract #6090)S. M. Belknap, C. H. Georgopoulos, S. A. Weitzman, L. Qualkenbush,A. T. Samaras, J. M. McKoy, B. J. Edwards, S. T. Rosen, D. P. WestBrd. 46G A national evaluation of response and factors affecting response toneoadjuvant therapy in breast and rectal cancer. (Abstract #6091)S. B. Edge, D. Gress, D. P. Winchester, A. StewartBrd. 46H Evaluation of cancer trial eligibility criteria (with focus on non-AIDS–definingcancers) for inclusion of persons with HIV infection. (Abstract #6092)S. A. Weiss, S. Gajavelli, A. Negassa, J. A. Sparano, M. Haigentz Jr.Brd. 47A Predictors of accrual to clinical trials in an integrated health care deliverysystem. (Abstract #6093)C. P. Somkin, L. M. Ackerson, G. Husson, T. Kolevska, D. Goldstein,L. FehrenbacherBrd. 47B Emerging trends in radiation therapy use among women older than age 70with stage I breast cancer from 2000–2007: A population-based analysis.(Abstract #6094)X. Shen, A. P. Wojcieszynski, M. V. Mishra, P. R. Anne, T. N. ShowalterBrd. 47C Assessment of clinical trials in oncology: An evaluation of 40,696 trials onClinicalTrials.gov. (Abstract #6095)B. R. Hirsch, R. M. Califf, A. Tasneem, K. Chiswell, J. Bolte, K. A. Schulman,A. P. AbernethyBrd. 47D Therapeutic clinical trial enrolment among young adults diagnosed withcancer. (Abstract #6096)P. S. Blanchette, M. Crump, A. A. GuptaSATURDAY125

Saturday, June 4, 2011SATURDAYBrd. 47E Use of radiation therapy after breast-conserving surgery among Medicaidrecipients with early-stage breast cancer. (Abstract #6097)S. B. Wheeler, Y. Wu, A. Meyer, W. R. Carpenter, L. C. Richardson, J. L. Smith,M. A. Lewis, B. WeinerBrd. 47F Risks and benefits of phase I trials: Twelve-years experience from a singleinstitution. (Abstract #6098)U. Swami, M. H. Ghalib, I. Chaudhary, J. Y. Hou, S. Aparo, M. H. Einstein,G. L. Goldberg, T. N. Elrafei, S. Gajavelli, B. Cohen, L. Rajdev, A. Kaubisch,M. Haigentz Jr., S. Mani, S. GoelBrd. 47G Framing the benefits of cancer treatment: How survival is describedinfluences preferences for care. (Abstract #6099)P. Lin, T. W. Concannon, D. Greenberg, G. P. Rossi, J. Hille, C. Fang,H. R. Auerbach, P. J. NeumannBrd. 47H Doctor, what do I have? Limited-English–proficient patients and cancerdiagnosis knowledge. (Abstract #6100)J. C. Leng, L. Yogendran, D. Massie, J. Ramirez, T. Lee, I. Lobach, F. GanyBrd. 48A The ASCO Breast Cancer Registry pilot: Implementation of a multisitecommunity practice registry and treatment plan/summary program. (Abstract#6101)A. H. Partridge, V. W. Norris, V. S. Blinder, B. A. Cutter, M. T. Halpern,J. Malin, M. N. Neuss, A. C. Wolff, ASCO Breast Cancer Registry Pilot SteeringGroupBrd. 48B Health-related quality-of-life (HRQoL) reporting by randomized cancer trials(RCT): Pitfalls for interpretation. (Abstract #6102)L. Testa, C. C. Barbosa, A. C. Chaves, P. M. Hoff, R. P. RiechelmannBrd. 48C Prospective validation of risk prediction models for acute and delayedchemotherapy-induced nausea and vomiting (CINV). (Abstract #6103)N. Bouganim, G. Dranitsaris, L. Vandermeer, S. Hopkins, S. Dent,P. Wheatley-Price, S. Verreault, C. Young, M. J. ClemonsBrd. 48D Pharmaceutical involvement in phase II breast cancer clinical trials. (Abstract#6104)A. Schneider, T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, J. M. PeppercornBrd. 48E Shifting patterns in the interpretation of phase III clinical trial outcomes in thetreatment of advanced NSCLC. (Abstract #6105)A. G. Sacher, N. B. LeighlBrd. 48F Relationship between physician characteristics and the use of newerchemotherapy for the treatment of colon cancer. (Abstract #6106)D. J. Becker, D. L. Hershman, B. J. Insel, A. I. NeugutBrd. 48G Uptake of bevacizumab for the treatment of colon cancer. (Abstract #6107)A. I. Neugut, D. J. Becker, B. J. Insel, D. L. HershmanBrd. 48H Population-based health care cost estimates related to breast cancer bystaging. (Abstract #6108)N. Mittmann, P. K. Isogai, R. Saskin, N. Liu, J. Hoch, N. B. Leighl, M. C. Cheung,M. E. Trudeau, W. K. Evans, K. Dainty, C. EarleBrd. 49A Oncology appointment compliance in navigated and non-navigated patientsreceiving radiation therapy in an urban public hospital. (Abstract #6109)E. A. Marcus, N. Holloway, C. Galligan, R. Cheng, M. McDunn, P. A. Robinson,K. DevineBrd. 49B Early success in narrowing age, gender, and racial disparities in clinical trialaccrual: Targeted screening efforts through the National Cancer InstituteCommunity Cancer Centers Program (NCCCP). (Abstract #6110)S. S. Grubbs, R. S. Go, M. Z. Berger, M. Gonzalez, M. A. Thompson, R. Enos,D. C. St. Germain, A. Denicoff, C. Servididio, J. D. Bearden, H. Zaren,K. Wilkinson, M. Krasna, W. McCaskill-Stevens, M. Bell, R. K. Freeman,S. Miesfeldt, T. S. Ravikumar, S. G. Nair, A. Bashey126

Saturday, June 4, 2011Brd. 49CBrd. 49DBrd. 49EBrd. 49FBrd. 49GBrd. 49HBrd. 50ABrd. 50BBrd. 50CBrd. 50DBrd. 50EBrd. 50FBrd. 50GBrd. 50HBrd. 51AA cost benefit analysis of the 21-gene breast cancer assay within a Canadianhealth care system. (Abstract #6111)S. Hassan, N. MittmannUse of high-cost imaging in elderly patients with metastatic cancer. (Abstract#6112)Y. Hu, A. C. Kwok, W. Jiang, N. Taback, S. R. Lipsitz, G. V. Ting, E. T. Loggers,J. C. Weeks, C. C. GreenbergThe Cancer Therapy Evaluation Program’s (CTEP) implementation of theOperational Efficiency Working Group (OEWG) recommendations. (Abstract#6113)K. DiPiazza, E. Souhan, S. Finnigan, A. Denicoff, S. Friedman, M. Montello,M. M. Mooney, P. Schettino, J. A. Zwiebel, J. H. Doroshow, J. S. AbramsCost-effectiveness of systemic therapies for metastatic pancreatic cancer.(Abstract #6114)V. C. Tam, Y. Ko, N. Mittmann, K. Kumar, S. Hassan, M. C. Cheung, K. K. ChanFinancial implications of changes in the initial treatment of prostate canceramong Medicare beneficiaries. (Abstract #6115)M. A. Dinan, T. J. Robinson, T. M. Zagar, C. D. Scales Jr., L. H. Curtis,S. D. Reed, K. A. Schulman, W. LeeThe 2010 National Comprehensive Cancer Network (NCCN) researchbenchmarking survey (RBS): Clinical trials in the academic cancer center.(Abstract #6116)S. L. Sherman, M. B. Waldinger, D. E. PaulSurvivorship care plan assessment checklist (SCPAC): A tool to evaluatebreast cancer survivorship care plans. (Abstract #6117)C. T. Stricker, L. A. Jacobs, A. DeMichele, A. Jones, B. C. Risendal, S. C. PalmerSurvival trends and patterns of chemotherapy use in elderly metastaticcolorectal cancer (mCRC) patients. (Abstract #6118)V. Shankaran, S. J. Beck, D. K. Blough, L. Koepl, Y. Yim, E. Yu, S. D. RamseyClinical trial availability compared to incidence rates for adolescent andyoung adult cancer. (Abstract #6119)D. J. Indelicato, A. Bleyer, LIVESTRONG Young Adult AllianceConflict of interest in economic analyses of targeted therapies in oncology.(Abstract #6120)A. D. Nearchou, A. Valachis, N. P. Polyzos, D. Mauri, P. A. LindLong-term surveillance and preventive practices among healthy young adultcancer survivors. (Abstract #6121)E. M. Del Giudice, L. F. Paszat, L. Rabeneck, R. Sutradhar, D. Urbach, D. Wilton,N. N. BaxterWas it worth it (WIWI)? Patient satisfaction with clinical trial participation:Results from North Central Cancer Treatment Group (NCCTG) phase III trialN0147. (Abstract #6122)J. A. Sloan, M. R. Mahoney, D. J. Sargent, J. M. Hubbard, H. Liu, E. M. Basch,A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. R. AlbertsPerspectives on electronic health information exchange among peopleaffected by cancer. (Abstract #6123)E. B. Beckjord, R. Rechis, L. N. Shulman, B. HesseDoes insurance coverage affect pancreatic cancer survival? The Medicareage threshold. (Abstract #6124)J. K. Smith, J. Dimick, E. R. Witkowski, E. Ragulin-Coyne, T. P. McDade, S. Ng,Z. Zhou, J. F. TsengThe impact of time to adjuvant chemotherapy (AC) on survival in colorectalcancer (CRC): A systematic review and meta-analysis. (Abstract #6125)M. Raphael, J. J. Biagi, W. J. Mackillop, W. Kong, W. D. King, C. M. BoothSATURDAY127

Saturday, June 4, 2011SATURDAYBrd. 51B Two decades of oncology randomized controlled trials: Factors associatedwith CONSORT clinical trial reporting checklist compliance. (Abstract #6126)G. Rodrigues, I. Arra, V. Velker, B. Rotenberg, T. SextonBrd. 51C Palliative chemotherapy: Does aggressive care beget aggressive care?(Abstract #6127)A. A. Wright, H. G. PrigersonBrd. 51D Appointment (appt) access for new cancer patients (pts). (Abstract #6128)K. Gogineni, K. ArmstrongBrd. 51E Impact of travel distance on early diagnosis of prostate cancer (CaP) andreceipt of curative treatment. (Abstract #6129)J. A. Holmes, W. R. Carpenter, Y. Wu, S. P. Hinton, M. Massing, A. P. Schenck,A. Meyer, S. B. Wheeler, P. A. Godley, R. C. ChenBrd. 51F Calibrating clinically significant effects in survival and response endpoints incancer clinical trials. (Abstract #6130)A. C. Dueck, D. J. Sargent, P. J. Novotny, P. A. Decker, H. Nelson, R. Qin,J. A. SloanBrd. 51G Sponsor/research ethics boards (REB) communications about informedconsent (IC) and time to local activation (LA): An NCIC CTG pilot study.(Abstract #6131)M. Walker, A. Szeto, Z. Meng, B. E. Chen, R. M. MeyerBrd. 51H Managing specialty medication services through a network of specialtypharmacies: A case of oral oncology medications. (Abstract #6132)S. Aslam, S. Tschida, L. S. Lal, T. T. Khan, W. H. Shrank, G. R. Bhattarai,J. C. Montague- Clouse, L. N. NewcomerBrd. 52A Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive,or FISH-negative early-stage breast cancer patients for HER2 status.(Abstract #6133)L. P. Garrison, D. Lalla, M. G. Brammer, B. Wang, J. Babigumira, E. A. PerezBrd. 52B Rapid improvement in evidence-based, quality care of cancer patients withinitiation of ASCO’s Quality Oncology Practice Initiative (QOPI). (Abstract#6134)M. A. Amin, M. H. Hashmi, S. A. TaylorBrd. 52C The effect of process engineering on the performance of a chemotherapyoutpatient clinic (CC). (Abstract #6135)J. Latreille, C. Mimeault, N. Moreau, S. Parent, J. Savaria, J. Bastien, J. Lafreniere,C. C. Prady, O. Blaizel, G. Pie, M. GannonBrd. 52D Computer-assisted outreach by patient care navigators using laptop wirelesscommunication. (Abstract #6136)M. Castaldi, T. N. Elrafei, M. Broderick, H. Delany, Albert Einstein College ofMedicine128

Saturday, June 4, 20118:00 AM - 1:00 PMPOSTER DISCUSSION SESSIONDevelopmental Therapeutics—Clinical Pharmacology and ImmunotherapyDisplay Time: 8:00 AM - 12:00 PMDisplay Location: S403Discussion Time: 12:00 PM - 1:00 PMDiscussion Location: S406CME credit: 1Track(s): Developmental TherapeuticsJeffrey R. Infante, MD—ChairThe Sarah Cannon Cancer CenterDiscussion12:00 PM Janet Dancey, MD (Abstracts #2515–2523)Ontario Institute for Cancer ResearchDiscussion12:15 PM S. Percy Ivy, MD (Abstracts #2524–2529)National Cancer InstituteDiscussion12:30 PM George Coukos, MD, PhD (Abstracts #2530–2535)University of Pennsylvania, Abramson Cancer CenterDiscussion12:45 PM Jeffrey R. Infante, MD (Abstracts #2536–2539)The Sarah Cannon Cancer CenterBrd. 1 First-in-human trial focusing on the immunologic effects of the survivinderivedmultiepitope vaccine EMD640744. (Abstract #2515)S. Gross, V. Lennerz, E. Gallerani, C. Sessa, N. Mach, S. Boehm, D. Hess,L. von Boehmer, A. Knuth, A. Ochsenbein, U. Gnad-Vogt, J. Zieschang,U. Forssmann, T. Woelfel, E. KaempgenBrd. 2 The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Resultsfrom phase I trial in Japanese patients with metastatic solid tumors.(Abstract #2516)T. Nishina, T. Hirashima, K. Sugio, K. Muro, S. Akinaga, H. Maeda, T. Takahashi,T. Naito, H. Murakami, H. Yasui, N. Boku, N. YamamotoBrd. 3 Phase I dose-finding study of trabectedin (T) in combination with cisplatin(C) in patients (pts) with advanced solid tumors. (Abstract #2517)C. Sessa, E. Gallerani, G. Del Conte, A. Christinat, A. Perotti, P. Lardelli,C. M. Kahatt, A. Florez, C. Fernandez, M. Miani, L. GianniBrd. 4 A phase I safety and pharmacokinetic (PK) study of navitoclax (N) incombination with docetaxel (D) in patients (pts) with solid tumors. (Abstract#2518)M. Puglisi, L. van Doorn, M. Blanco-Codesido, M. J. De Jonge, K. Moran, J. Yang,T. Busman, C. Franklin, M. Mabry, A. Krivoshik, R. Humerickhouse, L. R. Molife,F. EskensBrd. 5 A phase I clinical trial on the combined intravenous (IV) and intradermal (ID)administration of autologous TriMix-DC cellular therapy in patients withpretreated melanoma (TriMixIDIV). (Abstract #2519)B. Neyns, S. Wilgenhof, A. M. Van Nuffel, D. Benteyn, C. Heirman, I. Van Riet,A. Bonehill, J. Corthals, K. ThielemansBrd. 6 Phase I study of the PARP inhibitor olaparib (O) in combination withcarboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov)cancer (Ca). (Abstract #2520)J. Lee, C. M. Annunziata, L. M. Minasian, J. Zujewski, S. A. Prindiville, H. L. Kotz,J. Squires, N. D. Houston, J. J. Ji, M. Yu, J. H. Doroshow, E. C. KohnSATURDAY129

Saturday, June 4, 2011SATURDAYBrd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L)in combination with sorafenib (S) in patients with advanced refractory solidtumors. (Abstract #2521)M. Simonelli, P. A. Zucali, R. De Sanctis, E. Lorenzi, F. De Vincenzo, L. Rimassa,M. C. Tronconi, N. Personeni, G. Masci, M. Zuradelli, M. Perrino, M. Bertossi,L. Giordano, A. SantoroPhase I and pharmacodynamic study of high-dose NGR-hTNF in patientswith solid tumors. (Abstract #2522)P. A. Zucali, M. Simonelli, F. De Vincenzo, E. Lorenzi, L. Rimassa, L. Balzarini,V. Quagliuolo, A. Lambiase, C. Bordignon, A. SantoroIs there a therapeutic benefit for patients participating in modern phase Itrials? (Abstract #2523)M. N. Stein, A. R. Tan, J. M. Mehnert, D. Gibbon, R. S. DiPaola, R. A. Moss,E. Poplin, E. H. Rubin, B. Saraiya, M. P. Kane, P. Scott, M. LaRosiliere, H. Camisa,P. Kirin, C. M. Thomas, J. AisnerPhase I open-label, dose-escalation study of ANA773 tosylate, an oralprodrug of a toll-like receptor-7 agonist, in patients with advanced solidtumors. (Abstract #2524)G. A. Daniels, W. E. Carson III, A. C. Mita, K. L. Kendra, M. H. Rahimy,D. W. Inman, J. R. Appleman, J. L. Freddo, D. G. McNeelPhase I study of abiraterone acetate (AA) in patients (pts) with estrogenreceptor– (ER) or androgen receptor (AR)–positive advanced breastcarcinoma resistant to standard endocrine therapies. (Abstract #2525)B. Basu, J. Ang, D. Crawley, E. Folkerd, D. Sarker, M. Blanco-Codesido, K. Moran,S. Wan, N. Dobbs, F. Raynaud, S. R. Johnston, M. Dowsett, A. N. Tutt,J. F. Spicer, C. Swanton, J. S. De BonoHigh efficacy and continued tumor shrinkage with cyclophosphamide,vincristine, and dacarbazine (CVD) in patients (Pts) with malignantpheochromocytoma/paraganglioma harboring succinate dehydrogenasesubunit B (SDHB) mutations. (Abstract #2526)I. Jawed, L. Amiri-Kordestani, M. Velarde, K. Adams, S. Balasubramaniam,J. Reynolds, K. Pacak, A. T. FojoEarly assessment of efficacy of ixabepilone (IXA) by analysis of the rate oftumor growth and decay using data from phase II and phase III clinical trialsin metastatic breast cancer (MBC) patients (Pts). (Abstract #2527)L. Amiri-Kordestani, I. Jawed, J. Wilkerson, W. D. Stein, A. T. Fojo, S. M. Swain,S. E. BatesSurvival of 1,181 patients in a phase I clinic: The University of TexasUniversity of Texas M. D. Anderson Cancer Center experience. (Abstract#2528)B. Stephen, J. J. Wheler, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong,G. S. Falchook, S. A. Piha-Paul, S. Fu, F. Janku, S. L. Moulder, R. KurzrockBevacizumab changes in patients with naive, stage II-III breast cancerassessed by 18F-fluoromisonidazole and 18F-fluorotymidine PET-CT.(Abstract #2529)V. Boni, I. Dominguez, M. J. Garcia Velloso, J. Lopez Vega, P. Martinez,A. Plazaola, B. Hernando, A. Llombart Cussac, J. Lao, R. S. Gomez, I. Alvarez,J. J. Illarramendi, E. G. Calvo, S. Morales Murillo, T. Puertolas, L. J. Pina,E. Bernedo, G. Palacios, S. J. Scherer, J. Garcia-FoncillasIntraprostatic PSA-TRICOM vaccine administration in patients with locallyrecurrent prostate cancer. (Abstract #2530)C. R. Heery, P. A. Pinto, J. Schlom, K. Y. Tsang, R. A. Madan, D. Poole,M. Vergati, B. Walter Rodriguez, M. Merino, J. L. Gulley130

Saturday, June 4, 2011Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25A dose confirmation and signal-generating study of the immunocytokineL19-IL2 in combination with dacarbazine in patients with metastaticmelanoma. (Abstract #2531)T. K. Eigentler, B. Weide, G. Spitaleri, F. G. De Braud, A. Romanini,R. Gonzales-Inglesias, A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato,M. Kaspar, E. Trachsel, D. Neri, H. D. Menssen, C. GarbeMonitoring T-cell responses in a phase II study of AGS-003, an autologousdendritic cell–based therapy in patients with newly diagnosed advancedstage renal cell carcinoma in combination with sunitinib. (Abstract #2532)R. A. Figlin, A. Amin, A. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein,M. DeBenedette, S. K. Pal, V. Master, I. Y. Tcherepanova, R. Jain, W. L. Williams,T. Monesmith, F. Miesowicz, C. A. NicoletteA dendritic cell–based vaccine effects on T-cell responses compared with aviral vector vaccine when administered to patients following resection ofcolorectal metastases in a randomized phase II study. (Abstract #2533)H. K. Lyerly, A. Hobeika, D. Niedzwiecki, T. Osada, J. Marshall, C. R. Garrett,D. Z. Chang, M. Aklilu, T. S. Crocenzi, D. J. Cole, S. Dessureault,S. D. Hsu, A. Bulusu, B. M. Clary, R. Annechiarico, G. Devi,V. Chadaram, T. M. Clay, M. MorseLymphodepletion and tumor burden govern clinical responses in patientswith B-cell malignancies treated with autologous, CD19-targeted T cells.(Abstract #2534)R. J. Brentjens, I. Riviere, J. Park, M. Davilla, X. Wang, R. Yeh, N. Lamanna,M. G. Frattini, M. SadelainA feasibility study of combination therapy with trastuzumab (T),cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumorvaccine for the treatment of HER2 metastatic breast cancer. (Abstract#2535)L. A. Emens, R. Gupta, S. Petrik, M. Laiko, J. M. Leatherman, J. Levi,J. M. Asquith, M. M. Daphtary, E. Garrett-Mayer, B. J. Kobrin, N. E. Davidson,T. Dauses, S. Atay-Rosenthal, X. Ye, A. C. Wolff, V. Stearns, E. M. JaffeeAn umbrella protocol for histology-independent, phase I modular studybased on EGFR mutation status: Using erlotinib alone or in combination withcetuximab, bortezomib, or dasatinib to overcome resistance. (Abstract#2536)J. Fok, R. Kurzrock, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, F. Janku,G. S. Falchook, S. A. Piha-Paul, R. Katz, S. Fu, S. L. Moulder, J. J. WhelerPhase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8)agonist, in patients with advanced solid tumors. (Abstract #2537)P. A. Cohen, D. W. Northfelt, G. J. Weiss, D. D. Von Hoff, K. Manjarrez, G. Dietsch,R. M. Hershberg, R. K. RamanathanPhase I study of TAK-285, an investigational HER2/EGFR inhibitor, inpatients (pts) with advanced cancer: Updated results and assessment ofhuman CSF distribution. (Abstract #2538)E. G. Chiorean, E. A. Sausville, E. I. Heath, A. Weise, J. Gomez-Navarro,K. Venkatakrishnan, S. Sankoh, J. Wu, M. Corvez, P. LoRussoDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as apharmacodynamic (PD) biomarker in phase I trials of the humanizedmonoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A). (Abstract #2539)J. Fredrickson, I. Chang, M. Friesenhahn, E. Ashton, P. N. Munster, M. S. Gordon,D. S. Chen, L. Naumovski, A. de Crespigny, L. S. RosenSATURDAY131

Saturday, June 4, 20118:00 AM - 1:00 PMPOSTER DISCUSSION SESSIONLymphoma and Plasma Cell DisordersDisplay Time: 8:00 AM - 12:00 PMDisplay Location: E450bDiscussion Time: 12:00 PM - 1:00 PMDiscussion Location: E354aCME credit: 1Track(s): Lymphoma and Plasma Cell DisordersSATURDAYJohn Leonard, MD—Co-ChairWeill Cornell Medical CollegeSonali M. Smith, MD—Co-ChairThe University of ChicagoDiscussion12:00 PM Ann S. LaCasce, MD (Abstracts #8015–8016, 8023)Dana-Farber Cancer InstituteDiscussion12:15 PM David G. Maloney, MD, PhD (Abstracts #8017–8019)Fred Hutchinson Cancer Research CenterDiscussion12:30 PM Suzanne Lentzsch, MD, PhD (Abstracts #8021–8022, 8024)University of PittsburghDiscussion12:45 PM Jonathan L. Kaufman, MD (Abstracts #8025–8027)Emory UniversityBrd. 1 Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy foraggressive B-cell lymphomas: A phase I/II study. (Abstract #8015)G. S. Nowakowski, C. B. Reeder, B. LaPlant, T. M. Habermann, C. Rivera,W. R. Macon, D. J. Inwards, I. N. Micallef, P. B. Johnston,L. F. Porrata, S. M. Ansell, T. E. WitzigBrd. 2 Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP inthe first-line treatment of patients with intermediate- and high-risk diffuselarge B-cell lymphoma (DLBCL): Preliminary analysis. (Abstract #8016)J. D. Hainsworth, E. Arrowsmith, M. McCleod, L. Fayad, O. Hamid, L. Davis,B. K. LinBrd. 3 Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). (Abstract #8017)B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy,C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-ZamfirBrd. 4 Day 15 peripheral blood lymphocyte/monocyte ratio post-autologousperipheral hematopoietic stem cell transplantation and survival in diffuselarge B-cell lymphoma. (Abstract #8018)L. F. Porrata, D. J. Inwards, S. M. Ansell, I. N. Micallef, P. B. Johnston,W. J. Hogan, S. MarkovicBrd. 5 Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-riskCD20 NHL not eligible for standard ASCT: Five-year results. (Abstract#8019)L. Devizzi, A. Guidetti, C. Carlo-Stella, C. Tarella, E. Seregni, M. Magni,M. A. Di Nicola, E. Schiavello, P. Matteucci, S. Viviani, E. Bombardieri,A. M. Gianni132

Saturday, June 4, 2011Brd. 6Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan andautologous transplantation (MEL200) in newly diagnosed multiple myeloma(MM) patients: A phase III trial. (Abstract #8020)M. Boccadoro, F. Cavallo, A. Nagler, D. Ben Yehuda, P. Omedè, M. Cavalli,A. Levi, C. Crippa, A. Siniscalchi, P. Brasca, A. M. Carella, B. Zanetti, F. Patriarca,S. Pezzati, V. Montefusco, A. Stanevsky, B. Lupo, T. Caravita, F. Di Raimondo,A. P. PalumboSurvival outcomes in elderly patients with plasma cell myeloma: The threedecadeEastern Cooperative Oncology Group (ECOG) experience. (Abstract#8021)E. L. Campagnaro, S. J. Jacobus, H. Uno, M. M. Oken, R. A. Kyle, S. V. Rajkumar,P. R. Greipp, D. H. Vesole, M. Weiss, R. Fonseca, H. M. LazarusBortezomib plus DA-EPOCH-rituximab followed by bortezomib maintenanceversus observation in previously untreated mantle cell lymphoma (MCL).(Abstract #8022)C. Grant, K. Dunleavy, M. Tweito, S. M. Steinberg, S. Pittaluga, E. S. Jaffe,A. Wiestner, W. H. WilsonActivity of vorinostat (SAHA), cladribine (2-CdA), and rituximab in previouslyuntreated mantle cell lymphoma: A phase I/II study. (Abstract #8023)S. E. Spurgeon, A. I. Chen, B. Ratterree, C. Okada, G. Palmbach, K. Diaz,N. Subbiah, C. Capper, E. E. EpnerGeneration of an automated tool for querying myeloma transcriptomics formultiple gene expression signatures used in risk stratification. (Abstract#8024)R. Fonseca, E. Braggio, J. J. Keats, G. J. Ahmann, J. Mantei, A. K. Stewart,P. L. BergsagelInterim results from PX-171-006, a phase (Ph) II multicenter dose-expansionstudy of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone(loDex) in relapsed and/or refractory multiple myeloma (R/R MM). (Abstract#8025)M. Wang, W. Bensinger, T. Martin, M. Alsina, D. S. Siegel, N. Y. Gabrail, P. Hari,S. Singhal, R. A. Vescio, S. E. Assouline, L. A. Kunkel, M. Vallone,A. Wong, R. NiesvizkyThe effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naiverelapsed or refractory multiple myeloma (MM): Updated results from thePX-171–004 study. (Abstract #8026)A. K. Stewart, J. L. Kaufman, A. J. Jakubowiak, S. Jagannath, V. Kukreti,K. T. McDonagh, M. Alsina, N. J. Bahlis, A. Belch, N. Y. Gabrail, F. J. Reu,J. Matous, D. H. Vesole, R. Z. Orlowski, L. A. Kunkel, M. Le, P. Lee, M. Sebag,M. Wang, R. Vij, The Multiple Myeloma Research Consortium (MMRC)PX-171–003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib(CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/RMM): Long-term follow-up and subgroup analysis. (Abstract #8027)D. S. Siegel, T. Martin, M. Wang, R. Vij, S. Lonial, V. Kukreti, N. J. Bahlis,M. Alsina, G. Somlo, F. Buadi, F. J. Reu, K. W. Song, L. A. Kunkel, A. Wong,M. Vallone, R. Z. Orlowski, A. K. Stewart, S. Singhal, S. Jagannath,A. J. Jakubowiak, The Multiple Myeloma Research Consortium (MMRC)Phase II study of carfilzomib (CFZ) in combination with current agents forrelapsed and refractory multiple myeloma (RRMM). (Abstract #8028)J. Szymonifka, S. Z. Usmani, R. Sexton, S. Panozzo, B. P. Nair, S. Waheed,Y. Alsayed, J. Crowley, B. BarlogieSATURDAY133

Saturday, June 4, 20118:00 AM - 1:00 PMPOSTER DISCUSSION SESSIONSarcomaDisplay Time: 8:00 AM - 12:00 PMDisplay Location: E450aDiscussion Time: 12:00 PM - 1:00 PMDiscussion Location: E354bCME credit: 1Track(s): SarcomaSATURDAYRobin L. Jones, MD—Co-ChairUniversity of WashingtonChristian Frederick Meyer, MD, PhD—Co-ChairThe Johns Hopkins UniversityDiscussion12:00 PM Jayesh Desai, MBBS (Abstracts #10009–10017)Royal Melbourne HospitalDiscussion12:15 PM Richard F. Riedel, MD (Abstracts #10019–10023)Duke University Medical CenterDiscussion12:30 PM Warren Allen Chow, MD (Abstracts #10024–10028)City of HopeDiscussion12:45 PM Leo Mascarenhas, MBBS, MD, MS (Abstracts #10029–10033)Children’s Hospital Los AngelesBrd. 1 Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of aUniversity of Chicago Phase II Consortium trial. (Abstract #10009)H. L. Kindler, N. P. Campbell, K. Wroblewski, R. G. Maki, D. R. D’Adamo,W. A. Chow, D. R. Gandara, C. Antonescu, W. M. Stadler, E. E. VokesBrd. 2 A phase II study of sorafenib in patients with metastatic or unresectablegastrointestinal stromal tumors with failure of both imatinib and sunitinib: AKGSG study. (Abstract #10010)M. Ryu, S. Park, B. Ryoo, S. Im, H. Kwon, S. Lee, B. Kang, Y. KangBrd. 3 An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) inpatients (pts) with metastatic and/or unresectable GIST. (Abstract #10011)G. D. Demetri, M. C. Heinrich, B. Chmielowski, J. A. Morgan, S. George,R. Bradley, R. K. Blackman, F. Teofilovici, J. A. Fletcher, W. D. Tap,M. von MehrenBrd. 4 The effect of crenolanib (CP-868596) on phosphorylation of the imatinibresistantD842V PDGFRA activating mutation associated with advancedgastrointestinal stromal tumors. (Abstract #10012)M. C. Heinrich, D. Griffith, A. McKinley, A. Presnell, A. RamachandranBrd. 5 Definition of an imatinib trough concentration threshold in the treatment ofadvanced gastrointestinal stromal tumors (GIST). (Abstract #10013)M. Molimard, S. Bouchet, S. Poulette, E. Chauzit, K. Titier, N. Moore, R. Lassalle,A. Abouelfath, A. Italiano, C. Chevreau, F. Duffaud, M. Rios, D. Cupissol,A. Adenis, I. L. Ray-Coquard, O. Bouche, A. Le Cesne, J. Blay, B. Bui NguyenBrd. 6 Correlation between imatinib trough levels and clinical benefit ingastrointestinal stromal tumors (GIST): Results of a prospective populationpharmacokinetic study. (Abstract #10014)K. Eechoute, M. N. Fransson, U. De Giorgi, A. K. Reyners, F. A. de Jong,L. E. Friberg, W. Van Der Graaf, A. Sparreboom, J. Verweij, W. J. Loos,R. Mathijssen134

Saturday, June 4, 2011Brd. 7Brd. 8Brd. 9Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16Brd. 17Time to secondary resistance (TSR) after interruption of imatinib (IM) inadvanced GIST: Updated results of the prospective French Sarcoma Grouprandomized phase III trial on long-term survival. (Abstract #10015)A. Le Cesne, I. Ray-Coquard, B. Bui Nguyen, A. Adenis, M. Rios, F. Bertucci,F. Duffaud, D. Cupissol, C. Chevreau, E. Bompas, A. Cioffi, S. Chabaud, D. Perol,J. BlayFollow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial ofimatinib mesylate (IM) in patients (pts) with metastatic or unresectable KITgastrointestinal stromal tumors (GIST). (Abstract #10016)M. von Mehren, M. C. Heinrich, H. Joensuu, C. D. Blanke, E. Wehrle,G. D. DemetriAn analysis of arterial hypertension and mutational status as predictivefactors for results of sunitinib (SU) therapy in gastrointestinal stromaltumors (GIST). (Abstract #10017)P. Rutkowski, E. Bylina, T. Switaj, A. Klimczak, S. Falkowski, J. Kroc,I. A. Lugowska, M. Brzeskwiniewicz, A. Wozniak, J. Siedlecki, J. LimonTumor response and outcome in localized high-risk soft tissue sarcomas(STS) treated with preoperative chemotherapy (CHT) with or withoutradiation therapy (RT) within a phase III trial from the Italian Sarcoma Group(ISG) and the Spanish Sarcoma Group (GEIS). (Abstract #10019)S. Stacchiotti, P. Verderio, A. Messina, C. Morosi, A. Ferraro, V. Quagliuolo,J. Martin, A. Comandone, G. Grignani, P. Picci, S. Frustaci, A. Gronchi,P. G. CasaliPreoperative chemoradiation therapy for localized retroperitoneal soft tissuesarcoma (RSTS): A phase II study from the Italian Sarcoma Group. (Abstract#10020)A. Gronchi, A. De Paoli, C. Dani, F. Merlo, V. Quagliuolo, G. Grignani, G. Bertola,P. Navarria, A. P. Dei Tos, P. G. Casali, Italian Sarcoma GroupEffect of FNCLCC grade 2 versus grade 3 on survival after neoadjuvantchemotherapy (NAC) plus or minus regional hyperthermia (RHT) in softtissue sarcomas (STS): An analysis of the EORTC-ESHO Intergroup phase IIIstudy. (Abstract #10021)R. D. Issels, R. P. Laubender, L. Lindner, U. Mansmann, E. Kampmann, J. Verweij,P. Reichardt, B. Schem, S. Daugaard, M. Niederhagen, Z. Vujaskovic,R. Wessalowski, C. M. Wendtner, K. Jauch, H. Duerr, R. Windhager,W. Hiddemann, J. Blay, P. HohenbergerA randomized clinical trial of adjuvant chemotherapy with doxorubicin,ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81randomized patients. (Abstract #10022)P. Pautier, A. Floquet, L. Gladieff, D. Berton-Rigaud, S. Piperno-Neumann,F. Selle, C. Guillemet, I. Ray-Coquard, B. Weber, P. Duvillard, C. Haie-Meder,A. ReySensitivity of well-differentiated/dedifferentiated liposarcoma (WD/DD) andmyxoid round cell/liposarcoma (MRCL) to high-dose ifosfamide: Combinedanalysis from two European referral institutions. (Abstract #10023)R. Sanfilippo, A. Constantinidou, R. Bertulli, P. Coco, E. Fumagalli, M. Scurr,C. Morosi, S. Pilotti, I. R. Judson, P. G. CasaliA phase II dose expansion of TH-302 in combination with doxorubicin in softtissue sarcoma. (Abstract #10024)L. D. Cranmer, K. N. Ganjoo, D. Adkins, D. R. Reed, S. H. Okuno,J. E. Butrynski, D. A. Rushing, G. A. Lorente, S. Kroll, S. P. ChawlaA phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma(LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor(MPNST). (Abstract #10025)D. R. D’Adamo, M. Keohan, R. D. Carvajal, M. L. Hensley, C. Hirst, L. Qin,C. Antonescu, R. A. Lefkowitz, G. K. Schwartz, R. G. MakiSATURDAY135

Saturday, June 4, 2011SATURDAYBrd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25A dose-finding study of temsirolimus and liposomal doxorubicin for patientswith advanced soft tissue or bone sarcoma. (Abstract #10026)D. M. Loeb, K. A. DeLorenzo, A. R. Chen, C. F. Meyer, J. PowellPhase I study of irinotecan and temsirolimus in patients with refractorysarcomas. (Abstract #10027)S. Movva, T. Bocklage, B. Schmit, R. Quinn, B. J. Liem, C. F. VerschraegenPhase II AIDS Malignancy Consortium trial of imatinib in AIDS-associatedKaposi’s sarcoma (KS). (Abstract #10028)H. B. Koon, K. Honda, J. Y. Lee, A. Noy, AIDS Malignancy ConsortiumUse of cellular context to determine sarcoma phenotype in a new mousesarcoma model. (Abstract #10029)S. Hettmer, J. Liu, C. M. Miller, R. T. Bronson, D. M. Langenau, A. J. WagersPhase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patientswith plexiform neurofibromas. (Abstract #10030)K. A. Robertson, D. C. Bowers, F. Yang, T. Vik, C. Ho, J. Croop, L. E. Walsh,C. Hingtgen, K. R. Pradhan, G. Hutchins, J. W. Fletcher, M. Cohen,M. Edwards-Brown, J. B. Travers, M. Yu, G. Nalepa, S. Denne, D. Ingram,W. ClappCixutumumab combined with temsirolimus in patients with refractoryEwing’s sarcoma. (Abstract #10031)A. Naing, P. LoRusso, S. Fu, D. S. Hong, P. M. Anderson, R. S. Benjamin,J. A. Ludwig, H. X. Chen, L. A. Doyle, R. KurzrockPreliminary safety and outcome report of the metronomic therapy from theLatin American osteosarcoma treatment protocol 2006. (Abstract #10032)A. S. Petrilli, C. R. Macedo, S. R. Toledo, P. C. Pavoni-Ferreira, M. Grings,M. Scopinaro, S. Ferman, E. Boldrini, M. A. Almeida, C. T. de Oliveira, G. L. Rey,L. A. Castillo, M. Borsato, J. Barreto, V. L. Morais, A. L. Brunetto, D. Lustosa,Grupo Latino Americano para Tratamento de Osteosarcoma GLATO/GALOPActivity of toremifene in sporadic desmoid-type fibromatosis. (Abstract#10033)M. Fiore, C. Colombo, S. Radaelli, P. Prestianni, R. Sanfilippo, C. Morosi,F. Perrone, S. Stacchiotti, P. G. Casali, A. Gronchi136

Saturday, June 4, 20119:30 AM - 12:00 PMSPECIAL SESSIONOpening Session with Presidential Address, NCI Director’s Address, David A.Karnofsky Memorial Award and Lecture, ASCO Humanitarian Award, and theConquer Cancer Foundation Donor Recognition AwardsLocation: Hall B1CME credit: 1.5Track(s): Special SessionKenneth Carl Anderson, MD—Karnofsky Award RecipientDana-Farber Cancer InstituteBench-to-Bedside Translation of Targeted Therapies in Multiple MyelomaSATURDAY137

Saturday, June 4, 20119:45 AM - 11:00 AMMEET THE PROFESSOR SESSIONThe Role of Prevention Services in U.S. Health Care Reform (M01)—TicketedSessionLocation: E451aCME credit: 1.25Track(s): Cancer Prevention/Epidemiology, Health Services ResearchSteven Stranne, MD, JDPolsinelli ShughartThe Role of Prevention in the New Health Care Reform BillSATURDAY138

9:45 AM - 11:00 AMCLINICAL PROBLEMS IN ONCOLOGY SESSIONPractical Approaches to the Patient with Complex Gynecologic Cancer(C03)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Gynecologic CancerNadeem Abu-Rustum, MD—ChairMemorial Sloan-Kettering Cancer CenterPractical Management of Late-stage Complications of Ovarian CancerSaturday, June 4, 2011Krishnansu Sujata Tewari, MDUniversity of California, Irvine Medical CenterTreatment Challenges in the Management of the Advanced Cervical Cancer PatientLinda R. Duska, MDUniversity of Virginia Health SystemConservative Management of a Young Patient with Endometrial Cancer: Fertility-sparingOptionsSATURDAY139

Saturday, June 4, 20111:00 PM - 4:00 PMORAL ABSTRACT SESSIONGastrointestinal (Colorectal) CancerLocation: Hall D1CME credit: 3Track(s): Gastrointestinal (Colorectal) CancerSATURDAYMichael J. Hall, MD—Co-ChairFox Chase Cancer CenterJohn S. Kauh, MD—Co-ChairWinship Cancer Institute of Emory University1:00 PM The impact of capecitabine and oxaliplatin in the preoperative multimodalitytreatment in patients with carcinoma of the rectum: NSABP R-04. (Abstract#3503)M. S. Roh, G. A. Yothers, M. J. O’Connell, R. W. Beart, H. C. Pitot,A. F. Shields, D. S. Parda, S. Sharif, C. J. Allegra, N. J. Petrelli, J. C. Landry,D. P. Ryan, A. Arora, T. L. Evans, G. S. Soori, L. Chu, R. V. Landes, M. Mohiuddin,S. Lopa, N. Wolmark1:15 PM Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvantchemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Longtermresults of a randomized, phase III trial. (Abstract #3504)R. Hofheinz, F. K. Wenz, S. Post, A. Matzdorff, S. Laechelt, J. T. Hartmann,L. Müller, H. Link, M. H. Moehler, E. Kettner, E. Fritz, U. Hieber, H. Lindemann,M. Grunewald, S. Kremers, C. Constantin, M. Hipp, D. Gencer, I. Burkholder,A. Hochhaus1:30 PM Preoperative chemoradiotherapy and postoperative chemotherapy with5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advancedrectal cancer: First results of the German CAO/ARO/AIO-04 randomizedphase III trial. (Abstract #LBA3505)C. Roedel, H. Becker, R. Fietkau, U.Graeven, W. Hohenberger, T. Hothorn,M. Lang-Welzenbach, T. Liersch, L. Staib, H. Christiansen, C. Wittekind, R. Sauer1:45 PM An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3–4rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD9203 trials: Surrogacy in question? (Abstract #3506)F. Bonnetain, J. Bosset, J. Gerard, G. Calais, T. Conroy, L. Mineur, O. Bouche,P. Maingon, O. Chapet, L. Radosevic-Jelic, N. Methy, L. ColletteDiscussion2:00 PM Robert Glynne-Jones, MD (Abstracts #3503–3506)Mount Vernon Centre for Cancer Treatment2:15 PM The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin(FU/L) in stage II colon cancer. (Abstract #3507)G. A. Yothers, C. J. Allegra, M. J. O’Connell, T. J. George, S. Sharif, N. J. Petrelli,S. Lopa, N. Wolmark2:30 PM Overall survival (OS) and updated disease-free survival (DFS) results of theNSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer.(Abstract #3508)C. J. Allegra, G. A. Yothers, M. J. O’Connell, S. Sharif, N. J. Petrelli,L. H. Colangelo, N. Wolmark2:45 PM A multinational, randomized phase III study of bevacizumab (Bev) withFOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for coloncancer (CC): Subgroup analyses from the AVANT trial. (Abstract #3509)T. Andre, E. Van Cutsem, H. Schmoll, J. Tabernero, S. Clarke, M. J. Moore,D. Cunningham, T. H. Cartwright, J. R. Hecht, F. Rivera, S. Im, G. Bodoky,R. Salazar, F. Maindrault-Goebel, E. Shmueli, E. Bajetta, M. Makrutzki,A. Shang, A. De Gramont, P. M. Hoff140

Saturday, June 4, 2011Discussion3:00 PM Howard S. Hochster, MD (Abstracts #3507–3509)Yale Cancer Center3:15 PM Final results from PRIME: Randomized phase III study of panitumumab(pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC).(Abstract #3510^)J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel,Y. Humblet, D. Cunningham, F. Xu, K. Krishnan3:30 PM Influence of KRAS G13D mutations on outcome in patients with metastaticcolorectal cancer (mCRC) treated with first-line chemotherapy with orwithout cetuximab. (Abstract #3511)S. Tejpar, C. Bokemeyer, I. Celik, M. Schlichting, U. Sartorius, E. Van CutsemDiscussion3:45 PM Tanios S. Bekaii-Saab, MD (Abstracts #3510^–3511)The Ohio State University Medical CenterSATURDAY141

Saturday, June 4, 20111:15 PM - 2:30 PMSPECIAL SESSIONPediatric Oncology Award and LectureLocation: S504CME credit: 1.25Track(s): Special Session, Pediatric OncologyLee J. Helman, MDCenter for Cancer Research, National Cancer InstitutePathways to New Targets for Pediatric SarcomasSATURDAY142

Saturday, June 4, 20111:15 PM - 2:30 PMEDUCATION SESSIONSDirect-to-Consumer Genetic Testing for Cancer: What Physicians Need toKnowLocation: E353CME credit: 1.25Track(s): Cancer Genetics, General OncologySancy Ann Leachman, MD—ChairUniversity of Utah Hospitals and ClinicsDirect-to-Consumer Genetic Testing for Cancer: The Consumer PerspectiveDaniel B. Vorhaus, JDRobinson, Bradshaw, & Hinson, P.A.A Guide to the (Current) Direct-to-Consumer Genetic Testing LandscapeStacy W. Gray, MDDana-Farber Cancer InstituteDirect-to-Consumer Genetic Testing: What We Know about Consumer Attitudes and BehaviorSATURDAYAngela R. Bradbury, MDFox Chase Cancer CenterDirect-to-Consumer Genetic Testing for Cancer: Clinical Implications and ChallengesManagement of Prostate Cancer in Older Adults: To Treat or Not to TreatLocation: S100bcCME credit: 1.25Track(s): Geriatric Oncology, Genitourinary CancerAnthony Victor D’Amico, MD, PhD—ChairDana-Farber Cancer Institute/Brigham and Women’s HospitalLocalized DiseaseWilliam Dale, MD, PhDThe University of Chicago Medical CenterScreeningShabbir M. H. Alibhai, MD, MScUniversity Health NetworkBiochemical RecurrenceNewer Techniques and Controversies in Breast and Lung Imaging for CancerScreening and PreventionLocation: S100aCME credit: 1.25Track(s): Cancer Prevention/Epidemiology, Breast Cancer, Lung CancerDenise R. Aberle, MD—ChairUniversity of California, Los Angeles David Geffen School of MedicineLung Cancer Screening and CT ImagingConstance D. Lehman, MD, PhDUniversity of WashingtonBreast Cancer Screening: Magnetic Resonance Imaging, Ultrasound, Mammography—WhereDo We Stand?143

Saturday, June 4, 2011Post–Health Care Reform: Facing the New RealityLocation: E354bCME credit: 1.25Track(s): Practice Management and Information Technology, Health Services ResearchTom Main, MBA—ChairOliver WymanPreparing Your Practice for Post–Health Care Reform: How Do Accountable CareOrganizations Work? How Do We Define and Manage Risk?Lee Nisley Newcomer, MDUnited Health GroupPayer Perspectives in OncologySATURDAYCecil Wilson, MDAmerican Medical AssociationResponse from the Medical CommunityThe Therapy of High-risk Patients with Lung CancerLocation: Hall B1CME credit: 1.25Track(s): Lung Cancer, Geriatric OncologyJeffrey Bogart, MD—ChairState University of New York Upstate Medical UniversityTailoring Radiotherapy for High-risk/Compromised Patients with Early-stage or LocallyAdvanced Non-small Cell Lung CancerCesare Gridelli, MDSG Moscati HospitalTherapy of Elderly Patients with Advanced Lung CancerRogerio Lilenbaum, MDCleveland Clinic FloridaImplications of Comorbidities and Performance Status in Patients with Advanced Lung Cancer144

Saturday, June 4, 20111:15 PM - 2:30 PMMEET THE PROFESSOR SESSIONCirculating Tumor Cells: We Have the Technology, But What Do We Do withthe Information? (M06)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Developmental Therapeutics, Breast Cancer, Genitourinary CancerDaniel F. Hayes, MDUniversity of Michigan Medical CenterSATURDAY1:15 PM - 2:30 PMCLINICAL PROBLEMS IN ONCOLOGY SESSIONSubsequent Therapy after Treatment of Lung Cancer: Consensus?(C04)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Lung CancerKenneth Rosenzweig, MD—ChairMount Sinai Medical CenterThe Role of Postoperative Radiation Therapy in the Patient with Resected Lung Cancer: When,Why, and How?Jessica S. Donington, MDNew York University School of MedicineSurgical Concerns for Adjuvant TherapyJoan H. Schiller, MDUniversity of Texas Southwestern Medical CenterAdjuvant Therapy: Who, What, When, and Why?145

Saturday, June 4, 20111:15 PM - 2:45 PMCLINICAL SCIENCE SYMPOSIUMOvarian Cancer: Novel Approaches to Improve Treatment OutcomesLocation: E354aCME credit: 1.5Track(s): Gynecologic CancerSATURDAYAmit M. Oza, MD—ChairPrincess Margaret Hospital1:15 PM Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from363 formalin-fixed paraffin embedded (FFPE) specimens. (Abstract #5000)C. Gourley, C. O. Michie, K. E. Keating, S. Deharo, E. J. O’Brien, A. Winter,F. A. McDyer, J. M. Mulligan, L. A. Hill, T. S. Davison, T. Halsey, L. McCoy,C. Wilson, A. Williams, D. J. Harrison, D. P. Harkin, R. D. KennedyDiscussion1:30 PM Patricia Shaw, MD (Abstract #5000)University Health Network1:45 PM Effect of screening on ovarian cancer mortality in the Prostate, Lung,Colorectal, and Ovarian (PLCO) cancer randomized screening trial. (Abstract#5001)S. S. Buys, E. Partridge, A. Black, C. Johnson, L. Lamerato, C. Isaacs, D. Reding,R. Greenlee, B. Kessel, M. Fouad, D. Chia, L. Ragard, J. Rathmell, P. Hartge,P. Pinsky, G. Izmirlian, J. Xu, P. Prorok, C. D. BergDiscussion2:00 PM Usha Menon, PhD, RN (Abstract #5001)UCL Elizabeth Garrett Institute of Women’s Health2:15 PM Randomized double-blind placebo-controlled international trial ofabagovomab maintenance therapy in patients with advanced ovarian cancerafter complete response to first-line chemotherapy: The MonoclonalAntibody Immunotherapy for Malignancies of the Ovary by SubcutaneousAbagovomab (MIMOSA) Trial. (Abstract #LBA5002)J. Pfisterer, J. S. Berek, A. Casado, K. Cwiertka, T. Pinter, A. Pluzanska,E. Pujade-Lauraine, G. Scambia, J. B. Vermorken, C. Simonelli, M. Bertolotti,A. Capriati, P. Sabbatini, AGO-OVAR, COGI, GEICO, GINECODiscussion2:30 PM George Coukos, MD, PhD (Abstract #LBA5002)University of Pennsylvania, Abramson Cancer Center146

Saturday, June 4, 20111:15 PM - 2:45 PMCLINICAL SCIENCE SYMPOSIUMTranslational Science Advancing AR Targeting in Prostate CancerLocation: Hall D2CME credit: 1.5Track(s): Genitourinary CancerMark Garzotto, MD—Co-ChairPortland Veterans Affairs Medical CenterWilliam Kevin Kelly, DO—Co-ChairThomas Jefferson University Hospital1:15 PM Abiraterone acetate (AA) in patients with metastatic castration-resistantprostate cancer (mCRPC) and prior therapy with ketoconazole: A ProstateCancer Clinical Trials Consortium study. (Abstract #4500)C. J. Ryan, A. L. Harzstark, A. M. Lin, L. Fong, K. Grycz, R. Z. Szmulewitz,V. K. Weinberg, A. Molina, E. J. SmallDiscussion1:30 PM Mary-Ellen Taplin, MD (Abstract #4500)Dana-Farber Cancer Institute1:45 PM MDV3100 effects on androgen receptor (AR) signaling and bone marrowtestosterone concentration modulation: A preliminary report. (Abstract#4501)E. Efstathiou, M. A. Titus, D. Tsavachidou, A. Hoang, M. Karlou, S. Wen,P. Troncoso, R. Ashe, C. J. Berman, J. Mohler, C. LogothetisDiscussion2:00 PM Christopher P. Evans, MD (Abstract #4501)University of California, Davis2:15 PM An evaluation of clusterin antisense inhibitor OGX-011 in combination withthe second-generation antiandrogen MDV3100 in a castrate-resistantprostate cancer model. (Abstract #4502)H. Matsumoto, H. Kuruma, A. Zoubeidi, L. Fazli, M. E. GleaveDiscussion2:30 PM Peter Nelson, MD (Abstract #4502)Fred Hutchinson Cancer Research CenterSATURDAY147

Saturday, June 4, 20111:30 PM - 4:00 PMORAL ABSTRACT SESSIONLymphomaLocation: S406CME credit: 2.5Track(s): Lymphoma and Plasma Cell DisordersSATURDAYMyron Stefan Czuczman, MD—Co-ChairRoswell Park Cancer InstituteGilles A. Salles, MD, PhD—Co-ChairHospices Civils de Lyon and Universite de Lyon1:30 PM R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for thetreatment of patients with newly diagnosed diffuse large B-cell non-Hodgkinlymphoma. (Abstract #8000)D. Cunningham, P. Smith, P. Mouncey, W. Qian, A. S. Jack, C. Pocock,K. Ardeshna, J. A. Radford, A. J. Davies, A. McMillan, M. D. Linch1:45 PM Randomized phase III U.S./Canadian intergroup trial (SWOG S9704)comparing CHOPR for eight cycles to CHOP with or without R for six cyclesfollowed by autotransplant for patients with high-intermediate (H-Int) or highIPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). (Abstract #8001)P. J. Stiff, J. M. Unger, J. Cook, L. S. Constine, S. Couban, T. C. Shea,J. N. Winter, T. P. Miller, R. R. Tubbs, D. C. Marcellus, J. W. Friedberg, K. Barton,G. M. Mills, M. L. LeBlanc, L. Rimsa, S. J. Forman, R. I. Fisher2:00 PM Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy(R-Mega-CHOEP) for young, high-risk patients with aggressive B-celllymphoma: Final results of the randomized Mega-CHOEP trial of the GermanHigh-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). (Abstract#8002)N. Schmitz, M. Nickelsen, M. Ziepert, M. Haenel, P. Borchmann, C. Schmidt,A. Viardot, M. Bentz, N. Peter, G. Ehninger, G. Doelken, L. H. Truemper,M. Loeffler, M. Pfreundschuh, B. Glass2:15 PM First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 foryoung adults with diffuse large B-cell lymphoma: Preliminary results of theGOELAMS 075 prospective multicenter randomized trial. (Abstract #8003)S. Le Gouill, N. Milpied, T. Lamy, V. Delwail, R. Gressin, D. Guyotat, G. Damaj,C. Foussard, G. Cartron, H. Maisonneuve, E. Deconinck, F. Dreyfus, E. Gyan,L. Sutton, N. Morineau, M. Alexis, F. Perry, M. SauvezieDiscussion2:30 PM Julie Vose, MD (Abstracts #8000–8003)University of Nebraska Medical Center2:45 PM Maintenance with rituximab after autologous stem cell transplantation inrelapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORALfinal analysis. (Abstract #8004)C. Gisselbrecht, B. Glass, G. Laurent, D. S. Gill, M. D. Linch, M. Trneny, D. Bron,O. Shpilberg, H. Hagberg, M. Bargetzi, D. Ma, J. Briere, C. Moskowitz, N. Schmitz3:00 PM Systemic and intrathecal chemotherapy followed by high-dosechemotherapy with autologous stem cell transplantation (HD-ASCT) for CNSrelapse of aggressive lymphomas: A potentially curative approach?(Abstract #8005)L. Fischer, M. Haenel, R. Moehle, R. Schroers, T. Elter, M. Reiser, M. H. Dreyling,G. Illerhaus, J. Eucker, C. W. Scholz, B. Metzner, A. Roeth, J. Birkmann,U. Schlegel, P. Martus, E. Thiel, A. KorfelDiscussion3:15 PM James L. Rubenstein, MD, PhD (Abstracts #8004–8005)University of California, San Francisco148

Saturday, June 4, 20113:30 PM Predictors of early response and event-free survival in Hodgkin lymphoma(HL): PET versus CT imaging. (Abstract #8006)C. L. Schwartz, D. L. Friedman, K. McCarten, S. L. Wolden, S. Voss,L. S. Constine, L. Chen, Children’s Oncology GroupDiscussion3:45 PM Bruce D. Cheson, MD (Abstract #8006)Georgetown University Medical CenterSATURDAY149

Saturday, June 4, 20111:30 PM - 4:30 PMORAL ABSTRACT SESSIONMelanoma/Skin CancersLocation: Arie Crown TheaterCME credit: 3Track(s): Melanoma/Skin CancersSATURDAYPaolo Antonio Ascierto, MD—Co-ChairIstituto Nazionale TumoriCaroline Robert, MD, PhD—Co-ChairInstitute Gustave-Roussy1:30 PM A population-based, case-control study of MC1R variants, ultraviolet lightexposure, and melanoma. (Abstract #8504)E. Ng, E. Vega-Saenz de Miera, B. Tan, W. Gai, J. D. Goldberg, I. Osman,M. Berwick, D. Lazovich, D. Polsky1:45 PM Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeksinduction only in patients with intermediate- and high-risk melanoma(Intergroup trial E 1697). (Abstract #8505)S. S. Agarwala, S. J. Lee, L. E. Flaherty, M. Smylie, R. F. Kefford, W. E. Carson III,G. Cohen, J. M. Kirkwood2:00 PM Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvanttreatment of stage III melanoma: A randomized phase III Italian MelanomaIntergroup (IMI) trial (ISRCTN75125874). (Abstract #8506)V. Chiarion-Sileni, M. Guida, A. Romanini, R. Ridolfi, M. Mandala, P. Del Bianco,B. Silvestri, M. Medici, M. Michiara, M. Dalla Palma, O. Puccetti, J. Pigozzo,F. Laveder, G. De Salvo, Italian Melanoma Intergroup2:15 PM EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-a2b(PEG-IFN) versus observation in resected stage III melanoma: Long-termresults at 7.6-years follow-up. (Abstract #8506b)A. M. Eggermont, S. Suciu, M. Santinami, W. Kruit, A. Testori, J. Marsden, C. J. A.Punt, M. E. Gore, R. MacKie, R. Dummer, D. Schadendorf, P. Patel, A. Spatz, andU. KeilholzDiscussion2:30 PM Helen Gogas, MD (Abstracts #8504–8506b)Hellenic Cooperative Oncology Group (HeCOG)2:45 PM Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes(young TIL) in metastatic melanoma patients. (Abstract #8510)R. Shapira-Frommer, M. Besser, I. Kuchuk, R. Nave, D. Zippel, A. Treves,A. Nagler, S. Apter, A. Shimoni, R. Yerushalmi, E. Ben-Ami, A. Ben-Nun,G. Markel, O. Itzhaki, R. Catane, J. Schachter3:00 PM A phase I trial of ipilimumab plus bevacizumab in patients with unresectablestage III or stage IV melanoma. (Abstract #8511)F. S. Hodi, P. A. Friedlander, M. B. Atkins, D. F. McDermott, D. P. Lawrence,N. Ibrahim, X. Wu, J. Zhou, A. Giobbie-Hurder, G. Murphy, T. Hollman,E. Velazquez, S. Russell, P. Dipiro, J. T. Yap, A. D. Van Den AbbeeleDiscussion3:15 PM Mario Sznol, MD (Abstracts #8510–8511)Yale Cancer Center3:30 PM BRAF mutation by age-decade and body mass index in metastaticmelanoma. (Abstract #8507)A. M. Menzies, L. Visintin, M. D. Chatfield, M. S. Carlino, J. R. Howle,R. A. Scolyer, J. F. Thompson, R. F. Kefford, G. V. Long150

Saturday, June 4, 20113:45 PM Results from the first-in-human (FIH) phase I study of the oral RAF inhibitorRAF265 administered daily to patients with advanced cutaneous melanoma.(Abstract #8508)W. H. Sharfman, F. S. Hodi, D. P. Lawrence, K. T. Flaherty, R. K. Amaravadi,K. B. Kim, R. Dummer, S. Gobbi, I. Puzanov, J. A. Sosman, K. Dohoney, L. P. Lam,S. Kakar, Z. Tang, O. Krieter, M. B. Atkins4:00 PM BRIM-2: An open-label, multicenter phase II study of vemurafenib inpreviously treated patients with BRAF V600E mutation-positive metastaticmelanoma. (Abstract #8509)A. Ribas, K. B. Kim, L. M. Schuchter, R. Gonzalez, A. C. Pavlick, J. S. Weber,G. A. McArthur, T. E. Hutson, K. T. Flaherty, S. J. Moschos, D. P. Lawrence,P. Hersey, R. F. Kefford, B. Chmielowski, I. Puzanov, J. Li, K. B. Nolop, R. J. Lee,A. K. Joe, J. A. SosmanDiscussion4:15 PM Gary K. Schwartz, MD (Abstracts #8507–8509)Memorial Sloan-Kettering Cancer CenterSATURDAY151

Saturday, June 4, 20112:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONBreast Cancer—Triple-negative/Cytotoxics/Local TherapyDisplay Time: 2:00 PM - 6:00 PMDisplay Location: E450bDiscussion Time: 5:00 PM - 6:00 PMDiscussion Location: Hall B1CME credit: 1Track(s): Breast CancerSATURDAYFatima Cardoso, MD—Co-ChairChampalimaud Cancer CenterKaren A. Gelmon, MD—Co-ChairBritish Columbia Cancer AgencyDiscussion5:00 PM Reshma Jagsi, MD, DPhil (Abstracts #1011–1014)University of MichiganDiscussion5:15 PM George Somlo, MD (Abstracts #1015–1021)City of HopeDiscussion5:30 PM Stephen K. L. Chia, MD (Abstracts #1022–1027)British Columbia Cancer AgencyDiscussion5:45 PM Ian E. Krop, MD, PhD (Abstracts #1028–1033)Dana-Farber Cancer InstituteBrd. 1 Early toxicity results with 3D conformal external beam therapy (CEBT) fromthe NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial.(Abstract #1011)T. B. Julian, J. P. Costantino, F. A. Vicini, J. R. White, K. A. Winter, D. W. Arthur,R. R. Kuske, R. Rabinovitch, D. S. Parda, E. P. Mamounas, W. J. Curran Jr.,N. WolmarkBrd. 2 Observation or standard axillary dissection after sentinel-node biopsy inbreast cancer: Final results from the German KISS study. (Abstract #1012)C. Schem, W. Jonat, H. Ostertag, on behalf of the German KISS study groupBrd. 3 Contralateral breast cancer risk in patients with familial breast cancer testednegative for BRCA1 and BRCA2. (Abstract #1013)K. Rhiem, C. Engel, M. Graeser, W. Janni, M. Kiechle, N. Ditsch, C. Mundhenke,R. Kreienberg, J. Tio, M. Golatta, A. Honig, D. Gadzicki, D. Speiser, K. Kast,S. Briest, A. Meindl, R. SchmutzlerBrd. 4 Patient and tumor characteristics associated with contralateral breast cancerin a nested population-based case-control study. (Abstract #1014)M. J. Junqueira, M. Morrow, A. S. Reiner, K. Malone, C. Lynch, J. L. Bernstein,The WECARE Study Collaborative GroupBrd. 5 Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment inpatients with basal-like breast cancer. GEICAM 2006-03: A multicenter,randomized phase II study. (Abstract #1015)E. Alba, J. Chacon, A. Lluch, L. Garcia-Estevez, A. Anton, B. Cirauqui,J. Lopez Garcia-Asenjo, E. M. Carrasco, C. Rodriguez, M. Escudero, A. Sanchez,N. Ribelles, C. Romero, J. Alvarez, J. Albanell, on behalf of Spanish Breast CancerResearch Group (GEICAM)152

Saturday, June 4, 2011Brd. 6 Open label, randomized clinical trial of standard neoadjuvant chemotherapywith paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxeland RAD001 followed by FEC (TR-FEC) in women with triple receptornegativebreast cancer (TNBC). (Abstract #1016)A. M. Gonzalez-Angulo, M. C. Green, J. L. Murray, S. L. Palla, K. H. Koenig,A. M. Brewster, V. Valero, N. K. Ibrahim, S. L. Moulder, J. K. Litton, D. J. Crawford,P. R. Flores, M. J. Dryden, W. F. Symmans, S. H. Giordano, L. Pusztai, A. Buzdar,G. B. Mills, G. N. Hortobagyi, F. Meric-BernstamBrd. 7 A randomized study of individually tailored toxicity-based dosage offluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for earlybreast cancer. (Abstract #1017)H. Lindman, M. Andersson, P. Edlund, K. D. Bjerre, T. Hatschek, H. T. Mouridsen,H. Anderson, B. Ejlertsen, S. Møller, E. Lidbrink, C. Kamby, J. Ahlgren, J. Bergh,C. BlomqvistBrd. 8 Intense dose-dense (idd) sequential chemotherapy with epirubicin (E),paclitaxel (T), and cyclophosphamide (C) (ETC) compared withconventionally scheduled chemotherapy in high-risk breast cancer patients(> 3LN): Eight-year follow-up analysis. (Abstract #1018)V. Moebus, C. Thomssen, H. Lueck, W. Kuhn, A. Junker-Stein, C. M. Kurbacher,U. Nitz, R. Kreienberg, M. Untch, C. Jackisch, J. B. Huober, A. Hinke, A. Du Bois,A. SchneeweissBrd. 9 Anthracyline (A) use among women with breast cancer (BC). (Abstract #1019)S. H. Giordano, Y. Lin, Y. Kuo, G. N. Hortobagyi, J. S. GoodwinBrd. 10 Final multivariate analysis of obesity and survival in patients with nodalpositiveprimary breast cancer: The ADEBAR trial. (Abstract #1020)J. W. Janni, P. G. Hepp, U. Andergassen, N. Harbeck, B. K. Rack,J. K. Neugebauer, K. Annecke, A. Wischnik, W. Simon, M. Rezai, T. N. Fehm,A. Schneeweiss, P. A. Fasching, B. Gerber, T. Zwingers, H. L. Sommer, K. Friese,M. KiechleBrd. 11 Molecular subtypes, body mass index (BMI), and their time-varyingprognostic impact in node-positive breast cancer (BC): Pooled analysis fromthe WSG AM-01 and -02 trials. (Abstract #1021)O. Gluz, C. Liedtke, R. E. Kates, J. B. Huober, S. Mohrmann, A. Hartmann,C. Thomssen, V. Moebus, U. Nitz, N. Harbeck, West German Study GroupBrd. 12 Local versus central laboratory discrepancies in the determination oftriple-negative breast cancer (TNBC) status in a large phase III(CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C)maintenance therapy after standard chemotherapy (CT) in early breastcancer (EBC) patients (pts). (Abstract #1022)M. Ruiz-Borrego, C. H. Barrios, A. Lluch, J. Bines, J. Segalla, A. Ruiz,L. Torrecillas, A. Llombart-Cussac, R. Torres, J. Garcia Saenz,J. Lopez Garcia-Asenjo, H. L. Gomez, J. De la Haba, S. Reyes, E. Martinez,J. Baena, L. Perez-Michell, A. Rodriguez-Lescure, A. Anton, M. Martin,on behalf of CIBOMA/GEICAMBrd. 13 Impact of low estrogen- and progesterone-receptor expression on survivaloutcomes in breast cancers previously classified as triple-negative breastcancers. (Abstract #1023)K. P. Raghav, L. F. Hernandez-Aya, X. Lei, M. Chavez-Mac Gregor,F. Meric-Bernstam, T. A. Buchholz, A. A. Sahin, K. Do, G. N. Hortobagyi,A. M. Gonzalez-AnguloBrd. 14 Bcl2 as a surrogate prognostic and predictive marker in triple-negativebreast cancer. (Abstract #1024)T. M. Abdel-Fatah, P. D. Dickinson, P. Moseley, J. S. Reis-Filho, A. R. Green,I. O. Ellis, S. ChanSATURDAY153

Saturday, June 4, 2011SATURDAYBrd. 15Brd. 16Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23TBCRC009: A multicenter phase II study of cisplatin or carboplatin formetastatic triple-negative breast cancer and evaluation of p63/p73 as abiomarker of response. (Abstract #1025)S. J. Isakoff, P. E. Goss, E. L. Mayer, T. A. Traina, L. A. Carey, K. Krag,H. S. Rugo, M. C. Liu, V. Stearns, S. E. Come, D. R. Borger, C. A. Quadrino,D. Finkelstein, J. E. Garber, P. D. Ryan, E. P. Winer, L. W. Ellisen, on behalf of theTranslational Breast Cancer Research ConsortiumFoxp3 expression in breast cancer cells: A new predictor of response toanthracycline versus docetaxel in primary breast cancer treated withadjuvant chemotherapy in the phase III trial FNCLCC/PACS-01. (Abstract#1026)F. Ghiringhelli, P. Fumoleau, L. Arnould, G. Mignot, C. Dalban, F. Bonnetain,H. H. Roche, M. Spielmann, C. Levy, A. Lortholary, F. Eichler, C. Mesleard,S. LadoireUse of topoisomerase 2 alpha (TOP2A) protein overexpression to predictresponse to anthracycline-based chemotherapy. (Abstract #1027)S. Chan, J. S. Reis-Filho, P. D. Dickinson, P. Moseley, A. R. Green, I. O. Ellis,T. M. Abdel-FatahCorrelation of various pathological complete response (pCR) definitions withlong-term outcome and the prognostic value of pCR in various breast cancersubtypes: Results from the German neoadjuvant meta-analysis. (Abstract#1028)G. Von Minckwitz, M. Kaufmann, S. Kuemmel, P. A. Fasching, W. Eiermann,J. U. Blohmer, S. D. Costa, J. Hilfrich, C. Jackisch, B. Gerber, A. Du Bois,J. B. Huober, C. A. Hanusch, G. E. Konecny, W. Fett, E. Stickeler, N. Harbeck,K. Mehta, S. Loibl, M. Untch, GBG and AGO-B study groupsMultigene predictors developed on breast cancer cell lines to predict patientchemotherapy response: A validation study on the NSABP B-27 trial.(Abstract #1029)K. Shen, G. Tang, J. P. Costantino, S. J. Anderson, C. Kim, K. L. Pogue-Geile,N. Song, M. J. Gabrin, C. E. Geyer, N. WolmarkBlinded validation study of genomic predictions for survival followingadjuvant sequential anthracycline-docetaxel chemotherapy /- endocrinetherapy. (Abstract #1030)W. F. Symmans, F. Andre, M. C. Liu, J. Delacruz, F. Peintinger, S. Borstnar,H. Wang, P. Regitnig, M. Ota, S. Seevaratnam, S. Delaloge, C. HatzisBenefit from CMF with or without anthracyclines in relation to biologicprofiles in early breast cancer. (Abstract #1031)A. Rocca, A. Paradiso, P. Sismondi, E. Scarpi, A. Mangia, L. Medri, S. Bravaccini,D. Casadei Giunchi, D. Amadori, R. SilvestriniThe responsiveness of intrinsic subtypes to adjuvant anthracyclines versusnonanthracyclines in NCIC.CTG MA.5 randomized trial. (Abstract #1032)M. Cheang, D. Voduc, D. Tu, S. Jiang, S. Leung, S. K. Chia, L. E. Shepherd,M. N. Levine, K. I. Pritchard, T. Vickery, S. Davies, I. J. Stijleman,C. Davis, J. S. Parker, M. J. Ellis, P. S. Bernard, C. M. Perou, T. O. NielsenPrognostic relevance of circulating tumor cells (CTC) before adjuvantchemotherapy in patients with breast cancer patients: Results of the GermanSUCCESS trial. (Abstract #1033)J. K. Jueckstock, B. K. Rack, T. Zwingers, P. G. Hepp, A. Schneeweiss,M. W. Beckmann, W. Lichtenegger, H. L. Sommer, K. Pantel, H. Tesch,H. Forstbauer, R. Lorenz, M. Rezai, J. K. Neugebauer, U. Andergassen, K. Friese,W. Janni, SUCCESS Study Group154

Saturday, June 4, 2011Brd. 24Brd. 25Antitumor activity in a randomized phase II study comparing two schedulesof NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).(Abstract #1034)A. Awada, S. Chan, G. H. Jerusalem, R. E. Coleman, M. T. Huizing, A. Mehdi,S. M. O’Reilly, J. T. Hamm, P. J. Barrett-Lee, V. Cocquyt, K. Sideras, D. E. Young,M. Brown, C. Zhao, A. L. Hannah, L. K. Masuoka, A. Garcia, E. A. Perez,NKTR-102 Study GroupRelationship between OS and PFS in metastatic breast cancer (MBC): Reviewof FDA submission data. (Abstract #1035)P. Cortazar, J. J. Zhang, R. Sridhara, R. L. Justice, R. PazdurSATURDAY155

Saturday, June 4, 20112:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONDevelopmental Therapeutics—Experimental TherapeuticsDisplay Time: 2:00 PM - 6:00 PMDisplay Location: S403Discussion Time: 5:00 PM - 6:00 PMDiscussion Location: S406CME credit: 1Track(s): Developmental TherapeuticsSATURDAYR. Donald Harvey, PharmD—Co-ChairWinship Cancer Institute at Emory UniversityJan H. M. Schellens, MD, PhD—Co-ChairNetherlands Cancer InstituteDiscussion5:00 PM Patrick Schoffski, MD, MPH (Abstracts #3011–3016)University Hospitals LeuvenDiscussion5:15 PM Lillian L. Siu, MD (Abstracts #3017–3024)Princess Margaret HospitalDiscussion5:30 PM Carlos L. Arteaga, MD (Abstracts #3025–3029)Vanderbilt-Ingram Cancer CenterDiscussion5:45 PM Mark J. Ratain, MD (Abstracts #3030–3032)The University of ChicagoBrd. 1 First human dose (FHD) study of the oral transforming growth factor-betareceptor I kinase inhibitor LY2157299 in patients with treatment-refractorymalignant glioma. (Abstract #3011)J. Rodon Ahnert, J. Baselga, E. Calvo, J. Seoane, I. Brana, E. Sicart,I. Gueorguieva, A. Cleverly, M. M. Lahn, S. Pillay, M. Holdhoff, J. O. Blakeley,M. A. CarducciBrd. 2 A first-in-human phase I dose-escalation study of MK-1496, first-in-classorally available novel PLK1 inhibitor, in patients with advanced solid tumors.(Abstract #3012)T. Doi, H. Murakami, K. Wan, M. Miki, H. Kotani, N. Sakamoto, N. Yamamoto,A. OhtsuBrd. 3 MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, inpatients (pts) with advanced solid tumors: Phase I study of multipletreatment schedules. (Abstract #3013)J. S. Kauh, G. Shapiro, R. B. Cohen, J. W. Clark, R. Harvey, J. M. Cleary,D. Mahalingam, S. Kuan, A. McDonald, A. Berger, B. Dezube, J. SarantopoulosBrd. 4 A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients(pts) with advanced or metastatic solid tumors. (Abstract #3014)C. M. Rudin, A. Jimeno, W. H. Miller Jr., B. J. Eigl, S. N. Gettinger, A. L. Chang,K. Faia, J. Sweeney, G. Loewen, R. W. Ross, G. J. WeissBrd. 5 Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cellmalignancies. (Abstract #3015)D. Mahadevan, E. G. Chiorean, W. Harris, D. D. Von Hoff, A. Younger,D. M. Rensvold, F. Cordova, W. Qi, C. F. Shelton, M. D. Becker, J. R. Garlich,R. K. RamanathanBrd. 6 Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomizeddose-ranging trial of sorafenib (S). (Abstract #3016)M. L. Maitland, T. Karrison, G. L. Bakris, K. Fox, L. A. Janisch, S. Karovic,M. R. Levine, L. House, J. J. Wright, E. E. Cohen, G. F. Fleming, T. Y. Seiwert,V. M. Villaflor, W. M. Stadler, M. J. Ratain156

Saturday, June 4, 2011Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trialof a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastaticsolid tumor. (Abstract #3017)S. Leijen, M. R. Middleton, P. Tresca, F. Kraeber-Bodere, V. Dieras,M. E. Scheulen, J. Tessier, Z. X. Xu, E. Shochat, A. Walz, J. Deutsch, S. Blotner,V. Lopez Valverde, V. M. Naegelen, J. H. Schellens, W. E. EberhardtPhase I first-in-human study of the PI3 kinase inhibitor GSK2126458(GSK458) in patients with advanced solid tumors (study P3K112826).(Abstract #3018)P. N. Munster, R. van der Noll, E. E. Voest, E. C. Dees, A. R. Tan, J. M. Specht,G. S. Falchook, A. Daud, M. P. Lolkema, J. E. Grilley-Olson, E. Y. Yu, S. Fu,E. K. Bergsland, J. Kleha, S. Peng, D. A. Smith, T. A. Lampkin, J. H. Schellens,S. R. Morris, R. KurzrockSafety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, inpatients with advanced malignancies. (Abstract #3019)N. Houede, S. J. Faivre, A. Awada, E. Raymond, A. Italiano, T. Besse-Hammer,M. Donica, N. Rejeb, C. Luepfert, S. Ongarello, J. DelordA first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTORinhibitor, administered QD in patients with advanced solid tumors. (Abstract#3020)A. J. Wagner, J. C. Bendell, S. Dolly, J. A. Morgan, J. A. Ware, J. Fredrickson,K. E. Mazina, J. O. Lauchle, H. A. Burris III, J. S. De BonoA phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase(PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.(Abstract #3021)V. Moreno Garcia, R. D. Baird, K. J. Shah, B. Basu, N. Tunariu, M. Blanco,P. A. Cassier, J. V. Pedersen, M. Puglisi, D. Sarker, D. Papadatos-Pastos,A. G. Omlin, A. Biondo, J. A. Ware, H. Koeppen, G. G. Levy, K. E. Mazina,J. S. De BonoFirst-in-human phase I study evaluating the safety, pharmacokinetics (PK),and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitiveAkt inhibitor GDC-0068. (Abstract #3022)J. Tabernero, C. Saura, D. Roda Perez, R. Dienstmann, S. Rosello, L. Prudkin,J. A. Perez-Fidalgo, B. Graña, C. Jones, L. Musib, Y. Yan, P. H. Patel, J. Baselga,A. CervantesFinal results of a first-in-human phase I trial of PBI-05204, an inhibitor ofAKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients. (Abstract#3023)H. A. Henary, R. Kurzrock, G. S. Falchook, A. Naing, S. L. Moulder, J. J. Wheler,A. M. Tsimberidou, J. Durand, P. Yang, M. Johansen, R. Newman, R. Khan,U. Patel, D. S. HongA first-in-human phase I study of JNJ-26481585, a novel oral histonedeacetylase inhibitor (HDACi), in patients with advanced cancer withevidence of target modulation and antitumor activity. (Abstract #3024)R. D. Baird, B. Venugopal, R. S. Kristeleit, J. Charlton, M. Blanco-Codesido,E. Saunders, K. J. Shah, D. Crawford, P. Stephens, D. Wilkins, L. Sweeting,A. Forslund, J. W. Smit, P. A. Palmer, N. Fourneau, P. Hellemans, J. S. De Bono,R. Plummer, U. Banerji, T. EvansPhase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic forsolid tumors with liver involvement. (Abstract #3025)A. Cervantes, M. Alsina, J. Tabernero, J. R. Infante, P. LoRusso, G. Shapiro,L. G. Paz-Ares, R. Falzone, J. Hill, J. Cehelsky, A. White, I. Toudjarska,D. Bumcrot, R. Meyers, G. Hinkle, N. Svrzikapa, D. W. Sah, A. Vaishnaw,J. Gollob, H. A. Burris IIIA first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, inpatients (pts) with advanced solid tumors. (Abstract #3026)J. Berlin, V. L. Keedy, P. A. Janne, L. Yee, N. A. Rizvi, X. Jin, C. Copigneaux,T. Hettmann, D. M. Beaupre, P. LoRussoSATURDAY157

Saturday, June 4, 2011SATURDAYBrd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Two-dimensional phase I study of neratinib (NER) combined withtemsirolimus (TEM) in patients (Pts) with solid tumors. (Abstract #3027)L. Gandhi, R. Bahleda, J. M. Cleary, A. Hollebecque, E. L. Kwak, S. Pandya,S. Tolaney, R. Abbas, R. Ananthakrishnan, A. Berkenblit, J. Boni, J. Clancy,K. W. Turnbull, M. VoVan, G. Shapiro, J. SoriaA phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumaband lapatinib in patients with HER2-positive solid tumors. (Abstract #3028)H. S. Han, C. Swanton, Y. Y. Janjigian, S. C. Sutherland, S. Chandarlapaty,R. Lehman, N. Hamilton, J. Knowles, R. Lee, L. Yan, D. Sullivan, C. HudisA phase I study of doxorubicin-loaded anti-EGFR immunoliposomes inpatients with advanced solid tumors. (Abstract #3029)C. Mamot, R. Ritschard, B. Vogel, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster,R. Herrmann, C. RochlitzA phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic(PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered incombination with pemetrexed and carboplatin. (Abstract #3030)L. H. Brail, J. E. Gray, H. Burris, G. R. Simon, J. Cooksey, S. F. Jones,D. Farrington, T. Lam, K. Jackson, K. Chow, J. T. Brandt, J. R. InfantePhase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, incombination with cisplatin or carboplatin in patients with advanced solidtumors. (Abstract #3031)A. Deleporte, H. Dumez, A. Awada, J. Costermans, M. Meeus, T. Berghmans,M. Ould Kaci, N. Juhel, A. Berge, T. Taube, P. SchöffskiDetermination of the maximum tolerated dose (MTD) of MGCD265, an oralMet/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combinationwith docetaxel. (Abstract #3032)D. W. Rasco, A. Patnaik, R. K. Amaravadi, K. P. Papadopoulos, N. B. Haas,A. W. Tolcher, M. Beeram, K. Harlacker, M. A. Drouin, M. Tawashi, J. Wang,A. Karam, C. R. Maroun, C. Bonfils, M. Mehran, J. M. Besterman, P. J. O’Dwyer158

Saturday, June 4, 20112:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONGenitourinary (Prostate) CancerDisplay Time: 2:00 PM - 6:00 PMDisplay Location: E450aDiscussion Time: 5:00 PM - 6:00 PMDiscussion Location: Hall D2CME credit: 1Track(s): Genitourinary CancerLeonard Joseph Appleman, MD, PhD—Co-ChairUniversity of PittsburghIwona Anna Skoneczna, MD—Co-ChairInstitute of OncologyDiscussion5:00 PM Daniel W. Lin, MD (Abstracts #4521–4524)University of WashingtonDiscussion5:15 PM William K. Oh, MD (Abstracts #4525^–4530)Mount Sinai Medical CenterDiscussion5:30 PM Charles J. Ryan, MD (Abstracts #4531–4535)University of California, San FranciscoDiscussion5:45 PM Philip W. Kantoff, MD (Abstracts #4536–4545)Dana-Farber Cancer InstituteBrd. 1 Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) inlocalized intermediate-risk prostate cancer? Intermediary analysis of GETUG14 randomized trial (EU-20503/NCT00104741). (Abstract #4521)B. M. Dubray, V. Beckendorf, S. Guerif, E. Le Prise, A. Reynaud-Bougnoux,J. Hannoun Levi, T. D. Nguyen, C. Hennequin, J. Cretin, M. Fayolle-Campana,J. Lagrange, J. Bachaud, D. Azria, A. Grangirard, P. Pommier, J. Simon, V. Harter,M. Habibian, Groupe d’Etude des Tumeurs Uro-GenitalesBrd. 2 A phase II study of pomegranate extract for men with rising prostate-specificantigen following primary therapy. (Abstract #4522^)C. J. Paller, X. Ye, P. Wozniak, B. Gillespie, P. Sieber, R. Greengold, B. Stockton,B. Hertzman, M. Efros, R. Roper, H. Liker, M. A. CarducciBrd. 3 Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versusHT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Finalresults on PSA progression-free survival (Abstract #4523)S. Oudard, I. Latorzeff, P. Beuzeboc, E. Banu, A. Caty, E. Sevin, R. Delva,F. Rolland, F. Priou, R. Elaidi, S. CulineBrd. 4 PSA response and early PSA progression evaluated in patients randomizedin a phase III trial comparing androgen deprivation therapy (ADT) plusdocetaxel versus ADT alone in hormone-naive metastatic prostate cancer(GETUG-AFU 15/0403). (Abstract #4524)G. Gravis, K. Fizazi, F. Joly, S. Oudard, F. Priou, I. Latorzeff, R. Delva, B. Esterni,M. Habibian, M. SoulieBrd. 5 Survival benefit from first docetaxel treatment for cabazitaxel plusprednisone compared with mitoxantrone plus prednisone in patients withmetastatic castration-resistant prostate cancer (mCRPC) enrolled in theTROPIC trial. (Abstract #4525^)A. O. Sartor, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen,J. S. De Bono, For the TROPIC investigatorsSATURDAY159

Saturday, June 4, 2011SATURDAYBrd. 6Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16A subgroup analysis of the TROPIC trial exploring reason for discontinuationof prior docetaxel and survival outcome of cabazitaxel in metastaticcastration-resistant prostate cancer (mCRPC). (Abstract #4526^)J. S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen,A. O. Sartor, for the TROPIC investigatorsPhase III, randomized, open-label study of triweekly versus biweeklydocetaxel (T) as a treatment for advanced hormone-refractory prostatecancer (HRPC): Final analysis of the Finnish Uro-oncological Group Study1-2003. (Abstract #4527)P. Kellokumpu-Lehtinen, U. Harmenberg, T. K. Joensuu, R. McDermott,P. Hervonen, C. Ginman, M. Luukkaa, P. Nyandoto, T. Luukkaala, H. Joensuu,Prosty study groupA randomized, double-blind phase II trial of docetaxel plus prednisone (DP)combined with either AT-101 or placebo for the first-line therapy ofmetastatic castration-resistant prostate cancer (CRPC) (Abstract #4528)G. Sonpavde, V. B. Matveev, J. M. Burke, J. R. Caton, M. T. Fleming, P. A. Karlov,J. Holmlund, B. A. Wood, M. Brookes, L. H. LeopoldFinal results on phase II study of a weekly schedule of ixabepilone in patientswith metastatic castrate-refractory prostate cancer (E3803): A trial of theEastern Cooperative Oncology Group. (Abstract #4529)G. Liu, Y. Chen, R. S. DiPaola, M. A. Carducci, G. Wilding, Eastern CooperativeOncology GroupTolerability and efficacy of chemotherapy in older men with metastaticcastrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. (Abstract#4530)B. Seruga, A. M. Horgan, G. R. Pond, S. M. Alibhai, E. Amir, R. De Wit,M. A. Eisenberger, I. TannockSafety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updateddata from a phase I/II study. (Abstract #4531)D. B. Agus, W. M. Stadler, D. H. Shevrin, L. Hart, G. R. MacVicar, O. Hamid,J. D. Hainsworth, M. E. Gross, J. Wang, L. de Leon, D. MacLean, R. DreicerA noncomparative randomized phase II study of two dose levels ofitraconazole in men with metastatic castration-resistant prostate cancer(mCRPC): A DOD/PCCTC trial. (Abstract #4532)E. S. Antonarakis, E. I. Heath, D. C. Smith, D. E. Rathkopf, A. L. Blackford,D. C. Danila, S. King, A. Frost, M. A. Carducci, Prostate Cancer Clinical TrialsConsortium (PCCTC)Effect of denosumab versus zoledronic acid in patients with castrateresistantprostate cancer and bone metastases: Subgroup analyses by priorSRE and baseline pain. (Abstract #4533)N. D. Shore, M. R. Smith, M. Jievaltas, K. Fizazi, R. Damião, J. Chin, K. Miller,J. P. Maroto, Y. Qian, A. Feng, K. Chung, C. D. GoesslPost-progression treatment with APC8015F may have prolonged survival ofsubjects in the control arm of sipuleucel-T phase III studies. (Abstract #4534)L. G. Gomella, C. Nabhan, J. B. Whitmore, M. W. Frohlich, D. J. GeorgeFinal analysis of a phase I/IIa study with CV9103, an intradermallyadministered prostate cancer immunotherapy based on self-adjuvantedmRNA. (Abstract #4535)H. Kübler, T. Maurer, A. Stenzl, S. Feyerabend, U. Steiner, M. Schostak,W. Schultze-Seemann, F. vom Dorp, L. Pilla, G. Viatali, C. Hampel, S. Wedel,L. Trojan, K. Hiller, M. Sommerauer, D. Jocham, B. Scheel, T. Lander, K. Kallen,K. MillerMolecular characterization of neuroendocrine prostate cancer (NEPC) andidentification of new drug targets. (Abstract #4536)H. Beltran, D. Rickman, K. Park, A. Sboner, T. Macdonald, S. T. Tagawa,M. B. Gerstein, F. Demichelis, D. M. Nanus, M. A. Rubin160

Saturday, June 4, 2011Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25Validation of NF-kappaB p65 as a prostate cancer prognostic marker on alarge European cohort. (Abstract #4537)P. O. Gannon, L. Lessard, V. Forest, L. R. Begin, T. Schlomm, S. Minner,M. Graefen, A. Mes-Masson, F. SaadAssociation of angiotensin II blockers with survival among men with prostatecancer: Results from CaPSURE. (Abstract #4538)A. Bardia, J. E. Cowan, P. Carroll, A. V. D’Amico, M. A. CarducciA six-gene panel that predicts survival in men with castration-resistantprostate cancer. (Abstract #4539)S. K. Subudhi, G. Heller, A. Anand, D. C. Danila, M. Fleisher, H. I. ScherGenomic analysis of circulating tumor cells (CTC) from patients withcastration-resistant prostate cancer (CRPC) as predictive biomarkers.(Abstract #4540)D. C. Danila, A. Anand, J. Yao, M. Gierszewska, M. Kramer, S. Muller, M. Fleisher,W. R. McCombie, H. I. ScherUse of TMPRSS2-ERG gene rearrangement and quantitative ERG expressionto predict clinical recurrence after radical prostatectomy. (Abstract #4541)S. M. Falzarano, C. Magi-Galluzzi, W. F. Novotny, T. Maddala, D. B. Cherbavaz,C. Millward, E. A. KleinPrognostic value of a 46-gene cell cycle progression (CCP) RNA signaturefor prostate cancer death in a conservatively managed watchful waitingneedle biopsy cohort. (Abstract #4542)J. M. Cuzick, G. Fisher, D. Berney, D. Mesher, H. Møller, J. E. Reid, A. Gutin,J. S. Lanchbury, S. StoneRisk of second primary malignancy in U.S. men diagnosed with prostatecancer from 1992 to 2007. (Abstract #4543)E. Davis, C. A. Salinas, L. A. Okoth, K. A. CooneyRacial disparities in prostate cancer treatment: The contribution ofinappropriate care. (Abstract #4544)C. J. Presley, A. C. Raldow, L. D. Cramer, P. R. Soulos, J. B. Long,D. V. Makarov, J. B. Yu, C. P. GrossPARP inhibition reverses radiation resistance conferred by ETS fusions inprostate cancer. (Abstract #4545)F. Y. Feng, S. Han, C. Brenner, A. Sabolch, D. A. Hamstra, T. S. Lawrence,A. ChinnaiyanSATURDAY161

Saturday, June 4, 20112:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONTumor BiologyDisplay Time: 2:00 PM - 6:00 PMDisplay Location: S103Discussion Time: 5:00 PM - 6:00 PMDiscussion Location: S100bcCME credit: 1Track(s): Tumor BiologySATURDAYCharles D. Lopez, MD, PhD—Co-ChairOregon Health Science UniversityJoseph A. Sparano, MD—Co-ChairAlbert Einstein College of MedicineDiscussion5:00 PM Matthew James Ellis, MB, BChir, PhD (Abstracts #10509–10516)Washington University Medical CenterDiscussion5:15 PM Robert Arthur Kratzke, MD (Abstracts #10517–10521)University of MinnesotaDiscussion5:30 PM David B. Solit, MD (Abstracts #10522–10527)Memorial Sloan-Kettering Cancer CenterDiscussion5:45 PM Ravi Salgia, MD, PhD (Abstracts #10528–10533)The University of ChicagoBrd. 1 Use of gene expression patterns post neoadjuvant chemotherapy to identifya role for the MAPK phosphatase DUSP4 in therapeutic resistance and astem-like phenotype in basal-like breast cancer (BLBC). (Abstract #10509)J. M. Balko, R. S. Cook, T. W. Miller, N. E. Bhola, M. Sanders,N. M. Granja-Ingram, V. Sanchez, I. M. Meszoely, J. Salter, M. Dowsett,K. Stemke-Hale, A. M. Gonzalez-Angulo, G. B. Mills, C. L. ArteagaBrd. 2 Early drop of circulating tumor cells (CTC) and increase of circulatingendothelial cells (CEC) during neoadjuvant chemotherapy (CT) combinedwith bevacizumab in HER2-negative inflammatory breast cancer (IBC) inmulticenter phase II trial BEVERLY 1. (Abstract #10510)J. Pierga, F. Bidard, F. Andre, T. Petit, F. Dalenc, T. Delozier, G. Romieu,J. Bonneterre, J. Ferrero, P. Kerbrat, A. Martin, P. ViensBrd. 3 Identification of a novel breast cancer molecular subgroup associated with adeficiency in DNA-damage response. (Abstract #10511)J. M. Mulligan, L. A. Hill, S. Deharo, F. A. McDyer, T. S. Davison, M. Bylesjo,N. M. Lindor, L. Galligan, T. Delaney, I. A. Halfpenny, V. Farztdinov, N. Goffard,V. Proutski, K. E. Keating, P. B. Mullan, J. E. Quinn, P. G. Johnston, F. J. Couch,D. P. Harkin, R. D. KennedyBrd. 4 Improving detection methods for PIK3CA mutations in breast cancer usingperipheral blood from patients with metastastic breast cancer (MBC).(Abstract #10512)M. J. Higgins, D. Jelovac, E. Barnathan, B. Blair, S. Slater, P. Powers, J. Zorzi,S. C. Jeter, G. R. Oliver, F. Diehl, P. Angenendt, P. Huang, P. Argani, K. Murphy,A. C. Wolff, B. H. ParkBrd. 5 Quantitative copy number analysis by multiplex ligation-dependent probeamplification (MLPA) of BRCA1-associated breast cancer regions identifiesBRCAness, and as such treatment response. (Abstract #10513)E. H. Lips, L. Mulder, S. A. Joosse, S. Savola, M. A. Vollebergh, L. F. Wessels,J. Wesseling, P. M. Nederlof, S. Rodenhuis162

Saturday, June 4, 2011Brd. 6 Separation of breast cancer from normal tissues using GC-MS-basedmetabolite profiling. (Abstract #10514)J. Budczies, C. Denkert, B. Mueller, S. F. Brockmoeller, M. Dietel, C. Radke,S. Loibl, G. Von Minckwitz, J. L. Griffin, M. Oresic, G. Wohlgemut, O. FiehnBrd. 7 Global gene expression analysis of heterotypic interaction between cancercells and osteoblasts in vitro to detect signaling pathways relevant for bonemetastasis in breast cancer patients. (Abstract #10515)M. Buess, M. Rajski, B. Vogel, C. RochlitzBrd. 8 Targeting -catenin/CBP interaction in breast cancer. (Abstract #10516)A. Ring, O. Evgrafov, J. Knwoles, M. KahnBrd. 9 Concomitant EGFR mutation and EML4-ALK gene fusion in non-small celllung cancer. (Abstract #10517)J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. WuBrd. 10 Changes in molecular profile following platinum chemotherapy in NSCLC.(Abstract #10518)W. Huang, M. Skokan, Y. Chang, C. Wu, J. Lee, W. Feser, A. E. Barón, P. A. Bunn,M. Varella-GarciaBrd. 11 Insulin-like growth factor receptor-1 (IGF1R) and epidermal growth factorreceptor (EGFR) amplification and expression in surgically resected NSCLC.(Abstract #10519)V. Ludovini, A. Flacco, F. Bianconi, F. R. Tofanetti, M. Ragusa, J. Vannucci,G. Bellezza, M. G. Mameli, R. Chiari, V. Minotti, L. Pistola, A. Siggillino, E. Baldelli,A. Sidoni, F. Puma, M. Varella-Garcia, L. CrinóBrd. 12 Large-scale screening of ALK fusion oncogene transcripts in archivalNSCLC tumor specimens using multiplexed RT-PCR assays. (Abstract#10520)T. Li, P. C. Mack, S. Desai, K. Kelly, J. Cooc, P. V. Danenberg, K. D. Danenberg,D. R. GandaraBrd. 13 Blind prediction of response to erlotinib in early-stage non-small cell lungcancer (NSCLC) in a neoadjuvant setting based on kinase activity profiles.(Abstract #10521)R. Hilhorst, E. Schaake, R. van Pel, P. M. Nederlof, L. Houkes, M. Mommersteeg,R. de Wijn, M. van den Heuvel, P. Baas, R. Ruijtenbeek, H. M. KlompBrd. 14 Evaluation of p53 mutation as a predictive biomarker for outcome tochemotherapy in ovarian cancer. (Abstract #10522)A. H. Calvert, J. C. Jackson, C. Hutton, A. Swart, W. Qian, C. Kwakye, R. Fossati,A. Lissoni, P. G. Harper, N. Colombo, R. J. Edmondson, J. LunecBrd. 15 Molecular testing for BRAF V600 mutations in the BRIM-2 trial of the BRAFinhibitor vemurafenib in metastatic melanoma. (Abstract #10523)K. J. Bloom, S. M. Anderson, R. C. Schilling, J. Lee, H. Halait, S. Cheng,R. A. Langland, H. LawrenceBrd. 16 Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants.(Abstract #10524)M. Del Re, F. Loupakis, A. Michelucci, A. Di Paolo, A. Falcone, P. Simi, G. Bocci,M. Cantore, R. Bordonaro, A. Di Leo, C. Barbara, F. Cappuzzo, F. G. De Braud,R. DanesiBrd. 17 Circulating protein biomarkers of sunitinib (SU) and interferon- (IFN-)efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cellcarcinoma (mRCC). (Abstract #10525)C. S. Harmon, R. A. Figlin, T. E. Hutson, M. D. Michaelson, S. Négrier, S. T. Kim,X. Huang, J. A. Williams, R. J. MotzerBrd. 18 RNA-based molecular tumor typing and immunological infiltrate as responsepredictors to neoadjuvant chemotherapy: Prospective validation in theGeparQuinto-PREDICT substudy. (Abstract #10526)C. Denkert, R. Kronenwett, S. Loibl, V. Nekljudova, S. Darb-Esfahani, B. Gerber,B. Sinn, C. Petry, I. Bauerfeind, J. Budczies, M. Rezai, M. Dietel, I. Schrader,G. Kunz, G. Von Minckwitz, GBG and AGO-B study groupsSATURDAY163

Saturday, June 4, 2011SATURDAYBrd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25Effect of everolimus plus octreotide LAR treatment on chromogranin A and5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrinetumors: Phase III RADIANT-2 study results. (Abstract #10527)E. Baudin, E. M. Wolin, D. E. Castellano, G. Kaltsas, J. Lebrec, Z. Tsuchihashi,J. Klimovsky, S. Saletan, J. C. Yao, D. GrossA hepatocyte growth factor antagonist engineered by site-directedmutagenesis. (Abstract #10528)F. Cecchi, D. Pajalunga, A. Fowler, D. C. Rabe, B. Peruzzi, N. J. MacDonald,D. K. Blackman, S. J. Stahl, A. Byrd, D. P. BottaroActivity of the cancer metabolism inhibitor MPC-9528 in xenograft models:Comparison of different dosing schedules. (Abstract #10529)V. R. Baichwal, J. A. Willardsen, J. W. Lockman, B. R. Murphy, R. Gordillo,T. C. Fleischer, C. Bradford, D. I. Papac, G. G. Mather, R. O. CarlsonIn vivo tumor growth inhibition by novel PKM2 cancer metabolismmodulators. (Abstract #10530)O. M. Becker, V. Behar, O. Bohana-Kashtan, A. Shitrit, D. Sherman, E. Ben-Zeev,R. Ozeri, N. C. Schutz, A. YacovanNew microRNA-based diagnostic test for lung cancer classification.(Abstract #10531)T. B. Edmonston, H. Gibori, M. Kushnir, G. Lithwick Yanai, H. Benjamin, M. Bibbo,C. Thurm, L. Horowitz, Y. Huang, M. Feinmesser, I. Barshack, S. J. Hou, S. Gilad,S. Benjamin, K. Ashkenazi, M. Ezagouri, Y. Goren, C. Hogan, A. ChajutThe effect of fish oil on chemotherapy activity in mice: Clinical implications.(Abstract #10532)L. G. Daenen, J. M. Roodhart, E. C. Stigter, M. G. Gerritsen, R. H. Medema,A. B. Brenkman, E. E. VoestThe effects of targeting stromal and tumor cell platelet-derived growth factorreceptor (PDGFR) in non-small cell lung cancer (NSCLC). (Abstract #10533)D. E. Gerber, P. Gupta, M. T. Dellinger, J. Toombs, I. Valencia, M. Peyton,N. Loizos, R. A. Brekken164

Saturday, June 4, 20112:00 PM - 6:00 PMGENERAL POSTER SESSIONCancer Prevention/EpidemiologyLocation: Hall ATrack(s): Cancer Prevention/EpidemiologyBrd. 1A Gender, age, and ethnic representation in non-small cell lung cancer(NSCLC) U.S. registration trials: FDA review. (Abstract #1530)S. M. Malik, A. T. Farrell, Q. Xu, R. Sridhara, R. PazdurBrd. 1B Recruitment in the Internet era: An efficient strategy for a study of breastcancer risk. (Abstract #1531)L. M. Yackowski, F. R. Schnabel, R. Oratz, D. Roses, R. Wieder, C. Kowalczyk,H. OstrerBrd. 1C Clinical characteristics of affected BRCA1 and BRCA2 mutation carriers in anunderserved population. (Abstract #1532)M. El-Masry, C. Ricker, D. V. Spicer, D. TripathyBrd. 1D Prophylactic oophorectomy for patients with breast cancer with BRCAresults. (Abstract #1533)J. C. Schink, K. M. Doll, C. B. Weldon, J. R. Trosman, H. H. Wetzel,T. J. Fallen, W. J. GradisharBrd. 1E Prevalence of recognized bone metastases in the U.S. adult population.(Abstract #1534)S. Li, Y. Peng, E. D. Weinhandl, A. H. Blaes, K. Cetin, V. M. Chia, S. Stryker,J. J. Pinzone, J. F. Acquavella, T. J. ArnesonBrd. 1F Suicide in patients with cancer in California: 2000–2005. (Abstract #1535)H. R. Mirshahidi, K. Nasseri, P. K. MillsBrd. 1G Perceptions and practices of dietary cancer prevention: Comparisonbetween physicians and patients. (Abstract #1536)V. W. Li, J. Ko, W. W. LiBrd. 2A Cancer in young adults: Characteristics of a cohort of Brazilian patients.(Abstract #1537)C. S. Souza, A. V. Melo Mendes, S. D. SimonBrd. 2B Gestational diabetes and risk of incident primary cancer: A large populationbasedcohort study in Israel. (Abstract #1538)T. Sella, G. Chodick, M. Barchana, A. D. Heymann, A. Porath, E. Kokia, V. ShalevBrd. 2C Antioxidant supplement use after diagnosis and breast cancer outcomes.(Abstract #1539)H. Greenlee, M. L. Kwan, L. Kushi, J. Song, A. Castillo, E. Weltzien,C. Quesenberry, B. J. CaanBrd. 2D Outcome of effective intervention to improve screening colonoscopy in adowntown Brooklyn community hospital. (Abstract #1540)K. Veerabhadrappa, Z. M. Bo, K. T. Lyar, R. Sultana, G. M. VillaniBrd. 2E Diagnosis of breast cancer metastases with PET/TC in patients with elevationof tumor markers: First data update. (Abstract #1541)A. Mafodda, A. Prestifilippo, D. Aricò, A. Vadalà, M. Mare, C. Fornito, D. GiuffridaBrd. 2F Cancer with diabetes: Prevalence, metabolic control, and survival in ageneral oncology practice. (Abstract #1542)N. J. Karlin, A. C. Dueck, C. CookBrd. 2G The prevalence of human papillomavirus types 52 and 58 in uterine cervicallesions from Japanese women. (Abstract #1543)K. Takehara, T. Nishimura, J. Sakane, Y. Kawakami, T. Mizunoe, M. Nishiwaki,K. TaniyamaBrd. 3A Gender disparities in colorectal cancer screening. (Abstract #1544)S. Yager, W. Y. CheungSATURDAY165

Saturday, June 4, 2011SATURDAYBrd. 3BBrd. 3CBrd. 3DBrd. 3EBrd. 3FBrd. 3GBrd. 3HBrd. 4BBrd. 4CBrd. 4DBrd. 4EBrd. 4FBrd. 4GBrd. 4HEnvironmental organochlorine pesticide pollutants in patients with benignand malignant breast disease. (Abstract #1545)K. S. Sodhi, I. D. Sharma, A. ChaturvediEarly adulthood obesity, cumulative smoking, and esophageal cancersurvival. (Abstract #1546)L. E. Coate, R. Zhai, W. Xu, Z. Chen, K. Asomaning, M. Kulke, R. S. Heist,D. Christiani, G. LiuBreast cancer survival: The association of age within stage of disease.(Abstract #1547)C. Parise, K. Bauer, V. CaggianoTrends in survival by race for stomach cancer patients from the U.S. SEERcancer registry. (Abstract #1548)L. Chu, L. Wang, M. Shing, W. DongLong-term history of fasting blood glucose level and the risk of pancreaticcancer: A nested case-control study. (Abstract #1549)K. Stefani, H. Kim, S. Ahn, K. Choi, I. SuhDoes breast cancer in Asian geriatric patients have the same biologicalcharacteristics as in their Western counterparts? A comparison betweenShanghai and Vienna. (Abstract #1550)M. M. Tea, L. Tang, G. Di, Z. Shao, C. F. SingerStroger Hospital of Cook County (CCH) AIDS malignancy project: TheCHAMP study—A 13-year, single-institution retrospective study of cancers inpatients infected with HIV. (Abstract #1551)S. Gupta, H. Poola, K. K. Batra, J. M. Orsi, S. Velinova, S. Jain,S. B. Sreenivasappa, M. C. Telfer, M. R. Mullane, A. L. French, P. G. RubinsteinThe influence of sociodemographic factors on breast cancer tumor biology.(Abstract #1553)K. A. Dookeran, K. Ferrer, M. Sekosan, N. Holloway, W. J. McCaskill-Stevens,S. J. GehlertMulticenter, prospective, case-control, observational study on the influenceof venous thromboembolism on patient outcome. (Abstract #1554)M. Mandala, R. Labianca, G. Agnelli, L. Crino, E. Maiello, A. Santoro, D. Fagnani,for the MASTER ONCOLOGY InvestigatorsCompliance to adjuvant hormone therapy for black and white women withbreast cancer. (Abstract #1555)S. Bhatta, N. Hou, D. Huo, B. N. Polite, G. F. Fleming, O. I. Olopade, S. HongThe accuracy of tobacco assessment during definitive radiotherapy orchemoradiotherapy in patients with head and neck cancer. (Abstract #1556)M. R. Kudrimoti, S. M. Arnold, J. Valentino, T. Gal, A. Hyland, A. Singh,V. Rangnekar, K. M. Cummings, J. R. Marshall, G. W. WarrenProspective structured smoking behavior assessment at diagnosis andlong-term cancer survival. (Abstract #1557)G. W. Warren, K. Kasza, M. E. Reid, K. M. Cummings, J. R. MarshallFactors associated with on-time regular screening among the Koreanpopulation eligible to be screened for gastric cancer: A nationwideretrospective cohort study based on National Cancer Screening Program(NCSP) data. (Abstract #1558)M. Hahm, K. Choi, H. Lee, J. Jun, E. ParkGynecological cancer screening in women at high risk of Lynch syndrome.(Abstract #1559)C. Guillen-Ponce, C. Martinez-Sevila, R. Perea, M. Arenas, M. Molina-Garrido,M. Goicoechea, D. Salas, A. Carrato, Hereditary Cancer Group of the ComunindadValenciana (Spain)166

Saturday, June 4, 2011Brd. 5ABrd. 5BBrd. 5CBrd. 5DBrd. 5EBrd. 5FBrd. 5GBrd. 5HBrd. 6ABrd. 6BBrd. 6CBrd. 6DBrd. 6EBrd. 6FAn analysis of colorectal cancer (CRC) following a diagnosis of prostatecancer (CaP): Is it due to earlier diagnosis or increased incidence? (Abstract#1560)S. Bae, M. Asadi, J. L. Millar, I. Jones, S. McLaughlin, A. Bui, M. Steele,M. W. Chao, D. English, P. GibbsThe role of HPV genotypes and persistence in follow-up of cervicalintraepithelial neoplasia after treatment. (Abstract #1561)Y. Huang, L. Wu, J. Zuo, N. Li, J. An, J. Hu, M. HuangMultidisciplinary high-risk program: A community hospital’s experience.(Abstract #1562)H. Lowry, N. Dekhne, D. Fend, R. Lerman, N. Gregory, J. BouraResults from a longitudinal breast MRI surveillance study: Psychologicalimpact for high-risk women. (Abstract #1563)L. J. Patrick-Miller, A. R. Bradbury, R. Pius, K. Wroblewski, M. S. Verp, S. Jackson,C. Gulden, G. Newstead, H. Abe, O. I. OlopadeRacial differences in early-stage colorectal cancer outcomes and prognosticfactors. (Abstract #1564)J. D. Acoba, C. D. ChongIsolation of equol-producing bacterium to realize chemoprevention ofprostate cancer. (Abstract #1565)H. Tsuji, K. Moriyama, K. Nomoto, N. Miyanaga, H. AkazaManagement of breast cancer after childhood cancer and Hodgkinlymphoma. (Abstract #1566)M. Terenziani, S. Viviani, M. Massimino, A. Moliterni, M. Gennaro, L. Gandola,L. Boschetti, S. Catania, G. Cefalo, A. Di Russo, G. Goisis, G. Mariani,F. Spreafico, M. Zambetti, P. Valagussa, G. BonadonnaImpact of dietary habits on epidermal growth factor receptor (EGFR)mutation status of Japanese patients with lung adenocarcinomas. (Abstract#1567)Y. Yamane, M. Iwasaki, A. Kawase, K. Tsuchihara, G. Ishii, H. Ohmatsu, S. Niho,K. Yoh, K. Nagai, Y. Ohe, S. Tsugane, A. Ochiai, H. Esumi, K. GotoMetachronous contralateral breast cancer: An analysis of risk factors andprognosis in 42,670 women in Sweden. (Abstract #1568)V. Vichapat, H. Garmo, M. Holmqvist, L. Holmberg, G. Liljegren, F. Warnberg,M. Lambe, T. Fornander, J. Adolfsson, M. LüchtenborgThe burden of cancer in Japan, the United States, France, Germany, Italy,Spain, Sweden, and the United Kingdom. (Abstract #1569)N. Koinuma, N. E. Wilking, B. Jonsson, D. HogbergPreventing cancer in the colon: Effect of ginger root extract on markers ofinflammation in colon mucosa in people at high risk for colorectal cancer.(Abstract #1570)S. M. Zick, D. K. Turgeon, S. Vareed, M. T. Ruffin IV, Z. Djuric, A. J. Litzinger,B. Wright, D. P. Normolle, D. E. BrennerThe new generation of combined hormone contraceptives and risk ofgynecologic cancers. (Abstract #1571)R. Haque, G. Inzhakova, J. M. Shi, J. Chung, F. Niu, C. T. CheethamDisparities of incidence and survival in lung cancer: A SEER-based analysison Asian living in the United States 1973–2007. (Abstract #1572)R. N. Rahman, S. Rastogi, A. M. HossainDetermining the impact of the U.S. mammography screening guidelines onpatient survival in a predominantly African American population treated in apublic hospital. (Abstract #1573)I. Habtes, C. Raskind-Hood, K. Adams, E. R. Becker, C. D’Orsi, G. Birdsong II,K. Gundry, R. O’Regan, S. G. GabramSATURDAY167

Saturday, June 4, 2011SATURDAYBrd. 6G Fetal microchimerism in breast and colon cancer. (Abstract #1574)M. Kamper-Jørgensen, R. J. Biggar, C. L. Stamper, H. Hjalgrim, A. Tjønneland,A. Olsen, A. N. Andersen, K. Rostgaard, N. Kroman, V. K. GadiBrd. 7A Global cancer mortality: The effect of health care system resources onsurvival from cancer. (Abstract #1576)A. Batouli, P. Jahanshahi, J. B. YuBrd. 7B Observations on cancer of the breast among Arab-American women.(Abstract #1577)O. R. Signori, K. A. Schwartz, H. Dakhlallah, R. M. Pandit, E. E. SignoriBrd. 7C Association between contralateral prophylactic mastectomy and breastcancer outcomes. (Abstract #1578)A. M. Brewster, P. A. Parker, I. Bedrosian, W. Dong, S. K. Peterson, S. B. Cantor,M. Crosby, Y. ShenBrd. 7D Impact on stage distribution of gastric cancer by the National CancerScreening Program (NCSP) in Korea. (Abstract #1579)J. Jun, K. Choi, H. Lee, E. ParkBrd. 7E A combination of fecal tests for the detection of colon cancer: A new strategyfor appropriate prioritization of referrals to colonscopy—A prospectiveItalian study. (Abstract #1580)A. Ardizzoia, F. Parente, B. Marino, A. Ilardo, F. Perna, I. Saracino, A. Zullo,C. Hassan, P. Fracasso, R. A. Moretti, M. Cremaschini, D. Vaira, G. UcciBrd. 7F Knowledge and perceptions of breast cancer risk in adolescent girls at highrisk and population risk for breast cancer. (Abstract #1581)A. R. Bradbury, L. J. Patrick-Miller, L. Tuchman, C. Moore, P. Rauch, C. B. Sands,R. Shorter, B. Rowan, S. Malhotra, S. Van Decker, L. Bealin, H. Schmidheiser,M. B. DalyBrd. 7G A dose-finding clinical trial of mushroom powder in postmenopausal breastcancer survivors for secondary breast cancer prevention. (Abstract #1582)M. R. Palomares, J. Rodriguez, S. Phung, F. Z. Stanczyk, S. F. Lacey,T. W. Synold, S. Denison, P. H. Frankel, S. ChenBrd. 7H Peripheral blood eosinophil counts and risk of colorectal cancer mortality ina large general population-based cohort study. (Abstract #1583)N. Taghizadeh, J. M. Vonk, H. M. BoezenBrd. 8A Meta-analysis of insulin glargine and cancer risk. (Abstract #1584)P. Boyle, A. Koechlin, P. Boffetta, M. Boniol, G. Bolli, J. RosenstockBrd. 8B Healthcare service barriers to breast cancer screening among Egyptianfemales. (Abstract #1585)H. M. El-Mansy, H. M. Ismail, I. F. Kharboush, M. M. Tawfik, O. G. El Sharkawy,H. Mamdouh, H. SallamBrd. 8C Prospective analysis of association between use of statins or other lipidlowering agents and melanoma risk in the Women’s Health Initiative.(Abstract #1586)D. B. Jagtap, C. A. Rosenberg, L. Martin, M. Pettinger, P. Greenland,J. D. Khandekar, R. Levy, D. Lane, M. S. SimonBrd. 8D Breast ductal lavage (DL) and P16 immunocytochemistry. (Abstract #1587)C. Casadio, S. Di Vincenzo Jr., L. Chiapparini, B. Bonanni, M. CazzanigaBrd. 8E Risk of lymphoma in women with breast implants: Analysis of clinicalstudies. (Abstract #1588)J. A. Largent, M. Oefelein, H. M. Kaplan, T. Okerson, P. BoyleBrd. 8F Incidence of Kaposi sarcoma in HIV-infected patients receiving antiretroviraltherapy: A prospective multicohort study from southern Africa. (Abstract#1589)J. Bohlius, F. Valeri, M. Maskew, H. Prozesky, C. Chimbetete, P. Lumano-Mulenga,T. Gsponer, M. Egger, International epidemiologic Database to Evaluate AIDS(IeDEA)168

Saturday, June 4, 2011Brd. 8G Racial variation of leptin levels in women with breast cancer. (Abstract#1590)T. P. Avery, K. R. Sexton, A. Brewster, R. El-Zein, M. BondyBrd. 8H Time since last pregnancy and breast cancer survival: A systematic reviewand meta-analysis. (Abstract #1591)A. Valachis, A. D. Nearchou, D. Mauri, P. A. Lind, N. P. PolyzosBrd. 9A Aristolochic acid nephropathy in Taiwan: Harbinger of a global iatrogenicdisease. (Abstract #1592)A. P. Grollman, C. Chen, M. Moriya, K. Dickman, L. Wu, G. Mihalyne,K. L. Edwards, K. Snappin, Y. PuBrd. 9B Classification of the components of the MedDietScore in relation tocolorectal cancer prevalence. (Abstract #1593)N. Kontou, D. B. Panagiotakos, T. Psaltopoulou, N. Soupos, E. Polychronopoulos,D. Xynopoulos, D. Dimitroulopoulos, A. Linos, E. Paraskevas, M. A. DimopoulosBrd. 9D What we know from the semiannually repeated CT screening in a high-riskcohort over 15 years: Update of the Anti-lung Cancer Association Project.(Abstract #1595)N. Seki, K. Eguchi, M. Kaneko, H. Ohmatsu, R. Kakinuma, E. Matsui,M. Kusumoto, T. Tsuchida, H. Nishiyama, N. MoriyamaBrd. 9E MRI characteristics of BRCA-associated breast cancers. (Abstract #1596)A. K. Kelekar, S. Mukherjee, C. Mitri, F. Khan, W. Ducaine, L. Dohany, D. ZakalikBrd. 9F Do cancer survivors follow screening guidelines better? (Abstract #1597)A. B. Chagpar, T. B. Sanft, C. P. GrossBrd. 9G The impact of screening mammography in breast cancer patients age 40–49at an urban city hospital. (Abstract #1598)C. Checka, S. Dhage, S. Adams, E. Samii, T. Shah, S. Shaylor, K. P. JosephBrd. 9H Body mass index: A potential risk factor for breast cancer in minoritypatients. (Abstract #1599)V. Sharma, D. Patel, A. Abichandani, P. Saraf, A. J. CohenBrd. 10A Breast cancer characteristics among Hispanic women from a Southwesterncounty hospital. (Abstract #1600)M. N. Kundranda, S. AmarBrd. 10B Patterns of treatment in young women with early-stage cervical cancer.(Abstract #1601)S. Grover, L. L. Lin, G. SunejaBrd. 10C A survey of suspected familial breast cancer in Iraqi Kurdish women.(Abstract #1602)A. M. Saaed, A. K. Sheikha, S. S. Mohammed, H. A. Ameen, S. Y. Sheet,M. KhasrawBrd. 10D Clinical and pathological profile of breast cancer in a tertiary cancer center inSaudi Arabia. (Abstract #1603)S. AlShehri, O. A. Abulkhair, A. Al Kushi, S. Musaad, A. Al Olayan, A. R. JaziehBrd. 10E Pattern of malignant diseases in Lagos, Nigeria. (Abstract #1604)O. F. AdetayoSATURDAY169

Saturday, June 4, 20112:00 PM - 6:00 PMGENERAL POSTER SESSIONSATURDAYHead and Neck CancerLocation: Hall ATrack(s): Head and Neck CancerBrd. 11A Long-term results from EORTC24971/TAX323: Comparing TPF to PF inpatients with unresectable squamous cell carcinoma of the head and neck(SCCHN). (Abstract #5530)J. B. Vermorken, E. Remenar, C. Van Herpen, M. Degardin, J. S. Stewart,R. Karra Gurunath, C. FortpiedBrd. 11B Prognostic factors of overall survival in head and neck cancer: Post-hocexploratory results from the SPINNAKER trial—A phase III randomizedclinical trial of pemetrexed plus cisplatin versus cisplatin monotherapy.(Abstract #5531)S. Urba, J. Gatz, W. Shen, A. Hossain, K. Winfree, A. Koustenis, P. PetersonBrd. 11C The effect of cisplatin dose administered during concurrentchemoradiotherapy in patients with locoregionally advancednasopharyngeal carcinoma. (Abstract #5532)H. H. Loong, B. Ma, F. Mo, S. Leung, E. P. Hui, M. K. Kam, S. L. Chan, A. T. ChanBrd. 11D Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN):Analysis of disparities in care. (Abstract #5533)B. A. Murphy, A. Y. Chen, W. J. Curran Jr., A. S. Garden, P. M. Harari,S. J. Wong, L. A. Bellm, M. Schwartz, J. Newman, D. Adkins,D. N. Hayes, U. Parvathaneni, D. Brachman, B. Ghabach, C. Schneider,M. Greenberg, A. Abitbol, P. R. Anne, K. AngBrd. 11E Concomitant chemoradiation in locally advanced head and neck squamouscell carcinoma: A literature-based metanalysis on the platinum concomitantchemotherapy. (Abstract #5534)M. G. Ghi, A. Paccagnella, I. Floriani, D. GaravagliaBrd. 11F Long-term toxicity: A comparison between surgery plus radiotherapy andexclusive chemoradiation therapy regimes in oropharyngeal cancer patients.(Abstract #5535)L. Raimondo, M. Garzaro, G. Riva, G. Pecorari, C. Giordano, M. AiroldiBrd. 11G Neoadjuvant chemotherapy and prognostic subgroups defined by survivalbenefit in paitents with locoregionally advanced nasopharyngeal carcinoma.(Abstract #5536)X. Ji, Y. Zhong, Y. Zhou, F. Zhou, G. Zhang, G. Chen, D. Deng, H. Liu, J. Zhang,C. XieBrd. 11H Quality of life, physical, and psychologic functioning in patients affected byend-stage head and neck cancer. (Abstract #5537)M. Airoldi, M. Garzaro, L. Raimondo, G. Riva, G. Pecorari, C. GiordanoBrd. 12A A phase II study of pemetrexed combined with cisplatin in patients (pts) withrecurrent or metastatic nasopharyngeal carcinoma. (Abstract #5538)A. W. Lee, T. Yau, T. C. Shum, W. Ng, L. L. Chan, R. M. YeungBrd. 12B Long-term symptom burden after radiation treatment for oropharynx cancer:A comparison of 3D and IMRT techniques. (Abstract #5539)D. I. Rosenthal, G. B. Gunn, T. R. Mendoza, A. S. Garden, B. M. Beadle,W. H. Morrison, X. S. Wang, S. J. Frank, R. S. Weber, K. Ang, C. S. CleelandBrd. 12C Clinical characteristics of an incident cohort of patients with resectedsquamous cell carcinoma of the head and neck (SCCHN) in the UnitedKingdom. (Abstract #5540)K. Kim, M. Amonkar, D. Högberg, F. Kasteng170

Saturday, June 4, 2011Brd. 12DBrd. 12EBrd. 12FBrd. 12GBrd. 12HBrd. 13ABrd. 13BBrd. 13CBrd. 13DBrd. 13EBrd. 13FBrd. 13GBrd. 13HPretreatment PET and posttreatment pathologic nodal status as a predictorfor distant metastasis in locally advanced head and neck squamous cellcarcinoma treated with definitive concurrent chemoradiotherapy. (Abstract#5541)K. Hu, W. F. Mourad, M. Perksy, M. Urken, A. Jacobson, B. Culliney, T. Tran,S. P. Schantz, P. Costantino, L. B. HarrisonComparison of two schedules in locally advanced nasopharyngealcarcinoma observed in a nonendemic population. (Abstract #5542)M. Garzaro, L. Raimondo, G. Pecorari, F. Pedani, C. Giordano, M. AiroldiA phase II trial of induction chemotherapy with cisplatin, docetaxel, andcapecitabine followed by concurrent cisplatin-radiotherapy in advancednasopharyngeal carcinoma. (Abstract #5543)M. Yamouni, Y. Beldjilali, K. Benhadji, H. Khellafi, F. Betkaoui, Y. Kaid, L. Benchlef,F. Z. Daim, S. Toubal, A. Boukerche, A. Abdelaoui, L. DjellaliExploring factors in diagnostic delays of head and neck cancer at a publichospital. (Abstract #5544)D. W. Lai, S. A. Buckley, B. L. Schmidt, C. Viet, F. Muggia, I. Belitskaya-Levy,R. F. Cohen, M. D. DeLacure, N. Sanfilippo, D. Myssiorek, D. Hirsch,N. SeetharamuIncidence of esophageal cancers among oral cavity and pharynx cancerpatients: A review of the SEER database (1973–2007). (Abstract #5545)E. Kim, N. Chandra, J. KimChemoselection with induction chemotherapy followed by chemoradiation orsurgery versus chemoradiation for patients (pts) with locally advancedsquamous cell carcinoma of the oropharynx (LASCCOP). (Abstract #5546)I. Y. Dobrosotskaya, E. Light, J. M. Maxwell, S. A. Byrd, M. E. Spector, B. Kumar,F. Y. Feng, A. Eisbruch, G. T. Wolf, M. Prince, J. Moyer, T. N. Teknos,D. B. Chepeha, H. M. Walline, J. B. McHugh, K. G. Cordell, S. Urba,C. R. Bradford, T. Carey, F. P. WordenMeasurement of distress in patients with nasopharyngeal carcinoma.(Abstract #5547)Y. Jiang, Y. DengConcomitant chemoradiation using weekly cisplatin for advanced squamouscell carcinoma of head and neck: Experience from a tertiary cancer center inIndia. (Abstract #5548)A. Sharma, B. K. Mohanti, A. Thakar, S. P. Chaudhary, S. Bhasker, S. BahadurPaclitaxel (TLX) and cetuximab (CTX) combination efficiency after failure of aplatinum-based chemotherapy in recurrent/metastatic head and necksquamous cell carcinoma (RMHNSCC). (Abstract #5549)P. Ceruse, E. Lavergne, G. Buiret, B. Pham, S. Chabaud, B. Favier, D. Girodet,P. Zrounba, J. FayetteRecurrence of T1N0 oral tongue squamous cell carcinoma in Stockholm,Sweden 2000–2009. (Abstract #5550)M. RyottComprehensive volume hyperfractionated (HFx) re-irradiation (Re-RT) ofrecurrent head and neck (H/N) cancer is feasible. (Abstract #5551)P. Kumar, U. K. SinhaSurvival, tumor control, and toxicity with TPF before acceleratedradiotherapy potentiated with cetuximab for stage III-IV unresectable headand neck cancer: A phase II study. (Abstract #5552^)C. Mercke, H. Sjödin, H. Haugen, G. Adell, G. Wickart-Johansson,E. M. Munck-Wikland, G. von Dobeln, J. NymanConcurrent chemoradiotherapy with or without induction chemotherapy forlocally advanced head and neck cancer. (Abstract #5553)J. J. Caudell, S. Spencer, R. Meredith, L. Nabell, J. A. BonnerSATURDAY171

Saturday, June 4, 2011SATURDAYBrd. 14ABrd. 14BBrd. 14CBrd. 14DBrd. 14EBrd. 14FBrd. 14GBrd. 14HBrd. 15ABrd. 15BBrd. 15CBrd. 15DKinetic analysis of 18 f-fluoroerythronitroimidazole PET/CT duringradiotherapy correlates with outcome in head and neck cancer. (Abstract#5554)M. Hu, J. Yu, L. Kong, Z. FuWeekly and 3-weekly cisplatin concurrent with intensity-modulatedradiotherapy in locally advanced head and neck squamous cell cancer.(Abstract #5555)V. Espeli, E. Zucca, M. E. Ghielmini, A. Richetti, O. Giannini, F. MartucciChemoradiation for nasopharyngeal carcinoma (NPC) with pilot hypoxiaimaging with F18 misonidazole PET scanning. (Abstract #5556)A. D. Colevas, A. Quon, A. McMillan, Q. LeMultiple cases of squamous cell carcinoma of the tongue and oral cavity inpatients treated with long-term pegylated liposomal doxorubicin (PLD) forovarian cancer. (Abstract #5557)T. L. Cannon, F. Muggia, D. Hirsch, E. A. Andreopoulou, A. R. Kerr,M. D. DeLacureInfluence of induction chemotherapy on patient’s compliance to radiotherapyin patients with locally advanced head and neck squamous cell carcinoma.(Abstract #5558)B. Atassi, O. Ozgursoy, G. H. Yoo, J. R. Jacobs, N. Bhatti, M. Mal, H. Kim, H. Lin,A. SukariUse of buccal fat pad to correct defects in the oral cavity after excision ofcheek cancer: A prospective study. (Abstract #5559)S. K. Agrawala, S. GoshClinical response rate at primary tumor site (PTS) following a novelinduction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound(nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF)versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF C) in patients withlocally advanced head and neck squamous cell carcinoma (HNSCC).(Abstract #5560)D. Adkins, J. Ley, B. Nussenbaum, J. Diaz, R. Paniello, W. L. Thorstad, H. A. Gay,J. Subramanian, T. M. Wildes, J. Mathai, T. Rachocki, D. I. KupermanPhase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitorPF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM)squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5561)L. L. Siu, S. J. Hotte, S. A. Laurie, S. Singh, E. Winquist, S. K. Chia,E. X. Chen, K. K. Chan, T. Wang, I. Taylor, A. Ruiz-Garcia, C. Mormont,D. SoulieresPhase II trial of sorafenib in patients with advanced thyroid cancer. (Abstract#5562)S. M. Keefe, A. B. Troxel, S. Rhee, K. Puttaswamy, P. J. O’Dwyer, L. A. Loevner,S. J. Mandel, M. S. BroseA randomized phase II study of cetuximab (C) every 2 weeks at either 500 or750 mg/m 2 for patients (Pts) with recurrent or metastatic (R/M) head and necksquamous cell cancer (HNSCC). (Abstract #5563)M. G. Fury, E. J. Sherman, D. M. Lisa, N. Agarwal, K. M. Algazy, B. Brockstein,C. J. Langer, D. Lim, R. Mehra, S. K. Rajan, N. Jafri, S. Korte, B. Lipson, F. Yunus,T. Tanvetyanon, S. Smith-Marrone, K. K. Ng, H. Xiao, S. Haque, D. G. PfisterPhase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastaticsquamous cell carcinoma of the head and neck (SCCHN): Final results.(Abstract #5564)A. Argiris, A. P. Kotsakis, S. Kim, F. P. Worden, P. Savvides, M. K. Gibson,G. R. Blumenschein Jr., H. X. Chen, J. R. Grandis, M. S. KiesPhase I/II trial of vandetanib and bortezomib in adults with locally advancedor metastatic medullary thyroid cancer: Phase I results. (Abstract #5565)A. W. Gramza, S. A. Wells, S. Balasubramaniam, A. T. Fojo172

Saturday, June 4, 2011Brd. 15EBrd. 15FBrd. 15GBrd. 15HBrd. 16ABrd. 16BBrd. 16CBrd. 16DBrd. 16EBrd. 16FBrd. 16GBrd. 16HA phase II study of VEGF trap in patients with radioactive iodine(RAI)–refractory thyroid carcinoma. (Abstract #5566)E. J. Sherman, A. L. Ho, S. Haque, R. M. Tuttle, R. A. Ghossein, H. Schöder,M. S. Baum, K. Kelly, A. P. Chen, A. R. Shaha, D. G. PfisterCetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patientswith recurrent or metastatic (R/M) squamous cell carcinoma of the head andneck (SCCHN): First results of phase II trial GORTEC 2008-03. (Abstract#5567)J. Guigay, J. Fayette, A. Dillies, C. Sire, J. N. Kerger, I. Tennevet, J. H. Machiels,S. Zanetta, Y. Pointreau, L. Bozec Le Moal, L. Brugel Ribere, S. Henry,S. Temam, GORTECPilot study to evaluate the effect of erlotinib (E) administered before surgeryin operable patients with squamous cell carcinoma of the head and neck(SCCHN). (Abstract #5568)M. Porosnicu, J. D. Waltonen, C. Sullivan, L. McWilliams, G. L. Kucera, A. Thomas,R. Plasser, J. D. BrowneProspective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients withmetastatic/recurrent head and neck squamous cell carcinoma (HNSCC).(Abstract #5569)J. Ley, B. A. Siegel, F. Dehdashti, J. Subramanian, G. Ansstas, T. Rachocki,J. Mathai, T. M. Wildes, D. I. Kuperman, D. AdkinsTreatment (T) of T2 N0-1 larynx cancer (LC) with hyperfractionatedradiotherapy (HRT) and cetuximab (C): Final report. (Abstract #5570)R. E. Giglio, A. Navigante, M. D. Pereira, L. Califano, B. M. Roth, P. Saco,M. A. Castro, P. Menendez, P. Aguerre, R. Adan, C. Brosio, C. PoganyHuman papillomavirus (HPV)–related, p16 positive head and neck squamouscell carcinomas (HNSCCs) after stem cell transplantation (SCT) and solidorgan transplantation (SOT). (Abstract #5571)C. P. Rodriguez, D. Chute, R. Seth, B. Burkey, J. Scharpf, A. P. Hoschar, D. I. Ives,D. J. AdelsteinDifferent cellular p16 localization may signal different survival outcomes inhead and neck cancer. (Abstract #5572)D. N. Hayes, N. Zhao, M. Ang, M. Patel, M. D. Wilkerson, X. Yin, M. C. Hayward,W. K. Funkhouser Jr., A. OlshanPrognostic role of PI3KCA and TP53 in HPV-negative oropharyngeal cancers(OPCs). (Abstract #5573)P. Bossi, F. Perrone, R. Miceli, L. Locati, C. Bergamini, A. Mirabile, R. Granata,C. Resteghini, B. Cortelazzi, M. Orsenigo, C. Fallai, E. Orlandi, S. Pilotti,L. F. LicitraHPV prevalence and prognostic value in a prospective cohort of 255 patientswith locally advanced squamous cell carcinoma of the head and neck treatedwith chemoradiation therapy at Centre Hospitalier de l’Université deMontréal: A single-center experience. (Abstract #5574)E. Thibaudeau, D. Soulieres, B. Fortin, F. Coutlee, P. Nguyen-Tan, X. Weng,M. Audette, O. Abboud, L. Guertin, A. Christopoulos, J. TabetFactors predicting survival outcomes for patients with HPV-positive base oftongue cancer. (Abstract #5575)P. AttnerLymph node density and response to induction TPF in patients with HPVrelatedhead and neck cancer. (Abstract #5576)H. C. Agbahiwe, S. Marur, A. A. Forastiere, G. SanguinetiEffects of human papillomavirus (HPV) and other potential risk factors onsurvival in patients with oropharyngeal cancer. (Abstract #5577)M. Knoedler, A. Zakarneh, U. Zimmermann, K. Woelke, O. Kaschke, U. KeilholzSATURDAY173

Saturday, June 4, 2011SATURDAYBrd. 17ABrd. 17BBrd. 17CBrd. 17DBrd. 17EBrd. 17FBrd. 17GBrd. 17HBrd. 18ABrd. 18BBrd. 18CBrd. 18DBrd. 18EAssociation of p16 and pEGFR expression with high-risk HPV in head andneck squamous cell carcinoma. (Abstract #5578)R. AltahaDetection of novel genetic aberrations in salivary duct carcinoma (SDC) bySNaPshot analysis. (Abstract #5579)L. J. Wirth, V. Nardi, D. Juric, A. K. Cosper, K. Bergethon, V. Scialabba,D. R. Borger, A. J. Iafrate, L. W. Ellisen, D. Deschler, D. Zhao, P. M. Sadow,D. Dias-SantagataAdenoid cystic carcinoma of the head and neck (ACCHN) incidence andsurvival trends. (Abstract #5580)C. L. Ellington, S. A. Kono, T. K. Owonikoko, S. S. Ramalingam, F. R. Khuri,D. M. Shin, N. F. SabaHigh-grade transformation in acinic cell carcinoma of the salivary glands: Arare but important clinical entity. (Abstract #5581)K. A. Price, W. Shon, J. A. Davidson, J. E. Lewis, D. L. Price, J. J. Garcia17-allylaminogeldanamycin in advanced medullary and differentiated thyroidcarcinoma. (Abstract #5582)J. F. Moley, D. Adkins, K. C. Bible, A. M. Traynor, J. R. Molina, G. Colon-Otero,T. J. Pluard, M. H. Shah, R. Suresh, C. Erlichman, S. P. Ivy, V. Suman,S. M. Geyer, P. M. Fracasso, M. S. Cohen, H. Tang, E. Fialkowski, A. Traugott,R. C. Smallridge, P2CPreoperative recombinant adeno-viral human p53 gene (rAd-p53) therapy intreatment of locally advanced locally advanced papillary thyroid cancer(PTC) and folliculary thyroid cancer (FTC). (Abstract #5583)J. ZhuPrognostic factors of adenoid cystic carcinoma of head and neck. (Abstract#5584)Y. Choi, S. Kim, S. Nam, S. Choi, J. Roh, J. Lee, S. Lee, K. ChoComparison of native and adaptive immunity profiles of healthy volunteersand patients with well-differentiated thyroid cancer. (Abstract #5585)S. Hossain, C. Bhimani, Z. Chen, S. S. Ramalingam, D. M. Shin, C. Cohen,F. R. Khuri, E. Waller, T. K. OwonikokoPharmacogenetic variations in ABCG2 are associated with cisplatin toxicityin patients with head and neck squamous cell carcinoma. (Abstract #5586)B. Lee, R. Slack, J. J. Hwang, K. Steadman, W. Harter, B. J. Davidson,K. A. Newkirk, P. G. Shields, R. Goldman, J. F. DeekenERCC1 and XPF protein expression in patients with nasopharyngealcarcinoma (NPC) undergoing curative intent radiation with or withoutplatinum chemotherapy. (Abstract #5587)A. Jagdis, T. Phan, A. C. Klimowicz, J. J. Laskin, H. Lau, S. K. Petrillo,J. E. Siever, T. A. Thomson, A. M. Magliocco, D. HaoAssociation of increased lymphocyte infiltration with outcome in patientswith head and neck cancer treated with the IRX-2 regimen. (Abstract #5588)P. NaylorGene expression profiling predicts nonresponders to chemoradiation inHPV16-positive head and neck squamous cell carcinoma. (Abstract #5589)B. J. Thibodeau, T. J. Geddes, S. Ahmed, B. L. Pruetz, P. Y. Chen, G. D. Wilson,J. A. AkervallSerum C 18 -ceramide as a biomarker for response: Phase II trial ofgemcitabine plus doxorubicin in patients with HNSCC. (Abstract #5590)K. Shirai, S. Saddoughi, P. E. O’Brien, L. Afrin, E. Garrett-Mayer, G. R. Simon,U. B. Chaudhary, B. Ogretmen174

Saturday, June 4, 2011Brd. 18FBrd. 18GBrd. 18HBrd. 19AIdentification of signaling pathways involved in the mechanism of action ofthe immunomodulatory peptide gamma-D-glutamyl-L-tryptophan. (Abstract#5591)J. Papkoff, H. Lee, G. Singh, S. Singh, S. Chitta, K. Andrew, P. Quintel,J. S. Rosenberg, B. A. Watkins, S. T. Sonis, C. W. TuthillThe effect of the immunomodulatory peptidegamma-D-glutamyl-L-tryptophan in leukemia, lymphoma, and head and neckcancer xenograft models. (Abstract #5592)C. W. Tuthill, J. Papkoff, B. A. Watkins, S. T. SonisHigh dose rate intraoperative radiation therapy for recurrent head and neckcancer: The importance of in-field control on survival. (Abstract #5593)L. B. Harrison, W. F. Mourad, M. Perksy, M. Urken, A. Jacobson, B. Culliney,T. Tran, S. P. Schantz, P. Costantino, K. HuEfficacy and safety of weekly paclitaxel combined with cetuximab in thetreatment of pretreated recurrent/metastatic head and neck cancer patients.(Abstract #5594)B. Jimenez, J. Trigo Perez, M. Saez Medina, C. Quero Blanco, B. Pajares,A. Rueda, E. AlbaSATURDAY175

Saturday, June 4, 20112:00 PM - 6:00 PMGENERAL POSTER SESSIONSATURDAYLung Cancer—Local-regional and Adjuvant Therapy/Small CellLocation: Hall ATrack(s): Lung CancerBrd. 20A Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFRmutantlung cancers that recur after adjuvant TKI. (Abstract #7029)G. R. Oxnard, Y. Y. Janjigian, M. E. Arcila, M. G. Kris, M. Ladanyi,C. G. Azzoli, V. A. MillerBrd. 20B Tumor response and toxicity in neoadjuvant erlotinib in early-stage NSCLCpatients. (Abstract #7030)H. M. Klomp, E. Schaake, NEL Study groupBrd. 20C Chemotherapy influence EGFR mutation status for Chinese patients withregionally advanced non-small cell lung cancer. (Abstract #7031)J. Wang, K. Chen, H. Bai, J. Zhao, Z. Wang, M. Zhuo, T. An, J. Duan, L. Yang,M. Wu, Q. Guo, X. Liu, S. Wang, Y. WangBrd. 20D The role of EGFR mutation status in patients with stage III nonsquamousnon-small cell lung cancer treated with chemoradiotherapy. (Abstract #7032)F. Li, G. y. Zhu, X. N. Li, R. Yu, A. Shi, L. YinBrd. 20E Mutations of EGFR, K-ras, and EML-4ALK genes in resected lungadenocarcinoma and their clinical significance. (Abstract #7033)T. Ohba, K. Sugio, T. Kometani, M. Yamaguchi, M. Hamatake, K. Nosaki,H. Takeoka, H. Kitajima, F. Hirai, T. Seto, Y. IchinoseBrd. 20F The association of epidermal growth factor receptor (EGFR) mutation andsurvival in N2() non-small cell lung cancer patients treated with platinumbasedneoadjuvant concurrent chemoradiotherapy. (Abstract #7034)H. Ahn, Y. Choi, J. Sun, Y. Ahn, K. Kim, J. Kim, Y. Shim, J. Ahn, K. Park, M. AhnBrd. 20G Detection of EGFR mutations with mutation-specific antibodies in primarylesions of non-small cell lung cancer. (Abstract #7035)X. Zhang, L. Yin, X. Yang, J. Yang, Q. Zhou, J. Xu, Z. Xie, S. An, S. Chen,R. Wang, G. Zhu, Y. Gu, Y. WuBrd. 20H Impact of EGFR mutation status in patients with completely resected lungadenocarcinoma treated with adjuvant platinum-based chemotherapy.(Abstract #7036)K. Yoh, K. Goto, S. Niho, H. Ohmatsu, K. Nagai, Y. OheBrd. 21A Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer(NSCLC) patients (pts). (Abstract #7037)E. Felip, M. Salcedo, N. Murtra-Garrell, A. Navarro, C. Teixido, J. Hernandez-Losa,S. Cedres, P. Martinez, E. Lopez, M. Montero, V. Freixinos, G. Argiles, I. Nuñez,V. Peg, E. Pallisa, M. Canela, J. Tabernero, S. Ramon y Cajal, N. TalladaBrd. 21B Initial experience with erlotinib in advanced non-small cell lung cancer in thekingdom of Saudi Arabia. (Abstract #7038)A. A. Alolayan, S. Musaad, H. Bamefleh, M. Nounou, A. R. JaziehBrd. 21C SOCCAR: Sequential or concurrent chemotherapy and hypofractionatedaccelerated radiotherapy in inoperable stage III NSCLC. (Abstract #7039)J. Maguire, R. McMenemin, N. O’Rourke, C. Peedell, M. Snee, S. McNee, V. KellyBrd. 21D Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT)for poor-risk stage III non-small cell lung cancer (NSCLC). (Abstract #7040)Y. Chen, J. Moon, K. J. Pandya, K. Kelly, L. E. Gaspar, D. Lau, F. R. Hirsch,D. R. Gandara176

Saturday, June 4, 2011Brd. 21E Predictive factors for symptomatic radiation pneumonitis in 293consecutively treated non-small cell lung cancer (NSCLC) patients receivingdefinitive radiation therapy. (Abstract #7041)A. Orisamolu, E. Xanthopoulos, A. Fernandes, J. P. Christodouleas,S. Apisarnthanarax, N. Mitra, F. Wan, C. J. Langer, T. L. Evans, J. Stevenson,D. Sterman, A. Vachani, A. R. Haas, R. RenganBrd. 21F Long-term survival (LTS) and competing risks within a prospectivemulticenter German randomized trial comparing induction chemotherapy(CTx) followed by concurrent (cc) chemoradiation (CTx/RTx) plus surgery(SURG) ( TRIMODALITY) supplemented by PCI versus local treatment (Tx)alone (SURG RTx) in operable IIIA NSCLC. (Abstract #7042)T. C. Gauler, C. Poettgen, H. Wagner, S. Korfee, R. Hepp, G. Stamatis,J. Von Pawel, B. Passlick, V. Budach, H. Wilke, S. Seeber, M. Stuschke,W. E. EberhardtBrd. 21G Endostar in combination with radiotherapy and paclitaxel/carboplatin inpatients with unresectable non-small cell lung cancer of stage III: Preliminaryresults of a phase II study. (Abstract #7043)S. Ma, Y. Xu, X. Sun, Y. Ji, Y. Zheng, S. Wang, J. ChenBrd. 21H Phase II study of low-dose paclitaxel with timed thoracic radiotherapy (TTR)followed by gemcitabine and carboplatin consolidation in patients withunresectable stage III non-small cell lung cancer (NSCLC): NCT 00449657.(Abstract #7044)J. Zhang, S. M. Russo, H. A. Gay, T. Parent, Z. Nelson, S. Eubanks, P. R. WalkerBrd. 22A Oral vinorelbine (NVBo) at 3 weekly flat-dose intakes (FDI) as single agent orwith cisplatin (CDDP) concomitantly with thoracic radiotherapy (RT) in stageIII NSCLC: Escalation-dose phase I trial results. (Abstract #7045)D. M. Kowalski, M. J. Krzakowski, K. Zajda, C. LucasBrd. 22B A phase I study of nab-paclitaxel (nP) with carboplatin (C) and thoracicradiation (TRT) in patients with locally advanced NSCLC. (Abstract #7046)V. L. Keedy, B. Lu, L. Horn, Y. Shyr, C. F. Winkler, D. P. Carbone, A. SandlerBrd. 22C Long-term survival (S) of induction chemotherapy (CTx) with three cyclescisplatin (cis)/paclitaxel (pac) followed by concurrent (cc) chemoradiation(CTx/RTx) cis/etoposide (eto) and 45 Gy (1.5 Gy bid) plus surgery (SURG):Phase II results (CISTAXOL). (Abstract #7047)W. E. Eberhardt, T. C. Gauler, C. Le Pechoux, R. Hepp, S. Welter, B. Fischer,S. Bildat, D. Grunenwald, G. Stamatis, M. Stuschke, C. PoettgenBrd. 22D Long-term follow-up of phase III trial of docetaxel and cisplatin (DP) versusmitomycin, vindesine, and cisplatin (MVP) with concurrent thoracic radiationtherapy (TRT) for locally advanced non-small cell lung cancer (OLCSG 0007).(Abstract #7048)K. Kiura, N. Takigawa, K. Matsuo, S. Kuyama, S. Hosokawa, K. Fujiwara,A. Hisamoto, T. Kozuki, H. Ueoka, M. Tanimoto, Okayama Lung Cancer StudyGroupBrd. 22E Stereotactic body radiation therapy versus high-dose conventional radiationtherapy in early-stage NSCLC: A retrospective study on local failure andsurvival rates. (Abstract #7049)S. Jeppesen, T. Schytte, H. R. Jensen, C. Brink, O. HansenBrd. 22F Fiducial-less stereotactic radiotherapy for early-stage lung cancer: Efficacyand toxicity evaluation. (Abstract #7050)J. Bibault, B. Prevost, E. Dansin, X. Mirabel, T. Lacornerie, F. Dubus, E. LartigauBrd. 22G Outcomes of stereotactic body radiotherapy in patients with clinical stage Inon-small cell lung cancer who are fit to undergo surgery. (Abstract #7051)S. Senan, N. E. Verstegen, C. J. Haasbeek, B. J. Slotman, F. J. LagerwaardBrd. 22H Clinical outcome of cN0 non-small cell lung cancer patient staged by thinslice CT, FDG-PET, and EBUS-TBNA. (Abstract #7052)Y. Sakairi, H. Hoshino, T. Nakajima, T. Fujiwara, F. Ishibashi, H. Tamura, H. Wada,T. Iwata, T. Okamoto, T. Mizobuchi, Y. Moriya, S. Yoshida, K. Yasufuku, I. YoshinoSATURDAY177

Saturday, June 4, 2011SATURDAYBrd. 23ABrd. 23BBrd. 23CBrd. 23DBrd. 23EBrd. 23FBrd. 23GBrd. 23HBrd. 24ABrd. 24BBrd. 24CBrd. 24DBiologic risk model for recurrence in resected early-stage non-small cell lungcancer (ES NSCLC). (Abstract #7053)K. A. Gold, J. Lee, Y. Ping, C. Behrens, D. Liu, H. Lee, J. S. Koo, R. Lotan, L. Solis,W. Rinsurongkawong, D. J. Stewart, W. L. Hofstetter, S. Swisher, S. M. Lippman,I. I. Wistuba, W. K. Hong, E. S. KimSurvival analysis of patients with/without lymph node examination after lungcancer resection. (Abstract #7054)R. U. Osarogiagbon, R. A. Ramirez, C. Wang, L. E. Miller, M. Ul-Haq, A. Farooq,J. W. Allen, D. Spencer, A. Berry, A. B. Weir III, H. Cole, T. O’BrienFinal results of a trial comparing two neoadjuvant chemotherapy (CT)regimens followed by surgery in patients with resectable non-small cell lungcancer (NSCLC): A phase II randomized study by the European Lung CancerWorking Party. (Abstract #7055)T. Berghmans, J. Lafitte, V. Giner, M. Berchier, A. Scherpereel, M. Paesmans,A. Meert, T. Bosschaerts, N. Leclercq, J. P. SculierBRCA1 mRNA expression patterns in a large lung cancer cohort. (Abstract#7056)K. Kelly, P. Mack, X. Huang, P. Lara Jr., P. V. Danenberg, K. D. Danenberg,D. R. GandaraPI3K pathway and downstream signaling analysis in malignant pleuralmesothelioma (MPM). (Abstract #7057)S. Cedres Perez, M. Montero, D. Torrejon, P. Martinez, V. Freixinos,N. Mulet-Margalef, G. Argiles, I. Nuñez, E. Lopez, L. Prudkin, M. Salcedo,N. Tallada, S. Ramon y Cajal, E. FelipRole of solid tumor size compared with whole tumor size to predictpathological malignant grade or prognosis in clinical stage IA lungadenocarcinoma: A multicenter study. (Abstract #7058)Y. Tsutani, Y. Ibuki, T. Ikeda, Y. Miyata, H. Nakayama, M. OkadaMolecular studies support the association between germline genetic variantsin the vascular endothelial growth factor (VEGF) pathway and survival innon-small cell lung cancer (NSCLC) patients. (Abstract #7059)D. M. Glubb, W. Zhang, K. Owzar, C. Jiang, O. Mirza, S. Kashyap, W. Rzyman,J. Jassem, F. R. Hirsch, R. Dziadziuszko, F. InnocentiCharacteristics of the ground-glass opacity nodules showing growth duringfollow-up. (Abstract #7060)H. Matsuguma, A. Ui, N. Oohata, R. Nakahara, T. Kasai, Y. Kamiyama, S. Igarashi,K. Mori, T. Kodama, K. YokoiIncomplete intrapulmonary lymph node retrieval with routine pathologyevaluation of resected lung cancer. (Abstract #7061)R. A. Ramirez, C. Wang, L. E. Miller, C. A. Adair, T. O’Brien, A. Berry,R. U. OsarogiagbonA window-of-opportunity trial of vorinostat (V) in patients with resectablenon-small cell lung cancer (NSCLC). (Abstract #7062)K. H. Dragnev, T. Ma, F. Galimberti, C. P. Erkmen, V. Memoli, W. Nugent,J. R. Rigas, D. Johnstone, A. Frandsen, S. Simeone, J. Czum, H. Li, J. DiRenzo,S. Freemantle, E. DmitrovskyInduction chemotherapy with gemcitabine-carboplatin-paclitaxel (GEMCAP)in stage III non-small cell lung cancer (NSCLC). (Abstract #7063)G. L. Banna, H. Lipari, C. Buscarino, A. Seca, A. Basile, M. Ippolito, G. Novello,R. Condorelli, S. Cavallaro, G. Squadrito, M. D’Arrigo, V. Gebbia, A. Terminella,S. SaitaPrognostic role of nitrotyrosines in surgically resected non-small cell lungcancer (NSCLC). (Abstract #7064)L. Toschi, P. Colombo, C. Soldani, L. Giordano, G. Finocchiaro, L. Siracusano,L. Gianoncelli, M. Incarbone, A. Destro, M. Alloisio, L. Terracciano,M. Varella-Garcia, F. Cappuzzo, M. Roncalli, A. Viola, A. Santoro178

Saturday, June 4, 2011Brd. 24E Hedgehog inhibition and radiation therapy in non-small cell lung cancer.(Abstract #7065)J. Zeng, K. Aziz, M. Armour, B. Aftab, R. Gajula, S. Chettair, T. Salih, C. M. Rudin,P. T. Tran, R. HalesBrd. 24F Incidence and predictors of venous thromboembolism (VTE) amongambulatory patients with lung cancer. (Abstract #7066)G. C. Connolly, M. R. Dalal, J. Lin, A. A. KhoranaBrd. 24G Factors associated with adherence to chemotherapy guidelines in patientswith non-small cell lung cancer (NSCLC). (Abstract #7067)R. G. Salloum, T. J. Smith, J. Elston-Lafata, G. JensenBrd. 24H Examination of 12-lipoxygenase (12-LOX) as a therapeutic target in nonsmallcell lung cancer (NSCLC): Mechanisms controlling survival andinduction of apoptosis following selective inhibition. (Abstract #7068)M. Cathcart, V. Campbell, K. Gately, E. Kay, G. P. Pidgeon, K. J. O’ByrneBrd. 25A Smoking, passive smoking and lung cancer cell types among women inMorocco: Analysis of epidemiological profiling of 101 cases. (Abstract#7069)H. Errihani, S. Ouaouch, H. Abahssain, R. Razine, H. Mrabti, R. Abouqal, M. Ichou,N. Benjaafar, F. ZakkouriBrd. 25B Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapyfollowing definitive treatment in patients with stage I-III adenocarcinoma ofthe lung with G12C, G12D, or G12V KRAS mutations. (Abstract #7070)S. P. D’Angelo, B. J. Park, L. M. Krug, C. Crevar, C. E. Medina, D. K. Sumner,J. Richman, C. Coeshott, D. Apelian, A. Cohn, M. G. Kris, C. G. AzzoliBrd. 25C Prognostic role of integrin 1 , E-cadherin, and rac1 expression in small celllung cancer. (Abstract #7071)M. Chang, K. Lee, Y. Kim, J. KangBrd. 26A Liposomal cisplatin in cancer patients with renal failure. (Abstract #7072)G. Stathopoulos, S. Rigatos, J. Stathopoulos, S. BatziosBrd. 26B Phase I study to assess pharmacokinetics (PK), QT/QTc effect, and safety ofamrubicin in patients (pts) with advanced solid tumors. (Abstract #7073)N. Chen, S. P. Chawla, E. G. Chiorean, W. L. Read, M. Gorbaty, A. C. Mita,L. Yung, R. McNally, M. F. Renschler, S. SharmaBrd. 26C Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC):Findings from a North Central Cancer Treatment Group (NCCTG) pooledanalysis. (Abstract #7074)S. E. Schild, N. R. Foster, J. P. Meyers, K. R. Olivier, H. J. Ross, J. R. Molina,P. J. Stella, L. R. Past, Y. I. Garces, A. A. Adjei, North Central Cancer TreatmentGroupBrd. 27A Retrospective review of extrapulmonary small cell carcinoma and prognosticfactors. (Abstract #7075)J. E. Brammer, P. D. Lulla, M. A. Bilen, G. R. LynchBrd. 27B A pilot study of adjuvant chemotherapy with cisplatin and irinotecan forhigh-grade pulmonary neuroendocrine carcinona (large cell neuroendocrinecarcinoma and small cell lung cancer). (Abstract #7076)H. Kenmotsu, S. Niho, T. Ito, Y. Ishikawa, H. Tada, I. Sekine, S. Watanabe,M. Yoshimura, N. Yamamoto, F. Oshita, K. Kubota, K. NagaiBrd. 27C Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer(SCLC). (Abstract #7077)M. G. Viganò, R. Cavina, S. Novello, F. Grossi, A. Santoro, V. Gregorc,G. Scagliotti, I. M. Garassino, G. Rossoni, M. G. Levra, C. Genova,F. Caligaris-Cappio, A. Lambiase, C. BordignonSATURDAY179

Saturday, June 4, 2011SATURDAYBrd. 28A Predictors of pulmonary toxicity in limited-stage (LS) small cell lung cancer(SCLC) patients treated with concurrent chemotherapy (CTX) and high-dose(70 Gy) daily radiotherapy (RT): A pooled analysis of three CALGB studies.(Abstract #7078)J. K. Salama, L. Hodgson, H. Pang, M. R. Green, J. J. Urbanic, A. W. Blackstock,J. Crawford, J. Bogart, E. E. Vokes, CALGBBrd. 28B Phase II study of NK012 in relapsed small cell lung cancer. (Abstract #7079)E. Raefsky, D. R. Spigel, J. R. Infante, J. C. Bendell, S. F. Jones, A. J. Lipman,D. Trent, S. Kawamura, F. A. Greco, J. D. Hainsworth, H. A. Burris IIIBrd. 28C Adenovirus-mediated siRNA targeting c-Met inhibits proliferation andinvasion of small cell lung cancer (SCLC) cells. (Abstract #7080)Z. WangBrd. 29A A phase I study of weekly oral topotecan in patients (pts) with relapsed smallcell lung cancer (SCLC). (Abstract #7081)E. Kontopodis, L. Vamvakas, K. Kalbakis, N. K. Vardakis, G. Sfakiotaki,V. Georgoulias, S. AgelakiBrd. 29B A phase I study of amrubicin (AMR) and cyclophosphamide in patients withadvanced solid organ malignancies: A trial from the Hoosier OncologyGroup. (Abstract #7082)S. I. Jalal, J. A. Bufill, G. A. Masters, N. Somaiah, K. Koneru, J. McClean,R. E. Sanborn, J. Wu, Z. Yu, L. H. EinhornBrd. 29C Determinants of chemotherapy administration and effects of chemotherapyon survival in elderly patients with small cell lung cancer (SCLC): A SEER-Medicare analysis. (Abstract #7083)L. C. Caprario, D. M. Kent, T. A. Trikalinos, G. M. StraussBrd. 30A Phase II study of sunitinib in patients with relapsed or refractory small celllung cancer (SCLC). (Abstract #7084)J. Han, K. Lim, H. Kim, S. Oh, T. Yun, J. LeeBrd. 30B Systemic therapy usage and outcomes for patients diagnosed withmalignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario,Canada. (Abstract #7085)A. Hasani, B. Sun, G. Liu, W. Xu, R. Feld, N. B. LeighlBrd. 30C Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin asmarkers of patient response and outcome in malignant pleuralmesothelioma. (Abstract #7086)K. Hollevoet, K. Nackaerts, R. Gosselin, W. De Wever, L. Bosquée, P. De Vuyst,P. R. Germonpre, E. Kellen, C. Legrand, Y. Kishi, J. R. Delanghe,J. P. Van MeerbeeckBrd. 31A Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreatedmalignant pleural mesothelioma (MPM) patients (Italian SoMe Study).(Abstract #7087)V. Mutri, C. Pinto, S. Giaquinta, P. Di Tullio, V. Torri, B. Melotti, F. Sperandi,F. Di Fabio, F. L. Rojas Llimpe, S. Pini, F. Massari, A. MartoniBrd. 31B Repeated ambulatory intrapleural chemotherapy for malignant pleuralmesothelioma. (Abstract #7088)J. Javidfar, J. R. Sonett, M. E. Ginsburg, J. Miller, E. Hare, M. Bacchetta,R. Fawwaz, R. N. TaubBrd. 31C NGR-hTNF in previously treated patients with malignant pleuralmesothelioma (MPM). (Abstract #7089)F. De Vincenzo, G. Rossoni, A. Santoro, V. Gregorc, P. A. Zucali, G. Citterio,M. Simonelli, G. Petrella, F. Caligaris-Cappio, A. Lambiase, C. BordignonBrd. 31D Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgeryand radiation in the treatment of malignant pleural mesothelioma (MPM).(Abstract #7090)F. Rea, A. G. Favaretto, G. Marulli, L. Spaggiari, T. M. De Pas, A. Ceribelli,A. Paccagnella, G. Crivellari, F. Russo, M. Ceccarelli, F. Facciolo180

Saturday, June 4, 2011Brd. 31E Imatinib mesylate in thymic epithelial malignancies. (Abstract #7091)C. Buonerba, M. Marino, S. Sioletic, S. Conti, L. Petillo, P. Federico, V. Damiano,G. Merola, A. Evoli, M. Lalle, A. Ceribelli, M. Milella, G. PalmieriSATURDAY181

Saturday, June 4, 20112:00 PM - 6:00 PMGENERAL POSTER SESSIONSATURDAYLung Cancer—Metastatic/Non-small CellLocation: Hall ATrack(s): Lung CancerBrd. 32A Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-smallcell lung cancer (mNSCLC): A National Comprehensive Cancer Network(NCCN) outcomes database analysis. (Abstract #7537)K. E. Bickel, J. C. Niland, R. Mamet, C. C. Zornosa, D. S. Ettinger, K. Pisters,G. A. Otterson, M. Koczywas, M. E. Reid, M. S. Rabin, T. A. D’Amico, C. Earle,T. M. Pini, G. P. KalemkerianBrd. 32B Guideline adherence rates and costs of chemotherapy treatment for NSCLCpatients treated in U.S. community oncology practices. (Abstract #7538)Z. Wang, I. Aksamit, L. Tuscher, B. S. Tom, C. B. Del Buono, U. Campbell,S. Shields, T. Lam, K. B. Whitlock, M. Mayo, J. Huang, A. M. Christman,K. A. BergstromBrd. 32C The effect of 3 months of integrative cancer treatment on quality of life forpatients with lung cancer. (Abstract #7539)E. D. Staren, D. Gupta, J. F. Grutsch, D. P. BraunBrd. 32D Influence of crossover therapy on the association between progression-freesurvival (PFS) and overall survival (OS) in randomized trials of moleculartargetedagents for advanced non-small cell lung cancer (NSCLC). (Abstract#7540)K. Hotta, K. Kiura, E. Suzuki, N. Takigawa, Y. Fujiwara, E. Ichihara, M. Tabata,M. TanimotoBrd. 32E Factors influencing a specific histological diagnosis of non-small cell lungcancer. (Abstract #7541)J. A. Sulpher, S. P. Owen, H. Hon, K. Tobros, F. A. Shepherd, E. Sabri, G. Liu,C. M. Canil, P. Wheatley-PriceBrd. 32F Surgical, histopathologic, and patient-related factors associated withisolated brain metastases (IBM) in patients with stages I-IIIA non-small cellcarcinoma (NSCLC) undergoing surgical resection in comparison to patientsdeveloping other distal metastases (ODM). (Abstract #7542)J. M. Varlotto, L. N. Medford-Davis, J. Shelkey, J. C. Flickinger, A. Recht,M. Nikolov, M. Reed, J. Toth, M. M. DeCampBrd. 32G Retrospective review of MRIs in lung cancer patients with brain metastases:An assessment of early response. (Abstract #7543)R. Zinner, M. Debnam, G. W. Gladish, B. Konda, J. M. Hanneken, D. J. Stewart,R. F. Munden, L. ChiBrd. 32H Clinical outcome of patients with leptomeningeal metastasis from non-smallcell lung cancer: Okayama Lung Cancer Study Group. (Abstract #7544)S. Umemura, K. Kiura, K. Tsubouchi, N. Takigawa, K. Fujiwara, N. Horita,Y. Segawa, N. Hamada, I. Takata, M. TanimotoBrd. 33A Prospective study on incidence of bone metastasis (BM) and skeletal-relatedevents (SREs) in patients (pts) with stage IIIB and IV lung cancer (CSP-HOR13). (Abstract #7545)N. Katakami, A. Hata, H. Kunikane, K. Takeda, K. Eguchi, K. Takayama, T. Sawa,H. Saito, M. Harada, S. Yokota, K. Ando, Y. OhashiBrd. 33B Can we really treat patients over 70 years old with a chemotherapy doubletfor non-small cell lung cancer (NSCLC)? (Abstract #7546)M. G. Zauderer, C. S. Sima, B. Korc-Grodzicki, M. G. Kris, L. M. KrugBrd. 33C Meta-analysis of efficacy and safety of single-agent and doubletchemotherapy with or without platinum in advanced non-small cell lungcancer in the elderly. (Abstract #7547)G. Des Guetz, B. Uzzan, P. Nicolas, K. Chouahnia, G. Sebbane, J. F. Morere182

Saturday, June 4, 2011Brd. 33DBrd. 33EBrd. 33FBrd. 33GBrd. 33HBrd. 34ABrd. 34BBrd. 34CBrd. 34DBrd. 34EBrd. 34FPhase II study of bevacizumab and erlotinib in treatment-naive elderlypatients (older than age 65) with advanced non-small cell lung cancer(NSCLC). (Abstract #7548)H. Borghaei, R. Mehra, M. M. Millenson, H. Tuttle, K. Ruth, A. J. Magdalinski,D. M. Mintzer, J. Lee, J. Stevenson, C. J. LangerResults of a phase II study of single-agent sunitinib in elderly non-small celllung cancer patients. (Abstract #7549)C. Reynolds, A. I. Spira, W. L. Gluck, R. E. Pluenneke, K. A. Boehm, F. Zhan,L. AsmarDo elderly chemorefractory NSCLC patients derive benefit from salvagetargeted therapy? Subgroup analysis of clinical outcome and toxicity fromthe BATTLE trial. (Abstract #7550)A. S. Tsao, S. Liu, J. Lee, C. M. Alden, E. S. Kim, G. R. Blumenschein Jr.,R. S. Herbst, S. M. Lippman, I. I. Wistuba, W. K. HongSurvival results of a randomized, phase III trial of nab-paclitaxel andcarboplatin compared with cremophor-based paclitaxel and carboplatin asfirst-line therapy in advanced non-small cell lung cancer. (Abstract #7551)M. A. Socinski, I. N. Bondarenko, N. A. Karaseva, A. Makhson, I. Vynnychenko,I. Okamoto, J. K. Hon, V. Hirsh, P. Bhar, G. I. Berk, J. L. IglesiasPhase III study comparing the effects of carboplatin plus S-1 and carboplatinplus paclitaxel in chemotherapy-naive patients with advanced non-small celllung cancer: An updated report of the LETS study (WJTOG3605). (Abstract#7552)T. Hirashima, I. Okamoto, H. Yoshioka, S. Morita, M. Ando, K. Takeda, T. Seto,N. Yamamoto, H. Saka, K. Asami, S. Kudoh, M. Satouchi, N. Ikeda, Y. Iwamoto,T. Sawa, M. Miyazaki, K. Tamura, T. Kurata, M. Fukuoka, K. Nakagawa,West Japan Oncology GroupSingle-agent maintenance therapy for advanced-stage non-small cell lungcancer: A meta-analysis. (Abstract #7553)M. Behera, T. K. Owonikoko, Z. Chen, S. A. Kono, F. R. Khuri, C. P. Belani,S. S. RamalingamResults of a randomized phase IIb study estimating overall survival ofpralatrexate versus erlotinib in platinum-pretreated NSCLC. (Abstract #7554)J. D. Patel, C. G. Azzoli, G. A. Weems, A. Koutsoukos, P. Zatloukal, K. KellyPemetrexed versus pemetrexed plus carboplatin in pretreated patients withadvanced non-small cell lung cancer (NSCLC): Pooled analysis of tworandomized trials. (Abstract #7555)A. Ardizzoni, L. Boni, M. Tiseo, A. Vincent, R. Passalacqua, A. Camerini,R. Labianca, G. Genestreti, F. Zanelli, L. Ciuffreda, F. Di Costanzo, F. De Marinis,L. Crinò, A. Santo, A. Pazzola, F. Barbieri, N. Zilembo, I. Colantonio, C. Tibaldi,E. F. SmitPrognostic score for second-line chemotherapy of advanced non-small celllung cancer (NSCLC): External validation in a phase III trial comparingvinflunine with docetaxel. (Abstract #7556)M. J. Krzakowski, M. Di Maio, K. Perraud, D. M. Kowalski, C. GridelliThe role of gender in predicting for reduced drug clearance and increasedtoxicity in non-small cell lung cancer (NSCLC) patients receiving carboplatinand paclitaxel. (Abstract #7557)V. H. Phan, C. Tan, J. L. Vardy, A. Rittau, H. Xu, F. Zhang, A. J. McLachlan,P. J. Beale, S. J. ClarkeStandard chemotherapy strategy versus changing chemotherapy strategy asto FDG-PET response after first cycle of standard chemotherapy foradvanced NSCLC. (Abstract #7558)S. Kim, J. Kim, K. Kim, D. Lee, C. Choi, D. Moon, J. Ryu, S. Oh, C. Suh, J. LeeSATURDAY183

Saturday, June 4, 2011SATURDAYBrd. 34GBrd. 34HBrd. 35ABrd. 35BBrd. 35CBrd. 35DBrd. 35EBrd. 35FBrd. 35GBrd. 35HA randomized phase II trial of a vascular disrupting agent (VDA)fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P),bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer(NSCLC): Analysis of safety and activity of the FALCON trial. (Abstract#7559)E. B. Garon, F. F. Kabbinavar, J. A. Neidhart, J. D. Neidhart, N. Y. Gabrail,M. R. Oliveira, S. Lu, J. BalkissoonRandomized phase II study of vandetanib (V), docetaxel (D), and carboplatin(C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, orrecurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501—Update onmaintenance treatment and progression-free and overall survival (PFS, OS).(Abstract #7560)J. Aisner, J. Manola, S. R. Dakhil, P. J. Stella, J. H. Schiller, PrECOG, LLCBevacizumab (B) and erlotinib (E) as first-line therapy in metastaticnonsquamous non-small cell lung cancer (NSCLC) followed by platinumbasedchemotherapy (CT) at disease progression (PD): A multicenter phase IItrial SAKK 19/05. (Abstract #7561)F. Zappa, C. Droege, D. C. Betticher, R. von Moos, M. H. Brutsche, F. Baty,L. Bubendorf, A. Ochsenbein, E. Oppliger Leibundgut, O. Gautschi, P. Froesch,R. A. Stahel, D. Rauch, P. Schmid, M. Mayer, S. Crowe, P. Brauchli, K. Ribi,M. PlessAVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or withoutpemetrexed (pem) in patients (pts) with advanced nonsquamous non-smallcell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)-pem: Interim safety data. (Abstract #7562)F. Barlesi, A. Scherpereel, R. Gervais, V. A. Gorbunova, A. Vikström, M. J. Ahn,J. H. Kim, A. Chella, J. Aerts, N. Ferrer, J. M. Trigo Perez, B. Lutiger, A. RittmeyerPhase II study of topotecan and bevacizumab in advanced refractory nonsmallcell lung cancer (NSCLC). (Abstract #7563)S. F. Powell, A. Beitinjaneh, R. L. Bliss, R. A. Kratzke, J. W. Leach, A. DudekCediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients(pts) with recurrent non-small cell lung cancer (NSCLC). (Abstract #7564)S. M. Gadgeel, J. C. Ruckdeschel, A. J. Wozniak, W. Chen, D. Hackstock,C. Galasso, A. Burger, S. P. Ivy, P. LoRusso, M. J. EdelmanPhase I dose-escalation study of sorafenib in combination with bevacizumab(B), paclitaxel (P), and carboplatin (C) for the treatment of advancednonsquamous non-small cell lung cancer (NSCLC). (Abstract #7565)G. R. Blumenschein, J. R. Molina, C. D. Lathia, T. J. Ong, D. Roth, P. Rajagopalan,F. V. Fossella, M. S. Kies, R. S. Marks, A. A. Adjei, P. R. SundaresanALK rearrangement in a selected population of advanced non-small cell lungcancer patients: FISH and inmunohistochemistry diagnostic methods,prevalence and clinical outcomes. (Abstract #7566)P. Martinez, J. Hernandez-Losa, J. Castellvi, N. Tallada, S. Cedres, M. Montero,V. Rodriguez-Freixinos, I. Nuňez, G. Argiles, N. Mulet-Margalef, D. Torrejon,S. Ramon y Cajal, E. FelipVorinostat (V) and bortezomib (B) as third-line treatment in patients withadvanced non-small cell lung cancer (NSCLC): A Wisconsin OncologyNetwork Phase II Study. (Abstract #7567)M. W. Jones, C. Zhang, K. R. Oettel, J. H. Blank, E. G. Robinson, H. G. Ahuja,R. J. Kirschling, P. H. Johnson, M. S. Huie, J. Kolesar, M. Wims, H. Hernan,T. C. Campbell, A. M. Traynor, T. HoangRandomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapynaivepatients with non-small cell lung cancer (NSCLC): Preliminary results.(Abstract #7568)V. Gregorc, N. Zilembo, F. Grossi, G. Rossoni, F. Pietrantonio, E. Rijavec,A. Bulotta, M. Vitali, G. Barletta, L. Bergamaschi, M. Platania, F. Caligaris-Cappio,A. Lambiase, C. Bordignon184

Saturday, June 4, 2011Brd. 36A The effect of talactoferrin on overall survival in prognostically importantNSCLC subsets in a randomized, placebo-controlled phase II trial. (Abstract#7569)P. M. Parikh, A. Ranade, A. K. Vaid, S. H. Advani, A. Bapna, J. Zhu, Y. Wang,P. M. Ismail, R. K. MalikBrd. 36B A phase IB trial of iniparib (BSI-201) in combination with carboplatin(C)/paclitaxel (P) in patients with non-small cell lung cancer (NSCLC).(Abstract #7570)A. C. Mita, M. M. Mita, C. Rocha, C. R. Bradley, J. Sarantopoulos, P. O’Rourke,S. M. Gadgeel, A. J. Wozniak, E. I. HeathBrd. 36C Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growthfactor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) inAsian patients (pts) with NSCLC. (Abstract #7571)E. Tan, K. Park, W. T. Lim, M. Ahn, Q. Ng, J. Ahn, D. S. Tan, J. Sun, J. Jac,M. Han, F. C. Payumo, M. Credi, K. McKee, M. M. Cotreau, P. Bhargava,W. SlichenmyerBrd. 36D A phase I study of MM-10–001 in advanced non-small cell lung cancer.(Abstract #7572)M. C. Cristea, M. Koczywas, K. L. Reckamp, S. F. Lacey, A. Rotter, P. H. Frankel,S. Fouladi Rad, X. Liu, V. Tran, E. Reorizo, M. KalosBrd. 36E Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small celllung cancer (NSCLC). (Abstract #7573)P. C. Mack, N. Farneth, C. Mahaffey, P. Lara Jr., D. R. GandaraBrd. 36F Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategyfor patients with advanced and previously treated non-small cell lung cancer(NSCLC). (Abstract #7574)G. R. Simon, S. Saddoughi, A. Mukhopadhyay, Y. Peterson, C. E. Senkal, J. Oaks,D. Perrotti, Y. Hannun, B. OgretmenBrd. 36G DIRECT: DNA-mutation Inventory to Refine and Enhance CancerTreatment—A catalogue of clinically relevant somatic mutations in lungcancer. (Abstract #7575)L. Horn, H. Chen, C. M. Lovly, J. Andrews, P. Yeh, M. A. Levy, W. PaoBrd. 36H My Cancer Genome: Web-based clinical decision support for genomedirected lung cancer treatment. (Abstract #7576)M. A. Levy, C. M. Lovly, L. Horn, R. Naser, W. PaoBrd. 37A Screening for mutations in Colombian metastatic non-small cell lung cancer(NSCLC) patients (ONCOLGroup). (Abstract #7577)A. F. Cardona, P. L. Ramos, R. Duarte, H. Carranza, C. J. Castro, M. Lema,C. A. Vargas, A. Jimenez, H. A. Becerra, R. RosellBrd. 37B Development of prognostic biomarker in pathologic stage I NSCLC patients:Protein expressions involving in DNA damage response. (Abstract #7578)J. Ryu, C. Choi, S. Yang, H. Nam, H. Kim, M. H. LeeBrd. 37C Significance of thymidylate synthase and thyroid transcription factor 1expression in patients with nonsquamous non-small cell lung cancer treatedwith pemetrexed-based chemotherapy. (Abstract #7579)J. Sun, J. Ahn, K. Park, J. Han, M. AhnBrd. 37D Clinical outcome of KRAS mutated advanced non-small cell lung cancer(NSCLC) patients (pts): A mono-institutional analysis. (Abstract #7580)R. Chiari, V. De Angelis, C. Bennati, C. Molica, G. Metro, S. Duranti,F. R. Tofanetti, V. Ludovini, V. Minotti, L. CrinoBrd. 37F Role of basal inflammatory status as a predictor of survival in bevacizumabtreated advanced non-small cell lung cancer (NSCLC) patients. (Abstract#7582)C. Botta, A. Guglielmo, E. Bestoso, S. Apollinari, A. Licchetta, P. Blardi,P. Tassone, G. Chiriaco, V. Barbieri, G. Mantovani, P. Tagliaferri, P. CorrealeSATURDAY185

Saturday, June 4, 2011SATURDAYBrd. 37GBrd. 37HBrd. 38ABrd. 38BBrd. 38CBrd. 38DBrd. 38EBrd. 38FBrd. 38GBrd. 38HCirculating endothelial cells, endothelial progenitor cells, microparticles, andmarkers of inflammation and coagulation in advanced non-small cell lungcancer. (Abstract #7583)T. Fleitas, G. Reynes, V. Martinez-Sales, V. Vila, E. Reganon, D. Mesado,M. Martin, J. Gómez-Codina, J. MontalarInvestigation of predictive biomarkers for R1507, an anti-IGF1R antibody, inpatients with advanced non-small cell lung cancer with progression afterfirst-line chemotherapy. (Abstract #7584)K. Habben, P. Delmar, C. M. Brownstein, W. Koehler, K. Kuenkele, O. Splesis,S. S. Ramalingam, J. A. Engelman, D. ChenInfluence of expression of estrogen (ERS-1) and progesterone (PGR)receptors on metastatic spread and outcome in non-small cell lung cancer(NSCLC). (Abstract #7585)W. M. Brueckl, C. Eschbach, G. H. Wiest, J. H. Ficker, S. Zirlik, R. Hake, S. Eidt,A. Hartmann, R. M. WirtzThe nuclear factor kb (NFkB) and Notch signalling pathways and BRCA1mRNA expression in stage IV non-small cell lung cancer (NSCLC) patients(p). (Abstract #7586)M. Santarpia, M. Sanchez-Ronco, I. Magri, S. Viteri, C. Costa, A. Gasco,M. Gonzalez Cao, N. Mederos, F. Salazar, J. Bertran-Alamillo,A. Gimenez Capitan, G. Altavilla, S. Benlloch, Z. Yeste, E. Aldeguer, M. Taron,R. RosellClinical, pathological, and molecular characteristics of patients with nonsmallcell lung cancer harboring mutations in PIK3CA. (Abstract #7587)M. Pietanza, M. E. Arcila, J. E. Chaft, M. F. Zakowski, M. Ladanyi, G. J. Riely,M. G. KrisMutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treatednon-small cell lung cancer (NSCLC) patients (p) with epidermal growth factorreceptor (EGFR) mutations. (Abstract #7588)E. Carcereny, M. A. Molina, J. Sanchez, J. Bertran-Alamillo, C. Mayo, E. Aldeguer,A. Gimenez Capitan, Z. Yeste, C. Costa, S. Benlloch, A. Martinez, C. Buges,J. Bosch, D. Isla, M. Domine, M. Provencio, C. Camps, M. Taron, R. RosellIdentification of AEG-1 and BARD1 as predictors of erlotinib outcome inEGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multipletarget profiling. (Abstract #7589)M. Taron, S. Benlloch, R. Rosell, J. Sanchez, C. Costa, A. Gimenez Capitan,C. Mayo, J. Bertran-Alamillo, M. A. Molina, B. Massuti, C. Camps, M. Majem,D. Isla, M. Santarpia, S. Viteri, A. Gasco, T. Moran, E. Carcereny, C. Queralt,I. de AguirreInitial detection of the double epidermal growth factor receptor (EGFR)mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small celllung cancer (NSCLC) patients (p) with brain metastases (mets) and theinfluence of first-line chemotherapy on outcome to erlotinib. (Abstract #7590)T. Moran, J. Sanchez, M. A. Molina, J. Bertran-Alamillo, A. Gimenez Capitan,S. Benlloch, M. Taron, B. Massuti, C. Camps, R. Porta, D. Isla, G. Lopez-Vivanco,I. Bover, M. Garcia-Campelo, C. D. Rolfo, F. Salazar, E. Carcereny, F. Cardenal,I. Magri, R. Rosell[ 18 F]fluoro-L-thymidine (FLT) uptake in baseline positron emissiontomography (PET) as a prognostic marker in patients with advanced nonsmallcell lung cancer (NSCLC) treated first-line with erlotinib. (Abstract#7591)M. Scheffler, T. Zander Jr., L. Nogova, C. Kobe, D. Kahraman, M. Dietlein,I. Papachristou, S. Querings, E. Stoelben, W. Engel-Riedel, B. Neumaier, J. WolfAssociation of CA repeat number and R497K with PFS to EGFR TKIs inNSCLC patients having sensitive mutation of EGFR. (Abstract #7592)J. Kang, E. Jeon, J. Shin, J. Kim, M. Lee, Y. Kim, K. Lee, Y. Wang, E. Cho186

Saturday, June 4, 2011Brd. 39ABrd. 39BBrd. 39CBrd. 39DBrd. 39EBrd. 39FBrd. 39GBrd. 39HBrd. 40ABrd. 40BBrd. 40CBrd. 40DDAB2 interactive protein (DAB2IP) methylation in serum DNA of non-smallcell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor(EGFR) mutations. (Abstract #7593)J. Wei, J. Ramirez, M. Taron, J. Sanchez, S. Benlloch, R. Rosell, M. Botia,M. Perez-Cano, P. Mendez, M. Tierno, C. Queralt, I. de Aguirre, B. Sanchez,A. Martinez, C. Buges, J. Bosch, B. Massuti, C. Camps, T. MoranQuantitative detection of the T790M EGFR mutation in circulating tumor DNAof lung cancer patients subjected to EGFR-TKI treatment. (Abstract #7594)J. Uchida, K. Taniguchi, F. Imamura, K. Nishino, T. Kumagai, Y. Akazawa,T. Okuyama, K. KatoCirculating tumor cells and detection of EGFR mutation in cell-free tumorDNA in blood plasma in metastatic non-small cell lung cancer with EGFRmutation. (Abstract #7595)K. Isobe, Y. Hata, S. Sakaguchi, K. Sato, K. Sugino, G. Sano, S. Sakamoto,Y. Takai, K. Shibuya, K. Takagi, S. HommaThe surfactant protein B (SFTPB) as a surrogate of circulating tumor cells(CTC) with prognostic value in advanced-stage NSCLC. (Abstract #7596)R. Sirera, E. Jantus-Lewintre, A. Timon, M. Usó, A. Berrocal, S. Borrego,G. Marcaida, E. Sanmartin, R. Rosell, C. CampsFirst-line erlotinib in advanced non-small cell lung cancer (NSCLC) carryingan activating EGFR mutation: A multicenter academic phase II study incaucasian patients (pts) (NCT00339586)—FIELT study group. (Abstract#7597)J. De Greve, J. P. Van Meerbeeck, J. F. Vansteenkiste, E. Teugels, C. Geers,A. Meert, P. Vuylsteke, C. N. Focan, J. Canon, Y. Humblet, G. J. Berchem,B. Colinet, D. Galdermans, L. Bosquée, C. A. Dooms, L. Decoster, J. Vermeij,A. Dewaele, D. C. SchallierEpidermal growth factor receptor (EGFR) mutation testing and first-linetreatment with gefitinib as a strategy in the treatment of patients withadvanced non-small cell lung cancer (NSCLC). (Abstract #7598)G. Lopes, J. Segel, D. S. Tan, Y. Do, T. Mok, E. FinkelsteinTargeting therapies influence survival of refractory patients with lungadvanced adenocarcinoma: A phase III randomized trial. (Abstract #7599)K. Zarogoulidis, E. Boutsikou, T. Kontakiotis, P. Zarogoulidis, E. Eleftheriadou,L. Sacas, G. GalaktidouMeta-analysis of the chemotherapy versus EGFR-TKI in different selectionsof patients. (Abstract #7600)C. Xu, Q. Zhou, Y. WuPhase II study of dose-dense chemotherapy followed by dose-intenseerlotinib for initial treatment of metastatic NSCLC. (Abstract #7601)L. L. Waller, A. A. Miller, N. P. Streer, J. F. Lovato, W. J. PettySystematic comparative analysis of efficacy of EGFR tyrosine kinaseinhibitors (TKIs) in the frontline versus salvage therapy of NSCLC. (Abstract#7602)T. K. Owonikoko, M. Behera, H. N. Tran, Z. Chen, R. P. Chowdry, N. F. Saba,S. S. Ramalingam, F. R. KhuriRandomized phase III trial of gefitinib or pemetrexed as second-linetreatment in patients with non-small cell lung cancer previously treated withplatinum-based chemotherapy (KCSG-LU08-01). (Abstract #7603)M. Ahn, J. Sun, J. Ahn, S. Kim, K. Lee, Y. Min, H. Yun, H. Kim, H. Song, Y. H. Kim,B. Kim, I. Hwang, I. S. Woo, H. Ryoo, H. Yi, J. Jang, J. Kwon, K. ParkSafety data and patterns of progression in met diagnostic subgroups inOAM4558g: A phase II trial evaluating MetMAb in combination with erlotinibin advanced NSCLC. (Abstract #7604)A. Vashishtha, P. H. Patel, W. Yu, J. G. Bothos, J. Simpson, T. Maneatis,L. Doessegger, A. C. Peterson, C. Clement-Duchene, G. Robinet, M. Krzakowski,G. R. Blumenschein Jr., J. H. Goldschmidt Jr., D. B. Daniel, D. R. SpigelSATURDAY187

Saturday, June 4, 2011SATURDAYBrd. 40EBrd. 40FBrd. 40GBrd. 40HBrd. 41ABrd. 41BBrd. 41CA phase II study (CTONG0803) of erlotinib as second-line treatment inadvanced non-small cell lung cancer (NSCLC) patients (pts) withasymptomatic brain metastases (BM) after first-line chemotherapy (CT).(Abstract #7605)Y. Wu, C. Zhou, Y. Cheng, S. Lu, G. Chen, C. Huang, Y. Huang, H. Yan, J. Yang,Chinese Thoracic Oncology GroupEfficacy of epidermal growth factor receptor tyrosine kinase inhibitors forbrain metastasis in non-small cell lung cancer patients harboring either exon19 or 21 mutations. (Abstract #7606)K. Kim, D. Lee, J. Lee, C. Suh, S. Kim, C. Choi, S. Jang, J. ChoiRates of central nervous system (CNS) metastases in patients with advancednon-small cell lung cancer (NSCLC) and somatic EGFR mutations initiallytreated with gefitinib or erlotinib versus chemotherapy. (Abstract #7607)S. Heon, B. Y. Yeap, N. I. Lindeman, M. S. Rabin, D. M. Jackman, B. E. JohnsonCerebral penetration of gefitinib in patients with lung adenocarcinoma.(Abstract #7608)M. Wang, Z. Jing, C. MinjiangHow sensitive are epidermal growth factor receptor-tyrosine kinaseinhibitors for squamous cell carcinoma of the lung harboring epidermalgrowth factor receptor gene sensitive mutations? (Abstract #7609)A. Hata, N. Katakami, K. Kunimasa, H. Yoshioka, S. Fujita, R. Kaji, Y. Imai,K. Tomii, M. Iwasaku, A. Nishiyama, T. IshidaTime course of skin toxicity (tox) secondary to erlotinib (E) therapy inpatients (pts) with non-small cell lung cancer (NSCLC) enrolled in theSATURN study. (Abstract #7610)R. Perez-Soler, F. Cappuzzo, L. Leon, S. Wojtowicz-PragaImplementation of adherence to erlotinib by a treatment-monitoring program.(Abstract #7611)V. Gebbia, M. Bellavia, P. Russo, G. L. Banna, F. Ferraù, P. Tralongo,N. Borsellino188

Saturday, June 4, 20112:00 PM - 6:00 PMGENERAL POSTER SESSIONPatient and Survivor CareLocation: Hall ATrack(s): Patient and Survivor CareBrd. 42A Incidence and predictors of delayed congestive heart failure (CHF) afterhematologic malignancies treated with autologous hematopoietic celltransplantation (aHCT). (Abstract #9042)S. Armenian, C. Sun, T. Shannon, M. Shangguan, G. MIlls III, L. Francisco,F. L. Wong, S. J. Forman, S. BhatiaBrd. 42B The risk of subsequent malignancies in cervical cancer survivors ascompared with breast and colorectal cancer survivors: United States1992–2007. (Abstract #9043)J. Underwood, S. Rim, E. Tai, T. FairleyBrd. 42C Prevalence and correlates of suicidal ideation among outpatients at acomprehensive cancer center. (Abstract #9044)J. M. Randall, L. Bazhenova, M. White, A. A. Bharne, K. A. Shimabukuro,Y. Matusov, K. Messer, A. Lowery, M. Loscalzo, K. Clark, W. BardwellBrd. 42D Long-term effects of the diagnosis and treatment of breast cancer uponyoung breast cancer survivors. (Abstract #9045)P. H. Morrow, A. C. Broxson, M. Munsell, K. Basen-Engquist, C. K. Rosenblum,L. H. Nguyen, L. R. Schover, K. Hahn, J. K. Litton, G. N. HortobagyiBrd. 42E An evaluation of serum cytokine levels and fatigue and depression in ECOGE4Z02. (Abstract #9046)T. A. Rich, J. Manola, D. Cella, R. A. Cruciani, M. Fisch, Eastern CooperativeOncology GroupBrd. 42F Paclitaxel-associated acute pain syndrome (P-APS) and its association onthe development of peripheral neuropathy: NCCTG trial N08C1. (Abstract#9047)B. Reeves, S. R. Dakhil, J. A. Sloan, K. N. Burger, N. A. Le-Lindqwister,G. S. Soori, A. J. Jaslowski, J. Kelaghan, D. H. Lachance, C. L. LoprinziBrd. 42G Survival effect of darbepoetin alfa in patients with diffuse large B-celllymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6Bstudy. (Abstract #9048)R. Delarue, C. Haioun, B. Coiffier, L. Fornecker, M. Fournier, N. Mounier,T. J. Molina, S. Bologna, C. Fruchart, S. Picard, H. Tilly, A. BoslyBrd. 42H Randomized, multicenter, phase II trial of compound Chinese herbal extractLC09 versus placebo for external treatment of hand-foot syndrome inducedby anticancer therapy. (Abstract #9049)L. Jia, Y. Lou, A. Tian, S. Zhu, X. ZhangBrd. 43A Structural and functional MRI of the brain as biomarker for postcancerfatigue. (Abstract #9050)H. Prinsen, A. Heerschap, G. Bleijenberg, M. Zwarts, M. van der Graaf,M. Rijpkema, H. Van LaarhovenBrd. 43B Long-term survival rates of older breast cancer patients: Population-basedestimates over three decades. (Abstract #9051)B. Kanapuru, A. Jemal, C. S. Hesdorffer, W. B. Ershler, J. W. YatesBrd. 43C A risk stratification schema for predicting diabetes mellitus in cancersurvivors. (Abstract #9052)A. Moghaddamjou, A. Y. Tashakkor, P. Birks, W. Y. CheungBrd. 43D Quality-of-life concordance between patients with malignant gliomas andtheir caregivers: Updated data. (Abstract #9053)B. V. Stell, D. Jacobs, S. A. Grimm, A. Rademaker, L. Rice, M. A. Schwartz,K. Muro, M. H. Marymont, J. Chandler, I. B. Helenowski, L. I. Wagner, J. J. Raizer,C. L. BennettSATURDAY189

Saturday, June 4, 2011SATURDAYBrd. 43EBrd. 43FBrd. 43GBrd. 43HBrd. 44ABrd. 44BBrd. 44CBrd. 44DBrd. 44EBrd. 44FBrd. 44GBrd. 44HBrd. 45ACost-effectiveness of universal hepatitis B virus screening in patientsbeginning chemotherapy for solid tumors. (Abstract #9054)F. L. Day, J. Karnon, D. RischinA prospective, observational study of medication use among outpatientswith common solid tumors. (Abstract #9055)M. Weiss, J. Manola, M. A. Thompson, M. L. Thomas, M. FischReactivation of hepatitis B infection among patients with cancer. (Abstract#9056)J. Hwang, M. Fisch, H. Zhang, M. Kallen, M. Routbort, L. S. Lal, J. Vierling,M. Suarez-AlmazorAnalysis of overall survival and self-reported fatigue in patients with locallyadvanced esophageal cancer: A Mayo Clinic Esophageal Adenocarcinomaand Barrett’s Esophagus Registry Consortium study. (Abstract #9057)M. C. Stauder, Y. Romero, B. Kabat, P. J. Atherton, M. B. Fredericksen,C. Deschamps, A. Jatoi, J. A. Sloan, M. Botros, R. C. MillerAccrual of underrepresented minority women to breast cancer clinical trialsin the Inland Empire, California. (Abstract #9058)Y. Yuan, P. Uppala, S. S. Lum, C. Garberoglio, H. R. Mirshahidi, R. Cassady,J. Morgan, C. ChenIncidence and risk factors predictive of recurrent venous thromboembolismin patients with cancer at a comprehensive cancer center. (Abstract #9059)S. Vadhan-Raj, X. Zhou, R. S. Benjamin, G. W. GladishAchievement of personalized pain goal (PPG) in cancer patients referred to asupportive care clinic. (Abstract #9060)S. Dalal, D. Hui, L. M. Nguyen, R. Chacko, E. BrueraIncidence of febrile neutropenia with docetaxel plus cyclophosphamide in auniversity-based breast oncology clinic. (Abstract #9061)A. Soni, A. Brufsky, R. C. Jankowitz, P. Rastogi, V. G. Vogel, S. PuhallaParenthood in survivors of Hodgkin lymphoma: An EORTC-GELA generalpopulation case-control study. (Abstract #9062)M. A. van der Kaaij, N. Heutte, P. Meijnders, J. M. Raemaekers,E. Abeilard-Lemoisson, A. Allgeier, B. Meulemans, A. H. Simons, N. Mounier,M. Henry-Amar, J. C. Kluin-Nelemans, European Organization for Research andTreatment of Cancer (EORTC) Lymphoma Group and the Groupe d’Etude desLymphomes de l’Adulte (GELA)Is there an advantage to adding inferior vena cava filter (IVCF) placement toanticoagulation with fondaparinux in patients with cancer and venousthromboemboli (VTE): Results of the Cancer and Thrombosis (CAT)prospective randomized clinical trial (RCT). (Abstract #9063)M. F. Barginear, R. J. Gralla, M. Akerman, M. Lesser, T. P. Bradley, I. Shapira,N. J. Nier-Shoulson, C. R. Greben, D. R. BudmanSymptom burden and change among adolescent/young adult (AYA) patientswith breast, lung, colorectal, or prostate cancer. (Abstract #9064)V. T. Chang, F. Zhao, L. I. Wagner, S. D. Sanford, J. Salsman, M. FischPrognostic value of multidimensional geriatric assessment (MGA) onsurvival of a prospective cohort of 880 elderly cancer patients (ECP).(Abstract #9065)U. Basso, C. Falci, A. Brunello, V. Zafferri, P. Fiduccia, G. Sergi, S. Lonardi,E. Lamberti, E. Castegnaro, C. Soldà, F. Cossutta, V. Chiarion-Sileni,S. Monfardini, V. ZagonelOVERcome: An intervention study to improve sexual function in women withbreast cancer. (Abstract #9066)I. Juraskova, S. Jarvis, K. Mok, M. Peate, B. Meiser, S. Mireskandari,M. Friedlander190

Saturday, June 4, 2011Brd. 45BBrd. 45CBrd. 45DBrd. 45EBrd. 45FBrd. 45GBrd. 45HBrd. 46ABrd. 46BBrd. 46CBrd. 46DBrd. 46EBrd. 46FBrd. 46GBrd. 46HRecalling breast cancer presentation and therapy: Associations betweenpatient inaccuracy and demographic characteristics. (Abstract #9067)W. C. Mertens, C. Loke, D. Katz, R. Barham, G. Makari-JudsonUnderstanding the psychosocial needs of young adults with cancer:Identifying targets for clinical intervention. (Abstract #9068)K. M. Trevino, K. Fasciano, A. H. Partridge, P. Maciejewski, E. Kacel, R. Jimenez,S. Block, H. G. PrigersonSleep disturbance in patients with advanced cancer: Frequency and factorsassociated with response to specialist-based outpatient supportive care.(Abstract #9069)S. Yennurajalingam, G. Chisholm, S. L. Palla, E. BrueraQuality-of-life (QOL) evaluation within a randomized phase III study ofgemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) inunresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GESTstudy. (Abstract #9070)Y. Ohashi, M. Tanaka, N. Boku, H. Ueno, T. OkusakaPredicting the risk of cardiovascular comorbidity in cancer survivors.(Abstract #9071)A. Y. Tashakkor, A. Moghaddamjou, W. Y. CheungCancer-related fatigue and sexual functioning in women with early breastcancer: Is there a link? (Abstract #9072)K. Webber, K. Mok, B. K. Bennett, I. Juraskova, D. Goldstein, M. Friedlander,A. R. Lloyd, FOLCAN study groupClinical trial participation among patients with advanced cancer: Whatcharacteristics most influence enrollment? (Abstract #9073)R. Jimenez, B. Zhang, M. E. Nilsson, S. Joffe, C. Lathan, H. G. PrigersonStage I lung cancer survivorship: Incidence of secondary malignancies andneed for individualized care plan. (Abstract #9074)R. Surapaneni, K. Rajagopalan, A. HageboutrosZoledronic acid inhibits adjuvant letrozole-associated bone loss inpostmenopausal Japanese women with early breast cancer. (Abstract #9075)S. Takahashi, T. Iwase, N. Kohno, T. Ishikawa, T. Taguchi, M. Takahashi,J. Horiguchi, S. Nakamura, M. Fukunaga, S. NoguchiDoes time-to-antibiotics predict outcome of febrile neutropenia in pediatriccancer? (Abstract #9076)M. B. Fletcher, H. Hodgkiss, R. Browning, T. Hoffman, C. Hadden, N. J. Winick,T. L. McCavitHealth-related quality of life (HRQOL) of patients 3 years after radiationtherapy (RT) for early head and neck cancer (HNC). (Abstract #9077)I. Bairati, F. MeyerAprepitant is active in biologic therapies induced severe pruritus: Proof ofconcept study. (Abstract #9078)D. Santini, B. Vincenzi, F. Guida, A. Frezza, O. Venditti, M. Silletta, G. ToniniAntiemetic control of palonosetron in patients with gastrointestinal cancerreceiving a fluoropyrimidine-based regimen containing either irinotecan oroxaliplatin. (Abstract #9079)M. A. Blazer, J. Reardon, D. Efries, Y. T. Smith, L. M. Weatherby, K. Juergens,T. Criswell, J. S. Rose, G. S. Phillips, N. Griffith, T. S. Bekaii-SaabA randomized, double-blind, active control, multicenter, dose-finding studyof XM22, glycopegfilgrastim, in patients with breast cancer receivingmyelosuppressive therapy. (Abstract #9080)A. Buchner, P. Bias, M. KaufmannFrequency and predictors of patient deviation from prescribed opioids andbarriers to opioid pain management in patients (pts) with advanced cancer.(Abstract #9081)L. M. Nguyen, M. De la Cruz, D. Hui, J. L. Palmer, H. A. Parsons, E. Bruera191SATURDAY

Saturday, June 4, 2011SATURDAYBrd. 47ABrd. 47BBrd. 47CBrd. 47DBrd. 47EBrd. 47FBrd. 47GBrd. 47HBrd. 48ABrd. 48BBrd. 48CBrd. 48DBrd. 48EA population-based study of metastatic colorectal cancer (mCRC) in peopleage 80 or older: Findings from the South Australian Clinical Registry (SACR)for mCRC. (Abstract #9082)C. Beeke, K. Jain, T. J. Price, R. Padbury, D. Roder, G. P. Young, M. Ly,M. A. Khattak, A. Richards, A. R. Townsend, C. S. KarapetisA randomized, noninferiority study of recombinant human G-CSF/humanserum albumin fusion (CG-10639) and pegfilgrastim in patients with breastcancer receiving myelosuppressive therapy. (Abstract #9083)O. Gladkov, V. Moiseyenko, I. N. Bondarenko, J. V. Shparyk, S. Barash,J. M. HerpstCancer-related memory problems, demographic, and socioeconomicbackgrounds: A cross-sectional study of the United States population.(Abstract #9084)P. Jean-Pierre, P. Winters, T. Ahles, M. Antoni, D. Armstrong, F. Penedo,S. E. Lipshultz, T. L. Miller, K. FiscellaProspective cohort study of depression during androgen deprivation therapy(ADT) for nonmetastatic prostate cancer. (Abstract #9085)N. Timilshina, H. Breunis, S. M. AlibhaiMammography-detected breast cancer over time among patients age 75 andolder at a community-based cancer center: 1990–2008. (Abstract #9086)J. A. Malmgren, M. K. Atwood, H. G. KaplanCD4 T-cell count to predict the response to new H1N1 vaccination inpediatric patients with cancer. (Abstract #9087)A. M. Mavinkurve-Groothuis, M. van der Flier, F. Stelma, C. van Leer-Buter,F. Preijers, P. HoogerbruggeAge-dependent effects of intensive chemotherapy (IC) on quality of life (QOL)and physical function in patients with acute myeloid leukemia (AML).(Abstract #9088)H. Z. Mohamedali, H. Breunis, J. Brandwein, M. Li, N. Timilshina, M. Minden,G. A. Tomlinson, S. M. AlibhaiSurvivors’ perspectives on cancer: Results from a LIVESTRONG survey.(Abstract #9089)R. Rechis, E. B. Beckjord, S. Nutt, B. M. Hayes-LattinVenous thromboembolic complications in patients with malignant gliomatreated on a bevacizumab clinical trial. (Abstract #9090)A. L. Sumrall, D. A. Reardon, A. Desjardins, K. Peters, E. Lou, S. G. Turner,L. Bailey, H. S. Friedman, J. J. VredenburghAnalysis of phase III clinical studies for palonosetron, ondansetron,dolasetron, and granisetron in the prevention of chemotherapy-inducednausea and vomiting (CINV). (Abstract #9091)S. Y. Barbour, G. R. Morrow, R. Ahmed, G. Ballinari, M. D. Thorn, D. Cox,L. S. SchwartzbergDeveloping a community-based screening instrument that measuresproblem-related distress. (Abstract #9092)M. Golant, J. S. Buzaglo, M. Miller, K. Clark, M. Loscalzo, V. Kennedy,K. R. Dougherty, J. TaylorAn analysis of the prognostic value of handgrip strength and itsincorporation into the comprehensive geriatric assessment (CGA) in elderlyAsian patients with cancer. (Abstract #9093)R. Kanesvaran, K. Koo, W. Chen, D. PoonInflammatory cytokines and toxic effects of oxaliplatin-based chemotherapyin patients with colorectal cancer. (Abstract #9094)X. S. Wang, C. S. Cleeland, V. E. Johnson, J. M. Reuben, D. R. Fogelman,M. Malekifar, K. E. Liao, P. Liu, E. N. Cohen, K. R. Gilmore, C. Eng192

Saturday, June 4, 2011Brd. 48F Barriers to care faced by newly diagnosed patients with cancer. (Abstract#9095)S. K. Hendren, P. C. Raich, P. Winters, W. Thorland, S. Loader, S. Rousseau,P. Valverde, E. Whitley, K. FiscellaBrd. 48G Health-related quality of life in patients with advanced renal cell carcinomareceiving pazopanib or placebo in a randomized phase III trial. (Abstract#9096)A. Pickard, D. Cella, M. S. Duh, A. Guerin, N. Mishagina, L. Antràs, M. Neary,L. McCann, R. Hodge, C. SternbergBrd. 48H Effect of a nurse practitioner (ARNP)–directed intervention on the quality oflife of patients with metastatic cancer: Results of a randomized pilot study.(Abstract #9097)S. H. Dyar, M. Lesperance, R. P. Shannon, J. A. Sloan, G. Colon-OteroBrd. 49A To follow up or not? A new model of supportive care for early breast cancer.(Abstract #9098)J. Dent, A. Topping, C. Ferguson, J. Stephenson, M. McCoy, V. Allinson,S. BrayfordBrd. 49B The influence of age on intensity of care at the end of life among olderpatients with advanced cancer. (Abstract #9099)J. A. Zerillo, A. K. Smith, M. A. Schonberg, E. P. McCarthyBrd. 49C Functional impairment (FI) after hematopoietic cell transplantation (HCT) andimpact on quality of life (QOL). (Abstract #9100)A. Bosworth, F. L. Wong, H. Kim, R. Ferrer Danao, J. Gyorffy, S. Patel,S. J. Forman, S. BhatiaBrd. 49D Deep vein thrombosis (DVT) and pulmonary embolism (PE): Awareness andprophylaxis practices reported by patients with cancer. (Abstract #9101)F. R. Rickles, E. Varga, A. Brownstein, R. J. Friedman, G. A. Maynard, J. AnsellBrd. 49E Bupropion for hot flashes control in breast cancer survivors: A prospective,double-blind, randomized cross-over pilot phase II trial. (Abstract #9102)G. R. Nuňez, A. Del Giglio, H. Pinczowski, R. M. Zanellato, L. C. Tateyama,F. Schindler, F. A. FonsecaBrd. 49F Preventive skin care among cancer survivors. (Abstract #9103)S. C. Lau, W. Y. CheungBrd. 49G Quality of life in patients with dermatologic toxicities: Experience from theSERIES clinic. (Abstract #9104)J. Gordon, Y. Balagula, S. W. Dusza, D. Chen, S. Berg, D. P. West,M. E. LacoutureBrd. 49H The effect of a 3-day oral aprepitant regimen on the prevention of CINV overstandard therapy in Chinese patients receiving high-dose cisplatin. (Abstract#9105)Y. Cheng, L. Zhang, H. Zhang, C. Zhou, B. Han, Y. Zhang, C. Huang, J. Chang,X. Song, J. Liang, H. Liang, J. Hu, S. Yu, J. Chen, J. Wang, H. Pan, A. Carides,D. ChitkaraBrd. 50A Agreement between breast cancer survivors and oncologists on treatmentsreceived. (Abstract #9106)T. B. Sanft, V. Northrup, A. B. Chagpar, M. IrwinBrd. 50B What topics do patients and caregivers consider most important for supportgroups? An evidence-based analysis of 3,728 participants. (Abstract #9107)R. J. Gralla, K. D. Morse, C. N. Rittenberg, J. A. Petersen, K. Burg, B. J. Davis,C. Sison, L. M. Rosen, M. LesserBrd. 50C Assessing patients’ values when standard-of-care options are exhausted.(Abstract #9108)R. D. Pentz, Z. L. Farmer, M. J. Green, C. Daugherty, F. J. Hlubocky,S. K. Peterson, C. C. Sun, C. M. Lewis, T. K. Owonikoko, F. R. Khuri, R. D. HarveySATURDAY193

Saturday, June 4, 2011SATURDAYBrd. 50DBrd. 50EBrd. 50FBrd. 50GBrd. 50HBrd. 51ABrd. 51BBrd. 51CBrd. 51DBrd. 51EBrd. 51FBrd. 51GBrd. 51HFertility preservation treatment options: What do patients actuallyunderstand about their choices? (Abstract #9109)J. Mersereau, L. Kondapalli, U. BalthazarPredictors of quality of life (QOL) and mental health (MH) in caregivers ofpatients with advanced cancer. (Abstract #9110)D. Wadhwa, D. Burman, N. Swami, C. ZimmermannGeriatric factors to predict toxicity and dose-intensity reduction in FFCD2001–02 phase III study comparing a first-line chemotherapy of LV5FU2 orFOLFIRI in treatment of metastatic colorectal cancer (mCRC) in elderlypatients. (Abstract #9111)T. Aparicio, J. Jouve, L. Teillet, D. Gargot, V. Le Brun Ly, J. Cretin, C. Locher,O. Bouche, G. Breysacher, J. Charneau, J. Seitz, M. Gasmi, F. Ricard, F. Subtil,E. Mitry, Federation Francophone de Cancerologie DigestiveAssociation between a validated symptom assessment tool and nurseclinical impression in patients with cancer admitted to a palliative care unit.(Abstract #9112)W. Rhondali, D. Hui, S. Kim, K. L. Kilgore, J. Kang, L. M. Nguyen, E. BrueraQuality-of-life assessment in patients with malignant ascites: Results of amulticenter phase II/III study comparing paracentesis plus catumaxomabwith paracentesis alone. (Abstract #9113)A. Gonschior, M. M. Heiss, M. H. Moehler, S. L. Parsons, H. GiletPrevalence of psychosocial distress in a rural community oncology practiceand impact of interventions. (Abstract #9114)J. S. Smith, D. L. Limesand, M. A. AlikhanDenosumab versus zoledronic acid in patients with bone metastases fromsolid tumors other than breast and prostate cancers or multiple myeloma: Anumber needed to treat (NNT) analysis. (Abstract #9115)G. E. Richardson, T. E. Ciuleanu, L. Costa, S. J. Gans, J. Garcia Saenz, V. Hirsh,V. Hungria, M. Krzakowski, C. Manegold, H. Nahi, S. Novello, A. L. Petzer,M. E. Rader, P. Solal-Celigny, S. Vadhan-Raj, J. F. Vansteenkiste, P. J. Woll,C. Ke, K. Chung, H. YehResults from a randomized phase II study to evaluate the safety and efficacyof acetyl-L-carnitine in the prevention of sagopilone-induced peripheralneuropathy (REASON). (Abstract #9116)C. Lhomme, D. Berton-Rigaud, F. Joly, J. Baurain, F. Rolland, A. Stenzl,T. Schmelter, M. CamponeThe impact of less than 8% weight loss on overall survival in subjects withnon-small cell lung cancer (NSCLC) treated in a phase IIb trial of GTx-024.(Abstract #9117)S. Dodson, A. Dobs, M. L. Hancock, M. A. Johnston, M. S. SteinerA multicenter analysis of the predictors of fertility preservation in womenwith breast cancer: Role of neoadjuvant chemotherapy. (Abstract #9118)J. Kim, K. Oktay, C. Gracia, S. Lee, C. Morse, J. MersereauCognitive difficulties among patients with cancer receiving chemotherapyaffects quality of life: A University of Rochester Clinical CommunityOncology Program study of 439 patients. (Abstract #9119)M. C. Janelsins, K. Devine, K. M. Mustian, S. G. Mohile, L. J. Peppone, L. Sprod,M. Weiss, V. Vinciguerra, A. Jacobs, G. R. MorrowSexual side effects (SSE) reported by adolescent/young adult (AYA) versusolder cancer survivors. (Abstract #9120)C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, G. A. Di Lullo, J. M. MetzSerum 25-hydroxyvitamin D testing at Memorial Sloan-Kettering CancerCenter. (Abstract #9121)K. M. Wesa, K. Yeung, G. Jacobs, M. Coleton, B. R. Cassileth194

Saturday, June 4, 2011Brd. 52ABrd. 52BBrd. 52CBrd. 52DBrd. 52FBrd. 52GBrd. 52HBrd. 53ABrd. 53BBrd. 53CBrd. 53DBrd. 53EBrd. 53FImpact of geriatric vulnerability parameters on pegylated liposomaldoxorubicin (PLD) tolerance and outcome in elderly patients with metastaticbreast cancer: Results of the DOGMES multicenter phase II GINECO trial.(Abstract #9122)C. Falandry, E. Brain, M. Bonnefoy, F. Mefti, A. Savoye, O. Rigal,S. Oddou-Lagranière, C. El Kouri, L. Uwer, S. Abadie-Lacourtoisie, J. Cretin,J. Jacquin, G. FreyerThe status of oncofertility resources at NCI-designated comprehensivecancer centers. (Abstract #9123)M. L. Clayman, M. Harper, G. P. Quinn, S. Shah, J. ReineckeSafety and efficacy of implanted central venous catheters during adjuvanttreatment of breast cancer and in a general oncology population. (Abstract#9124)M. Wilson, D. J. Porter, A. MaherQuality of life in male patients with hormone-independent cancers: The roleof testosterone. (Abstract #9125)P. Homel, S. B. Fleishman, M. Suhail, V. RosenwaldDo high symptom scores trigger clinical actions by providers? Assessing theeffect of standardized symptom screening. (Abstract #9127)J. Sussman, H. Seow, D. Bainbridge, G. R. Pond, L. Martelli-ReidPhysician preferences and knowledge gaps regarding the care of childhoodcancer survivors: A survey of the American Academy of Family Physicians(AAFP). (Abstract #9128)T. O. Henderson, P. C. Nathan, M. Kigin, F. J. Hlubocky, K. Wroblewski,T. V. Stewart, J. M. Galliher, K. C. Oeffinger, C. DaughertyThe trajectory of physical functioning during breast cancer treatment of olderwomen. (Abstract #9129)C. Owusu, M. D. Schluchter, S. M. Koroukian, N. A. BergerDocumenting the complete resolution rates of venous thromboemboli (VTE)with the factor Xa inhibitor fondaparinux sodium (FS) in patients with cancer.(Abstract #9130)D. R. Budman, M. F. Barginear, R. J. Gralla, T. P. Bradley, I. Shapira,N. J. Nier-Shoulson, C. R. Greben, M. Akerman, M. LesserSurvivorship care plans for colorectal cancer survivors: What do primarycare providers want and need? (Abstract #9131)T. Salz, K. C. Oeffinger, P. R. Lewis, R. Rhyne, R. L. Williams, M. W. YeazelIntensity of end-of-life cancer care among seniors: Variations by principalhealth care provider. (Abstract #9132)K. Murray, L. Lucas, S. MiesfeldtComparison of patient-reported symptoms and health behaviors to cliniciandocumentation among patients with breast cancer in follow-up care.(Abstract #9133)M. E. Melisko, M. Bock, D. H. Moore, D. Hamolsky, M. Mendelsohn, L. Lawson,H. Orlando, H. S. Rugo, A. J. Chien, J. W. Park, M. M. Moasser, P. N. Munster,A. Goga, L. EssermanGeriatric assessment (GA) of older patients with cancer in Australia: Anational, multicenter audit. (Abstract #9134)S. S. Joshi, C. B. Steer, J. Yoong, R. Lakhanpal, S. Kirsop, T. Dunlop,L. R. Mileshkin, D. Yip, G. M. Marx, E. J. Hovey, S. Della-Fiorentina,Clinical Oncology Society of AustraliaAggressiveness of end-of-life care before and after the utilization of apalliative care service. (Abstract #9135)W. Gonsalves, T. Tashi, T. Davies, S. Ortman, R. Thota, J. Krishnamurthy,I. T. Aldoss, M. Kalaiah, A. Ganta, N. Didwaniya, C. Eberle, A. Ganti, S. Subbiah,P. T. SilbersteinSATURDAY195

Saturday, June 4, 2011SATURDAYBrd. 53GBrd. 53HBrd. 54ABrd. 54BBrd. 54CPatient experience with survivorship care plans: Findings from an onlineregistry of breast cancer survivors. (Abstract #9136)J. S. Buzaglo, K. R. Dougherty, M. Amsellem, M. GolantProspective assessment of symptom burden among cancer survivors withcommon solid tumors: Results from ECOG trial E2Z02. (Abstract #9137)L. I. Wagner, L. Zickl, M. Smith, D. Cella, C. Coles, L. J. Patrick-Miller, J. Manola,M. FischHodgkin lymphoma of the elderly veterans: Veterans Affairs Cancer Registryanalysis. (Abstract #9138)J. Krishnamurthy, T. Tashi, W. Gonsalves, R. Thota, P. T. Silberstein, S. SubbiahBRCA mutation carriers: Risk factors for psychosocial and physiologicdisruption. (Abstract #9139)L. B. Wenzel, K. Osann, J. Gross, R. Kurz, E. L. Nelson, B. Y. KarlanThe effectiveness of a structured exercise and education program on clinicaland quality-of-life outcomes in patients with cancer who are activelyundergoing therapy compared with patients not currently receiving therapy.(Abstract #9140)L. M. Leach, A. Kleski, K. Spencer, J. Anthony, M. LaLonde, T. J. Sweeney,T. Caulin-Glaser196

Saturday, June 4, 20113:00 PM - 4:15 PMSPECIAL SESSIONASCO/Radiological Society of North America (RSNA) Joint Session: CancerScreening—Can We See Clearly Now?Location: E354bCME credit: 1.25Track(s): Practice Management and Information Technology, Cancer Prevention/Epidemiology,Special SessionGeorge W. Sledge Jr., MD—Co-ChairIndiana University Simon Cancer CenterN. Reed Dunnick, MD—Co-ChairUniversity of MichiganDenise R. Aberle, MDUniversity of California, Los Angeles David Geffen School of MedicineLung Cancer Screening: Results and Implications of the National Lung Screening Trial (NLST)Mark Helvie, MDUniversity of MichiganBreast Cancer Screening: U.S. Preventive Services Task Force Recommendations—Why theControversy?SATURDAYElizabeth Burnside, MD, MPHUniversity of WisconsinEvaluating Screening Studies: Translating the Science to Practice197

Saturday, June 4, 20113:00 PM - 4:15 PMEDUCATION SESSIONSImmunologics and Biologics for Sarcomas: Is There a Role?Location: S100aCME credit: 1.25Track(s): Sarcoma, Pediatric OncologyPeter Houghton, PhD—ChairNationwide Children’s HospitalEmerging Biologic Strategies for SarcomasSATURDAYPaul Robbins, PhDNational Cancer Institute Center for Cancer ResearchAdoptive Immunotherapy of Synovial-cell Sarcoma Targeting Cancer/Testis AntigensCrystal Mackall, MDNational Cancer InstituteThe Future of Immunotherapy for SarcomasLung Cancer Whole-genome Sequencing: What a Clinician Should KnowLocation: Hall D2CME credit: 1.25Track(s): Lung Cancer, Tumor BiologyRamaswamy Govindan, MD—ChairWashington University School of MedicineWhole-genome Sequencing of Lung Cancer: Update and Implications for Clinical ResearchElaine Mardis, PhDWashington UniversityWhole-genome Sequencing: A Primer for the CliniciansNeil Caporaso, MDNational Cancer InstituteLung Cancer Whole-genome Sequencing: Insights into Lung Cancer BiologyNext-generation Sequencing in Cancer GeneticsLocation: E353CME credit: 1.25Track(s): Cancer GeneticsStephen B. Gruber, MD, PhD, MPH—ChairUniversity of MichiganNext-generation Sequencing: What Are the Clinical Implications?Veda N. Giri, MDFox Chase Cancer CenterBeyond Genome-wide Association Studies in Cancer SusceptibilityArul Chinnaiyan, MD, PhDUniversity of Michigan Medical CenterNext-generation Sequencing and Susceptibility to Prostate Cancer198

Saturday, June 4, 2011Prediction, Prevention, and Treatment of Chemotherapy Toxicity in OlderPatientsLocation: S100bcCME credit: 1.25Track(s): Geriatric Oncology, General OncologySupriya Gupta Mohile, MD, MS—ChairUniversity of Rochester Medical CenterPrevention and Management of Nonhematologic Toxicity in Elderly Patients ReceivingChemotherapyArti Hurria, MDCity of HopePrediction of Chemotherapy Toxicity in Elderly PatientsGary H. Lyman, MD, MPHDuke UniversityPrevention and Management of Hematologic Toxicity in Elderly Patients ReceivingChemotherapySATURDAY199

Saturday, June 4, 20113:00 PM - 4:15 PMMEET THE PROFESSOR SESSIONIssues in Therapy for Rectal Cancer (M07)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Gastrointestinal (Colorectal) CancerBlase N. Polite, MD, MPHThe University of ChicagoWhich Chemotherapy and When: Understanding the Timing and Type of Chemotherapy inPatients with Rectal CancerSATURDAYClaus Roedel, MDUniversity of FrankfurtRadiation Therapy for Rectal Cancer: When Can It Be Omitted or Shortened?200

3:00 PM - 4:15 PMCLINICAL PROBLEMS IN ONCOLOGY SESSIONIntegrative Oncology: A Mainstream Look at Approaches for Patients withAdvanced Cancer (C06)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Professional Development, Cancer Prevention/Epidemiology, Patient and SurvivorCareNancy E. Davidson, MD—ChairUniversity of Pittsburgh Cancer InstituteClinical Trial Design in Integrative Oncology: Advanced CancerSaturday, June 4, 2011Edith P. Mitchell, MDKimmel Cancer Center at Thomas Jefferson UniversityEvidence-based Interventions in Integrative Oncology for Patients with Metastatic CancerBrent Bauer, MDMayo ClinicWhat Alternative Therapies Are Hot for Advanced Cancer Patients?SATURDAY201

Saturday, June 4, 20113:00 PM - 4:30 PMCLINICAL SCIENCE SYMPOSIUMHost Genomics and Treatment Outcomes in Breast CancerLocation: Hall B1CME credit: 1.5Track(s): Breast CancerSATURDAYChristos Sotiriou, MD, PhD—ChairJules Bordet InstituteDiscussion3:00 PM Mark J. Ratain, MDThe University of Chicago3:15 PM Genetic associations with taxane-induced neuropathy by genome-wideassociation study (GWAS) in E5103. (Abstract #1000)B. P. Schneider, L. Li, K. Miller, D. Flockhart, M. Radovich, B. A. Hancock,N. Kassem, T. Foroud, D. L. Koller, S. S. Badve, Z. Li, A. H. Partridge,A. M. O’Neill, J. A. Sparano, C. T. Dang, D. W. Northfelt, M. Smith, E. Railey,G. W. Sledge Jr.Discussion3:30 PM Howard L. McLeod, PharmD (Abstract #1000)University of North Carolina Eshelman School of Pharmacy3:45 PM Genes regulating estradiol and estrone-conjugate levels in postmenopausalwomen with resected early-stage breast cancer detected by a genome-wideassociation study (GWAS). (Abstract #1001)J. N. Ingle, B. L. Fridley, A. Buzdar, M. E. Robson, M. Kubo, M. Liu,I. Ibrahim-Zada, A. Batzler, G. D. Jenkins, M. P. Goetz, D. W. Northfelt,E. A. Perez, C. V. Williard, L. Wang, D. J. Schaid, Y. Nakamura,R. M. Weinshilboum4:00 PM ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L)versus tamoxifen (T) or their sequence for early breast cancer. (Abstract#1002)M. Bouzyk, K. P. Gray, M. M. Regan, O. Pagani, W. Tang, R. Kammler,R. Maibach, G. Viale, P. Dell’Orto, B. J. Thurlimann, E. Hitre, M. Lyng, H. J. Ditzel,P. Neven, G. MacGrogan, K. N. Price, R. D. Gelber, A. S. Coates, A. Goldhirsch,B. Leyland-Jones, BIG 1-98 Collaborative and International Breast Cancer StudyGroupsDiscussion4:15 PM James M. Rae, MD (Abstracts #1001–1002)University of Michigan202

Saturday, June 4, 20113:00 PM - 5:30 PMORAL ABSTRACT SESSIONPediatric Oncology ILocation: S504CME credit: 2.5Track(s): Pediatric OncologyPaul C. Nathan, MD, MSc—Co-ChairThe Hospital for Sick ChildrenJennifer Lynn McNeer, MD—Co-ChairThe University of Chicago3:00 PM Results of a prospective clinical trial for VAMP alone without irradiation forpediatric favorable, early-stage Hodgkin lymphoma patients who achieve anearly complete response. (Abstract #9503)M. Metzger, H. J. Weinstein, M. M. Hudson, A. Billett, E. C. Larsen,A. M. Friedmann, S. S. Donaldson, M. J. Krasin, L. E. Kun, K. C. Marcus,T. I. Yock, N. Tarbell, C. Billups, J. Wu, M. P. Link3:15 PM Dexamethasone (DEX) versus prednisone (PRED) during induction forchildren with high-risk acute lymphoblastic leukemia (HR-ALL): A reportfrom the Children’s Oncology Group Study AALL0232. (Abstract #9504)N. J. Winick, W. L. Salzer, M. Devidas, J. B. Nachman, E. A. Raetz, M. L. Loh,N. A. Heerema, A. J. Carroll, J. M. Gastier-Foster, M. J. Borowitz, B. L. Wood,C. L. Willman, S. Hunger, W. L. Carroll, E. C. LarsenDiscussion3:30 PM Andrea Biondi, MD (Abstract #9504)University of Milano-Bicocca3:45 PM Relationship of CRLF2 expression and outcome in pediatric B-cell precursoracute lymphoblastic leukemia (BCP-ALL): A report from the Children’sOncology Group. (Abstract #9505)I. Chen, R. Harvey, C. G. Mullighan, M. L. Loh, M. Devidas, M. J. Borowitz,S. K. Tasian, D. Payne-Turner, W. Wharton, J. Pullen, A. J. Carroll, W. L. Carroll,B. M. Camitta, S. Hunger, N. J. Winick, C. L. Willman4:00 PM Treatment outcomes in older adolescent and young adult (AYA) patients withnewly diagnosed AML. (Abstract #9506)J. A. Canner, T. A. Alonzo, J. Franklin, D. R. Freyer, A. S. Gamis, R. B. Gerbing,B. Lange, S. Meshinchi, W. G. Woods, J. P. Perentesis, J. Horan4:15 PM Impact of traditional cardiovascular disease risk factors on long-termcardiovascular outcome in adult survivors of childhood cancer: A reportfrom the Childhood Cancer Survivor Study. (Abstract #9507)G. T. Armstrong, Y. Chen, T. Kawashima, C. A. Sklar, D. A. Mulrooney, E. J. Chow,W. Border, J. Durand, A. Mertens, M. Stovall, W. Leisenring, Y. Yasui,L. L. Robison, K. C. Oeffinger, L. Meacham4:30 PM Impact of HFE mutations on cardiac status in survivors of childhood highriskALL: Dana-Farber Cancer Institute Childhood ALL 05–159. (Abstract#9508)S. E. Lipshultz, S. R. Lipsitz, J. Kutok, T. L. Miller, S. D. Colan, D. S. Neuberg,S. E. Dahlberg, L. B. Silverman, J. M. Henkel, V. I. Franco, S. E. Sallan,Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium4:45 PM Cardiorespiratory fitness in adult survivors of childhood acute lymphoblasticleukemia (ALL). (Abstract #9509)K. C. Oeffinger, P. G. Snell, C. S. Moskowitz, J. F. Chou, D. A. Kent,E. S. Tonorezos, A. L. Dunn, S. M. Smith, T. S. ChurchSATURDAY203

Saturday, June 4, 20115:00 PM Melanoma as a subsequent neoplasm in survivors of childhood cancer: Areport from the Childhood Cancer Survivor Study. (Abstract #9510)A. S. Pappo, G. T. Armstrong, W. Liu, D. K. Srivastava, W. Leisenring,S. Hammond, M. Stovall, J. P. Neglia, L. L. RobisonDiscussion5:15 PM Louise C. Strong, MD (Abstract #9510)University of Texas M. D. Anderson Cancer CenterSATURDAY204

Saturday, June 4, 20113:00 PM - 6:00 PMORAL ABSTRACT SESSIONGynecologic CancerLocation: E354aCME credit: 3Track(s): Gynecologic CancerRonald J. Buckanovich, MD—Co-ChairUniversity of MichiganGottfried E. Konecny, MD—Co-ChairUniversity of California, Los Angeles3:00 PM Phase II randomized placebo-controlled study of olaparib (AZD2281) inpatients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).(Abstract #5003)J. A. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. B. Vergote, G. J. Rustin,C. Scott, W. Meier, R. Shapira-Frommer, T. Safra, D. Matei, E. Macpherson,C. Watkins, J. Carmichael, U. Matulonis3:15 PM A phase II trial of iniparib (BSI-201) in combination withgemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrentovarian cancer. (Abstract #5004)R. T. Penson, C. Whalen, B. Lasonde, C. N. Krasner, P. Konstantinopoulos,T. E. Stallings, C. R. Bradley, M. J. Birrer, U. Matulonis3:30 PM A phase II trial of iniparib (BSI-201) in combination withgemcitabine/carboplatin (GC) in patients with platinum-resistant recurrentovarian cancer. (Abstract #5005)M. J. Birrer, P. Konstantinopoulos, R. T. Penson, M. Roche, A. Ambrosio,T. E. Stallings, U. Matulonis, C. R. BradleyDiscussion3:45 PM Stanley B. Kaye, MD (Abstracts #5003–5005)The Royal Marsden Hospital4:00 PM Result of interim analysis of overall survival in the GCIG ICON7 phase IIIrandomised trial of bevacizumab in women with newly diagnosed ovariancancer. (Abstract #LBA5006)G. Kristensen, T. Perren, W. Qian, J. Pfisterer, J. A. Ledermann, F. Joly,M. S. Carey, P. J. Beale, A. Cervantes, A. M. Oza4:15 PM OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial ofchemotherapy with or without bevacizumab (BEV) in patients with platinumsensitiverecurrent epithelial ovarian (EOC), primary peritoneal (PPC), orfallopian tube cancer (FTC). (Abstract #LBA5007)C. Aghajanian, N. J. Finkler, T. Rutherford, D. A. Smith, J. Yi, H. Parmar,L. R. Nycum, M. A. Sovak4:30 PM Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts):Results from a phase II randomized discontinuation trial (RDT). (Abstract#5008)R. J. Buckanovich, R. Berger, A. Sella, B. I. Sikic, X. Shen, D. A. Ramies,D. C. Smith, I. B. VergoteDiscussion4:45 PM Anil Sood, MD (Abstracts #LBA5006–5008)University of Texas M. D. Anderson Cancer Center5:00 PM A randomized phase II (RP2) trial of ridaforolimus (R) compared withprogestin (P) or chemotheraphy (C) in female adult patients with advancedendometrial carcinoma. (Abstract #5009)A. M. Oza, A. Poveda, A. R. Clamp, S. Pignata, G. Scambia, J. Del Campo,M. McCormack, L. Sevcik, B. M. Schwartz, S. Guan, R. Lee, J. D. Cheng,F. G. HaluskaSATURDAY205

Saturday, June 4, 20115:15 PM A comparative randomized, placebo-controlled, double-blind phase II studywith and without enzastaurin in combination with paclitaxel and carboplatinas first-line treatment for advanced ovarian cancer. (Abstract #5010)I. B. Vergote, P. Harter, N. Kovalenko, T. Bauknecht, K. Mansouri, Y. Zhang,J. Sehouli5:30 PM A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC). (Abstract #5011)D. Matei, C. Shen, F. Fang, J. Schilder, M. Li, A. Arnold, Y. Zeng, J. M. Pilrose,C. Kulesavage, C. Balch, W. Berry, P. Wulfridge, T. H. Huang, K. P. NephewDiscussion5:45 PM Helga B. Salvesen, MD, PhD (Abstracts #5009–5011)Haukeland University Hospital, The University of BergenSATURDAY206

Saturday, June 4, 20114:30 PM - 6:00 PMCLINICAL SCIENCE SYMPOSIUMFinding the Targets, Restoring the VisionLocation: Hall D1CME credit: 1.5Track(s): Gastrointestinal (Colorectal) CancerRavi Salgia, MD, PhD—ChairThe University of Chicago4:30 PM A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab(AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients(pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primaryand biomarker analyses. (Abstract #3500)C. Eng, E. Van Cutsem, E. Nowara, A. Swieboda-Sadlej, N. C. Tebbutt,E. P. Mitchell, I. Davidenko, K. Oliner, L. Chen, J. Huang, I. McCaffery, E. Loh,D. Smethurst, J. TaberneroDiscussion4:45 PM Ravi Salgia, MD, PhD (Abstract #3500)The University of ChicagoColorectal Cancer: Exploiting the Targets5:00 PM A randomized phase II/III study of the anti-IGF-1R antibody MK-0646(dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in thetreatment of chemorefractory metastatic colorectal cancer (mCRC) withwild-type (wt) KRAS status. (Abstract #3501)D. J. Watkins, J. Tabernero, H. Schmoll, T. Trarbach, F. J. Ramos, J. Howe,H. M. Brown, J. Clark, K. Hsu, B. D. Lu, D. CunninghamDiscussion5:15 PM Margaret M. Mooney, MD, MBA (Abstract #3501)National Cancer InstituteThe Importance of Biomarker Codevelopment to Success5:30 PM A phase II study of the PARP inhibitor ABT-888 plus temozolomide inpatients with heavily pretreated, metastatic colorectal cancer. (Abstract#3502)M. J. Pishvaian, R. Slack, A. Witkiewicz, A. R. He, J. J. Hwang, A. Hankin,K. Dorsch-Vogel, D. Kuda, T. McAndrew, L. M. Weiner, J. Marshall, J. R. BrodyDiscussion5:45 PM Andrew Nicholas James Tutt, PhD, MBChB (Abstract #3502)Breakthrough Breast Cancer Research Unit, Guy’s HospitalSATURDAY207

Saturday, June 4, 20114:45 PM - 6:00 PMSPECIAL SESSIONASCO/American Society of Hematology (ASH) Joint SessionLocation: Arie Crown TheaterCME credit: 1.25Track(s): Leukemia, Myelodysplasia, and Transplantation, Lymphoma and Plasma CellDisorders, Special SessionGeorge W. Sledge Jr., MD—Co-ChairIndiana University Simon Cancer CenterWelcome and IntroductionSATURDAYArmand Keating, MD—Co-ChairPrincess Margaret HospitalWelcome and IntroductionAnna Jankowska, MScCleveland ClinicImpaired Hydroxylation of 5-Methylcytosine in TET2-mutated Patients with MyeloidMalignancies (ASH #33807)Menno Volkert Huisman, MD, PhDLeiden University Medical CenterOutpatient Treatment in Patients with Acute Pulmonary Embolism: The Hestia Study (ASH#34998)Kaan Boztug, MDCeMM Research Center for Molecular MedicineCorrection of Wiskott-Aldrich Syndrome by Hematopoietic Stem Cell Gene Therapy (ASH#33064)Kirit Ardeshna, MDUniversity College London HospitalsAn Intergroup Randomized Trial of Rituximab versus a Watch-and-Wait Strategy in Patientswith Stage II, III, IV, Asymptomatic, Nonbulky Follicular Lymphoma (Grades 1, 2, and 3a). APreliminary Analysis (ASH #27692)208

Saturday, June 4, 20114:45 PM - 6:00 PMEDUCATION SESSIONSDesign and Interpretation of Randomized Controlled Trials in Oncology toAchieve Meaningful Benefits for Patients and SocietyLocation: S100aCME credit: 1.25Track(s): Clinical Trials, EthicsRalph M. Meyer, MD—ChairNCIC Clinical Trials Group, Queen’s UniversityExplanatory versus Pragmatic Randomized Controlled Trials in Oncology: How and Why toMake This Distinction in the Design and Interpretation of Clinical TrialsAntonio Tito Fojo, MD, PhDNational Cancer Institute, National Institutes of HealthHow Much Is Life Worth: The Multibillion Dollar Question in Contemporary OncologyAlberto F. Sobrero, MDOspedale San MartinoRaising the Bar for Efficacy in Cancer TherapeuticsSATURDAYNew Developments in Lynch Syndrome and DNA Mismatch Repair: Screening,Genetics, Prognosis, and TreatmentLocation: E353CME credit: 1.25Track(s): Cancer Genetics, Gastrointestinal (Colorectal) CancerMichael J. Hall, MD—ChairFox Chase Cancer CenterControversies in Screening for Lynch SyndromeNoralane M. Lindor, MDMayo ClinicUpdate on the Genetics of Lynch Syndrome: New Genes, New Mechanisms, New InsightsZsofia Kinga Stadler, MDMemorial Sloan-Kettering Cancer CenterThe Importance of DNA Mismatch Repair in the Prognosis and Treatment of Colorectal Cancer209

Saturday, June 4, 2011Nonphysician Providers in Oncology: Examining Collaborative Approachesand Next StepsLocation: E354bCME credit: 1.25Track(s): Practice Management and Information Technology, Patient and Survivor Care,Professional DevelopmentDean F. Bajorin, MD—ChairMemorial Sloan-Kettering Cancer CenterSATURDAYElaine L. Towle, CMPEOncology MetricsPartnering with Nonphysician Providers in the Community Setting: Results of the Study ofCollaborative Practice Arrangements Funded by Susan G. Komen for the Cure ®Shirley Shuster, APRN, BC, OCNCommonwealth Hematology OncologySuccessful Implementation of the Nonphysician Provider in the Community SettingMichael Goldstein, MDBeth Israel Deaconess Medical Center/Harvard Medical SchoolThe Past Will Not Predict the Future of the Oncology Workforce210

Saturday, June 4, 20114:45 PM - 6:00 PMMEET THE PROFESSOR SESSIONInitial Management of Hepatocellular Carcinoma (M08)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Gastrointestinal (Noncolorectal) CancerJeff H. Geschwind, MDThe Johns Hopkins University School of MedicineNonsurgical Strategies for Hepatocellular CarcinomaTimothy M. Pawlik, MD, MPHThe Johns Hopkins University School of MedicineWhat Are the Upfront Surgical Options for Hepatocellular Cancer?SATURDAY4:45 PM - 6:00 PMCLINICAL PROBLEMS IN ONCOLOGY SESSIONMultimodality Approach to Mucosal Melanoma (C05)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Melanoma/Skin CancersVernon Keith Sondak, MD—ChairH. Lee Moffitt Cancer Center & Research InstituteRole of Surgery for Subtypes of Mucosal MelanomaBryan Burmeister, MBBSPrincess Alexandra HospitalRadiotherapy for Primary and Advanced Mucosal MelanomaLeslie Anne Fecher, MDUniversity of Pennsylvania Abramson Cancer CenterSystemic Therapy for Advanced Mucosal Melanoma211

Sunday, June 5, 20117:30 AM - 9:00 AMHIGHLIGHTS OF THE DAY SESSIONHighlights of the Day I Including Clinical Trials Participation AwardsLocation: Hall D1CME credit: 1.5Track(s): Special Session, General OncologyDouglas W. Blayney, MD—Co-ChairStanford UniversityDaniel F. Hayes, MD—Co-ChairUniversity of Michigan Medical Center7:30 AMClinical Trials Participation Awards7:45 AMJoel E. Tepper, MDUniversity of North Carolina at Chapel Hill School of MedicineGastrointestinal (Colorectal) CancerSUNDAY8:00 AMGottfried E. Konecny, MDUniversity of California, Los AngelesGynecologic Cancer8:15 AMBruce D. Cheson, MDGeorgetown University Medical CenterLymphoma8:30 AMAntoni Ribas, MDJonsson Comprehensive Cancer Center, University of California, Los AngelesMelanoma/Skin Cancers212

Sunday, June 5, 20118:00 AM - 9:15 AMSPECIAL SESSIONASCO–American Cancer Society Award and LectureLocation: S100aCME credit: 1.25Track(s): Special SessionJamie Von Roenn, MDNorthwestern UniversityPersonalized Medicine: A Comprehensive DefinitionSUNDAY213

Sunday, June 5, 20118:00 AM - 9:15 AMEDUCATION SESSIONSDiffuse Large B-cell Lymphoma: Present and FutureLocation: E354aCME credit: 1.25Track(s): Lymphoma and Plasma Cell DisordersJeremy S. Abramson, MD—ChairMassachusetts General HospitalTreatment of Diffuse Large B-cell Lymphoma in 2011Ari Melnick, MDWeill Cornell Medical CollegeTranscript Profiling and Novel Targets in Diffuse Large B-cell LymphomaChristian Gisselbrecht, MDHopital Saint LouisNovel Therapies for Diffuse Large B-cell LymphomaImproving Drug Safety: From Toxicity Assessment to Post-marketingSurveillanceLocation: S504CME credit: 1.25Track(s): Health Services ResearchSUNDAYDavid Cella, PhD—ChairRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityUsing Patient-reported Outcomes to Measure Toxicities in Clinical TrialsRichard Pazdur, MDU.S. Food and Drug AdministrationImproving Drug Safety: The U.S. Food and Drug Administration Past and FutureJulia Bohlius, MD, MScPHInstitute for Social and Preventive Medicine, University of BernThe Importance of Post-marketing PharmacovigilanceMolecular and Pathologic Controversies for Potentially Curative Lung CancersLocation: S406CME credit: 1.25Track(s): Lung CancerElisabeth Brambilla, MD—ChairCHU GrenobleThe Histologic Reclassification of Adenocarcinoma of the Lung: Implications for Diagnosis andTherapyDavid Harpole Jr., MDDuke University Medical CenterGenomic Prognostication in Early-stage Non-small Cell Lung Cancer: Past, Present, and FutureEthan Dmitrovsky, MDDartmouth Medical SchoolMicroRNA Profiling: Clinical Studies in Lung Cancer214

Oncology Practice Models: Strategies to Overcome CompetitiveDisadvantagesLocation: E353CME credit: 1.25Track(s): Practice Management and Information Technology, Professional DevelopmentHarvey D. Bichkoff, MPH—ChairCalifornia Cancer CarePractice Model for Success: Community-based/Single-specialtyDenis Brin Hammond, MDNew Hampshire Oncology-HematologyPractice Model for Success: Hospital/University-affiliatedR. Steven Paulson, MDTexas OncologyPractice Model for Success: Regional/MultispecialtySunday, June 5, 2011Standard Management of Stage IV Colorectal Cancer: Start and Stop,Maintenance, Bevacizumab beyond Progression? (eQuestions Session)Location: Hall D2CME credit: 1.25Track(s): Gastrointestinal (Colorectal) CancerAxel Grothey, MD—ChairMayo ClinicBevacizumab beyond ProgressionJeffrey A. Meyerhardt, MD, MPHDana-Farber Cancer InstituteStart and Stop, Maintenance, Chemotherapy HolidayWells A. Messersmith, MDUniversity of Colorado Cancer CenterToxicity of ChemotherapySUNDAYThe Molecular Biology, New Targets, and Pathways in Head and Neck CancerLocation: E354bCME credit: 1.25Track(s): Head and Neck Cancer, Developmental Therapeutics, Tumor BiologyDavid Sidransky, MD—ChairThe Johns Hopkins UniversityGenetic and Epigenetic Targets, High-throughput TechnologyChristine H. Chung, MDThe Johns Hopkins UniversityTargeted Pathways from Bench to ClinicEzra E. W. Cohen, MDThe University of ChicagoClinical Advances in Targeted Therapies215

Sunday, June 5, 20118:00 AM - 9:15 AMMEET THE PROFESSOR SESSIONBone Protection in Prostate Cancer: Benefits and Pitfalls (M09)—TicketedSessionLocation: E451aCME credit: 1.25Track(s): Genitourinary Cancer, Geriatric OncologyMatthew Raymond Smith, MD, PhDMassachusetts General Hospital Cancer CenterBisphosphonates, RANK-ligand Inhibitors, and Other “Bone Protecting” Agents: The Standardof CareIan Tannock, MD, PhDPrincess Margaret Hospital and University of TorontoBone-protective Agents: Do They Have Questionable Efficacy and Unacceptable Cost?SUNDAY8:00 AM - 9:15 AMCLINICAL PROBLEMS IN ONCOLOGY SESSIONSoft-tissue Sarcomas: A Continuing Clinical Conundrum for the Clinician?(C07)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): SarcomaRaphael E. Pollock, MD, PhD—ChairUniversity of Texas M. D. Anderson Cancer CenterSurgery for Soft-tissue SarcomasThomas F. DeLaney, MDMassachusetts General HospitalRadiation for Soft-tissue SarcomasRashmi Chugh, MDUniversity of MichiganChemotherapy for Soft-tissue Sarcomas216

Sunday, June 5, 20118:00 AM - 10:00 AMSPECIAL SESSIONTraining Program Directors’ Breakfast (Training Program Directors Only)Location: S404Track(s): Special Session, Professional DevelopmentThomas H. Davis, MD—ChairNorris Cotton Cancer Center, Dartmouth-Hitchcock Medical CenterACGME Open Discussion; MATCH Update; How Can ASCO Recognize Teachers?Michael P. Kosty, MDScripps ClinicInformational Items: WAG, Classic References, QOPI for FellowsFrances A. Collichio, MDUniversity of North Carolina at Chapel Hill School of MedicineASCO MedOnc In-training Exam StatisticsHoward R. Terebelo, DOProvidence HospitalMy Experience with Education Essentials for Oncology Fellows (EEOF)SUNDAY217

Sunday, June 5, 20118:00 AM - 11:00 AMORAL ABSTRACT SESSIONCentral Nervous System TumorsLocation: S100bcCME credit: 3Track(s): Central Nervous System TumorsSUNDAYEric L. Chang, MD—Co-ChairUniversity of Texas M. D. Anderson Cancer CenterMartin Nicholas, MD, PhD—Co-ChairThe University of Chicago8:00 AM Prognostic factors for response and survival in primary central nervoussystem lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1). (Abstract #2004)K. Jahnke, A. Korfel, P. Martus, S. Lokka, R. Moehle, F. Griesinger, M. Rauch,A. Roeth, B. Hertenstein, T. Fischer, T. Hundsberger, H. Mergenthaler,M. Leithäuser, T. Birnbaum, U. Herrlinger, J. Schubert, A. Florschütz, L. Fischer,M. Weller, E. Thiel8:15 AM Prognostic factors for chemotherapy-related toxicity in primary centralnervous system lymphoma (PCNSL) treated with high-dose methotrexate(HDMTX) with or without ifosfamide: Results from a German phase III trial(G-PCNSL-SG-1). (Abstract #2005)P. Martus, K. Jahnke, A. Korfel, T. Rose, L. Fischer, R. Moehle, H. A. Klasen,M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, T. Hundsberger, H. Mergenthaler,M. Leithäuser, T. Birnbaum, U. Herrlinger, J. Schubert, J. Birkmann, M. Weller,E. ThielDiscussion8:30 AM Lisa Marie DeAngelis, MD (Abstracts #2004–2005)Memorial Sloan-Kettering Cancer Center8:45 AM RTOG 0525: A randomized phase III trial comparing standard adjuvanttemozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosedglioblastoma (GBM). (Abstract #2006)M. R. Gilbert, M. Wang, K. D. Aldape, R. Stupp, M. Hegi, K. A. Jaeckle,T. S. Armstrong, J. S. Wefel, M. Won, D. T. Blumenthal, A. Mahajan,C. J. Schultz, S. C. Erridge, P. D. Brown, A. Chakravarti, W. J. Curran Jr.,M. P. Mehta9:00 AM Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX)followed by ENZ maintenance therapy in patients with newly diagnosedglioblastoma (GBM) without hypermethylation of the O 6 -methylguanylDNA-methyltransferase (MGMT) promoter: A multicenter, open-label,uncontrolled phase II study. (Abstract #2007)W. Wick, J. Steinbach, S. E. Combs, M. Platten, C. Hartmann, F. K. Wenz,U. Boecker, C. StoffregenDiscussion9:15 AM Jeffrey S. Abrams, MD (Abstracts #2006–2007)National Cancer Institute9:30 AM Correlation of treatment effects on progression-free survival at 6 months(PFS-6) and overall survival (OS) in patients with newly diagnosedglioblastoma (GBM). (Abstract #2008)X. Ye, S. A. Grossman, S. Desideri, S. Piantadosi, for the ABTC CNS ConsortiumDiscussion9:45 AM Martin J. Van Den Bent, MD (Abstract #2008)Daniel den Hoed Cancer Center218

Sunday, June 5, 201110:00 AM Magnetic resonance (MR) perfusion imaging to differentiate earlyprogression from pseudoprogression following chemoradiotherapy forglioblastoma (GBM). (Abstract #2009)J. J. Graber, R. J. Young, A. Gupta, A. D. Shah, T. A. Chan, Z. Zhang, W. Shi,K. Beal, A. M. Omuro10:15 AM A phase II study of daily afatinib (BIBW 2992) with or without temozolomide(21/28 days) in the treatment of patients with recurrent glioblastoma.(Abstract #2010)D. D. Eisenstat, L. B. Nabors, W. P. Mason, J. R. Perry, W. R. Shapiro, P. Kavan,S. Phuphanich, Y. Fu, X. J. Cong, M. Shahidi, D. A. Reardon10:30 AM Outcome of infants and young children with newly diagnosedmedulloblastoma treated on Head Start III protocol. (Abstract #2011)G. Dhall, L. Ji, K. Haley, J. P. Grimm, F. H. Gilles, S. L. Gardner, J. C. Allen,A. Cornelius, K. R. Pradhan, J. H. Garvin, R. S. Olshefski, J. Hukin, M. Comito,S. Goldman, S. J. Thompson, A. Hirt, M. P. Atlas, A. W. Walter, R. Sposto,J. L. FinlayDiscussion10:45 AM Marc C. Chamberlain, MD (Abstracts #2009-2011)University of WashingtonSUNDAY219

Sunday, June 5, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONSUNDAYGenitourinary CancerLocation: Hall ATrack(s): Genitourinary CancerBrd. 1A Identification of mutations of the SWI/SNF complex gene PBRM1 by exomesequencing in renal carcinoma. (Abstract #4571)B. T. Teh, I. Varela, P. Tarpey, K. Raine, D. Huang, C. Ong, K. A. Furge,P. J. Campbell, M. R. Stratton, P. FutrealBrd. 1B The asociation between the number of nodes removed at retroperitoneallymph node dissection and overall- and cancer-specific survival in patientswith nonseminomatous germ cell tumor. (Abstract #4572)D. Lewinshtein, A. Schatz, C. R. PorterBrd. 1C CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90inhibition in prostate cancer. (Abstract #4573)F. Lamoureux, M. Yin, A. Zoubeidi, M. E. GleaveBrd. 1D Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), andprednisone (P) in patients (pts) with metastatic castration-resistant prostatecancer (mCRPC). (Abstract #4574)X. Huang, Y. M. Ning, M. Mulquin, R. A. Madan, J. L. Gulley, P. G. Kluetz,D. Adelberg, P. M. Arlen, H. L. Parnes, B. Adesunloye, S. M. Steinberg,J. J. Wright, J. B. Trepel, C. Chen, C. Bassim, A. B. Apolo, W. D. Figg, W. L. DahutBrd. 1E A phase II trial of dasatinib in subjects with hormone-refractory prostatecancer previously treated with chemotherapy. (Abstract #4575)P. Twardowski, C. Chen, A. S. Kraft, G. S. Chatta, E. Alexson, M. Mitsuhashi,W. Ye, M. LillyBrd. 1F The association of PTEN loss on outcome in patients with early high-riskprostate cancer (CaP) treated with adjuvant docetaxel following radicalprostatectomy (RP). (Abstract #4576)D. Keizman, Z. Zhang, V. J. Sinibaldi, A. DeMarzo, B. Gurel, T. Lotan, J. Hicks,E. Rosenbaum, E. S. Antonarakis, J. J. Kim, M. A. Carducci, M. A. EisenbergerBrd. 1G An evaluation of blood mRNA expression array signatures derived fromunsupervised analyses in the identification of prostate cancers with pooroutcome. (Abstract #4577)D. Olmos, J. Clark, D. Brewer, L. Barwell, G. Attard, A. H. Reid, S. K. Sandhu,A. Zivi, D. Bianchini, N. Babu Oomen, E. Thompson, L. R. Molife, S. B. Kaye,C. Parker, C. Cooper, R. J. Jones, J. S. De BonoBrd. 2A The effect of tobacco exposure in renal cell carcinoma (RCC) overall andcancer-specific survival. (Abstract #4578)N. Kroeger, T. Klatte, F. D. Birkhaeuser, E. N. Rampersaud, D. B. Seligson,N. Zomorodian, F. F. Kabbinavar, A. S. Belldegrun, A. J. PantuckBrd. 2B Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastaticgerm cell tumors (GCT). (Abstract #4579)A. Jain, M. J. Brames, D. J. Vaughn, L. H. EinhornBrd. 2C Phase III trial comparing long-term versus short-term androgen deprivationcombined with high-dose radiotherapy for localized prostate cancer: GICORprotocol DART01/05. (Abstract #4580)A. Zapatero, A. Guerrero, X. Maldonado, A. Alvarez, C. González San Segundo,A. Cabeza, V. Macías, F. Casas, A. Pedro-Olivé, S. Villa, A. Boladeras,M. Vazquez de La Torre, C. Martin de Vidales, F. A. Calvo, GICOR (GrupoInvestigacion Clinica Oncologia Radioterapica)Brd. 2D Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) inprevention of skeletal-related events (SREs) in castration-resistant prostatecancer metastatic to the bone (mCRPC). (Abstract #4581)S. J. Snedecor, J. A. Carter, S. Kaura, M. Botteman220

Sunday, June 5, 2011Brd. 2E Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10cycles in men with metastatic castration-resistant prostate cancer (mCRPC).(Abstract #4582)G. R. Pond, A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, W. R. Berry,R. De Wit, M. A. Eisenberger, I. Tannock, G. SonpavdeBrd. 2F Association of progression-free survival (PFS) at 2 or 3 years with overallsurvival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluationof individual patient data (IPD) from seven randomized trials comparing localtherapy with or without neoadjuvant chemotherapy (NC). (Abstract #4583)G. J. Chen, G. Sonpavde, C. L. Vale, D. Fisher, T. Powles, Advanced BladderCancer Meta-analysis Collaborators (ABCMAC)Brd. 2G The prognostic significance of LDH levels in patients withrelapsed/refractory seminoma and their predictive value of the newinternational prognostic score. (Abstract #4584)T. Powles, C. Mollevi, A. Kramar, A. Lorch, J. Beyer, for the InternationalPrognostic Factors Study Group (IPFSG)Brd. 3A The interval to biochemical failure versus biochemical failure as predictorsfor cause-specific and overall survival following dose-escalated externalbeam radiation therapy for prostate cancer. (Abstract #4585)N. S. Kapadia, F. Y. Feng, K. B. Olson, H. M. Sandler, D. A. HamstraBrd. 3B Prognostic factors in second-line treatment of urothelial cancers withgemcitabine and paclitaxel: German Association of Urological Oncology(AUO) trial AB 20/99. (Abstract #4586)G. Niegisch, R. Fimmers, R. Siener, S. Park, P. Albers, German Association ofUrological Oncology (AUO)Brd. 3D Everolimus as first-line therapy in nonrapidly progressive metastaticcastration-resistant prostate cancer (mCRPC): A multicenter phase II trial(SAKK 08/08). (Abstract #4588)A. Templeton, C. Rothermundt, R. Cathomas, D. Baertschi, C. Droege,O. Gautschi, M. M. Borner, E. Fechter, F. Stenner, R. C. Winterhalder, B. Mueller,V. Dutoit, P. Dietrich, R. Schiess, P. Wild, G. N. Thalmann, D. Klingbiel,S. GillessenBrd. 3E Increased risk of overall and cardiovascular mortality after radicalnephrectomy for renal cell carcinoma less than or equal to 2 cm. (Abstract#4589)M. Kates, G. M. Badalato, N. Sadeghi, M. S. Pitman, J. M. McKiernanBrd. 3F An analysis of STAT3 polymorphism on outcomes of interferon-alphatreatment in patients with metastatic renal cell carcinoma. (Abstract #4590)M. Eto, T. Kamba, H. Miyake, M. Fujisawa, K. Yoshida, H. Uemura, T. Tsukamoto,Y. Katsuoka, A. Matsubara, K. Nishimura, T. Nakamura, O. Ogawa, S. NaitoBrd. 3G Progression-free survival (PFS) of first-line VEGF-targeted therapy as aprognostic parameter for overall survival (OS) in patients with metastaticrenal cell carcinoma (mRCC). (Abstract #4591)C. Seidel, M. Fenner, C. W. Reuter, A. Ganser, V. GruenwaldBrd. 3H Interim results of a randomized phase II study with window-design toevaluate antitumor activity of the survivin antisense oligonucleotide (ASO)LY2181308 in combination with docetaxel for first-line treatment of castrateresistantprostate cancer (CRPC). (Abstract #4592)P. J. Wiechno, P. Chlosta, J. Smok-Kalwat, J. Pikilel, D. H. Henry,D. F. Christianson, B. G. Somer, B. Mellado, I. Duran, D. E. Castellano, S. Callies,V. Andre, K. Hurt, M. M. Lahn, M. Stöckle, C. Reuter, B. HeinrichBrd. 4A Impact of carboplatin plus weekly docetaxel as salvage chemotherapy indocetaxel-resistant and castration-resistant prostate cancer (DRPC) on freetestosterone levels. (Abstract #4593)C. W. Reuter, M. A. Morgan, M. Fenner, P. Ivanyi, V. Gruenwald, A. GanserSUNDAY221

Sunday, June 5, 2011SUNDAYBrd. 4B Prognositic value of suppressed markers of bone turnover (BTO) after 6months of androgen deprivation therapy (ADT) in prostate cancer. (Abstract#4594)J. Sharma, C. T. Yiannoutsos, N. M. Hahn, C. SweeneyBrd. 4C Risk of high-grade liver toxicity with pazopanib in patients with cancer: Ameta-analysis. (Abstract #4595)S. Kapadia, S. Hapani, S. WuBrd. 4D Observation versus adjuvant radiation or chemotherapy in the managementof stage I seminoma. (Abstract #4596)M. S. Soper, J. R. Hastings, M. Tome, K. LodinBrd. 4E LH-receptor polymorphisms and response to androgen deprivation therapyin prostate cancer. (Abstract #4597)S. V. Liu, T. B. Dorff, Q. Wang, S. Xiong, E. Thara, M. Keng, S. A. Ingles,J. K. PinskiBrd. 4F Cytokines’ profiles to predict chemotherapy outcome in castration-resistantprostate cancer (CRPC). (Abstract #4598)K. L. Mahon, M. D. Chatfield, M. Lee-Ng, S. N. Breit, D. A. Brown, M. P. Molloy,G. M. Marx, N. Pavlakis, M. J. Boyer, M. R. Stockler, R. Wykes, S. M. Henshall,R. L. Sutherland, L. HorvathBrd. 4G A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone,and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory,and angiostatic treatment in patients (pts) with castration-refractory prostatecancer (CRPC) . (Abstract #4599)A. Reichle, M. Vogelhuber, S. Feyerabend, T. Suedhoff, M. Schulze, J. Hubner,R. Oberneder, M. Baier, A. Ruebel, K. Birkholz, A. Bakhshandeh-Bath,R. AndreesenBrd. 4H Sorafenib and sunitinib in renal cell cancer: A study based on register data.(Abstract #4600)A. E. Ambring, U. K. Stierner, A. S. Oden, I. N. BjorholtBrd. 5A Final results of the international, expanded-access program of everolimus inpatients with advanced renal cell carcinoma who progress after priorvascular endothelial growth factor receptor–tyrosine kinase inhibitor(VEGFr-TKI) therapy. (Abstract #4601)V. Grünwald, P. I. Karakiewicz, S. E. Bavbek, K. Miller, J. H. Machiels, S. Lee,J. M. Larkin, P. Bono, S. Y. Rha, D. E. Castellano, C. U. Blank, J. J. Knox,R. Hawkins, R. R. Yuan, M. Rosamilia, J. L. Booth, I. Bodrogi, on behalf of theREACT Study GroupBrd. 5B Quantifying the effect of everolimus on both tumor growth and newmetastases in metastatic renal cell carcinoma (RCC): A dynamic tumormodel of the RECORD-1 phase III trial. (Abstract #4602^)A. M. Stein, A. Carter, N. Hollaender, R. J. Motzer, C. SarrBrd. 5C A study of methylated glutathione s-transferase 1 (mGSTP1) as a potentialplasma epigenetic marker of response to chemotherapy and prognosis inmen with castration-resistant prostate cancer (CRPC). (Abstract #4603)L. Horvath, K. L. Mahon, W. Qu, J. Devaney, M. D. Chatfield, C. Paul, R. Wykes,M. J. Boyer, M. R. Stockler, G. M. Marx, R. L. Sutherland, S. J. ClarkBrd. 5D A pooled analysis of the efficacy and safety of sunitinib in elderly patients(pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4604)T. E. Hutson, R. M. Bukowski, B. I. Rini, M. E. Gore, J. M. Larkin, R. A. Figlin,C. H. Barrios, B. Escudier, X. Lin, K. D. Fly, B. Martell, E. Matczak, R. J. MotzerBrd. 5E Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, incombination with docetaxel-prednisone regimen for patients (pts) withcastration-resistant prostate cancer (CRPC). (Abstract #4605)J. Medioni, J. Ferrero, G. Deplanque, T. Maurina, J. P. Rodier, E. Raymond,J. Allyon, S. Renaux, J. Dufour-Lamartinie, S. Oudard222

Sunday, June 5, 2011Brd. 5FBrd. 5GBrd. 5HBrd. 6ABrd. 6BBrd. 6CBrd. 6DBrd. 6EBrd. 6FBrd. 6GBrd. 6HBrd. 7ABrd. 7BFinal results of a phase II study of everolimus (RAD001) in metastatictransitional cell carcinoma (TCC) of the urothelium. (Abstract #4606)M. I. Milowsky, A. M. Regazzi, I. R. Garcia-Grossman, A. Trout, A. Flaherty,S. Gerst, H. Al-Ahmadie, I. Ostrovnaya, D. F. BajorinDoes enrollment setting influence patient attributes and outcomes in RTOGprostate cancer trials? (Abstract #4607)W. Lee, J. Dignam, D. Bruner, J. A. Efstathiou, Y. Yan, G. E. Hanks, M. Roach III,M. V. Pilepich, H. M. SandlerLate toxicity rates following definitive radiotherapy for prostate cancer: Ameta-analysis revealing interactions between dose and technique. (Abstract#4608)N. Ohri, W. Shi, A. Dicker, T. N. ShowalterEfficacy and safety of intrapatient dose escalation of sorafenib as first-linetreatment for metastatic renal cell carcinoma (mRCC). (Abstract #4609^)M. E. Gore, R. J. Jones, A. Ravaud, M. Kuczyk, T. Demkow, A. Bearz,N. Laferriere, U. P. Strauss, C. PortaAnalysis of the relationship between Karnofsky performance status (KPS)and tumor response in the RECORD-1 phase III trial of everolimus in patientswith advanced renal cell carcinoma (RCC). (Abstract #4610)C. Porta, B. Escudier, T. E. Hutson, R. A. Figlin, E. Calvo, V. Grünwald, S. Osanto,A. Ravaud, A. Panneerselvam, J. J. Knox, R. J. MotzerSingle-nucleotide polymorphisms (SNPs) in the endothelial nitric oxidesynthase (NOS3) and vascular endothelial growth factor (VEGF) and itsrelationship to sunitinib-induced hypertension. (Abstract #4611)A. A. van der Veldt, K. Eechoute, S. Oosting, M. H. Kappers, J. B. Haanen,A. K. Reyners, H. Gelderblom, H. Guchelaar, C. Van Herpen, E. Boven,R. MathijssenTumor marker rise during second course high-dose chemotherapy inrecurrent testicular cancer: Outcome analysis. (Abstract #4612)M. Pant-Purohit, M. J. Brames, R. Abonour, L. H. EinhornFinal results of a risk-adapted policy of adjuvant chemotherapy (ACT) inpatients with invasive bladder carcinoma (IBC). (Abstract #4613)J. Arranz Arija, Y. Jerez Gilarranz, A. Soria Lovelle, C. López López,P. Sabin Dominguez, M. Riesco, J. Adeva Alfonso, D. Urosa Velasco,E. López Juárez, R. González Beca, M. MartinThe ZOTECT study: Effect of intravenous zoledronic acid on bonemetabolism in patients with metastatic bone disease in prostate cancer (PC)and breast cancer (BC). (Abstract #4614)P. Hadji, M. Ziller, T. Maurer, M. Muth, A. Ruebel, C. May, K. Birkholz,J. E. GschwendLong-term response to sunitinib for metastatic renal cell carcinoma (mRCC)patients treated on clinical trials at Memorial Sloan-Kettering Cancer Center.(Abstract #4615)A. M. Molina, X. Jia, M. S. Ginsberg, S. Velasco, D. R. Feldman, S. Patil,R. J. MotzerDoes absolute neutrophil count predict adverse tumor grade in AfricanAmerican men with prostate cancer? (Abstract #4616)N. Sadeghi, G. M. Badalato, G. W. Hruby, V. R. Grann, J. M. McKiernanEffect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel(TAX) in previously treated metastatic (MET) urothelial cancer. (Abstract#4617)Y. Wong, S. Litwin, D. J. Vaughn, E. R. Plimack, W. Song, J. W. Lee,M. B. Dabrow, M. Brody, H. Tuttle, G. R. HudesUpdated results of INT70/09 phase II study of pazopanib (PZP) monotherapyfor patients with relapsed/refractory urothelial cancer (UC). (Abstract #4618)A. Necchi, N. Nicolai, C. Ortega, T. Sava, C. Messina, C. Sacco, F. Crippa,C. Morosi, R. Lanocita, M. Colecchia, L. Mariani, N. Zaffaroni, R. Salvioni223SUNDAY

Sunday, June 5, 2011SUNDAYBrd. 7CBrd. 7DBrd. 7EBrd. 7FBrd. 7GBrd. 7HBrd. 8ABrd. 8BBrd. 8CBrd. 8DBrd. 8EPresurgical docetaxel (Doc) and androgen deprivation therapy (ADT) inlymph node-positive prostate cancer (PCa). (Abstract #4619)L. C. Pagliaro, A. J. Zurita, J. C. Araujo, J. F. Ward, J. W. Davis, C. A. Pettaway,S. Tu, J. Kim, P. Dieringer, C. Logothetis, L. L. PistersAlkaline phosphatase (ALP) normalization and overall survival in patientswith bone metastases from castration-resistant prostate cancer (CRPC)treated with radium-223. (Abstract #4620^)S. Nilsson, C. G. O’Bryan-Tear, B. Bolstad, A. Lokna, C. C. ParkerThe association of pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR)with outcome of sunitinib tx in patients (pts) with metastatic renal cellcarcinoma (mRCC). (Abstract #4621)P. Huang, M. A. Carducci, M. A. Eisenberger, R. Pili, J. J. Kim, E. S. Antonarakis,H. J. Hammers, D. KeizmanPhase II trial of everolimus monotherapy in the palliative treatment ofpatients with metastatic transitional cell carcinoma (TCC) after failure ofplatinum-based therapy: Activity and biomarkers. . (Abstract #4622)E. Seront, B. Sautois, S. Rottey, L. A. D’Hondt, J. Canon, J. Vandenbulcke,N. Whenham, J. Goeminne, O. Feron, J. H. MachielsThioredoxin reductase RNA levels in expressed prostatic secretions asprognostic indicators of prostate cancer. (Abstract #4623)J. A. Linehan, R. Torrey, J. P. Clark, G. Babilonia, D. D. Smith, K. Chan, C. Lau,D. Y. Josephson, M. H. Kawachi, T. G. Wilson, S. S. SmithA multicenter, randomized phase II study of the second-line maximumandrogen blockade with an alternative antiandrogen combined with tegafururacil(UFT) for prostate cancer with relapse after initial hormonal therapy.(Abstract #4624)M. Takahashi, R. Kawabata, A. Kawano, Y. Murakami, Y. Sutou, T. Inai,S. Akazawa, T. Hamao, H. Hayashi, T. Fukawa, M. Takemura, Y. Yamamoto,K. Yamaguchi, H. Nakatsuji, T. Kishimoto, H. Izaki, T. Fukumori, H. KanayamaPhase II trial of sunitinib in renal cell cancer with untreated brain metastases.(Abstract #4625)C. Chevreau, A. Ravaud, B. Escudier, A. Caty, R. Delva, F. Rolland, S. Oudard,R. Herve, E. Blanc, C. Ferlay, N. Lignon, S. Negrier, French Group on RenalCancerAnalysis of blood-derived circulating microvesicles for microRNAbiomarkers of metastatic and nonmetastatic prostate cancer. (Abstract#4626)F. C. Hamdy, R. J. Bryant, T. L. Pawlowski, G. Marsden, S. Smith, R. Vessella,C. D. KuslichMicrobubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for theassessment of vascular response to sunitinib in renal cell carcinoma (RCC).(Abstract #4627)G. A. Bjarnason, R. Williams, J. M. Hudson, C. Bailey, C. R. Lee, B. A. Lloyd,S. Kandel, J. M. Ebos, A. Kiss, R. S. Kerbel, L. M. Milot, M. Atri, G. J. Stanisz,P. BurnsRandomized phase II study of danusertib (D) in second-line metastaticcastration-resistant prostate cancer (CRPC). (Abstract #4628)J. P. Bleuse, H. J. Meulenbeld, E. M. Vinci, E. Raymond, G. Vitali, A. Santoro,L. Dogliotti, R. Berardi, F. Cappuzzo, S. T. Tagawa, C. N. Sternberg, M. Jannuzzo,M. Mariani, A. Petroccione, R. De WitSorafenib and everolimus (RAD001) in the treatment of patients withadvanced clear cell renal carcinoma (RCC): A Sarah Cannon ResearchInstitute phase I/II trial. (Abstract #4629)D. M. Waterhouse, W. C. Penley, C. D. Webb, F. A. Greco, H. A. Burris III,J. D. Hainsworth224

Sunday, June 5, 2011Brd. 8FBrd. 8GBrd. 8HBrd. 9ABrd. 9BBrd. 9CBrd. 9DBrd. 9EBrd. 9FBrd. 9GBrd. 9HBrd. 10ABrd. 10BBrd. 10CObservation prior to systemic therapy in patients with metastatic renal cellcarcinoma in the kinase inhibitor era. (Abstract #4630)R. A. Fisher, A. Pender, K. Thillai, S. Chowdhury, L. M. Pickering, S. St. Rose,M. E. Gore, J. M. LarkinAssociation of Raynaud’s phenomenon after bleomycin etoposide cisplatin(BEP) chemotherapy for testicular cancer (TC) with acceleratedatherosclerosis. (Abstract #4631)R. Altena, H. Boer, C. Meijer, J. Nuver, A. M. van Roon, N. Zwart, E. De Vries,J. D. Lefrandt, A. J. Smit, J. A. GietemaRelationship of T lymphocytes, T regulatory cells, and B lymphocytes toclinical outcome in prostate cancer. (Abstract #4632)M. Trepel, A. Flammiger, L. Weisbach, T. Schlomm, H. Huland, S. Minner,P. Tennstaedt, C. Bokemeyer, G. SauterIncidence of thyroid dysfunction in renal cell carcinoma (RCC) patientstreated with pazopanib in prospective clinical trials. (Abstract #4633)P. Wolter, L. McCann, C. N. Sternberg, T. E. Hutson, F. Mehmud, L. N. Pandite,P. SchoffskiEffect of sunitinib (SU) administration on post-treatment survival in patientswith metastatic renal cell carcinoma (mRCC) treated on the upfrontrandomized phase III trial of sunitinib or interferon alfa (IFN). (Abstract #4634)K. B. Blagoev, J. Wilkerson, W. D. Stein, R. J. Motzer, S. E. Bates, A. T. FojoThe PCCTC imaging data capture toolset: An analysis of its impact onprostate cancer clinical trial accuracy and workload. (Abstract #4635)E. R. Dennis, J. J. Fox, S. M. Larson, J. S. Farrelly, L. H. Schwartz,H. Schöder, E. C. Haupt, L. S. Borwick, H. I. Scher, M. J. MorrisQuantifying the tradeoffs of active surveillance for low-risk prostate cancer:A clinical decision analysis. (Abstract #4636)D. Liu, H. P. Lehmann, K. D. Frick, B. CarterPrevalence of prostate cancer (PC) clinical states (CS) in the United States:Estimates using a dynamic progression model. (Abstract #4637)K. Solo, M. Mehra, R. Dhawan, J. Valant, H. I. ScherA phase II multicenter evaluation of ARQ 197 monotherapy in patients withrelapsed or refractory germ cell tumors (GCTs). (Abstract #4638)D. R. Feldman, L. H. Einhorn, D. I. Quinn, A. Horwich, Y. Loriot, J. K. Joffe,D. J. Vaughn, A. Flechon, J. Hajdenberg, A. U. Pande, K. Liu,I. Gorbatchevsky, R. J. MotzerPilot study of cisplatin, 5-fluorouracil, and a taxane (TPF) for advancedsquamous cell carcinoma (SCC) of the penis. (Abstract #4639)R. Salvioni, N. Nicolai, L. Piva, M. Catanzaro, T. Torelli, D. Biasoni, S. Stagni,A. Milani, A. NecchiImpact of 24 months of androgen deprivation therapy (ADT) on physicalfunction in men with nonmetastatic prostate cancer. (Abstract #4640)S. M. Alibhai, H. Breunis, N. Timilshina, S. Duff Canning, N. Fleshner, M. Krahn,I. Tannock, G. A. Tomlinson, P. R. Warde, G. NaglieThe prognostic significance of prenephrectomy absolute lymphocyte countin clear cell renal cell carcinoma. (Abstract #4641)S. Saroha, R. Uzzo, G. R. Hudes, E. R. Plimack, K. Ruth, T. I. Al-SaleemA phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) inpatients (pts) with high-risk localized prostate cancer. (Abstract #4642)W. K. Oh, M. D. Galsky, M. Barry, F. Fennessey, J. P. Richie, J. H. Hayes,R. S. Bhatt, M. Taplin, P. G. Febbo, R. W. RossRandomized phase II trial evaluating different schedules of zoledronic acidadministration on bone mineral density in patients with stage D prostatecancer beginning androgen deprivation. (Abstract #4643)J. M. Lang, J. C. Eickhoff, N. C. Binkley, M. J. Staab, G. Liu, G. Wilding,D. G. McNeelSUNDAY225

Sunday, June 5, 2011SUNDAYBrd. 10DBrd. 10EBrd. 10FBrd. 10GBrd. 10HBrd. 11ABrd. 11BBrd. 11CBrd. 11DBrd. 11EBrd. 11FBrd. 11GAdoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) forbladder cancer: A population-based study. (Abstract #4644)C. M. Booth, D. R. Siemens, I. Tannock, Y. Peng, G. Li, W. J. MackillopA case-control study examining associations of germ-line oxidative DNArepair single-nucleotide polymorphisms (SNPs) with lethal prostate cancer(PCa) risk. (Abstract #4645)N. M. Hahn, J. Jung, J. Dantzer, S. Philips, Y. R. Patel, K. A. Carr, Y. Mohammadi,D. Magjuka, C. Camp, M. Bolden, E. F. Dropcho, J. A. Knight II, M. L. Moore,A. D. Reed, M. J. Waddell, J. E. Klaunig, L. Li, C. Sweeney, T. C. SkaarEfficacy and safety of sunitinib in patients with metastatic renal cellcarcinoma on hemodialysis. (Abstract #4646)J. Casper, D. Goebel, V. Gruenwald, A. Flörcken, D. Mueller, K. Toussaint,B. MetznerVariation in sex steroid methyl transferases associated with androgendeprivation therapy (ADT) efficacy in advanced prostate cancer. (Abstract#4647)M. Kohli, D. W. Mahoney, H. S. Chai, D. W. Hillman, D. R. Rider, B. A. Costello,J. R. CerhanQuality-of-life assessment in a randomized, double-blind study of sipuleucel-T in men with androgen-dependent prostate cancer. (Abstract #4648)T. M. Beer, P. F. Schellhammer, J. M. Corman, L. M. Glode, S. Hall, Y. Xu,M. W. Frohlich, D. F. PensonA randomized phase II study of bone-targeted therapy in advancedandrogen-dependent prostate cancer. (Abstract #4649)M. A. Bilen, D. Liu, P. Mathew, L. C. Pagliaro, C. Logothetis, J. C. Araujo,A. Aparicio, P. G. Corn, J. Hajdenberg, S. R. Dakhil, S. TuProstate-specific membrane antigen antibody–drug conjugate (PSMA ADC):A phase I trial in taxane-refractory prostate cancer. (Abstract #4650)D. P. Petrylak, P. W. Kantoff, R. C. Frank, N. D. Shore, Y. Rotshteyn,R. J. Israel, W. C. Olson, T. Ramakrishna, S. MorrisEvaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer byFISH and immunohistochemistry to address intra- and intertissueheterogeneity and disease progression. (Abstract #4651)A. M. Joshua, A. Evans, J. Squire, M. Yoshimoto, O. Ludkovski, S. Tan, A. Dobi,B. Furusato, G. Petrovics, S. Srivastava, I. Sesterhenn9q32-q33.1 amplification as a prognostic factor for overall survival inmetastatic germ cell tumors. (Abstract #4652)J. M. Piulats, A. Vidal, M. Nadal, A. Pisa, J. R. Germa-Lluch, E. Condom,A. Villanueva, X. Garcia del MuroUse of P63 expression to define a lethal subset of muscle-invasive bladdercancers. (Abstract #4653)W. Choi, J. B. Shah, M. Tran, R. S. Svatek, L. Marquis, I. C. Lee, D. Yu, L. Adam,J. E. Bondaruk, S. Wen, Y. Shen, C. P. Dinney, B. Czerniak, D. J. McConkey,A. O. Siefker-RadtkeLymphovascular invasion in clinical stage I testicular nonseminoma:Potential marker of more aggressive relapses and implications for activesurveillance. (Abstract #4654)C. R. Nichols, S. Daneshmand, S. Tyldesley, K. N. Chi, N. Murray, A. I. So,P. C. Black, B. M. Hayes-Lattin, C. K. KollmannsbergerDetection of metastatic disease as a leading cause of screening failure in aphase III trial of zibotentan versus placebo in patients with nonmetastaticcastration-resistant prostate cancer (CRPC). (Abstract #4655)E. Y. Yu, F. E. Nathan, C. S. Higano226

Sunday, June 5, 2011Brd. 11HBrd. 12ABrd. 12BBrd. 12CBrd. 12DBrd. 12EBrd. 12FBrd. 12GBrd. 12HBrd. 13ABrd. 13BClinical features of germ cell tumors (GCT) in men age 50 or older:Successful outcome and tolerability to chemotherapy for advanced disease.(Abstract #4656)M. H. Voss, E. P. Jacobsen, S. Patil, S. Turkula, X. Jia, J. Sheinfeld, D. F. Bajorin,G. J. Bosl, R. J. Motzer, D. R. FeldmanFollow-up study of chemotherapy plus hormone therapy for biochemicalrelapse after definitive local therapy for prostate cancer. (Abstract #4657)M. Nakabayashi, W. Xie, G. Buckle, G. Bubley, M. S. Ernstoff, W. V. Walsh,D. Morganstern, P. W. Kantoff, M. M. Regan, M. TaplinProstate-specific membrane antigen (PSMA)–targeted imaging of metastaticprostate cancer (PCa) via small molecule inhibitors: Comparison to bonescan, CT/MRI, and 111 In capromab. (Abstract #4658)R. Coleman, J. A. Barrett, A. Hussain, K. M. Slawin, T. Armor, N. D. LaFrance,J. W. BabichPazopanib in patients with metastatic renal cell carcinoma previously treatedwith sunitinib or bevacizumab: A Sarah Cannon Research Institute phase IItrial. (Abstract #4659)J. A. Reeves, D. R. Spigel, D. B. Daniel, E. K. Friedman, H. A. Burris III,J. D. HainsworthComparison of two major prognostic models for patients with metastaticrenal cell carcinoma treated in the contemporary era of targeted therapies.(Abstract #4660)M. Crepel, B. J. Escudier, J. H. Machiels, M. D. Staehler, A. Ravaud, G. Gravis,F. Joly, C. Chevreau, L. Zini, H. Lang, L. Salomon, P. Bigot Jr., J. Rigaud,J. Patard Sr.Time to disease-related pain after sipuleucel-T in asymptomatic patients withmetastatic castrate-resistant prostate cancer (mCRPC): Results from threerandomized phase III trials. (Abstract #4661)E. J. Small, C. S. Higano, P. W. Kantoff, J. B. Whitmore, M. W. Frohlich,D. P. PetrylakPhase I/II study of neoadjuvant docetaxel plus intensity-modulatedradiotherapy (IMRT) prior to surgery for high-risk prostate cancer. (Abstract#4662)M. Garzotto, A. Hung, T. M. Beer, J. J. Alumkal, J. N. Graff, P. E. Farris,J. F. Flamiatos, S. Mongoue-Tchokote, S. N. CarterQuantitative gene expression in primary and highest Gleason pattern cancerspecimens identifies genes associated with clinical recurrence and prostatecancer–specific survival after radical prostatectomy. (Abstract #4663)E. A. Klein, S. M. Falzarano, T. Maddala, M. Lee, R. J. Pelham, W. F. Novotny,S. Shak, C. Magi-GalluzziInvestigator-initiated pilot study of sunitinib malate in patients with newlydiagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCFProstate Cancer Clinical Trials Consortium. (Abstract #4664)D. J. George, S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull,S. E. Yenser Wood, A. J. Armstrong, R. J. Varley, J. Madden, J. W. MoulDoes prostate brachytherapy that avoids the central zone prevent long-termurinary incontinence? Five-year results of a multi-institutional comparativecohort study. (Abstract #4665)J. A. Talcott, A. L. Zietman, I. D. Kaplan, J. A. Clark, A. V. D’AmicoCharacterization of the anaplastic prostate carcinomas: A prospectivetwo-stage phase II trial of frontline carboplatin and docetaxel (CD) andsalvage etoposide and cisplatin (EP). (Abstract #4666)A. Aparicio, A. L. Harzstark, E. Lin, P. G. Corn, J. C. Araujo, S. Tu, L. C. Pagliaro,R. E. Millikan, W. Arap, J. Kim, C. J. Ryan, A. J. Zurita, N. M. Tannir, A. M. Lin,E. J. Small, P. Mathew, D. M. Jones, P. Troncoso, P. F. Thall, C. Logothetis,Prostate Cancer Clinical Trials ConsortiumSUNDAY227

Sunday, June 5, 2011Brd. 13CBrd. 13DBrd. 13EBrd. 13FAgent Orange as a risk factor for high-grade prostate cancer detected oninitial prostate biopsy. (Abstract #4667)N. J. Ansbaugh, J. Shannon, M. Mori, P. E. Farris, L. Collins, M. GarzottoPreoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) inmetastatic renal cell carcinoma (mRCC). (Abstract #4668)A. Finelli, A. M. Horgan, A. Evans, T. Kim, K. Durrant, S. Yap, C. A. Cassol,W. Dubinski, N. Fleshner, M. A. Jewett, A. M. Joshua, S. S. Sridhar,A. Zlotta, J. J. Knox11 C-choline-PET/CT (C-PET) versus transrectal ultrasound–guided prostatebiopsies (TRUS-BP) to diagnose locally recurrent prostate cancer (PCA)following radiation therapy (RT). (Abstract #4669)A. Heidenreich, B. Brehmer, R. Epplen, D. J. Pfister, EURO Prostate CenterAachenResults of a phase I/II clinical trial of BPX-101, a novel drug-activateddendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer(mCRPC). (Abstract #4670)K. M. Slawin, G. Sonpavde, J. D. McMannis, Y. Bai, M. Seethammagari, J. M. Bull,V. Hawkins, T. Dancsak, N. Lapteva, J. M. Levitt, D. M. SpencerSUNDAY228

Sunday, June 5, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONGynecologic CancerLocation: Hall ATrack(s): Gynecologic CancerBrd. 14A A phase I/II study of cisplatin and radiation in combination with sorafenib incervical cancer: Evaluation of biomarkers. (Abstract #5037)C. A. Townsley, M. Milosevic, M. A. Haider, H. Mackay, I. Yeung, S. Kim, W. Levin,L. Manchul, S. Bindra, K. MacAlpine, L. M. Tinker, L. Wang, J. Quintos,A. W. Fyles, A. M. OzaBrd. 14B Response rate and toxicity of primary concomitant radiochemotherapy inlocally advanced cervical cancer: Results of an open prospective,multicenter phase II study of the NOGGO. (Abstract #5038)A. Mustea, A. Belau, J. Sehouli, K. Drzewiecki, M. H. Eichbaum, K. Bartz,E. Angelidou, S. Saegner, M. O. Langenbruch, P. Ledwon, M. Zygmunt,G. Koehler, D. Koensgen, North-Eastern Society of Gynaecological OncologyBrd. 14C Expression of embryonic stem cell factor SOX2 in serous ovariancarcinomas. (Abstract #5039)T. N. Fehm, D. Pham, V. Scheible, C. Lengerke, S. Perner, H. Neubauer,A. StaeblerBrd. 14D Akt-mTOR pathway in uterine leiomyosarcoma. (Abstract #5040)G. Garg, A. Short, J. Liu, A. R. Munkarah, R. Morris, R. Ali-FehmiBrd. 14E Treatment of cervical intraepithelial neoplasia with topical imiquimod.(Abstract #5041)S. Polterauer, C. Grimm, C. Natter, J. Rahhal, L. Hefler, A. Reinthaller, P. SpeiserBrd. 14F MRI prior to systematic lymphadenectomy in patients with locally advancedcervical cancer. (Abstract #5042)M. Gold, Z. Zhang, H. Marques, J. Gorelick, L. M. Landrum, R. S. Mannel,L. T. Chuang, J. Q. Yu, C. K. McCourt, M. Harisinghani, A. Sohaib, D. Koh,S. Raman, M. S. Gee, H. Choi, M. AtriBrd. 14G Treatment and outcome of patients with invasive extramammary Paget’sdisease. (Abstract #5043)A. Karam, O. DorigoBrd. 14H Confirmatory factor analysis of the sexual adjustment and body image scalein women with a diagnosis of gynecologic cancer. (Abstract #5044)S. E. Ferguson, C. Massey, C. Classen, M. Wegener, N. Quartey, M. Pulandiran,D. Wiljer, S. UrowitzBrd. 15A PRECEDENT: A randomized phase II trial comparing EC145 and pegylatedliposomal doxorubicin (PLD) in combination, versus PLD alone, in subjectswith platinum-resistant ovarian cancer. (Abstract #5045)R. W. Naumann, R. L. Coleman, R. A. Burger, T. J. Herzog, R. Morris,E. A. Sausville, E. Kutarska, S. A. Ghamande, N. Y. Gabrail, S. De Pasquale,E. Nowara, L. Gilbert, J. R. Caton, R. H. Gersh, M. G. Teneriello, W. A. Harb,P. Konstantinopoulos, J. T. Symanowski, C. Lovejoy, R. A. MessmannBrd. 15B Final survival results of the randomized phase III study of trabectedin withpegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovariancancer. (Abstract #5046)B. J. Monk, T. J. Herzog, S. B. Kaye, C. N. Krasner, J. B. Vermorken, F. Muggia,E. Pujade-Lourraine, P. Zintl, T. V. Parekh, A. PovedaBrd. 15C The role of NKTR-102 in women with platinum resistant/refractory ovariancancer and failure on pegylated liposomal doxorubicin (PLD). (Abstract#5047)A. A. Garcia, I. B. Vergote, J. P. Micha, C. H. Pippitt Jr., G. G. Rao, D. L. Spitz,N. Reed, G. G. Dark, E. N. Ibrahim, V. A. Armenio, L. R. Duska, C. J. Poole,C. Gennigens, L. Y. Dirix, J. West, C. Zhao, A. C. Leung, L. K. Masuoka,G. J. RustinSUNDAY229

Sunday, June 5, 2011SUNDAYBrd. 15D Catumaxomab treatment of malignant ascites in patients with chemotherapyrefractoryovarian cancer: A phase II study. (Abstract #5048)J. S. Berek, R. P. Edwards, L. Parker, L. R. DeMars, T. J. Herzog, S. S. Lentz,R. Morris, W. L. Akerley, R. W. Holloway, M. Method, S. C. Plaxe, J. L. Walker,T. Schindler, E. Schulze, C. N. Krasner, Cooperative Ovarian Cancer Group(COGI)Brd. 15E Fibroblast growth factor receptor 4 (FGFR4) expression as a prognosticindicator in high-grade serous ovarian carcinoma (HGSC): Signalingpathway, mechanism, and implication for therapeutic targeting. (Abstract#5049)T. M. Zaid, M. Thompson, K. Wong, T. Yeung, Z. Yeung, D. M. Gershenson,M. J. Birrer, S. C. MokBrd. 15F The relationship of polymorphism Mad1 1673 G>A on outcomes in patientswith advanced ovarian cancer treated with carboplatine-paclitaxel. (Abstract#5050)M. Santibañez, D. Prada, C. Diaz, C. Castro, F. Morales-Vasquez,D. Gallardo Rincon, L. A. HerreraBrd. 15G Analysis of polymorphisms in sodium channel, voltage-gated, type I, alphasubunit (SCN1A) as predictors of clinical outcome and toxicity in advancedovarian cancer patients enrolled in a phase III trial treated with patupilone.(Abstract #5051)Y. Ning, W. Zhang, D. Yang, D. Weber, F. Souami, P. O. Bohanes, A. Gerger,M. J. Labonte, L. Benhaim, H. LenzBrd. 15H Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxeland carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients(pts): Treatment at recurrence and overall survival (OS) final analysis fromCALYPSO phase III GCIG trial. (Abstract #5052)C. Marth, J. Alexandre, L. C. Hanker, C. Brown, J. Kaern, M. Heywood,A. Bonaventura, I. B. Vergote, S. Pignata, A. Ferrero, V. Gebski, M. Gropp,T. Skeie-Jensen, C. Giede, P. A. Vasey, C. Schauer, N. Reed, G. Ferrandina,R. Fossati, E. Pujade-LauraineBrd. 16A A risk model for secondary cytoreductive surgery in recurrent ovariancancer: An evidence-based proposal for patient selection. (Abstract #5053)W. Tian, D. Chi, J. Sehouli, C. Trope, R. Jiang, A. Ayhan, G. Cormio, Y. Xing,G. Breitbach, E. I. Braicu, C. A. Rabbitt, H. Oksefjell, C. Fotopoulou, H. Meerpohl,A. Du Bois, J. S. Berek, R. Zang, P. HarterBrd. 16B Intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin in patientswith epithelial ovarian, fallopian tube, or peritoneal carcinoma: A feasibilitystudy. (Abstract #5054)S. Nagao, T. Nishikawa, A. Kurosaki, R. Ohishi, N. Iwasa, K. Hasegawa,K. FujiwaraBrd. 16C Multimodality evaluation of excision repair cross-complementation 1(ERCC1) expression as a predictive biomarker for platinum resistance inepithelial ovarian cancer (EOC). (Abstract #5055)C. O. Michie, L. Song, D. Faratian, J. Orr, T. Rye, J. Clark, J. M. Bartlett,D. J. Harrison, D. Melton, A. Williams, C. GourleyBrd. 16D Phase I safety study of farletuzumab, carboplatin, and pegylated liposomaldoxorubicin (PLD) in subjects with platinum-sensitive epithelial ovariancancer (EOC). (Abstract #5056)D. Jelovac, D. K. Armstrong, S. Weil, M. Phillips, B. M. Schwartz, J. M. Estes,R. D. AlvarezBrd. 16E Age-specific prognostic factors for survival in patients with advancedovarian cancer (OC) treated with platinum/taxane-based primarychemotherapy: A combined explorative analysis of three prospective phaseIII trials from the AGO study group. (Abstract #5057)F. Hilpert, A. Hempel, J. Hedderich, O. Junge, P. Harter, A. Du Bois, J. Pfisterer,AGO Study Group230

Sunday, June 5, 2011Brd. 16FBrd. 16GBrd. 16HBrd. 17ABrd. 17BBrd. 17CBrd. 17DBrd. 17EBrd. 17FBrd. 17GBrd. 17HExpression profiles in matched primary and recurrent serous ovariancarcinomas. (Abstract #5058)D. A. Zajchowski, B. Y. Karlan, L. K. ShawverCarboplatin and pegylated liposomal doxorubicin versus carboplatin andpaclitaxel in very platinum-sensitive ovarian cancer patients: Results from asubset analysis of the CALYPSO phase III GCIG trial. (Abstract #5059)S. Mahner, W. Meier, A. Du Bois, C. Brown, D. Lorusso, A. Ferrero, J. Cretin,H. Havsteen, P. Bessette, L. Angleitner-Boubenizek, I. B. Vergote, P. A. Vasey,V. Gebski, B. Slama, J. Herrstedt, L. Kaizer, A. Georgoulopoulos, N. Reed,U. WagnerPhase II trial of trabectedin (T) in heavily pretreated recurrent ovarian cancer(ROC) patients. (Abstract #5060)D. Lorusso, P. Malaguti, V. Masciullo, S. Mainenti, A. di Legge, M. Ludovisi,A. Pesce, F. Mascilini, E. Fusco, G. ScambiaPegylated liposomal doxorubicin and carboplatin plus bevacizumab inpatients with platinum-sensitive recurrent ovarian, fallopian tube, or primaryperitoneal cancers: Results of a phase II study. (Abstract #5061)M. G. del Carmen, J. P. Micha, L. A. Small, D. G. Street, A. Londhe, T. McGowanA North American population-based outcome for early-stage ovarian clearcell carcinoma (OCCC). (Abstract #5062)P. Hoskins, J. S. Albarrak, N. Le, A. Tinker, K. Swenerton, J. Santos, C. B. GilksImplications of BRCA1 and BRCA2 mutations on taxane sensitivity inpatients (pts) with advanced ovarian cancer. (Abstract #5063)D. S. Tan, T. A. Yap, M. M. Hutka, P. Roxburgh, E. Grzybowska, C. Gourley,M. E. Gore, S. B. KayePharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeatdoses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) withovarian cancer. (Abstract #5064)H. Gungor, A. Saleem, R. Agarwal, S. P. Blagden, A. Michael, E. A. Stronach,M. Chen, E. Pickford, N. R. Rama, Y. L. Lewis, S. C. Carme, C. Salinas,D. A. Smith, E. Krachey, A. Santiago-Walker, R. N. Gunn, M. El-Bahrawy,S. A. Babar, S. R. Morris, H. GabraMathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC)patients treated with chemotherapy and predictive value of early modeledkinetic parameters in CALYPSO trial: A GCIG study. (Abstract #5065)B. You, O. Colomban, M. Heywood, C. Lee, M. Davy, N. Reed, S. Pignata,R. Fossati, G. Emons, K. L. Rehman, K. D. Steffensen, E. Petru, V. Gebski,A. Burges, N. Tubiana-Matthieu, M. Hansen, P. A. Vasey, U. Denison,P. De Bruyne, A. M. OzaPhase I feasibility study of intraperitoneal cisplatin and intravenouspaclitaxel followed by intraperitoneal paclitaxel in untreated ovarian,fallopian tube, and primary peritoneal carcinoma: Gynecologic OncologyGroup study 9921. (Abstract #5066)D. S. Dizon, M. Sill, N. S. Gould, S. C. Rubin, S. D. Yamada, R. DeBernardo,R. S. Mannel, E. L. Eisenhauer, L. R. Duska, P. M. Fracasso, GynecologicOncology GroupPrediction of progression-free survival (PFS) adjusted by continuousplatinum-free interval (PFI) at fixed timepoints in patients with recurrentovarian cancer (ROC): Results from OVA-301. (Abstract #5067)A. Poveda, B. J. Monk, S. B. Kaye, J. B. Vermorken, I. B. Vergote,I. B. Runnebaum, E. Pujade-Lauraine, T. V. Parekh, A. Nieto, J. Gomez,Y. C. Park, N. ColomboAcquired drug resistance in gynecologic cancer detected by drug responsemarker testing. (Abstract #5068)I. Benjamin, H. J. Dalton, B. J. MonkSUNDAY231

Sunday, June 5, 2011SUNDAYBrd. 18ABrd. 18BBrd. 18CBrd. 18DBrd. 18EBrd. 18FBrd. 18GBrd. 18HBrd. 19ABrd. 19BBrd. 19CBrd. 19DBrd. 19EA novel plasma amino acid profile-based biomarker for early detection ofovarian cancer. (Abstract #5069)E. Miyagi, R. Numazaki, Y. Ihata, T. Muramatsu, A. Imaizumi, H. Yamamoto,M. Yamakado, N. Okamoto, M. Asai-Sato, F. HiraharaOperative morbidity and mortality in octogenarians and nonagenarians withovarian cancer. (Abstract #5070)C. L. Walters, K. E. Schneider, J. M. Whitworth, J. M. Fauci, J. M. Straughn,M. N. BarnesFirst quality-of-life data of a sequential dose-dense regimen in advancedovarian cancer: A multicenter phase II study of the Northeastern GermanSociety of Gynecological Oncology. (Abstract #5071)G. Oskay-Özcelik, R. Richter, K. Pietzner, H. Hindenburg, H. L. Sommer,R. Chekerov, O. Camara, E. Keil, J. Einenkel, W. Lichtenegger, J. SehouliPatterns of recurrence in advanced epithelial ovarian, fallopian tube, andperitoneal cancers treated with intraperitoneal chemotherapy. (Abstract#5072)K. M. Esselen, N. Rodriguez, N. S. Horowitz, S. M. CamposExtended duration of response with second-line intraperitoneal platinumbasedtherapy for epithelial ovarian cancer. (Abstract #5073)M. E. Skaznik-Wikiel, J. L. Lesnock, W. C. McBee Jr., S. D. Richard, J. L. Kelley,K. K. Zorn, T. C. Krivak, R. P. EdwardsRegulation of the tumor suppressor gene PAEP in the transition from serousborderline ovarian tumors to low-grade serous ovarian carcinomas.(Abstract #5074)E. R. King, Y. T. Tsang, Z. Zu, D. M. Gershenson, S. C. Mok, K. WongIncreased expression of C-terminal binding protein-2 in epithelial ovariancarcinoma modulates DNA repair pathways and decreases tumor responseto histone deacetylase inhibitors. (Abstract #5075)T. May, L. M. Barroilhet, J. Yang, M. Singh, W. R. Welch, S. P. Sugrue,R. S. Berkowitz, S. NgUse of contrast-enhanced ultrasound imaging with microbubbles targeted tov3 integrins to enhance detection of early-stage ovarian tumors. (Abstract#5076)A. Barua, A. Yellapa, P. Bitterman, J. M. Bahr, S. Sharma, D. B. Hales,J. L. Luborsky, J. S. AbramowiczSurveillance for ovarian carcinoma patients after curative-intent treatment.(Abstract #5077)F. E. Johnson, K. S. Virgo, F. Gao, D. G. MutchAnti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients withadvanced platinum resistant/refractory (PRR) ovarian cancer (OC), primaryperitoneal cancer (PPC), or fallopian tube cancer (FTC). (Abstract #5078)O. Smaletz, M. Diz, C. C. Carmo, J. Sabbaga, G. F. Cunha, S. J. Azevedo,F. C. Maluf, C. H. Barrios, R. L. Costa, A. G. Fontana, V. A. Alves, A. M. Moro,A. M. Scott, E. W. Hoffman, L. J. OldIs there a place for neoadjuvant chemotherapy in the management ofadvanced malignant germ cell tumors of the ovary? (Abstract #5079)L. Kumar, S. Talukdar, R. Hariprasad, A. Gupta, A. Mookerjee, S. Kumar,N. Bhatla, S. MathurFDG-PET/CT imaging in gynecologic cancers: Is there an advance on patientmanagement? (Abstract #5080)M. Dalla Palma, M. Gregianin, L. Evangelista, A. Cervino, G. Saladini, L. Borgato,M. O. Nicoletto, V. ZagonelPrognostic significance of serum HE4 in epithelial ovarian cancer. (Abstract#5081)M. Marinaccio, E. Mele, V. Lorusso, A. Larocca, C. Pellegrino, R. Chiappetta,F. Sozzi232

Sunday, June 5, 2011Brd. 19FBrd. 19GBrd. 19HBrd. 20ABrd. 20BBrd. 20CBrd. 20DBrd. 20EBrd. 20FBrd. 20GBrd. 20HBrd. 21AIntra- and postoperative catumaxomab in patients with epithelial ovariancancer: Two-year efficacy results from a multicenter, single-arm, phase IIstudy. (Abstract #5082)J. Sehouli, A. Reinthaller, C. Marth, D. Reimer, T. Reimer, W. Stummvoll,L. Angleitner-Boubenizek, B. Lehnert, M. Marquardt, M. M. Essing, R. ChekerovAssessing the value of weekly full blood counts (FBC) in patients withadvanced serous gynecologic cancers receiving weeklycarboplatin/paclitaxel (wCP) chemotherapy. (Abstract #5083)D. Ulahannan, G. J. Rustin, M. HallRelationship between relative dose intensity and mortality in womenreceiving combination chemotherapy for stage III-IV epithelial ovariancancer. (Abstract #5084)L. J. Havrilesky, R. K. Hanna, M. S. Poniewierski, R. Laskey, A. A. Secord,P. A. Gehrig, M. A. Lopez, A. Shafer, L. Van Le, D. C. Dale, J. Crawford,G. H. LymanEffects of weekly bevacizumab and paclitaxel/carboplatin with or withoutsorafenib on heavily pretreated patients with recurrent or persistent cervicalcancer. (Abstract #5085)Y. Kikuchi, M. Takano, T. Goto, H. Kouta, R. Kikuchi, K. Kudoh, T. Kita, K. Furuya,K. Umayahara, K. TakizawaCyclin D1 and p57 expression in advanced ovarian epithelial carcinoma: AGOG study. (Abstract #5086)E. Hill, W. Brady, M. J. Birrer, K. M. Darcy, W. P. McGuire III, W. J. Hoskins,D. P. Warshal, R. D. Drake, P. Hanjani, J. HurteauThe phase II study of efficacy and safety of oxaliplatin with doxorubicin inrecurrent ovarian cancer (OC). (Abstract #5087)I. Pokataev, G. M. Manikhas, V. Borisov, M. Stenina, A. Tjulandina, S. TjulandinThe impact of dose intensity on the efficacy of gemcitabine plus carboplatin(GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): Aretrospective analysis of AGO-OVAR 2.5. (Abstract #5088)C. Kurzeder, L. Zhao, E. A. Eisenhauer, I. B. Vergote, A. Du Bois, D. Tai, Y. Wang,J. F. Gill, H. W. Hirte, B. Richter, L. C. Hanker, J. Bentley, U. A. Wagner, M. Plante,R. Kimmig, J. PfistererPhase II trial of weekly irinotecan and carboplatin for relapsed ovariancancer: A Kansai Clinical Oncology Group study. (Abstract #5089)H. Tsubamoto, K. Inoue, R. Kawaguchi, K. Ito, S. Takeuchi, T. Shiozaki, Y. Itani,A. Arakawa, T. Tabata, S. ToyodaEribulin mesylate (halichondrin B analog E7389) in platinum-sensitiveovarian cancer: A phase II study, CTEP #7431. (Abstract #5090)M. L. Hensley, S. J. Kravetz, X. Jia, W. P. Tew, L. Pereira, P. Sabbatini, C. Whalen,C. Aghajanian, C. Zarwan, S. T. BerlinLarge international multicenter evaluation of the clinical significance ofL1-CAM expression in FIGO stage I, type 1 endometrial cancer. (Abstract#5091)A. G. Zeimet, S. Abdel-Azim, D. Reimer, E. Mueller-Holzner, B. Winterhoff,U. Puistola, A. Ben-Arie, L. vanKempen, F. Amant, E. Petru, S. Jahn,S. Polterauer, P. Oppelt, M. Weigert, P. Altevogt, M. Huszar, C. Marth, M. FogelImpact of the MDM2 promoter polymorphisms SNP285 and SNP309 onendometrial cancer risk among Caucasians. (Abstract #5092)S. Knappskog, J. Trovik, J. Marcickiewisz, S. Tingulstad, A. Staff, K. Hveem,L. Vatten, H. B. Salvesen, P. LonningPegylated liposomal doxorubicin and carboplatin in malignant mixedepithelial mesenchymal and mesenchymal gynecologic tumors: A phase IItrial of the AGO study group. (Abstract #5093)P. Harter, U. Canzler, H. Lueck, A. Reuss, W. Meier, T. N. Fehm, A. Staehle,A. Burges, C. Kurzeder, J. Sehouli, K. H. Baumann, L. C. Hanker, P. Wimberger,W. Schroeder, M. Gropp, S. Mahner, A. Du BoisSUNDAY233

Sunday, June 5, 2011SUNDAYBrd. 21BBrd. 21CBrd. 21DBrd. 21EBrd. 21FBrd. 21GBrd. 21HBrd. 22ABrd. 22BBrd. 22CBrd. 22DBrd. 22EBrd. 22FThe presence of racial disparities in histopathologic characteristics ofuterine cancer in an equal-access environment. (Abstract #5094)K. E. Oliver, L. Enewold, K. Zhu, T. P. Conrads, G. S. Rose, G. L. Maxwell,J. H. FarleyMolecular analysis of endometrial pathogenesis in Lynch syndrome.(Abstract #5095)M. Huang, B. Djordjevic, D. Urbauer, S. N. Westin, C. C. Sun, J. K. Burzawa,L. Meyer, D. C. Bodurka, R. Broaddus, K. H. LuRecombinant adenovirus-p53 (rAd-p53) in combination with radiotherapy fortreating cervical cancer. (Abstract #5096)S. ZhangA phase II study of recombinant adeno-viral human p53 gene combined withradiotherapy in treatment of patients with locally advanced cervicalcarcinoma. (Abstract #5097)J. PanGemcitabine for advanced endometrial carcinoma (EMC): A review of theMSKCC experience. (Abstract #5098)R. N. Grisham, C. H. Adaniel, D. M. Hyman, W. Ma, A. Iasonos, C. Aghajanian,J. A. KonnerValidation of the predictive value of modeled hCG decline profiles in low-riskgestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX).(Abstract #5099)G. Freyer, B. You, R. Harvey, F. Golfier, H. Mitchell, P. Savage, M. Tod, C. Philip,T. Hajri, M. SecklExploration of biomarkers for lymph node metastasis in patients withendometrial cancer using exon-expression microarray. (Abstract #5100)S. Sudo, Y. Konno, T. Odagiri, T. Kato, M. Hosaka, M. Takeda, H. Watari,M. Kaneuchi, N. SakuragiThe use of bevacizumab and concurrent radiation for recurrent gynecologiccancers. (Abstract #5101)A. N. Viswanathan, J. Szymonifka, C. Tanaka, S. T. Berlin, S. M. Campos,N. S. Horowitz, J. Lee, C. Whalen, U. MatulonisPhase II trial of paclitaxel and nedaplatin in patients with advanced/recurrentuterine cervical cancer: A Kansai Clinical Oncology Group study. (Abstract#5102)M. Takekuma, Y. Hirashima, K. Ito, H. Tsubamoto, T. Tabata, A. Arakawa, Y. Itani,N. Furukawa, H. Murakoshi, S. TakeuchiParadigm shift in the management of high intermediate–risk stage Iendometrial cancer. (Abstract #5103)J. O. Schorge, A. H. Russell, L. A. Garrett, A. Goodman, M. G. del Carmen,W. B. Growdon, D. M. Boruta IILaparoscopic intraoperative sentinel lymph node detection by technetium-99hysteroscopically injected in endometrial cancer patients. (Abstract #5104)G. FaveroGenome-wide single nucleotide polymorphism (SNP) arrays as a noveldiagnostic tool in synchronous carcinomas. (Abstract #5105)Y. Ikeda, K. Oda, S. Nakagawa, S. Murayama-Hosokawa, K. Shoji, S. Yamamoto,S. Ishikawa, Y. Uehara, Y. Miyamoto, M. Tanikawa, T. Kashiyama, Y. Takazawa,D. Maeda, O. Hiraike-Wada, K. Miyagawa, F. McCormick, M. Fukayama,H. Aburatani, T. Yano, Y. TaketaniOvarian preservation in premenopausal patients with early-stageendometrial cancer: A multicenter retrospective matched cohort study.(Abstract #5106)T. Lee, S. Seong, J. Kim, J. Lee, H. Ryu234

Sunday, June 5, 2011Brd. 22GBrd. 22HBrd. 23ABrd. 23BBrd. 23CFactors associated with synchronous ovarian and endometrial cancer: Apopulation-based case control study. (Abstract #5107)M. M. AlHilli, S. C. Dowdy, A. Weaver, J. St. Sauver, G. L. Keeney, A. Mariani,K. C. Podratz, J. N. Bakkum-GamezEndometrial cancer screening in patients with Lynch syndrome. (Abstract#5108)A. Bats, M. Le Frere-Belda, U. Metzger, P. Laurent-Puig, F. LecuruAdjuvant sequential chemoradiation therapy in high-risk endometrial cancer:Results of a prospective, multicenter phase II study of the NOGGO. (Abstract#5109)D. Koensgen, A. Belau, J. Sehouli, H. L. Sommer, K. Bartz, S. Markmann,L. Schneidewind, J. P. Scharf, M. Ehmke, D. Stengel, P. Ledwon, H. Guba,M. Zygmunt, G. Koehler, A. Mustea, North-Eastern Society of GynaecologicalOncologyGenotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235,and an mTOR inhibitor, RAD001, in endometrial carcinomas. (Abstract #5110)K. Oda, K. Shoji, S. Nakagawa, T. Kashiyama, Y. Ikeda, Y. Miyamoto,M. Tanikawa, H. Kuramoto, M. Nishida, O. Hiraike-Wada, T. Yano, S. Kozuma,Y. TaketaniObesity, diabetes, and race in Type 1 and Type 2 endometrial cancers.(Abstract #5111)E. M. Ko, J. Franasiak, K. Sink, W. R. Brewster, P. A. Gehrig, V. L. Bae-JumpSUNDAY235

Sunday, June 5, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONSUNDAYMelanoma/Skin CancersLocation: Hall ATrack(s): Melanoma/Skin CancersBrd. 24A IL-6 as a prognostic biomarker in patients with metastatic melanoma.(Abstract #8538)L. Hoejberg, L. Bastholt, J. S. Johansen, K. Fode, H. SchmidtBrd. 24B Heterogeneity of FDG-PET response to GSK2118436, an inhibitor ofoncogenic mutant BRAF kinase in BRAF-mutant metastatic melanoma.(Abstract #8539)M. S. Carlino, C. A. Saunders, V. Gebski, A. M. Menzies, B. Ma, P. F. Lebowitz,R. Kefford, G. V. LongBrd. 24C Distinguishing between nodular and superficial spreading melanoma usingspecific microRNA alterations. (Abstract #8540)L. Poliseno, A. Haimovic, D. Hanniford, M. F. Segura, P. J. Christos, R. L. Shapiro,A. C. Pavlick, R. S. Berman, E. Hernando, J. Zavadil, I. OsmanBrd. 24D An analysis of altered melanoma matrix metalloproteinase-23 (MMP-23)expression and response to immune biologic therapy. (Abstract #8541)M. Krogsgaard, M. W. Ma, E. B. Friedman, E. Vega-Saenz de Miera, F. Darvishian,A. Perez-Garcia, R. S. Berman, R. L. Shapiro, P. J. Christos, I. Osman,A. C. PavlickBrd. 24E Morphologic and immunohistochemical (IHC) changes in metastaticmelanoma (MM) tissue and associations with clinical outcome in patients(pts) on BRAF inhibitors (BRAFi). (Abstract #8542)G. V. Long, J. S. Wilmott, J. R. Howle, M. D. Chatfield, V. Tembe, J. F. Thompson,P. Hersey, G. J. Mann, G. A. McArthur, H. Rizos, R. J. Young, L. L. Scurr,R. N. Sharma, R. F. Kefford, R. A. ScolyerBrd. 24F Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy inpatients with unresectable melanoma. (Abstract #8543)P. Boasberg, R. W. Weber, S. Cruickshank, O. Hamid, S. O’Day, L. E. SpitlerBrd. 24G A randomized phase II trial of 1 month versus 1 year of adjuvant high-doseinterferon alfa-2b in high-risk acral melanoma patients. (Abstract #8544)L. Si, L. L. Mao, Z. H. Chi, C. L. Cui, X. N. Sheng, S. M. Li, B. X. Tang, J. GuoBrd. 24H Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report oftoxicity and clinical efficacy in metastatic melanoma patients with normallactate dehydrogenase (LDH). (Abstract #8545)J. L. Chang, P. A. Ott, C. Sorlie, C. Escano, E. Yepes, S. Mendoza, A. Gandhi,L. Liebes, A. C. PavlickBrd. 25A A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF instage IV melanoma. (Abstract #8546)J. P. Fruehauf, Z. Eroglu, K. M. Kong, J. G. Jakowatz, W. L. Akerley,W. E. SamlowskiBrd. 25B Health-related quality of life (HRQOL) in the Nordic randomized trial ofadjuvant intermediate-dose interferon alfa-2b in high-risk melanoma.(Abstract #8547)J. Hansson, S. Aamdal, L. Bastholt, M. Hernberg, B. Nilsson, U. K. Stierner,H. von der Maase, Y. Brandberg, Nordic Melanoma Cooperative GroupBrd. 25C An open-label pilot study of vemurafenib in previously treated metastaticmelanoma patients with brain metastases. (Abstract #8548)R. Dummer, J. Rinderknecht, S. M. Goldinger, I. Wagner, L. Mitchell, M. Veronese,S. Nick, P. Hilfiker, S. Gobbi236

Sunday, June 5, 2011Brd. 26ABrd. 26BBrd. 26CBrd. 27ABrd. 27BBrd. 27CBrd. 28ABrd. 28BBrd. 28CBrd. 29ABrd. 29BBrd. 29CBrd. 30ABrd. 30BMicroRNA oncogenes and tumor suppressors controlling malignantmelanoma cell growth, apoptosis, migration, and invasion. (Abstract #8549)R. W. Georgantas, K. Streicher, W. Zhu, R. Carrasco, Z. Xiao, Z. Liu, P. Brohawn,C. Morehouse, D. Tice, B. W. Higgs, L. Richman, P. Kiener, B. Jallal, Y. YaoUltrasound (US)-guided fine-needle aspiration cytology (FNAC) for theprediction of sentinel node (SN) metastases and its effect on the nomogramfor melanoma patients. (Abstract #8550)C. A. Voit, A. C. Van Akkooi, P. Siegel, W. Sterry, A. Schoengen,G. Schaefer-Hesterberg, A. M. EggermontA gene expression profile associated with clinical outcome in stage IIImelanoma. (Abstract #8551)J. Falkenius, J. Lindberg, H. Johansson, M. Frostvik-Stolt, J. Lundeberg,J. Hansson, S. EgyhaziSomatostatin receptor scintigraphy in patients with metastatic uvealmelanoma. (Abstract #8552)M. E. Valsecchi, D. Summers, C. M. Intenzo, S. Kim, M. J. Mastrangelo, T. SatoIntratumoral neutrophils, plasmacytoid dendritic cells, and pSTAT3 in AJCCstage I/II melanoma prognosis. (Abstract #8553)T. O. Jensen, H. Schmidt, H. J. Moller, F. Donskov, M. Hoyer, P. Sjoegren,I. J. Christensen, T. SteinicheEffectiveness of treatment guidance on diarrhea and colitis acrossipilimumab studies. (Abstract #8554)S. O’Day, J. S. Weber, J. D. Wolchok, J. M. Richards, P. Lorigan, D. F. McDermott,W. J. Urba, V. DePril, K. N. Heller, R. A. Ibrahim, A. HauschildTwo phase I studies of PTI-188, a radiolabeled murine antimelanin antibody,in patients with metastatic melanoma (MM). (Abstract #8555)M. Lotem, T. Peretz, S. Mizrachi, Y. Liberman, E. Dadachova, A. Casadevall,A. de Kater, N. Friedmann, G. B. Thornton, M. KleinAssociation of CT antigen expression and survival in stage III melanoma.(Abstract #8556)N. H. Turner, T. John, S. Deb, A. M. Campbell, A. Azad, P. C. Boutros, Y. Chen,J. S. CebonA phase II trial of riluzole, an antagonist of metabotropic glutamate receptor(GRM1) signaling, in advanced melanoma. (Abstract #8557)J. M. Mehnert, Y. Wen, J. H. Lee, L. Dudek, L. Pruski-Clark, W. Shih, S. Chen,J. S. GoydosA germ-line polymorphism in the RET proto-oncogene predicts risk andrecurrence in desmoplastic melanoma. (Abstract #8558)N. Kounalakis, C. M. Amato, J. Barr, W. RobinsonExploratory analysis of technical factors that influence sentinel lymph nodebiopsy (SLNB) performance. (Abstract #8559)D. Silbermins, M. E. Valsecchi, N. de Rosa, S. L. Wong, G. H. LymanPrimary melanoma features associated with increased risk of brainmetastasis. (Abstract #8560)M. W. Ma, M. Qian, D. Lackaye, R. S. Berman, R. L. Shapiro, A. C. Pavlick,J. Golfinos, E. Parker, E. Hernando, Y. Shao, I. OsmanImpact of immune modulation on sentinel lymph node positivity andoutcome in melanoma patients. (Abstract #8561)R. C. Medicherla, M. W. Ma, M. Qian, E. Vega-Saenz de Miera, R. S. Berman,R. L. Shapiro, A. C. Pavlick, N. Bhardwaj, Y. Shao, I. Osman, F. DarvishianThe prognostic relevance of altered antiglycan antibody profiles in the seraof primary melanoma patients. (Abstract #8562)A. Haimovic, M. W. Ma, M. I. Vuskovic, T. Miller, M. DiBenedetto, J. Grossman,R. L. Shapiro, A. C. Pavlick, R. S. Berman, H. I. Pass, M. Huflejt, I. OsmanSUNDAY237

Sunday, June 5, 2011SUNDAYBrd. 30CBrd. 31ABrd. 31BBrd. 31CBrd. 31DBrd. 31EBrd. 31GBrd. 31HBrd. 32ABrd. 32BBrd. 32CBrd. 32DBrd. 32EMelanoma pigmentation affects melanoma-specific survival and provides apotential target for radiopharmaceutical-based imaging and therapy.(Abstract #8563)D. Kee, W. Liu, B. A. Devitt, R. Wolfe, R. Ware, R. Salemi, A. Dobrovic,S. Brglevska, J. Kelly, J. Callahan, A. Katsifis, P. Roselt, O. C. Neels, T. Bourdier,R. J. Hicks, G. A. McArthurClinical outcome of patients with metastasic melanoma undergoing phase Iclinical trials. (Abstract #8564)M. Blanco-Codesido, A. Brunetto, S. Frentzas, V. Moreno Garcia,D. Papadatos-Pastos, J. V. Pedersen, L. Trani, M. Puglisi, D. Sarker, L. R. Molife,U. BanerjiThe burden of metastatic melanoma (mM): Treatment patterns, healthcareuse, and costs. (Abstract #8565)C. Reyes, S. DaCosta Byfield, S. Satram-Hoang, A. H. TeitelbaumThe effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), onBRAF wild-type melanoma. (Abstract #8566)Y. Funahashi, J. Matsui, Y. Minoshima, A. Yokoi, T. Abe, K. Okamoto,K. Takahashi, T. Kadowaki, G. Kuznetsov, S. AgoulinkMechanism of antitumor activity of E7080, a selective VEGFR and FGFRtyrosine kinase inhibitor (TKI), in combination with selective mutant BRAFinhibition. (Abstract #8567)J. Matsui, Y. Narita, T. Semba, Y. Adachi, T. Kadowaki, J. Oestreicher,M. Matijevic, M. Byrne, Y. FunahashiAberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese melanomapatients and their significance: Large-scale analysis of 644 patients.(Abstract #8568)Y. Kong, L. Si, J. Guo, Z. H. Chi, C. L. Cui, X. N. Sheng, B. X. TangPotency of new duplex drugs linking 3-C-ethynylcytidine and 5-fluoro-2deoxyuridineagainst human melanoma in vitro and in vivo. (Abstract #8570)S. Schott, H. Niessner, T. Sinnberg, S. Venturelli, A. Berger, S. Noor,D. Mailaender-Sanchez, C. Garbe, C. BuschPhase I trial of temozolomide, thalidimide, and lomustine in patients withmetastatic melanoma in the brain. (Abstract #8571)N. E. Papadopoulos, W. Hwu, S. Cain, L. Posada, K. B. Kim, J. Homsi,A. Y. Bedikian, M. A. Davies, P. HwuAssociation of response and survival in Allovectin melanoma trials.(Abstract #8572)D. D. Kharkevitch, A. Chu, L. G. Strause, L. R. Muenz, R. T. Kenney, A. RollandA phase I, open-label, cohort study of two doses of coxsackievirus A21 givenintratumorally in stage IV melanoma. (Abstract #8573)D. Shafren, B. M. Smithers, M. FormbyMutation frequency in BRAF and NRAS genes among primary tumors anddifferent types of metastasis from melanoma patients. (Abstract #8574)M. Colombino, M. Capone, M. Maio, V. De Giorgi, A. Cossu, A. Lissia, C. Rubino,B. Massidda, S. Staibano, O. Nappi, G. Botti, C. Caraco, N. Mozzillo, A. Manca,M. Sini, P. A. Ascierto, G. Palmieri, Italian Melanoma Intergroup (IMI)Feasability and reliabity of the assessment of BRAF and c-KIT mutations incytologic samples from metastatic melanoma. (Abstract #8575)M. D. Lozano, T. Labiano, J. I. Echeveste, M. Montana, N. Gomez,M. F. Sanmamed, A. Gurpide, M. A. Idoate, S. Martin-AlgarraRoutine imaging to detect recurrences in high-risk melanoma patients.(Abstract #8576)T. S. Park, K. H. Lagisetty, R. M. Sherry, J. C. Yang, M. S. Hughes, K. Morton,D. E. White, Y. Klionsky, S. A. Rosenberg, G. Q. Phan238

Sunday, June 5, 2011Brd. 32F The results of a randomized phase II study using embolization with orwithout granulocyte-macrophage colony-stimulating factor (GM-CSF) inuveal melanoma patients with hepatic metastasis. (Abstract #8577)D. J. Eschelman, C. F. Gonsalves, M. Terai, M. Laudadio, K. L. Sullivan,M. J. Mastrangelo, T. SatoBrd. 32G Identification of predictive biomarkers for dasatinib treatment of metastaticmelanoma. (Abstract #8578)A. J. Eustace, S. Kennedy, A. Larkin, T. Mahgoub, D. Tryfonopoulos, L. O’Driscoll,M. Clynes, J. Crown, N. O’DonovanBrd. 32H Ipilimumab plus temozolomide in metastatic melanoma. (Abstract #8579)S. P. Patel, A. Y. Bedikian, N. E. Papadopoulos, W. Hwu, K. B. Kim, J. Homsi,M. A. Davies, S. E. Woodman, L. G. Radvanyi, K. Woodard, S. Mahoney, P. HwuBrd. 33A Overall survival (OS) in the management of pretreated patients withunresectable stage III/IV melanoma: A systematic literature review andmeta-analysis. (Abstract #8580)S. Kotapati, P. Dequen, M. Ouwens, M. van Baardewijk, R. A. Ibrahim, S. Wagner,J. P. JansenBrd. 33B Safety and survival analysis of ipilimumab therapy in patients with stableasymptomatic brain metastases. (Abstract #8581)K. N. Heller, A. C. Pavlick, F. S. Hodi, J. A. Thompson, K. A. Margolin,D. P. Lawrence, D. F. McDermott, W. E. Samlowski, T. Michener, M. KarasaridesBrd. 33C Plasma Tie-2 and its ligand Ang-2 in metastatic malignant melanoma:Relationships to clinicopathological parameters and tumor burden. (Abstract#8582)R. Mouawad, J. Thery, S. Vignot, R. Conforti, D. Khayat, J. SpanoBrd. 33D Ipilimumab safety profile: Summary of findings from completed trials inadvanced melanoma. (Abstract #8583)R. A. Ibrahim, D. M. Berman, V. DePril, R. W. Humphrey, T. Chen, M. Messina,K. M. Chin, H. Y. Liu, M. Bielefield, A. HoosBrd. 33E Multicohort model of prevalence estimation of advanced malignantmelanoma in the United States: An increasing public health concern.(Abstract #8584)A. Y. Lin, P. F. Wang, J. KolkerBrd. 33F Correlation between lymphocyte counts and response to outpatientintravenous interleukin-2 preceded by famotidine in metastatic melanoma.(Abstract #8585)W. Quan, K. N. Donkor, F. M. QuanBrd. 33H Sentinel lymph node detection using laser-assisted indocyanine green dyelymphangiography in melanoma and breast cancer patients. (Abstract #8587)B. Phillips, V. Jain, N. Conkling, C. R. PameijerBrd. 34A Analysis of CTLA-4 gene polymorphisms in patients with advancedmelanoma treated with anti-CTLA-4 therapy. (Abstract #8588)P. Queirolo, A. Morabito, P. Piccioli, S. Lastraioli, S. Callegari, M. Camoriano,P. A. Ascierto, S. Laurent, B. Dozin, M. PistilloBrd. 34BBrd. 34CBRAF, NRAS, and KIT mutational analysis of spindle cell melanoma.(Abstract #8589)S. J. Dorkhom, J. Kim, A. J. Lazar, M. A. Davies, J. Homsi, N. E. Papadopoulos,W. Hwu, A. Y. Bedikian, S. E. Woodman, S. P. Patel, P. Hwu, K. B. KimThe prognostic utility of LDH and disease-specific graded prognosticassessment for melanoma brain metastases. (Abstract #8590)M. Lowe, A. Cavitt, J. Shelton, N. Maynard, I. R. Crocker, G. W. Carlson,K. A. Delman, D. H. Lawson, M. RizzoSUNDAY239

Sunday, June 5, 2011SUNDAYBrd. 34DBrd. 34EBrd. 34FBrd. 34GBrd. 34HBrd. 35ABrd. 35BUse of microRNA signature to predict patient sensitivity to dendritic cellvaccination in metastatic melanoma. (Abstract #8591)L. Ridolfi, I. Vannini, F. Fanini, L. Fiammenghi, M. Petrini, V. Ancarani, A. Granato,M. Guidoboni, E. Pancisi, A. Riccobon, R. Ridolfi, C. Fernandez-Cymering,S. Volinia, C. Milandri, C. M. Croce, M. FabbriAcral lentiginous melanoma in Hawaii: Characterization of the mTORpathway in the non-Caucasian population. (Abstract #8592)S. Y. Morita, S. Jim, C. A. Lum, D. E. Hemmings, J. DavisA pilot study of endogenous heat shock protein vaccines for metastaticmelanoma. (Abstract #8593)J. M. Heun, W. K. Nevala, J. B. Allred, V. Suman, M. R. Callstrom, T. D. Atwell,M. A. Farrell, E. Galanis, L. A. Erickson, W. J. Charboneau, S. MarkovicAntitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma. (Abstract#8594)T. Traore, M. Mihollen, J. Garnsey, A. Berger, M. Manfredi, K. Cosmopolous,J. Donelan, P. G. SmithMolecular profiling of melanoma tumor biopsies to identify a responsesignature to the multi-RTK inhibitor, E7080. (Abstract #8595)J. J. Nemunaitis, D. S. Hong, R. Kurzrock, N. N. Senzer, N. C. Twine, T. Kadowaki,M. Ren, Y. Funahashi, J. P. O’Brien, J. S. Simon, A. EisenAdjuvant GM-CSF therapy for patients with resected stage III/IV melanoma: Aretrospective review of a single-center experience. (Abstract #8596)S. Markovic, P. A. Burch, B. LaPlant, J. M. Heun, R. BradshawFrequency of mutations associated with targeted therapy in malignantmelanoma patients. (Abstract #8597)S. Cheng, P. Chu, M. Hinshaw, K. Smith, J. Maize, A. Sferruzza240

Sunday, June 5, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONPediatric OncologyLocation: Hall ATrack(s): Pediatric OncologyBrd. 38A The impact of surveillance imaging on overall survival in patients withrecurrent Wilms tumor: A report from the Children’s Oncology Group.(Abstract #9536)E. A. Mullen, J. R. Anderson, K. J. Steacy, J. I. Geller, D. M. Green, P. Norkool,C. V. Fernandez, G. Khanna, M. H. Malogolowkin, J. DomeBrd. 38B Association of GSTP1 hypermethylation with reduced protein expressionand its correlation with clinical stage in neuroblastoma. (Abstract #9537)F. Gumy-Pause, B. Pardo, M. Khoshbeen-Boudal, M. Ansari, E. F. Attiyeh,H. OzsahinBrd. 38C BMP signaling activity in pediatric germ cell tumors. (Abstract #9538)N. J. Fustino, D. Rakheja, J. F. AmatrudaBrd. 38D Ewing sarcoma prognostic score (ESPS) at diagnosis, based on fever andmetastatic status. (Abstract #9539)N. Gaspar, G. Le Teuff, A. Defachelles, C. Schmitt, D. Levy, M. Castex, O. Lejars,C. Verite, E. Plouvier, L. Claude, O. OberlinBrd. 38E The effect of topotecan in advanced intraocular retinoblastoma withmanageable toxicity. (Abstract #9540)I. A. Qaddoumi, C. Billups, C. F. Stewart, J. Wu, K. Helton, B. McCarville,T. E. Merchant, R. C. Brennan, B. Haik, C. Rodriguez-Galindo, M. W. WilsonBrd. 38F Pilot immunotherapy trial in high-risk pediatric sarcomas. (Abstract #9541)M. O. Amoako, M. S. Merchant, D. B. Bernstein, K. Baird, C. MackallBrd. 38G Changes in incidence of infant cancer: Analysis of SEER data 1992–2007.(Abstract #9542)G. A. Pereira, K. B. Ribeiro, C. Rodriguez-Galindo, L. G. Spector, A. L. FrazierBrd. 38H A comparison of safety and efficacy of cytotoxic versus molecularly targeteddrugs in pediatric phase I solid tumor oncology trials. (Abstract #9543)K. M. Dorris, T. R. Hummel, A. M. Ingle, M. Kim, J. P. Perentesis, M. FouladiBrd. 39A Incidence and outcomes of patients with late recurrence of Wilms tumor(WT): The international experience. (Abstract #9544)M. H. Malogolowkin, F. Spreafico, J. Dome, N. Breslow, H. van Tinteren,K. Pritchard-Jones, M. van den Heuvel, C. Bergeron, J. De Kraker, N. Graf,COG Renal Tumors Committee and SIOP Renal Tumors Study GroupBrd. 39B A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatricpatients with refractory solid tumors. (Abstract #9545)L. M. McGregor, S. L. Spunt, D. Ward, J. Wu, C. Billups, S. P. Ivy, V. M. Santana,M. Fouladi, W. L. FurmanBrd. 39C Cell cycle and apoptotic effects of PM00104 in pediatric cell lines andxenographs. (Abstract #9546)A. Beaugrand, C. Lanvers-Kaminsky, P. Aviles Marin, C. Cuevas Marchante,P. Opolon, L. Le Dret, A. Verschuur, G. Vassal, B. Geoerger, ITCC Biology andPreclinical Evaluation CommitteeBrd. 39D Quantifying alkylating agent exposure: Evaluation of the cyclophosphamideequivalent dose—A report from the Childhood Cancer Survivor Study.(Abstract #9547)D. M. Green, V. G. Nolan, D. K. Srivastava, W. Leisenring, J. P. Neglia, C. A. Sklar,M. M. Hudson, L. Diller, M. Stovall, L. L. RobisonBrd. 39F Toxicity of 131 I-MIBG combined with high-dose chemotherapy in childrenwith refractory neuroblastoma. (Abstract #9549)L. Amoroso, G. Villavecchia, M. Cabria, A. Piccardo, M. Conte, M. Nantron,A. Garaventa, B. De BernardiSUNDAY241

Sunday, June 5, 2011SUNDAYBrd. 39G Exposure-response analysis as evidence for antitumor activity of everolimusin the treatment of patients with subependymal giant-cell astrocytoma(SEGA) associated with tuberous sclerosis (TS). (Abstract #9550)N. Mehrotra, E. Pfuma, C. Garnett, Q. Liu, B. Booth, N. Rahman, A. H. Shahlaee,K. LiuBrd. 39H Changes in cardiovascular signaling proteins during doxorubicin treatmentin children with high-risk ALL. (Abstract #9551)T. L. Miller, S. E. Lipshultz, R. E. Scully, D. Sawyer, S. R. Lipsitz,L. B. Silverman, H. Smith, J. M. Henkel, V. I. Franco, L. L. Cushman, S. E. SallanBrd. 40A Allogeneic transplantation for patients with high-risk or refractoryneuroblastoma. (Abstract #9552)T. A. Driscoll, P. L. Martin, J. Moffet, M. Daniel, K. Page, S. Parikh, V. Prasad,P. Szabolcs, J. KurtzbergBrd. 40B Reversal of glucocorticoid resistance by the g-secretase inhibitor PF-03084014 in T-cell acute lymphoblastic leukemia. (Abstract #9553)J. B. Samon, M. Castillo-Martin, J. L. Jakubczak, S. Randolph, C. Cordon-Cardo,A. A. FerrandoBrd. 40C Phase I trial of TPI 287 as a single agent and in combination withtemozolomide (TMZ) in patients with refractory or recurrent neuroblastoma(NB) or medulloblastoma (MB). (Abstract #9554)G. L. Saulnier Sholler, D. Eslin, W. D. Roberts, J. Kaplan, G. Bergendahl,T. Ashikaga, T. Higgins, S. Lenox, S. Silberman, W. FergusonBrd. 40D NOTCH1 inhibition by the gamma-secretase inhibitor RO4929097 in pediatricglial tumors. (Abstract #9555)G. Berghtold, C. Dantas Barbosa, G. Dieffenbach, E. Daudigeos-Dubus, H. Blokus,C. Ferreira, J. Boylan, M. Abely, G. Vassal, J. Grill, B. GeoergerBrd. 40E INI1 and mib-1 expression in childhood chordomas. (Abstract #9556)H. Yin, K. M. Dorris, L. M. Wagner, M. H. Collins, A. Towbin, R. NagarajanBrd. 40F Nimotuzumab and vinorelbine concomitantly to radiation and asmaintenance for diffuse pontine glioma in childhood: Results from a seriesof 12 patients. (Abstract #9557)M. Massimino, V. Biassoni, L. Gandola, E. Schiavello, E. Pecori, F. BachBrd. 40G Survivin expression in Ewing sarcoma family of tumors. (Abstract #9558)P. Hingorani, D. Azorsa, A. white-Collins, P. Dickman, M. SeidelBrd. 40H PARP-1 inhibitor MK-4827 in combination with radiation as a treatmentstrategy for metastatic neuroblastoma. (Abstract #9559)S. Bhargava, S. Mueller, L. Wehmeijer, X. Yang, A. Gragg, K. K. Matthay,W. A. Weiss, D. A. Haas-KoganBrd. 41A Treatment of Ewing sarcoma family of tumors with a modified P6 protocol inchildren and adolescents: Analysis of growth signaling pathways expressionand clinical outcome. (Abstract #9560)J. Mora, C. de Torres, E. Rodriguez, T. M. Cardesa, E. de Alava, O. CruzBrd. 41B Oncologic outcomes of partial versus radical nephrectomy for unilateralWilms tumor. (Abstract #9561)N. G. Cost, J. D. Lubahn, H. A. Penn, C. F. Granberg, B. J. Schlomer,J. E. Wickiser, D. Rakheja, P. C. Gargollo, D. Leonard, L. A. Baker, G. Raj,V. MargulisBrd. 41C Back pain and hip pain among survivors of childhood acute lymphoblasticleukemia. (Abstract #9562)D. C. Bowers, T. Griffith, L. Gargan, C. Cochran, B. Kleiber, A. Foxwell,A. Farrow-Gillespie, A. Orlino, J. N. GermannBrd. 41D A phase I study of temsirolimus and valproic acid for refractory solid tumorsin children. (Abstract #9563)D. W. Coulter, S. H. Gold, B. Weston, I. Davis, J. Blatt242

Sunday, June 5, 2011Brd. 41E Feasibility and pharmacokinetic study of potential ABCG2 inihibitor, gefitinib(GB), in combination with irinotecan (IRN) for adolescents and young adults(AYA). (Abstract #9564)H. Kawamoto, Y. Tabei, T. Kimura, K. Hishima, A. MakimotoBrd. 41F Randomized double-blind controlled trial (RCT) of pegfilgrastim asprophylactic therapy in pediatric patients with solid tumors duringmyelosuppressive chemotherapy. (Abstract #9565)S. Anaya Aguirre, V. Wanzke Del Angel, H. Rivera Marquez, M. Villasis Keever,E. Lopez Aguilar, F. Cerecedo DiazBrd. 41G Characteristics of childhood cancer survivors who attend long-term followup(LTFU) clinic. (Abstract #9566)K. Devine, J. R. Andolina, N. Murray, G. R. Morrow, O. J. SahlerBrd. 41H Central nervous system relapse in pediatric acute lymphoblastic leukemia:Should we be making the diagnosis sooner? (Abstract #9567)A. E. Aguilar, A. K. Agrawal, J. H. FeusnerBrd. 42A A survey of insurance retention in pediatric patients diagnosed withmalignancies in a vertically integrated health care system. (Abstract #9568)R. M. Cooper, V. Y. ChiuBrd. 42B B-cell non-Hodgkin lymphomas in childhood: Twenty years experience in asingle institution. (Abstract #9569)A. Pourtsidis, M. Servitzoglou, M. Baka, D. Bouhoutsou, M. Varvoutsi, D. Doganis,C. Strantzia-Michail, H. KosmidisBrd. 42C Effect of selenium supplemantation on anthracycline-induced cardiactoxicity in children treated for cancer: Correlation with pro-brain natriureticpeptide levels. (Abstract #9570)N. Tacyildiz, D. Ozyoruk, G. Ozelci Kavas, H. Dincaslan, G. Yavuz, E. Unal,S. Atalay, A. Ikinciogullari, T. Ucar, B. Doganay, G. Oktay, A. Cavdar, O. KucukBrd. 42D Surviving childhood cancer: What next? Challenges in developing countries.(Abstract #9571)P. Kurkure, V. Dhamankar, S. Goswami, N. Dalvi, E. Rawat-PawarBrd. 42E Influence of prognostic factors in pediatric high-grade osteosarcomasurvival. (Abstract #9572)A. Castellanos-Toledo, R. Rivera-Luna, R. Cardenas-Cardos, J. Figueroa Carbajal,C. Leal-CavazosBrd. 42F Second malignant tumors in childhood cancer survivors. (Abstract #9573)R. Kebudi, I. Ayan, O. Gorgun, F. Y. Agaoglu, G. N. Ozdemir, Y. Dizdar, B. Zulfikar,E. DarendelilerBrd. 42H Sorafenib (Soraf) and bevacizumab (Beva) for recurrent metastatichepatoblastoma (HB). (Abstract #9575)A. Marsh, L. Lo, J. H. FeusnerBrd. 43A Long-term echocardiogram monitoring and cardiac outcomes of childhoodcancer survivors with exposure to high doses of anthracyclines. (Abstract#9576)R. Nagarajan, J. Correll, D. A. Kent, N. Bakeer, J. P. Perentesis, K. C. BurnsBrd. 43B Secondary leukemia 15 years or more after treatment for childhood cancer: Areport from the Childhood Cancer Survivor Study. (Abstract #9577)K. Nottage, J. Lanctot, Z. Li, J. P. Neglia, S. Bhatia, S. Hammond, W. Leisenring,A. T. Meadows, D. K. Srivastava, L. L. Robison, G. T. ArmstrongBrd. 43C Cardiopulmonary outcomes in pediatric surivors of Hodgkin’s lymphoma.(Abstract #9578)K. C. Burns, J. Correll, D. A. Kent, N. Bakeer, J. P. Perentesis, R. NagarajanSUNDAY243

Sunday, June 5, 2011Brd. 43D A pediatric phase I trial of vorinostat and temozolomide in relapsed orrefractory primary brain or spinal cord tumors: A Children’s Oncology GroupPhase I Consortium Study. (Abstract #9579)T. R. Hummel, L. M. Wagner, C. H. Ahern, R. M. McGovern, M. M. Ames,R. J. Gilbertson, T. M. Horton, A. M. Ingle, B. Weigel, S. Blaney,Children’s Oncology GroupBrd. 43E Evaluation of traditional and novel measures of cardiac function to detectanthracycline-induced cardiotoxicity in survivors of childhood cancer.(Abstract #9580)A. C. Dietz, S. Sivanandam, C. Kaufman, A. Kelly, J. P. Neglia, P. R. Gaillard,D. A. MulrooneyBrd. 43F School attendance in childhood cancer survivors. (Abstract #9581)A. E. French, E. Tsangaris, S. Guger, M. Barrera, R. Brown, S. Urbach,D. Stephens, P. C. NathanSUNDAY244

Sunday, June 5, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONSarcomaLocation: Hall ATrack(s): SarcomaBrd. 44A Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interimresults from a phase II study. (Abstract #10034)J. Blay, S. P. Chawla, J. Martin Broto, E. Choy, M. Dominkus, J. Engellau,R. Grimer, R. M. Henshaw, E. Palmerini, P. Reichardt, P. Rutkowski, K. M. Skubitz,D. M. Thomas, Y. Zhao, Y. Qian, I. A. JacobsBrd. 44B A novel combined radiologic method for evaluation of the response tochemotherapy for primary bone sarcoma. (Abstract #10035)S. Miwa, T. Shirai, J. Taki, N. Yamamoto, H. Nishida, K. Hayashi, H. Kimura,A. Takeuchi, K. Igarashi, H. TsuchiyaBrd. 44C Primary osteosarcomas of the mandible: Joint study of the Groupe SarcomeFrancais (GSF), Rare Cancer Network, and Groupe d’Etude des Tumeurs dela Tete et du Cou (GETTEC). (Abstract #10036)J. Thariat, I. Ray-Coquard, A. Thyss, A. Italiano, J. Sarini, R. C. Miller, E. Bompas,A. Brouchet, O. Dassonville, S. Salas, P. Maingon, J. Kurtz, H. Reychler,T. de La Motte Rouge, K. Aldabbagh, J. Usseglio, P. Kerbrat, J. Lotz,L. Chaigneau, M. Julieron, Groupe Sarcome Francais-Groupe d’Etude desTumeurs Ossseuses (GSF-GETO), Rare Cancer Network, Groupe d’Etude desTumeurs de la Tete et du Cou (GETTEC)Brd. 44D Effects of denosumab on pain reduction in giant cell tumor of bone (GCTB):Interim phase II study results. (Abstract #10037)C. S. Cleeland, A. P. Staddon, S. Schuetze, A. Powell, A. Lopez Pousa, A. Cioffi,J. R. Kroep, S. Stacchiotti, K. Chung, C. Atchison, Y. Qian, Y. Zhao, I. A. JacobsBrd. 44E Functional characterization of IGFBP5 in the inhibition of osteosarcomatumorgenicity. (Abstract #10038)G. Luther, E. Wagner, H. Luu, R. Haydon, T. HeBrd. 44F Osteosarcoma of the pelvis and sacrum: A retrospective analysis of 73patients. (Abstract #10039)E. Palmerini, N. Fabbri, E. L. Staals, E. Marchesi, M. Alberghini, A. Tienghi,F. Fagioli, P. Picci, M. Mercuri, S. FerrariBrd. 44G Phase II study of 153-samarium-EDTMP followed by haematopoietic stem cellfor patients with osteosarcoma with bone metastasis. (Abstract #10040)B. Massimo, G. Grignani, A. Giostra, M. Pagano, S. Ferrari, B. Elia,F. Carnevale-Scianca, M. Aglietta, R. Pellerito, F. FagioliBrd. 44H Clinical outcomes of adult patients with relapsed Ewing sarcoma: A 30-yearsingle institution experience. (Abstract #10041)S. I. Robinson, S. K. Ahmed, N. N. Laack, P. S. Rose, S. H. OkunoBrd. 45A High-dose chemotherapy plus autologous stem cell transplation (HDCT/SCT) in patients with sarcoma: A single institution experience. (Abstract#10042)A. Stradella, A. Lopez-Pousa, M. Quintana, P. Murata, M. Ortin, O. Gallego,I. Sullivan, L. Robert, A. Sebio, I. Gracia, J. De Vega, A. BarnadasBrd. 45B Prevalence of hereditary GIST susceptibility in adults with GIST. (Abstract#10043)I. R. Rainville, E. J. Root, M. Salerno, L. DiGianni, D. A. Nelson, C. L. Corless,M. C. Heinrich, M. E. Robson, J. E. GarberSUNDAY245

Sunday, June 5, 2011SUNDAYBrd. 45CBrd. 45DBrd. 45EBrd. 45FBrd. 45GBrd. 45HBrd. 46ABrd. 46BBrd. 46CBrd. 46DPatterns of care, prognosis, and survival of patients with metastaticgastrointestinal stromal tumors (GIST) refractory to first-line imatinib andsecond-line sunitinib. (Abstract #10044)A. Italiano, A. Cioffi, R. G. Maki, P. Schoffski, P. Rutkowski, A. Le Cesne,F. Duffaud, A. Adenis, N. Isambert, E. Bompas, J. Blay, P. G. Casali, P. Coco,D. R. D’Adamo, M. Keohan, M. Toulmonde, C. Antonescu, M. Debiec-Rychter,J. Coindre, B. Bui NguyenIdentification of SDHA (subunit A of the succinate dehydrogenase) mutationsin KIT/PDGFRA WT gastrointestinal stromal tumors (GISTs). (Abstract#10045)M. A. Pantaleo, A. Astolfi, V. Indio, P. Paterini, S. Formica, R. Casadio, P. Martelli,A. Maleddu, M. Nannini, A. P. Dei Tos, M. C. Heinrich, D. Santini, F. Catena,C. Ceccarelli, M. Fiorentino, M. di Battista, R. Moore, N. Thiessen, C. Gnocchi,G. BiascoIdentification of single nucleotide variants in gastrointestinal stromal tumorKIT/PDGFRA wild-type (WT GISTs) by massively parallel sequencing.(Abstract #10046)V. Indio, M. A. Pantaleo, A. Astolfi, R. Casadio, P. Paterini, S. Formica, P. Martelli,R. Moore, N. Thiessen, M. di Battista, F. Catena, D. Santini, M. C. Heinrich,C. Gnocchi, A. P. Dei Tos, G. BiascoKIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine twodifferent subpopulations in KIT-negative GIST-like (KNGL) patients. (Abstract#10047)J. Martin Broto, X. Garcia del Muro, A. Gutierrez, J. Martinez-Trufero, T. Serrano,J. Rubió, N. Lainez, I. Sevilla, J. Cruz, R. Ramos, L. Ortega, A. Poveda,M. Ramirez, R. Cubedo, J. Lopez-Guerrero, Spanish Group for Sarcoma Research(GEIS)Who are the long responders to imatinib (IM) in patients with advancedGIST? Results of the BFR14 prospective French Sarcoma Group randomizedphase III trial. (Abstract #10048)A. Blesius, P. A. Cassier, I. Ray-Coquard, A. Italiano, A. Adenis, M. Rios,F. Bertucci, T. Huynh, D. Cupissol, Y. Berge, E. Bompas, J. Emile, S. Chabaud,D. Perol, A. Le CesneMechanism of early radiographic response to imatinib in GIST. (Abstract#10049)J. Gao, J. C. McAuliffe, A. J. Lazar, W. Wang, H. Choi, K. Hunt, D. M. Araujo,R. E. Pollock, R. S. Benjamin, J. C. TrentAssessment of regorafenib activity with FDG-PET/CT in a multicenter phaseII study in patients (pts) with advanced gastrointestinal stromal tumor (GIST)following failure of standard therapy (Rx). (Abstract #10050)A. D. Van Den Abbeele, Y. Tanaka, T. Locascio, C. Sakellis, M. C. Heinrich,M. von Mehren, E. Choy, W. D. Tap, J. Manola, G. D. Demetri, S. George,J. T. YapFDG-PET as a predicitve marker for primary resistance to imatinib (IM) inpatients with gastrointestinal stromal tumors (GIST) (Abstract #10051)S. Oosting, M. W. Den Hollander, B. Rikhof, D. B. Rouw, J. R. De Jong,P. L. Jager, A. H. Brouwers, W. Van Der Graaf, E. De Vries, J. A. Gietema,A. K. ReynersOutcome of adjuvant imatinib in patients with gastrointestinal stromal tumor:Results of a population-based, matched cohort study. (Abstract #10052)H. T. Hatoum, J. C. Trent, A. Guo, S. Lin, L. A. Sirulnik, M. SasaneGastrointestinal stromal tumors (GIST) of the duodenum: A French SarcomaGroup (FSG) retrospective review of 90 patients (pts). (Abstract #10053)F. Duffaud, I. Ray-Coquard, A. Blesius, T. Huynh, E. Boucher, O. Bouche, J. Bay,F. Marchal, J. Spano, F. Bertucci, B. Bui Nguyen, O. Collard, L. Chaigneau,N. Isambert, A. Adenis, J. Mancini, A. Le Cesne, J. Blay, French Sarcoma Group(GSF-GETO)246

Sunday, June 5, 2011Brd. 46EBrd. 46FBrd. 46GBrd. 46HBrd. 47ABrd. 47BBrd. 47CBrd. 47DBrd. 47EBrd. 47FBrd. 47GInfluence of imatinib interruption and imatinib rechallenge on the residualtumor volume in patients with advanced GIST: Results of the BFR14prospective French Sarcoma Group randomized phase III trial. (Abstract#10054)J. Domont, J. Blay, I. Ray-Coquard, B. Bui Nguyen, A. Adenis, M. Rios, F. Bertucci,F. Duffaud, D. Cupissol, C. Chevreau, E. Bompas, V. Bourne-Branchu,S. Chabaud, A. Le CesneRetrospective analysis of surgery in metastatic GIST patients sensitive toimatinib: A Spanish Group for Research on Sarcoma (GEIS) study. (Abstract#10055)J. Rubió, J. Martinez-Trufero, A. Lopez-Pousa, X. Garcia del Muro, J. Fra,A. Redondo, N. Lainez, A. Poveda, A. Casado, C. M. Valverde, A. De Juan,I. Sevilla, R. Andres, J. Cruz, M. Safont, J. Martin Broto, X. Garcia-Albeniz,J. MaurelMicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlationwith KIT/PDGFRA kinase genotype. (Abstract #10056)S. Formica, A. Astolfi, M. Nannini, M. A. Pantaleo, M. Ferracin, B. Zagatti,M. Negrini, D. Santini, P. Paterini, M. di Battista, A. Maleddu, M. Saponara,M. Pallotti, A. Mandrioli, C. Lolli, F. Catena, A. P. Dei Tos, G. BiascoPhase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advancedprimary and metastatic/recurrent operable gastrointestinal stromal tumor(GIST): Long-term follow-up results of RTOG 0132. (Abstract #10057)D. Wang, Q. Zhang, C. D. Blanke, G. D. Demetri, M. C. Heinrich, J. C. Watson,J. P. Hoffman, S. H. Okuno, J. M. Kane, M. vonMehren, B. L. EisenbergExploring the relation between overall survival (OS) and progression-freesurvival (PFS) in gastrointestinal stromal tumor (GIST) via meta-analysis.(Abstract #10058)R. L. Keyser, K. E. Tranbarger Freier, D. C. Hoaglin, S. Tzivelekis, D. Muston,I. Ozer-StillmanTumor volumes measurement (3D) versus Response Evaluation Criteria inSolid Tumors (RECIST version 1.1, 1D) and Choi criteria (C) in assessingresponse of gastrointestinal stromal tumors (GIST) to imatinib (IM). (Abstract#10059)G. Schiavon, A. Ruggiero, S. Sleijfer, K. Eechoute, G. P. Krestin, J. Verweij,R. MathijssenValidating innovation: A population-based study of gastrointestinal stromaltumors (GIST) to estimate the survival benefit of imatinib. (Abstract #10060)D. Goldstein, C. Lee, E. Tracey, C. Cook-Yarborough, S. LordHypertension monitoring as a tool to predict congestive heart failure (CHF)during sunitinib (SU) therapy in GIST and renal cell carcinoma (RCC).(Abstract #10061)D. Galizia, C. Ortega, E. Palesandro, V. Prati, S. Gallo, L. D’Ambrosio, A. Bonzano,D. Rota Scalabrini, S. Aliberti, G. Grignani, M. AgliettaStudy of dynamic contrast-enhanced ultrasound (DCE-US) for the earlyevaluation of imatinib. (Abstract #10062)G. Abboud, N. Lassau, S. Koscielny, B. Benatsou, F. Tabarout, L. Chami,E. Girard, S. Bidault, J. Domont, A. Cioffi, S. Bonvalot, A. Le CesneImatinib efficacy by tumor genotype in Asian patients with metastatic orrecurrent gastrointestinal stromal tumors (GISTs): A retrospective study ofKorean GIST Study Group (KGSG). (Abstract #10063)H. Kang, M. Ryu, K. Kim, Y. Park, W. Kim, S. Im, S. Park, K. Lee, H. Song, Y. KangA phase II study of low-dose protracted irinotecan in patients with advancedsarcomas. (Abstract #10064)S. N. Dumont, J. C. Trent, S. Patel, D. M. Araujo, A. G. Dumont, R. S. BenjaminSUNDAY247

Sunday, June 5, 2011SUNDAYBrd. 47HBrd. 48ABrd. 48BBrd. 48CBrd. 48DBrd. 48EBrd. 48FBrd. 48GBrd. 48HBrd. 49ABrd. 49BBrd. 49CBrd. 49DHigh rates of histopathologic discordance in sarcoma with implications forclinical care. (Abstract #10065)C. P. Raut, S. George, J. L. Hornick, J. E. Butrynski, J. A. Morgan, J. Ready,A. F. Nascimento, C. D. Fletcher, G. D. Demetri, E. H. BaldiniDifferences between neurofibromatosis-1-associated malignant peripheralnerve sheath tumors (MPNST) and sporadic MPNST: The Mayo Clinicexperience. (Abstract #10066)K. N. Johnson, C. H. Stucky, B. A. Pockaj, R. J. Gray, P. S. Rose, N. WasifMulticentric phase II clinical trial evaluating the role of everolimus (RAD001)in endemic or classic Kaposi’s sarcoma (C06–46). (Abstract #10067)R. Porcher, D. Kerob, N. Dupin, B. Guillot, T. Jouary, A. Mathieu-Boue, K. Slimane,V. Furlan, M. Battistella, F. Agbalika, S. Mourah, C. LebbéEffect of Notch3 to regulate rhabdomyosarcoma growth in vitro and in vivo.(Abstract #10068)R. Rota, L. Raimondi, R. Ciarapica, F. Verginelli, M. Gueguen, R. Boldrini,L. De Sio, A. Inserra, M. Locatelli, T. Dang, L. Miele, S. Stifani, I. Limon, F. LocatelliQuantitative analysis of IGF-1R expression in FFPE humanrhabdomyosarcoma tumor tissue by mass spectrometry. (Abstract #10069)S. Malempati, T. A. Hembrough, S. Thyparambil, L. Cao, M. Darfler, D. Krizman,D. S. Hawkins, S. Skapek, L. J. Helman, J. BurrowsOutcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospectivestudy from the French Group Sarcoma (GSF-GETO). (Abstract #10070)E. Bompas, L. Campion, A. Italiano, A. l. Cesne, M. Giaj Levra, C. Chevreau,S. Piperno-Neumann, N. Isambert, A. Thyss, M. Rios, J. Kurtz, C. Delcambre,J. Bay, F. Duffaud, M. Trassard, P. Soulie, J. BlayAdvanced well-differentiated/dedifferentiated liposarcomas: Role ofchemotherapy and survival. (Abstract #10071)M. Toulmonde, A. Italiano, N. Penel, A. Cioffi, A. Le Cesne, N. Isambert,E. Bompas, F. Duffaud, A. Patrikidou, R. G. Maki, J. Coindre, J. Blay,B. Bui NguyenA phase II study of a new formulation of nonpegylated liposomal doxorubicin(doxorubicin GP-pharm) as first-line treatment in patients with advancedsoft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial. (Abstract#10072)A. Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Balañá,J. Lavernia, J. Cruz, J. Maurel, R. Andres, C. M. Valverde, J. Fra,J. Martinez-Trufero, J. A. Lopez-Martin, I. Sevilla, R. Cubedo, J. BlayA phase I dose-escalation study of azacitidine in combination withtemozolomide in patients with soft tissue sarcomas. (Abstract #10073)I. Matushansky, K. E. Coakley, T. S. Uldrick, R. N. TaubExpression of MGMT and response to treatment with temozolomide inpatients with leiomyosarcoma. (Abstract #10074)A. Marrari, J. L. Hornick, N. H. Ramaiya, J. Manola, A. J. WagnerA phase II consortium trial of vorinostat and bortezomib for advanced softtissue sarcomas. (Abstract #10075)S. Attia, M. R. Mahoney, S. H. Okuno, D. Adkins, H. G. Ahuja, T. P. Ducker,W. J. Maples, L. Ochs, N. L. Wentworth-Hartung, C. Erlichman, H. H. BaileyA phase II trial evaluating efficacy of neo-/adjuvant EIA CTX, surgery, andradiation therapy in high-risk soft tissue sarcoma. (Abstract #10076)T. Schmitt, B. Kasper, M. Bischof, B. Lehner, S. Dietrich, A. Dimitrakopoulou-Strauss, L. G. Strauss, G. Mechtersheimer, P. Wuchter, A. D. Ho, G. EgererGrowth factor receptors and cell cycle proteins as new molecular prognosismarkers in high-grade undifferentiated pleomorphic sarcoma (HGUPS).(Abstract #10077)C. Serrano, S. Simonetti, C. M. Valverde, R. Morales, C. Suarez, T. Moline,J. Carles, S. Ramon y Cajal, C. Romagosa248

Sunday, June 5, 2011Brd. 49EBrd. 49FBrd. 49GBrd. 49HBrd. 50ABrd. 50BBrd. 50CBrd. 50DBrd. 50EBrd. 50FBrd. 50GAdjuvant and neoadjuvant chemotherapy (NAC) with ifosfamide (IFO) anddoxorubicin hydrochloride (ADM) for high-grade soft tissue sarcomas (STS)in the extremities: Japan Clinical Oncology Group study JCOG030404.(Abstract #10078)K. Tanaka, J. Mizusawa, H. Fukuda, N. Araki, H. Chuuman, M. Takahashi,T. Ozaki, T. Hiruma, H. Tsuchiya, H. Morioka, T. Morita, T. Wada, M. Hatori,Y. Yoshida, J. Toguchida, S. Abe, A. Matsumine, R. Yokoyama, Y. IwamotoMetastatic epitheloid hemangioendothelioma (EHE): Role of systemictherapy and survival. (Abstract #10079)A. Cioffi, A. Italiano, N. Penel, Y. Berge, M. Toulmonde, S. Salas, C. Chevreau,A. Le Cesne, F. Duffaud, D. R. D’Adamo, M. Keohan, C. Genebes, C. Antonescu,J. Coindre, B. Bui Nguyen, R. G. MakiEffect of the combination of mTOR inhibitor ridaforolimus and HDACinhibitor vorinostat on in vitro synergism in synovial sarcoma,osteosarcoma, and a range of other tumor subtypes. (Abstract #10080)S. S. Morgan, L. D. CranmerIdentification of potential molecular candidate lesions by molecular analysisof desmoid tumors with QRT-PCR and high-density SNP arrays. (Abstract#10081)P. Erben, D. Nowak, W. Hofmann, R. Hofheinz, P. Hohenberger, B. KasperHeterogeneity of metastatic behavior among high-grade pleomorphic softtissue sarcomas identified by gene expression analysis. (Abstract #10082)K. M. Skubitz, P. Francis, A. Skubitz, X. Luo, M. NilbertFeasibility of vincristine, dactinomycin, and cyclophosphamide (VAC)chemotherapy for adult rhabdomyosarcoma (RMS) with regard to doseintensity (DI). (Abstract #10083)Y. Kojima, K. Hashimoto, M. Ando, K. Yonemori, H. Yamamoto, M. Kodaira,M. Yunokawa, C. Shimizu, K. Tamura, N. Katsumata, A. Makimoto, Y. FujiwaraTopoisomerase-based chemotherapy in adults with relapsed or refractorypediatric-type sarcoma: A retrospective analysis of the German AIO SarcomaGroup/BMBF SAREZ registry. (Abstract #10084)J. T. Hartmann, I. Sturm, R. D. Issels, S. W. Krause, V. Gruenwald, A. Kunitz,L. Lindner, K. San Nicolo, F. Mayer, B. Hertenstein, L. Mueller, U. Kontny,J. Topaly, R. U. Trappe, W. GrotheMetastatic angiosarcomas (mAS): Identification of treatments thatsignificantly improve the outcome. (Abstract #10085)E. Amela, A. Italiano, I. Ray-Coquard, L. Chaigneau, C. Delcambre, B. Bui Nguyen,F. Bertucci, N. Isambert, D. Cupissol, E. Bompas, J. Bay, F. Duffaud, C. Guillemet,N. Corradini, P. A. Cassier, C. Chevreau, J. Blay, N. Penel, French Sarcoma Group(GSF/GETO)Predictive role of topoisomerase II, gp170, Bcl-2, tumor burden, andhistology in neoadjuvant chemotherapy for soft tissue sarcomas of theextremities. (Abstract #10086)A. Comandone, P. Porrino, E. Berardengo, A. Linari, A. Boglione, C. Oliva,G. Gino, C. Faletti, P. Bergnolo, P. Pochettino, A. Bernardi, E. M. Brach del Prever,R. PianaCreatinine clearance and serum albumin as factors for encephalopathy withambulatory 14-day infusional ifosfamide for advanced liposarcomas.(Abstract #10087)S. M. Alam, C. Benson, R. L. Jones, E. Thanopoulou, S. Mitchell, O. Al-Muderis,A. Dunlop, C. Propert-Lewis, I. R. Judson, M. R. ScurrPulmonary metastasectomy in soft tissue sarcomas (STS): A singleinstitutionexperience. (Abstract #10088)M. Glogowski, L. Talarek, I. A. Lugowska, S. Falkowski, T. Switaj, M. Zmijewski,R. Wlodarczyk, H. Kosela, M. Turski, M. J. Krzakowski, P. RutkowskiSUNDAY249

Sunday, June 5, 2011SUNDAYBrd. 50HBrd. 51ABrd. 51BBrd. 51CBrd. 51DBrd. 51EBrd. 51FBrd. 51GBrd. 51HBrd. 52AHistology and outcome in localized high-risk soft tissue sarcomas (STS)treated with preoperative chemotherapy (CHT) with or without radiationtherapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) andthe Spanish Sarcoma Group (GEIS). (Abstract #10089)P. G. Casali, S. Stacchiotti, P. Verderio, P. Collini, A. P. Dei Tos, M. Alberghini,A. Llombart-Bosch, C. Morosi, A. Messina, M. Mercuri, A. GronchiExploratory analysis of prognostic factors for patients (pts) with advancedsoft tissue sarcoma (ASTS) receiving combination chemotherapy: A joinedstudy of the EORTC Soft Tissue and Bone Sarcoma Group and the FrenchSarcoma Group. (Abstract #10090)N. Penel, M. M. Van Glabbeke, B. Bui Nguyen, M. Ouali, S. Mathoulin-Pelissier,S. Marreaud, A. Italiano, V. Brouste, P. C. Hogendoorn, J. Coindre, J. Blay,P. HohenbergerMucocutaneous angiosarcoma (MC-AS) versus non-MC-AS: Clinicopathologicfeatures and treatment outcomes in 44 patients (pts). (Abstract#10091)R. H. Quek, M. R. Harunal Rashid, W. Ong, M. J. Lee, R. Jeevan, Z. Ho, F. Chin,L. Soh, D. Poon, M. TeoClinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treatedwith vincristine, dactinomycin, and cyclophosphamide (VAC)/VAC-likechemotherapy. (Abstract #10092)K. Harano, Y. Kojima, K. Hashimoto, M. Ando, A. Hirakawa, K. Yonemori,M. Kodaira, M. Yunokawa, C. Shimizu, K. Tamura, N. Katsumata, A. Makimoto,Y. FujiwaraManagement and outcomes for primary cardiac sarcomas (PCS): Aretrospective study of the French Sarcoma Group (FSG). (Abstract #10093)N. Isambert, I. Ray-Coquard, B. Bui Nguyen, M. Rios, P. Kerbrat, A. Blouet,L. Chaigneau, F. Duffaud, S. Piperno-Neumann, J. Kurtz, J. Thariat, N. Girard,O. Collard, E. Bompas, N. Penel, J. Bay, C. Guillemet, F. Collin, J. Blay,A. Le CesneDoxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients(pts) with locally advanced or metastatic leiomyosarcoma (LMS) andliposarcoma (LPS). (Abstract #10094)U. Bitz, D. Pink, C. Busemann, P. ReichardtPrognostic factors in leiomyosarcoma (LMS): Does primary site influenceoutcome? (Abstract #10095)M. R. Harunal Rashid, W. Ong, M. Teo, M. Tan, L. Foo, Y. Lim, F. Chin, M. J. Lee,Z. Ho, R. Jeevan, J. W. Chia, L. Soh, D. Poon, R. H. QuekThe role of E-cadherin expression in response and outcome in patients withleiomyosarcoma treated with chemotherapy. (Abstract #10096)V. Ravi, J. Yang, D. M. Araujo, M. S. Park, R. S. Benjamin, W. Zhang, J. C. Trent,S. PatelThe role of chemotherapy in advanced hemangiopericyoma/solitary fibroustumor. (Abstract #10097)M. S. Park, S. Patel, V. Ravi, A. P. Conley, J. C. Trent, A. J. Lazar, D. Lev,X. Wang, R. S. Benjamin, D. M. AraujoDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)evaluation of preoperative therapy for extremity soft tissue sarcomas (STS).(Abstract #10098)J. M. Meyer, K. S. Perlewitz, S. L. Hemmingson, J. B. Hayden, A. Hung,A. Mansoor, M. L. Holtorf, W. J. Woodward, C. S. Springer, W. Huang, C. W. Ryan250

Sunday, June 5, 20118:00 AM - 12:30 PMPOSTER DISCUSSION SESSIONPatient and Survivor CareDisplay Time: 8:00 AM - 12:00 PMDisplay Location: S102Discussion Time: 11:30 AM - 12:30 PMDiscussion Location: S100bcCME credit: 1Track(s): Patient and Survivor CareThomas J. Smith, MD—ChairMassey Cancer Center of Virginia Commonwealth UniversityDiscussion11:30 AM James Lloyd Wade, MD (Abstracts #9017–9022)Cancer Care Specialists of Central IllinoisDiscussion11:45 AM Pamela Jean Goodwin, MD (Abstracts #9023–9029)Mount Sinai HospitalDiscussion12:00 PM Patricia A. Ganz, MD (Abstracts #9030–9035)University of California, Los Angeles Schools of Medicine and Public HealthDiscussion12:15 PM Teresa Gilewski, MD (Abstracts #9036–9041)Memorial Sloan-Kettering Cancer CenterBrd. 1 Gabapentin for the prevention of chemotherapy-induced nausea andvomiting: A pilot study. (Abstract #9017)F. M. Cruz, A. Del Giglio, D. d. Cubero, P. Taranto, T. Lerner, A. T. Lera,M. C. Miranda, M. C. Vieira, A. B. Fede, F. Schindler, S. O. Afonseca,H. PinczowskiBrd. 2 Antiemetic choice based on economic advantage. (Abstract #9018)E. Z. Touloukian, A. Yakan, R. E. BloomBrd. 3 Phase III study of single-dose casopitant in combination with ondansetronand dexamethasone for the prevention of oxaliplatin-induced nausea andvomiting. (Abstract #9019)P. J. Hesketh, V. Moiseyenko, G. Rosati, A. Makhson, J. Levin, M. W. RussoBrd. 4 A randomized, double-blind, placebo-controlled cross over trial of the effecton quality of life (QOL) of continuing dexamethasone beyond 24 hoursfollowing moderately emetogenic chemotherapy in women with breastcancer. (Abstract #9020)J. L. Vardy, G. R. Pond, A. Dodd, D. Warr, B. Seruga, M. J. Clemons, L. Bordeleau,I. TannockBrd. 5 Testing the cutaneous absorption of lorazepam, diphenhydramine, andhaloperidol gel (ABH gel) used for cancer-related nausea. (Abstract #9021)T. J. Smith, J. K. Ritter, P. J. Coyne, G. L. Parker, P. Dodson, D. S. FletcherBrd. 6 Effect of GTx-024, a selective androgen receptor modulator (SARM), onphysical function in patients with non-small cell lung cancer (NSCLC) withcancer cachexia. (Abstract #9022)M. S. Steiner, A. Dobs, M. L. Hancock, M. A. Johnston, G. Barnette, S. DodsonBrd. 7 Buspirone treatment of dyspnea in outpatients receiving chemotherapy: AUniversity of Rochester Cancer Center Community Clinical OncologyProgram (URCC CCOP) study. (Abstract #9023)P. W. Bushunow, J. A. Roscoe, D. J. Dudgeon, J. J. Kirshner, C. E. Heckler,G. R. Morrow, S. R. Dakhil, T. S. Collins, D. A. Churchill, University of RochesterCancer Center Community Clinical Oncology Program (URCC CCOP)SUNDAY251

Sunday, June 5, 2011SUNDAYBrd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16Brd. 17Brd. 18Brd. 19Brd. 20Mortality reduction by talactoferrin alfa (TLF) in severe sepsis with differenttypes of infections. (Abstract #9024)J. Crawford, K. K. Guntupalli, N. C. Dean, P. E. Morris, R. K. Malik,J. P. SchaumbergCost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) inprevention of skeletal-related events (SREs) in metastatic breast cancer(mBC). (Abstract #9025)J. A. Carter, S. J. Snedecor, S. Kaura, M. BottemanVitamin D repletion and prevention of bone loss in nonosteoporotic womenwith breast cancer. (Abstract #9026)S. Servitja, D. Prieto-Alhambra, M. Martinez-Garcia, L. Garrigos, M. J. Pena,A. Diez-Perez, J. Albanell, X. Nogues, I. TusquetsPhase III randomized, double-blind, placebo-controlled trial of soy proteinand venlafaxine for treatment of hot flashes in men with prostate cancer.(Abstract #9027)M. Vitolins, L. Griffin, W. V. Tomlinson, J. Vuky, D. B. Fried, P. T. Adams,D. Moose, B. Frizzell, J. E. Radford, T. Shah, E. G. ShawFinal results of a randomized phase II trial (NCT00637975) evaluating activityand toxicity of fixed-dose oxycodone and increasing dose of pregabalinversus increasing dose of oxycodone and fixed-dose pregabalin for thetreatment of oncologic neuropathic pain (NEUROPAIN-01). (Abstract #9028)M. C. Garassino, A. Bianchi, A. Febbraro, I. Spagnoletti, V. Iorno, A. Bramati,C. Carbone, L. Isa, E. Breda, R. Magarotto, V. Torri, G. FarinaAcupuncture for chemotherapy-induced fatigue: A randomized controlledtrial. (Abstract #9029)G. E. Deng, Y. Chan, K. Yeung, A. J. Vickers, B. R. CassilethLong-term protective effects of the angiotensin-receptor blocker telmisartanon epirubucin-induced inflammation, oxidative stress, and myocardialdysfunction. (Abstract #9030)G. Mantovani, C. Madeddu, M. Dessì, E. Massa, G. Antoni, A. Piras, C. Cadeddu,M. Deidda, G. MercuroThe relationship between serum hepcidin levels and clinical outcomes inpatients with chemotherapy-associated anemia treated in a controlled trial.(Abstract #9031)D. P. Steensma, B. J. Sasu, J. A. Sloan, D. Tomita, C. L. LoprinziRole of hypoalbuminemia in the development of venous thromboembolism incancer chemotherapy patients. (Abstract #9032)Z. Li, W. B. Webb III, J. Mao, S. Gautam, S. Singh, G. H. LymanMolecular diagnosis of bacteriemia in patients with neutropenic febrileoncohematologic. (Abstract #9033)E. Gimeno, L. Sorli, E. Abella, A. Alvarez-Larran, J. Horcajada, L. Garrigos,A. Taus, A. Salar, B. Sanchez, C. Pedro, C. Besses, M. SalvadoEffect of YOCAS yoga on circadian rhythm, anxiety, and mood: A URCCCCOP randomized, controlled clinical trial among 410 cancer survivors.(Abstract #9034)K. M. Mustian, L. Sprod, L. J. Peppone, S. G. Mohile, M. C. Janelsins, O. Palesh,K. Devine, P. S. Reddy, M. Melnik, J. K. Giguere, G. R. MorrowEffect of medical Qigong on cognitive function, quality of life, and abiomarker of inflammation in patients with cancer: A randomized controlledtrial. (Abstract #9035)B. Oh, P. Butow, N. Pavlakis, P. J. Beale, S. J. Clarke, D. S. Rosenthal, L. Larkey,J. L. VardyExercise and side effects among 417 older patients with cancer during andafter cancer treatment: A URCC CCOP study. (Abstract #9036)L. Sprod, S. G. Mohile, K. Devine, M. C. Janelsins, L. J. Peppone, G. R. Morrow,R. S. Lord, H. M. Gross, K. M. Mustian252

Brd. 21Brd. 22Brd. 23Sunday, June 5, 2011Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts)older than age 65 with advanced cancer (Ca) and toxicity outcomes.(Abstract #9037)A. Gajra, M. Hardt, W. P. Tew, S. G. Mohile, C. Owusu, H. D. Klepin, C. P. Gross,S. M. Lichtman, R. Ramani, J. Brown, V. Katheria, R. Jayani, K. Hansen,K. Togawa, S. Klapper, A. Hurria, Cancer and Aging Research GroupScarring, disfigurement, and quality of life in long-term survivors ofchildhood cancer: A report from the Childhood Cancer Survivor Study.(Abstract #9038)K. E. Kinahan, L. K. Sharp, A. Didwania, K. Seidel, W. Leisenring, M. E. Lacouture,M. Stovall, L. L. Robison, K. R. KrullDisability pension among patients with breast cancer: A Norwegianpopulation-based controlled study. (Abstract #9039)B. Hauglann, J. Šaltytë Benth, S. D. Fossa, A. A. DahlBrd. 24 What leads to better quality of life at the end of life? (Abstract #9040)M. E. Nilsson, B. Zhang, E. Reitschuler-Cross, A. A. Wright, X. Gao, J. S. Temel,T. A. Balboni, H. G. PrigersonBrd. 25 Do the preferences of patients with terminal cancer or their family caregiversand end-of-life care discussions influence utilization of hospice-palliativecare? (Abstract #9041)A. An, Y. Yun, W. Lee, K. Jung, Y. Do, S. Kim, D. S. Heo, J. Choi, S. Park,H. Jeong, J. Kang, J. RoSUNDAY253

Sunday, June 5, 20118:00 AM - 12:30 PMPOSTER DISCUSSION SESSIONPediatric OncologyDisplay Time: 8:00 AM - 12:00 PMDisplay Location: Hall ADiscussion Time: 11:30 AM - 12:30 PMDiscussion Location: S504CME credit: 1Track(s): Pediatric OncologySUNDAYBirgit Geoerger, MD, PhD—ChairInstitut Gustave RoussyDiscussion11:30 AM Julia Lynne Glade Bender, MD (Abstracts #9520–9523)Columbia UniversityDiscussion11:45 AM Paul Graham Fisher, MD (Abstract #9524)Stanford Cancer CenterDiscussion12:00 PM William D. Tap, MD (Abstracts #9526–9531)University of California, Los AngelesDiscussion12:15 PM Lillian Sung, MD, PhD (Abstracts #9532–9535)The Hospital for Sick ChildrenBrd. 36A A phase I trial of IMC-A12 and temsirolimus in children with refractory solidtumors: A Children’s Oncology Group Study. (Abstract #9520)M. Fouladi, J. P. Perentesis, L. M. Wagner, A. M. Ingle, J. Gammon, G. Thomas,D. A. Krueger, P. Houghton, S. Vinks, B. Weigel, S. BlaneyBrd. 36B Phase I study of clofarabine and liposomal daunorubicin in childhood acutemyeloid leukemia. (Abstract #9521)P. Kearns, N. J. Graham, M. Cummins, B. Gibson, J. D. Grainger, R. Keenan,D. Lancaster, G. Shenton, J. Vormoor, D. Webb, I. Hawley, P. J. JohnsonBrd. 36C A phase I trial of vorinostat and bortezomib in children with refractory orrecurrent solid tumors: A Children’s Oncology Group study. (Abstract #9522)J. A. Muscal, P. A. Thompson, T. M. Horton, A. M. Ingle, C. H. Ahern,R. M. McGovern, J. M. Reid, M. M. Ames, B. Weigel, S. BlaneyBrd. 36D A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in childrenwith refractory or recurrent neuroblastoma: Early-phase evaluation.(Abstract #9523)F. Navid, R. C. Barfield, R. Handgretinger, P. M. Sondel, B. L. Shulkin,R. Kaufman, C. Billups, J. Wu, W. L. Furman, L. M. McGregor, M. Otto, S. Gillies,V. M. SantanaBrd. 36E Vinorelbine in progressive unresectable low-grade glioma in children.(Abstract #9524)A. M. Cappellano, E. Bouffet, F. Silva, P. Paiva, M. d. Alves, S. Cavalheiro,N. S. SilvaBrd. 36G Pilot study of adding vincristine, topotecan, and cyclophosphamide tointerval-compressed chemotherapy in newly diagnosed patients withlocalized Ewing sarcoma family of tumors: A Children’s Oncology Grouptrial. (Abstract #9526)L. Mascarenhas, J. L. Felgenhauer, M. C. Bond, J. D. Femino, N. N. Laack,S. Ranganathan, M. D. Krailo, N. Marina, Children’s Oncology GroupBrd. 36H The management of pulmonary nodules at diagnosis in patients with Ewingsarcoma (ES). (Abstract #9527)C. Owens, M. Le Deley, J. M. Michon, I. Marzouk, E. Thebault, P. Marec Bérard,O. Oberlin254

Sunday, June 5, 2011Brd. 37A Proposal of a prognostic score system for the Brazilian OsteosarcomaTreatment Group (BOTG) patients. (Abstract #9528)M. Cypriano, A. Ferraro, C. M. Costa, V. Odone, D. Lustosa, M. Borsato,A. L. Brunetto, L. Calheiros, J. Barreto, S. Epelman, E. Carvalho, W. V. Pereira,E. M. Pontes, R. J. Garcia Filho, M. d. Alves, C. R. Macedo, O. P. de Camargo,P. Pericles, V. Penna, A. S. Petrilli, Sociedade Brasileira de Oncologia Pediatrica(SOBOPE)Brd. 37B Parameningeal rhabdomyosarcoma: Results of a pooled analysis from U.S.and European Cooperative Groups. (Abstract #9529)J. H. Merks, G. De Salvo, C. Bergeron, G. Bisogno, A. Rey, O. Oberlin, A. Kelsey,I. Zanetti, J. M. Michalski, D. S. Hawkins, J. R. AndersonBrd. 37C Anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma. (Abstract #9530)J. C. van Gaal, U. E. Flucke, M. H. Roeffen, E. S. de Bont, A. J. Suurmeijer,W. Van Der Graaf, Y. M. Versleijen-JonkersBrd. 37D Can the well-credentialed neuroblastoma tumor antigen GD2 be exploited forT-cell-based immunotherapy of pediatric sarcomas? (Abstract #9531)S. Ramakrishna, S. Gottschalk, R. Morgan, G. Dotti, M. K. Brenner, R. Orentas,C. MackallBrd. 37E Performance-based physical function in long-term survivors of Hodgkinlymphoma. (Abstract #9532)K. K. Ness, M. Metzger, T. T. Huang, G. T. Armstrong, L. L. Robison,M. M. HudsonBrd. 37F Risk factors for clostridium difficile infection in children with malignancy.(Abstract #9533)P. M. De Blank, T. Zaoutis, B. Fisher, A. B. Troxel, J. Kim, R. AplencBrd. 37G L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a largecompassionate-use protocol. (Abstract #9534)P. V. Plourde, S. Jeha, L. B. Silverman, J. B. Nachman, S. R. Rheingold,G. V. Dahl, E. A. Raetz, T. Mercedes, T. CornBrd. 37H Palonosetron in the prevention of chemotherapy-induced nausea andvomiting in children with acute lymphoblastic leukemia treated with highdose methotrexate. (Abstract #9535)H. Schroeder, S. Nadaraja, S. Rosthoej, P. S. Wehner, H. ThomassenSUNDAY255

Sunday, June 5, 20119:00 AM - 12:00 PMORAL ABSTRACT SESSIONBreast Cancer—HER2/ERLocation: Hall B1CME credit: 3Track(s): Breast CancerSUNDAYHarold J. Burstein, MD, PhD—Co-ChairDana-Farber Cancer InstituteRebecca Alexandra Dent, MD—Co-ChairSunnybrook Health Sciences Centre9:00 AM Exemestane for primary prevention of breast cancer in postmenopausalwomen: NCIC CTG MAP.3—A randomized placebo-controlled clinical trial.(Abstract #LBA504)P. E. Goss, J. N. Ingle, J. Ales-Martinez, A. Cheung, R. T. Chlebowski,J. Wactawski-Wende, A. McTiernan, J. Robbins, K. Johnson, L. Martin,E. Winquist, G. Sarto, J. E. Garber, C. J. Fabian, P. Pujol, E. Maunsell, P. Farmer,K. A. Gelmon, D. Tu, H. RichardsonDiscussion9:15 AM Andrea Decensi, MD (Abstract #LBA504)Ente Ospedaliero Ospedali Galliera9:30 AM TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib andtrastuzumab in patients with HER2-overexpressing breast cancer. (Abstract#505)J. C. Chang, I. A. Mayer, A. Forero-Torres, R. Nanda, M. P. Goetz,A. A. Rodriguez, A. C. Pavlick, T. Wang, S. G. Hilsenbeck, C. Gutierrez, R. Schiff,C. K. Osborne, M. F. Rimawi, on behalf of the Translational Breast CancerResearch Consortium9:45 AM Correlation of molecular effects and pathologic complete response topreoperative lapatinib and trastuzumab, separately and combined, prior toneoadjuvant breast cancer chemotherapy. (Abstract #506)F. A. Holmes, Y. M. Nagarwala, V. A. Espina, L. A. Liotta, M. A. Danso,R. I. Gallagher, K. McIntyre, C. R. Osborne, J. M. Mahoney, A. M. Florance,T. C. Anderson, J. O’Shaughnessy10:00 AM Final results of a phase II randomized trial of neoadjuvant anthracyclinetaxanechemotherapy plus lapatinib, trastuzumab, or both in HER2-positivebreast cancer (CHER-LOB trial). (Abstract #507)V. Guarneri, A. Frassoldati, A. Bottini, D. G. Generali, K. Cagossi, F. Artioli,G. Bisagni, C. Boni, A. Ravaioli, D. Amadori, A. Musolino, L. Cavanna, M. Untch,L. Orlando, G. Giardina, F. Piacentini, E. Tagliafico, M. Bagnalasta,R. D’Amico, P. F. ConteDiscussion10:15 AM Gunter Von Minckwitz, MD, PhD (Abstracts #505–507)German Breast Group10:30 AM A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, inFGFR1 amplified and nonamplified metastatic breast cancer. (Abstract #508)F. Andre, T. D. Bachelot, M. Campone, F. Dalenc, J. M. Perez-Garcia,S. A. Hurvitz, N. C. Turner, H. S. Rugo, M. M. Shi, Y. Zhang, A. C. Kay,A. J. Yovine, J. Baselga10:45 AM LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine(C) in patients with brain metastases (BM) from HER2-positive () metastaticbreast cancer (MBC) before whole brain radiotherapy (WBR). (Abstract #509)T. D. Bachelot, G. Romieu, M. Campone, V. Dieras, C. Cropet, H. H. Roche,M. Jimenez, E. Le Rhun, J. Pierga, A. Gonçalves, M. Leheurteur, J. Domont,M. Gutierrez, H. Cure, J. Ferrero, C. Labbe256

Sunday, June 5, 2011Discussion11:00 AM Nancy U. Lin, MD (Abstract #509)Dana-Farber Cancer Institute11:15 AM Patterns and correlates of adjuvant breast cancer endocrine therapy use.(Abstract #510)T. M. Pini, J. J. Griggs, A. S. Hamilton, S. J. Katz11:30 AM When to intervene to increase use of adjuvant hormone therapy amongwomen with hormone-sensitive breast cancer. (Abstract #511)V. P. Quinn, J. A. Strauss, J. E. Schottinger, C. T. Cheetham, R. HaqueDiscussion11:45 AM Dawn L. Hershman, MD, MS (Abstracts #510–511)Columbia University Medical CenterSUNDAY257

Sunday, June 5, 20119:30 AM - 12:30 PMORAL ABSTRACT SESSIONDevelopmental Therapeutics—Experimental TherapeuticsLocation: Arie Crown TheaterCME credit: 3Track(s): Developmental TherapeuticsSUNDAYPatricia LoRusso, DO—Co-ChairKarmanos Cancer InstituteE. Gabriela Chiorean, MD—Co-ChairIndiana University Melvin and Bren Simon Cancer CenterDiscussion9:30 AM Sarat Chandarlapaty, MD, PhDMemorial Sloan-Kettering Cancer Center9:45 AM Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activityof the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-humanstudy. (Abstract #3003)H. A. Burris, L. L. Siu, J. R. Infante, J. J. Wheler, C. Kurkjian, J. Opalinska,D. A. Smith, J. M. Antal, J. L. Gauvin, T. Gonzalez, L. M. Adams, P. Bedard,J. F. Gerecitano, R. Kurzrock, K. N. Moore, S. R. Morris, C. Aghajanian10:00 AM A phase I dose escalation study of oral MK-2206 (allosteric AKT inhibitor)with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced ormetastatic solid tumors. (Abstract #3004)A. W. Tolcher, R. D. Baird, A. Patnaik, V. Moreno Garcia, K. P. Papadopoulos,C. R. Garrett, D. Olmos, K. A. Shannon, V. Zazulina, E. H. Rubin, I. C. Smith,J. Ryan, P. D. Smith, A. Taylor, M. Learoyd, L. Lupinacci, L. Yan, J. S. De Bono10:15 AM Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitorGDC-0941: A first-in-human phase Ib study testing daily and intermittentdosing schedules in patients with advanced solid tumors. (Abstract #3005^)G. Shapiro, P. LoRusso, E. L. Kwak, J. M. Cleary, L. Musib, C. Jones,A. de Crespigny, M. Belvin, M. McKenzie, M. R. Gates, I. T. Chan, J. C. BendellDiscussion10:30 AM Pasi A. Janne, MD, PhD (Abstracts #3003–3005 ∧ )Dana-Farber Cancer Institute10:45 AM First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK)trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients withadvanced or metastatic solid tumors. (Abstract #3006^)S. O. Dolly, J. Albanell, F. Kraeber-Bodere, U. Banerji, R. Bahleda,M. Martinez Garcia, Z. X. Xu, E. Guarin, J. Tessier, E. Shochat, J. Deutsch,S. Blotner, V. Meresse, J. Soria11:00 AM Safety, pharmacokinetics, and pharmacodynamics results from a phase Itrial of BAY 86–9766 (RDEA119), a MEK inhibitor, in patients with advancedcancer. (Abstract #3007)L. Gore, K. Lewis, D. D. Von Hoff, G. J. Weiss, R. K. Ramanathan, A. A. Adjei,G. K. Dy, W. Ma, N. J. Clendeninn, D. P. Leffingwell, B. Sheedy, C. Iverson,J. N. Miner, Z. Shen, L. Yeh, R. L. Dubowy, M. Jeffers, P. Rajagopalan,C. D. WeekesDiscussion11:15 AM Patrick G. Johnston, MD, PhD (Abstracts #3006 ∧ –3007)Queen’s University Belfast11:30 AM Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, aninhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advancedsolid tumors: Results of a phase I study. (Abstract #3008)B. I. Sikic, S. G. Eckhardt, G. Gallant, H. A. Burris III, D. R. Camidge,A. D. Colevas, S. F. Jones, W. A. Messersmith, H. A. Wakelee, H. Li,P. G. Kaminker, S. Morris, J. R. Infante258

Sunday, June 5, 201111:45 AM Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFreceptor involved in tumor angiogenesis. (Abstract #3009)L. W. Goff, R. B. Cohen, J. Berlin, C. Noberasco, H. Borghaei, C. Gallo-Stampino,E. Wang, D. Hu Lowe, W. J. Levin, F. G. De Braud12:00 PM Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase IIrandomized discontinuation trial (RDT) in patients (pts) with advanced solidtumors. (Abstract #3010)M. S. Gordon, N. J. Vogelzang, P. Schoffski, A. Daud, A. I. Spira, B. A. O’Keeffe,T. Rafferty, Y. Lee, R. Berger, G. ShapiroDiscussion12:15 PM Jaap Verweij, MD, PhD (Abstracts #3008–3010)Erasmus University Medical CenterSUNDAY259

Sunday, June 5, 20119:30 AM - 12:30 PMORAL ABSTRACT SESSIONLung Cancer—Metastatic/Non-small CellLocation: Hall D1CME credit: 3Track(s): Lung CancerSUNDAYD. Ross Camidge, MD, PhD—Co-ChairUniversity of Colorado DenverScott Arthur Kono, DO—Co-ChairWinship Cancer Institute at Emory University9:30 AM Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer(NSCLC) patients (p) with epidermal growth factor receptor (EGFR)mutations: Interim results of the European erlotinib versus chemotherapy(EURTAC) phase III randomized trial. (Abstract #7503)R. Rosell, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, F. Cardenal,R. Garcia Gomez, C. Pallares, J. Sanchez, R. Porta, M. Cobo, M. Di Seri,P. Garrido Lopez, A. Insa, F. De Marinis, R. Corre, M. Carreras, E. Carcereny,M. Taron, L. G. Paz-Ares, Spanish Lung Cancer Group9:45 AM Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B)compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment ofadvanced nonsquamous (NS) non-small cell lung cancer (NSCLC). (Abstract#7504)M. Thomas, A. Reuss, J. R. Fischer, S. Andreas, C. Kortsik, C. Grah, M. H. Serke,M. von Eiff, C. Witt, J. Kollmeier, E. Müller, L. Müller, M. Schenk, R. Heine,D. M. Behringer, M. Schroeder, N. Reinmuth, P. Schnabel, T. Acker, M. Wolf10:00 AM Final efficacy results from OAM4558g, a randomized phase II studyevaluating MetMAb or placebo in combination with erlotinib in advancedNSCLC. (Abstract #7505)D. R. Spigel, T. J. Ervin, R. Ramlau, D. B. Daniel, J. H. Goldschmidt Jr.,G. R. Blumenschein Jr., M. J. Krzakowski, G. Robinet, C. Clement-Duchene,F. Barlesi, R. Govindan, T. Patel, S. V. Orlov, M. S. Wertheim, J. Zha, A. Pandita,W. Yu, R. L. Yauch, P. H. Patel, A. C. PetersonDiscussion10:15 AM Tony Mok, MD (Abstracts #7503–7505)Prince of Wales Hospital10:30 AM Identification of driver mutations in tumor specimens from 1,000 patientswith lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium(LCMC). (Abstract #CRA7506)M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba,S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon,W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler,J. D. Minna, P. A. Bunn10:45 AM Impact of crizotinib on survival in patients with advanced, ALK-positiveNSCLC compared with historical controls. (Abstract #7507)A. T. Shaw, B. Y. Yeap, B. J. Solomon, G. J. Riely, A. J. Iafrate, G. Shapiro,D. B. Costa, M. Butaney, S. I. Ou, R. G. Maki, Y. Bang, M. Varella-Garcia,R. Salgia, K. D. Wilner, K. Kulig, P. Selaru, Y. Tang, E. L. Kwak, J. W. Clark,D. R. CamidgeDiscussion11:00 AM Ramaswamy Govindan, MD (Abstracts #CRA7506–7507)Washington University School of Medicine260

Sunday, June 5, 201111:15 AM Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P)combination with triweekly D alone in elderly patients (pts) with advancednon-small cell lung cancer (NSCLC): An intergroup trial ofJCOG0803/WJOG4307L. (Abstract #7509)T. Abe, A. Yokoyama, K. Takeda, Y. Ohe, S. Kudoh, Y. Ichinose, H. Okamoto,N. Yamamoto, H. Yoshioka, K. Minato, T. Sawa, Y. Iwamoto, H. Saka,J. Mizusawa, T. Shibata, S. Nakamura, M. Ando, K. Nakagawa, N. Saijo,T. Tamura11:30 AM PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus bestsupportive care (BSC) versus placebo plus BSC immediately followinginduction treatment with pem plus cisplatin for advanced nonsquamousnon-small cell lung cancer (NSCLC). (Abstract #CRA7510)L. G. Paz-Ares, F. De Marinis, M. Dediu, M. Thomas, J. Pujol, P. Bidoli, O. Molinier,T. P. Sahoo, E. Laack, M. Reck, J. Corral, S. A. Melemed, W. J. John, N. Chouaki,A. Zimmerman, C. M. Visseren Grul, C. Gridelli11:45 AM Efficacy, tolerability and biomarker analyses from a phase III, randomized,placebo-controlled, parallel group study of gefitinib as maintenance therapyin patients with locally advanced or metastatic non-small cell lung cancer(NSCLC; INFORM; C-TONG 0804). (Abstract #LBA7511)L. Zhang, M. Shenglin, X. Song, B. Han, Y. Cheng, C. Huang, S. Yang, X. Q. Liu,L. Yun-Peng, M. Wang, and X. ZhangDiscussion12:00 PM Martin J. Edelman, MD (Abstracts #7509–LBA7511)University of Maryland Greenebaum Cancer CenterSUNDAY261

Sunday, June 5, 20119:30 AM - 12:30 PMORAL ABSTRACT SESSIONMyelomaLocation: E354aCME credit: 3Track(s): Lymphoma and Plasma Cell DisordersSUNDAYAndrzej J. Jakubowiak, MD, PhD—Co-ChairUniversity of MichiganTaimur Sher, MBBS—Co-ChairRoswell Park Cancer Institute9:30 AM Incidence of second primary malignancy (SPM) in melphalan-prednisonelenalidomidecombination followed by lenalidomide maintenance (MPR-R) innewly diagnosed multiple myeloma patients (pts) age 65 or older. (Abstract#8007)A. P. Palumbo, M. Delforge, J. Catalano, R. Hajek, M. Kropff, M. Petrucci, Z. Yu,J. M. Mei, M. A. Dimopoulos9:45 AM Incidence of second primary malignancies (SPM) after 6-years follow-up ofcontinuous lenalidomide in first-line treatment of multiple myeloma (MM).(Abstract #8008)A. C. Rossi, T. M. Mark, D. Jayabalan, P. J. Christos, F. Zafar, K. Pekle, T. Shore,R. N. Pearse, J. Leonard, S. Chen-Kiang, M. Coleman, R. Niesvizky10:00 AM Lenalidomide and dexamethasone (LEN plus DEX) treatment inrelapsed/refractory multiple myeloma (RRMM) patients (pts) and risk ofsecond primary malignancies (SPM): Analysis of MM-009/010. (Abstract#8009)M. A. Dimopoulos, R. Z. Orlowski, R. Niesvizky, S. Lonial, N. A. Brandenburg,D. M. WeberDiscussion10:15 AM Ola Landgren, MD, PhD (Abstracts #8007–8009)National Cancer Institute10:30 AM Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) andimprove progression-free survival (PFS) in patients (Pts) with multiplemyeloma (MM) with or without bone disease? MRC myeloma IX study results.(Abstract #8010)K. Boyd, G. Morgan, F. Davies, P. Wu, W. Gregory, S. E. Bell, A. Szubert,N. Navarro Coy, M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne,H. Roddie, C. Rudin, G. Cook, G. H. Jackson, J. A. Child10:45 AM Are there temporal benefits to long-term bisphosphonate treatment inmultiple myeloma (MM)? Insights from temporal analyses of zoledronic acid(ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial. (Abstract #8011)F. Davies, G. Morgan, P. Wu, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy,M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie,C. Rudin, G. Cook, G. H. Jackson, K. Boyd, J. A. ChildDiscussion11:00 AM G. David Roodman, MD, PhD (Abstracts #8010–8011)University of Pittsburgh Medical Center11:15 AM Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib inpatients with previously treated multiple myeloma. (Abstract #8012)N. S. Raje, R. J. Hohl, E. A. Faber, P. G. Richardson, A. Forero-Torres,G. J. Schiller, A. D. Cohen, S. P. Carpenter, D. Cronier, M. Pashkevich,J. Wooldridge, K. C. Anderson262

Sunday, June 5, 201111:30 AM Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combinationwith lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). (Abstract#8013)J. G. Berdeja, S. Ailawadhi, S. D. Weitman, S. Zildjian, J. J. O’Leary, J. O’Keeffe,R. Guild, K. Whiteman, A. A. Chanan-Khan11:45 AM Elotuzumab with lenalidomide and low-dose dexamethasone in patients withrelapsed multiple myeloma: A randomized phase II study. (Abstract #8014)P. G. Richardson, P. Moreau, A. J. Jakubowiak, T. Facon, S. Jagannath, R. Vij,D. E. Reece, D. White, M. Raab, L. Benboubker, J. Rossi, C. Tsao, T. Parli,D. M. Berman, A. K. Singhal, S. LonialDiscussion12:00 PM Asher Alban Akmal Chanan-Khan, MD (Abstracts #8012–8014)Roswell Park Cancer InstituteSUNDAY263

Sunday, June 5, 20119:45 AM - 11:00 AMSPECIAL SESSIONInnovation in Delivering Quality Care in Low-resource ScenariosLocation: S504CME credit: 1.25Track(s): Health Services Research, International, Special SessionClement Adebayo Adebamowo, MD, ScD—ChairInstitute of Human Virology, University of Maryland School of MedicineChallenges for Improving the Quality of Care in Low-resource ScenariosBenjamin O. Anderson, MDUniversity of WashingtonLessons from the Breast Health Global InitiativeWilliam Tierney, MDIndiana University School of MedicineSolutions for Improving Quality in Low-resource Areas: Lessons Learned from HIVSUNDAY264

Sunday, June 5, 20119:45 AM - 11:00 AMEDUCATION SESSIONSDutasteride, Fenasteride, Micronutrients, and Vitamins for Prostate CancerPrevention: How Do We Apply What We Have Learned to the Community?Location: S100aCME credit: 1.25Track(s): Cancer Prevention/Epidemiology, Genitourinary CancerIan Thompson, MD—ChairUniversity of Texas Health Science Center at San AntonioPCPT and SELECT: The Southwest Oncology Group ExperienceGerald L. Andriole, MDWashington University School of MedicineDutasteride and Prostate Cancer PreventionOtis W. Brawley, MDAmerican Cancer SocietyTranslating Prostate Cancer Prevention Research to the Community: Barriers to UptakeIntegration of Molecularly Targeted Therapy and Chemotherapy in theTreatment of Advanced Head and Neck CancersLocation: E354bCME credit: 1.25Track(s): Head and Neck CancerDavid G. Pfister, MD—ChairMemorial Sloan-Kettering Cancer CenterUpdates on Concomitant ChemoradiationDavid Raben, MDUniversity of Colorado DenverIntegration of Targeted Therapy with RadiationSUNDAYAthanassios Argiris, MD, PhDUniversity of PittsburghMolecularly Targeted Therapy and Combinations with Chemotherapy for Recurrent/MetastaticHead and Neck CancerMoving the Bar in Upper Gastrointestinal Malignancies: A Review of RecentUpper Gastrointestinal Phase III Studies—Clinically Meaningful or JustStatistically Positive? (eQuestions Session)Location: Hall D2CME credit: 1.25Track(s): Gastrointestinal (Noncolorectal) CancerEileen Mary O’Reilly, MD—ChairMemorial Sloan-Kettering Cancer CenterReview of Recent Phase III Studies in Upper Gastrointestinal MalignanciesNeal J. Meropol, MDCase Western Reserve UniversityHealth Care Economics in Relation to Upper Gastrointestinal CancersDonna Niedzwiecki, PhDDuke UniversityStatistical Review of the Benefit: Is It Meaningful?265

Sunday, June 5, 2011Weight of Evidence: Associations between Body Weight and Health Outcomes(Including Survival) in Cancer PopulationsLocation: S406CME credit: 1.25Track(s): Patient and Survivor Care, Cancer Prevention/Epidemiology, General OncologyJennifer A. Ligibel, MD—ChairDana-Farber Cancer InstituteOverview of the Current Evidence Supporting Body Weight Status, Adiposity, and Weight Losson Cancer OutcomesRudolf Kaaks, PhDGerman Cancer Research Center DKFZBiological Mechanisms whereby Weight Status and Weight Loss Affects Cancer ProgressionCheryl L. Rock, PhDUniversity of California, San DiegoPresentation of the ENERGY Trial in Terms of Rationale, Design, Methods, and OutcomesSUNDAY266

Sunday, June 5, 20119:45 AM - 11:00 AMMEET THE PROFESSOR SESSIONCA-125 Use in Practice: The Promise and Pitfalls (M10)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Gynecologic CancerRobert C. Bast, MDUniversity of Texas M. D. Anderson Cancer CenterCurrent State and Future Use of CA-125 in the Management of Ovarian CancerM. E. L. Van Der Burg, MD, PhDErasmus University Medical CenterBreaking the Addiction to CA-1259:45 AM - 11:00 AMCLINICAL PROBLEMS IN ONCOLOGY SESSIONSUNDAYTreatment of HIV-related Lymphomas: Integration of New Strategies to Controland Monitor HIV while Treating High-risk Lymphomas (C08)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Lymphoma and Plasma Cell DisordersAmrita Y. Krishnan, MD—ChairCity of HopeStem Cell Transplantation for Treatment of HIV-related MalignanciesSteven G. Deeks, MDUniversity of California, San Francisco School of MedicineTherapy of HIV Infection: New Antiretrovirals and Monitoring StrategiesWyndham Hopkins Wilson, MD, PhDNational Cancer InstituteOverview of HIV-related Lymphoma267

Sunday, June 5, 201110:30 AM - 12:30 PMSPECIAL SESSIONTraining Program Directors Session: Talking Business—The Finances of YourProgram and Teaching Interprofessional Communication Skills (TrainingProgram Directors Only)Location: S404CME credit: 2Track(s): Special Session, Professional DevelopmentThomas H. Davis, MD—ChairNorris Cotton Cancer Center, Dartmouth-Hitchcock Medical CenterWelcome and IntroductionWalter F. Baile, MDUniversity of Texas M. D. Anderson Cancer CenterThe Principles of Communication MentoringDaniel E. Epner, MDUniversity of Texas M. D. Anderson Cancer CenterMeasuring Competency in CommunicationLori K. Mihalich-Levin, JDAssociation of American Medical CollegesMedicare Funding of Graduate Medical Education: Fundamentals and the FutureSUNDAYRobert A. Wolff, MDUniversity of Texas M. D. Anderson Cancer CenterThe Business of Running a Training Program: Microeconomics268

Sunday, June 5, 201111:30 AM - 12:45 PMEDUCATION SESSIONSAdvanced Renal Cell Cancer: Which Drug to Use and in What Way?(eQuestions Session)Location: Hall D2CME credit: 1.25Track(s): Genitourinary CancerSandy Srinivas, MD—ChairStanford Medical CenterToday’s Renal Cell Cancer Therapeutic LandscapeThomas E. Hutson, DO, PharmDBaylor Sammons Cancer Center-Texas Oncology PAManagement of Unique Subsets of Patients with Renal Cell CancerEric Jonasch, MDUniversity of Texas M. D. Anderson Cancer CenterSequential versus Combination Therapy: Which One Wins?Diabetes and Antidiabetic Drugs: Association with Cancer Risk and Potentialfor Primary and Secondary PreventionLocation: S100aCME credit: 1.25Track(s): Cancer Prevention/EpidemiologyPamela Jean Goodwin, MD—ChairMount Sinai HospitalMetformin and Cancer PreventionLorraine Lipscombe, MDUniversity of TorontoAssociation of Diabetes and Cancer: Epidemiology DataSUNDAYAnn D. Thor, MDUniversity of Colorado DenverMetformin: In Vivo and in Vitro StudiesIs Patient and Physician Acceptance of Palliative and End-of-Life Care Sociallyand Culturally Determined?Location: E353CME credit: 1.25Track(s): Ethics, Patient and Survivor Care, Professional DevelopmentAntonella Surbone, MD, PhD—ChairNew York UniversityVariables in Patients’ and Caregivers’ Acceptance of Palliative and End-of-Life CareGuido Biasco, MDUniversity of BolognaCultural Dynamics in Providing Palliative CareMarjorie Kagawa-Singer, PhD, MA, MN, RNUniversity of California, Los Angeles School of Public HealthOvercoming Patients, Caregivers, and Health Professionals Cross-cultural Differences at theEnd of Life269

Sunday, June 5, 2011Melanoma: Therapeutic Decisions for the Practicing Oncologist in 2011Location: E354bCME credit: 1.25Track(s): Melanoma/Skin Cancers, General OncologyAntoni Ribas, MD—ChairJonsson Comprehensive Cancer Center, University of California, Los AngelesImmunotherapeutic Options in Advanced Melanoma (IL-2, Ipilimumab, Adoptive Cell Therapy,GM-CSF)Jeffrey Alan Sosman, MDVanderbilt University Medical CenterState of Targeted Therapy and How Testing and Treatment Can Be Incorporated into the Careof Patients with Melanoma in 2011Christopher D. Lao, MDUniversity of MichiganWhen Is Cytotoxic Therapy or Palliative Therapy Indicated in the Era of Increasing Therapeuticand Clinical Trial OptionsSUNDAY270

Sunday, June 5, 201111:30 AM - 12:45 PMMEET THE PROFESSOR SESSIONPrognostic Utility of B-RAF Mutation in the Management of Papillary ThyroidCancer (M11)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Head and Neck CancerMichael Xing, MD, PhDThe Johns Hopkins UniversityPrognostic Utility of B-RAF Mutation in the Management of Papillary Thyroid Cancer11:30 AM - 12:45 PMCLINICAL PROBLEMS IN ONCOLOGY SESSIONSUNDAYDoctor, Is There Any Hope? Communicating Prognosis while Maintaining Hopeat the End of Life (C09)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Professional Development, Ethics, Patient and Survivor CareRoss C. Donehower, MD—ChairSidney Kimmel Comprehensive Cancer Center at Johns Hopkins UniversityDeveloping Effective Communication Strategies to Discuss Poor PrognosisPhilip C. Hoffman, MDUniversity of Chicago Medical CenterManaging End-of-Life Decisions271

Sunday, June 5, 20111:00 PM - 4:00 PMPLENARY SESSIONPlenary Session Including Science of Oncology Award and LectureLocation: Hall B1CME credit: 3Track(s): Special Session, General OncologyKathy Miller, MD—Co-ChairIndiana University Simon Cancer CenterGeorge W. Sledge Jr., MD—Co-ChairIndiana University of Simon Cancer CenterSUNDAY1:00 PM Robert Weinberg, PhD—Science of Oncology Award RecipientWhitehead Institute for Biomedical Research, Massachusetts Institute ofTechnologyThe EMT and the Pathogenesis of High-grade Carcinomas1:45 PM Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operableGIST with a high risk of recurrence: Final results of a randomized trial(SSGXVIII/AIO). (Abstract #LBA1)H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt,M. Schlemmer, E. Wardelmann, G. Ramadori, S. E. Al-Batran, B. E. Nilsson,O. Monge, R. Kallio, M. Sarlomo-Rikala P. Bono, M. Leinonen, P. Hohenberger,T. Alvegard, P. ReichardtDiscussion2:00 PM Charles D. Blanke, MD (Abstract #LBA1)University of British Columbia/British Columbia Cancer Agency2:15 PM Busulphan-melphalan as a myeloablative therapy (MAT) for high-riskneuroblastoma: Results from the HR-NBL1/SIOPEN trial. (Abstract #2)R. L. Ladenstein, U. Poetschger, R. Luksch, P. Brock, V. Castel, I. Yaniv,V. Papadakis, G. Laureys, J. Malis, W. Balwierz, E. Ruud, P. Kogner,H. Schroeder, A. Forjaz De Lacerda, M. Beck Popovic, P. Bician, M. Garami,T. Trahair, A. D. Pearson, D. Valteau CouanetDiscussion2:30 PM Julie R. Park, MD (Abstract #2)Seattle Children’s Hospital2:45 PM Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexateplus asparaginase (C-MTX/ASNase) in children and young adults withhigh-risk acute lymphoblastic leukemia (HR-ALL): A report from theChildren’s Oncology Group Study AALL0232. (Abstract #3)E. C. Larsen, W. L. Salzer, M. Devidas, J. B. Nachman, E. A. Raetz, M. L. Loh,N. A. Heerema, A. J. Carroll, J. M. Gastier-Foster, M. J. Borowitz, B. L. Wood,C. L. Willman, N. J. Winick, S. Hunger, W. L. CarrollDiscussion3:00 PM Martin S. Tallman, MD (Abstract #3)Memorial Sloan-Kettering Cancer Center3:15 PM Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAFinhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAFmutatedmelanoma. (Abstract #LBA4)P. B. Chapman, A. Hauschild, C. Robert, J. M. G. Larkin, J. B. A. G. Haanen,A. Ribas, D. Hogg, S. O’Day, P. A. Ascierto, A. Testori, P. Lorigan, R. Dummer,J. A. Sosman, C. Garbe, R. J. Lee, K. B. Nolop, B. Nelson, J. Hou, K. T. Flaherty,and G. A. McArthur272

Sunday, June 5, 20113:30 PM Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC)versus DTIC alone as first-line treatment in patients with unresectable stageIII or IV melanoma. (Abstract #LBA5)J. D. Wolchok, L. Thomas, I. N. Bondarenko, S. O’Day, J. S. Weber, C. Garbe,S. Francis, R. A. Ibrahim, A. Hoos, and C. RobertDiscussion3:45 PM Kim Allyson Margolin, MD (Abstracts #LBA4–LBA5)University of WashingtonSUNDAY273

Sunday, June 5, 20114:30 PM - 5:30 PMCLINICAL SCIENCE SYMPOSIUMAntiangiogenic Therapies and Biomarkers in Pediatric CancerLocation: S504CME credit: 1Track(s): Pediatric OncologySUNDAYSteven G. DuBois, MD—ChairUniversity of California, San Francisco4:30 PM Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide(CYC) in children and young adults with refractory solid tumors. (Abstract#9500)V. M. Santana, S. D. Baker, B. McCarville, C. F. Stewart, J. Wu, C. Billups,S. L. Spunt, W. L. Furman, L. M. McGregor, S. Hu, J. C. Panetta, W. E. Reddick,A. Davidoff, W. H. Leung, F. Navid4:45 PM Phase I study of pazopanib in children with relapsed or refractory solidtumors (ADVL0815): A Children’s Oncology Group Phase I Consortium Trial.(Abstract #9501)J. L. Glade Bender, A. Lee, P. C. Adamson, A. M. Ingle, C. H. Ahern, B. Wu,S. Baruchel, P. J. Harris, M. M. Ames, B. Weigel, S. Blaney, Children’s OncologyGroup5:00 PM Surrogate biomarkers of antiangiogenesis in Children’s Oncology Group(COG) phase I trials. (Abstract #9502)S. Baruchel, B. Wu, R. B. Mokhtari, J. L. Glade Bender, S. G. DuBois,B. C. Widemann, J. R. Park, D. Stempak, C. H. Ahern, B. WeigelDiscussion5:15 PM Michael L. Maitland, MD, PhD (Abstracts #9500–9502)The University of Chicago274

Sunday, June 5, 20114:30 PM - 6:00 PMCLINICAL SCIENCE SYMPOSIUMGeriatric Biology, Screening Tools, Dose Intensity, and Impact on SurvivalLocation: S406CME credit: 1.5Track(s): Patient and Survivor Care, Geriatric OncologyGretchen Genevieve Kimmick, MD, MS—Co-ChairDuke University Medical CenterChristine Ritchie, MD, MSPH—Co-ChairUniversity of Alabama at Birmingham4:30 PM Relationship between components of the comprehensive geriatricassessment (CGA), chemotherapy dose intensity, and overall survival in acolorectal cancer (CRC) cohort age 65 and older. (Abstract #9000)E. E. Ramsdale, B. N. Polite, K. A. Bylow, H. L. Kindler, W. Dale4:45 PM Validation of the G8 screening tool in geriatric oncology: The ONCODAGEproject. (Abstract #9001)P. Soubeyran, C. Bellera, J. Goyard, D. Heitz, H. Cure, H. Rousselot, G. Albrand,V. Servent, O. Saint Jean, C. Roy, S. Mathoulin-Pelissier, M. RainfrayDiscussion5:00 PM Gretchen Genevieve Kimmick, MD, MS (Abstract #9001)Duke University Medical Center5:15 PM P16 INK4a expression after chemotherapy in older women with early-stagebreast cancer. (Abstract #9002)H. B. Muss, J. Krishnamurthy, S. M. Alston, A. C. Lacy, T. A. Jolly, G. Williams,L. A. Carey, E. C. Dees, C. K. Anders, W. J. Irvin Jr., N. E. Sharpless5:30 PM Predictors of primary dose reduction (PDR) among patients (pts) age 65 andolder receiving adjuvant chemotherapy (chemo). (Abstract #9003)H. D. Klepin, A. Gajra, M. Hardt, W. P. Tew, S. G. Mohile, C. Owusu, C. P. Gross,S. M. Lichtman, R. Ramani, V. Katheria, J. Brown, R. Jayani, K. Hansen,K. Togawa, S. Klapper, F. L. Wong, A. Hurria, on behalf of the Cancer and AgingResearch GroupDiscussion5:45 PM Matti S. Aapro, MD (Abstracts #9002–9003)Clinique De GenolierSUNDAY275

Sunday, June 5, 20114:30 PM - 6:00 PMCLINICAL SCIENCE SYMPOSIUMPK/PD According to Dr. Merrill Egorin: A Tribute to a Great TranslationalScientistLocation: Arie Crown TheaterCME credit: 1.5Track(s): Developmental TherapeuticsSUNDAYDuncan Ian Jodrell, MSc, DM, MRCP—Co-ChairNIHR Cambridge Biomedical Research CentreS. Percy Ivy, MD—Co-ChairNational Cancer Institute4:30 PM Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics(PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888;V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advancedsolid tumors. (Abstract #3000)P. LoRusso, J. J. Ji, J. Li, L. K. Heilbrun, G. Shapiro, E. A. Sausville, S. A. Boerner,D. W. Smith, M. Pilat, J. Zhang, A. P. Chen, N. Nechiporchik, R. E. ParchmentDiscussion4:45 PM James H. Doroshow, MD (Abstract #3000)National Cancer Institute5:00 PM Final results of a translational phase l study assessing a QOD schedule ofthe potent AKT inhibitor MK-2206 incorporating predictive,pharmacodynamic (PD), and functional imaging biomarkers. (Abstract#3001^)T. A. Yap, L. Yan, A. Patnaik, D. Olmos, I. Fearen, R. D. Baird,K. P. Papadopoulos, N. Tunariu, A. Biondo, H. Keilhack, L. M. Delgado, A. Taylor,S. C. Blackman, C. L. Carpenter, S. Decordova, S. Heaton, M. D. Garrett,D. Sullivan, J. S. De Bono, A. W. TolcherDiscussion5:15 PM Jerry M. Collins, PhD (Abstract #3001 ∧ )National Cancer Institute5:30 PM Phase I study of PF-04554878, a second-generation focal adhesion kinase(FAK) inhibitor, in patients with advanced solid tumors. (Abstract #3002)S. F. Jones, G. Shapiro, J. C. Bendell, E. X. Chen, P. Bedard, J. M. Cleary,S. Pandya, K. J. Pierce, B. Houk, N. Hosea, K. S. Zandi, W. G. Roberts,S. M. Shreeve, L. L. SiuDiscussion5:45 PM Alan Hilary Calvert, MD (Abstract #3002)University College London276

Sunday, June 5, 20114:30 PM - 6:00 PMCLINICAL SCIENCE SYMPOSIUMPredictive Markers in Breast Cancer: How Many Tests Do We Need, and WhatDo They Tell Us?Location: Hall B1CME credit: 1.5Track(s): Breast CancerHarold J. Burstein, MD, PhD—ChairDana-Farber Cancer Institute4:30 PM Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide(AC) 3 docetaxel (T) with or without capecitabine (X), in high-risk EBC:Exploratory Ki-67 analyses. (Abstract #500)J. E. Pippen, D. Paul, C. T. Stokoe, J. L. Blum, L. Krekow, F. A. Holmes,D. L. Lindquist, S. M. Sedlacek, R. R. Rivera, R. J. Brooks, S. J. Vukelja,K. McIntyre, C. Lopez-Diaz, J. O’Shaughnessy4:45 PM Neoadjuvant anastrozole or tamoxifen for premenopausal breast cancer:Ki67 expression data from the STAGE study. (Abstract #501^)T. Kinoshita, N. Masuda, Y. Sagara, H. Iwata, S. Nakamura, Y. Yanagita,R. Nishimura, H. Iwase, S. Kamigaki, H. Takei, H. Tsuda, S. NoguchiDiscussion5:00 PM Mitchell Dowsett, PhD (Abstracts #500–501 ∧ )The Royal Marsden Hospital5:15 PM Concordance among gene-expression-based predictors for ER-positivebreast cancer treated with adjuvant tamoxifen. (Abstract #502)A. Prat, J. S. Parker, C. Fan, M. Cheang, L. D. Miller, J. Bergh, S. K. Chia,P. S. Bernard, T. O. Nielsen, M. J. Ellis, L. A. Carey, C. M. Perou5:30 PM Using the PAM50 breast cancer intrinsic classifier to assess risk in ERbreast cancers: A direct comparison to Oncotype DX. (Abstract #503)R. R. Bastien, M. T. Ebbert, K. M. Boucher, C. M. Kelly, B. Wang, T. Iwamoto,S. Krishnamurthy, L. Pusztai, P. S. BernardDiscussion5:45 PM Daniel F. Hayes, MD (Abstracts #502–503)University of Michigan Medical CenterSUNDAY277

Sunday, June 5, 20114:45 PM - 6:00 PMSPECIAL SESSIONB. J. Kennedy Award and Lecture for Scientific Excellence in GeriatricOncologyLocation: S100bcCME credit: 1.25Track(s): Special Session, Geriatric OncologyJohn M. Bennett, MDUniversity of Rochester Medical CenterEnhancing Geriatric Oncology Training to Care for Elders with MalignanciesSUNDAY278

Sunday, June 5, 20114:45 PM - 6:00 PMEDUCATION SESSIONSChronic Lymphocytic Leukemia Therapy: An Update on Frontline and NovelTherapiesLocation: E354bCME credit: 1.25Track(s): Leukemia, Myelodysplasia, and TransplantationSusan Mary O’Brien, MD—ChairUniversity of Texas M. D. Anderson Cancer CenterNovel Therapies in Chronic Lymphocytic LeukemiaMichael J. Hallek, MDUniversity of CologneUpdate on Frontline Therapy for Chronic Lymphocytic Leukemia: Is Fludarabine,Cyclophosphamide, and Rituximab (FCR Regimen) the Treatment of Choice?John C. Byrd, MDThe Ohio State University Comprehensive Cancer Center and Arthur G. James Cancer Hospitaland Solove Research InstituteMolecular, Biochemical, and Clinical Predictive Factors in Chronic Lymphocytic Leukemia: AnUpdateClinical Problems in Management of Multiple Myeloma (eQuestions Session)Location: Hall D2CME credit: 1.25Track(s): Lymphoma and Plasma Cell Disorders, General OncologyAsher Alban Akmal Chanan-Khan, MD—ChairRoswell Park Cancer InstituteComplications of Antimyeloma TherapiesIvan Borrello, MDThe Johns Hopkins University School of MedicineSmoldering and Asymptomatic MyelomaSUNDAYG. David Roodman, MD, PhDUniversity of Pittsburgh Medical CenterBone Disease and Its Management in Multiple MyelomaEarly-phase Cancer Clinical Trials: Are the Goals Therapeutic or Scientific?Location: E353CME credit: 1.25Track(s): Ethics, Clinical Trials, Developmental TherapeuticsSteven Joffe, MD, MPH—ChairDana-Farber Cancer InstituteIntroduction to the Ethics of Early-phase Clinical TrialsNancy King, JDWake Forest University School of MedicineThe Need to Emphasize the Research Orientation of Early-phase Clinical TrialsRazelle Kurzrock, MDUniversity of Texas M. D. Anderson Cancer CenterEarly-phase Trials as Optimal Therapy in Some Settings279

Sunday, June 5, 2011Genetic Syndromes in Upper Gastrointestinal Cancer for the ClinicalOncologist: Syndromes, Testing, and ScreeningLocation: Hall D1CME credit: 1.25Track(s): Gastrointestinal (Noncolorectal) Cancer, Cancer GeneticsManish A. Shah, MD—ChairMemorial Sloan-Kettering Cancer CenterIncidence of Hereditable Upper Gastrointestinal Cancers: How Common Are They and WhatAre the Genetic Considerations?Zsofia Kinga Stadler, MDMemorial Sloan-Kettering Cancer CenterGenetic Testing: Indications, Insurance/Legal Ramifications, and What Tests Should Be DoneMarcia Canto, M.D.The Johns Hopkins UniversityIndications for Screening: Pancreatic, Esophageal, and Stomach CancersInclusion of Patients with Brain Metastases in Clinical TrialsLocation: E354aCME credit: 1.25Track(s): Clinical Trials, Central Nervous System Tumors, Developmental TherapeuticsLauren E. Abrey, MD—ChairMemorial Sloan-Kettering Cancer CenterOverview of the Treatment of Brain Metastases in Patients with Solid TumorsSUNDAYKaren Kelly, MDUniversity of California, Davis Cancer CenterPharmacokinetic/Pharmacodynamic Issues in the Treatment of Brain MetastasesMinesh P. Mehta, MDNorthwestern UniversityRadiation Therapy for Brain Metastases: Techniques, Trials, and OutcomesNext-generation Therapeutic Targets and DrugsLocation: S404CME credit: 1.25Track(s): Tumor Biology, Developmental TherapeuticsKapil N. Bhalla, MD—ChairUniversity of Kansas Cancer CenterMolecular Chaperones in Tumor Biology and TherapyJean-Pierre J. Issa, MDUniversity of Texas M. D. Anderson Cancer CenterDeregulated Epigenetic Mechanisms: Developing Therepeutic OpportunitiesAnil Sood, MDUniversity of Texas M. D. Anderson Cancer CentersiRNA and miRNA Therapeutics: Rapid Translation from Bench to Bedside280

Sunday, June 5, 2011You Can Write an Outstanding ManuscriptLocation: S100aCME credit: 1.25Track(s): Professional DevelopmentDaniel G. Haller, MD—ChairUniversity of PennsylvaniaAn Editor’s PerspectiveStephen A. Cannistra, MDBeth Israel Deaconess Medical CenterHow to Reach Meaningful ConclusionsCynthia Dunbar, MDNational Heart, Lung, and Blood InstituteHow to Present Data EffectivelySUNDAY281

Sunday, June 5, 20114:45 PM - 6:00 PMMEET THE PROFESSOR SESSIONTherapy of the Elderly Patient with Acute Myeloid Leukemia (M12)—TicketedSessionLocation: E451aCME credit: 1.25Track(s): Leukemia, Myelodysplasia, and Transplantation, Geriatric OncologyCharles Alan Schiffer, MDWayne State UniversityTherapy of the Elderly Patient with Acute Myeloid LeukemiaHarry Paul Erba, MD, PhDUniversity of Michigan Medical CenterControversies in Treating the Elderly Patient with Acute Myeloid LeukemiaSUNDAY4:45 PM - 6:00 PMCLINICAL PROBLEMS IN ONCOLOGY SESSIONCurrent State of Neuro-oncology: Successes, Failures, and the Future(C10)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Central Nervous System TumorsJohn L. Villano, MD, PhD—ChairUniversity of IllinoisHenry S. Friedman, MDDuke University Medical CenterJan C. Buckner, MDMayo Clinic282

Monday, June 6, 20117:30 AM - 9:00 AMHIGHLIGHTS OF THE DAY SESSIONHighlights of the Day II Including Partners in Progress AwardLocation: Hall D1CME credit: 1.5Track(s): Special Session, General OncologyCharles D. Blanke, MD—ChairUniversity of British Columbia/British Columbia Cancer Agency7:30 AMBenjamin O. Anderson, MD—Partners in Progress Award RecipientUniversity of Washington7:40 AMStepen R. D. Johnston, MA, MD, PhDRoyal Marsden HospitalBreast Cancer—HER2/ER7:55 AMJyoti D. Patel, MDNorthwestern UniversityLung Cancer—Metastatic/Non-small Cell8:10 AMIvan Borrello, MDThe Johns Hopkins University School of MedicineMyeloma8:25 AMGregory T. Armstrong, MD, MSCESt. Jude Children’s Research HospitalPediatric OncologyMONDAY283

Monday, June 6, 20118:00 AM - 9:15 AMSPECIAL SESSIONASCO/European Society for Medical Oncology (ESMO) Joint Session: Cancerin Low- and Middle-income CountriesLocation: S406CME credit: 1.25Track(s): Developmental Therapeutics, Clinical Trials, International, Special SessionDavid J. Kerr, MD, PhD—Co-ChairUniversity of OxfordGeorge W. Sledge Jr., MD—Co-ChairIndiana University Simon Cancer CenterPeter Boyle, PhDInternational Prevention Research InstituteEpidemiologic Overview of Cancer in Low- and Middle-income CountriesJan Agosti, MDBill and Melinda Gates FoundationCervical Cancer and HPV Vaccines in Low- and Middle-income CountriesHenry L. Y. Chan, MDChinese University of Hong KongHepatocellular Carcinoma: Prevention and Control in Low- and Middle-income CountriesMONDAY284

Monday, June 6, 20118:00 AM - 9:15 AMEDUCATION SESSIONSBreast Cancer in Older Women: The Whole PictureLocation: Hall B1CME credit: 1.25Track(s): Breast Cancer, Geriatric Oncology, InternationalRichard C. Zellars, MD—ChairThe Johns Hopkins University School of MedicineLocoregional Implications for Therapy in Older WomenArti Hurria, MDCity of HopePatterns of Care and Outcomes Disparities in Older Patients inside and outside of theUnited StatesHyman Bernard Muss, MDUniversity of North Carolina Lineberger Comprehensive Cancer CenterOverview and Medical Therapeutic Implications of Breast Cancer in Elderly PatientsCommunicating Effectively across the Trajectory of Cancer Care andSurvivorship (eQuestions Session)Location: E353CME credit: 1.25Track(s): Patient and Survivor Care, Health Services ResearchEdward G. Shaw, MD—ChairWake Forest University School of MedicineCommunication from the Perspective of the PhysicianNeeraj Arora, PhDNational Cancer InstituteEnhancing the “Patient Centeredness” of Communication between the Care Team and Patientsand Their Family Members: Understanding Patient PerspectivesJessie Gruman, PhDCenter for Advancing HealthCommunication on Both the Giving and Receiving End: Perspectives from a Physician and aPatientIntraperitoneal Chemotherapy and Cytoreductive Surgery in Colon Cancer: ADebateLocation: Arie Crown TheaterCME credit: 1.25Track(s): Gastrointestinal (Colorectal) CancerMONDAYDavid P. Ryan, MD—ChairMassachusetts General Hospital and Harvard Medical SchoolSurgical Debulking and Hyperthermic Chemotherapy for Metastatic Colon Cancer: StopSelecting Patients and Start Proving EfficacyPaul H. Sugarbaker, MDWashington Hospital CenterSurgical Debulking and Hyperthermic Chemotherapy for Metastatic Colon Cancer: If You Selectthe Right Patients, Long-term Survival Can Be Achieved285

Monday, June 6, 2011Optimizing the Use of Alkylators in Neuro-oncologyLocation: S100aCME credit: 1.25Track(s): Central Nervous System TumorsJames R. Perry, MD—ChairSunnybrook Health Sciences CentreTemozolomide in Upfront Therapy for Low- and High-grade GliomasWolfgang Wick, MDUniversity Hospital HeidelbergTemozolomide in Refractory Disease-alternative SchedulesMichael Weller, MDUniversity Hospital ZurichWhat about the Older Generation Alkylators? Revisiting the Role of Nitrosoureas in NeurooncologyThe Patient Protection and Affordable Care Act of 2010: Reform Initiatives andTheir ImplicationsLocation: E354bCME credit: 1.25Track(s): Health Services Research, Practice Management and Information TechnologyDavid Christopher Miller, MD, MPH—ChairUniversity of MichiganACOs and Their Implications for Cancer-related Quality and SpendingLee Nisley Newcomer, MDUnited Health GroupPayment Bundling and Its Implications for Improving Cancer-related QualityScott Gottlieb, MDAmerican Enterprise Institute for Public Policy ResearchThe IPAB and Implications for Cancer-related Medicare SpendingMONDAYTransition from Therapy Improvement to Potential Cure for ChronicMyelogenous Leukemia: Roadblocks and OpportunitiesLocation: E354aCME credit: 1.25Track(s): Leukemia, Myelodysplasia, and TransplantationMoshe Talpaz, MD—ChairUniversity of Michigan Comprehensive Cancer CenterThe Frontline Therapy of Chronic Myelogenous Leukemia: Nilotinib or Imatinib?Jorge E. Cortes, MDUniversity of Texas M. D. Anderson Cancer CenterResistant Disease: Assessment, Monitoring, and TherapyRavi Bhatia, MDCity of HopeThe Chronic Myelogenous Leukemia Stem Cell: The Roadblock to Cure?286

Monday, June 6, 20118:00 AM - 9:15 AMMEET THE PROFESSOR SESSIONSManagement of Neuroendocrine Tumors of the Lung Exclusive of Small CellLung Cancer (M13)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Lung CancerWilliam D. Travis, MDMemorial Sloan-Kettering Cancer CenterNeuroendocrine Tumors of the Lung: Update on HistologyUpdate in Hereditary Renal Cancer (M20)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Cancer Genetics, Genitourinary CancerW. Marston Linehan, MDNational Institutes of HealthMONDAY287

Monday, June 6, 20118:00 AM - 11:00 AMORAL ABSTRACT SESSIONGenitourinary (Nonprostate) CancerLocation: Hall D2CME credit: 3Track(s): Genitourinary CancerMONDAYEvan Y. Yu, MD—Co-ChairFred Hutchinson Cancer Research CenterCarsten Bokemeyer, MD—Co-ChairUniversity Medical Center Hamburg-Eppendorf8:00 AM Axitinib versus sorafenib as second-line therapy for metastatic renal cellcarcinoma (mRCC): Results of phase III AXIS trial. (Abstract #4503)B. I. Rini, B. Escudier, P. Tomczak, A. Kaprin, T. E. Hutson, C. Szczylik,J. C. Tarazi, B. Rosbrook, S. Kim, R. J. Motzer8:15 AM Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versussorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).(Abstract #4504)D. Cella, B. Escudier, B. I. Rini, C. Chen, H. Bhattacharyya, J. C. Tarazi,B. Rosbrook, S. Kim, R. J. Motzer8:30 AM Final results from an EORTC (GU Group)/NCRI randomized phase III trial ofadjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with ahigh risk of relapse after nephrectomy for renal cell carcinoma (RCC).(Abstract #4505)M. Aitchison, C. A. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes,L. McMahon, P. A. Vasey8:45 AM Do genetic polymorphisms predict risk of recurrence in patients withlocalized renal cell carcinoma? Results from a cohort study. (Abstract #4506)F. A. Schutz, K. P. Gray, M. Pomerantz, M. B. Atkins, J. E. Rosenberg,M. S. Hirsch, D. F. McDermott, G. M. Lee, S. Signoretti, P. W. Kantoff,M. L. Freedman, T. K. ChoueiriDiscussion9:00 AM Bruce G. Redman, DO (Abstracts #4503–4506)University of Michigan9:15 AM Superior survival after sequential high-dose chemotherapy (HDCT) ascompared to single HDCT in patients with relapsed or refractory germ celltumors (GCT): Six-year long-term follow-up of a prospective, randomizedphase II trial. (Abstract #4507)A. Lorch, A. Kleinhans, A. Kramar, J. T. Hartmann, C. Bokemeyer, O. Rick,J. Beyer, for the German Testicular Cancer Study Group9:30 AM A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP)and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK05/014, ISRCTN53643604). (Abstract #4508)R. A. Huddart, R. Gabe, F. Cafferty, P. Pollock, J. D. White, J. Shamash,S. P. Stenning, TE23 Trial Management Group and Collaborators, NCRI TestisCancer Clinical Studies Group9:45 AM A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standardBEP in patients with in intermediate prognosis germ cell cancer (GCC): Anintergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCCgroup (EORTC 30983). (Abstract #4509)R. De Wit, I. A. Skoneczna, K. Gedske Daugaard, M. de Santis, A. Garin, N. Aass,J. A. Witjes, P. Albers, J. White, J. Germa-Lluch, S. Osanto, S. Marreaud,L. ColletteDiscussion10:00 AM Christopher Sweeney, MBBS (Abstracts #4507–4509)Dana-Farber Cancer Institute288

Monday, June 6, 201110:15 AM Prospective, randomized phase III study comparing two intensified regimens(methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC]versus gemcitabine/cisplatin) in patients with inoperable or recurrenturothelial cancer. (Abstract #4510)A. Bamias, A. Karadimou, S. Lampaki, G. Aravantinos, I. Xanthakis,C. Papandreou, G. Lainakis, F. Zagouri, N. Soupos, E. Kostouros, E. Samantas,C. Hatzimouratidis, C. Konstantinidis, C. Deliveliotis, D. G. Pectasides,G. Fountzilas, M. A. Dimopoulos, Hellenic Cooperative Oncology Group10:30 AM Association of germ-line variation with platinum-based chemotherapyresponse in patients (pts) with urothelial carcinoma (UC). (Abstract #4511)D. J. Gallagher, V. Joseph, R. J. Hamilton, I. Ostrovnaya, I. R. Garcia-Grossman,J. C. Riches, A. M. Regazzi, J. A. Przybylo, M. Gaudet, M. I. Milowsky, K. Offit,D. F. BajorinDiscussion10:45 AM Maria De Santis, MD (Abstracts #4510–4511)KFJ Spital AustriaMONDAY289

Monday, June 6, 20118:00 AM - 11:00 AMORAL ABSTRACT SESSIONPediatric Oncology IILocation: S504CME credit: 3Track(s): Pediatric OncologyMONDAYEdward F. Attiyeh, MD—Co-ChairChildren’s Hospital of PhiladelphiaAlejandro Gutierrez, MD—Co-ChairDana-Farber Cancer Center8:00 AM The prognostic value of semi-quantitative 123 I mIBG scintigraphy atdiagnosis in high-risk neuroblastoma: Validation of the SIOPEN scoremethod. (Abstract #9511)V. Lewington, U. Poetschger, A. Boubaker, Z. Bar-Sever, B. Drake,A. Staudenherz, M. Castellani, B. Lambert, K. Grange, P. Brock, A. Garaventa Sr.,I. Yaniv, D. Valteau Couanet, V. Castel, A. Forjaz De Lacerda, J. Malis,H. Schroeder, R. Luksch, K. Beiske, R. L. Ladenstein8:15 AM Dosimetry, toxicity, and response in a phase IIa trial of no-carrier addediobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy(NANT) study. (Abstract #9512)K. K. Matthay, B. D. Weiss, J. Villablanca, J. M. Maris, G. A. Yanik, S. G. Groshen,H. Jackson, R. Hawkins, F. Goodarzian, A. Panigrahy, S. G. DuBois, J. Stubbs,A. Towbin, J. A. Barrett, N. D. LaFrance, J. W. Babich8:30 AM Phase I study of vincristine, irinotecan, and 131 I-MIBG for patients withrelapsed or refractory neuroblastoma: A New Approach to NeuroblastomaTherapy (NANT) study. (Abstract #9513)S. G. DuBois, L. Chesler, S. G. Groshen, R. Hawkins, F. Goodarzian, G. A. Yanik,C. F. Stewart, Y. P. Mosse, J. M. Maris, J. Villablanca, K. K. MatthayDiscussion8:45 AM Mark Gaze, MD (Abstracts #9511–9513)University College London9:00 AM Stratification of patients with neuroblastoma for targeted ALK inhibitortherapy. (Abstract #9514)D. Weiser, M. Laudenslager, E. Rappaport, E. Carpenter, E. F. Attiyeh, S. Diskin,W. B. London, J. M. Maris, Y. P. Mosse9:15 AM Ototoxicity in children with high-risk neuroblastoma: Prevalence, riskfactors, and concordance of grading scales—A report from the Children’sOncology Group (COG). (Abstract #9515)W. Landier, K. R. Knight, F. L. Wong, J. K. Lee, O. Thomas, H. Kim,S. G. Kreissman, M. L. Schmidt, L. Chen, W. B. London, S. Bhatia,J. G. Gurney, Children’s Oncology Group9:30 AM Shorter duration therapy that includes vincristine (V), dactinomycin (A), andlower doses of cyclophosphamide (C) with or without radiation therapy forpatients with newly diagnosed low-risk embryonal rhabdomyosarcoma(ERMS): A report from the Children’s Oncology Group (COG). (Abstract#9516)D. Walterhouse, A. S. Pappo, J. L. Meza, J. C. Breneman, A. A. Hayes-Jordan,D. Parham, T. P. Cripe, W. H. Meyer, D. S. Hawkins9:45 AM Randomized comparison of VAC versus VAI chemotherapy (CT) asconsolidation for standard risk (SR) Ewing sarcoma tumor (ES): Results ofthe Euro-EWING.99-R1 trial. (Abstract #9517)O. Oberlin, M. Le Deley, U. Dirksen, I. J. Lewis, A. Ranft, J. M. Michon,M. Paulussen, J. Whelan, R. L. Ladenstein, B. Brennan, P. Marec Bérard,V. Laurence, H. Van Den Berg, L. Hjorth, C. Douglas, K. Wheatley,M. M. Van Glabbeke, I. R. Judson, A. W. Craft, H. Juergens, European EwingTumour Working Initiative of National Groups290

Monday, June 6, 201110:00 AM Outcome of Head Start III multinational protocol for newly diagnosed centralnervous system (CNS) primitive neuroectodermal tumors (pnet) of youngchildren. (Abstract #9519)T. B. Davidson, L. Ji, K. Haley, G. Dhall, J. P. Grimm, F. H. Gilles, S. L. Gardner,J. C. Allen, A. A. Bedros, M. M. Etzl, R. S. Olshefski, A. Cornelius, J. Torkildson,G. A. Kennedy, J. R. Fangusaro, S. R. Rassekh, M. J. Joyce, S. J. Bertolone,R. Sposto, J. L. FinlayDiscussion10:15 AM Roger Packer, MD (Abstract #9519)Children’s National Medical Center10:30 AM Relevance of germ-line genetic variations for treatment response in pediatricosteosarcoma patients. (Abstract #9518)M. Hagleitner, P. Hoogerbrugge, B. W. Schreuder, U. E. Flucke, M. J. Coenen,D. M. Te LooMONDAY291

Monday, June 6, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONMONDAYDevelopmental Therapeutics—Clinical Pharmacology and ImmunotherapyLocation: Hall ATrack(s): Developmental TherapeuticsBrd. 1A Immunotherapy of advanced melanoma by intratumoral injections ofautologous, purified dendritic cells transduced with gene construct ofinterleukin-12, with dose-dependent expression under the control of an oralactivator ligand. (Abstract #2540)D. J. Schwartzentruber, J. M. Kirkwood, M. J. Guarino, J. M. Richards, O. Hamid,S. O’Day, J. J. Nemunaitis, J. E. Talmadge, S. Chada, K. B. Menander,K. Shafer-Weaver, J. H. Senesac, M. O. Thornton, J. J. Lewis, R. B. HerbermanBrd. 1B Effect of a costimulatory endodomain on the performance of T cellsexpressing CD19-directed chimeric antigen receptors (CARs) in subjectswith relapsed/refractory B-cell malignancies (Abstract #2541)C. A. Ramos, B. Savoldo, E. Liu, C. M. Bollard, M. P. Mims, M. J. Keating,A. P. Gee, Z. Mei, C. M. Rooney, H. E. Heslop, M. K. Brenner, G. DottiBrd. 1C Identification of pre- and post-treatment markers of efficacy in patients withrenal cancer treated with MVA-5T4 in a phase III study. (Abstract #2542)R. Harrop, W. H. Shingler, M. McDonald, P. Treasure, R. J. Amato, R. E. Hawkins,H. Kaufman, J. de Belin, M. Goonewardena, S. NaylorBrd. 1D Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma(RCC): Analysis of pts receiving extended therapy. (Abstract #2543)E. M. Posadas, N. M. Tannir, Y. Wong, M. S. Ernstoff, C. K. Kollmannsberger,J. Qian, P. J. Ansell, E. M. McKeegan, M. D. McKee, J. L. Ricker, D. M. Carlson,D. MichaelsonBrd. 1E Eribulin dosing in patients with advanced solid tumors and hepaticimpairment. (Abstract #2544)L. A. Devriese, P. Witteveen, E. E. Voest, E. N. Overkleeft, M. Langenberg,J. H. Beijnen, L. Reyderman, J. Wanders, D. R. Mould, A. Gupta, Z. Hussein,J. H. SchellensBrd. 1F The role of the electrocardiogram (ECG) in phase I drug development inpatients with cancer: The University of Texas M. D. Anderson Cancer Centerexperience with 8,966 ECGs. (Abstract #2545)H. Veasey Rodrigues, A. Naing, D. S. Hong, G. S. Falchook, S. Fu, J. J. Wheler,A. M. Tsimberidou, S. L. Moulder, F. Janku, S. Wen, S. N. Fessahaye,E. C. Golden, D. I. Westerhold, M. Ewer, R. KurzrockBrd. 1G A phase I study of once-weekly aminoflavone prodrug (AFP464) in solidtumor patients. (Abstract #2546)M. P. Goetz, J. M. Reid, Y. Qi, A. Chen, R. M. McGovern, M. J. Kuffel,P. D. Scanlon, C. Erlichman, M. M. AmesBrd. 2A The effect of enoxaparin on inflammatory and thrombotic mediators incancer patients as studied using protein and biochip array approaches.(Abstract #2547)D. Hoppensteadt, E. Litinas, H. Khan, J. Cunanan, I. Thethi, J. FareedBrd. 2B T-cells targeted with anti-CD3 x anti-HER2 bispecific antibody for treatmentof women with stage IV breast cancer (phase I): Clinical and immune functionresults. (Abstract #2548)L. G. Lum, R. Rathore, Z. Al-Kadhimi, P. Davol, A. Thakur, C. Pray, Q. Liu,E. Tomaszewski, F. Cummings, P. Steele, J. Wedge, N. Kouttab, A. Maizel,W. Colaiace, R. Joyrich, V. Ratanatharathorn, J. P. UbertiBrd. 2C Population pharmacokinetics and pharmacogenomics of erlotinib: Effect ofdrug exposure on treatment outcomes in Japanese patients with non-smallcell lung cancer. (Abstract #2549)M. Fukudo, Y. Ikemi, Y. Togashi, K. Masago, Y. Kim, T. Mio, M. Mishima, K. Inui,T. Katsura292

Monday, June 6, 2011Brd. 2DBrd. 2EBrd. 2FBrd. 2GBrd. 3ABrd. 3BBrd. 3CBrd. 3DBrd. 3EBrd. 3FBrd. 3GCellular function of the mononuclear phagocyte system (MPS) as aphenotypic probe for pegylated liposomal doxorubicin (PLD)pharmacokinetics (PK) in patients with recurrent ovarian cancer. (Abstract#2550)W. P. Caron, J. C. Lay, A. M. Fong, N. M. La-Beck, S. E. Newman,D. L. Clarke-Pearson, W. R. Brewster, L. Van Le, V. L. Bae-Jump,P. A. Gehrig, W. ZamboniSafety and immunogenicity of heat-treated zoster vaccine (ZV HT ) in adultswith solid tumor malignancy (STM). (Abstract #2551)K. M. Mullane, M. R. Mullane, B. M. Wong, Y. Zhao, T. Sterling, S. Manoff,P. W. AnnunziatoEvaluation of response rate and disease control rate as potential predictorsof overall survival in anthracycline-pretreated women receiving first-linechemotherapy for metastatic breast cancer (MBC). (Abstract #2552)J. Liu, K. S. Albain, S. Chan, A. D. Seidman, D. Tai, Y. Wang, L. ZhaoProcoagulant and inflammatory mediators in small cell lung carcinoma:Potential role in thromboembolic complications. (Abstract #2553)I. Thethi, D. Hoppensteadt, H. Khan, M. Demir, C. Adiguzel, E. Litinas, J. FareedPhase I study of anti-VEGF monoclonal antibody bevacizumab and HDACinhibitor valproic acid in patients with advanced cancers. (Abstract #2554)J. J. Wheler, F. Janku, T. Jackson, S. Fu, M. Sun, H. Yang, A. Naing,S. L. Moulder, A. M. Tsimberidou, D. S. Hong, G. S. Falchook, S. A. Piha-Paul,G. Garcia-Manero, R. KurzrockUtility of novel dynamic clinical indices in patients (pts) enrolled in a phase I(Ph I) oncology trial as markers of prognosis and treatment benefit. (Abstract#2555)J. Ang, D. Olmos, V. Moreno Garcia, A. Brunetto, D. Papadatos-Pastos,H. Arkenau, M. Blanco, R. D. Baird, P. A. Cassier, D. S. Tan, R. S. Kristeleit,S. Dolly, K. J. Shah, B. Amin, B. G. Anghan, L. R. Molife, U. Banerji, J. S. De Bono,S. B. KayePhase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patientswith EpCAM-positive advanced solid tumors. (Abstract #2556)J. P. Connor, R. Stupp, M. C. Cristea, N. Lewis, L. D. Lewis, M. R. Mattiacci,M. Felder, S. Stewart, J. Henslee-Downey, R. Neugebauer, P. B. KomarnitskyAdoptive immunotherapy with autologous CD3/CD28-costimulated T-cellsafter fludarabine-based chemotherapy in patients with chronic lymphocyticleukemia. (Abstract #2557)S. J. Schuster, C. Hosing, E. J. Shpall, B. Levine, N. Aqui, E. A. Chong,J. Svoboda, A. Gordon, J. D. McMannis, D. Bosque, J. Cotte, A. Brennan,Z. Zheng, L. Leinbach, Y. Xu, E. A. Veloso, W. Decker, C. M. Bollard,M. J. Keating, C. H. JuneEffect of cellular vaccination of prostate cancer patients on IgG responses topeptide epitopes predicted from prostate tumor–associated autoantigens.(Abstract #2558)G. P. Hemstreet, V. M. Pisarev, C. A. Enke, R. J. Hauke, G. R. Rossi,L. Tennant, W. J. Ramsey, N. N. Vahanian, C. J. LinkBlinded independent radiologic review (BIRR) versus investigator radiologicevaluation (IRE) for response assessment in metastatic colorectal cancer(mCRC): Systematic review and meta-analysis. (Abstract #2559)J. S. Lima, F. M. Carcano, F. H. Souza, L. V. dos SantosClinical effects of Wilms tumor protein (WT) 1 peptide vaccination in patientswith WT1-expressing solid tumors as compared to patients with AML/MDS.(Abstract #2560)A. Letsch, C. Scheibenbogen, A. Asemissen, K. Zimmermann, S. Bauer,M. Voelker-Call, D. Stather, E. Thiel, U. KeilholzMONDAY293

Monday, June 6, 2011MONDAYBrd. 3HBrd. 4ABrd. 4BBrd. 4CBrd. 4DBrd. 4EBrd. 4FBrd. 4GBrd. 4HBrd. 5ABrd. 5BBrd. 5CBrd. 5DPosterior reversible encephalopathy syndrome in patients with cancer.(Abstract #2561)A. M. Paker, L. Chi, M. C. Ruiz, M. E. LoghinExpected benefits versus actual outcomes in oncology phase III randomizedcontrolled trials (RCTs). (Abstract #2562)H. K. Gan, B. You, G. R. Pond, E. X. ChenRECIST 1.0 versus 1.1: Implications for trial interpretation and design inadvanced prostate cancer. (Abstract #2563)C. I. Piatek, B. B. Desai, D. Wei-Tsao, R. Tang, F. Acosta, J. K. Pinski, T. B. Dorff,A. Goldkorn, H. Jadvar, D. I. QuinnA dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC(polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose) in immunosuppressed (IS) patients (pts) with advancedprostate cancer (PCa) . (Abstract #2564)A. K. Patel, L. J. Appleman, W. E. Gooding, D. Friedland, J. McKolanis,A. M. Salazar, O. J. Finn, G. S. ChattaAutologous heat shock protein vaccine (HSPPC-96) for patients withrecurrent glioblastoma (GBM): Results of a phase II multicenter clinical trialwith immunological assessments. (Abstract #2565)A. Parsa, C. Crane, S. Han, V. Kivett, A. Fedoroff, N. A. Butowski, S. M. Chang,J. L. Clarke, M. S. Berger, M. McDermott, M. Aghi, C. Yanes, M. Prados,A. E. Sloan, J. N. BruceIncidence of hypersensitivity reactions (HSRs) to albumin-bound paclitaxel(ABI) in patients (pts) with a history of HSR to cremophor-based paclitaxel(P). (Abstract #2566)J. P. Timoney, D. McGuffy, D. DeRitis, E. Tyler, J. Sumka, M. Pozotrigo, V. Bhatt,A. Chan, N. T. SklarinComparison of 12 current staging systems for advanced hepatocellularcarcinoma not amendable to locoregional therapy as inclusion criteria forclinical trials. (Abstract #2567)X. Li, Q. Lin, M. Dong, X. Wu, L. Wei, J. Wen, X. Ma, Z. ChenFirst-in-human phase I study of the antiangiogenic vaccine (OTS11101)targeting VEGFR-1 in patients with solid tumors. (Abstract #2568)H. Hayashi, T. Kurata, Y. Fujisaka, T. Satoh, M. Takeda, M. Miyazaki, T. Okabe,H. Kiyota, K. Tanaka, T. Tsunoda, K. NakagawaPro- versus antitumor effects of bisphosphonate-activated T cells incancer immunotherapy. (Abstract #2569)V. Kunzmann, M. Smetak, B. Kimmel, K. Weigang-Koehler, M. Goebeler,J. Birkmann, J. Becker, I. Schmidt-Wolf, H. Einsele, M. WilhelmInfluence of renal dysfunction on the pharmacokinetic of intravenousvinflunine: Results of a phase I trial in patients with cancer. (Abstract #2570)J. Delord, N. Isambert, P. Fumoleau, A. Ravaud, T. Nguyen, P. Ferre, S. Favrel,M. Pinel, J. TouraniPopulation pharmacokinetic analysis from phase I and phase II studies of thehumanized monovalent antibody, MetMAb, in patients with advanced solidtumors. (Abstract #2571)S. Bai, Y. Xin, D. Jin, S. Kaur, I. Nijem, J. G. Bothos, A. C. Peterson, P. H. PatelThe effect of elotuzumab on natural killer (NK) cell function against multiplemyeloma (MM). (Abstract #2572)S. M. Collins, C. E. Bakan, Y. Alghothani, H. Kwon, B. Balasa, G. Starling, A. Rice,D. M. Benson Jr.Melphalan and whole-blood stem cell reinfusion in castration-resistantprostate cancer (CRPC): A phase I/II study. (Abstract #2573)J. Shamash, J. Jacob, T. Powles, S. Agrawal, K. Mutsvangwa, N. Saunders,P. Wilson, J. Stebbing294

Monday, June 6, 2011Brd. 5EBrd. 5FSystemic immune responses induced by intratumoral plasmid IL-12electroporation in patients with melanoma. (Abstract #2574)E. Cha, A. Daud, D. G. McNeel, R. Heller, L. FongHumoral tumor-associated immune responses induced by catumaxomab inpatients with malignant ascites. (Abstract #2575)P. Ruf, M. Jäger, B. Foerster, H. Martinius, D. Seimetz, H. LindhoferBrd. 5G Reduction of toxicity by reversing the order of infusion in docetaxel andcyclophosphamide (TC). (Abstract #2576)D. Miura, M. Fujii, T. Iwatani, T. Takano, H. KawabataBrd. 5H A phase I clinical trial of a genetically modified and imageable oncolyticvaccinia virus GL-ONC1 with clinical green fluorescent protein (GFP)imaging. (Abstract #2577)J. V. Pedersen, E. M. Karapanagiotou, A. Biondo, N. Tunariu, M. Puglisi,K. A. Denholm, S. Sassi, D. Mansfield, T. A. Yap, J. S. De Bono, K. J. HarringtonBrd. 6A A phase 0 microdosing trial of an in vivo assay for predictingchemoresistance to platinum. (Abstract #2578^)C. Pan, S. Wang, R. deVere White, D. R. Gandara, P. Lara Jr., T. Li, P. Mack,A. Rodriguez-Fahrni, J. S. Lee, M. Malfatti, K. Turteltaub, P. T. HendersonBrd. 6B New lesions versus growth of existing disease: Does it impact prognosis?(Abstract #2579)A. Grothey, J. M. Heun, M. Branda, R. M. Goldberg, D. J. SargentBrd. 6C Effect of hepatic impairment on sorafenib pharmacokinetics: Results of amulticenter, open-label, single-dose, phase I trial. (Abstract #2580)J. T. Lettieri, A. L. Mazzu, L. Huang, C. D. LathiaBrd. 6D Functional and clinical evidence of the influence of sorafenib binding toalbumin on sorafenib disposition in adult patients with cancer with advancedsolid tumors. (Abstract #2581)A. Thomas-Schoemann, M. Tod, O. Mir, N. Bancelin, R. Coriat, F. Taieb,P. Boudou-Rouquette, H. Abbas, S. Ropert, J. Durand, A. Dauphin, F. Goldwasser,B. BlanchetBrd. 6E Technetium-99m sulfur colloid (TSC) as a phenotypic probe for thepharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomaldoxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer(EOC). (Abstract #2582)M. D. Walsh, H. Giovinazzo, A. Sheikh, M. Ivanovic, A. B. Whitlow, S. E. Newman,N. M. La-Beck, R. J. Kowalsky, B. A. Zamboni, D. L. Clarke-Pearson,W. R. Brewster, L. Van Le, V. L. Bae-Jump, P. A. Gehrig, W. ZamboniBrd. 6F Meta-analysis of the pharmacokinetic variability of liposomal anticanceragents compared with nonliposomal anticancer agents. (Abstract #2583)B. Sidone, B. A. Zamboni, W. ZamboniBrd. 6G Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinicaltrial. (Abstract #2584)M. Sebastian, L. von Boehmer, A. Zippelius, F. Mayer, M. Reck, D. Atanackovic,M. Thomas, F. Schneller, J. Stoehlmacher, E. Goekkurt, H. Bernhard,A. Groeschel, R. Bals, S. Schmidt, B. Scheel, S. D. Koch, T. Lander, K. Kallen,A. KnuthBrd. 6H Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992)with intravenous weekly vinorelbine in advanced solid tumors. (Abstract#2585)R. Bahleda, J. Soria, Y. Berge, C. Massard, S. Wind, M. M. Uttenreuther-Fischer,F. Fleischer, H. De-Montserrat, F. Solca, I. Tschoepe, J. DelordBrd. 7A Population pharmacokinetic (PK) analysis supports fixed dosing for thehumanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A)administered intravenously in patients with advanced solid tumors. (Abstract#2586)Y. Xin, M. S. Gordon, D. Jin, E. Wakshull, D. S. Chen, L. S. Rosen, P. N. Munster,L. Naumovski, S. BaiMONDAY295

Monday, June 6, 2011MONDAYBrd. 7BBrd. 7CBrd. 7DBrd. 7EBrd. 7FBrd. 7GBrd. 7HBrd. 8ABrd. 8BBrd. 8CBrd. 8DBrd. 8EBrd. 8F296Assessment of association between BRAF mutation status in melanomatumors and response to ipilimumab. (Abstract #2587)J. Jackson, G. Whitney, O. Hamid, H. Schmidt, S. D. Chasalow, S. Alaparthy,Y. Bao, V. ShahabiUse of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy toreduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) andesophagogastric cancer (EGC). (Abstract #2588)R. F. Gabitass, N. E. Annels, J. Crawshaw, H. S. Pandha, G. W. MiddletonTumor-targeted cancer vaccination (GeneVieve Protocol): A phase I/II studyof intravenous Rexin-G and Reximmune-C for chemotherapy-resistantcancers. (Abstract #2589)J. G. Ignacio, H. Bruckner, R. E. Manalo, F. S. San Juan, L. Baniqued,A. Madamba, E. M. Gordon, F. L. HallOutcomes in phase II trials of metastatic breast cancer: Where is the bar?(Abstract #2590)A. Kamal, T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom,J. M. PeppercornAIDS malignancy consortium (AMC) study 061: A phase I/PK study ofsunitinib (S) with highly active antiretroviral therapy (HAART) in HIVpatients with solid tumors. (Abstract #2591)J. F. Deeken, M. A. Rudek, D. M. Aboulafia, R. J. Sullivan, J. F. Gerecitano,M. E. Cianfrocca, D. H. Henry, L. Ratner, B. J. Dezube, K. Mosby, M. Tibbals,R. F. Little, S. P. Ivy, P. C. Moore, R. T. MitsuyasuA phase I trial of recombinant modified vaccinia ankara (MVA) vaccineencoding Epstein-Barr virus (EBV) antigens. (Abstract #2592)E. P. Hui, G. S. Taylor, B. Ma, S. L. Chan, R. Ho, W. Wong, H. Jia, C. Edwards,A. B. Rickinson, A. T. Chan, N. M. StevenMetabolic profiles as predictive biomarkers of erlotinib-induced adverseeffects in patients with non-small cell lung cancer. (Abstract #2593)A. Hamada, J. Sasaki, S. Saeki, N. Iwamoto, M. Inaba, S. Ushijima, H. Kishi,S. Fujii, H. Semba, K. Kashiwabara, Y. Tsubata, Y. Kai, T. Isobe, H. Kohrogi,H. SaitoAn evaluation of plasma homocysteine levels and the hematological toxicityof pemetrexed even with folate supplementation. (Abstract #2594)A. Horiike, H. Tanaka, T. Sakatani, R. Saito, K. Kaburaki, N. Yanagitani, K. Kudo,F. Ohyanagi, S. Hagiwara, T. Horai, M. NishioCombination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel inpatients with solid tumors: Results from two phase Ib trials. (Abstract #2595)F. G. De Braud, C. Catania, A. Onofri, C. Pierantoni, S. Cascinu, M. Maur,C. Masini, P. F. Conte, L. Giovannoni, A. Tasciotti, V. Lovato, D. Neri,H. D. MenssenNAD(P)H oxidase genetic polymorphisms and anthracyclines-inducedcardiac lesions in patients with cancer. (Abstract #2596)A. Cascales, F. Pastor, B. Sanchez-Vega, J. Corral, A. Vicente, T. Garcia,V. Vicente, F. AyalaKey drug development features in the design of early-phase oncology trials:An FDA perspective. (Abstract #2597)R. Charlab Orbach, G. M. Blumenthal, P. Cortazar, K. K. Filipski, C. Grimstein,L. Zhang, P. Mummaneni, B. Booth, I. ZinehPopulation pharmacokinetics of NKTR-102, a topoisomerase I inhibitorpolymerconjugate, in patients with advanced solid tumors. (Abstract #2598)M. A. Eldon, U. HochA pilot study of vaccination with sialyl Lewis a (sLe a )–keyhole limpethemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21 inmetastatic breast cancer patients (pts). (Abstract #2599)A. Diab, G. Ragupathi, W. W. Scholz, K. Panageas, C. Hudis, P. O. Livingston,T. Gilewski

Monday, June 6, 2011Brd. 8GBrd. 8HBrd. 9ABrd. 9BBrd. 9CBrd. 9DBrd. 9EBrd. 9FBrd. 9GBrd. 9HBrd. 10ABrd. 10BBrd. 10CA phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administeredeither on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim(peg) every 21 days (NCT01214642). (Abstract #2600)K. C. Shih, J. R. Infante, K. P. Papadopoulos, J. C. Bendell, A. W. Tolcher,H. A. Burris III, M. Beeram, L. Jackson, R. Arcos, E. H. Westin, D. Farrington,A. McGlothlin, S. Hynes, J. Leohr, J. T. Brandt, A. Nasir, A. PatnaikThe effect of the trifunctional anti-EpCAM antibody catumaxomab on thedevelopment of tumor-specific immune responses in patients with gastriccancer. (Abstract #2601)H. Reinhard, S. K. Meyer, K. Bartels, R. Fischer, D. Seimetz, C. Bokemeyer,D. AtanackovicCorrelation between adverse event reports of hypothyroidism and clinicalresponse in patients treated with vascular endothelial growth factor receptorinhibitors (VEGFR-I). (Abstract #2602)G. Speranza, L. Rubinstein, S. P. Ivy, P. J. HarrisAdded value of pre- and on-treatment tumor growth kinetics assessment toRECIST in patients (pts) treated with molecularly targeted agents (MTAs).(Abstract #2603)C. Le Tourneau, V. Servois, L. Ollivier, X. PaolettiA phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA.(Abstract #2604)R. A. Madan, M. Bilusic, J. W. Hodge, K. Y. Tsang, P. M. Arlen, C. R. Heery,M. Rauckhorst, S. McMahon, C. Intrivici, T. A. Ferrara, A. Cohn, D. Apelian,A. Franzusoff, Z. Guo, J. Schlom, J. L. GulleyDevelopment and validation of a prediction tool for hand-foot skin reaction(HFSR) in patients receiving sorafenib. (Abstract #2605)J. Yu, G. Dranitsaris, M. D. Vincent, L. Huang, F. Fang, M. E. LacoutureUnderstanding the role of carbonyl reductase polymorphisms ondoxorubicin-induced cardiotoxicity with population pharmacokinetics (PK).(Abstract #2606)G. J. Fetterly, K. E. Thudium, J. Kalabus, M. Murphy, P. D. Zagst, J. Prey,E. Kittleman, A. A. Adjei, T. L. O’Connor, J. G. BlancoA phase I dose escalation study of NKP-1339 in patients with advanced solidtumors refractory to treatment. (Abstract #2607)N. R. Dickson, S. F. Jones, H. A. Burris III, R. K. Ramanathan, G. J. Weiss,J. R. Infante, J. C. Bendell, W. McCulloch, D. D. Von HoffThe effect of metformin (M) on overall survival (OS) of patients (Pts) withcolorectal cancer (CRC) treated with chemotherapy (CTX). (Abstract #2608)M. Bansal, E. Siegel, R. GovindarajanPhase I study of ATI-1123, a novel human serum albumin-stabilizeddocetaxel liposomal formulation, in patients with advanced solidmalignancies. (Abstract #2609)S. Vemulapalli, A. C. Mita, N. S. Gallegos, G. Anderson, J. Charles, J. M. Rogers,A. Kousba, K. K. Sankhala, J. J. NemunaitisEnrichment of allogeneic tumor antigen-specific T-cells from bone marrow(BM) of patients treated with high-dose post-transplant cyclophoshamide(Cy): A novel approach to adoptive immunotherapy. (Abstract #2610)K. Noonan, L. Luznik, I. BorrelloReturning research results to clinical trial participants: A survey of patientswith cancer. (Abstract #2611)K. Elzinga, C. V. Fernandez, D. Y. Heng, P. A. TangPhase I study evaluating the pharmacokinetics (PK) of components of S-1 inpatients with impaired hepatic function. (Abstract #2612)D. Mahalingam, J. Sarantopoulos, M. S. Gordon, N. B. Pandya, B. R. Tan,A. C. Mita, C. Zergebel, K. Saito, C. H. Takimoto, M. SaifMONDAY297

Monday, June 6, 2011Brd. 10DBrd. 10EPhase II, open-label trial to assess the effect of continuous oral afatinib(BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacyin relapsed or refractory solid tumors including brain metastases andglioblastoma that is not amenable to other therapy. (Abstract #2613^)H. Kristeleit, M. Puglisi, G. W. Middleton, D. Propper, M. T. Kelleher, L. Trani,K. A. Denholm, G. Wallenstein, P. Stopfer, S. Buschke, M. M. Uttenreuther-Fischer, E. Bent, D. O’Brien, J. F. Spicer, L. R. MolifeA first-in-human phase Ia open-label dose-escalation study of the safety,pharmacokinetics (PK), and pharmacodynamics (PD) of the humanizedmonoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administeredintravenously in patients with advanced solid tumors. (Abstract #2614)L. S. Rosen, M. S. Gordon, S. Bai, P. Hegde, J. Fredrickson, D. S. Chen, I. Chang,R. P. Funke, G. S. Chandler, L. Naumovski, P. N. MunsterMONDAY298

Monday, June 6, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONDevelopmental Therapeutics—Experimental TherapeuticsLocation: Hall ATrack(s): Developmental TherapeuticsBrd. 10F Phase I, open-label, dose-escalation study of AZD7762 in combination withirinotecan (irino) in patients (pts) with advanced solid tumors. (Abstract#3033)A. L. Ho, J. C. Bendell, J. M. Cleary, G. K. Schwartz, H. A. Burris III, P. Oakes,F. Agbo, P. N. Barker, A. M. Senderowicz, G. ShapiroBrd. 10G Efficacy in selected tumor types in a phase I study of the c-MET inhibitorARQ 197 in combination with sorafenib. (Abstract #3034)A. A. Adjei, J. A. Sosman, R. E. Martell, G. K. Dy, L. W. Goff, W. Ma, L. Horn,G. J. Fetterly, S. A. Michael, J. A. Means, F. Chai, M. Lamar, G. M. Strauss,W. Chiang, J. Jarboe, B. E. Schwartz, I. PuzanovBrd. 10H A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 inpatients with advanced solid tumors: Results of dose-escalation phase.(Abstract #3035)A. Patnaik, L. J. Appleman, J. M. Mountz, R. K. Ramanathan, M. Beeram,A. W. Tolcher, K. P. Papadopoulos, M. T. Lotze, D. P. Petro, C. Laymon, L. Paige,P. Rajagopalan, M. Jeffers, D. Roth, R. L. DubowyBrd. 11A A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589)and epirubicin in patients with solid tumor malignancies. (Abstract #3036)A. P. Moore, S. Thomas, C. J. Ryan, T. M. Jahan, S. G. DuBois, J. K. Chan,K. T. Thurn, E. A. Collisson, A. Reinert, A. Daud, P. N. MunsterBrd. 11B Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a onceweekly (QW) dose regimen in patients with advanced solid tumors. (Abstract#3037^)A. Biondo, T. A. Yap, L. Yan, A. Patnaik, I. Fearen, R. D. Baird,K. P. Papadopoulos, L. M. Delgado, A. Taylor, L. Lupinacci, S. C. Blackman,S. Decordova, M. Tall, S. Heaton, M. D. Garrett, D. Sullivan,J. S. De Bono, A. W. TolcherBrd. 11C A phase I trial of VB-111, a tissue- and condition-specific dual action vasculardisruptive and antiangiogenic agent, for treatment of patients with advancedmetastatic cancer. (Abstract #3038)A. J. Brenner, Y. Cohen, F. J. Giles, E. C. Borden, E. Breitbart, L. Bangio, N. Sher,P. L. TriozziBrd. 11D Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oralmurine double minute 2 (MDM2) antagonist, in patients with leukemias andsolid tumors. (Abstract #3039)A. Beryozkina, G. L. Nichols, M. Reckner, L. T. Vassilev, R. Rueger, L. Jukofsky,S. Middleton, M. Andreeff, S. Padmanabhan, R. Strair, M. L. Delioukina,P. G. Maslak, P. Hillmen, R. Kurzrock, L. Gore, A. Patnaik, R. G. Maki,G. K. Schwartz, A. J. Wagner, J. ZhiBrd. 11E A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P)and etoposide (E) in patients (pts) with advanced solid tumors and extensivestagesmall cell lung cancer (ES-SCLC). (Abstract #3040)A. M. Traynor, J. Kolesar, R. M. Marnocha, J. C. Eikhoff, D. B. Alberti, N. Takebe,G. Wilding, G. Liu, W. R. SchelmanBrd. 11F Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP)inhibitor, in combination with doxorubicin and cyclophosphamide in breastcancer and other solid tumors. (Abstract #3041)A. R. Tan, D. Toppmeyer, M. N. Stein, R. A. Moss, M. Gounder, D. C. Lindquist,J. J. Ji, A. P. Chen, M. J. Egorin, B. Kiesel, J. H. Beumer, R. S. DiPaolaMONDAY299

Monday, June 6, 2011MONDAYBrd. 11GBrd. 11HBrd. 12ABrd. 12BBrd. 12CBrd. 12DBrd. 12EBrd. 12FBrd. 12GBrd. 12HBrd. 13ADevelopment and validation of biomarker assays to assesspharmacodynamic modulation of MET. (Abstract #3042)A. K. Srivastava, M. G. Hollingshead, J. Weiner, S. Khin, S. Borgel, P. Risbood,T. D. Pfister, S. M. Lawrence, R. J. Kinders, D. P. Bottaro,J. E. Tomaszewski, R. E. Parchment, J. H. DoroshowOral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) withadvanced solid tumors: An update on safety and efficacy. (Abstract #3043)B. Grana, H. A. Burris III, J. Rodon Ahnert, A. R. Abdul Razak, M. J. De Jonge,F. Eskens, L. L. Siu, Q. C. Ru, N. F. Homji, D. Demanse, E. Di Tomaso,J. G. Cosaert, C. Quadt, J. Baselga, J. C. BendellA phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 withpaclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), inpatients with advanced non-small cell lung cancer (NSCLC). (Abstract #3044)B. Besse, J. Soria, C. Gomez-Roca, J. A. Ware, A. A. Adjei, G. K. Dy, G. Shankar,R. K. Brachmann, H. J. GroenGenetic correlations with chemotherapy-induced hepatic injury. (Abstract#3045)C. H. Pilgrim, K. Brettingham-Moore, A. Pham, W. Murray, E. Link, M. Smith,V. Usatoff, P. M. Evans, S. Banting, B. N. Thomson, M. Michael, W. A. PhillipsA phase I dose escalation study of the polo-like kinase 1 inhibitor volasertib(BI 6727) with two different dosing schedules in patients with advanced solidmalignancies. (Abstract #3046)C. Lin, W. Su, C. Yen, A. Cheng, Y. Lu, C. Hsu, D. C. Huang, H. Fritsch, F. Voss,R. Schreck, T. Taube, C. YangAngiogenic factors and soluble receptors in NCIC CTG BR.24. (Abstract#3047)C. L. Addison, K. Ding, H. Zhao, A. Le Maitre, S. A. Laurie, G. D. Goss,F. A. Shepherd, P. A. Bradbury, L. SeymourImaging with [ 18 f]-fluorodeoxyglucose positron emission tomography(FDG-PET) and dynamic contrast enhanced magnetic resonance imaging(DCE-MRI) as markers of drug effect in a phase I dose-escalation study ofcombined RAD 001 and cetuximab. (Abstract #3048)C. A. Martin, R. F. Perini, A. N. Avadhani, M. Redlinger, K. Harlacker,K. T. Flaherty, M. A. Rosen, C. R. Divgi, P. J. O’DwyerA phase I schedule optimization study of pegylated glutaminase (PEG-PGA)plus 6-diazo-5-oxo-l-norleucine (DON) in patients (pts) with advanced solidtumors. (Abstract #3049)C. Unger, C. Mueller, M. P. Bausch, K. Krzemieniecki, S. Ochenduszko, B. Wilk,E. Jaeger, S. Al-BatranA phase Ib study for MNRP1685A (anti-NRP1) administered intravenouslywith bevacizumab with or without paclitaxel to patients with advanced solidtumors. (Abstract #3050^)C. D. Weekes, P. LoRusso, V. Ramakrishnan, L. M. Shih, W. C. Darbonne,P. Hegde, Y. Xin, R. Yu, H. Xiang, R. K. Brachmann, A. PatnaikA phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updatedreport. (Abstract #3051)D. C. Cho, E. I. Heath, J. M. Cleary, E. L. Kwak, L. Gandhi, D. P. Lawrence,C. Zack, F. Teofilovici, R. Bradley, M. D. Karol, G. Shapiro, P. LoRussoA phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor,administered QD or BID in patients with advanced or metastatic solid tumors.(Abstract #3052^)D. D. Von Hoff, P. LoRusso, G. D. Demetri, G. J. Weiss, G. Shapiro,R. K. Ramanathan, J. A. Ware, R. Raja, J. Jin, G. G. Levy, K. E. Mazina,A. J. Wagner300

Monday, June 6, 2011Brd. 13BBrd. 13CBrd. 13DBrd. 13EBrd. 13FBrd. 13GBrd. 13HBrd. 14ABrd. 14BBrd. 14CBrd. 14DIntegrated research platform (iGXT) for enhancing drug development andpersonalizing cancer therapy: Pilot study results. (Abstract #3053)D. R. Gandara, T. A. Van Dyke, Z. Weaver Ohler, T. Li, P. Lara Jr., P. C. Mack,R. F. Calhoun, R. Gandour-Edwards, K. D. Danenberg, R. de Vere White,N. GoodwinPoly (ADP ribose) polymerase (PARP) inhibition in peripheral bloodlymphocytes (PBLs): Does it reflect PARP inhibition in tumor? (Abstract#3054)D. R. Shalinsky, D. D. Wang, K. A. Kern, P. English, N. J. Curtin, R. PlummerFirst-in-human dose-escalation safety and PK trial of a novel humanizedmonoclonal CovX body dual inhibitor of angiopoietin 2 and vascularendothelial growth factor. (Abstract #3055)D. S. Mendelson, L. S. Rosen, M. S. Gordon, J. W. Goldman, A. J. Olszanski,H. Dai, R. Perea, A. GollerkeriClinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of thenovel dual PI3K/mTOR inhibitor BEZ235. (Abstract #3056)D. Bottino, J. Tabernero, H. A. Burris III, C. Britten, L. Chen, J. C. Bendell,O. Chiparus, V. Duval, E. Di Tomaso, C. Sarr, W. Hackl, J. Baselga,J. Rodon AhnertFirst-in-human phase I study of Atu027, a liposomal small interfering RNAformulation, targeting protein kinase N3 (PKN3) in patients with advancedsolid tumors. (Abstract #3057)D. Strumberg, B. Schultheis, U. Traugott, C. Vank, A. Santel, O. Keil, K. Giese,J. Kaufmann, J. DrevsPhase I dose-escalation study of AZD7762 in combination with gemcitabine(gem) in patients (pts) with advanced solid tumors. (Abstract #3058)E. A. Sausville, P. LoRusso, M. A. Carducci, P. N. Barker, F. Agbo, P. Oakes,A. M. SenderowiczEffects of the antiangiogenic drug bevacizumab on tumor perfusion and drugdelivery of 11 C-labeled docetaxel in patients with non-small cell lung cancer(NSCLC): Implications for scheduling of antiangiogenic agents. (Abstract#3059)E. F. Smit, M. Lubberink, I. Bahce, M. Walraven, M. P. de Boer, H. N. Greuter,N. Hendrikse, J. Eriksson, A. D. Windhorst, P. E. Postmus, H. M. Verheul,E. H. Serne, A. A. Lammertsma, A. A. van der VeldtEarly targeted drug development: Pilot FDA review of PI3K inhibitor phase Istudies using a knowledge management database. (Abstract #3060)G. M. Blumenthal, R. Charlab Orbach, I. Zineh, P. Cortazar, R. L. Justice,R. PazdurInvestigation of hand-foot syndrome (HFS) observed in pazopanib (P)-treatedpatients (pts) with renal cell carcinoma (RCC). (Abstract #3061)H. A. Ball, Y. Lin, Z. Xue, B. Suttle, C. Xu, L. Huang, L. McCann, T. E. Hutson,C. N. Sternberg, L. N. PanditePhase I study of LDE225 in advanced solid tumors: Updated analysis ofsafety, preliminary efficacy, and pharmacokinetic-pharmacodynamiccorrelation. (Abstract #3062)H. A. Tawbi, J. Rodon Ahnert, R. Dummer, A. L. Thomas, C. Granvil, Y. Shou,J. Dey, M. M. Mita, D. D. Amakye, A. C. MitaA first-in-human phase I clinical trial of CXR1002 in patients (pts) withadvanced cancer. (Abstract #3063)I. R. MacPherson, D. Bissett, R. D. Petty, B. Tait, L. M. Samuel, J. MacDonald,M. Smith, J. A. Birse-Archbold, A. L. Barnett, C. R. Wolf, C. R. Elcombe,A. Jeynes-Ellis, T. EvansMONDAY301

Monday, June 6, 2011MONDAYBrd. 14EBrd. 14FBrd. 14GBrd. 14HBrd. 15ABrd. 15BBrd. 15CBrd. 15DBrd. 15EBrd. 15FBrd. 15G302A phase I study of CAL-101, an isoform-selective inhibitor ofphosphatidylinositol 3-kinase P110, in combination with anti-CD20monoclonal antibody therapy and/or bendamustine in patients withpreviously treated B-cell malignancies. (Abstract #3064)I. W. Flinn, M. T. Schreeder, S. E. Coutre, J. Leonard, N. D. Wagner-Johnston,S. De Vos, R. V. Boccia, L. Holes, S. Peterman, L. L. Miller, A. S. YuDual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranibin advanced solid tumors. (Abstract #3065)I. Garrido-Laguna, R. Kurzrock, J. J. Wheler, G. S. Falchook, S. A. Piha-Paul,S. Fu, A. Naing, C. Hinojosa, R. Mistry, A. Scamardo, K. S. Culotta,S. Ekmekcioglu, S. Wen, L. H. Camacho, S. P. Ivy, D. S. HongA dose-escalation study with the novel formulation of the oral pan-class IPI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients withadvanced solid tumors. (Abstract #3066)J. D. Peyton, J. Rodon Ahnert, H. Burris, C. Britten, L. Chen, J. Tabernero,V. Duval, N. Rouyrre, A. P. Silva, C. Quadt, J. BaselgaCombination study of navitoclax with gemcitabine (G) in patients (pts) withsolid tumors. (Abstract #3067)J. M. Cleary, C. S. Rocha Lima, H. Hurwitz, A. J. Montero, G. Shapiro, C. Franklin,J. Yang, A. M. Graham, T. Busman, M. Mabry, K. D. Holen, A. Krivoshik,R. Humerickhouse, H. UronisUpdate on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination withgemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.(Abstract #3068)J. H. Schellens, G. Shapiro, A. C. Pavlick, R. Tibes, S. Leijen, S. M. Tolaney,I. Diaz-Padilla, R. K. Ramanathan, T. Demuth, J. Viscusi, J. D. Cheng,R. Lam, Y. Xu, A. M. OzaResults of a study of the oral inhibitor PTC299 on tumor VEGF synthesis.(Abstract #3069)J. J. Luke, L. A. Callahan, C. H. Darby, E. Moss, J. Winkelman, J. Barth,G. L. Elfring, A. Ogden, G. K. Schwartz, M. M. GounderPhase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis,in patients with advanced solid tumors. (Abstract #3070)J. C. Bendell, M. S. Gordon, H. Hurwitz, C. H. Condon, Y. Yang, D. Wilson,K. M. Attie, M. L. Sherman, S. SharmaThe effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment ofpatients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): Aphase I study. (Abstract #3071)J. A. Thompson, A. Forero-Torres, E. I. Heath, S. M. Ansell, S. K. Pal, J. R. Infante,S. De Vos, P. A. Hamlin, B. Zhao, K. Klussman, N. C. WhitingPhase I pharmacokinetic study of temsirolimus (CCI-779) in patients withadvanced malignancies and normal and impaired liver function: An NCIOrgan Dysfunction Working Group (ODWG) study. (Abstract #3072)J. Sarantopoulos, H. Lenz, P. LoRusso, S. Shibata, S. Kummar, D. Mulkerin,R. K. Ramanathan, M. M. Mita, P. O’Rourke, S. C. Remick, S. Goel, M. Gutierrez,S. S. Ramalingam, A. Murgo, A. M. Davies, S. Mani, J. Boni, M. Shapiro, S. P. Ivy,C. H. Takimoto, National Cancer Institute Organ Dysfunction Working GroupA phase I study of TRC105 (anti-CD105 antibody) in patients with advancedsolid tumors. (Abstract #3073)J. W. Goldman, M. S. Gordon, H. Hurwitz, R. Pili, D. S. Mendelson, B. J. Adams,D. Alvarez, B. K. Seon, C. P. Theuer, B. R. Leigh, L. S. RosenAmuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNArepair: Final results from a 100-patient, 5-arm phase Ib trial in combinationwith five standard of care (SOC) anticancer regimens. (Abstract #3074)K. K. Sankhala, A. W. Tolcher, M. M. Mita, M. S. Gordon, L. S. Rosen,K. P. Papadopoulos, A. Patnaik, R. L. Drengler, A. C. Mita, J. Sarantopoulos,R. G. Bristow, G. Fine, G. S. Choy, M. Azab

Monday, June 6, 2011Brd. 15HBrd. 16ABrd. 16BBrd. 16CBrd. 16DBrd. 16EBrd. 16FBrd. 16GBrd. 16HBrd. 17AA phase I, open-label, dose-escalation study of the novel oral proteasomeinhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solidtumors. (Abstract #3075)K. P. Papadopoulos, D. S. Mendelson, A. W. Tolcher, A. Patnaik, H. A. Burris III,D. W. Rasco, J. C. Bendell, M. S. Gordon, G. Kato, H. Wong, D. Bomba, S. Lee,H. H. Gillenwater, T. Woo, J. R. InfanteFirst-in-human study with ARQ 621, a novel inhibitor of Eg5: Final resultsfrom the solid tumors cohort. (Abstract #3076)L. Chen, L. S. Rosen, T. Iyengar, J. W. Goldman, R. Savage, J. Kazakin,T. C. Chan, B. E. Schwartz, G. Abbadessa, D. D. Von HoffPhase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabinein a cohort of patients (pts) with advanced breast, ovarian, and uterinetumors. (Abstract #3077)L. H. Camacho, S. Pant, M. N. Saleh, G. Abbadessa, J. Kazakin, B. E. Schwartz,J. C. BendellOpen-label, sequential, ascending, multi-dose, phase I study of KW-2450 asmonotherapy in subjects with previously treated advanced solid tumors.(Abstract #3078)M. A. Dickson, P. LoRusso, E. A. Sausville, N. Rao, E. Kobayashi, M. R. Kurman,S. Akinaga, G. K. SchwartzBrivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase IIrandomized discontinuation trial (RDT). (Abstract #3079)M. J. Ratain, G. K. Schwartz, A. M. Oza, C. M. Rudin, S. B. Kaye, M. J. De Jonge,D. Khayat, A. Awada, M. B. Sawyer, J. C. Obel, J. Medioni, T. Evans, J. De Greve,P. M. Soetekouw, J. Baurain, P. J. O’Dwyer, C. Hartman, V. Poulart, I. B. WaltersA phase I study of the CDK inhibitor dinaciclib (SCH 727965) administeredevery 3 weeks in patients (pts) with advanced malignancies: Final results.(Abstract #3080)M. M. Mita, A. C. Mita, J. Moseley, J. Poon, K. A. Small, Y. Jou, P. Kirschmeier,D. Zhang, P. Statkevich, K. K. Sankhala, J. Sarantopoulos, J. M. Cleary,L. R. Chirieac, S. Rodig, R. Bannerji, G. ShapiroPhase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) inadvanced solid tumors (STs). (Abstract #3081)M. Kittaneh, A. J. Montero, K. Kovacs, V. D. Guardiola Amado, A. M. Flores,A. Ferrell, M. Vulfovich, M. D. Pegram, P. W. Benedetto, C. S. Rocha Lima,J. R. MerchanQuality appraisal of clinical validation studies for multigene predictionassays of chemotherapy response in early-stage breast cancer. (Abstract#3082)N. M. Kuderer, E. Culakova, M. Huang, M. S. Poniewierski, G. S. Ginsburg,W. T. Barry, P. K. Marcom, N. Ready, A. P. Abernethy, G. H. LymanMGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinaseinhibitor, in combination with erlotinib: Phase I clinical experience. (Abstract#3083)P. J. O’Dwyer, K. P. Papadopoulos, A. W. Tolcher, U. R. Teitelbaum, K. Harlacker,M. Beeram, D. Sohal, M. Mehran, M. Tawashi, M. A. Drouin, C. R. Maroun,J. Wang, M. Fournel, A. Karam, J. M. Besterman, A. PatnaikDose-response relationship in phase I clinical trials: A European DrugDevelopment Network (EDDN) collaboration study. (Abstract #3084)P. A. Cassier, V. Moreno Garcia, C. Gomez-Roca, D. Olmos, R. Morales,G. Del Conte, E. Gallerani, A. Brunetto, P. Schoffski, S. Marsoni, J. H. Schellens,N. Penel, E. E. Voest, T. Evans, R. Plummer, R. H. Wilson, J. Soria, J. Tabernero,J. Verweij, S. B. Kaye, European Drug Development NetworkMONDAY303

Monday, June 6, 2011MONDAYBrd. 17BBrd. 17CBrd. 17DBrd. 17EBrd. 17FBrd. 17GBrd. 17HBrd. 18ABrd. 18BBrd. 18CBrd. 18DPhase I dose escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212)dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).(Abstract #3085)R. Kurzrock, A. Patnaik, L. Rosenstein, S. Fu, K. P. Papadopoulos, D. A. Smith,G. S. Falchook, G. Chambers, J. L. Gauvin, A. Naing, L. S. Smith,T. Gonzalez, A. M. Tsimberidou, T. A. Mays, D. S. Cox, D. S. Hong, D. J. DeMarini,N. T. Le, S. R. Morris, A. W. TolcherA first-in-human phase I study of MORAb-004 (MOR4), a humanizedmonoclonal antibody recognizing TEM-1 (endosialin), in patients with solidtumors. (Abstract #3086)R. D. Carvajal, M. M. Gounder, C. M. Coughlin, J. Fishel, J. Heyburn,D. O’Shannessy, L. Grasso, C. Schweizer, J. Parno, L. J. Old, N. S. Azad,L. A. Diaz Jr.Findings from the phase I clinical trials of CX-4945, an orally availableinhibitor of CK2. (Abstract #3087)R. F. Marschke, M. J. Borad, R. W. McFarland, R. H. Alvarez, J. K. Lim,C. S. Padgett, D. D. Von Hoff, S. E. O’Brien, D. W. NorthfeltPhase II/pharmacodynamic trial of PD0332991 in patients with breast, colon,germ cell, and epithelial tumors containing amplification of CCND1. (Abstract#3088)R. F. Perini, A. DeMichele, D. J. Vaughn, M. Gallagher, W. Sun, B. J. Giantonio,U. R. Teitelbaum, S. Randolph, J. G. Christensen, R. D. Courtney, D. A. Pryma,C. R. Divgi, P. J. O’DwyerPhase I trial of the first-in-class EGFR antibody mixture, Sym004, in patientswith advanced solid tumors. (Abstract #3089)R. Dienstmann, A. W. Tolcher, K. P. Papadopoulos, D. W. Rasco, J. Tabernero,I. Brana, A. Piera, N. Skartved, H. Aladdin, J. Petersen, A. PatnaikA phase I study of paclitaxel, carboplatin, and YM155 (survivin suppressor)in subjects with solid tumors. (Abstract #3090)R. J. Kelly, A. Rajan, G. Chun, A. Lopez-Chavez, G. GiacconeA phase I dose escalation study of INCB028060, an inhibitor of c-METreceptor tyrosine kinase, in patients with advanced solid tumors. (Abstract#3091)R. C. Donehower, A. Scardina, M. Hill, J. Bowman, R. C. Newton, X. Liu,P. Scherle, Q. Wang, S. Diamond, J. Boer, F. Lee, T. Gau, H. A. Burris III,J. C. Bendell, S. F. Jones, J. R. InfantePhase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449.(Abstract #3092)S. R. Palmer, C. Erlichman, M. Fernandez-Zapico, Y. Qi, L. Almada,A. McCleary-Wheeler, M. J. Borad, J. R. Molina, A. Grothey, H. C. Pitot,A. Jatoi, D. W. Northfelt, R. R. McWilliams, S. H. Okuno, P. Haluska, G. P. Kim,G. Colon-OteroPharmacodynamic activity demonstrated in phase I for PLX3397, a selectiveinhibitor of FMS and Kit. (Abstract #3093)S. P. Anthony, I. Puzanov, P. S. Lin, K. B. Nolop, B. West, D. D. Von HoffPhase I dose-escalation study of the investigational Aurora A kinase (AAK)inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patientswith nonhematologic malignancies. (Abstract #3094)S. Sharma, R. Kurzrock, L. Gouw, D. S. Hong, K. Jones, X. Zhou, H. Shi,H. Fingert, G. S. FalchookA phase I/II study of the hypomethylating agent azacitadine with thenanoparticle albumin bound paclitaxel in the treatment of patients withadvanced or metastatic solid tumors. (Abstract #3095^)T. L. Dumlao, T. W. Butler, D. L. Dyess, H. T. Khong304

Monday, June 6, 2011Brd. 18E First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2inhibitor. (Abstract #3096)U. Banerji, C. Aghajanian, E. Raymond, R. Kurzrock, M. Blanco-Codesido,E. Oelmann, L. Grinsted, W. Burke, S. B. Kaye, A. NaingBrd. 18F Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor ofErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors.(Abstract #3097)U. Keilholz, V. Moiseyenko, A. Makhson, V. Semiglazov, M. Learoyd, A. Saunders,M. Stuart, S. TjulandinBrd. 18G Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growthfactor-1 receptor (IGF-1R) and insulin receptor (IR) in combination witherlotinib (E) in patients with advanced solid tumors. (Abstract #3098^)V. M. Macaulay, M. R. Middleton, S. G. Eckhardt, R. A. Juergens, C. M. Rudin,A. Manukyants, S. Gogov, S. Poondru, R. Gedrich, S. M. GadgeelBrd. 18H A phase I study evaluating the combination of OSI-906, a dual inhibitor ofinsulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) withweekly paclitaxel (PAC) in patients with advanced solid tumors. (Abstract#3099)W. A. Harb, C. Sessa, H. W. Hirte, S. B. Kaye, R. Simantov, S. N. Banerjee,A. Christinat, D. W. Sternberg, M. Singh, R. Light, S. PoondruBrd. 19A A phase I dose-escalation study of the novel gamma secretase inhibitorPF-03084014 in patients (pts) with advanced solid tumors. (Abstract #3100)W. A. Messersmith, P. LoRusso, J. M. Cleary, A. Dasari, X. Zhang, M. N. Shaik,R. D. Courtney, S. Randolph, G. ShapiroBrd. 19B Final results of a phase I study of the combination of a novel cell cycleinhibitor ON 01910.Na with gemcitabine in patients with advanced pancreaticand other solid tumors. (Abstract #3101)W. Ma, W. A. Messersmith, G. K. Dy, E. Freas, A. Whitworth, F. Wilhelm,S. G. Eckhardt, A. A. Adjei, A. JimenoBrd. 19C First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitorMK-4827 in advanced cancer patients with antitumor activity in BRCAdeficienttumors and sporadic ovarian cancers (soc). (Abstract #3102)W. R. Schelman, S. K. Sandhu, V. Moreno Garcia, G. Wilding, L. Sun, C. Toniatti,M. Stroh, N. Kreischer, C. L. Carpenter, L. R. Molife, S. B. Kaye, J. S. De Bono,R. M. WenhamBrd. 19D Predictive value of Fc gamma receptor IIIa genotype in response toconatumumab in three phase II studies. (Abstract #3103)Y. Pan, V. Haddad, T. Sabin, N. Baker, Y. Hei, F. Galimi, J. Graves, C. Huang,S. CottrellBrd. 19E Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699in BRCA 1 and 2–mutated, advanced ovarian and/or locally advanced ormetastatic breast cancer. (Abstract #3104)Y. Drew, J. A. Ledermann, A. Jones, G. Hall, G. C. Jayson, M. Highley, D. Rea,R. M. Glasspool, S. E. Halford, G. Crosswell, S. Colebrook,A. V. Boddy, N. J. Curtin, E. R. PlummerBrd. 19F Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3receptor signaling, in combination with paclitaxel (P). (Abstract #3105)J. A. Lopez-Martin, M. Vidal Losada, J. Cortes, B. Bermejo, A. Lluch Fernandez,M. Learoyd, A. Saunders, M. Stuart, J. BaselgaBrd. 19G FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors.(Abstract #3106)J. Chang, M. Rand, G. M. Blumenthal, P. Cortazar, C. Kulick, E. Hausman,S. Chang, R. Pratt, B. Habtemarium, Y. Chen, J. Bullock, R. Charlab Orbach,I. Zineh, R. L. Justice, R. PazdurMONDAY305

Monday, June 6, 20118:00 AM - 12:00 PMGENERAL POSTER SESSIONMONDAYTumor BiologyLocation: Hall ATrack(s): Tumor BiologyBrd. 20A Evaluation of the prognostic significance of human mammaglobinexpression in pleural effusion from patients with negative thoracoscopy.(Abstract #10534)A. Vigani, P. A. Canessa, C. Manta, P. Ferro, M. C. Franceschini, A. Morabito,M. Sivori, V. Fontana, F. Fedeli, M. Pistillo, S. RoncellaBrd. 20B Clinical characterstics and outcomes of patients with BRAF-mutantadvanced cancer in a phase I clinic: The University of Texas M. D. AndersonCancer Center experience. (Abstract #10535)H. E. El-Osta, G. S. Falchook, A. M. Tsimberidou, D. S. Hong, A. Naing, K. B. Kim,S. Wen, F. Janku, R. KurzrockBrd. 20C The association of long pentraxin 3 on prognosis in pancreatic carcinomapatients on gemcitabine-based chemotherapy. (Abstract #10536)S. Kondo, H. Ueno, C. Morizane, F. Koizumi, K. Tamura, T. OkusakaBrd. 20D The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, onepithelial–mesenchymal transition (EMT) in non-small cell lung cancer(NSCLC) cells lines and its effect on erlotinib and cisplatin. (Abstract #10537)M. Maitah, S. Ali, P. LoRusso, F. H. Sarkar, S. M. GadgeelBrd. 20E Indoleamine 2,3-dioxygenase activity and clinical outcome followinginduction chemotherapy and concurrent chemoradiation in stage III nonsmallcell lung cancer. (Abstract #10538)B. C. Creelan, G. Bepler, S. Antonia, T. Garrett, H. H. SolimanBrd. 20F The predictive role of midtreatment changes in survivin, GSTP1, andtopoisomerase 2 alpha expressions for pathologic complete response toneoadjuvant chemotherapy in patients with locally advanced breast cancer.(Abstract #10539)S. Keskin, Y. Eralp, E. Akisik, A. Igci, M. Muslumanoglu, S. Yilmaz, M. Tunaci,H. Camlica, S. Tuzlali, P. Saip, N. Dalay, V. Ozmen, E. TopuzBrd. 20G Role of the type III TGF- receptor in modulating antitumor immunity duringbreast cancer progression. (Abstract #10540)B. A. Hanks, O. M. Campbell, J. D. Lee, M. Morse, T. M. Clay, H. K. Lyerly,G. C. BlobeBrd. 20H Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lungcancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR)mutations. (Abstract #10541)S. Viteri, R. Rosell, C. Costa, M. Taron, J. Sanchez, S. Benlloch, T. Moran,B. Massuti, C. Camps, M. Majem, E. Carcereny, F. Cardenal, A. Gasco,N. Mederos, I. Magri, C. D. Rolfo, M. Garcia-Campelo, A. Gimenez Capitan,I. de Aguirre, C. QueraltBrd. 21A The relationship between the number of aberrantly methylated regions andthe methylation status of p73 and RARB genes and prognosis in patientswith breast cancer. (Abstract #10542)D. M. Marzese, F. Gago, J. I. Orozco, O. M. Tello, L. M. Vargas-Roig, M. RoquéBrd. 21BAn evaluation of molecular imaging with 11 c-PD153035 PET/CT and itsassociation in predicting outcomes in non-small cell lung cancer treated withEGFR-TKI. (Abstract #10543)X. Meng, J. Yu, B. W. Loo, L. Ma, X. Sun, J. D. Murphy, S. Q. Zhao, L. Kong,G. R. Yang, W. L. Li, X. G. Zhao306

Monday, June 6, 2011Brd. 21C A metabolic phenotyping approach to understanding relationships betweenmetabolic syndrome and breast tumor responses to chemotherapy. (Abstract#10544)J. Stebbing, A. Sharma, B. North, T. J. Athersuch, A. Zebrowski, D. Pchejetski,R. C. Coombes, J. K. Nicholson, H. C. KeunBrd. 21D The prognostic role of calretinin expression and neutrophil-to-lymphocyteratio (NLR) in patients with malignant pleural mesothelioma (MPM)undergoing extrapleural pneumonectomy (EPP). (Abstract #10545)S. C. Kao, S. Klebe, D. Henderson, G. Reid, M. D. Chatfield, N. Armstrong, T. Yan,J. L. Vardy, S. J. Clarke, N. Van Zandwijk, B. McCaughanBrd. 21E The relationship of HOXB9 expression promoting tumor cell proliferation andangiogenesis to clinical outcomes of patients with breast cancer. (Abstract#10546)T. Hayashida, H. Jinno, H. Seki, M. Takahashi, M. Sakata, S. Hirose, M. Mukai,Y. KitagawaBrd. 21F Correlation of 18F-FDG uptake and EGFR/KRAS mutations in surgicallyresected lung cancer. (Abstract #10547)K. Takamochi, S. Oh, M. Fukui, K. SuzukiBrd. 21G The potential of circulating microRNA (miRNA) levels as a biomarker in drugdevelopment: An analysis of tumor-serum samples from patients on a phaseI trial of saracatinib-paclitaxel (P)-carboplatin (C). (Abstract #10548)D. S. Tan, S. Aamdal, G. Freyer, R. J. Jones, S. B. Kaye, E. Pujade-Lauraine,J. Fog, M. Wrang Teilum, C. Glue, A. Baker, U. A. Emeribe, P. Elvin, C. Stephens,M. Stuart, J. Walker, E. BovenBrd. 21H Molecular characterization of primary breast cancer in older women usingpartitional clustering and correlation with long-term clinical outcome.(Abstract #10549)B. M. Syed, A. R. Green, D. Soria, E. C. Paish, J. Garibaldi, D. A. Morgan,I. O. Ellis, K. CheungBrd. 22A Single molecule RNA sequencing of formalin-fixed paraffin-embedded tissuederived from lung cancer patients. (Abstract #10550)A. J. Yee, T. Raz, A. Amzallag, D. Lipson, E. Giladi, H. Lopez, D. R. Borger,M. Mino-Kenudson, J. F. Thompson, A. J. Iafrate, P. Milos, D. A. Haber,S. RamaswamyBrd. 22B MicroRNA expression patterns in lobular neoplasia. (Abstract #10551)L. A. Stead, A. Ramnauth, S. Fineberg, O. LoudigBrd. 22C Identification of LASEP3 as a new serological and prognostic biomarker forlung cancer. (Abstract #10552)A. Takano, Y. Nakamura, Y. DaigoBrd. 22D Clinical relevance of circulating CK-19mRNA-positive tumor cells at firstdiagnosis in patients with metastatic breast cancer. (Abstract #10553)N. E. Androulakis, M. Perraki, S. Apostolaki, V. Bozionelou, A. G. Pallis,K. Kalbakis, S. Agelaki, A. Xyrafas, D. Mavroudis, V. GeorgouliasBrd. 22E Differential effect of adjuvant taxane-based and taxane-free chemotherapyregimens on the CK-19 mRNA-positive circulating tumor cells in patientswith early breast cancer. (Abstract #10554)N. Xenidis, M. Perraki, S. Apostolaki, S. Agelaki, K. Kalbakis, N. K. Vardakis,A. Kalykaki, A. Xyrafas, S. Kakolyris, D. Mavroudis, V. GeorgouliasBrd. 22F Microarray-based gene expression profiles reliably predict ELISA-deriveduPA and PAI-1 levels in breast cancer biopsies, a comparison between freshfrozen (FF) and formalin-fixed paraffin-embedded (FFPE) samples. (Abstract#10555)C. Matuschek, H. Prisack, E. Boelke, W. Budach, M. Peiper, M. Rezai, W. Janni,H. BojarMONDAY307

Monday, June 6, 2011MONDAYBrd. 22GBrd. 22HBrd. 23ABrd. 23BBrd. 23CBrd. 23DBrd. 23EBrd. 23FBrd. 23GBrd. 23HBrd. 24ABrd. 24BBrd. 24CThe role of IGF-1R in EGFR TKI resistance in NSCLC using IHC and AQUAtechnology. (Abstract #10556)Y. Kato, C. Mascaux, M. W. Wynes, B. Reyna Asuncion, C. Tran, K. Yoshida,J. Matsubayashi, E. Nakajima, T. Ohira, T. Nagao, K. Furukawa, N. Ikeda,F. R. HirschClinical relevance of mesenchymal stem cell–induced resistance tochemotherapy. (Abstract #10557)J. M. Roodhart, L. G. Daenen, E. C. Stigter, R. H. Medema, A. C. Martens,A. B. Brenkman, E. E. VoestA polymorphism in the coding sequence of WT1 is an independentprognostic marker in 1,101 patients with lobular breast cancer. (Abstract#10558)M. Heuser, F. Damm, P. Schuermann, M. Zucknick, M. Shah, P. Harrington,P. Pharoah, M. Schmidt, A. Broeks, R. van Hien, R. A. Tollenaar, H. Nevanlinna,T. Heikkinen, K. Aittomaki, C. Blomqvist, J. Krauter, P. Hillemanns, A. Ganser,T. Park-Simon, T. DorkThe prognosic value of the downregulation of leukocyte cell–derivedchemotaxin 2 gene of hepatocellular carcinoma. (Abstract #10559)C. Yang, M. Ho, C. Chen, H. Hsu, P. Lee, M. KuoMolecular tumor profiling (MTP) in cancer of unknown primary site (CUP): Acomplement to standard pathologic diagnosis. (Abstract #10560)D. S. Thompson, J. D. Hainsworth, C. M. Lane, W. J. Lennington, D. R. Spigel,F. A. GrecoNon-small cell lung cancer biomarkers: Discovery using mab proteomics.(Abstract #10561)L. Takacs, M. Guergova-Kuras, I. Kurucz, N. Tardieu, J. Kadas,C. Malderez-Bloes, A. Jullien, Y. Kieffer, B. Dezso, B. KargerPerformance characteristics and validation of automated tumor-infiltratinglymphocyte counting. (Abstract #10562)C. C. Hoyt, I. S. Hagemann, A. R. Hagemann, L. Wang, E. Hung, K. Lane,G. Coukos, M. D. FeldmanThymidylate synthase expression in adenosquamous carcinoma of lung.(Abstract #10563)C. Shu, H. Cheng, A. Wang, M. Mansukhani, C. A. Powell, B. Halmos,A. C. BorczukComprehensive next-generation sequencing for clinically actionablemutations from formalin-fixed cancer tissues. (Abstract #10564)J. S. Ross, D. Lipson, R. Yelensky, M. Jarosz, A. Parker, C. E. Sheehan, F. Juhn,Z. Zwirko, K. Brennan, T. Bloom, S. Downing, J. Curran, M. T. CroninModulation of angiogenic biomarkers in patients treated on a phase I studyof TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors.(Abstract #10565)Y. Liu, M. Starr, H. Pang, J. Marcello, B. R. Leigh, C. P. Theuer, H. Hurwitz,A. B. NixonDisparities in the prognostic significance of proliferation amongst differentmolecular subtypes in node-negative breast cancer. (Abstract #10566)M. Schmidt, I. Petry, D. Boehm, A. Lebrecht, S. Gebhard, H. Koelbl, M. Gehrmann,J. G. HengstlerSmgGDS splice variants: Potential novel targets for breast cancertherapeutics. (Abstract #10567)C. Bergom, A. Hauser, E. L. Lorimer, R. Li, A. C. Mackinnon, C. L. WilliamsDiscovery of oncoproteins as cancer biomarkers and molecular targets forantibody-based immunotherapy. (Abstract #10568)Y. Daigo, A. Takano, Y. Nakamura308

Monday, June 6, 2011Brd. 24EBrd. 24FBrd. 24GBrd. 24HBrd. 25BBrd. 25CBrd. 26ABrd. 26BBrd. 26CBrd. 27ABrd. 27BExonic expression variations of EGFR and KRAS in small bronchoscopicbiopsies from patients with advanced non-small cell lung cancer treated bycombined bevacizumab/erlotinib therapy followed by platinum-basedchemotherapy at disease progression: A multicenter phase II trialSAKK19/05. (Abstract #10570)M. H. Brutsche, M. Frueh, S. Crowe, K. Na, C. Droege, D. C. Betticher,R. von Moos, F. Zappa, M. Pless, L. Bubendorf, F. Baty, on behalf of the SwissGroup for Clinical Cancer Research (SAKK)An integrated analysis of three distinct IBC/non-IBC affymetrix geneexpression data sets to study the transcriptional heterogeneity both betweenIBC and non-IBC and within IBC. (Abstract #10571)S. J. Van Laere, N. T. Ueno, P. Finetti, P. B. Vermeulen, A. Lucci Jr., D. Birnbaum,F. Robertson, T. Iwamoto, P. A. van Dam, W. A. Woodward, P. Viens, L. Y. Dirix,J. M. Reuben, F. BertucciCirculating tumor cell (CTC) as a clinical marker in malignant pleuralmesothelioma (MPM). (Abstract #10572)F. Tanaka, K. Yoneda, N. Kondo, M. Hashimoto, T. Takuwa, S. Matsumoto,S. Hasegawa, Y. Okumura, T. Tsujimura, K. Fukuoka, T. NakanoPathway analysis of primary human non-small cell lung cancer (NSCLC).(Abstract #10573)N. Daraselia, Y. Wang, A. Budoff, A. Lituev, O. Potapova, J. Monforte,V. OssovskayaA second generation microRNA-based assay for diagnosing tumor tissueorigin. (Abstract #10575)R. T. Aharonov, S. Rosenwald, T. B. Edmonston, I. Barshack, M. Feinmesser,M. Huszar, W. C. Mueller, F. Fogt, H. Shomin, L. Cohen, I. Burnstein, E. Goren,B. St. Cyr, Y. Spector, N. Dromi, E. MeiriNY-ESO-1 as a predictive marker for neoadjuvant chemotherapy in stage IIIanon-small cell lung cancer (NSCLC). (Abstract #10576)T. John, Y. Chen, M. H. Starmans, M. Walkiewicz, P. Russell, A. Azad, S. Deb,N. K. Altorki, P. C. Boutros, P. Mitchell, J. S. CebonCirculating endothelial cell (CEC), a surrogate of tumor angiogenesis, as adiagnostic and prognostic marker in malignant pleural mesothelioma (MPM).(Abstract #10577)K. Yoneda, F. Tanaka, N. Kondo, H. Orui, M. Hashimoto, T. Takuwa,S. Matsumoto, Y. Okumura, A. Sato, T. Tsujimura, N. Tsubota, K. Kuribayashi,K. Fukuoka, T. Nakano, S. HasegawaA microRNA-based diagnostic test for kidney tumor classification. (Abstract#10578)A. Chajut, E. Fridman, I. Barshack, Z. A. Dotan, M. Zepeniuk, S. Tabak,D. Lebanony, E. Klinke, S. Rosenwald, O. Zion, A. Faerman, M. Ben-David,A. Bokish, Y. SpectorUse of immunohistochemical evaluation of DNA repair proteins todemonstrate cisplatin response prediction in resected NSCLC squamous cellcarcinoma. (Abstract #10579)W. E. Pierceall, K. M. Sprott, E. Brambilla, R. Pirker, H. H. Popper, X. Wang,Y. Chen, S. Quan, M. Filipits, L. Alaparthi, J. Kutok, D. T. Weaver, M. Al-Adhami,F. Andre, T. Le Chevalier, B. E. Ward, J. SoriaMYC and human telomerase gene (TERC) gene copy number gain in resectedin non-small cell lung cancer (NSCLC). (Abstract #10580)A. Flacco, V. Ludovini, F. R. Tofanetti, F. Bianconi, G. Bellezza, M. G. Mameli,G. Metro, C. Bennati, L. Cagini, N. Daddi, L. Pistola, A. Siggillino, E. Baldelli,A. Sidoni, F. Puma, M. Varella-Garcia, L. CrinòA novel inflammatory-based prognostic score in hepatocellular carcinoma.(Abstract #10581)D. J. Pinato, H. S. Wasan, L. Maslen, B. North, R. SharmaMONDAY309

Monday, June 6, 2011MONDAYBrd. 27C Disseminated tumor cells in the bone marrow of ductal carcinoma in situpatients. (Abstract #10582)N. Sänger, K. E. Effenberger, S. Riethdorf, E. Ruckhäberle, L. C. Hanker,I. Wiegratz, K. Strebhardt, K. Pantel, M. KaufmannBrd. 28A SOX2-related micrornas, miR-145 and miR-367, as prognostic markers oftime to recurrence (TTR) in surgically resected non-small cell lung cancer(NSCLC) patients (p). (Abstract #10583)A. Navarro, M. Campayo, N. Vinolas, V. Ciria, T. Diaz, R. M. Marrades, L. Molins,J. Ramirez, M. MonzoBrd. 28B Evaluation of anti-CTLA4 treatment in a murine model of intestinal polyposis.(Abstract #10584)J. D. Phillips, N. R. Blatner, M. F. Mulcahy, P. Beckhove, D. J. Bentrem, K. KhazaieBrd. 28C ALK chromosomal alterations in neuroendocrine tumors. (Abstract #10585)C. Montagut, E. Arriola, A. B. Galvan, F. G. Rojo, M. Salido, M. Gallen, M. Garcia,A. Martinez, F. Pons, S. Servitja, M. Iglesias, S. Menendez, S. Serrano, F. Sole,A. Rovira, J. Albanell, J. BellmuntBrd. 29A Correlation of high levels of immature blood vessels in colorectal tumorswith longer survival following bevacizumab treatment. (Abstract #10586)S. Noonan, P. Martin, M. Biniecka, A. Maguire, M. Tosetto, J. Hyland, K. Sheahan,D. O’Donoghue, H. Mulcahy, D. Fennelly, J. O’SullivanBrd. 29B A single nucleotide polymorphism (SNP) in a microRNA (miRNA)-binding siteof KRT81 and time to recurrence (TTR) in patients (p) with surgically resectednon-small cell lung cancer (NSCLC). (Abstract #10587)M. Campayo, A. Navarro, N. Vinolas, R. Tejero, C. Munoz, T. Diaz, R. M. Marrades,M. L. Cabanas, J. M. Gimferrer, J. Ramirez, P. Gascon, M. MonzoBrd. 29C Gastrin-releasing peptide receptor expression in Brazilian and Japanesepatients with lung cancer and normal lung tissue samples from healthyindividuals. (Abstract #10588)J. Mattei, Y. Kato, M. W. Wynes, C. Cano, R. D. Achcar, B. Reyna Asuncion,B. R. de Macedo, L. Meurer, J. Kulczynski, R. Roesler, K. Yoshida,J. Matsubayashi, T. Ohira, T. Nagao, K. Furukawa, N. Ikeda, A. Brunetto,G. SchwartsmannBrd. 30A Prognostic value of CA27.29 trend during adjuvant chemotherapy and until 2years thereafter in patients with primary breast cancer. (Abstract #10589)B. K. Rack, P. G. Hepp, U. Andergassen, J. K. Neugebauer, J. Salmen,G. Heinrich, J. Schreier, A. Hoenig, D. Finas, T. Zwingers, R. Kreienberg,M. W. Beckmann, W. Lichtenegger, H. L. Sommer, K. Friese, W. Janni, SUCCESSStudy GroupBrd. 30B Body mass index (BMI) and DNA mismatch repair status in colon cancersfrom patients treated in adjuvant therapy trials. (Abstract #10590)N. R. Foster, F. Sinicrope, G. A. Yothers, C. J. Allegra, D. J. SargentBrd. 30C Reactivation of oncogene-induced senescence in KRAS mutant non-smallcell lung cancer by inhibition of TWIST1. (Abstract #10591)T. F. Burns, I. Dobromilskaya, S. Murphy, S. Thiyagarajan, S. Das, P. T. Tran,C. M. RudinBrd. 31A Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjectswith metastatic breast cancer (MBC). (Abstract #10592)M. C. Liu, M. Mego, S. Nakamura, F. Nole, J. Pierga, M. Toi, E. Munzone,H. Yagata, M. T. Sandri, F. Bidard, H. Wang, D. F. Hayes, M. CristofanilliBrd. 31B Computer-aided volumetry analysis in assessing pulmonary chemotherapyresponse in advanced NSCLC comparing with RECIST criteria. (Abstract#10593)L. Ding, R. L. Bliss, M. Ingebrand, T. Allen, P. Ives, A. Dudek, R. A. Kratzke310

Monday, June 6, 2011Brd. 31C Prospective comparison of recurrence score, uPA/PAI-1, central grade andmolecular classification in early breast cancer: Interim results from theWSG-Plan B trial. (Abstract #10594)T. Degenhardt, O. Gluz, H. H. Kreipe, R. E. Kates, C. Liedtke, S. Shak,M. R. Clemens, D. Augustin, U. Nitz, N. Harbeck, on behalf of the Plan BinvestigatorsBrd. 31D Association of the MDM2 T309G polymorphism and gastroesophageal refluxdisease (GERD) with overall survival (OS) in esophageal adenocarcinoma(EAC). (Abstract #10595)D. J. Renouf, B. Sun, R. Zhai, W. Xu, R. S. Heist, M. Kulke, L. Su, D. C. Christiani,G. LiuBrd. 31E Molecular and clinicopathologic characteristics of HER2-mutant lungadenocarcinoma (ADC). (Abstract #10596)M. E. Arcila, J. E. Chaft, K. Nafa, M. G. Kris, M. F. Zakowski, M. LadanyiBrd. 31F PAM50 breast cancer intrinsic classifier: Clinical validation of a multianalytelaboratory developed test. (Abstract #10597)M. T. Ebbert, R. R. Bastien, L. R. Rowe, P. A. Miller, D. Anderson, K. M. Boucher,L. M. Pappas, C. Fauron, B. W. Lyons, T. Dowell, D. E. Wall, L. Barley,P. S. BernardBrd. 31G Activation of the mTOR pathway in primary medullary thyroid carcinoma andlymph node metastases. (Abstract #10598)A. Tamburrino, A. A. Molinolo, P. Salerno, R. Chernock, M. Raffeld, L. Xi,J. S. Gutkind, J. F. Moley, S. A. Wells, M. SantoroBrd. 31H Molecular predictors of metastases and stage of thymoma. (Abstract #10599)S. S. Badve, C. Goswami, Y. Gokmen-Polar, R. P. Nelson Jr., J. Henley, N. Miller,R. K. Jain, R. J. Mehta, N. A. Zaheer, G. W. Sledge Jr., L. Li, K. Kesler,P. J. LoehrerBrd. 32A Expression of Adam28 as a prognostic biomarker of survival in patients withearly-stage non-small cell lung cancer. (Abstract #10600)Y. Zhang, X. Zhang, Y. Wu, G. Zhang, H. Cheng, S. DongBrd. 32B An analysis of serum heparan sulfate concentration and EGFR tyrosinekinase inhibitor treatment in patients with non-small cell lungadenocarcinoma. (Abstract #10601)M. Nishio, T. Yamanaka, K. Matsumoto, H. Kimura, K. Sakai, A. Sakai, T. Sone,A. Horiike, F. Koizumi, K. Kasahara, T. Ohira, N. Ikeda, N. Saijo, T. Arao, K. NishioBrd. 32C Signatures of drug sensitivity in non-small cell lung cancer. (Abstract#10602)H. Gong, D. G. Beer, S. SinghBrd. 32D Elucidating the biological basis of prognosis in young women with earlybreast cancer (BC) using gene expression profiling. (Abstract #10603)H. A. Azim, S. Michels, P. Bedard, D. Fumagalli, S. K. Singhal, B. Haibe-Kains,M. Piccart, C. Sotiriou, S. LoiBrd. 32E A mouse model of rectal cancer that mimics the clinical disease. (Abstract#10604)H. Kishimoto, M. Momiyama, R. Aki, H. Kimura, A. Suetsugu, M. Bouvet,T. Fujiwara, R. M. HoffmanBrd. 32F MicroRNA analysis as a potential diagnostic tool in the cytological diagnosisof non-small cell lung cancer. (Abstract #10605)A. Fassina, R. Cappellesso, A. Olivotto, M. FassanBrd. 32G TGF1 gene polymorphisms with the risk of radiation pneumonitis in nonsmallcell lung cancer in different ethnic study. (Abstract #10606)X. Niu, S. Lu, H. Li, Y. Liu, Z. Chen, D. Zhou, M. Kan, Z. Li, Y. Yu, C. LVBrd. 32H Functional metabolic tomographic optical breast imaging (TOBI) to monitorresponse to neoadjuvant therapy in breast cancer. (Abstract #10607)S. Carp, C. Wanyo, M. Specht, L. Schapira, B. Moy, D. Finkelstein, D. Boas,S. J. IsakoffMONDAY311

Monday, June 6, 2011MONDAYBrd. 33ABrd. 33BBrd. 33CBrd. 33DBrd. 33EBrd. 33FBrd. 33GBrd. 33HBrd. 34ABrd. 34BBrd. 34CDiagnostic and therapeutic significance of the cerebrospinal fluid (CSF)EGFR mutation analysis for the patients with NSCLC suffering meningitiscarcinomatosa harboring active EGFR mutation, after gefitinib therapyfailure. (Abstract #10608)S. Sasaki, Y. Yoshioka, R. Ko, Y. Katsura, Y. Namba, K. Koike, M. Yoshioka,S. TominagaKRAS and BRAF mutation analysis on paired biopsy and resectionspecimens of patients with colorectal cancer: Molecular analysis usinghigh-resolution melting, direct sequencing, KRAS ARMS-scorpion PCR andBRAF pyrosequencing. (Abstract #10609)L. C. Krol, N. A. Hart, N. Methorst, A. J. Knol, C. Prinsen, J. E. BoersAn evaluation of bone marrow stromal-derived growth factor-1 andinterleukin-8 levels in stage I-III breast cancer patients with disseminatedtumor cells. (Abstract #10610)C. Hall, S. Krishnamurthy, A. Lodhi, A. Bhattacharyya, A. Anderson, H. M. Kuerer,I. Bedrosian, A. Lucci Jr.Circulating levels of RANK/RANKL and OPG in patients with bone metastasistreated with zoledronic acid: A prospective study. (Abstract #10611)T. Ibrahim, L. Mercatali, E. Sacanna, R. Ricci, E. Scarpi, P. Serra, F. Fabbri,C. Tison, D. AmadoriDifferential efficacy of pemetrexed in non-squamous NSCLC based onhuman cytokeratin fragment antigen 21-1 (CYFRA21–1) serum levels.(Abstract #10612)K. Kaburaki, A. Horiike, T. Sakatani, R. Saito, H. Tanaka, N. Yanagitani, K. Kudo,F. Ohyanagi, S. Hagiwara, T. Horai, M. NishioCombined use of MammaPrint and molecular subtyping profile (BluePrint) toidentify subgroups with marked differences in response to neoadjuvanttreatment. (Abstract #10613)F. De Snoo, P. Roepman, O. Krijgsman, R. A. Bender, R. Bernards, A. GlasA miRNA assay for the classification of benign and neoplastic lesions inpancreatic fine needle aspirates. (Abstract #10614)A. E. Schwarzbach, A. Adai, M. Lloyd, B. F. AndrussCollecting tissue for research purposes: A survey of 16 institutions in theTranslational Breast Cancer Research Consortium (TBCRC). (Abstract#10615)E. S. Frank, R. T. Burns, N. E. Carbine, L. Cargen, C. Chauhan, D. K. Cline,R. Kleban, S. A. Mertz, A. H. Meyn, J. Perlmutter, C. A. Rufenbarger, M. Smith,P. A. Spears, L. V. Vincent, A. C. WolffUse of the DEPArray platform to detect, isolate, and molecularly characterizepure tumor cells from peripheral blood samples enriched using theCellSearch system. (Abstract #10616)G. Medoro, S. Gross, N. Manaresi, M. Sergio, F. Fontana, S. Gianni, A. Calanca,E. Peruzzi, M. Banzi, G. Signorini, C. Rao, J. Patel, J. Karkera, G. Giorgini,M. Mata, M. C. ConnellyThe prognostic impact of circulating tumor cells in patients with small celllung cancer. (Abstract #10617)T. Naito, F. Tanaka, K. Yoneda, T. Takahashi, H. Murakami, Y. Nakamura,A. Tsuya, M. Endo, H. Kenmotsu, K. Kaira, T. Shukuya, A. Ono, H. Akamatsu,S. Miura, M. Kimura, N. YamamotoSignificance of FANCJ expression as a predictive marker of sensitivity to5-fluorouracil in colorectal cancer. (Abstract #10618)R. Nakanishi, H. Kitao, N. Yamashita, N. Kubo, Y. Fujinaka, M. Iimori, E. Oki,M. Morita, Y. Kakeji, Y. Maehara312

Monday, June 6, 2011Brd. 34D Implications of specific T-cell responses by different novel and knownimmunogenic tumor-associated antigens (TAA) in patients with metastaticlung cancer. (Abstract #10619)A. M. Babiak, M. Steinhauser, S. Hofmann, J. Conzelmann, V. Schneider,M. Goetz, L. Zhang, H. Dohner, J. GreinerBrd. 34E Influence of KRAS status of colorectal cancer liver metastases in patientsreceiving neoadjuvant chemotherapy including bevacizumab prior liverresection. (Abstract #10620)S. Stremitzer, J. Maresch, T. Aschacher, B. Wolf, F. Wrba, T. Gruenberger,B. GruenbergerBrd. 34F Intravital evaluation of time-course efficacy of anticancer drugs on colorectalliver metastases in the same living mice using two-photon laser scanningmicroscopy. (Abstract #10621)K. Tanaka, Y. Morimoto, Y. Toiyama, S. Saigusa, Y. Okugawa, Y. Inoue,K. Uchida, K. Matsushita, M. Kawamura, A. Mizoguchi, M. KusunokiBrd. 34G Clinical, biological, and pathological features predicting non-sentinel lymphnode (NSLN) status in breast cancer (BC). (Abstract #10622)J. Furlanetto, E. Fiorio, G. Pollini, Z. Franchini, P. Pietrarota, Q. Piubello,F. Bonetti, R. Micciolo, E. Manfrin, G. L. Cetto, A. MolinoBrd. 34H Prognostic role of interleukin-1B and interleukin-1-receptor antagonistpolymorphisms in localized gastric cancer. (Abstract #10623)E. Goekkurt, G. Folprecht, S. Lehmann, L. Obermann, M. Kramer, A. Rentsch,S. Wilop, G. Ehninger, T. H. Brummendorf, J. Stoehlmacher-WilliamsBrd. 35A Effect of everolimus treatment on chromogranin A, neuron-specific enolase,gastrin, and glucagon levels in patients with advanced pancreaticneuroendocrine tumors (pNET): Phase III RADIANT-3 study results. (Abstract#10624)E. De Vries, L. B. Anthony, L. Sideris, L. Chen, J. Lebrec, Z. Tsuchihashi,R. E. Winkler, J. C. Yao, K. E. ObergBrd. 35B Comparison of predictive and prognostic impact of molecular subtypes andcentral grade regarding taxane-based therapy in intermediate-risk breastcancer: Results from the EC-Doc trial. (Abstract #10625)U. Nitz, O. Gluz, C. Liedtke, J. B. Huober, A. Hartmann, R. E. Kates, H. H. Kreipe,E. Pelz, W. Kuhn, N. Harbeck, on behalf of the EC-Doc investigators (WestGerman Study Group/AGO-B)Brd. 35C Correlation of CA 27.29 and circulating tumor cells before, at the end, and 2years after adjuvant chemotherapy in patients with primary breast cancer:The SUCCESS trial. (Abstract #10626)P. G. Hepp, B. K. Rack, H. Tesch, M. Rezai, T. Beck, J. Salmen, U. Andergassen,U. Ortmann, T. Zwingers, M. W. Beckmann, W. Lichtenegger, J. W. Janni,SUCCESS Study GroupBrd. 35D Determining argininosuccinate synthetase (ASS) expression in melanomapatients treated with arginine depleting therapy. (Abstract #10627)V. Dinh, M. You, N. Savaraj, C. Wu, M. T. Kuo, M. Wangpaichitr, L. G. FeunBrd. 35E Pathoepidemiological patterns of contralateral breast cancers in Black andWhite women. (Abstract #10628)H. Nsouli-Maktabi, A. M. Schwartz, S. D. Cleary, N. Younes, H. A. Young,D. E. HensonBrd. 35F Thymidilate synthase gene copy number as predictive marker ofcapecitabine efficacy in patients with breast cancer. (Abstract #10629)R. Audet, R. Duchnowska, K. Adamowicz, J. Zok, W. Rogowski, M. M. Litwiniuk,S. Debska, M. Jaworska, M. Foszczynska-Kloda, M. Kulma-Kreft, K. Zabkowska,C. Shen, S. Edgerton, K. V. Nielsen, A. D. Thor, J. C. Chang, K. Miller, J. Jassem,G. W. Sledge Jr., B. Leyland-JonesBrd. 35G Biomarkers affecting metastasis and survival in paired tissues of 107patients with metastatic breast cancer. (Abstract #10630)E. Kim, H. Lee, G. Gong, K. Jung, J. Ahn, B. Son, S. Ahn, H. Kim, S. KimMONDAY313

Monday, June 6, 2011Brd. 35HBrd. 36ARedefining CTCs: Detection of additional circulating tumor cells using anantibody capture cocktail and HER2 FISH. (Abstract #10631)F. Z. Bischoff, T. J. Pircher, T. Pham, K. Wong, S. Mikolajczyk, P. Cotter,J. A. MayerProof of concept of immuno-PET molecular imaging of met using 76 Br- and89 Zr-labeled MetMAb. (Abstract #10632)M. Merchant, J. Marik, J. Peng, S. P. Williams, A. Ogasawara, J. N. Tinianow,V. Bhadrasetty, L. Lang, S. M. Lee, I. Kim, M. Williams, L. Szajek,K. E. Raffensperger, F. Cecchi, E. Jagoda, P. L. Choyke, C. Paik, D. P. BottaroMONDAY314

Monday, June 6, 20118:00 AM - 12:00 PMTRIALS IN PROGRESS POSTER SESSIONTrials in Progress Poster SessionLocation: Hall ATrack(s): Clinical Trials; Special SessionBrd. 36B A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK)4/6 inhibitor, in combination with letrozole for first-line treatment of patientswith postmenopausal, estrogen receptor (ER)-positive, human epidermalgrowth factor receptor 2 (HER2)-negative advanced breast cancer. (Abstract#TPS100)R. S. Finn, K. Boer, I. Lang, R. J. Parikh, R. Patel, M. Schmidt, C. T. Hagenstad,H. J. Lim, T. Pinter, D. Amadori, D. Chan, R. Dichmann, S. T. Kim,S. Randolph, D. J. Slamon, J. P. CrownBrd. 36C Incorporating comparative effectiveness research study endpoints into thetreatment for positive-node, endocrine-responsive breast cancer(RxPONDER) study. (Abstract #TPS101)S. D. Ramsey, W. E. Barlow, C. Moinpour, A. M. Gonzalez-Angulo,G. N. Hortobagyi, D. L. Veenstra, L. P. Garrison, S. R. Tunis, L. H. BakerBrd. 36D MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) withor without pertuzumab (P) compared with trastuzumab (H) plus taxane forfirst-line treatment of HER2-positive, progressive, or recurrent locallyadvanced or metastatic breast cancer (MBC). (Abstract #TPS102)P. A. Ellis, C. H. Barrios, Y. Im, M. Patre, F. Branle, E. A. PerezBrd. 36E A phase III randomized trial of metformin versus placebo on recurrence andsurvival in early-stage breast cancer (BC; NCIC Clinical Trials Group MA.32).(Abstract #TPS103)W. Parulekar, B. E. Chen, C. Elliott, L. E. Shepherd, K. A. Gelmon, K. I. Pritchard,T. J. Whelan, J. A. Ligibel, D. L. Hershman, I. A. Mayer, T. J. Hobday, P. Rastogi,J. Lemieux, P. A. Ganz, V. Stambolic, P. J. GoodwinBrd. 36F SWOG S1007: A phase III, randomized clinical trial of standard adjuvantendocrine therapy with or without chemotherapy in patients with one to threepositive nodes, hormone receptor (HR)-positive, and HER2-negative breastcancer with recurrence score (RS) of 25 or less. (Abstract #TPS104)A. M. Gonzalez-Angulo, W. E. Barlow, J. Gralow, F. Meric-Bernstam, D. F. Hayes,C. Moinpour, S. D. Ramsey, A. F. Schott, D. B. Sparks, K. S. Albain,G. N. HortobagyiBrd. 36G Ongoing clinical development of lapatinib in HER2-positive (HER2)metastatic breast cancer (MBC): An innovative approach to recruit patients inclinical studies. (Abstract #TPS105)S. R. Johnston, K. A. Gelmon, X. B. Pivot, W. J. Gradishar, A. Conner, D. Kothari,P. Legenne, M. Leigh, L. O’Rourke, R. ParikhBrd. 36H A phase I dose-escalation study of ABT-888 (veliparib) in combination withcarboplatin in HER2-negative metastatic breast cancer (MBC). (Abstract#TPS106)S. Viswanathan, R. Wesolowski, R. M. Layman, G. Alejandra, B. Miller,J. J. Chalmers, S. Bejastani, W. Zhao, G. Pierluigu, J. Cotrill, M. A. Phelps,L. J. Schaaf, S. M. Geyer, N. Hall, M. V. Knopp, C. L. Shapiro,M. A. Villalona-Calero, A. Chen, M. R. Grever, B. RamaswamyBrd. 37A An open-label positron emission tomography (PET) study to investigate andquantify brain and tumor penetration of carbon-11 labeled lapatinib inpatients with HER2-overexpressing (HER2) advanced or metastatic breastcancer (MBC). (Abstract #TPS107)R. C. Coombes, J. A. Reise, M. Lau, S. C. Carme, G. E. Searle, M. Huiban,P. Burgess, K. Koch, A. Das-Gupta, A. SaleemMONDAY315

Monday, June 6, 2011MONDAYBrd. 37BBrd. 37CBrd. 37DBrd. 37EBrd. 37FBrd. 37GBrd. 37HBrd. 38ABrd. 38BBrd. 38CPhase III study of taxane chemotherapy with lapatinib or trastuzumab asfirst-line therapy for women with HER2/neu-positive metastatic breast cancer(BC) (NCIC Clinical Trials Group (NCICCTG )MA.31/GSK EGF 108919).(Abstract #TPS108)W. Parulekar, J. W. Chapman, S. Aparicio, Y. Murray, F. M. Boyle, A. Di Leo,B. Kaufman, C. Levy, A. Manikhas, M. Martin, K. I. Pritchard, L. S. Schwartzberg,M. J. Burnell, S. Dent, S. Ellard, K. S. Tonkin, T. J. Whelan, J. Lemieux,L. Bordeleau, K. A. GelmonSafety and efficacy of single-agent adjuvant trastzumab in older women withbreast cancer. (Abstract #TPS109)C. Owusu, H. D. Klepin, G. G. Kimmick, L. Sutton, A. BrufskyA phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) inestrogen receptor-positive (ER) breast cancer. (Abstract #TPS110)S. Ebbinghaus, J. L. Blum, J. Cortes, H. S. Rugo, C. Swanton, L. Eaton, Y. Song,T. Zhang, J. BaselgaPhase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or withoutletrozole in aromatase inhibitor-resistant breast cancer. (Abstract #TPS111)P. Haluska, A. Dhar, X. Hou, F. Huang, D. S. Nuyten, J. Park, A. H. Brodie,J. N. Ingle, J. M. Carboni, M. M. Gottardis, A. C. Wolff, F. G. FinckensteinA randomized, double-blind phase II trial of exemestane with or withoutMM-121 in postmenopausal women with locally advanced or metastaticestrogen receptor-positive (ER) and/or progesterone receptor-positive(PR), HER2-negative breast cancer. (Abstract #TPS112)V. M. Moyo, M. J. Higgins, R. Aravelo-Araujo, N. Iannotti, V. Charu, N. Dhindsa,P. E. GossHER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515). (Abstract #TPS113)N. U. Lin, M. A. Danso, A. K. David, J. J. Muscato, C. E. Ellis, S. Lahiri,T. Sessa, Y. M. Nagarwala, E. WinerRandomized, double-blind, placebo-controlled phase II trial of low-dosemetronomic cyclophosphamide alone or in combination with veliparib(ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neunegativemetastatic breast cancer: New York Cancer Consortium trial P8853.(Abstract #TPS114)E. Andreopoulou, A. P. Chen, J. Zujewski, M. Kim, D. L. Hershman, K. Kalinsky,T. Cigler, L. T. Vahdat, G. Raptis, B. Ramaswamy, Y. Novik, F. Muggia,J. A. SparanoA phase III, multicenter, double-blind, randomized trial of celecoxib versusplacebo in primary breast cancer patients: Randomized European CelecoxibTrial (REACT). (Abstract #TPS115)R. C. Coombes, G. Von Minckwitz, J. Hicks, P. Klare, A. A. Evans, M. Schmidt,A. Makris, R. Grieve, S. Loibl, L. Maher, K. Mousa, K. Buchsenscuhtz, R. A’Hern,J. M. BlissEMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1(T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients withHER2-positive locally advanced or metastatic breast cancer (MBC) andpreviously treated with a trastuzumab-based regimen. (Abstract #TPS116)S. Verma, V. Dieras, L. Gianni, D. Miles, M. Welslau, M. D. Pegram, J. Baselga,E. Guardino, L. Fang, C. M. Linehan, K. L. BlackwellTrial of perioperative endocrine therapy: Individualizing care (POETIC).(Abstract #TPS117)I. E. Smith, L. Johnson, M. Dowsett, J. F. Robertson, L. E. Robison, J. S. Kokan,A. A. Evans, C. Holcombe, K. Horgan, A. Skene, R. Prasad, M. S. Absar, R. Vidya,N. J. Bundred, C. Harding-Mackean, D. A. Wheatley, M. W. Kissin, I. F. Pinhel,L. S. Kilburn, J. M. Bliss, on behalf of the POETIC Trialists316

Monday, June 6, 2011Brd. 38DBrd. 38EBrd. 38FBrd. 38GBrd. 38HBrd. 39ABrd. 39BBrd. 39CBrd. 39DBrd. 39ETrastuzumab plus capecitabine with or without pertuzumab in patients withHER2-positive MBC whose disease has progressed during or followingtrastuzumab-based therapy for first-line metastatic disease: A multicenter,randomized, two-arm, phase II study (PHEREXA). (Abstract #TPS118)M. Munoz-Mateu, A. Urruticoechea, R. Separovic, J. Erfán, T. D. Bachelot,J. Canon, N. Kovalenko, E. Staroslawska, B. Pikó, C. Veyret, O. Pribylova,D. L. Ciule, J. Ratnayake, S. Das, K. Mayne, G. RossA phase I/II study of MM-111, a novel bispecific antibody that targets theErB2/ErB3 heterodimer, in combination with trastuzumab in advancedrefractory HER2-positive breast cancer. (Abstract #TPS119)M. J. Higgins, N. Y. Gabrail, K. Miller, S. V. Agresta, S. Sharma, C. McDonagh,J. Murray, K. Andreas, S. Frye, V. M. Moyo, C. Niyikiza, P. D. RyanA randomized trial assessing the use of electro-acupuncture for aromataseinhibitor-induced arthralgia. (Abstract #TPS120)J. M. Beith, E. Segelov, K. Orme, A. McLean, B. OhSerum NT pro-BNP and individual genetic polymorphisms as predictors oftrastuzumab-related cardiotoxicity. (Abstract #TPS121)S. Goel, J. Lynch, L. A. Chantrill, J. J. Rutovitz, B. Murray, E. A. Abdi, R. Bell,A. L. Sullivan, A. Goldrick, T. M. Hayes, G. Asghari, N. Wilcken, N. J. McCarthy,J. M. BeithTBCRC 011: Targeting the androgen receptor (AR) for the treatment ofAR/ER-/PR- metastatic breast cancer (MBC). (Abstract #TPS122)A. Gucalp, S. M. Tolaney, S. J. Isakoff, J. N. Ingle, M. C. Liu, L. A. Carey,K. L. Blackwell, H. S. Rugo, L. Nabell, A. Abbruzzi, J. Gonzalez, D. D. Giri, S. Patil,K. Feigin, G. D’Andrea, M. Theodoulou, P. Drullinsky, N. T. Sklarin, C. Hudis,T. A. Traina, Translational Breast Cancer Research ConsortiumTesetaxel, an advanced-generation oral taxane, as first-line treatment inwomen with metastatic breast cancer. (Abstract #TPS123)L. S. Schwartzberg, M. Beeram, A. Patnaik, A. W. Tolcher, L. Itri, A. L. Olson,A. D. SeidmanDesign of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) incombination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locallyadvanced (adv) or metastatic HER2-negative breast cancer (BC). (Abstract#TPS124)J. Baselga, L. S. Schwartzberg, O. Petrenciuc, M. Shan, W. J. GradisharACRIN 6688 phase II study of fluorine-18 3-deoxy-3 fluorothymidine (FLT) ininvasive breast cancer. (Abstract #TPS125)P. R. Jolles, L. Kostakoglu, H. D. Bear, M. O. Idowu, K. A. Kurdziel, L. Shankar,D. A. Mankoff, F. Duan, D. L’HeureuxANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy ofTamoxifen—A single-arm, phase II study of the efficacy of tamoxifen intriple-negative but oestrogen receptor beta-positive metastatic breastcancer. (Abstract #TPS126)B. E. Kiely, K. Phillips, P. A. Francis, F. M. Boyle, J. F. Forbes, S. B. Fox,L. Murphy, V. Gebski, D. F. Lindsay, R. L. Sutherland, H. BadgerTBCRC 018: Phase II study of iniparib plus chemotherapy to treat triplenegativebreast cancer (TNBC) brain metastases (BM). (Abstract #TPS127)C. K. Anders, R. Nanda, M. C. Liu, K. L. Blackwell, C. H. Van Poznak,V. G. Abramson, A. M. Storniolo, N. U. Lin, V. Stearns, A. Melhem, S. Puhalla,J. T. Carpenter, M. E. Melisko, A. M. Deal, C. Hudis, E. P. Winer, C. M. Perou,C. R. Bradley, A. C. Wolff, L. A. Carey, Translational Breast Cancer ResearchConsortiumMONDAY317

Monday, June 6, 2011MONDAYBrd. 39FBrd. 39GBrd. 39HBrd. 40ABrd. 40BBrd. 40CBrd. 40DBrd. 40EBrd. 40FBrd. 40GTBCRC 019: An open-label, randomized, phase II trial of nanoparticlealbumin-bound paclitaxel with or without the anti-death receptor 5 (DR5)monoclonal antibody tigatuzumab in patients with metastatic, triple-negative(ER, PR, and HER2-negative) breast cancer. (Abstract #TPS128)A. Forero-Torres, N. U. Lin, M. C. Liu, H. S. Rugo, S. Puhalla, R. Nanda,I. A. Mayer, A. M. Storniolo, T. A. Traina, D. F. Hayes, M. F. Rimawi, M. P. Goetz,F. J. Esteva, W. J. Irvin Jr., A. C. Wolff, on behalf of the Translational BreastCancer Research ConsortiumAn observational study using -H2AX foci to investigate cardiac doses ofradiation following adjuvant radiotherapy for breast cancer: Standardexternal beam radiotherapy to the breast versus intraoperative radiotherapy.(Abstract #TPS129)D. Woolf, R. Bakhshi, S. Fawcitt, M. Worku, D. B. Ghosh, S. Sivabalasingham,N. R. Williams, S. Short, K. Pigott, M. R. KeshtgarPARP inhibition after preoperative chemotherapy in patients with triplenegativebreast cancer (TNBC) or known BRCA1/2 mutations: HoosierOncology Group BRE09-146. (Abstract #TPS130)S. R. Malireddy, S. M. Perkins, S. S. Badve, G. W. Sledge Jr., K. MillerPhase III randomized French multicentric study to evaluate the impact of alocalized 16-Gy boost after conservative surgery and a 50-Gy whole-breastirradiation in breast ductal carcinoma in situ (the BONBIS trial). (Abstract#TPS131)D. Azria, D. Cowen, C. Bourgier, B. de la Lande, S. Gourgou-Bourgade,Z. Douadi Gaci, M. Leblanc-Onfroy, I. Latorzeff, O. Pradier, P. Maingon,I. Lecouillard, P. Bontemps, S. Ellis, C. Levy, A. Benyoucef, S. Racadot,H. Laharie-Mineur, P. Lagarde, C. Marchal, C. LemanskiA phase IIa clinical biomarker trial of aspirin and dietary arginine restrictionin colorectal cancer patients. (Abstract #TPS132)J. A. Zell, C. E. McLaren, C. G. Albers, E. W. Gerner, L. B. Wenzel, F. L. MeyskensRadiotherapy (RT), temozolomide (TMZ), procarbazine (PCB) and the integrininhibitor cilengitide in patients with glioblastoma (GBM) without methylationof the MGMT gene promoter (ExCentric). (Abstract #TPS133^)M. Khasraw, S. McCowatt, Z. Kerestes, M. E. Buyse, M. Back, H. WheelerCeCil: A randomized, noncomparative phase II clinical trial of the effect ofradiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide orcetuximab on the 1-year overall survival of patients with newly diagnosedMGMT-promoter unmethylated glioblastoma. (Abstract #TPS134)V. Verschaeve, L. A. D’Hondt, L. M. Verbeke, F. Van Fraeyenhove, S. Du Four,J. Duerinck, B. NeynsA phase II and pharmacodynamic trial of RO4929097 for patients withrecurrent/progressive glioblastoma. (Abstract #TPS135)D. M. Peereboom, J. N. Rich, J. G. Supko, K. Lamborn, X. Ye, A. E. Sloan,M. Prados, S. A. Grossman, Adult Brain Tumor Consortium (ABTC)AVAglio: A phase III trial of bevacizumab added to standard radiotherapy andtemozolomide in patients with newly diagnosed glioblastoma. (Abstract#TPS136)O. L. Chinot, W. Wick, F. Saran, W. P. Mason, R. Henriksson, R. Nishikawa,A. H. Zeaiter, N. Moore, A. Das, T. F. CloughesyA phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) inwomen with early-stage HER2 breast cancer (BC). (Abstract #TPS137)P. E. Goss, C. H. Barrios, A. Chan, S. K. Chia, S. Delaloge, B. Ejlertsen,J. N. Ingle, B. Moy, H. Iwata, F. A. Holmes, J. Mansi, G. Von Minckwitz, L. Han,A. Thiele, V. Agrapart, A. Freyman, J. Truscello, A. Berkenblit, D. Finkelstein318

Monday, June 6, 2011Brd. 40HBrd. 41ABrd. 41BBrd. 41CBrd. 41DBrd. 41EBrd. 41FBrd. 41GBrd. 41HBrd. 42ABrd. 42BBrd. 42CA phase II randomized study of lenalidomide or lenalidomide and rituximabas maintenance therapy following standard chemotherapy for patients withhigh/high-intermediate risk diffuse large B-cell lymphoma. (Abstract#TPS138)N. M. Reddy, R. Simmons, M. Caldwell, M. H. Jagasia, D. S. Morgan, S. I. Park,J. P. Greer, K. L. RichardsRandomized, double-blinded, phase II trial of a WT1 peptide vaccine asadjuvant therapy in patients with malignant pleural mesothelioma (MPM).(Abstract #TPS139)L. M. Krug, A. S. Tsao, S. Kass, V. W. Rusch, W. D. Travis, K. Panageas,P. S. Adusumili, M. G. Kris, P. G. Maslak, D. A. ScheinbergCYPTAM-BRUT 2: A prospective multicenter observational study in theneoadjuvant and metastatic setting investigating tamoxifen responsebetween women with a favorable versus unfavorable endoxifen profile.(Abstract #TPS140)A. Dieudonné, H. Wildiers, D. Lambrechts, H. Guchelaar, V. O. Dezentje,M. Joerger, K. Zaman, I. B. Vergote, P. NevenA phase I study of NPC-1C, a novel therapeutic antibody to treat pancreasand colorectal cancers. (Abstract #TPS141)N. S. Azad, L. A. Diaz Jr., C. E. Devoe, D. Laheru, D. T. Le, D. Cosgrove, L. Zheng,A. De Jesus-Acosta, R. C. Donehower, P. M. Arlen, J. A. BristolA pilot study of the safety, efficacy, and effects on functional imaging of thecombination of cG250 and sunitinib in patients (pts) with advanced renal cellcarcinoma (RCC). (Abstract #TPS142)M. Ciprotti, I. D. Davis, D. W. Pook, F. T. Lee, T. Cavicchiolo, S. Lee, B. Chappell,G. J. O’Keefe, H. Tochon-Danguy, F. E. Smyth, W. Hopkins, A. M. ScottValidation of the phase 0 concept. (Abstract #TPS143)J. R. Westin, S. Fu, D. S. Hong, T. Helgason, F. Ouyang, L. S. Angelo,K. S. Culotta, S. N. Westin, R. KurzrockA multicenter, randomized, controlled study of CO-1.01 versus gemcitabinein patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) andlow tumor expression of human equilibrative nucleoside transporter-1(hENT1) determined by metastasis biopsy. (Abstract #TPS144)T. Ikdahl, I. Davidenko, C. Bassi, E. Tomasetto, L. Smith, S. McLachlan, S. Jones,M. Raponi, J. Isaacson, C. Voong, L. Rolfe, A. R. Allen, E. PoplinFirst-in-human, multicenter, dose-escalation, phase I study of theinvestigational drug TAK-733, an oral MEK inhibitor, in patients (pts) withadvanced nonhematologic malignancies and melanoma. (Abstract #TPS145)J. A. Sosman, A. A. Adjei, P. LoRusso, S. A. Michael, G. K. Dy, A. Bowditch,B. Chmielowski, S. Lee, R. M. Walker, S. Faucette, E. S. Izmailova, V. Bozon,A. RibasA phase I clinical trial of QBI-139, a human ribonuclease variant, in solidtumors. (Abstract #TPS146)L. E. Strong, J. A. Kink, B. Mei, M. N. Shahan, R. T. RainesPresurgical evaluation of the AKT inhibitor MK-2206 in patients with operableinvasive breast cancer. (Abstract #TPS147)K. Kalinsky, J. A. Sparano, M. Kim, K. D. Crew, M. A. Maurer, B. Taback,S. M. Feldman, H. Hibshoosh, L. Wiechmann, K. B. Adelson, D. L. HershmanValproic Acid Signature Trial (VAST): A proof-of-principle study correlatingpharmacology, pathology, and advanced imaging with genomic prediction ofdrug sensitivity in breast cancer. (Abstract #TPS148)A. L. Cohen, M. Schabel, A. Bild, T. L. WernerFirst-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patientswith advanced solid tumors. (Abstract #TPS149)J. Soria, F. G. De Braud, R. Cereda, R. Bahleda, A. Delmonte, E. Angevin,A. Varga, C. Noberasco, E. Dall’O’, N. Lassau, C. Dromain, M. Bellomi, F. Farace,F. Bertolini, M. Zucchetti, S. Marsoni, M. G. CamboniMONDAY319

Monday, June 6, 2011MONDAYBrd. 42DBrd. 42EBrd. 42FBrd. 42GBrd. 42HBrd. 43ABrd. 43BBrd. 43CBrd. 43DBrd. 43EPhase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjectswith advanced solid tumors refractory to standard therapy or for which nostandard therapy is available. (Abstract #TPS150)R. E. Martell, E. G. Chiorean, H. Youssoufian, M. D. Rutstein, B. Pytowski,L. Benjamin, L. Abad, J. Patel, T. Steele, M. Dowd, A. Qin, C. F. Kukel, F. E. Fox,A. Dontabhaktuni, A. MorozovRandomized phase II study of capecitabine with or without ramucirumab(IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced ormetastatic breast cancer (mBC) previously treated with anthracycline andtaxane therapy (CP20–0903/NCT01234402). (Abstract #TPS151)L. T. Vahdat, K. Miller, J. A. Sparano, H. Youssoufian, J. D. Schwartz, S. Nanda,W. Wang, L. Abad, A. Dontabhaktuni, M. D. RutsteinA randomized, double-blind, placebo-controlled multicenter phase III studycomparing denosumab with placebo as adjuvant treatment for women withearly-stage breast cancer who are at high risk of disease recurrence (D-CARE). (Abstract #TPS152)P. E. Goss, C. H. Barrios, R. Bell, D. Finkelstein, H. Iwata, M. Martin, A. H. Braun,R. D. Dansey, R. E. ColemanIntegrative and multidisciplinary clinical trial using imaging, molecular, anddynamic biomarkers to predict bevacizumab plus chemotherapy response inbreast cancer. (Abstract #TPS153)J. Lopez Vega, E. G. Calvo, A. Plazaola, B. Hernando, S. Morales Murillo,A. Anton, R. S. Gomez, I. Alvarez, J. J. Illarramendi, A. De Juan, P. Martinez,A. Llombart, S. J. Scherer, L. Sabariz, A. la Huerta, L. J. Pina, I. Dominguez,M. J. Garcia Velloso, V. Boni, J. Garcia-FoncillasQuantitative diffusion-weighted (DW) MR imaging of microcapillary perfusionand tissue diffusivity as biomarkers of response of renal cell carcinoma(RCC) to treatment with sunitinib. (Abstract #TPS154)A. Leary, L. M. Pickering, J. M. Larkin, M. O. Leach, M. E. Gore, A. Sohaib,D. J. Collins, D. KohPharmacodynamic study of antiangiogenic therapy in patients with renal cellcarcinoma. (Abstract #TPS155)G. Anandappa, E. Sala, H. K. Cheow, N. J. Bird, A. Shaw, A. N. Priest, A. Gill,T. Fryer, Y. T. Hong, R. Smith, A. Backen, B. Whitcher, A. Jonson, D. Richards,L. Cookson, W. M. Lee, C. Dive, K. M. Fife, D. I. Jodrell, T. EisenA phase I, single-institution open label, dose-escalation trial with anexpansion cohort evaluating the safety and tolerability of AZD6244 andIMC-A12 in subjects with advanced solid malignancies. (Abstract #TPS156)S. R. Ahmed, D. Cosgrove, D. Ball, R. C. Donehower, B. Nelkin, E. Petito,M. Downs, H. X. Chen, A. Doyle, A. Scardina, M. A. Carducci, N. S. AzadPhase I study of everolimus (RAD001) and AMG 479 in patients (pts) withadvanced solid tumors and colorectal cancer (CRC). (Abstract #TPS157)M. R. Khawaja, A. Younger, J. M. Funke, M. J. Waddell, D. R. Jones, K. Pollok,N. K. Prasad, W. Berry, G. Sandusky, E. G. ChioreanA pharmacokinetics/pharmacodynamics study of sequence specificity of thePARP inhibitor olaparib with carboplatin in refractory/recurrent women’scancers: NCT01237067. (Abstract #TPS158)J. Lee, J. Squires, J. L. Hays, H. L. Kotz, D. Nielsen, N. D. Houston, E. C. KohnA phase I first-in-human study of REGN910, a fully human and selectiveangiopoietin-2 monoclonal antibody, in patients with advanced solid tumormalignancies. (Abstract #TPS159)K. P. Papadopoulos, N. G. Chau, A. Patnaik, L. Adriaens, A. S. Lalani, C. Daly,L. L. Siu320

Monday, June 6, 2011Brd. 43FBrd. 43GBrd. 43HBrd. 44ABrd. 44BBrd. 44CBrd. 44DBrd. 44EBrd. 44FBrd. 44GA phase 0 exploratory study to assess the pharmacodynamic effects ofsingle intratumoral dose of a novel bispecific targeting/immune-activatingagent on the melanoma tumor microenvironment. (Abstract #TPS160)L. A. Fecher, Y. McGrath, D. D. Williams, N. J. Hassan, M. Kalos, L. M. Schuchter,R. K. Amaravadi, A. Chew, E. A. Veloso, B. J. Czerniecki, G. Karakousis,G. P. Linette, B. K. Jakobsen, C. H. JuneA randomized phase II study of irinotecan, 5-fluorouracil, and folinic acid(FOLFIRI) with or without the addition of an endothelin receptor antagonist inpatients with metastatic colorectal cancer after failure ofoxaliplatin-containing chemotherapy. (Abstract #TPS161)A. L. Thomas, R. H. Wilson, W. P. Steward, R. A. Adams, S. E. Bridges,A. C. Casbard, T. S. Maughan, G. Griffiths, NCRI Colorectal Clinical Studies GroupA phase Ib/II study of second-line therapy with panitumumab, irinotecan, andeverolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).(Abstract #TPS162)A. R. Townsend, L. Pirc, J. Hardingham, C. S. Karapetis, N. C. Tebbutt, N. Singhal,T. J. PriceA phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV)versus placebo in patients with chemotherapy-refractory KRAS wild-type(WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.(Abstract #TPS163)J. D. Shapiro, L. L. Siu, J. R. Zalcberg, M. J. Moore, J. Ringash, N. Mittmann,J. Simes, C. J. O’Callaghan, D. Tu, I. B. Walters, N. Magoski, P. Smith,D. Nomikos, L. Zhu, M. Savoie, S. Virk, F. El-Tahche, R. Gill, T. J. Price,D. J. JonkerPULSE: An open-label, phase II study assessing double positivity (phosphoinsulin-growthfactor receptor-1 [pIGF-IR] and matrilysin [MMP7])expression, as a predictive marker of resistance in previously untreatedmetastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treatedwith panitumumab plus mFOLFOX6—A GEMCAD study. (Abstract #TPS164)J. Maurel, X. Garcia-Albeniz, C. Méndez Méndez, M. Martin-Richard, C. Pericay,R. Vera, J. Aparicio, M. Rubini, M. Cuatrecasas, on behalf of the GEMCADCooperative GroupDeveloping a biomarker-stratified trial design in advanced colorectal cancer:The MRC FOCUS 3 feasibility study. (Abstract #TPS165)T. S. Maughan, R. H. Wilson, G. T. Williams, M. T. Seymour, S. Richman,P. Quirke, M. Pope, J. Pope, M. Parmar, A. Nelson, A. M. Meade, S. L. Kenny,B. Jasani, E. Hodgkinson, D. Fisher, R. Butler, J. A. Bridgewater, R. A. Adams,R. S. KaplanLICC: L-BLP25 in patients with colorectal carcinoma after curative resectionof hepatic metastases—A randomized, double-blind, placebo-controlled,multicenter, multinational, phase II trial. (Abstract #TPS166)C. C. Schimanski, P. R. Galle, H. Lang, M. Schoen, M. H. MoehlerThe PARSC trial, a prospective study for the assessment of recurrence riskin stage II colon cancer (CC) patients using ColoPrint. (Abstract #TPS167)R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall, J. J. Van Der Hoeven,B. Glimelius, F. Bibeau, L. Stork-Sloots, R. A. Bender, J. CapdevilaA phase II, multicenter, randomized, double-blind, placebo-controlled,ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients withrefractory symptomatic carcinoid syndrome. (Abstract #TPS168)M. Kulke, T. M. O’Dorisio, A. T. Phan, R. M. Langdon Jr., B. J. Marek, N. Iklaque,E. K. Bergsland, J. Freiman, K. Frazier, J. Jackson, B. ZambrowiczIMAGE, a randomized phase Ib/II study of elisidepsin in pretreated advancedgastroesophageal cancer. (Abstract #TPS169)S. A. Szyldergemajn, A. Gonçalves, J. Metges, K. Gunzer, C. Montagut,R. Salazar, M. Alsina, T. Evans, D. Swinson, R. D. Petty, H. Singer, C. M. KahattMONDAY321

Monday, June 6, 2011MONDAYBrd. 44HBrd. 45ABrd. 45BBrd. 45CBrd. 45DBrd. 45EBrd. 45FBrd. 45GBrd. 45HBrd. 46ABrd. 46BA phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil andoxaliplatin (modified FOLFOX-6) in patients with metastatic pancreaticcancer. (Abstract #TPS170)M. J. Pishvaian, R. Slack, A. Witkiewicz, A. R. He, J. J. Hwang, A. Hankin, L. Ley,S. K. Apte, S. J. Littman, L. M. Weiner, J. Marshall, J. R. BrodyPAZONET: A phase II trial of pazopanib in patients with metastaticneuroendocrine tumors (NETs) who may have previously receivedantiangiogenic or mTOR treatment. (Abstract #TPS171)J. Capdevila, A. Teule, D. E. Castellano, J. Sastre, R. Garcia-Carbonero, I. Sevilla,I. Duran, P. Escudero, J. Fuster, E. Grande PulidoPhase I trial of sorafenib in hepatocellular carcinoma (HCC) patients afterliver transplantation (LT). (Abstract #TPS172)A. B. Siegel, R. Hidalgo, D. Tsushima, J. Zaretsky, J. Emond, T. Kato,R. S. Brown Jr.A randomized, double-blind placebo-controlled phase II study of FOLFOXwith or without GDC-0449 (vismodegib) in patients with advanced gastric andgastroesophageal junction carcinoma (NCI 8376). (Abstract #TPS173)D. J. Cohen, L. Liebes, R. Xu, N. Takebe, J. A. Sparano, New York CancerConsortiumA phase I study of dovitinib in combination with capecitabine and oxaliplatinin upfront treatment of advanced colorectal and gastric cancer with a doseexpansion cohort in advanced gastric cancer. (Abstract #TPS174)W. M. D. Tai, W. S. Ooi, J. Y. Ngeow, N. Deng, H. Wang, C. K. Tham, H. Y. Lim,S. P. Choo, P. Tan, H. C. Toh, I. B. TanEvaluation of sorafenib in combination with local microtherapy guided bygadolinium-EOB-DTPA enhanced MRI in patients with inoperablehepatocellular carcinoma. (Abstract #TPS175)J. Ricke, K. Schuette, I. W. Graziadei, A. Jakob, C. Verslype, B. Sangro,J. Walecki, H. Klümpen, B. Peynircioglu, S. Yalcin, C. Bartolozzi, H. Amthauer,P. MalfertheinerRandomized phase II study of the efficacy and safety of gemcitabine plusTH-302 versus gemcitabine alone in previously untreated patients withadvanced pancreatic cancer. (Abstract #TPS176)M. J. Borad, D. Sigal, H. Uronis, J. Stephenson Jr., N. Bahary, M. U. Rarick,L. C. DeMarco, T. J. Finnegan, E. G. Chiorean, D. P. Ryan, A. L. Cohn,B. K. Ulrich, V. C. Harish, E. N. Anderes, W. Ma, P. P. Yu, F. Sinicrope, C. Eng,U. K. Sunkara, S. G. ReddyACRIN 6690: Can contemporary imaging reduce false-positive rate in livertransplant (LT) allocation? A multicenter comparison of CT and MRI fordiagnosis of hepatocellular carcinoma (HCC). (Abstract #TPS177)C. Wald, M. Nalesnik, E. A. Pomfret, M. Russo, M. A. Rosen, D. M. Hartfeil, P. Fox,M. L. Heckel, C. GatsonisMet or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA):FOLFOX alone or in combination with AMG 102 or panitumumab as first-linetreatment in patients with advanced gastroesophageal adenocarcinoma:FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phaseII trial. (Abstract #TPS178)D. Malka, S. Gourgou-Bourgade, J. Emile, P. Laurent-Puig, J. TaïebThe Personalized RNA Interference to Enhance the Delivery of IndividualizedCytotoxic and Targeted Therapeutics (PREDICT) approach to biomarkerdiscovery in renal cell carcinoma. (Abstract #TPS179)M. Gerlinger, L. Albiges, on behalf of the PREDICT Consortium(www.predictconsortium.eu)SYNERGY: A randomized phase III study comparing first-linedocetaxel/prednisone to docetaxel/prednisone plus custirsen in metastaticcastrate-resistant prostate cancer (mCRPC). (Abstract #TPS180)K. N. Chi, J. S. De Bono, C. S. Higano322

Monday, June 6, 2011Brd. 46CBrd. 46DBrd. 46EBrd. 46FBrd. 46GBrd. 46HBrd. 47ABrd. 47BBrd. 47CBrd. 47DBrd. 47EA randomized, double-blind, phase III trial comparing ipilimumab versusplacebo following radiotherapy (RT) in patients (pts) with castration-resistantprostate cancer (CRPC) who have received prior treatment with docetaxel(D). (Abstract #TPS181)C. G. Drake, H. I. Scher, W. R. Gerritsen, R. Ezzeddine, T. F. Fitzmaurice,J. Cuillerot, K. M. Chin, P. GagnierRandomized, double-blind, phase III trial to compare the efficacy ofipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomaticpatients (pts) with metastatic chemotherapy-naïve castration-resistantprostate cancer (CRPC). (Abstract #TPS182)T. M. Beer, C. Logothetis, P. Sharma, W. R. Gerritsen, R. Ezzeddine,J. P. Fairchild, P. Gagnier, K. M. Chin, J. CuillerotIMA901 Multipeptide Vaccine Randomized International Phase III Trial(IMPRINT): A randomized, controlled study investigating IMA901multipeptide cancer vaccine in patients receiving sunitinib as first-linetherapy for advanced/metastatic RCC. (Abstract #TPS183)B. I. Rini, T. Eisen, A. Stenzl, W. Brugger, T. Weinschenk, A. Mahr, J. Fritsche,N. Hilf, R. Mendrzyk, J. Lindner, A. Schmid, A. Kirner, S. Walter, H. Singh,C. ReinhardtA phase III, randomized study of the investigational agent TAK-700 plusprednisone for patients with chemotherapy-naive metastatic castrationresistantprostate cancer (mCRPC). (Abstract #TPS184)F. Saad, H. Akaza, M. A. Eisenberger, J. Nelson, H. I. Scher, K. Suzuki, M. Wirth,I. J. Webb, J. Wang, D. MacLean, R. De WitPhase I/II trial to establish the safety and preliminary efficacy of thecombination of docetaxel, prednisone, and SOM 230 in metastatic castrateresistantprostate cancer (CRPC). (Abstract #TPS185)H. M. Vankayala, L. K. Heilbrun, J. A. Fontana, U. N. VaishampayanA multicenter, open-label phase II trial of dovitinib (TKI258) in advancedurothelial carcinoma patients with either mutated or wild-type FGFR3.(Abstract #TPS186)M. I. Milowsky, G. L. Carlson, M. M. Shi, G. Urbanowitz, Y. Zhang, C. N. SternbergDesign of a phase II randomized, open-label trial of DN24–02, an autologouscellular immunotherapy targeting HER2/neu, in patients with surgicallyresected urothelial cancer at high risk of recurrence. (Abstract #TPS187)D. F. Bajorin, P. Sharma, R. B. Sims, A. Sandler, S. P. LernerA randomized, controlled phase III global trial comparing sipuleucel-T plusandrogen deprivation therapy versus androgen deprivation therapy alone inmen with metastatic androgen dependent (hormone sensitive) prostatecancer. (Abstract #TPS188)K. Fizazi, T. Powles, D. J. George, C. H. PoehleinDesign of an open-label randomized phase II trial examining the effect ofsequencing of sipuleucel-T and androgen deprivation therapy (ADT) onimmune markers in prostate cancer patients with a rising prostate-specificantigen (PSA) after primary therapy. (Abstract #TPS189)E. S. Antonarakis, A. S. Kibel, D. W. Lin, R. C. Tyler, M. Tabesh, C. G. DrakeA first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-ofconceptstudy of ARN-509 in patients with progressive advanced castrationresistantprostate cancer (CRPC). (Abstract #TPS190)D. E. Rathkopf, D. C. Danila, S. F. Slovin, M. J. Morris, J. E. Steinbrecher, Y. Chen,M. Fleisher, S. M. Larson, C. L. Sawyers, H. I. ScherPredicting response to platinum chemotherapy in metastatic castrationresistantprostate cancer (mCRPC) using a genomic signature for“BRCAness”: A phase II clinical trial of satraplatin in men with mCRPC whohave progressed on docetaxel. (Abstract #TPS191)S. M. Seng, M. D. Galsky, C. Tsao, J. Li, P. G. Febbo, W. K. OhMONDAY323

Monday, June 6, 2011MONDAYBrd. 47FBrd. 47GBrd. 47HBrd. 48ABrd. 48BBrd. 48CBrd. 48DBrd. 48EBrd. 48FA randomized phase II study of MK-2206 in comparison with everolimus inrefractory renal cell carcinoma (NCI 8727). (Abstract #TPS192)E. Jonasch, P. Lara Jr., N. M. TannirRadiolabeled antiprostate specific membrane antigen (PSMA) monoclonalantibody J591 ( 177 Lu-J591) for nonmetastatic castration-resistant prostatecancer (CRPC): A randomized phase II trial. (Abstract #TPS193)S. T. Tagawa, N. M. Hahn, D. A. Vaena, D. I. Quinn, W. K. Kelly, P. J. Christos,J. Osborne, S. Vallabhajosula, K. Nadeau, G. Mileo, L. Tyrell, A. Saran, C. Ecker,H. Beltran, S. J. Goldsmith, D. M. NanusPhase I/II study of BNC105P in combination with everolimus or followingeverolimus for progressive metastatic renal cell carcinoma following priortyrosine kinase inhibitors. (Abstract #TPS194)T. E. Hutson, J. Sarantopoulos, T. Logan, G. Sonpavde, M. D. Galsky,C. Sweeney, D. C. Bibby, G. Kremmidiotis, E. E. Doolin, N. M. Hahn,Hoosier Oncology GroupA phase II study to evaluate the efficacy and safety of catumaxomab asconsolidation treatment in patients with epithelial ovarian cancer in secondor third complete remission. (Abstract #TPS195)A. M. Oaknin, L. Chiva, I. Romero, A. Romero, M. M. Essing, A. González-Martín,GEICOConcomitant chemoradiation or RT/cetuximab versus induction TPFfollowed by chemoradiation or RT/cetuximab in locally advanced head andneck squamous cell carcinoma: A randomized phase III factorial study.(Abstract #TPS196)A. Paccagnella, M. G. Ghi, I. Floriani, A. Gava, A. Buffoli, on behalf of the GSTTCItalian Collaborative GroupEORTC 22071–24071: Randomized, phase III trial of EGFR-antibodycombined with adjuvant chemoradiation for patients with head and necksquamous cell carcinoma (HNSCC) at high risk of recurrence. (Abstract#TPS197)C. Liberatoscioli, J. A. Langendijk, C. Van Herpen, L. Collette, E. M. Ozsahin,R. Karra Gurunath, D. A. Lacombe, A. Gulyban, N. Gosselin, W. BudachPAPILLOPHAR: Impact of the human papillomavirus (HPV) status in theprognosis of oropharynx squamous cell carcinoma (OSCC). (Abstract#TPS198)J. Lacau Saint Guily, J. Pretet, G. Agius, A. Rousseau, B. Barry, X. Dufour,S. Perie, M. Lefevre, P. Birembaut, C. Mougin, T. Simon, C. Clavel,PAPILLOPHAR GroupCALGB 10603 (RATIFY): A randomized phase III study of induction(daunorubicin/cytarabine) and consolidation (high-dose cytarabine)chemotherapy combined with midostaurin or placebo in treatment-naïvepatients with FLT3 mutated AML. (Abstract #TPS199)R. M. Stone, H. Dohner, G. Ehninger, M. Villeneuve, T. Teasdale, J. D. Virkus,L. R. Bressler, M. M. Seiler, G. Marcucci, R. A. Larson, on behalf of all studyinvestigatorsA global phase II, single-arm, open-label study to determine the efficacy ofmidostaurin in patients with aggressive systemic mastocytosis (ASM) ormast cell leukemia (MCL) with or without an associated hematologic clonalnonmast cell lineage disease (AHNMD). (Abstract #TPS200)J. R. Gotlib, H. Kluin-Nelemans, M. J. Mauro, O. Hermine, E. O. Hexner,J. H. Lipton, F. T. Awan, Z. G. Nikolova, S. H. Gross, C. Dutreix, B. Dharan,T. George, P. Horny, C. Akin, K. Hartmann, P. Valent, A. Reiter, on behalf of allPKC412 D2201 study investigators324

Monday, June 6, 2011Brd. 48GBrd. 48HBrd. 49ABrd. 49BBrd. 49CBrd. 49DBrd. 49EBrd. 49FBrd. 49GAdaptive design of VALOR, a phase III trial of vosaroxin or placebo incombination with cytarabine for patients with first relapsed or refractoryacute myeloid leukemia. (Abstract #TPS201)C. R. Mehta, G. Michelson, M. Salganik, J. Feaster, R. Allen, A. L. Cahill, J. A. Fox,S. B. Ketchum, F. Ravandi, H. P. Erba, G. J. Schiller, R. K. Stuart, N. Vey,E. J. FeldmanMulticenter, single-arm phase II study of nilotinib in Philadelphiachromosome-positive (Ph) chronic myeloid leukemia in chronic-phase(CML-CP) patients with low imatinib trough plasma concentrations. (Abstract#TPS202)S. Lim, R. C. Holdridge, M. Talpaz, C. N. Abboud, S. Yi, E. Noon, S. Ericson,M. JonesRESPONSE: A randomized, open label, phase III study of INC424 inpolycythemia vera (PV) patients resistant to or intolerant of hydroxyurea(HU). (Abstract #TPS203)S. Verstovsek, J. Kiladjian, R. J. Waltzman, V. Sandor, J. Lukawy, W. M. Garrett,K. Malek, R. M. Huber, A. M. VannucchiA single-arm, open-label, multicenter study of complete molecular response(CMR) in patients with newly diagnosed Philadelphia-chromosome positive(Ph) chronic myeloid leukemia in chronic phase (CML-CP) treated withnilotinib. (Abstract #TPS204)I. W. Flinn, S. Goldberg, R. L. Robles, D. Rizzieri, J. P. Radich, M. J. Mauro,S. Ericson, J. E. CortesProspective, observational registry of branded imatinib and nilotinibexposure in pregnant women: Voluntary postauthorization safety study.(Abstract #TPS205)M. Juma, S. Ericson, D. Eng, A. AdeoyeA randomized phase III study of elacytarabine versus limited investigator’schoice in patients with refractory acute myeloid leukemia (AML). (Abstract#TPS206)D. Rizzieri, N. Vey, M. Gobbi, D. L. Selleslag, M. W. Dennis, K. Kuliczkowski,U. Krug, F. Moscardo, D. Bron, A. D. Moicean, A. Venditti, T. F. Jacobsen,O. Foss, F. J. GilesA phase II study of elacytarabine plus idarubicin as second-courseremission-induction therapy in patients with acute myeloid leukemia.(Abstract #TPS207)D. Rizzieri, U. Krug, R. F. Schlenk, N. Vey, X. G. Thomas, F. Huguet, M. Johansen,T. F. JacobsenSCAT trial: Phase III Spanish customized adjuvant treatment accordingBRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer. (Abstract#TPS208)B. Massuti, U. Jimenez, J. M. Rodriguez Paniagua, Y. W. Pun, M. Cobo,E. Carcereny Costa, R. Arrabal, J. Astudillo, I. Barneto, R. De Las Penas,C. Baamonde, G. Sales, J. Gonzalez-Larriba, G. Lopez-Vivanco,F. Hernando-Trancho, J. Pac, A. Artal-Cortes, J. Rivas, R. Rosell, J. Sanchez,Spanish Lung Cancer Group / SLCG-GECPThe SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) inpatients with resected, early-stage non-small cell lung cancer (NSCLC) andconfirmed mutations in the epidermal growth factor receptor (EGFR).(Abstract #TPS209)N. A. Pennell, J. W. Neal, R. Govindan, P. A. Janne, T. L. Evans, D. B. Costa,R. P. Rosovsky, M. Lanuti, C. G. Azzoli, L. V. SequistMONDAY325

Monday, June 6, 2011MONDAYBrd. 49HBrd. 50ABrd. 50BBrd. 50CBrd. 50DBrd. 50EBrd. 50FBrd. 50GBrd. 50HMAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy(ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIANSCLC. (Abstract #TPS210)P. Therasse, J. F. Vansteenkiste, M. Zielinski, T. M. De Pas, D. Atanackovic,L. V. Sequist, E. Vallieres, S. Swisher, S. Adams, B. Passlick, W. E. Eberhardt,D. Grunenwald, T. Mok, M. Boyer, A. Katz, J. Douillard, M. Debois, V. G. Brichard,N. K. AltorkiErlotinib beyond progression study: Randomized phase II study comparingchemotherapy plus erlotinib with chemotherapy alone in EGFRTKI-responsive, advanced non-small cell lung cancer (NSCLC) thatsubsequently progresses. (Abstract #TPS211)B. Halmos, P. Fu, N. A. Pennell, G. A. Otterson, T. Mekhail, M. R. Snell,J. P. Kuebler, S. M. Gadgeel, A. Conrad, A. T. Stefanski, A. DowlatiA phase II randomized trial of anastrozole (A) and fulvestrant (F) asconsolidation therapy in postmenopausal women with advanced non-smallcell lung cancer who have received first-line platinum-based chemotherapywith or without bevacizumab. (Abstract #TPS212)B. T. McLaughlin, S. Land, A. A. Tarhini, J. Siegfried, A. ArgirisRandomized phase II study of ficlatuzumab (formerly AV-299), an antihepatocytegrowth factor (HGF) monoclonal antibody (MAb) in combinationwith gefitinib (G) in Asian patients (pts) with NSCLC. (Abstract #TPS213)T. Mok, E. Tan, K. Park, J. Jac, M. Han, F. C. Payumo, M. Credi, K. McKee,M. M. Cotreau, P. Bhargava, W. SlichenmyerPROSE: Randomized proteomic stratified phase III study of second-lineerlotinib versus chemotherapy in patients with inoperable non-small celllung cancer (NSCLC). (Abstract #TPS214)C. Sorlini, S. Barni, F. Petrelli, S. Novello, F. De Marinis, T. M. De Pas, F. Grossi,A. Bearz, M. Mencoboni, M. Aieta, A. Caprioli, P. Antonelli, N. Zilembo, A. Bachi,I. Floriani, H. Roder, J. Roder, J. Grigorieva, C. Lazzari, V. GregorcA phase I/II trial of MM-121 in combination with erlotinib in patients (pts) withnon-small cell lung cancer (NSCLC). (Abstract #TPS215)L. V. Sequist, W. A. Harb, M. Modiano, D. M. Jackman, K. Wong, J. A. Engelman,R. Nering, M. Onsum, V. M. MoyoRandomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant(F) in previously treated advanced non-small cell lung cancer (NSCLC).(Abstract #TPS216)E. B. Garon, S. M. Dubinett, F. F. Kabbinavar, K. L. Reckamp,D. C. Marquez-Garban, L. Goodglick, S. Sharma, L. P. Stabile, J. Siegfried,R. J. PietrasA phase III, randomized, double-blind, placebo-controlled study of erlotinibplus ARQ 197 versus erlotinib plus placebo in previously treated subjectswith locally advanced or metastatic, nonsquamous, non-small cell lungcancer (NSCLC) . (Abstract #TPS217)A. Sandler, J. H. Schiller, V. Hirsh, L. V. Sequist, J. Soria, J. Von Pawel, Q. Wang,A. U. Pande, B. E. Schwartz, E. G. Garmey, I. Gorbatchevsky, G. ScagliottiA randomized phase III study of maintenance therapy with bevacizumab (B),pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm)following carboplatin, paclitaxel, and bevacizumab (PCB) for advancednonsquamous NSCLC: ECOG trial 5508 (NCT01107626). (Abstract #TPS218)S. E. Dahlberg, S. S. Ramalingam, C. P. Belani, J. H. Schiller326

Monday, June 6, 2011Brd. 51ABrd. 51BBrd. 51CBrd. 51DBrd. 51EBrd. 51FBrd. 51GBrd. 51HBrd. 52AStudy ESOGIA-GFPC 08–02: Phase III, randomized, multicenter trialinvolving subjects over age 70 with stage IV non-small cell lung cancer andcomparing a “classical” strategy of treatment allocation (dual-agent therapybased on carboplatin or monotherapy with docetaxel alone), based onperformance status and age, with an “optimized” strategy allocating thesame treatments according to a simplified geriatric screening scale, plus amore thorough geriatric evaluation if necessary. (Abstract #TPS219)R. Corre, C. Chouaid, F. Barlesi, H. Le Caer, E. Dansin, A. Vergnenegre,P. Fournel, GFPCRandomized phase III trial of gemcitabine/carboplatin with or without iniparib(BSI-201) in patients with previously untreated stage IV squamous non-smallcell lung cancer (NSCLC). (Abstract #TPS220)D. R. Spigel, P. G. Harper, J. D. Hainsworth, F. De Marinis, F. F. Kabbinavar,E. S. Kim, T. J. Lynch, R. Rosell, F. A. Shepherd, M. A. Socinski, A. VergnenegreE3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), andbevacizumab (B) with or without IMC-A12 (cixutumumab) in patients withadvanced nonsquamous, non-small cell lung cancer (NSCLC). (Abstract#TPS221)A. Argiris, J. Lee, J. H. Schiller, Eastern Cooperative Oncology GroupRandomized phase IV trial comparing efficacy and tolerability oftemsirolimus with and without an elevated starting dose in patients withrelapsed, refractory mantle cell lymphoma. (Abstract #TPS222)A. Bair, G. Hess, J. Boni, F. OffnerA phase II trial of bortezomib plus lenalidomide for relapsed/refractorymantle cell lymphoma (MCL) (CALGB 50501). (Abstract #TPS223)V. A. Morrison, S. Jung, J. L. Johnson, J. Leonard, B. D. Cheson,Cancer and Leukemia Group BAn open-label phase II study of intravenous bortezomib and oralpanobinostat (LBH589) in adult patients with relapsed/refractory peripheralT-cell lymphoma (PTCL) or NK/T-cell lymphoma (NKL) after failure ofconventional chemotherapy. (Abstract #TPS224)D. C. Tan, P. Chan, B. L. Ng, B. K. Yap, Y. H. Chan, L. P. Koh, F. A. Wahid,S. Lim, N. S. Chin, W. Kim, S. Y. Tan, Y. T. GohA randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ),lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients(Pts) with relapsed multiple myeloma (MM). (Abstract #TPS225)P. Moreau, A. P. Palumbo, A. K. Stewart, V. Rajkumar, A. J. Jakubowiak, K. Halka,S. Goranov, H. Bumbea, K. B. Pendergrass, A. Lupu, A. Dimopoulos,A. O. Rocafiguera, J. G. Gandhi, G. Mihaylov, T. Masszi, J. Matous, G. Fonseca,R. Bryce, D. S. SiegelPYRAMID and LYM2034: Targeted randomized phase II studies of bortezomibwith or without immunochemotherapy in newly diagnosed nongerminalcenter B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), includingrapid prospective non-GCB subtype identification. (Abstract #TPS226)J. Leonard, J. Reeves, B. Ferhanoglu, K. T. Doner, H. Eom, I. W. Flinn, J. Raposo,N. M. Chowhan, C. Suh, S. Noga, G. Tumyan, S. Aung, J. Hajdenberg,B. K. Ulrich, K. B. Pendergrass, G. Mulligan, A. Rizo, S. Kussick, F. OffnerPANORAMA1: A randomized, double-blind, placebo controlled phase IIIstudy of panobinostat in combination with bortezomib and dexamethasonein patients with relapsed multiple myeloma. (Abstract #TPS227)J. F. San-Miguel, S. Lonial, V. Hungria, P. Moreau, H. Einsele, J. Lee, S. Yoon,P. Corradini, W. W. Jedrzejczak, D. C. Tan, K. Yong, A. Guenther,M. M. Wroclawska-Swacha, H. J. Weber, P. M. Bourquelot, P. G. RichardsonMONDAY327

Monday, June 6, 2011MONDAYBrd. 52CBrd. 52DBrd. 52EBrd. 52FBrd. 52GBrd. 52HBrd. 53ABrd. 53BBrd. 53CBrd. 53DBrd. 53EA phase II trial of nilotinib in the treatment of patients with KIT mutatedadvanced acral and mucosal melanoma (NICAM). (Abstract #TPS229)J. M. Larkin, S. Turajlic, P. D. Nathan, P. Lorigan, G. Stamp,D. Gonzalez de Castro, N. Martin, J. Griffiths, K. Edmonds, S. Sarker,M. G. James, R. A’Hern, G. Coombes, C. Snowdon, J. M. Bliss, M. E. Gore,R. MaraisA phase II study combining ipilimumab and fotemustine in patients withmetastatic melanoma: The NIBIT-M1 trial. (Abstract #TPS230)A. Di Giacomo, P. A. Ascierto, E. Fonsatti, E. Pittiglio, P. Queirolo, L. Pilla,R. Ridolfi, M. Santinami, A. Testori, G. Parmiani, M. MaioPREDICT phase II: A trial to prospectively validate a gene signatureassociated with clinical benefit from MAGE-A3 antigen-specific cancerimmunotherapeutic (ASCI) in patients with unresected metastatic cutaneousmelanoma. (Abstract #TPS231)P. Saiag, J. S. Weber, B. Dreno, A. Hauschild, C. Jamoul, O. Peeters, P. TherasseDERMA phase III trial of MAGE-A3 antigen-specific cancerimmunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. (Abstract #TPS232)J. M. Kirkwood, B. Dreno, A. Hauschild, D. Schadendorf, A. Testori, P. Hersey,C. Jamoul, O. Peeters, P. TherasseA randomized multicenter phase II trial on efficacy of high-slip skin care padfor hand-foot skin reaction caused by sorafenib in patients with renal cellcarcinoma. (Abstract #TPS233)N. Shinohara, N. Nonomura, G. Kimura, M. Eto, H. Minami, N. Yamazaki, S. Naito,Japanese Society of Renal CancerThe use of subcutaneous natural ghrelin to treat cachexia (CC) relatedsymptom distress, nutritional intake (NI), and physical functioning: Atwo-step phase I/II study with an intrapatient dose escalation followed bymaintenance treatment. (Abstract #TPS234)F. Strasser, D. Blum, R. Oberholzer, S. deWolf-Linder, C. Driessen, T. CernyA phase II/III study of sotatercept (ACE-011), an activin antagonist, forchemotherapy-induced anemia in patients with metastatic non-small celllung cancer treated with first-line platinum-based chemotherapy. (Abstract#TPS235)H. Raftopoulos, A. Laadem, M. Puccio, R. D. KnightPhase II trial of subcutaneous methylnaltrexone in the treatment of severeopioid-induced constipation in cancer patients. (Abstract #TPS236)M. Mori, T. Ashikaga, S. M. GrunbergRandomized clinical trial to evaluate an e-health intervention for fear ofcancer recurrence, anxiety, and depression among cancer survivors.(Abstract #TPS237)L. I. Wagner, J. Duffecy, K. A. Lehman, S. D. Sanford, M. Begale, E. Nawacki,D. C. MohrA randomized placebo-controlled trial of testosterone replacement forfatigue in male hypogonadic patients with advanced cancer. (Abstract#TPS238)E. Del Fabbro, J. Garcia, R. Dev, J. L. Palmer, C. Klingner-Winton, L. E. Roberts,J. Allo, G. Cardwell, E. BrueraLenalidomide in solid tumor patients with inflammatory cancer cachexia: Amulticenter, randomized, double-blind, proof-of-concept study of fixed doseor CRP-response-guided dose or placebo. (Abstract #TPS239)F. Strasser, R. Oberholzer, D. Blum, M. Joerger, C. Driessen, S. deWolf-Linder,S. R. Haile, R. von Moos, N. Zerkiebel, A. Jatoi, R. Woelky, K. Fearon, T. Cerny,Swiss Group for Clinical Cancer Research (SAKK 96/10)328

Monday, June 6, 2011Brd. 53FBrd. 53GBrd. 53HBrd. 54ABrd. 54BBrd. 54CBrd. 54DBrd. 54EBrd. 54FBrd. 54GA longitudinal study of alterations in cognitive function and brainmetabolites among women receiving chemotherapy for primary breastcancer. (Abstract #TPS240)S. Kohli, J. C. Buckner, J. H. Cerhan, K. Kantarci, D. L. Barton, J. A. Sloan,P. J. NovotnyMeasuring subjective improvement as well as objective response to estimatethe benefit of palliative chemotherapy in women with platinum-resistant orrefractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG). (Abstract #TPS241)M. Friedlander, M. R. Stockler, M. King, A. M. Oza, M. Voysey, J. Martyn, K. Gillies,K. M. Sjoquist, P. Butow, Australia New Zealand Gynaecological Oncology Group(ANZGOG), Psycho-Oncology Group (PoCoG), Gynecologic Cancer Intergroup(GCIG)A multicenter study assessing 12-weekly intravenous bisphosphonatetherapy in women with low-risk bone metastases from breast cancer: TheTRIUMPH trial. (Abstract #TPS242)N. Bouganim, J. F. Hilton, L. Vandermeer, S. Hopkins, D. Robbins, E. Amir,S. Dent, C. Milano, O. C. Freedman, R. A. Dent, G. Dranitsaris, M. J. ClemonsEffect of Chinese herbal medicine JDXZO on epidermal growth factorreceptor inhibitor (EGFRIs)–related skin toxicity. (Abstract #TPS243)H. Lin, J. LiClinical performance, efficacy, and safety of the DigniCap system, a scalphypothermiasystem, in preventing chemotherapy (CTX)-induced alopecia inpatients (pts) with early-stage breast cancer (BC). (Abstract #TPS244)A. Glencer, M. E. Melisko, L. Esserman, S. A. Melin, H. S. RugoA single-arm multicenter proof-of-concept study of denosumab to treathypercalcemia of malignancy in patients who are refractory to IVbisphosphonates. (Abstract #TPS245)M. I. Hu, R. Gucalp, K. L. Insogna, I. Glezerman, H. G. Bone, A. Jaccard,W. Misiorowski, B. W. Yu, H. YehAMC 070: A phase I/II study of lenalidomide in patients with AIDS-associatedKaposi sarcoma (Abstract #TPS246)K. A. Shimabukuro, E. G. Reid, AMC 070 Study TeamCancer Research UK Stratified Medicine Programme. (Abstract #TPS247)J. Peach, A. Tuff, J. Bull, F. Hemsley, L. Jones, M. Jones, C. Westwood,P. W. JohnsonA pilot study of tumor-derived exosomes as diagnostic and prognosticmarkers in breast cancer patients receiving neoadjuvant chemotherapy.(Abstract #TPS248)R. E. Raab, T. L. Pawlowski, D. Spetzler, M. R. Klass, C. D. Kuslich,L. S. Bellin, J. H. Wong, A. S. AschACRIN 6691 monitoring and predicting breast cancer neoadjuvantchemotherapy response using diffuse optical spectroscopic imaging (DOSI).(Abstract #TPS249)B. J. Tromberg, J. A. Butler, D. A. Mankoff, S. J. Isakoff, N. M. Hylton, A. G. Yodh,D. Boas, K. Paulsen, B. W. Pogue, P. A. Kaufman, R. S. Mehta, P. M. Carpenter,A. Cerussi, Z. Zhang, D. M. Hartfeil, D. L’HeureuxMONDAY329

Monday, June 6, 20118:00 AM - 12:30 PMPOSTER DISCUSSION SESSIONCancer Prevention/EpidemiologyDisplay Time: 8:00 AM - 12:00 PMDisplay Location: S102Discussion Time: 11:30 AM - 12:30 PMDiscussion Location: S100aCME credit: 1Track(s): Cancer Prevention/EpidemiologyMONDAYGary E. Goodman, MD—Co-ChairSwedish Cancer InstituteMarie Wood, MD—Co-ChairUniversity of VermontDiscussion11:30 AM Claudine Isaacs, MD (Abstracts #1509–1513)Lombardi Comprehensive Cancer CenterDiscussion11:45 AM Susan M. Domchek, MD (Abstracts #1514–1518)Abramson Cancer Center, University of PennsylvaniaDiscussion12:00 PM Stephen B. Gruber, MD, PhD, MPH (Abstracts #1519–1524)University of MichiganDiscussion12:15 PM Kala Visvanathan, MD, MHS (Abstracts #1525–1529)The Johns Hopkins University Bloomberg School of Public HealthBrd. 1 Feasibility and yield of offering genetic counseling to all patients with newlydiagnosed high-grade epithelial ovarian cancer. (Abstract #1509)A. G. Arnold, J. Bhatia, M. F. Phillips, G. J. Gardner, K. M. Bell-McGuinn,C. Aghajanian, R. R. Barakat, K. Offit, N. D. KauffBrd. 2 Does maternal or paternal inheritance of BRCA mutation affect the age ofcancer diagnosis? (Abstract #1510)I. Shapira, R. J. Gralla, M. Akerman, L. R. Weiselberg, V. S. John, H. Raftopoulos,V. Vinciguerra, J. L. Lovecchio, A. Menzin, S. CohenBrd. 3 Effect of rapid genetic testings on the rate of bilateral prophylacticmastectomy in BRCA1/2 mutation carriers. (Abstract #1511)L. Cortesi, E. De Matteis, E. Razzaboni, V. Medici, G. Tazzioli, A. Andreotti,M. FedericoBrd. 4 Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductalcarcinoma in situ. (Abstract #1512)N. Elsayegh, S. Bayraktar, A. M. Gutierrez-Barrera, H. Lin, H. M. Kuerer,K. I. Muse, K. Ready, J. K. Litton, F. Meric-Bernstam, G. N. Hortobagyi, B. ArunBrd. 5 Identification of BRCA1/BRCA2 carriers by screening in the healthypopulation and its implications. (Abstract #1513)E. Levy-Lahad, E. Gabai-Kapara, B. Kaufman, R. Catane, S. Segev, P. Renbaum,U. Beller, M. King, A. LahadBrd. 6 Prevalence and ancestral origin of hispanic BRCA mutations: Insights forancestry-informed genetic cancer risk assessment. (Abstract #1514)J. N. Weitzel, J. N. DeHart, R. M. Ogaz, A. E. Martir-Negron, J. Herzog, C. Ricker,J. Congleton, C. Cina, P. R. Duncan, G. W. Unzeitig, J. Saldivar, M. Beattie,N. R. Feldman, S. Sand, D. Port, E. M. John, C. Haiman, R. Varma,S. L. Neuhausen, G. P. Larson, Cancer Genetics Community Research NetworkBrd. 7 Analysis of genomic ancestry in a sample of hereditary breast cancer highrisk patients from Bahia, Brazil. (Abstract #1515)I. O. Nascimento, T. B. Machado, B. Toralles, L. A. Ferreira, M. Romeo,C. A. Sandes, L. Meyer, B. Garicochea, R. Meyer, S. Freire, K. Abe-Sandes330

Monday, June 6, 2011Brd. 8 Prospective study of breast cancer risk in mutation-negative women fromBRCA1 or BRCA2 mutation-positive families in the Kathleen CuninghamFoundation Consortium for Research into Familial Breast Cancer (kConFab).(Abstract #1516)S. Harvey, R. L. Milne, K. E. Birch, P. Weideman, S. McLachlan, M. Friedlander,D. Goldgar, J. L. Hopper, K. PhillipsBrd. 9 Correlation of germ-line BRCA2 mutations with aggressive prostate cancerand outcome. (Abstract #1517)E. Castro, C. L. Goh, D. Olmos, D. Leongamornlert, E. Saunders,M. Tymrakiewicz, N. Mahmud, T. Dadaev, K. Govindasami, M. Guy, L. OBrien,E. Sawyer, A. Hall, R. Wilkinson, Z. Kote-Jarai, R. A. Eeles, The UKGPCScollaboratorsBrd. 10 Risk of breast cancer (BC) after BRCA-mutation associated ovarian cancer(BRCA-OC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience.(Abstract #1518)K. L. Jhaveri, S. Patil, M. Khasraw, J. Bhatia, Z. K. Stadler, N. D. Kauff, C. Hudis,K. Offit, M. E. RobsonBrd. 11 Breast cancer phenotype in women with TP53 germ-line mutations: An LFSconsortium effort. (Abstract #1519)S. Masciari, D. Dillon, M. G. Dick, M. E. Robson, J. N. Weitzel, J. M. Ford,J. Balmaña, S. B. Gruber, D. Euhus, J. E. GarberBrd. 12 Li-Fraumeni syndrome: Retesting archival DNA samples identifies previouslyunrecognized germline p53 mutations. (Abstract #1520)A. Novokmet, B. Baskin, D. MalkinBrd. 13 Factors associated with type I and type II endometrial cancers in women witha germline mutation in a mismatch repair gene. (Abstract #1521)Y. C. Antill, A. Win, P. Webb, J. L. Hopper, S. Gallinger, N. M. Lindor,P. A. Newcomb, R. W. Haile, J. Church, L. Le Marchand, I. Winship, A. B. Spurdle,M. A. Jenkins, Colon Cancer Family RegistryBrd. 14 Incremental impact of breast cancer SNP panel on risk classification andscreening. (Abstract #1522)K. Armstrong, E. Conant, J. Chen, E. Handorf, M. Jones, L. Boghossian,S. M. DomchekBrd. 15 Single nucleotide polymorphisms and expression/amplification of HER2 inpatients with breast cancer. (Abstract #1523)A. V. Boddy, N. Cresti, D. Jamieson, M. Pinkilgton, M. W. VerrillBrd. 16 Prognostic value of single nucleotide polymorphisms (SNPs) of candidategenes associated with inflammation in early-stage breast cancer. (Abstract#1524)J. L. Murray, P. Thompson, R. Zhou, S. Y. Yoo, Y. Liu, K. Do, A. A. Sahin,M. Bondy, A. M. BrewsterBrd. 17 Performance of the Gail model in individual women with benign breastdisease. (Abstract #1525)Y. Tarabishy, L. C. Hartmann, M. H. Frost, S. D. Maloney, R. A. Vierkant,V. S. PankratzBrd. 18 Presentation of breast cancer (BC) diagnosed at or before age 30:Implications for screening women at hereditary risk. (Abstract #1526)P. de Alcantara Filho, T. A. King, E. A. Morris, C. Hudis, M. E. RobsonBrd. 19 Safety and efficacy of HRT and low dose tamoxifen in a phase II trial (HOT):Analysis of mammographic density and endometrial thickness. (Abstract#1527)B. Bonanni, P. Maisonneuve, D. Serrano, C. Varricchio, M. Cazzaniga,M. Lazzeroni, B. Santillo, R. Di Pace, L. Meneghetti, A. Tagliafico, U. Veronesi,A. De CensiMONDAY331

Monday, June 6, 2011Brd. 20Brd. 2125-hydroxy vitamin D (VitD) and associated variables as predictors of breastcancer (BC) risk and tamoxifen benefit in NSABP-P1. (Abstract #1528)E. Amir, R. S. Cecchini, P. A. Ganz, J. P. Costantino, S. Beddows, N. Hood,P. J. GoodwinRelationship of body mass index to the intrinsic subtypes of breast cancer.(Abstract #1529)C. A. Santa-Maria, Y. Zhao, N. Ketring, I. Rodriguez, A. Condren, D. EuhusMONDAY332

Monday, June 6, 20118:00 AM - 12:30 PMPOSTER DISCUSSION SESSIONGastrointestinal (Colorectal) CancerDisplay Time: 8:00 AM - 12:00 PMDisplay Location: E450bDiscussion Time: 11:30 AM - 12:30 PMDiscussion Location: Hall D1CME credit: 1Track(s): Gastrointestinal (Colorectal) CancerBlase N. Polite, MD, MPH—Co-ChairThe University of ChicagoSharlene Gill, MD—Co-ChairBritish Columbia Cancer AgencyDiscussion11:30 AM John S. Kauh, MD (Abstracts #3512–3517)Winship Cancer Institute of Emory UniversityDiscussion11:45 AM Chris R. Garrett, MD (Abstracts #3518–3522)University of Texas M. D. Anderson Cancer CenterDiscussion12:00 PM Josep Tabernero, MD (Abstracts #3523–3528)Vall d’Hebron University HospitalDiscussion12:15 PM Sabine Tejpar, MD, PhD (Abstracts #3529–3536)University Hospital GasthuisbergBrd. 1 The dose-effect relationship in preoperative chemoradiation of locallyadvanced rectal cancer: Preliminary results of a phase III trial. (Abstract#3512)A. K. Jakobsen, A. L. Appelt, J. Lindebjerg, J. Ploeen, S. R. Rafaelsen, T. VuongBrd. 2 EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvantcapecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation(CRT) with or without cetuximab followed by total mesorectal excision (TME)in patients with MRI-defined, high-risk rectal cancer. (Abstract #3513)A. Dewdney, J. Capdevila, B. Glimelius, A. Cervantes, D. M. Tait, G. Brown,A. Wotherspoon, D. Gonzalez de Castro, Y. Chua, R. Wong, Y. Barbachano,J. R. Oates, I. Chau, D. CunninghamBrd. 3 Impact of neoadjuvant chemotherapy following chemoradiation on tumorresponse, adverse events, and surgical complications in patients withadvanced rectal cancer treated with TME. (Abstract #3514)J. Garcia-Aguilar, J. Marcet, T. Coutsoftides, P. Cataldo, A. Fichera, L. E. Smith,S. Oommen, S. R. Hunt, D. Herzig, D. Dietz, M. G. Varma, C. A. Ternent,M. J. Stamos, K. Avila, D. D. SmithBrd. 4 Postoperative adjuvant chemotherapy (CTX) use in patients (Pts) with stageII/III rectal treated with neoadjuvant therapy: A National ComprehensiveCancer Network (NCCN) analysis. (Abstract #3515)P. Khrizman, J. C. Niland, A. ter Veer, D. Milne, K. Bullard Dunn, W. E. Carson III,P. F. Engstrom, S. Shibata, J. M. Skibber, M. R. Weiser, D. Schrag, A. B. BensonBrd. 5 Preoperative versus postoperative chemoradiotherapy for locally advancedrectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase IIItrial after a median follow-up of 11 years. (Abstract #3516)R. Sauer, T. Liersch, S. Merkel, H. Becker, W. Hohenberger, H. Witzigmann,C. F. Hess, R. Fietkau, C. Wittekind, C. Roedel, German Rectal Cancer StudyGroupMONDAY333

Monday, June 6, 2011MONDAYBrd. 6Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Efficacy endpoints of RTOG 0247: A randomized phase II study ofneoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) withconcurrent radiation therapy (RT) for locally advanced rectal cancer.(Abstract #3517)S. J. Wong, J. Moughan, N. J. Meropol, P. R. Anne, L. A. Kachnic, A. Rashid,J. C. Watson, E. P. Mitchell, J. Pollock, M. G. Haddock, B. Erickson, C. G. WillettValidation of a 12-gene colon cancer recurrence score (RS) in patients (pts)with stage II colon cancer (CC) from CALGB 9581. (Abstract #3518)A. P. Venook, D. Niedzwiecki, M. Lopatin, M. Lee, P. N. Friedman, W. Frankel,K. Clark-Langone, C. Yoshizawa, C. Millward, S. Shak, R. M. Goldberg,N. N. Mahmoud, R. L. Schilsky, M. M. Bertagnolli, Cancer and Leukemia Group BImpact of the type and modalities of preoperative chemotherapy on theoutcome of liver resection for colorectal metastases. (Abstract #3519)R. Adam, E. Barroso, C. Laurent, G. Nuzzo, C. Hubert, G. Mentha, J. Ijzermans,L. Capussotti, S. Lopezben, D. Mirza, G. Kaiser, E. Oussoultzoglou,T. Gruenberger, G. J. Poston, O. Skipenko, The LiverMetSurvey CentersAn Ontario Clinical Oncology Group (OCOG) randomized controlled trial(RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinomametastases (CAM). (Abstract #3520)C. Moulton, M. N. Levine, C. Law, R. Hart, L. Ruo, C. Gu, A. Hendler,K. Y. Gulenchyn, M. A. Haider, M. Marcaccio, V. Tandan, D. Quan, D. Jalink,R. Fairfull Smith, S. Hanna, P. D. Greig, M. Husien, T. Finch, J. A. Julian,S. GallingerFollow-up after colorectal cancer surgery: Preliminary observational findingsfrom the UK FACS trial. (Abstract #3521)J. N. Primrose, A. Fuller, P. Rose, R. Perera-Salazar, J. Mellor, A. Corkhill,S. George, D. MantPilot experience with adjuvant FOLFIRI with or without cetuximab in patientswith resected stage III colon cancer: NCCTG Intergroup N0147. (Abstract#3522)J. Huang, D. J. Sargent, M. R. Mahoney, A. F. Shields, E. Chan, R. M. Goldberg,S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, F. Sinicrope,S. G. Nair, S. R. AlbertsAddition of panitumumab to irinotecan: Results of PICCOLO, a randomizedcontrolled trial in advanced colorectal cancer (aCRC). (Abstract #3523)M. T. Seymour, S. R. Brown, S. Richman, G. W. Middleton, T. S. Maughan,C. Olivier, S. J. Gwyther, J. Wadsley, I. Chau, T. Hickish, L. K. Dawson, S. Falk,A. O’Callaghan, K. Benstead, N. Wadd, A. Oliver, P. Chambers, H. Marshall,V. Napp, P. Quirke, UK NCRI Colorectal Clinical Studies GroupA randomized phase III study of SOX (S-1/oxaliplatin) versus COX(capecitabine/oxaliplatin) in patients with advanced colorectal cancer.(Abstract #3524)Y. Park, H. Lim, J. Lee, T. Kim, Y. Hong, S. Kim, J. Baek, J. Kim, K. Lee, I. Chung,S. Cho, S. J. Shin, H. Kang, D. Shin, S. JoPhase II trial of figitumumab in patients with refractory, metastatic colorectalcancer (mCRC). (Abstract #3525)C. Becerra, R. Salazar, R. Garcia-Carbonero, A. L. Thomas, F. Vázquez-Mazón, J. Cassidy, T. Maughan, M. Gallén, T. Iveson, M. Hixon, A. Gualberto,D. Yin, D. Li, E. K. BergslandA randomized phase III trial on maintenance treatment with bevacizumab(bev) alone or in combination with erlotinib (erlo) after chemotherapy andbev in metastatic colorectal cancer (mCRC). (Abstract #3526)A. Johnsson, J. Frodin, A. Berglund, H. Hagman, J. Sundberg, D. Bergstrom,R. D. Christensen, N. Keldsen, K. G. Spindler, A. K. Jakobsen334

Monday, June 6, 2011Brd. 16Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25A double-blind, randomized, placebo-controlled, phase II study ofmaintenance enzastaurin with 5-FU/leucovorin plus bevacizumab followingfirst-line therapy for metastatic colorectal cancer (mCRC). (Abstract #3527)R. A. Wolff, W. Schepp, M. Di Bartolomeo, A. Hossain, C. Stoffregen, S. Nicol,V. HeinemannAn international consortium study in chemorefractory metastatic colorectalcancer (mCRC) patients (pts) to assess the impact of FCGR polymorphismson cetuximab efficacy. (Abstract #3528)R. Geva, B. V. Jensen, G. Fountzilas, T. Yoshino, D. Paez, C. Montagut,I. Sougklakos, F. Cappuzzo, A. Cervantes-Ruiperez, D. Papamichael, M. Frattini,B. Vincenzi, T. Macarulla, F. Loupakis, K. G. Spindler, C. Qvortrup, F. Ciardiello,S. TejparIdentification of polymorphisms in ultraconserved elements (UCEs)associated with clinical outcomes in patients (pts) with stage II/III colorectalcancer (CRC). (Abstract #3529)M. Lin, E. Hawk, M. Huang, J. Lin, J. Gu, L. M. Ellis, X. Wu, C. EngEvaluation of gene mutations beyond KRAS as predictive biomarkers ofresponse to panitumumab in a randomized, phase III monotherapy study ofmetastatic colorectal cancer (mCRC). (Abstract #3530)K. Oliner, M. Peeters, S. Siena, E. Van Cutsem, J. Huang, Y. Humblet,J. Van Laethem, T. Andre, J. S. Wiezorek, S. D. PattersonVascular endothelial growth factors (VEGF) and VEGF receptor expressionas predictive biomarkers for benefit with bevacizumab in metastaticcolorectal cancer (mCRC): Analysis of the phase III MAX study. (Abstract#3531)A. J. Weickhardt, D. Williams, C. Lee, J. Simes, C. Murone, K. Wilson,M. Cummins, K. Asadi, T. J. Price, J. Mariadason, N. C. Tebbutt,Australasian GI Trials GroupPrediction of survival in patients with metastatic colorectal cancer treatedwith third-line cetuximab and irinotecan through changes in microRNAexpression in whole blood during treatment (Abstract #3532)J. V. Schou, K. K. Andersen, B. V. Jensen, D. L. Nielsen, P. Pfeiffer, E. V. Høgdall,M. Yilmaz, M. Kruhoffer, J. S. JohansenThe association of alternate VEGF ligands with resistance to anti-VEGFtherapy in metastatic colorectal cancer. (Abstract #3533)C. H. Lieu, H. T. Tran, Z. Jiang, M. Mao, M. J. Overman, C. Eng, J. Morris,L. M. Ellis, J. Heymach, S. KopetzThe role of activating mutations of KRAS, BRAF, and PIK3CA pathwayconvergence at the transcriptional level and prediction of treatmentresponse to cetuximab in colorectal cancer. (Abstract #3534)I. Simon, S. Tian, V. Moreno, P. Roepman, J. Tabernero, M. Snel, T. Macarulla,L. van’t Veer, R. Bernards, G. CapellaPrimary colorectal tumors and their metastasis are genetically not the same:Implications for choice of targeted treatment? (Abstract #3535)J. S. Vermaat, I. J. Nijman, M. J. Koudijs, W. M. Roessingh, F. L. Gerritse,M. Mokry, R. H. Giles, P. J. van Diest, E. Cuppen, E. E. VoestMutational analysis and clinical correlation of 185 consecutive metastaticcolorectal patients: Similarities and differences between colon and rectalpatients. (Abstract #3536)A. L. Russo, D. R. Borger, D. P. Ryan, K. C. Fan, H. Lopez, V. Scialabba,L. S. Blaszkowsky, E. L. Kwak, J. W. Clark, J. N. Allen, R. C. Wadlow, A. X. Zhu,R. Wang, D. Dias-Santagata, T. S. Hong, A. J. IafrateMONDAY335

Monday, June 6, 20118:00 AM - 12:30 PMPOSTER DISCUSSION SESSIONLung Cancer—Local-regional and Adjuvant Therapy/Small CellDisplay Time: 8:00 AM - 12:00 PMDisplay Location: E450aDiscussion Time: 11:30 AM - 12:30 PMDiscussion Location: Hall D2CME credit: 1Track(s): Lung CancerMONDAYKatherine Pisters, MD—Co-ChairUniversity of Texas M. D. Anderson Cancer CenterWilliam J. Petty, MD—Co-ChairWake Forest UniversityDiscussion11:30 AM Tetsuya Mitsudomi, MD, PhD (Abstracts #7007–7010)Aichi Cancer Center HospitalDiscussion11:40 AM Enriqueta Felip, MD (Abstracts #7011–7015)Vall d’Hebron University HospitalDiscussion11:55 AM Joseph Kamel Salama, MD (Abstracts #7016–7020)Duke University Medical CenterDiscussion12:05 PM Kaoru Kubota, MD (Abstracts #7021–7023)National Cancer CenterDiscussion12:20 PM Nasser H. Hanna, MD (Abstracts #7024–7028)Indiana UniversityBrd. 1 Use of a three-microRNA signature to discriminate prognostic groups inearly-stage NSCLC patients in the IFCT-0002 trial. (Abstract #7007)C. Mascaux, G. Levallet, E. Bergot, L. Baudrin, M. Antoine, G. Anthoine,V. Westeel, A. Lavole, E. A. Quoix, D. Debieuvre, J. Mazieres, J. Pujol,D. Moro-Sibilot, F. Morin, B. Milleron, G. Zalcman, on behalf of the IntergroupeFrancophone de Cancerologie Thoracique (IFCT)Brd. 2 Association between DNA-repair gene and glutathione S-transferase genepolymorphisms and clinical outcome in patients (pt) with localized nonsmall-celllung cancer (NSCLC) treated with sequential radiochemotherapy.(Abstract #7008)J. Stoehlmacher-Williams, B. Krassler, M. Kramer, G. Ehninger, G. Hoeffken,E. GoekkurtBrd. 3 Genetic variations in multiple drug action pathways and survival inadvanced-stage non-small cell lung cancer treated with chemotherapy.(Abstract #7009)P. Yang, Y. Li, Z. Sun, J. M. Cunningham, M. Aubry, J. A. Wampfler, G. Croghan,C. Johnson, D. Wu, J. Aakre, J. R. Molina, L. Wang, V. S. PankratzBrd. 4 Use of a gene expression signature related to epithelial-to-mesenchymaltransition (EMT) to predict for overall survival (OS) in cohorts of lung andhead and neck cancer (HNSCC) patients. (Abstract #7010)J. S. Yordy, L. Shen, L. Diao, J. Wang, K. Coombes, U. Giri, Y. Xie, J. D. Minna,L. Girard, J. Weinstein, J. Heymach, K. Ang, M. D. Story, R. MeynBrd. 5 Oncologists’, physicians’, and surgeons’ opinions on the perceived valueand appropriateness of the speciality to inform patients on adjuvantchemotherapy after radical surgery for non-small cell lung cancer. (Abstract#7011)K. Khor, D. Tai, S. Popat, M. Beckles, M. Leung, M. Al Sahaf, E. K. Lim336

Monday, June 6, 2011Brd. 6Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer(NSCLC) in the elderly: A population-based outcomes study. (Abstract#7012)S. Cuffe, C. M. Booth, Y. Peng, G. E. Darling, G. Li, W. Kong, W. J. Mackillop,F. A. ShepherdInterim report of on-study demographics and toxicity from E1505, a phase IIIrandomized trial of adjuvant (adj) chemotherapy (chemo) with or withoutbevacizumab (B) for completely resected early stage non-small cell lungcancer (NSCLC). (Abstract #7013)H. A. Wakelee, S. E. Dahlberg, S. M. Keller, D. R. Gandara, S. L. Graziano,N. B. Leighl, A. A. Adjei, J. H. Schiller, Eastern Cooperative Oncology GroupPlatinum-based adjuvant chemotherapy (ACT) in elderly patients withnon-small cell lung cancer (NSCLC) in the SEER-Medicare database:Comparison between carboplatin- and cisplatin-based regimens. (Abstract#7014)F. Gu, G. M. Strauss, J. P. WisniveskyAdjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC):Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633.(Abstract #7015)G. M. Strauss, X. F. Wang, M. Maddaus, D. Johnstone, E. Johnson, D. Harpole,H. H. Gillenwater, L. Gu, D. Sugarbaker, M. R. Green, S. L. Graziano,R. A. Kratzke, R. L. Schilsky, J. Crawford, E. E. VokesPhase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) andconcurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracicconformal radiotherapy (TCRT) in stage III non-small cell lung cancer(NSCLC). (Abstract #7016)T. Stinchcombe, M. A. Socinski, D. T. Moore, S. N. Gettinger, R. H. Decker,W. J. Petty, A. W. Blackstock, G. Schwartz, S. Lankford, D. E. MorrisPhase II study of high-dose proton therapy with concurrent chemotherapyfor unresectable stage III non-small cell lung cancer. (Abstract #7017)J. Y. Chang, R. Komaki, C. Lu, H. Y. When, P. Allen, A. S. Tsao, M. Gillin,R. Mohan, J. D. CoxAn Ontario Clinical Oncology Group (OCOG) randomized trial (PET START)of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC):Predictors of overall survival. (Abstract #7018)Y. Ung, C. Gu, K. Cline, A. Sun, R. M. MacRae, J. R. Wright, E. Yu, L. Ehrlich,K. Y. Gulenchyn, H. Shulman, I. S. Dayes, S. K. Dhesy-Thind, G. E. Darling,N. B. Leighl, W. K. Evans, J. A. Julian, M. N. LevineMulticenter phase II study of cetuximab (C) with concomitant radiotherapy(RT) followed by consolidation chemotherapy (CT) in locally advancednon-small cell lung cancer (NSCLC). (Abstract #7019)A. P. Kotsakis, S. S. Ramalingam, A. A. Tarhini, D. E. Heron, R. Smith,D. Friedland, D. P. Petro, L. E. Raez, J. R. Brahmer, J. S. Greenberger, S. Dacic,P. Hershberger, R. J. Landreneau, C. P. Belani, J. D. Luketich, A. ArgirisPhase II trial of erlotinib and radiotherapy following chemoradiotherapy forpatients with stage III non-small cell lung cancer. (Abstract #7020)R. Komaki, G. R. Blumenschein Jr., I. I. Wistuba, J. Lee, P. Allen, X. Wei, J. Welsh,M. O’Reilly, R. S. Herbst, X. Tang, R. Meyn, D. Liu, W. K. HongSurgical resection in early limited stage small cell lung cancer: Time torethink? A retrospective analysis of the VA Central Cancer Registry.(Abstract #7021)T. Tashi, I. T. Aldoss, W. Gonsalves, A. Ganti, P. T. Silberstein, P. Townley,S. SubbiahMONDAY337

Monday, June 6, 2011Brd. 16Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatinbasedchemotherapy (CT) as first-line treatment of small cell lung cancer(SCLC). (Abstract #7022)A. Rossi, M. Di Maio, P. Chiodini, R. Rudd, H. Okamoto, D. Skarlos, M. Frueh,W. Qian, T. Tamura, E. Samantas, T. Shibata, F. Perrone, C. Gallo, C. Gridelli,O. Martelli, S. M. LeeThymoma: A population-based study of the management and outcomes forthe province of British Columbia. (Abstract #7023)C. J. Mariano, D. Ionescu, W. Y. Cheung, R. Ali, J. J. Laskin, H. Carolan, K. Evans,N. MurrayPredictive value of thymidylate synthase and folylpoly-glutamate synthetasefor clinical benefit from pemetrexed in malignant pleural mesothelioma.(Abstract #7024)D. C. Christoph, C. Mascaux, M. W. Wynes, B. Reyna Asuncion, J. Wohlschlaeger,D. Theegarten, T. C. Gauler, M. H. Schuler, W. E. Eberhardt, F. R. HirschDoes disease control rate (DCR) at 9 and 18 weeks predict overall survival(OS) in patients with malignant pleural mesothelioma (MPM)? An individualpatient data combined analysis of 10 European Organisation for Researchand Treatment of Cancer (EORTC) Lung Cancer Group (LCG) studies.(Abstract #7025)L. Greillier, B. Hasan, P. Baas, J. J. Welch, J. P. Van Meerbeeck, R. M. Gaafar,R. Sylvester, D. A. Lacombe, M. O’BrienAntitumor activity of SS1P with pemetrexed and cisplatin for front-linetreatment of pleural mesothelioma and utility of serum mesothelin as amarker of tumor response. (Abstract #7026)R. Hassan, E. Sharon, B. Schuler, Y. Mallory, J. Zhang, A. Ling, I. PastanCediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase IItrial of The University of Chicago phase II consortium. (Abstract #7027)N. P. Campbell, R. Kunnavakkam, N. B. Leighl, M. D. Vincent, D. R. Gandara,M. Koczywas, B. J. Gitlitz, E. S. Agamah, S. P. Thomas, W. M. Stadler,E. E. Vokes, H. L. KindlerForced vital capacity (FVC) as a reproducible measure of pulmonary function(PF) in chemotherapy-pretreated patients with malignant pleuralmesothelioma (MPM). (Abstract #7028)L. M. Krug, J. Arduino, X. Sun, H. L. Kindler, C. Manegold, D. Fennell,G. M. Lubiniecki, P. BaasMONDAY338

Monday, June 6, 20118:00 AM - 12:30 PMPOSTER DISCUSSION SESSIONMelanoma/Skin CancersDisplay Time: 8:00 AM - 12:00 PMDisplay Location: S403Discussion Time: 11:30 AM - 12:30 PMDiscussion Location: S406CME credit: 1Track(s): Melanoma/Skin CancersBartosz Chmielowski, MD, PhD—Co-ChairUniversity of California, Los AngelesGeorgina V. Long, MBBS, PhD—Co-ChairRoyal Prince Alfred HospitalDiscussion11:30 AM David Fisher, MD, PhD (Abstracts #8513–8520)Massachusetts General HospitalDiscussion11:45 AM Michael S. Sabel, MD (Abstracts #8521–LBA8526 ∧ )University of MichiganDiscussion12:00 PM Christopher D. Lao, MD (Abstracts #8527–8532)University of MichiganDiscussion12:15 PM F. Stephen Hodi, MD (Abstracts #8533–8537)Dana-Farber Cancer InstituteBrd. 1 An analysis of sera-based microRNAs as biomarkers of recurrence inmelanoma. (Abstract #8513)E. B. Friedman, S. Shang, E. Vega-Saenz de Miera, M. W. Ma, R. S. Berman,R. L. Shapiro, A. C. Pavlick, E. Hernando, Y. Shao, I. OsmanBrd. 2 Functional characterization of an oncogenic role for the miRNA-506–514cluster in initiating melanocyte transformation and promoting melanomagrowth. (Abstract #8514)K. Streicher, W. Zhu, K. Lehmann, R. W. Georgantas III, C. Morehouse,P. Brohawn, R. Carrasco, Z. Xiao, D. Tice, B. W. Higgs, L. Richman, B. Jallal,Y. YaoBrd. 3 Whole-genome expression profiling of brain metastases from melanoma(BrMM) provides preliminary insights into its biology and mechanisms ofdevelopment. (Abstract #8515)M. T. Krauze, R. H. Hamilton, S. Bortoluzzi, S. C. Buch, M. Romkes, A. H. Mintz,D. Kondziolka, J. M. Kirkwood, S. J. MoschosBrd. 4 Targeting histone deacetylase to overcome resistance of B-RAF V600Emelanoma cells to apoptosis. (Abstract #8516)P. Hersey, Chen Chen Jiang, Fritz Lai, Xu Dong ZhangBrd. 5 Molecular mechanisms underlying disease relapse on treatment withselective BRAF inhibitor vemurafenib (RG7204, PLX4032). (Abstract #8517)F. Su, H. Yang, B. Higgins, K. D. Kolinsky, K. Packman, M. Kim, B. J. Lestini,G. Bollag, D. C. HeimbrookBrd. 6 Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 inBRAFV600E melanoma cells through regulation of endoplasmic reticulumstress-related genes. (Abstract #8518)F. E. Meier, D. Beck, H. Niessner, K. T. Flaherty, J. Iovanna, D. Kulms,D. Schadendorf, C. GarbeMONDAY339

Monday, June 6, 2011MONDAYBrd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 14Brd. 15Brd. 16Brd. 17Brd. 18Brd. 19Pattern and outcome of disease progression in phase I study of vemurafenib(RG7204) in patients with metastatic melanoma (MM). (Abstract #8519)K. B. Kim, K. T. Flaherty, P. B. Chapman, J. A. Sosman, A. Ribas, G. A. McArthur,R. K. Amaravadi, R. J. Lee, K. B. Nolop, I. PuzanovPresence of frequent underlying RAS mutations in cutaneous squamous cellcarcinomas and keratoacanthomas (cuSCC/KA) that develop in patientsduring vemurafenib therapy. (Abstract #8520)M. E. Lacouture, P. B. Chapman, A. Ribas, J. A. Sosman, G. A. McArthur,K. T. Flaherty, K. B. Kim, I. Puzanov, K. B. Nolop, A. K. Joe, O. Spleiss, A. Koehler,W. Wu, C. Robert, A. Hauschild, D. Schadendorf, J. L. Troy, M. Duvic, K. TrunzerImpact of population genetic substructure on association studies and riskassessment for melanoma. (Abstract #8521)I. Lobach, I. Belitskaya-Levy, J. D. Goldberg, H. Ostrer, R. S. Berman,A. C. Pavlick, R. L. Shapiro, I. Osman, P. MangaDisparities in the management of melanoma in elderly patients: An analysisof patients from the National Cancer Database. (Abstract #8522)S. Tsai, S. Soong, C. M. Balch, J. R. LangeThe impact of gender on the outcome of malignant melanoma: Overview ofseven EORTC phase III trials. (Abstract #8523)A. Joosse, S. Collette, S. Suciu, E. de Vries, T. Nijsten, P. Patel, U. R. Kleeberg,U. Keilholz, A. M. Eggermont, J. W. Coebergh, EORTC Melanoma GroupThe effect of beta-blocker treatment in patients with cutaneous melanoma.(Abstract #8524)V. De Giorgi, M. Grazzini, S. Gandini, S. Benemei, T. Lotti, N. Marchionni,S. Rossari, A. Gori, P. GeppettiA phase III study of receptor-targeted 99m Tc-tilmanocept versus blue dye inevaluation of SLNs in breast cancer and melanoma. (Abstract #LBA8526^)F. O. Cope, V. K. Sondak, A. M. WallaceAssessment of clinical activity of E7080, a multitargeted kinase inhibitor, inpatients with advanced melanoma treated in two phase I trials. (Abstract#8527)D. S. Hong, D. S. Boss, H. Glen, J. Mink, M. Ren, C. Andresen, J. P. O’Brien,R. Kurzrock, J. H. Schellens, J. J. Nemunaitis, T. EvansA phase II clinical/translational trial of sequential axitinib/carboplatin/paclitaxel in melanoma. (Abstract #8528)A. P. Algazi, E. Cha, C. Soon, S. Ortiz-Urda, B. Cortez, L. Ziani, F. V. Coakley,A. DaudMLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, inpatients (pts) with metastatic melanoma: Results of a phase I study.(Abstract #8529)S. Bhatia, O. Hamid, A. C. Pavlick, G. Mulligan, P. G. Smith, M. D. Pickard,M. Shultz, R. M. Walker, B. Dezube, S. O’DayFinal results of phase I/II study of decitabine (DAC) combined withtemozolomide (TMZ) in metastatic melanoma (MM). (Abstract #8530)J. H. Beumer, H. A. Tawbi, A. A. Tarhini, S. J. Moschos, M. J. Egorin, S. C. Buch,Y. Lin, J. M. KirkwoodSurvival in a phase III, randomized, double-blind study of dacarbazine with orwithout oblimersen (Bcl-2 antisense) in patients with advanced melanomaand low-normal serum lactate dehydrogenase (LDH; AGENDA). (Abstract#8531)A. Y. Bedikian, C. Lebbé, C. Robert, S. S. Agarwala, T. Cousin, J. Wu, C. Garbe,J. J. Grob340

Monday, June 6, 2011Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV)or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) inpatients with unresectable stage IV metastatic melanoma: A North CentralCancer Treatment Group Study (N0775). (Abstract #8532)L. A. Kottschade, V. Suman, D. G. Perez, R. R. McWilliams, J. S. Kaur,T. Amatruda, F. J. Geoffroy, H. M. Gross, P. A. Cohen, A. J. Jaslowski, M. L. Kosel,S. MarkovicPhase II study of recombinant adeno-viral human p53 (rAd-p53) gene therapycombined with surgery in treatment of melanomas of oral mucosa. (Abstract#8533)L. LiCombination immunotherapy for high-risk and advanced melanoma patients.(Abstract #8534)A. I. Riker, N. N. Vahanian, C. J. Link, L. Tennant, W. J. Ramsey, G. R. Rossi,L. C. Alsfeld, E. Davila, M. HarrisonActive immunization toward the MAGE-A3 antigen in patients with metastaticmelanoma: Four-year follow-up results from a randomized phase II study(EORTC16032-18031). (Abstract #8535)W. Kruit, S. Suciu, B. Dreno, V. Chiarion-Sileni, L. Mortier, C. Robert, M. Maio,F. Lehmann, V. G. Brichard, A. Spatz, A. M. Eggermont, U. KeilholzNeoadjuvant ipilimumab in patients with stage IIIB/C melanoma:Immunogenicity and biomarker analysis. (Abstract #8536)A. A. Tarhini, H. Edington, L. H. Butterfield, M. Sinha, S. J. Moschos, H. Tawbi,Y. Shuai, J. Shipe-Spotloe, M. Simonettta, C. Milburn, M. Horak, C. Sander,J. M. KirkwoodClinical benefit of ipilimumab in patients with metastatic melanoma whoprogress on high-dose IL-2. (Abstract #8537)R. W. Joseph, P. Hwu, M. A. Davies, M. B. Atkins, R. J. SullivanMONDAY341

Monday, June 6, 20119:30 AM - 12:30 PMORAL ABSRACT SESSIONBreast Cancer—Triple-negative/Cytotoxics/Local TherapyLocation: Hall B1CME credit: 3Track(s): Breast CancerMONDAYLisa Yee, MD—ChairThe Ohio State University9:30 AM NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in earlybreast cancer (Abstract #LBA1003)T. J. Whelan, I. Olivotto, I. Ackerman, J. A. W. Chapman, B. Chua, A. Nabid,K. A. Vallis, J. R. White, P. Rousseau, A. Fortin, L. J. Pierce, L. Manchul,P. Craighead, M. C. Nolan, J. Bowen, D. R. McCready, K. I. Pritchard,M. N. Levine, and W. ParulekarDiscussion9:45 AM Thomas A. Buchholz, MD (Abstract #LBA1003)University of Texas M. D. Anderson Cancer Center10:00 AM First analysis of SWOG S0221: A phase III trial comparing chemotherapyschedules in high-risk early breast cancer. (Abstract #1004)G. T. Budd, W. E. Barlow, H. C. Moore, T. J. Hobday, J. A. Stewart, C. Isaacs,M. Salim, J. K. Cho, K. Rinn, K. S. Albain, H. K. Chew, G. V. Burton, T. D. Moore,G. Srkalovic, B. A. McGregor, L. E. Flaherty, R. B. Livingston, D. Lew, J. Gralow,G. N. Hortobagyi, SWOG10:15 AM The effect on pCR of bevacizumab and/or antimetabolites added to standardneoadjuvant chemotherapy: NSABP protocol B-40. (Abstract #LBA1005)H. D. Bear, G. Tang, P. Rastogi, C. E. Geyer, A. Robidoux, J. N. Atkins, L. Baez,A. Brufsky, R. S. Mehta, L. Fehrenbacher, E. R. Pajon, F. M. Senecal, R. Gaur,R. G. Margolese, P. T. Adams, H. M. Gross, S. M. Swain, E. P. Mamounas,J. P. Costantino, N. Wolmark10:30 AM Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in686 triple-negative primary breast cancers: Seconday endpoint analysis ofthe GEPARQUINTO study (GBG 44). (Abstract #1006)B. Gerber, H. Eidtmann, M. Rezai, P. A. Fasching, H. Tesch, H. Eggemann,I. Schrader, K. Kittel, C. A. Hanusch, R. Kreienberg, C. Solbach, C. Jackisch,G. Kunz, J. U. Blohmer, J. B. Huober, M. Hauschild, S. Loibl, V. Nekljudova,M. Untch, G. Von Minckwitz, GBG/AGO Study GroupsDiscussion10:45 AM Hope S. Rugo, MD (Abstracts #1004–1006)University of California, San Francisco11:00 AM A randomized phase III study of iniparib (BSI-201) in combination withgemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer(TNBC). (Abstract #1007)J. O’Shaughnessy, L. S. Schwartzberg, M. A. Danso, H. S. Rugo, K. Miller,D. A. Yardley, R. W. Carlson, R. S. Finn, E. Charpentier, M. Freese, S. Gupta,A. Blackwood-Chirchir, E. P. WinerDiscussion11:15 AM Lisa A. Carey, MD (Abstract #1007)University of North Carolina at Chapel Hill11:30 AM Randomized, phase II trial comparing continuous versus intermittentcapecitabine (X) monotherapy for metastatic breast cancer (MBC): Resultsfrom the GEICAM 2009–05 study. (Abstract #1008)M. Martin, N. Martinez, M. Ramos, L. Calvo, A. Lluch, P. Zamora,M. Munoz-Mateu, D. Caronia, E. M. Carrasco, J. Garcia Saenz, A. Casado,I. Chacón, B. Hernando, M. Ruiz-Borrego, A. Gonzalez-Neira342

Monday, June 6, 201111:45 AM Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced(adv) breast cancer (BC) previously treated with bevacizumab (BEV).(Abstract #1009)C. Hudis, K. W. Tauer, R. C. Hermann, G. Makari-Judson, C. Isaacs, J. T. Beck,V. G. Kaklamani, E. J. Stepanski, H. S. Rugo, W. Wang, K. M. Bell-McGuinn,H. Chera, B. Zaugg, S. Ro, S. Li, L. S. Schwartzberg12:00 PM Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT)for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. (Abstract#1010)A. Brufsky, V. Valero, B. Tiangco, S. R. Dakhil, A. Brize, N. Bousfoul, H. S. Rugo,D. A. YardleyDiscussion12:15 PM Stephen R. D. Johnston, MA, MD, PhD (Abstracts #1008–1010)Royal Marsden HospitalMONDAY343

Monday, June 6, 20119:30 AM - 12:30 PMORAL ABSTRACT SESSIONHealth Services ResearchLocation: S404CME credit: 3Track(s): Health Services ResearchMONDAYMonika K. Krzyzanowska, MD—Co-ChairPrincess Margaret HospitalChristopher Ryan Friese, RN, PhD—Co-ChairUniversity of Michigan9:30 AM Identification of barriers to clinical trials: The impact of education level.(Abstract #CRA6003)J. R. Eads, T. L. Albrecht, B. Egleston, J. S. Buzaglo, R. B. Cohen, L. Fleisher,T. Foster, M. Katz, T. Kinzy, S. Manne, D. M. Miller, S. M. Miller, S. Raivitch,N. Roach, A. Silver, N. J. Meropol9:45 AM The impact of socioeconomic status on cancer care and survival. (Abstract#6004)S. L. Wong, N. Gu, M. Banerjee, J. D. Birkmeyer, N. J. Birkmeyer10:00 AM The impact of economic recession on the incidence and treatment of cancer.(Abstract #6005)K. Y. Ennis, M. Chen, G. C. Smith, A. V. D’Amico, Y. Zhang, L. B. Harrison,R. D. Ennis10:15 AM Impact of out-of-pocket expenses on cancer care. (Abstract #6006)Y. Zafar, A. M. Goetzinger, R. Fowler, A. Gblokpor, D. Warhadpande, D. H. Taylor,D. Schrag, J. M. Peppercorn, A. P. Abernethy10:30 AM Cancer diagnosis as a risk factor for personal bankruptcy. (Abstract #6007)S. D. Ramsey, C. R. Fedorenko, K. S. Snell, A. C. Kirchhoff, W. Hollingworth,D. K. BloughDiscussion10:45 AM Neal J. Meropol, MD (Abstracts #CRA6003–6007)Case Western Reserve University11:00 AM Prospective and observational study of pain and analgesic prescribing inmedical oncology outpatients with breast, colorectal, lung, or prostatecancer. (Abstract #CRA6008)M. Fisch, J. Lee, M. Weiss, L. I. Wagner, V. T. Chang, D. Cella, J. Manola,L. M. Minasian, W. J. McCaskill-Stevens, T. R. Mendoza, C. S. Cleeland11:15 AM Effect of early palliative care on chemotherapy utilization and end-of-life carein patients with metastatic non-small cell lung cancer (NSCLC). (Abstract#6009)J. A. Greer, W. F. Pirl, V. A. Jackson, I. T. Lennes, R. S. Heist,E. R. Gallagher, J. S. TemelDiscussion11:30 AM Susan Yount, PhD (Abstracts #CRA6008–6009)Northwestern University, Feinberg School of Medicine11:45 AM Correlates of contralateral prophylactic mastectomy in a population-basedsample. (Abstract #6010)S. T. Hawley, R. Jagsi, M. Morrow, S. J. Katz12:00 PM Quality of non-small cell lung cancer (NSCLC) care in the Veterans HealthAdministration (VHA): Impact of patient preference and clinical judgment.(Abstract #6011)J. J. Ryoo, B. Kim, D. L. Ordin, S. M. Oishi, S. M. Asch, A. M. Antonio, R. He,M. K. Gould, J. Malin344

Monday, June 6, 2011Discussion12:15 PM David J. Bentrem, MD (Abstracts #6010–6011)Northwestern University, Feinberg School of MedicineMONDAY345

Monday, June 6, 20119:30 AM - 12:30 PMORAL ABSTRACT SESSIONLeukemia, Myelodysplasia, and TransplantationLocation: Arie Crown TheaterCME credit: 3Track(s): Leukemia, Myelodysplasia, and TransplantationMONDAYAttaya Suvannasankha, MD—Co-ChairIndiana UniversityGuido Marcucci, MD—Co-ChairThe Ohio State University Comprehensive Cancer Center9:30 AM Results of COMFORT- I, a randomized double-blind phase III trial of JAK 1/2inhibitor INCB18424 (424) versus placebo (PB) for patients withmyelofibrosis (MF). (Abstract #6500)S. Verstovsek, R. A. Mesa, J. R. Gotlib, R. S. Levy, V. Gupta, J. F. DiPersio,J. Catalano, M. Deininger, C. B. Miller, R. T. Silver, M. Talpaz, E. F. Winton,J. H. Harvey, K. Vaddi, S. K. Erickson-Viitanen, I. Koumenis, W. Sun, V. Sandor,H. Kantarjian, on behalf of all COMFORT-I investigators9:45 AM Results of a randomized study of the JAK inhibitor ruxolitinib (INC424)versus best available therapy (BAT) in primary myelofibrosis (PMF), postpolycythemiavera-myelofibrosis (PPV-MF), or post-essentialthrombocythemia-myelofibrosis (PET-MF) (Abstract #LBA6501)C. N. Harrison, J. J. Kiladjian, H. K. Al-Ali, H. Gisslinger, R. J. Waltzman,V. Stalbovskaya, M. McQuitty, D. S. Hunter, R. S. Levy, F. Cervantes,A. M. Vannucchi, T. Barbui, G. Barosi10:00 AM The incidence of BCR-ABL mutations in patients (pts) with newly diagnosedchronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinibor imatinib in ENESTnd: Twenty-four-month follow-up. (Abstract #6502)G. Saglio, H. Kantarjian, J. Reiffers, S. Jootar, M. E. Kalaycio, H. Shibayama,X. Fan, N. J. Gallagher, Y. Shou, R. A. Larson, T. P. Hughes, A. HochhausDiscussion10:15 AM Ross L. Levine, MD (Abstracts #6500–6502)Memorial Sloan-Kettering Cancer Center10:30 AM Clofarabine plus cytarabine compared to cytarabine alone in older patientswith relapsed or refractory (R/R) acute myelogenous leukemia (AML):Results from the phase III CLASSIC 1 trial. (Abstract #6503^)S. Faderl, M. Wetzler, D. Rizzieri, G. J. Schiller, M. H. Jagasia, R. K. Stuart,S. Ganguly, D. Avigan, M. Craig, R. Collins, M. B. Maris, T. Kovacsovics,S. Goldberg, K. Seiter, P. Hari, F. Ravandi, E. S. Wang, S. Eckert, D. Huebner,H. Kantarjian10:45 AM Results from a randomized phase III trial of decitabine versus supportivecare or low-dose cytarabine for the treatment of older patients with newlydiagnosed AML. (Abstract #6504)X. G. Thomas, A. Dmoszynska, A. Wierzbowska, K. Kuliczkowski, J. Mayer,T. Shelekhova, J. Gau, W. Chou, R. Buckstein, J. Cermak, C. Kuo,A. O. Rocafiguera, V. Koza, F. Ravandi, H. Kantarjian11:00 AM Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia:completed results of the phase I study. (Abstract #6505)D. A. Pollyea, H. E. Kohrt, L. Gallegos, B. Zhang, M. Figueroa, A. Melnick,C. Berube, S. E. Coutre, J. R. Gotlib, J. L. Zehnder, M. Liedtke, B. S. Mitchell,B. C. Medeiros346

Monday, June 6, 201111:15 AM Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts)with relapsed/refractory myeloid malignancies: Evidence of activity in ptswith RAS mutation. (Abstract #6506)G. Borthakur, L. Popplewell, M. H. Kirschbaum, J. M. Foran, T. M. Kadia,E. Jabbour, M. Boyiadzis, A. Verma, R. B. Walter, P. S. Wissel,L. Xu, J. W. Bauman, J. Z. Zhu, J. Mazumdar, M. Baccus, J. M. Connor,J. E. Cortes, H. KantarjianDiscussion11:30 AM Gail J. Roboz, MD (Abstracts #6503 ∧ –6506)Weill Medical College of Cornell University11:45 AM Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attachedto calicheamycin, produces complete response (CR) plus complete marrowresponse (mCR) of greater than 50% in refractory relapse (R-R) acutelymphocytic leukemia (ALL). (Abstract #6507)E. Jabbour, S. M. O’Brien, D. A. Thomas, F. Ravandi, S. York, M. Kwari, S. Faderl,T. M. Kadia, C. Wilson, R. Tarnai, A. S. Advani, G. Garcia-Manero, J. E. Cortes,H. Kantarjian12:00 PM The Bruton’s tyrosine kinase (Btk) inhibitor PCI-32765 is highly active andtolerable in patients with chronic lymphocytic leukemia/small lymphocyticlymphoma (CLL/SLL): Interim results of a phase Ib/II study. (Abstract #6508)J. C. Byrd, K. A. Blum, J. A. Burger, S. E. Coutre, J. P. Sharman,R. R. Furman, I. W. Flinn, B. W. Grant, D. A. Richards, W. Zhao, N. A. Heerema,A. J. Johnson, R. Izumi, A. Hamdy, S. M. O’BrienDiscussion12:15 PM Ross L. Levine, MD (Abstracts #6507–6508)Memorial Sloan-Kettering Cancer CenterMONDAY347

Monday, June 6, 20119:45 AM - 11:00 AMSPECIAL SESSIONAIDS-associated Malignancies in Low- and Middle-income CountriesLocation: E354bCME credit: 1.25Track(s): Special Session, Cancer Prevention/Epidemiology, InternationalClement Adebayo Adebamowo, MD, ScD—ChairInstitute of Human Virology, University of Maryland School of MedicineAIDS-associated Malignancies: An Epidemic ForetoldRonald T. Mitsuyasu, MDUniversity of California, Los Angeles Care CenterConducting Clinical Trials in Resource Low-income Countries: Challenges and OpportunitiesWilliam A. Blattner, MDUniversity of Maryland BaltimorePatterns and Trends in HIV-associated MalignancyE. Akin Abayomi, MBBS, MRCP, MPhilStellenbosch UniversityEffect of Antiretroviral Therapy on the Evolving Pattern and Incidence of HIV-related Lymphomain South AfricaMONDAY348

Monday, June 6, 20119:45 AM - 11:00 AMEDUCATION SESSIONSAssessing Patients’ Psychosocial Needs: How to Do This in (Your Busy)PracticeLocation: S100aCME credit: 1.25Track(s): Patient and Survivor Care, Breast CancerMichelle Joy Naughton, PhD—ChairWake Forest University School of MedicineOverview of Psychosocial Problems and Risk Factors among Cancer SurvivorsPaul B. Jacobsen, PhDH. Lee Moffitt Cancer Center & Research InstitutePsychosocial Screening for Patients with Cancer: Opportunities and ChallengesDavid Goldstein, MDPrince of Wales HospitalTranslating Research into Everyday Patient Care: Applying the Outcomes of PsychosocialScreening and Intervention Trials into Clinical PracticeImmunotherapy for Advanced and High-risk Melanoma: Lessons Learned andFuture DirectionsLocation: E354aCME credit: 1.25Track(s): Melanoma/Skin CancersJohn M. Kirkwood, MD—ChairUniversity of Pittsburgh Medical CenterHistorical Perspective of Immunotherapy for Advanced or Metastatic MelanomaThomas Gajewski, MD, PhDThe University of ChicagoLimitations of Immunotherapy, Mechanisms of Resistance, Immune Escape, Effect of TumorMicroenvironment, and Why Immunotherapy Strategies May Have Been IneffectiveSuzanne Louise Topalian, MDThe Johns Hopkins University School of MedicineOverview of the Future of Immunotherapy Strategies for Advanced MelanomaNew Targeted Therapies in Neuroendocrine Cancers: What Should Be theSequence of Therapy?Location: Hall D1CME credit: 1.25Track(s): Gastrointestinal (Noncolorectal) Cancer, Developmental TherapeuticsMONDAYMatthew Kulke, MD, MMSc—ChairDana-Farber Cancer InstituteWhat Is the Best Sequence of Therapy for Pancreatic Neuroendocrine Tumors?Emily K. Bergsland, MDUniversity of California, San Francisco Cancer CenterWhat Is the Best Sequence of Treatment for Carcinoid Tumors?Martyn Caplin, MDRoyal Free Hampstead NHS TrustThe Role of Somatostatin Analogs in the Treatment of Neuroendocrine Tumors: When ShouldThey Be Started and When Do We Add Other Agents?349

Monday, June 6, 2011What Is Going on with Mesothelioma?Location: S406CME credit: 1.25Track(s): Lung Cancer, SarcomaHarvey I. Pass, MD—ChairNew York University School of MedicineSurgery for Pleural Mesothelioma: Are We Closer to Personalized Selection?Michele Carbone, MD, PhDUniversity of Hawaii Cancer CenterNew Concepts in Mesothelial Carcinogenesis: Fibers, Inflammation, and HotspotsAnna K. Nowak, MBBS, PhDSir Charles Gairdner HospitalMesothelioma Chemotherapy, Biologic Therapy, and Immunotherapy: Pathways, PersonalizedPrediction, and Results to DateMONDAY350

Monday, June 6, 20119:45 AM - 11:00 AMMEET THE PROFESSOR SESSIONSFollicular Lymphoma Case Studies: Blending the Art and Science of MedicineTogether (M14)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Lymphoma and Plasma Cell DisordersMyron Stefan Czuczman, MDRoswell Park Cancer InstitutePreparing for New Cultural Competence Requirements for OncologyProfessionals (M21)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Ethics, Patient and Survivor Care, Professional DevelopmentMarjorie Kagawa-Singer, PhD, MA, MN, RNUniversity of California, Los Angeles School of Public HealthUnderstanding the Notion of Culture and Its Influence on Health-related Matters and OncologyPracticeAntonella Surbone, MD, PhDNew York UniversityMeeting Oncologists’ Educational Needs in Preparation for the Joint Commission 2012Standards in Cultural CompetenceMONDAY351

Monday, June 6, 20119:45 AM - 11:15 AMSPECIAL SESSIONASCO/American Association for Cancer Research (AACR) Joint Session:Telomeres and Telomerase in CancerLocation: S100bcCME credit: 1.5Track(s): Tumor Biology, Special SessionGeorge W. Sledge Jr., MD—Co-ChairIndiana University Simon Cancer CenterWelcome and IntroductionElizabeth H. Blackburn, PhD—Co-ChairUniversity of California, San FranciscoTelomeres and Telomerase in Human Cancer and in the Aging PopulationSteven Artandi, MD, PhDStanford School of MedicineFunctional Involvement of Telomerase in New Cellular FunctionsKathy Miller, MDIndiana University Simon Cancer CenterThe Clinical Perspective: Where We Are Going with Telomeres and TelomeraseMONDAY352

Monday, June 6, 201111:30 AM - 12:45 PMEDUCATION SESSIONSAdvances in Risk Stratification, Biology, and Treatment of NeuroblastomaLocation: S504CME credit: 1.25Track(s): Pediatric OncologySusan Lerner Cohn, MD—ChairUniversity of Chicago Pritzker School of MedicineRefining Risk Classification for Children with NeuroblastomaMeredith Irwin, MDThe Hospital for Sick ChildrenWhat Role Do “Stem Cells” Play in Neuroblastoma?Rochelle Bagatell, MDThe Children’s Hospital of PhiladelphiaAdvances in the Treatment of Patients with High-risk NeuroblastomaConsiderations When Standard of Care Fails (eQuestions Session)Location: E353CME credit: 1.25Track(s): Ethics, Clinical Trials, Practice Management and Information TechnologyJeffrey M. Peppercorn, MD, MPH—ChairDuke University Medical CenterOptions to Consider in Developing an Individualized Approach to Advanced Cancer CareRobert L. Erwin, MSMarti Nelson Cancer FoundationA Patient’s Perspective on Options to Consider When Standard Interventions Are ExhaustedThomas J. Smith, MDMassey Cancer Center of Virginia Commonwealth UniversityHow and Why to Discuss Palliative Care with Patients with Advanced Cancer after StandardCare Has FailedManagement of Complications and Palliative Care for Patients with BrainTumorsLocation: E354bCME credit: 1.25Track(s): Central Nervous System Tumors, Patient and Survivor CareDenise Correa, PhD—ChairMemorial Sloan-Kettering Cancer CenterAn Overview of Cognitive Functions in Patients with Brain TumorsMONDAYNigel Key, MDUniversity of North Carolina at Chapel HillApproach to Thromboembolic Disease in Patients with Brain TumorsAlan D. Valentine, MDUniversity of Texas M. D. Anderson Cancer CenterPharmacologic Stimulant Therapies, Such As Methylphenidate and Modafinil353

Monday, June 6, 2011The Art and Business of a Successful Early Clinical Trials Program: Academic,Private, and Industry PerspectivesLocation: E354aCME credit: 1.25Track(s): Developmental Therapeutics, Clinical TrialsChris H. M. Takimoto, MD, PhD—ChairUniversity of Texas Health Science Center at San AntonioIndustry Considerations for Phase I PartnershipsPatricia LoRusso, DOKarmanos Cancer InstituteAcademic Phase I Program: If You Build It, Will They Come?Lee S. Rosen, MDPremiere OncologyA Private Model for a Successful Phase I Clinical Trials ProgramMONDAY354

Monday, June 6, 201111:30 AM - 12:45 PMMEET THE PROFESSOR SESSIONSMelanoma FISH ’n’ Chips (M15)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Melanoma/Skin CancersHensin Tsao, MDMassachusetts General HospitalMultidisciplinary Treatment of Skull Base Tumors (M22)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Head and Neck CancerFrancis P. Worden, MDUniversity of Michigan Cancer CenterChemotherapy for Skull Base MaliganciesEhab Y. Hanna, MDUniversity of Texas M. D. Anderson Cancer CenterSurgical Management of Base of Skull TumorsMONDAY355

Monday, June 6, 20111:00 PM - 4:00 PMORAL ABSTRACT SESSIONDevelopmental Therapeutics—Clinical Pharmacology and ImmunotherapyLocation: Arie Crown TheaterCME credit: 3Track(s): Developmental TherapeuticsMONDAYTyler J. Curiel, MD—ChairUniversity of Texas Health Science Center at San Antonio1:00 PM Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes incombination with poly-ICLC in patients with recurrent malignant glioma.(Abstract #2506)H. Okada, P. Kalinski, A. H. Mintz, J. A. Engh, L. H. Butterfield, R. H. Hamilton,D. M. Potter, A. M. Salazar, F. S. Lieberman1:15 PM Effect of denileukin diftitox on serum GM-CSF and clinical responses instage IV melanoma. (Abstract #2507)J. Chesney, M. Rasku, A. C. Klarer, D. M. Miller, S. Telang1:30 PM Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 byNewcastle disease virus. (Abstract #2508)J. Nesselhut, D. Marx, D. Lorenzen, N. Cillien, W. Goebel, R. Y. Chang,W. Brockmann, J. Peters, K. Nesselhut, F. Fändrich, T. NesselhutDiscussion1:45 PM Tyler J. Curiel, MD (Abstract #2506–2508)University of Texas Health Science Center at San Antonio2:00 PM Immunotransplant for mantle cell lymphoma: Phase I/II study preliminaryresults. (Abstract #2509)J. Brody, R. Advani, W. Weng, D. Czerwinski, A. A. Alizadeh, H. E. Kohrt,R. Negrin, R. Levy2:15 PM Phase I clinical trial of cancer vaccine with five novel epitope peptides forpatients with metastatic colorectal cancer (mCRC). (Abstract #2510)S. Hazama, M. Oka, K. Yoshida, T. Tsunoda, S. Yoshino, Y. Hinoda, Y. Nakamura2:30 PM The role of relative lymphocyte count as a new biomarker for the effect ofcatumaxomab on overall survival in patients with malignant ascites: Followupresults from a phase ll/lll study. (Abstract #2512)M. M. Heiss, M. A. Ströhlein, C. Bokemeyer, D. Arnold, S. L. Parsons, M. G. Ott,E. Schulze, H. Lindhofer, D. Seimetz, M. HennigDiscussion2:45 PM Eduardo M. Sotomayor, MD (Abstracts #2509–2510, 2512)H. Lee Moffitt Cancer Center & Research Institute3:00 PM A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediatedpeptide inhibitor of p53 ubiquitination in patients with metastatic refractorysolid tumors. (Abstract #2511)J. M. Richards, M. A. Warso, D. Mehta, K. Christov, C. M. Schaeffer, T. Yamada,C. W. Beattie, L. R. Bressler, T. K. Das Gupta3:15 PM Phase I/II study with trabedersen (AP 12009) monotherapy for the treatmentof patients with advanced pancreatic cancer, malignant melanoma, andcolorectal carcinoma. (Abstract #2513)H. Oettle, A. Hilbig, T. Seufferlein, A. Tsianakas, T. Luger, R. M. Schmid,G. von Wichert, E. Endlicher, C. Garbe, K. K. Kaehler, A. Hauschild, A. Enk,P. Kiessling, S. Schmaus, H. Heinrichs, K. Schlingensiepen356

Monday, June 6, 20113:30 PM A phase Ib dose-escalation study of the safety, pharmacokinetics (PK),pharmacodynamics (PD), and antitumor activity of the humanizedmonoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination withbevacizumab with or without paclitaxel in patients with advanced solidtumors. (Abstract #2514)L. Naumovski, M. S. Gordon, P. N. Munster, P. Hegde, J. Fredrickson, S. Bai,R. P. Funke, I. Chang, G. S. Chandler, D. S. Chen, L. S. RosenDiscussion3:45 PM Padmanee Sharma, MD, PhD (Abstracts #2511–2514)University of Texas M. D. Anderson Cancer CenterMONDAY357

Monday, June 6, 20111:00 PM - 4:00 PMORAL ABSTRACT SESSIONGenitourinary (Prostate) CancerLocation: Hall D1CME credit: 3Track(s): Genitourinary CancerMONDAYJoshi J. Alumkal, MD—Co-ChairOregon Health & Science UniversityAjjai Shivaram Alva, MBBS, MS—Co-ChairUniversity of Michigan1:00 PM Randomized, placebo-controlled, phase III trial of sunitinib in combinationwith prednisone (SUP) versus prednisone (P) alone in men withprogressive metastatic castration-resistant prostate cancer (mCRPC).(Abstract #4515)M. D. Michaelson, Y. Ou, L. Sengeløv, F. Saad, N. Houede, P. J. Ostler, A. Stenzl,G. Daugaard, R. J. Jones, F. Laestadius, A. Bahl, D. E. Castellano, J. Gschwend,T. Maurina, D. Ye, I. Chen, S. Wang, E. C. Maneval, S. Oudard1:15 PM Cabozantinib (XL184) in metastatic castration-resistant prostate cancer(mCRPC): Results from a phase II randomized discontinuation trial. (Abstract#4516)M. Hussain, M. R. Smith, C. Sweeney, P. G. Corn, A. Elfiky, M. S. Gordon,N. B. Haas, A. L. Harzstark, R. Kurzrock, P. Lara Jr., C. Lin, A. Sella, E. J. Small,A. I. Spira, U. N. Vaishampayan, N. J. Vogelzang, C. Scheffold, M. D. Ballinger,F. Schimmoller, D. C. Smith1:30 PM Evaluation of circulating tumor cell (CTCs) enumeration as an efficacyresponse biomarker of overall survival (OS) in metastatic castration-resistantprostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, arandomized, double-blind, placebo-controlled, phase III study of abirateroneacetate (AA) plus low-dose prednisone (P) post docetaxel. (Abstract#LBA4517)H. I. Scher, G. Heller, A. Molina, T. S. Kheoh, G. Attard, J. Moreira, S. K. Sandhu,C. Parker, C. Logothetis, R. T. McCormack, K. Fizazi, A. Anand, D. C. Danila,M. Fleisher, D. Olmos, C. M. Haqq, J. S. De BonoDiscussion1:45 PM Daniel J. George, MD (Abstracts #4515–LBA4517)Duke Cancer Institute2:00 PM Toward a rational strategy for prostate cancer screening based on long-termrisk of prostate cancer metastases and death: Data from a large, unscreened,population-based cohort followed for up to 30 years. (Abstract #4512)H. Lilja, C. Savage, A. Gerdtsson, T. Bjork, J. Manjer, P. Nilsson, A. Dahlin,A. Bjartell, P. T. Scardino, D. Ulmert, A. J. Vickers2:15 PM Docetaxel-estramustine in high-risk localized prostate cancer: First results ofthe French Genitourinary Tumor Group phase III trial (GETUG 12). (Abstract#4513)K. Fizazi, F. Lesaunier, R. Delva, G. Gravis, F. Rolland, F. Priou, J. Ferrero,N. Houede, L. Mourey, C. Theodore, I. Krakowski, J. Berdah, M. Baciuchka,P. Kerbrat, J. Davin, J. Berille, M. Habibian, J. Ichante, A. Laplanche, S. Culine2:30 PM A phase III randomized trial of intermittent versus continuous androgensuppression for PSA progression after radical therapy (NCIC CTGPR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013).(Abstract #4514)J. M. Crook, C. J. O’Callaghan, K. Ding, G. Duncan, D. P. Dearnaley, C. S. Higano,E. M. Horwitz, E. Frymire, S. Malone, J. Chin, A. Nabid, P. R. Warde, T. B. Corbett,S. Angyalfi, S. L. Goldenberg, M. K. Gospodarowicz, F. Saad, J. P. Logue,P. F. Schellhammer, L. Klotz358

Monday, June 6, 2011Discussion2:45 PM Joel B. Nelson, MD (Abstracts #4512–4514)University of Pittsburgh3:00 PM Randomized phase III study of docetaxel with or without risedronate inpatients with bone metastases from castration-resistant prostate cancer(CRPC): The Netherlands Prostate Study (NePro). (Abstract #4518)H. J. Meulenbeld, E. D. van Werkhoven, J. L. Coenen, G. Creemers,O. J. Loosveld, P. C. De Jong, A. J. Ten Tije, S. D. Fossa, M. Polee,W. R. Gerritsen, O. Dalesio, R. De Wit3:15 PM Effect of abiraterone acetate (AA) on pain control and skeletal-related events(SRE) in patients (pts) with metastatic castration-resistant prostate cancer(mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.(Abstract #4520)C. Logothetis, J. S. De Bono, A. Molina, E. M. Basch, K. Fizazi, S. A. North,K. N. Chi, R. J. Jones, O. B. Goodman, P. N. Mainwaring, C. N. Sternberg,D. D. Gagnon, R. Dhawan, M. Rothman, Y. Hao, C. S. Liu, T. S. Kheoh,H. I. Scher, C. M. HaqqDiscussion3:30 PM Michael J. Morris, MD (Abstracts #4518 and 4520)Memorial Sloan-Kettering Cancer CenterMONDAY359

Monday, June 6, 20111:00 PM - 4:00 PMORAL ABSTRACT SESSIONPatient and Survivor CareLocation: S404CME credit: 3Track(s): Patient and Survivor CareMONDAYTeresa Gilewski, MD—ChairMemorial Sloan-Kettering Cancer Center1:00 PM Does circulating tumor necrosis factor (TNF) play a role inpost-chemotherapy cerebral dysfunction in breast cancer survivors (BCS)?(Abstract #9008)P. A. Ganz, S. A. Castellon, D. H. Silverman, L. Kwan, J. E. Bower, M. R. Irwin,S. W. Cole1:15 PM Effect of yoga on QOL, cortisol rhythym, and HRV for women with breastcancer undergoing radiotherapy. (Abstract #9009)L. Cohen, K. Chandwani, N. Raghuram, R. Haddad, G. H. Perkins, A. Spelman,R. Nagarathna, K. Johnson, A. Fortier, B. Arun, Q. Wei, C. Kirschbaum,H. NagendraDiscussion1:30 PM Karen Michelle Mustian, PhD, MPH (Abstracts #9008–9009)University of Rochester Medical Center1:45 PM A randomized, double-blinded, placebo-controlled trial of oral alpha lipoicacid to prevent platinum-induced polyneuropathy. (Abstract #9010)Y. Guo, J. L. Palmer, A. Forman, S. R. Dakhil, M. R. Velasco, M. Weiss, P. Gilman,G. M. Mills, S. J. Noga, C. Eng, M. J. Overman, M. Fisch2:00 PM A phase III study for prevention of delayed nausea: A University of RochesterCCOP study of 1,021 patients receiving chemotherapy. (Abstract #9012)G. R. Morrow, J. A. Roscoe, C. Heckler, S. R. Dakhil, J. L. Wade,J. P. Kuebler, S. G. Mohile, L. J. Peppone, M. C. Janelsins2:15 PM Phase III, double-blind, placebo-controlled, crossover study evaluating a5HT 3 antagonist with dexamethasone with or without aprepitant in patientswith germ cell tumor receiving 5-day cisplatin combination chemotherapy: AHoosier Oncology Group (HOG) study. (Abstract #9013)M. J. Brames, J. Picus, M. Yu, E. L. Johnston, B. Bottema, C. E. Williams,L. H. EinhornDiscussion2:30 PM Debra L. Barton, PhD, AOCN, RN (Abstracts #9010–9013)Mayo Clinic2:45 PM The ultra-low molecular weight heparin (ULMWH) semuloparin for preventionof venous thromboembolism (VTE) in cancer patients receivingchemotherapy: SAVE ONCO study. (Abstract #LBA9014)G. Agnelli, D. J. George, W. Fisher, A. K. Kakkar, M. R. Lassen, P. Mismetti,P. Mouret, U. Chaudhari, A. G. G. Turpie3:00 PM The evaluation of flaxseed for hot flashes: Results of a randomized,controlled trial, NCCTG study N08C7. (Abstract #CRA9015)S. Pruthi, R. Qin, S. A. Terstriep, H. Liu, C. L. Loprinzi, T. Shah, K. F. Tucker,S. R. Dakhil, M. J. Bury, R. L. Carolla, P. D. Steen, J. Vuky, D. L. Barton360

Monday, June 6, 20113:15 PM Does L-arginine/Korean ginseng/gingko biloba/damiana-based supplementimprove the sexual function and quality of life of female cancer survivors? Arandomized trial. (Abstract #9016)K. Greven, L. D. Case, L. R. Nycum, P. J. Zekan, D. D. Hurd, E. P. Balcueva,G. M. Mills, R. Zon, P. J. Flynn, D. Biggs, E. G. Shaw, Comprehensive CancerCenter of Wake Forest University CCOP Research BaseDiscussion3:30 PM Vered Stearns, MD (Abstracts #LBA9014–9016)The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins UniversityMONDAY361

Monday, June 6, 20111:00 PM - 5:00 PMGENERAL POSTER SESSIONMONDAYBreast Cancer—HER2/ERLocation: Hall ATrack(s): Breast CancerBrd. 1A Use of a gene profile to identify molecular subtypes of breast cancer.(Abstract #537)W. Zwart, F. De Snoo, O. Krijgsman, P. Roepman, S. Tian, A. Glas, R. A. Bender,J. Carroll, R. BernardsBrd. 1B Use of insulin-like growth factor (IGF) pathway polymorphism IGF1Rrs2016347 to predict tumor recurrence in estrogen receptor–positive breastcancer patients. (Abstract #538)T. Winder, G. Giamas, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, A. Gerger,M. J. Labonte, J. Stebbing, H. LenzBrd. 1C Role of Ki67 labeling index (LI) in subdividing homogeneous ER-positivegrading groups of early breast cancer (EBC) in distinct biologic entities.(Abstract #539)A. Ferro, M. Barbareschi, C. Eccher, A. Caldara, D. Aldovini, R. Triolo, L. Cuorvo,F. Berloffa, S. Brugnara, O. Caffo, M. di Pasquale, M. Frisinghelli, V. Murgia,B. Soini, F. Valduga, A. Veccia, E. GalligioniBrd. 1D Estrogen and vascular endothelial growth factor (VEGF): Their role in breastcancer (BC) carcinogenesis and disease progression in premenopause.(Abstract #540)F. Recchia, G. Candeloro, G. Desideri, S. Necozione, S. ReaBrd. 1E An evaluation of PI3K pathway activation on the efficacy of both trastuzumaband lapatinib. (Abstract #541)X. Hu, L. Wang, Q. Zhang, J. Zhang, H. Guo, S. Sun, B. Y. Wang, Z. Jia, Z. Shao,Z. WangBrd. 1F Long-term results of the Toronto magnetic resonance imaging (MRI) breastsurveillance study of women with BRCA1 or BRCA2 mutations. (Abstract#542)K. Passaperuma, D. B. Plewes, P. Causer, K. A. Hill, S. J. Messner, J. Wong,R. A. Jong, F. Wright, M. Yaffe, E. Ramsay, S. Balasingham, L. Verity, A. Eisen,B. Curpen, R. Shumak, S. Narod, E. WarnerBrd. 1G Survival after brain metastases in Asian patients with HER2 breast cancer.(Abstract #543)Y. Yap, B. C. Devi, C. Khorprasert, G. H. Cornelio, N. Sutandyo, E. Yeoh,S. Landis, M. Kobayashi, H. Moon, J. RoBrd. 2A A randomized, placebo-controlled phase II study of AMG 386 plusbevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapyin patients (pts) with HER2-negative, locally recurrent or metastatic breastcancer (LR/MBC). (Abstract #544)V. Dieras, J. Jassem, L. Y. Dirix, J. P. Guastalla, P. Bono, S. A. Hurvitz,A. Gonçalves, G. Romieu, S. A. Limentani, G. H. Jerusalem,K. Lakshmaiah, H. H. Roche, P. Sánchez-Rovira, T. Pienkowski, M. Seguí-Palmer,A. Li, Y. Sun, C. A. Pickett-Gies, H. WildiersBrd. 2B Clinical significance of metastatic-tumor HER2 status in patients withHER2-positive primary breast cancer. (Abstract #545)N. Niikura, J. Liu, N. Hayashi, E. A. Mittendorf, Y. Gong, S. L. Palla, Y. Tokuda,A. M. Gonzalez-Angulo, G. N. Hortobagyi, N. T. UenoBrd. 2C Prognosis in women with small (T1mic,T1a,T1b) node-negative operablebreast cancer by immunohistochemically selected subtypes. (Abstract #546)G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua,G. Pruneri, E. Montagna, S. Dellapasqua, M. Iorfida, A. Cardillo, P. Veronesi,A. Luini, M. Intra, O. D. Gentilini, E. Scarano, D. Pastrello, A. Goldhirsch,M. Colleoni362

Monday, June 6, 2011Brd. 2DBrd. 2EBrd. 2FBrd. 2GBrd. 3ABrd. 3BBrd. 3CBrd. 3DBrd. 3EBrd. 3FHLA-DRB1*07:01-DQA1*02:01 and UGT1A1*28 allele carriage in hepaticserious adverse event cases identified during lapatinib clinical trials.(Abstract #547)C. F. Spraggs, L. R. Budde, L. P. Briley, C. Cox, E. Rappold, G. Aktan,L. S. Williams, V. E. Mooser, L. R. CardonCorrelation between miRNA and gene expression profiles and response toneoadjuvant chemotherapy in patients with locally advanced andinflammatory breast cancer. (Abstract #548)G. Somlo, S. M. Li, X. Wu, S. Lau, P. H. Frankel, L. Kruper, H. Gao, G. Sun,J. H. Yim, A. Hurria, J. E. Mortimer, F. De Snoo, I. B. Paz, J. Rossi, E. Wang,P. Roepman, Y. Yen, L. van’t Veer, R. A. BenderResults of a Belgian multicenter retrospective study to determine theincidence of HER2 gene amplification in patients scored asimmunohistochemistry 0 or 1. (Abstract #549)D. Larsimont, C. Colpaert, R. Salgado, N. Vermeesen, V. D’hondt, T. De CelleDouble-blind, placebo-controlled, multicentric randomized phase IIbneoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative,hormone receptor-positive operable breast cancer. (Abstract #550)P. F. Conte, V. Guarneri, D. G. Generali, A. Bottini, L. Bazzola, F. Piacentini,F. Artioli, K. Cagossi, G. Bisagni, M. Bagnalasta, E. Tagliafico, E. Barbieri,L. Cavanna, A. Ravaioli, R. D’Amico, R. Vicini, A. FrassoldatiT1abN0M0 HER2 invasive breast cancer recurrence: Population-basedcohort of 17,000 consecutive breast cancers 2000–2006 at KaiserPermanente, Northern California (KPNC). (Abstract #551)L. Fehrenbacher, P. Shiraz, M. Sattavat, A. Capra, C. Quesenberry, R. Fulton,L. A. HabelPharmacogenetic investigation of lapatinib-associated diarrhea in metastaticbreast cancer clinical trials. (Abstract #552)L. P. Briley, M. Chiano, K. King, M. Casey, A. J. Preston, F. Sapunar, V. E. Mooser,L. R. Cardon, C. F. SpraggsEfficacy results of node-negative HER2-amplified breast cancer subset fromBCIRG 006 study: A phase III randomized trial comparing doxorubicin andcyclophosphamide followed by docetaxel (AC-T) with doxorubicin andcyclophosphamide followed by docetaxel and trastuzumab (AC-TH) withdocetaxel, carboplatin, and trastuzumab (TCH). (Abstract #553)V. Valero, D. J. Slamon, W. Eiermann, N. J. Robert, T. Pienkowski, M. Martin,J. R. Mackey, M. Lindsay, V. Bee-Munteanu, M. F. Press, G. Sauter, J. CrownPAM50 intrinsic subtyping and pathological responses to neoadjuvanttrastuzumab-based chemotherapy in HER2-positive breast cancer. (Abstract#554)P. Gomez Pardo, A. Prat, G. Bianchini, M. Pickl, A. Belousov, A. Koehler,V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti,F. Vázquez-Mazón, L. Gianni, J. BaselgaA molecular portrait of circulating free DNA of patients with breast cancer:High resolution analysis using SNP 6.0 arrays. (Abstract #555)J. A. Shaw, K. Page, K. Blighe, N. Hava, D. Guttery, B. Ward, J. Brown,C. Ruangpratheep, R. Payne, C. Palmieri, S. Cleator, R. Walker, C. CoombesEvaluation of the prognostic and predictive value of tumor-infiltratinglymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC)trial (BIG 2–98) of node-positive (N) BC comparing the addition of docetaxelto doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). (Abstract#556)S. Loi, R. Salgado, F. Piette, N. Sirtaine, F. Van Eenoo, R. Kammler, G. Rouas,P. A. Francis, J. Crown, B. Nordenskjold, J. Gutierrez, M. Andersson, M. M. Vila,R. Jakesz, G. Viale, E. M. Quinaux, A. Di Leo, S. Michiels,C. Sotiriou, M. J. Piccart-GebhartMONDAY363

Monday, June 6, 2011MONDAYBrd. 3GBrd. 3HBrd. 4ABrd. 4BBrd. 4CBrd. 4DBrd. 4EBrd. 4FBrd. 4GBrd. 4HBrd. 5ATreatment of small node-negative HER2 invasive breast carcinomas:Forty-month update of the joint Aerio/Remagus study. (Abstract #557)J. Wassermann, L. Albiges, M. J. Rodrigues, E. Brain, S. Delaloge,J. Guinebretiere, M. Mathieu, E. Guillot, A. Vincent-Salomon, P. H. Cottu,AERIO/REMAGUSA study of the recurrence score by the 21-gene signature assay as apredictor of clinical response to neoadjuvant exemestane for 24 weeks inestrogen receptor–positive breast cancer. (Abstract #558)N. Masuda, M. Toi, T. Ueno, T. Yamanaka, S. Saji, K. Kuroi, N. Sato, H. Takei,Y. Yamamoto, S. Ohno, H. Yamashita, K. Hisamatsu, K. Aogi, H. Iwata, H. SasanoA phase II clinical trial of drug withdrawal in women with progressive breastcancer while on aromatase inhibitor therapy. (Abstract #559)T. Cigler, M. J. Higgins, J. Szymonifka, A. H. Partridge, J. A. Ligibel, D. Finkelstein,S. E. Come, P. D. Ryan, P. E. GossMeasurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers foroutcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvantchemotherapy in premenopausal women with early breast cancer. (Abstract#560)M. Basik, D. Keilty, O. Aleynikova, D. Tu, X. Li, L. E. Shepherd, V. BramwellA functional assay for the identification of DNA double strand break repairdeficiency in heterozygous carriers of BRCA1/2 and RAD51C mutations.(Abstract #561)A. Becker, M. Graeser, C. Landwehr, T. Hilger, W. Baus, R. Weber,B. Wappenschmidt, R. SchmutzlerAssociation between endoxifen serum concentration and predicted CYP2D6phenotype in a prospective cohort of patients with early-stage breast cancer.(Abstract #562)V. O. Dezentje, J. den Hartigh, H. Guchelaar, T. Hessing, T. van der Straaten,J. M. Vletter - Bogaartz, R. Vree, E. Maartense, C. H. Smorenburg, H. Putter,A. Dieudonné, P. Neven, J. W. Nortier, H. GelderblomElevated pretreatment serum CA9 (carbonic anhydrase 9) and correlationwith progression-free and overall survival in trastuzumab-treated metastaticbreast cancer. (Abstract #563)K. Leitzel, H. Hou, U. Anyanwu, V. Shrivastava, M. S. Evans, S. M. Ali,W. Koestler, E. Fuchs, F. J. Esteva, W. P. Carney, A. LiptonSequential administration of trastuzumab and a CD8 T cell-elicitingHER2/neu peptide vaccine in patients with breast cancer compared totrastuzumab alone. (Abstract #564)A. K. Sears, G. T. Clifton, R. Patil, N. M. Shumway, M. G. Carmichael,D. C. Van Echo, J. P. Holmes, S. Ponniah, E. A. Mittendorf, G. E. PeoplesFc-receptor IIa polymorphism and cardiotoxicity in patients with breastcancer treated with adjuvant trastuzumab. (Abstract #565)N. Cresti, D. Jamieson, M. W. Verrill, M. Pinkilgton, A. V. BoddyBody mass index (BMI) and prognosis in women with metastatic breastcancer (MBC). (Abstract #566)A. Gennari, M. Puntoni, O. Nanni, P. F. Conte, D. Amadori, V. Lorusso,A. De Censi, M. Sormani, V. Guarneri, M. D’Amico, A. Gozza, P. BruzziStandardized uptake value (SUV) by positron emission tomography/computed tomography (PET/CT) as a prognostic variable in metastatic breastcancer (MBC). (Abstract #567)P. G. Morris, M. Fazio, K. L. Jhaveri, C. Serna-Tamayo, A. Eaton, S. Patil,G. Ulaner, J. Howard, S. M. Larson, C. Hudis, M. S. Jochelson, H. L. McArthur364

Monday, June 6, 2011Brd. 5BBrd. 5CBrd. 5DBrd. 5EBrd. 5FBrd. 5GBrd. 5HBrd. 6ABrd. 6BBrd. 6CBrd. 6DBrd. 6ERetreatment with trastuzumab (T)-based therapy in patients (pts) withHER2-positive (HER2) metastatic breast cancer (MBC) resistant to lapatinib(L)-based therapy. (Abstract #568)S. Gori, F. Montemurro, S. Spazzapan, G. Metro, J. Foglietta, G. Bisagni, A. Ferzi,R. R. Silva, T. Gamucci, M. Clavarezza, L. Stocchi, A. Fabi, F. Cognetti, E. Torrisi,D. CrivellariPost-operative complications in neoadjuvant treatment includingbevacizumab for HER2 positive inflammatory breast cancer (IBC): Resultsfrom a phase II prospective trial. (Abstract #569^)R. Rouzier, E. Lambaudie, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone,J. Gligorov, F. Lerebours, H. Roche, D. Pau, P. Viens, R. J. SalmonPhase I study of lapatinib (L) and temozolomide (T) combination for thetreatment of progressive brain metastases (BM) in HER2-positive metastaticbreast cancer patients (Pts) (LAPTEM, LAP 111172). (Abstract #570)E. De Azambuja, M. Lemort, J. R. Rossari, C. Moulin, A. Buttice, V. D’hondt,F. Lebrun, Y. Lalami, F. Cardoso, C. Sotiriou, T. Gil, D. Devriendt, W. Marinus,M. Paesmans, M. Piccart, A. AwadaFirst results of a phase II study of bevacizumab in combination withtrastuzumab and capecitabine as first-line treatment of HER2 LA/MBC.(Abstract #571)S. Tjulandin, A. Makhson, J. Gligorov, M. Lichinitser, A. Lluch, V. Semiglazov,N. Scotto, L. Mitchell, M. MartinImpact of HER2-targeted therapy on overall survival (OS) in patients (pts)with HER2-positive (HER2) metastatic breast cancer (MBC). (Abstract #572)A. Berghoff, R. Bartsch, Z. Bago-Horvath, P. C. Dubsky, M. Rudas, U. Pluschnig,C. Wiltschke, M. Gnant, G. G. Steger, C. ZielinskiThe role of the genomic breast cancer index in predicting pathologicalcomplete response in breast cancer patients treated with neoadjuvantanthracycline plus taxane. (Abstract #573)M. Mathieu, N. C. Kesty, H. Li, V. Scott, V. Marty, P. Viehl, J. Delacruz,S. Delaloge, C. Schnabel, M. G. Erlander, F. AndreCombined inhibition of mTORC1 with temsirolimus and HER2 with neratinib:A phase I study in patients with metastatic HER2-amplified breast cancer.(Abstract #574)D. Gajria, T. A. King, H. Pannu, R. Sakr, A. D. Seidman, A. Syldor, S. Patil,M. Maybody, L. Norton, N. Rosen, C. Hudis, S. ChandarlapatyTrastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer. (Abstract #575)I. Lang, R. Bell, F. Feng, R. I. Lopez, J. Jassem, V. Semiglazov, N. Al-Sakaff,E. Carreras, J. ChangAre St. Gallen endocrine response classes predictive for recurrence ratesover time? (Abstract #576)R. H. Koornstra, K. J. Beelen, A. Vincent, P. J. van Diest, S. C. LinnMeasurement of baseline serum SDF-1 levels as a predictive biomarker foroutcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analoguein postmenopausal breast cancer. (Abstract #577)A. Aguilar-Mahecha, M. Basik, J. W. Chapman, K. Jahan, S. Hassan, L. Zhu,C. F. Wilson, K. I. Pritchard, L. E. Shepherd, M. N. PollakDiscordance in estrogen receptor status between primary, metastatic, andsecond primary breast cancers: Impact of misclassification. (Abstract #578)D. Huo, J. Liu, O. I. OlopadeLong-term cardiac safety and outcomes of dose dense (dd) doxorubicin andcyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) withand without lapatinib (L) in patients (pts) with early breast cancer (BC).(Abstract #579)C. T. Dang, P. G. Morris, S. Patil, C. Chen, A. Abbruzzi, R. Lehman, R. Steingart,L. Norton, C. HudisMONDAY365

Monday, June 6, 2011MONDAYBrd. 6FBrd. 6GBrd. 6HBrd. 7ABrd. 7BBrd. 7CBrd. 7DBrd. 7EBrd. 7FBrd. 7GBrd. 7HBrd. 8APredicting invasive disease at excision of ductal carcinoma in situ in corebiopsies: A predictive model. (Abstract #580)C. McGathey, A. Fought, D. Scholtens, S. A. KhanSalvage stereotactic radiosurgery (SRS) after previous whole brain radiationtherapy (WBRT) for breast cancer brain metastases: Outcomes andprognostic factors including tumor phenotype. (Abstract #581)P. J. Kelly, N. U. Lin, E. B. Claus, S. E. Weiss, B. M. AlexanderMutations of the catalytic domain of PI3 kinase and correlation with clinicaloutcome in trastuzumab-treated metastatic breast cancer (MBC). (Abstract#582)J. W. Cook, E. Paxinos, L. J. Goodman, S. M. Ali, K. Leitzel, W. Koestler, A. Rivera,J. M. Weidler, W. Huang, J. Sperinde, S. J. Williams, M. Bates, A. LiptonLapatinib-induced senescent-like phenotype in HER2-positive breast cancercells. (Abstract #583)M. McDermott, B. Browne, J. Crown, N. O’Brien, D. J. Slamon, N. O’DonovanThe effect of a tamoxifen dose increase from 20 mg to 40 mg in patients withat least one inactive CYP2D6 variant allele and/or concomitant use of aCYP2D6 inhibitor. (Abstract #584)M. E. Welzen, V. O. Dezentje, R. H. van Schaik, E. P. Colbers, H. Guchelaar,J. den Hartigh, D. M. Burger, H. Van LaarhovenDiscordance in pathology report after central pathology review in earlybreast cancer and its impact on treatment choice. (Abstract #585)L. Orlando, G. Viale, P. Schiavone, P. Fedele, A. Nacci, P. Rizzo, N. Calvani,F. Sponziello, C. Chetri, E. Mazzoni, M. D’ Amico, A. Marino, M. Cinefra, S. CinieriQuantitative measurements of p95HER2 (p95) and total HER2 (H2T) proteinexpression in patients with trastuzumab-treated, metastatic breast cancer(MBC): Independent confirmation of clinical cutoffs. (Abstract #586)W. Biernat, R. Duchnowska, B. Szostakiewicz, J. Sperinde, M. Haddad, A. Paquet,Y. Lie, J. Weidler, W. Huang, J. Winslow, T. Jankowski, B. Arlukowicz-Czartoryska,P. J. Wysocki, M. Foszczynska-Kloda, B. Radecka, M. M. Litwiniuk, S. Debska,M. Bates, J. JassemIGF1R and phosphorylated IGF1R in HER2-positive breast cancer. (Abstract#587)B. Browne, J. Crown, A. J. Eustace, S. Kennedy, N. O’Brien, A. Larkin, J. Ballot,T. Mahgoub, Z. Qadir, F. Sclafani, S. F. Madden, M. J. Kennedy, M. J. Duffy,N. O’DonovanPreliminary results of centralized HER2 testing in DCIS of the breast: NSABPB-43. (Abstract #588)K. P. Siziopikou, M. A. Cobleigh, S. J. Anderson, T. B. Julian, D. W. Arthur,P. Zheng, E. P. Mamounas, E. R. Pajon, R. J. Behrens, L. Chu, N. C. Leasure,J. N. Atkins, J. Polikoff, T. E. Seay, W. J. McCaskill-Stevens, R. Rabinovitch,N. WolmarkBcl2 expression and prediction of outcomes to anthracycline-basedneoadjuvant chemotherapy in ER-positive breast cancer and tononanthracycline adjuvant therapy. (Abstract #589)P. D. Dickinson, T. M. Abdel-Fatah, A. R. Green, P. Moseley, J. S. Reis-Filho,I. O. Ellis, S. ChanEfficacy and safety of retaspimycin hydrochloride (IPI-504) in combinationwith trastuzumab in patients (pts) with pretreated, locally advanced ormetastatic HER2-positive breast cancer. (Abstract #590)S. Modi, C. Saura, C. A. Henderson, N. U. Lin, R. L. Mahtani, J. Goddard,E. Rodenas, J. O’Shaughnessy, J. BaselgaStrategies for protecting patients from anthracyline-induced cardiacdysfunction. (Abstract #591)A. K. Dickey, C. Geisberg, Y. R. Su, I. A. Mayer, J. A. Means-Powell, C. Silverstein,X. Peng, D. Freehardt, B. White, D. J. Lenihan, D. Sawyer366

Monday, June 6, 2011Brd. 8BBrd. 8CBrd. 8DBrd. 8EBrd. 8FBrd. 8GBrd. 8HBrd. 9ABrd. 9BBrd. 9CBrd. 9DUsing the 21-gene recurrence score and the recently developed recurrencescore clinical pathologic to assess recurrence risk in patients with nodenegative,ER-positive early-stage breast cancer receiving aromatase inhibitortreatment alone. (Abstract #592)M. Crager, G. Tang, S. ShakPopulation-based comparison of breast cancer screening and treatmentutilization by remoteness of residence in British Columbia. (Abstract #593)R. A. Olson, N. R. Caron, I. Olivotto, C. Speers, A. Davidson, S. K. Chia,A. Coldman, A. Nichol, C. Bajdik, S. TyldesleyAssociation between bone turnover markers and skeletal-related events inpatients with breast cancer and bone metastases on treatment withbisphosphonates (ZOMAR study results at 9 months of follow-up). (Abstract#594)A. Barnadas, C. De la Piedra, C. Crespo, P. Gomez Pardo, L. Calvo, E. G. Calvo,M. Ruiz-Borrego, J. Rifa, L. Manso, A. Anton, M. Codes, M. Margeli, A. Murias,J. Salvador, M. Seguí-Palmer, A. De Juan, J. Gavila, D. Perez, M. Luque,I. TusquetsEvaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictorof response to neoadjuvant chemotherapy (NACT) in primary breast cancer.(Abstract #595)A. Wenners, K. Mehta, S. Loibl, H. Park, N. Arnold, S. Hamann, J. Weimer,B. Ataseven, C. Schem, F. Khandan, C. Thomssen, W. Jonat, H. Holzhausen,G. Von Minckwitz, C. Denkert, M. BauerAn analysis of vitamin D (Vit D) and serum estrogens in postmenopausal(PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs).(Abstract #596)D. W. Cescon, M. Ennis, P. A. Ganz, S. Beddows, F. Z. Stanczyk, S. S. Sridhar,P. J. GoodwinSystemic therapy and overall survival (OS) in patients (pts) with brainmetastases from HER2-positive (HER2) metastatic breast cancer (MBC).(Abstract #597)R. Bartsch, A. Berghoff, U. Pluschnig, Z. Bago-Horvath, P. C. Dubsky,A. Rottenfusser, C. Wenzel, M. Rudas, F. Fitzal, K. Dieckmann, M. Gnant,C. Zielinski, G. G. StegerA phase II study of lonafarnib (LF) in patients with locally advanced andmetastatic breast cancer (MBC): Hoosier Oncology Group BRE07–126.(Abstract #598)B. Leyland-Jones, K. Miller, P. Silverman, C. Shen, C. E. Williams, T. Breen,G. W. Sledge Jr.The expression of GATA-3 and FOXA1 in breast cancer: The biomarkers ofhormonal sensitivity in luminal type tumors. (Abstract #599)Y. Hisamatsu, E. Tokunaga, S. Akiyoshi, S. Okada, N. Yamashita, E. Oki,M. Morita, Y. Kakeji, Y. MaeharaDoes metformin use influence outcome in diabetic women with invasivebreast cancer? (Abstract #600)B. Oppong, S. Oskar, M. Stempel, A. Eaton, S. Patil, T. A. KingThe prognostic value of the cocaine and amphetamine-regulated transcript(CART) in breast cancer (BC). (Abstract #601)D. P. O’Connor, D. J. Brennan, H. Laursen, S. F. McGee, S. McCarthy,R. Zagozdzon, E. Rexhepaj, A. Culhane, F. M. Martin, M. J. Duffy, G. Landberg,L. Ryden, S. M. Hewitt, M. J. Kuhar, R. Bernards, R. C. Millikan, J. Crown,K. Jirstrom, W. M. GallagherCosts associated with chemotherapy-related complications in the treatmentof metastatic breast cancer in a real-world setting. (Abstract #602)A. Guerin, D. Lalla, D. Latremouille-Viau, A. P. Yu, E. Q. Wu, M. Brammer,S. A. HurvitzMONDAY367

Monday, June 6, 2011MONDAYBrd. 9EBrd. 9FBrd. 9GBrd. 9HBrd. 10ABrd. 10BBrd. 10CBrd. 10DBrd. 10EBrd. 10FBrd. 10GBrd. 10HHigh false-negative rate of HER2 qRT-PCR of the Oncotype DX test: Anindependent quality assurance study. (Abstract #603)D. J. Dabbs, M. Klein, S. Mohsin, R. R. Tubbs, R. BhargavaAssociation of GP88 (progranulin) tumor expression with decreased diseasefreeand overall survivals in patients with breast cancer with estrogenreceptor-positive invasive ductal carcinoma. (Abstract #604)G. Serrero, D. M. Hawkins, B. Yue, O. B. Ioffe, P. Bejarano, J. T. Phillips,J. F. Head, R. L. Elliott, A. K. Godwin, J. Weaver, W. Kim, S. KamimuraA semiphysiologic population pharmacokinetic/pharmacodynamic (PK/PD)model of thrombocytopenia (TCP) characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC.(Abstract #605)B. C. Bender, F. Schaedeli Stark, A. Joshi, Y. Chu, H. S. Rugo, I. E. Krop,S. Girish, M. GuptaGenomic grade: Feasibility in routine practice and influence on treatmentdecision in early breast cancer. (Abstract #606)O. Metzger, A. Catteau, S. Michiels, M. E. Buyse, K. V. Saini, V. Fasolo, J. Canon,P. Delrée, M. Coibion, V. Jossa, J. Kains, D. Larsimont, V. Richard, D. Faverly,N. Cornez, P. Vuylsteke, B. Vanderschueren,H. P. Peyro Saint Paul, M. J. Piccart-Gebhart, C. SotiriouAdjuvant treatment strategy and results in small breast cancer tumors (pT1)with HER2 overexpression. (Abstract #607)A. Hinke, P. Dall, G. Lenzen, C. Schumacher, D. Rezek, N. Gazawi, A. Ammon,F. G. Foerster, F. Beldermann, U. Cirrincione, J. WilkePolymorphisms of the aromatase gene (CYP19A1) and benefit of aromataseinhibitors (AIs) in metastatic breast cancer (mBC) patients. (Abstract #608)M. Arnedos, R. Ferraldeschi, R. A’Hern, K. Hadfield, S. Roberts, S. Drury,A. Howell, D. G. Evans, A. M. Wardley, I. E. Smith, W. G. Newman, M. DowsettHigh recurrence risk in pT1bc HER2-positive, triple-negative, node-negativeearly breast cancer patients. (Abstract #609)A. Vaccaro, F. Ciancola, L. Pizzuti, I. Sperduti, L. Moscetti, P. Vici, F. Longo,E. Ruggeri, M. Di Seri, M. Giampaolo, T. GamucciCirculating tumor cells as a prognostic factor independent of obesity inmetastatic breast cancer patients. (Abstract #610)M. Giuliano, A. Giordano, A. Patt, L. Hsu, R. H. Alvarez, N. T. Ueno, V. Valero,G. N. Hortobagyi, M. Cristofanilli, J. M. ReubenDetermining agreement between immunohistochemistry and RT-qPCR forstandard biomarkers in breast cancer: Validation on GEICAM 9906 clinicaltrial. (Abstract #611)P. S. Bernard, C. Davis, B. Munarriz, I. J. Stijleman, M. Ruiz-Borrego, M. T. Ebbert,A. Rodriguez-Lescure, R. R. Bastien, C. Crespo, C. M. Perou, C. Rodriguez,F. I. Aranda, V. Furió, I. Alvarez, M. Seguí, E. Alba, A. Anton, E. M. Carrasco,R. Caballero, M. MartinEvaluation of HER2 gene status by qPCR in breast cancer samples withnonconclusive FISH. (Abstract #612)V. Koudelakova, J. Berkovcova, R. Trojanec, L. Radova, J. Ehrmann, Z. Kolar,B. Melichar, M. HajduchDetection of HER2 status of circulating tumor cells and disseminated tumorcells using a microfluidic platform (cell enrichment and extractiontechnology, CEE). (Abstract #613)S. Krishnamurthy, F. Z. Bischoff, J. A. Mayer, K. Wong, S. Mikolajczyk, T. Pham,H. M. Kuerer, A. Lodhi, A. Bhattacharyya, C. Hall, A. Lucci Jr.Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatmentin postmenopausal women with advanced breast cancer (ABC). (Abstract#614)L. Chow, B. Xu, L. Y. Dirix, B. Moy, E. Leip, N. Bardy-Bouxin, L. Duvillie,T. Sarosiek368

Monday, June 6, 2011Brd. 11A Predictive value of sphingosine kinase-1 expression in neoadjuvanttreatment of breast cancer. (Abstract #615)E. Ruckhäberle, T. Karn, C. Denkert, S. Loibl, B. Ataseven, T. Reimer,L. C. Hanker, N. Sänger, U. Holtrich, M. Kaufmann, S. Darb-Esfahani,V. Nekljudova, G. Von MinckwitzBrd. 11B Prognostic impact of phosphorylated HER2 in HER2-positive primary breastcancer using reverse-phase protein array. (Abstract #616)N. Hayashi, T. Iwamoto, A. M. Gonzalez-Angulo, J. Ferrer-Lozano, A. Lluch,N. Niikura, C. Bartholomeusz, S. Nakamura, G. N. Hortobagyi, N. T. UenoBrd. 11C Long-term survival in patients with HER2-positive metastatic breast cancertreated with trastuzumab as first-line therapy: Seven-year follow-up of theFrench observational hermine study. (Abstract #617)E. Antoine, F. Dalenc, C. Hebert, P. Rivera, G. Romieu, N. Varoqueaux,J. P. Guastalla, M. NamerBrd. 11D A multicenter phase II trial of neoadjuvant letrozole plus low dosecyclophosphamide in postmenopausal patients with estrogen receptorpositivebreast cancer (JBCRG07): The efficacy and its correlation withcirculating endothelial cells. (Abstract #618)T. Ueno, N. Masuda, S. Kamigaki, T. Morimoto, S. Nakamura, K. Kuroi, H. Iwata,S. Ohno, S. Tanaka, M. ToiBrd. 11E Protection of adjuvant trastuzumab in sites of early relapses. (Abstract #619)M. Campiglio, E. Tagliabue, A. Balsari, R. Bufalino, E. Ferri, L. Gianni, S. Ménard,on the behalf of GHEA groupBrd. 11F Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in AfricanAmerican (AA) and Caucasian (C) patients with hormone receptor-positive(HR), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer(BC). (Abstract #620)K. B. Kabaker, J. Canar, R. D. Rao, M. A. CobleighBrd. 11G Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locallyadvanced breast cancer: A Sarah Cannon Research Institute phase II trial.(Abstract #621)J. D. Zubkus, D. B. Daniel, J. F. Eakle, R. G. Bechhold, M. Shastry, P. S. Tucker,H. A. Burris III, J. D. Hainsworth, D. A. YardleyBrd. 11H Hormonal therapy versus chemotherapy as first-line line treatment forestrogen receptor–positive metastatic breast cancer (MBC) patients.(Abstract #622)T. Y. Chang, C. Lin, Y. Lu, S. H. Kuo, S. Huang, C. Huang, A. ChengBrd. 12A Epithelial-mesenchymal transition in patients with HER2 metastatic breastcancer. (Abstract #623)A. Giordano, M. Mego, B. Lee, S. Anfossi, C. A. Parker, R. H. Alvarez, N. T. Ueno,V. Valero, M. Cristofanilli, J. M. ReubenBrd. 12B Treatment patterns in patients with HER2-positive early-stage breast cancer(ESBC) receiving adjuvant treatment with a trastuzumab containing regimen.(Abstract #624)K. Sail, D. Lalla, M. Brammer, M. Halm, D. A. PattBrd. 12C Evaluating utilization characteristics for the Oncotype DX recurrence scorein early-stage breast cancer. (Abstract #625)C. Chen, D. A. Patt, D. R. Kazzaz, J. Shankleton, M. T. Forsyth, R. GaneshBrd. 12D BRCA test result impact and timing on surgical treatment decisions forpatients with breast cancer. (Abstract #626)K. M. Doll, C. B. Weldon, J. R. Trosman, H. H. Wetzel, T. J. Fallen,W. J. Gradishar, J. C. SchinkBrd. 12E Weekly paclitaxel versus standard 3-week schedule in patients withmetastatic breast cancer. (Abstract #627)I. I. Abdel Halim, M.El Ashri, W. El Sadda, Clinical Oncology and Nuclear MedicineDepartmentMONDAY369

Monday, June 6, 2011MONDAYBrd. 12FBrd. 12GBrd. 12HBrd. 13ABrd. 13BBrd. 13CBrd. 13DBrd. 13EBrd. 13FProteomics-based characterization of potential biomarkers in tamoxifenresistance in breast cancer. (Abstract #628)B. C. Sanchez, H. Johansson, J. Forshed, O. Stål, J. Lehtio, B. K. LinderholmNine versus 52 weeks of adjuvant trastuzumab in early breast cancer: Anobservational study of Turkish Oncology Group. (Abstract #629)F. Icli, K. Altundag, U. Coskun, S. Paydas, G. Basaran, P. Saip, G. G. Dogu,Y. Eralp, R. Uslu, A. Sevinc, H. Onur, N. M. Mandel, C. Sezgin, M. Altinbas,N. Guler, A. Isikdogan, E. Gokmen, K. Uygun, Z. Ustuner, A. Yaren,Turkish Oncology GroupFinal analysis of dose density with zoledronic acid treatment in metastaticbreast cancer patients: ZARAS study. (Abstract #630)J. De la Haba, A. Rodriguez-Lescure, J. Baena, J. Martin Liberal, S. Morales,J. Chacon, J. Lopez, I. Fernandez, D. Aguiar, A. Garcia-Palomo, R. Llorente,J. Barea, E. Alvarez, I. Blancas, Y. Fernandez, P. Sanchez Rovira, G. VinyesBosutinib and exemestane (EXE) versus EXE alone in postmenopausal(postm) women with hormone receptor–positive (HR) HER2-negative(HER2–) advanced breast cancer (ABC). (Abstract #631)B. Moy, F. Lebrun, M. Bellet, L. Chow, I. Lang, B. Xu, R. A. Badwe,D. L. Hershman, E. Leip, N. Bardy-Bouxin, L. Duvillie, P. NevenEvaluation of recurrence score and traditional clinicopathologicassessments in a large ER-positive, lymph node-negative patient cohort.(Abstract #632)N. Liebermann, F. L. Baehner, L. Soussan-Gutman, S. Klang, C. Yoshizawa,S. Shak, N. Siegelmann-DanieliPharmacokinetic and pathophysiological covariates influencing treatmentoutcomes with t-DM1 in patients with HER2-positive metastatic breast cancer(MBC). (Abstract #633)M. Gupta, P. LoRusso, H. A. Burris III, B. Wang, A. Joshi, Y. B. Tong, Y. Chu,S. GirishRAD51 and brain metastases (BM) in patients (pts) with HER2 breastcancer. (Abstract #634)R. Duchnowska, J. Jassem, E. Szutowicz, W. Biernat, T. Jankowski, W. Och,R. Staszkiewicz, M. Chudzik, W. Rogowski, N. Flores, S. Woditschka, L. Li,C. Goswami, M. A. Thorat, Y. Gokmen-Polar, G. W. Sledge Jr., P. S. Steeg,D. Palmieri, S. S. BadveEffect of a soy isoflavone intervention on estrogen-related gene expressionin the healthy high risk breast. (Abstract #635)S. A. Khan, O. Lee, I. B. Helenowski, D. Ivancic, B. Jovanovic, R. C. BerganA randomized trial of exercise versus control for musculoskeletal symptomsfrom adjuvant anastrozole (A) for postmenopausal early breast cancer(PEBC). (Abstract #636)C. A. Lohrisch, D. McKenzie, P. Truong, D. Jesperson, K. A. Gelmon, S. Premji,H. F. Kennecke370

Monday, June 6, 20111:00 PM - 5:00 PMGENERAL POSTER SESSIONBreast Cancer—Triple-negative/Cytotoxics/Local TherapyLocation: Hall ATrack(s): Breast CancerBrd. 14A Predictors of recurrence among patients with breast cancer who achieved apathological complete response (pCR) after neoadjuvant systemicchemotherapy. (Abstract #1036)M. Chavez-MacGregor, X. Lei, J. K. Litton, A. Melhem, E. A. Mittendorf,F. Meric-Bernstam, A. A. Sahin, V. Valero, G. N. Hortobagyi, A. M. Gonzalez-AnguloBrd. 14B Radiation and survival in women over 70 with T1 N0 M0 ER-negative breastcancer from 1990–2007: A population-based analysis. (Abstract #1037)A. P. Wojcieszynski, X. Shen, M. V. Mishra, P. R. Anne, T. N. ShowalterBrd. 14C Systematic comparison of tumor phenotype in primary breast cancer versuscorresponding lymph nodes and disease recurrences: Results of theretrospective multicenter WSG/DETECT PriMet study. (Abstract #1038)C. Liedtke, O. Gluz, F. Heitz, R. Wuerstlein, R. E. Kates, J. Tio, U. Nitz, A. Du Bois,T. N. Fehm, N. HarbeckBrd. 14D Incidence of brain metastases as a first site of recurrence among womenwith triple receptor-negative breast cancer. (Abstract #1039)X. Lei, S. S. Dawood, J. K. Litton, T. A. Buchholz, G. N. Hortobagyi,A. M. Gonzalez-AnguloBrd. 14E Multi-institutional evaluation of sentinel lymph node (SLN) examination byone-step nucleic acid amplification (OSNA) assay in breast cancer:Performance of metastases detection and prediction of additional nonsentinellymph node (non-SLN) involvement. (Abstract #1040)N. Sato, K. Honma, S. Noguchi, Y. Tamaki, H. Tsuda, T. Kinoshita, S. Nakamura,K. Tsugawa, K. Suzuki, M. Tsujimoto, K. Yoshidome, F. Akiyama, T. Iwase,D. Takabatake, R. Nishimura, K. Taniyama, H. Kato, S. Umemura, Y. Tokuda,T. Kamio, OSNA Researchers’ GroupBrd. 14F A multicenter randomized phase III trial of nonpegylated liposomeencapsulateddoxorubicin citrate plus cyclophosphamide (MC) versusliposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-linein locally advanced (LABC) or metastatic breast cancer (MBC). (Abstract#1041)V. Lorusso, F. Giotta, R. Bordonaro, E. Maiello, S. Del Prete, V. Gebbia,G. Filippelli, S. Pisconti, S. Cinieri, S. Romito, F. Riccardi, G. Cairo, V. E. Chiuri,M. Ciccarese, R. Forcignano, L. Petrucelli, V. Saracino, G. ColucciBrd. 14G Pathologic characteristics of second breast cancers (SBC) among womenpreviously treated for ductal carcinoma in situ (DCIS) with breastconservation. (Abstract #1042)N. D. Arvold, R. S. Punglia, M. E. Hughes, W. Jiang, S. B. Edge, S. H. Javid,C. Laronga, J. C. Niland, R. L. Theriault, J. C. Weeks, Y. Wong, S. J. Lee,M. J. HassettBrd. 14H Identification of pathogenic macrophages in breast cancer as markers oftumor aggressiveness. (Abstract #1043)R. Mukhtar, A. P. Moore, V. Tandon, O. Nseyo, A. Au, F. L. Baehner, C. A. Adisa,N. Eleweke, O. I. Olopade, D. H. Moore, M. Campbell, L. EssermanBrd. 15A Capecitabine (Cap) combined with bevacizumab (Bev) with or withoutvinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safetyresults from the randomized CARIN trial. (Abstract #1044)S. Hegewisch-Becker, C. A. Lerchenmuller, A. Welt, T. Decker, M. Just,C. Steffens, A. Hipper, N. MarschnerMONDAY371

Monday, June 6, 2011MONDAYBrd. 15BBrd. 15CBrd. 15DBrd. 15EBrd. 15FBrd. 15GBrd. 15HBrd. 16ABrd. 16BBrd. 16CBrd. 16DBrd. 16EBrd. 16F372Close or positive margins after mastectomy in early-stage, node-negativebreast cancer: The association of tumor grade with local recurrence.(Abstract #1045)J. R. Hastings, S. Iganej, D. M. Bugoci, C. HuangPrevalence and impact of correlative science in breast cancer phase II trials.(Abstract #1046)T. Zhang, E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, J. M. PeppercornOverall survival effect of lower chemotherapy dosing in extremely obese(BMI > 35) patients with breast cancer based on adjusted BSA. (Abstract#1047)P. Sharma, T. A. Samuel, J. C. Wells, E. Mebel, J. T. French, J. A. Crozier,S. W. LooneyLong-term survival after high-dose chemotherapy followed by peripheralstem cell rescue for high-risk locally advanced/inflammatory and metastaticbreast cancer. (Abstract #1048)A. M. Vanderwalde, W. Ye, P. H. Frankel, D. G. Asuncion, R. D. Pezner, T. H. Luu,S. Shibata, L. A. Leong, K. A. Margolin, R. Morgan, M. Koczywas, W. A. Chow,P. Twardowski, J. Y. Wong, J. H. Doroshow, S. J. Forman, G. SomloCan preoperative dynamic contrast enhanced breast MRI predict extensiveoccult axillary lymph node metastases in patients with positive sentinel nodebiopsy? (Abstract #1049)C. R. Loiselle, P. R. Eby, J. N. Kim, K. E. Calhoun, K. H. Allison, V. K. Gadi,S. Peacock, B. Storer, D. A. Mankoff, S. C. Partridge, C. D. LehmanRisk and health care costs of chemotherapy-induced neutropeniccomplications in women with metastatic breast cancer. (Abstract #1050)D. Weycker, J. Edelsberg, A. Kartashov, R. Barron, G. H. LymanA randomized phase II study of pemetrexed-carboplatin and gemcitabinevinorelbinein patients with anthracycline- and taxane-pretreated advancedbreast cancer. (Abstract #1051)D. Amadori, I. La Torre, E. M. Carrasco, S. Roesel, R. Labianca, V. Moreau-Donnet, D. Desaiah, M. MartinPhase II study of gemcitabine (G) and bevacizumab (B) as first-line treatmentin taxane-pretreated, HER2-negative, locally recurrent or metastatic breastcancer (MBC). (Abstract #1052)R. Borson, W. G. Harker, J. E. Reeves, D. Drosick, J. T. Beck, S. J. Hager,W. L. Horvath, J. Bromund, H. Zeigler, D. Tai, D. A. YardleyLocoregional recurrence after breast cancer surgery: A meta-analysis bymolecular subtype. (Abstract #1053)A. J. Lowery, M. R. Kell, R. W. Glynn, M. J. Kerin, K. J. SweeneyThe effect of tetrathiomolybdate on endothelial progenitor cells in patients athigh risk for breast cancer recurrence. (Abstract #1054)S. Jain, J. A. Cohen, M. M. Ward, J. O’Loughlin, M. Boeck, N. Wiener, E. Chuang,T. Cigler, A. Moore, D. Donovan, C. Lam, M. E. Cobham, S. E. Schneider,P. J. Christos, M. E. Lane, R. Baergen, V. Mittal, S. Rafii, L. T. VahdatRechallenging taxanes in recurrent breast cancer in patients treated with(neo)adjuvant taxane-based therapy. (Abstract #1055)X. Guo, S. Loibl, M. Untch, V. Möbus, K. Schwedler, P. A. Fasching, J. Barinoff,F. Holms, C. Thomssen, D. Zahm, R. Kreienberg, M. Hauschild, H. Eidtmann,S. Tauchert, K. Mehta, G. Von Minckwitz, German Breast Group and AGO-BStudy GroupPrognostic significance of Ki-67 in node-negative (pN0), triple-negative (TN)breast cancer (BC). (Abstract #1056)E. Munzone, E. Botteri, A. Sciandivasci, G. Curigliano, F. Nole, N. Rotmensz,M. Colleoni, G. Viale, A. Esposito, A. Luini, M. G. Mastropasqua, A. GoldhirschClinical outcome of triple-negative primary breast cancer in older women:Comparison with their younger counterparts. (Abstract #1057)K. Cheung, B. M. Syed, A. R. Green, D. A. Morgan, I. O. Ellis

Monday, June 6, 2011Brd. 16GBrd. 16HBrd. 17ABrd. 17BBrd. 17CBrd. 17DBrd. 17EBrd. 17FBrd. 17GBrd. 17HBrd. 18ABrd. 18BBrd. 18C0 6 -methylguanine-DNA methyltransferase (MGMT) promoter genemethylation in triple-negative breast cancer (TNBC). (Abstract #1058)C. Fumagalli, P. Possanzini, M. O. Biasi, M. Manzotti, M. Barberis, B. Bonanni,M. Barile, I. Feroce, G. VialeSOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC)plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in womenwith primary breast cancer (BC; GBG 45). (Abstract #1059)B. Conrad, N. Harbeck, G. Von Minckwitz, M. Wuellner, M. Warm, K. Schwedler,B. Gerber, I. Schrader, H. Eidtmann, K. Mehta, S. Loibl, GBG/AGO-B StudyGroupsThe relationship between age and survival outcomes for eribulin inmetastatic breast cancer. (Abstract #1060)C. Twelves, L. T. Vahdat, J. Cortes, J. Wanders, C. E. Dutcus, S. Seegobin,H. B. MussPARP1 in triple-negative breast cancer: Expression and therapeuticpotential. (Abstract #1061)M. B. Cotter, A. Pierce, P. M. McGowan, S. F. Madden, L. Flanagan, C. Quinn,D. Evoy, J. Crown, E. McDermott, M. J. DuffyADAMs as new therapeutic targets for triple-negative breast cancer.(Abstract #1062)M. Mullooly, P. M. McGowan, S. Sukor, S. F. Madden, E. McDermott, J. Crown,N. O’Donovan, M. J. DuffyTriple-negative breast cancer: The effect of guideline adherent adjuvanttreatment on the cumulative survival. A retrospective multicenter cohortstudy of 3,658 patients. (Abstract #1063)L. Schwentner, R. Wolters, M. Wischnewsky, R. Kreienberg, A. WöckelEffect of neoadjuvant ixabepilone (Ixa) on cell cycle genes and on tumorinitiatingcell (TIC) signature in breast cancer (BC). (Abstract #1064)H. Chang, C. E. Horak, P. Mukhopadhyay, C. Lowery, J. Baselga, J. A. SparanoBreast conservation therapy: The influence of molecules and margins.(Abstract #1065)S. Demirci, G. Broadwater, L. B. Marks, R. Clough, L. R. ProsnitzIxabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory oncotype DX assessments: A SarahCannon Research Institute phase II trial. (Abstract #1066)N. W. Peacock, D. A. Yardley, C. B. Hendricks, S. Y. Huh, S. L. Ketchum, C. Chao,C. Yoshizawa, M. Shastry, B. Strike, H. A. Burris III, J. D. HainsworthA phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixeddosecapecitabine in metastatic breast cancer (MBC). (Abstract #1067)R. M. Connolly, M. A. Rudek, H. L. Mc Leod, E. Garrett-Mayer, S. C. Jeter,L. A. Wright, V. Stearns, D. K. Armstrong, J. H. Fetting, S. P. Watkins,N. E. Davidson, A. C. WolffThe effects of acellular dermal matrix in expander-implant breastreconstruction after total skin-sparing mastectomy: Results of a prospectivepractice improvement study. (Abstract #1068)A. W. Peled, R. D. Foster, E. Garwood, C. A. Ewing, M. Alvarado, E. S. Hwang,L. EssermanEffect of estrogen receptor beta expression (ERße) in triple-negative breastcancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. (Abstract#1069)F. Heitz, B. Sinn, S. Loibl, A. Du Bois, C. Jackisch, S. Kuemmel, C. Denkert,J. Barinoff, K. Mehta, G. Von Minckwitz, on behalf the GeparTrio trialistsThe SUCCESS-C trial: Interim analysis of toxicity evaluating the role of ananthracycline-free chemotherapy regimen in the adjuvant treatment ofHER2/neu-negative breast cancer. (Abstract #1070)U. Ortmann, J. Salmen, P. G. Hepp, M. W. Beckmann, T. N. Fehm, H. Hindenburg,W. Lichtenegger, B. K. Rack, A. Schneeweiss, W. Janni373MONDAY

Monday, June 6, 2011MONDAYBrd. 18DBrd. 18EBrd. 18FBrd. 18GBrd. 18HBrd. 19ABrd. 19BBrd. 19CBrd. 19DBrd. 19EBrd. 19FBrd. 19GClinical significance of time to relapse and the distinction between breastcancer recurrences and new primary tumors. (Abstract #1071)A. Patt, T. Li, M. Cristofanilli, G. M. Freedman, E. R. Sigurdson, R. J. BleicherCosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy orexternal beam radiotherapy for early breast cancer: An objective assessmentof patients from a randomized controlled trial. (Abstract #1072)M. R. Keshtgar, N. R. Williams, T. Corica, C. Saunders, D. J. Joseph, M. Bulsara,on behalf of the TARGIT Trialists’ GroupBreast cancer carcinomatous meningitis: Differences in survival dependingon biological subtype, performance status, and treatment methods. (Abstract#1073)A. M. Niwinska, H. Rudnicka, M. MurawskaClinical risk factors as predictors of potential cardiotoxicity related tononpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer(MBC) patients (pts) previously treated with conventional anthracyclines (A).(Abstract #1074)E. Muñoz-Couselo, J. M. Perez-Garcia, C. Saura, M. Vidal, M. Bellet Ezquerra,J. Balmaña, B. Graña, P. Gomez Pardo, L. De Mattos-Arruda, S. Di Cosimo,S. Muñoz, O. Vidal, B. Garcia Castro, R. Espallargas, V. Esteban, J. Tabernero,J. Baselga, J. CortesPhase II trial report of the new preoperative chemotherapy with S-1 anddocetaxel for advanced breast cancer. (Abstract #1075)M. Nakagawa, M. Aoyama, M. Ikeda, M. Morimoto, H. Takechi, Y. Kawakami,K. Kennzaki, A. TangokuBreast cancer subtypes and outcome after local and regional relapse.(Abstract #1076)E. Montagna, V. Bagnardi, N. Rotmensz, G. Viale, G. Renne, G. Cancello,A. Balduzzi, E. Scarano, D. Pastrello, P. Veronesi, A. Luini, S. Zurrida, S. Monti,M. G. Mastropasqua, L. Bottiglieri, A. Goldhirsch, M. ColleoniIs E-cadherin a useful surrogate marker to predict chemosensitivity ofchemotherapy for triple-negative breast cancer? (Abstract #1077)S. Kashiwagi, M. Yashiro, T. Takashima, N. Aomatsu, H. Kawajiri, N. Onoda,B. Nakata, T. Ishikawa, K. HirakawaSurvival of triple-negative and HER2-positive breast cancer by AJCC stage.(Abstract #1078)V. Caggiano, K. Bauer, C. PariseEfficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel(Pac): An observational study in 786 patients (pts) with HER2-negativemetastatic breast cancer (mBC). (Abstract #1079)P. Klare, F. G. Foerster, M. Geberth, A. Schneeweiss, H. Tesch, S. Kuemmel,C. Schumacher, W. Hollburg, U. Soeling, M. SchmidtCapecitabine (X) in the first-line treatment of metastatic breast cancer (MBC).(Abstract #1080)N. Harbeck, M. Kaufmann, F. Siedentopf, P. Dalivoust, M. Debled, N. J. Robert,J. O’ShaughnessyPrognostic implications of phosphatidylinositol 3-kinase (PI3K) pathwayalterations in metastatic triple-negative breast cancer (mTNBC). (Abstract#1081)M. Oliveira, L. De Mattos-Arruda, G. Sánchez-Ollé, B. Graña, J. Cortes,J. M. Perez-Garcia, E. Muñoz-Consuelo, M. Vidal, M. Bellet, S. Di Cosimo,P. Gomez Pardo, J. Rodon Ahnert, J. Hernandez-Losa, A. Vivancos, L. Prudkin,C. Aura, V. Serra, J. Baselga, J. Tabernero, C. SauraRoles of miRNAs in breast cancer stem cells, drug sensitivity, andspontaneous metastases in orthotopic human-in-mouse models. (Abstract#1082)H. Liu, J. Bockhorn, R. Dalton, M. Dolan, C. M. Perou, O. I. Olopade, M. F. Clarke,G. Greene374

Monday, June 6, 2011Brd. 19H Efficacy and safety of ixabepilone plus capecitabine in elderly patients withanthracycline- and taxane-pretreated metastatic breast cancer. (Abstract#1083)L. T. Vahdat, E. Vrdoljak, H. Gomez, R. K. Li, E. Thomas, L. D. Bosserman,J. A. Sparano, J. Baselga, P. Mukhopadhyay, V. ValeroBrd. 20A Adjuvant chemotherapy in American and Italian patients with BRCA1/2-associated breast cancer. (Abstract #1084)A. Cappetta, R. Nanda, C. Liao, D. Huo, L. F. Chen, G. Artioli, V. Zagonel,O. I. OlopadeBrd. 20B Modeling the risk of secondary lung malignancy in patients treated withbreast radiation therapy. (Abstract #1085)J. Ng, I. Shuryak, A. Xu, I. Deutsch, R. J. Burri, D. J. BrennerBrd. 20C Utility of breast MRI for patients with breast cancer scheduled for breastconserving surgery. (Abstract #1086)H. Shin, W. Han, H. Moon, C. Yom, S. Ahn, H. Kim, D. NohBrd. 20D Comparison of lesion size between preoperative imaging and postoperativehistopathology in unifocal breast cancer. (Abstract #1087)C. R. Abraham, B. Whiteside, M. Schuster, D. Jones, J. Pollard, L. MacFarlan,K. Hena, M. A. HenaBrd. 20E Repeat use of chemotherapy in metastatic breast cancer. (Abstract #1088)A. Im, A. Brufsky, J. G. Reeder, M. Q. Rosenzweig, S. Y. JungBrd. 20F Prognostic impact on FOXP3 expression in triple-negative breast cancer(TNBC). (Abstract #1089)S. Lee, Y. Park, E. Cho, Y. Ham, J. Seo, J. Ahn, Y. ImBrd. 20G Platinum-based chemotherapy in triple-negative breast cancer. (Abstract#1090)C. Villarreal-Garza, M. Clemons, F. Kassam, K. Enright, S. Verma, J. A. Myers,R. A. DentBrd. 20H Is there any utility to frozen section or immunohistochemistry examination ofthe sentinel lymph node (SLN) in patients with ductal carcinoma in situ(DCIS)? (Abstract #1091)U. K. Ballehaninna, A. R. Reeves, R. S. ChamberlainBrd. 21A Combination of tivozanib (AV-951) with weekly paclitaxel for metastaticbreast cancer: Results of a phase I study. (Abstract #1092)E. L. Mayer, M. E. Scheulen, J. Beckman, H. Richly, A. Poli, P. Bhargava,A. Duarte, M. M. Cotreau, A. L. Strahs, M. N. DicklerBrd. 21B Incidence of anthracycline-induced cardiotoxicity in patients with breastcancer: A single center’s experience. (Abstract #1093)O. Nadeem, C. Rauwerdink, V. L. Beggs, D. D. Parr, A. T. Kono, G. N. SchwartzBrd. 21C Sunitinib as adjuvant therapy for women with early-stage breast cancer anddisseminated tumor cells in bone marrow. (Abstract #1094)J. Li, M. E. Melisko, P. N. Munster, M. Pelayo, M. M. Moasser, A. J. Chien, J. Scott,L. Esserman, J. W. Park, H. S. RugoBrd. 21E Prevalence of synchronous metastases of breast cancer depends both ontumor subtypes and tumor burden. (Abstract #1096)C. Boutros, C. Mazouni, M. Saghatchian, J. Domont, C. Balleyguier, C. Bourgier,M. Mathieu, M. Spielmann, S. DelalogeBrd. 21F Prognostic index for patients with brain metastases from breast cancer: Avalidation and refinement of the breast-specific graded prognosticassessment (GPA) index. (Abstract #1097)H. Ahn, S. Lee, J. Sohn, S. Park, Y. Ham, J. Seo, E. Cho, D. Nam, J. Lee, D. Choi,W. Park, S. Huh, Y. Park, J. Ahn, Y. ImBrd. 21G Basoluminal and luminal phenotypes in triple-negative breast cancer:Immunohistochemical profiling and survival. (Abstract #1098)H. Sinn, Z. Elsawaf, J. L. Bermejo, S. Aulmann, J. Rom, A. SchneeweissMONDAY375

Monday, June 6, 2011MONDAYBrd. 21HBrd. 22ABrd. 22BBrd. 22CBrd. 22DBrd. 22EBrd. 22FBrd. 22GBrd. 22HBrd. 23ABrd. 23BBrd. 23CBrd. 23DOutcomes of children exposed to chemotherapy in utero for breast cancer.(Abstract #1099)J. K. Litton, S. Hodge, D. Mattair, M. M. Ramirez, P. H. Morrow,A. M. Gonzalez-Angulo, C. M. Barnett, G. N. Hortobagyi, R. L. TheriaultReduction of serum VEGF and IL-6 levels in patients with metastatic breastcancer: Results of a study of PTC299, an oral inhibitor of tumor VEGFsynthesis, and aromatase inhibitors. (Abstract #1100)M. N. Dickler, B. P. Schneider, M. Volm, J. L. Speyer, Y. Novik, L. A. Callahan,C. H. Darby, J. Barth, G. L. Elfring, A. Ogden, A. TierstenFebrile neutropenia rates during docetaxel and cyclophosphamide (TC)adjuvant therapy in early breast cancer (EBC). (Abstract #1101)D. KotasekMagnetic resonance imaging (MRI) as compared to mammogram (MMG) inthe evaluation of size, number of lesions, and nodal positivity in breastcancer (BrCa). (Abstract #1102)A. Korant, M. Kanaan, S. Sirop, H. Nuthakki, L. Lawrence, R. Hicks, D. Strahle,S. Nagpal, D. Wiese, S. SahaTITAN: Ixabepilone versus weekly paclitaxel followingdoxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triplenegativebreast cancer (TNBC): Preliminary toxicity of a Sarah CannonResearch Institute phase III trial. (Abstract #1103)D. A. Yardley, J. D. Hainsworth, W. N. Harwin, S. A. Goble, B. R. Daniel,M. A. Ackerman, D. Shipley, D. R. Drosick, S. E. Hanson, P. L. Griner,H. A. Burris IIIIncreasing use of mastectomy with immediate reconstruction andcontralateral prophylactic mastectomy in breast conservation candidates: A14-year report from a comprehensive cancer center. (Abstract #1104)A. E. Dragun, J. Pan, E. C. Riley, B. B. Kruse, M. R. Wilson, S. Rai, D. JainAre we improving the outcomes of metastatic breast cancer (MBC)? A singleacademic institution experience. (Abstract #1105)A. Florescu, S. Giilck, C. Victor, U. Zurawska, D. A. Baribeau, S. VermaAlterations in breast cancer resistance protein in human placentas exposedto chemotherapy. (Abstract #1106)M. G. Holland, A. McCampbell, J. K. Litton, R. L. Theriault, M. M. RamirezOral etoposide monotherapy for Chinese patients with metastatic breastcancer: Efficacy and tolerance regardless of heavy prior therapy. (Abstract#1107)P. Yuan, B. Xu, F. Ma, J. Wang, Y. FanComparison of indocyanine green (ICG) fluorescence imaging plus blue dyeand blue dye alone in sentinel node navigation surgery (SNNS) for breastcancer. (Abstract #1108)A. Hirano, T. Shimizu, M. Kamimura, K. Ogura, N. Kim, Y. Setoguchi, F. Okubo,H. Inoue, R. Miyamoto, J. Kinoshita, K. OgawaClinical outcome of triple-negative breast cancer with BRCA mutation in thecontext of dose-dense and or metronomic chemotherapy. (Abstract #1109)R. S. Mehta, C. LiuPrimary systemic therapy with metronomic doxorubicin, cyclophosphamide,and capecitabine in locally advanced and metastatic triple-negative breastcancer. (Abstract #1110)M. Skrypnikova, M. Frolova, E. Ignatova, I. Pokataev, M. Stenina, S. TjulandinPrediction of the nonsentinel node metastasis in patients who receivedneoadjuvant chemotherapy for clinically axillary lymph node metastasis.(Abstract #1111)S. Lee, S. Y. Jung, S. W. Kim, H. S. Kang, I. Park, K. S. Lee, J. Ro, K. Ko, Y. Kwon,K. Shin, S. Kim376

Monday, June 6, 2011Brd. 23E First line with bevacizumab in combination with paclitaxel (P) andgemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFSanalysis. (Abstract #1112)J. Salvador, A. Jaen, E. Ciruelos, M. Codes, M. Gil, A. Murias, A. Galan,J. De la Haba, C. Jara, J. L. Bayo, J. Baena, J. Casal, J. Mel, I. Blancas,E. Gonzalez, D. Perez, L. MansoBrd. 23F Paclitaxel-carboplatin (P-C) regimen for metastatic breast cancer (MBC):Single-institution retrospective evaluation. (Abstract #1113)M. Zambetti, G. Goisis, A. Moliterni, A. Marchianò, D. Scaramuzza, M. Carcangiu,G. Saibene, G. Mariani, G. V. Bianchi, P. Valagussa, L. GianniBrd. 23G Poly (ADP-ribose) polymerase-1 (PARP) expression in triple-negative breastcancer. (Abstract #1114)P. Possanzini, M. O. Biasi, C. Fumagalli, M. Barberis, M. Barile, B. Bonanni,G. VialeBrd. 23H Lymphocyte infiltration (LI) and immunohistochemistry (IHC) classificationof metastatic breast cancer (MBC) correlation with medical survival.(Abstract #1115)C. S. Yau, A. R. Trumbly, C. O. Ruud, V. O. Speight, C. Chisholm, J. SongBrd. 24A Amrubicin as second- or third-line treatment for patients with HER2-negativemetastatic breast cancer (MBC): A Sarah Cannon Research Institute phase Itrial. (Abstract #1116)J. H. Barton, K. C. Shih, E. Raefsky, D. W. Haines III, B. Strike, J. D. Hainsworth,H. A. Burris III, D. A. YardleyBrd. 24B Body mass index in breast cancer subtypes. (Abstract #1117)I. Petekkaya, C. Arslan, E. Dogan, M. Solak, Ö. Keskin, N. Kertmen, Y. Y. Ozisik,K. AltundagBrd. 24C Final results from randomized phase II trial of preoperative docetaxel (D) andcapecitabine (C) given sequentially or concurrently for HER2-negative breastcancers. (Abstract #1118)A. B. Zelnak, S. Harichand-Herdt, T. M. Styblo, M. Rizzo, S. G. Gabram,H. L. Bumpers, R. C. Hermann, J. Srinivasiah, F. M. Schnell, R. O’ReganBrd. 24D Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel(wPac) for HER2-negative metastatic breast cancer (MBC): Results of aJapanese phase II study (n120). (Abstract #1119)Y. Ito, K. Aogi, N. Masuda, S. Ohno, T. Oda, H. Iwata, M. Kashiwaba, Y. Fujiwara,S. Kamigaki, T. Ueno, S. TakashimaBrd. 24E Oral paricalcitol (19-nor-1,25-Dihydroxyvitamn D 2 ) in women with metastaticbreast cancer receiving taxanes or ixabepilone: A feasibility trial. (Abstract#1120)J. Lawrence, J. Lovelace, S. A. Akman, S. A. Melin, L. D. Case, G. SchwartzBrd. 24F What is the survival length from the late lines of treatment in metastaticbreast cancer? (Abstract #1121)M. Mouret-Reynier, E. Planchat, E. Thivat, C. Abrial, C. Pomel, P. Dubray-Longeras, H. Devaud, B. Nayl, A. Dillies, Q. Wang-Lopez, P. J. Chollet, H. Cure,J. Nabholtz, X. DurandoBrd. 24G Validation study on the clinical usefulness of the ICG fluorescence methodfor detecting sentinel lymph node in early-stage breast cancer in comparisonwith the dye method. (Abstract #1122)T. Sugie, T. Sawada, N. Tagaya, T. Kinoshita, K. Yamagami, H. Suwa,K. Yoshimura, M. Sumi, M. ToiBrd. 24H Association of BRCA1 promoter methylation in triple-negative breast cancer(TNBC) with resistance to standard anthracyline-based adjuvantchemotherapy. (Abstract #1123)P. Sharma, B. F. Kimler, Y. A. Park, S. R. Stecklein, Q. J. Khan, B. K. Petroff,O. W. Tawfik, R. A. JensenMONDAY377

Monday, June 6, 2011MONDAYBrd. 25ABrd. 25BBrd. 25CBrd. 26ABrd. 26BBrd. 26CBrd. 27ABrd. 27BBrd. 27CBrd. 28ABrd. 28BBrd. 28CA multidisciplinary protocol for planned skin-preserving delayed breastreconstruction for patients with locally advanced breast cancer requiringpostmastectomy radiation therapy: Three-year follow-up. (Abstract #1124)S. J. Kronowitz, W. Tereffe, K. Hunt, H. M. Kuerer, V. Valero, G. L. Robb, L. Feng,T. A. BuchholzFinal results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC)patients (pts). (Abstract #1125)K. L. Tedesco, J. L. Blum, A. Goncalves, J. Lubinski, C. R. Osborne, P. Lardelli,J. C. Tercero, A. Florez, F. A. Holmes, S. DelalogePhase II trial combining nab-paclitaxel (NP), gemcitabine (G), andbevacizumab (B) in patients (pts) with metastatic breast cancer (MBC):NCCTG N0735. (Abstract #1126)D. W. Northfelt, A. C. Dueck, T. P. Flynn, P. J. Zander, P. J. Stella, M. Melnik,E. S. Pavey, E. A. PerezRetrospective analysis of the effect on overall-survival of radiotherapy andchemotherapy sequence as treatment for primary breast cancer. (Abstract#1127)E. H. Gort, S. G. Elias, O. Visser, P. H. Elkhuizen, S. C. LinnThe effect of delay in time to adjuvant chemotherapy (TTAC) on survival inbreast cancer (BC): A systematic review and meta-analysis. (Abstract #1128)J. J. Biagi, M. Raphael, W. D. King, W. Kong, C. M. Booth, W. J. MackillopThe other triple-negative breast cancer: Immunohistochemical andclinicopathological characterization of the claudin-low subtype. (Abstract#1129)D. Voduc, M. Cheang, A. Prat, X. He, S. Tyldesley, J. Snider, K. DeSchryver,S. Davies, M. J. Ellis, C. M. Perou, T. O. NielsenEffect of body mass index on survival outcome among women with earlystage,triple-negative breast cancer. (Abstract #1130)S. S. Dawood, X. Lei, J. K. Litton, T. A. Buchholz, G. N. Hortobagyi,A. M. Gonzalez-AnguloSignificantly different costs of adjuvant chemotherapy regimens in theUnited States. (Abstract #1131)R. G. Chellappah, P. RavdinNeoadjuvant rh-endostatin, docetaxel, and epirubicin for breast cancer:Efficacy and safety in a prospective, randomized, phase II study. (Abstract#1132)L. Wang, J. Chen, Q. Yao Sr., J. Zhang, T. Wang, H. Wang, X. Zhou, Y. Huan,J. WangNeoadjuvant chemotherapy (NACT) in hormonal receptor-positive (HR)ortriple-negative (TN), operable breast cancer (BC): A randomized studycomparing standard to response–adapted sequence. (Abstract #1133)H. Cure, Q. Wang-Lopez, M. Mouret-Reynier, X. Durando, C. Jouannaud,J. Charpentier, J. Eymard, P. J. Chollet, C. Garbar, E. Brabencova, I. Raoelfils,F. Penault-Llorca, J. NabholtzFebrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) withprophylactic pegfilgrastim in patients with breast cancer: A retrospectiveanalysis. (Abstract #1134)N. Ngamphaiboon, P. P. Advani, T. L. O’Connor, F. O. Ademuyiwa, E. G. Levine,G. Riebandt, E. B. KossoffPhase II trial, open, single arm: Cisplatin combined with paclitaxel anddoxorubicin in operable or locally advanced, triple-negative breast cancer.(Abstract #1135)A. Alvarado Miranda, F. Lara Medina, C. Arce, N. Castañeda-Soto,C. Cano Blanco, J. Aguilar Ponce, E. Bargallo Rocha, V. Perez-Sanchez378

Monday, June 6, 20111:00 PM - 5:00 PMGENERAL POSTER SESSIONLeukemia, Myelodysplasia, and TransplantationLocation: Hall ATrack(s): Leukemia, Myelodysplasia, and TransplantationBrd. 29A Correlation of RASGRP1:APTX expression assay with response to tipifarnibplus etoposide in elderly patients with newly diagnosed AML. (Abstract#6534)T. I. Vener, C. Derecho, S. Galkin, J. Greer, M. J. Levis, C. D. Gocke, S. Malek,J. F. Palma, M. Raponi, Y. Wang, J. J. Wright, J. E. KarpBrd. 29B Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloidleukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) ornilotinib (NIL). (Abstract #6535)T. H. Brummendorf, J. E. Cortes, H. Kantarjian, C. Gambacorti-Passerini,M. Baccarani, D. Kim, A. Zaritskey, J. Navarro, A. Rapoport, P. E. Dorlhiac-Llacer,J. Milone, M. Zanichelli, N. Besson, E. Leip, V. Kelly, H. J. KhouryBrd. 29C Tyrosine kinase inhibitors in BCR/ABL positive ALL . (Abstract #6536)A. T. Lopez-EnriquezBrd. 30A A phase II study with decitabine, low dose cytarabine, and G-CSF priming inhigh-risk myelodysplastic syndromes, refractory/relapsed acutemyelogenous leukemia, or acute myeloid leukemia in patients withsignificant comorbidities. (Abstract #6537)J. Butera, E. Winer, C. Wang, J. J. Castillo, A. G. Thomas, H. Safran, A. E. Mega,G. A. Colvin, B. Rathore, P. J. Quesenberry, Brown Oncology GroupBrd. 30B Serum galactomannan (GM) assay for invasive aspergillosis (IA) in acuteleukemia (AL) and hematopoietic stem cell transplantation (HSCT). (Abstract#6538)I. Ghosh, V. Raina, L. Kumar, A. Sharma, S. Bakhshi, S. IqbalBrd. 30C Etoposide and cytarabine as an effective and safe cytoreductive regimen forrelapsed or refractory acute myeloid leukemia. (Abstract #6539)G. Nair, R. Karmali, S. A. Gregory, J. M. Shammo, H. C. Fung, A. Jimenez,P. Venugopal, M. L. LarsonBrd. 31A Successful autologous hematopoietic stem cell (AHSC) mobilization withsalvage etoposide (VP16)-ifosfamide-platinum (VIP) followed by high-dosechemotherapy (HDC) and AHSC transplantation (AHSCT) in relapsedmalignancies: preliminary single center experience. (Abstract #6540)C. Kosmas, A. Athanasopoulos, P. Politis, T. Papachrysanthou, T. Daladimos,A. Papadaki, E. Panagiotidi, D. Moschovis, N. Ziras, A. Karabelis, N. MylonakisBrd. 31B Results of employing a plerixafor dosing algorithm to mobilize hematopoieticstem cells in patients with multiple myeloma and lymphoma. (Abstract #6541)T. Bechtel, Y. A. Efebera, S. M. Devine, P. ElderBrd. 31C A meta-analysis of the complete remission ratio with replaced or refractoryacute promyelocytic leukemia. (Abstract #6542)B. Jiang, Q. Gong, H. Watanabe, S. Zhu, J. Xie, Y. OhashiBrd. 31D Prevention of mucositis with KGF in patients undergoing allogeneic stem celltransplantation. (Abstract #6543)J. D. Goldberg, J. Zheng, H. Castro-Malaspina, A. A. Jakubowski, G. Heller,M. R. Van Den Brink, M. PeralesBrd. 31E FLT3 positive acute myeloid leukemia: Does timed sequential inductiontherapy influence outcome? (Abstract #6544)D. Rifai, M. L. Larson, M. C. Keller, P. VenugopalBrd. 31F High-dose melphalan on day 2 versus 1 before autologous stem celltransplantation for multiple myeloma. (Abstract #6545)K. Rakszawski, J. J. Drabick, N. G. Dolloff, J. M. Sivik, J. Malysz, D. Claxton,W. C. Ehmann, W. B. Rybka, G. TalamoMONDAY379

Monday, June 6, 2011MONDAYBrd. 31GBrd. 31HBrd. 32ABrd. 32BBrd. 32CBrd. 32DBrd. 32EBrd. 32FBrd. 32GBrd. 32HBrd. 33ABrd. 33BBrd. 33CTargeting multiple signal pathways simultaneously might provide effectivetherapeutic strategies in acute myeloid leukemia . (Abstract #6546)H. Liu, E. Diaz-Flores, X. Poire, G. Koval, G. Malnassy, M. M. Le Beau,K. Shannon, O. Odenike, W. StockImmunosupressive properties of human placenta-derived mesenchymalstem cells on control of acute graft-versus-host disease in mice. (Abstract#6547)M. Jang, S. Oh, H. Kim, H. Shin, G. Kim, S. Chong, D. Oh, H. ChungSecond cancers after hematopoietic stem cell transplantation with total bodyirradiation conditioning regimen in hematologic disorders. (Abstract #6548)J. Kim, M. Chung, J. Lee, B. Choi, S. ChungStudy of oral clofarabine plus low-dose cytarabine in previously treated AMLand high-risk MDS patients at least 60 years of age. (Abstract #6549)K. M. Smith, E. Estey, J. M. PagelLong-term follow-up results of imatinib mesylate therapy in chronic phasechronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure.(Abstract #6550)J. Shan, S. M. O’Brien, G. Garcia-Manero, S. Faderl, F. Ravandi, E. Jabbour,J. E. Cortes, H. KantarjianPopulation pharmacokinetic modelling of decitabine in patients withmyelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).(Abstract #6551)B. Mistry, L. Gibiansky, Z. HusseinHealthcare utilization and costs in patients with early onset myelodysplasticsyndrome in a commercially insured population. (Abstract #6552)A. Powers, K. Stein, R. L. Knoth, M. Broder, E. ChangImpact of cytogenetics at diagnosis on outcome of CML: Results from therandomized German CML Study IV. (Abstract #6553)A. Leitner, S. Saussele, C. Haferlach, G. Goehring, B. Schlegelberger,S. Jung-Munkwitz, U. Proetel, M. Lauseker, M. Pfirrmann, J. Hasford,A. Hochhaus, R. Hehlmann, German CML Study groupHyper-CVAD plus nelarabine in the treatment of newly diagnosed patientswith T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL). (Abstract #6554)A. Al-Ameri, D. A. Thomas, F. Ravandi, S. M. O’Brien, H. Kantarjian, G. Borthakur,T. M. Kadia, M. Kelly, R. Garris, S. FaderlSurvival differences in chronic myeloid leukemia by race in pre- and postimatinibera. (Abstract #6555)R. Mandal, D. M. Bolt, B. K. ShahLeukemiaNet: A transnational model for cooperative leukemia research.(Abstract #6556)R. Hehlmann, B. Simonsson, M. Baccarani, D. Grimwade, J. Apperley, T. Barbui,M. C. Bene, T. Buchner, T. J. de Witte, R. Foà, C. Haferlach, M. Hallek,J. Hasford, A. Hochhaus, D. Hoelzer, P. Ljungman, D. Niederwieser, M. . Sanz,S. SausseleImproved survival in chronic myeloid leukemia (CML) since introduction ofimatinib therapy: A single-institution experience in 1,570 patients referredwithin 1 month from diagnosis. (Abstract #6557)A. Quintas-Cardama, J. E. Cortes, E. Jabbour, S. M. O’Brien, G. Garcia-Manero,J. Shan, F. Ravandi, S. Faderl, T. M. Kadia, G. Borthakur, H. KantarjianLenalidomide following rituximab and fludarabine in untreated CLL.(Abstract #6558)C. S. Ujjani, S. Jamshed, K. Fitzpatrick, E. A. Gehan, J. Crawford, C. M. Broome,P. Cohen, C. Kessler, B. D. Cheson380

Monday, June 6, 2011Brd. 33DBrd. 33EBrd. 33FBrd. 33GBrd. 33HBrd. 34ABrd. 34BBrd. 34CBrd. 34DBrd. 34EBrd. 34FIntermediate-dose cyclophosphamide (1.5 Gm/M2) with G-CSF as the primaryperipheral blood progenitor mobilization strategy: A single institutionexperience. (Abstract #6559)A. Padmanabhan, J. W. Hayslip, G. P. Monohan, S. D. Sutphin, H. Weiss,D. S. HowardRelationship between age and healthcare utilization in patients withmyelodysplastic syndrome receiving supportive care. (Abstract #6560)K. Stein, A. Powers, R. L. Knoth, M. Broder, E. ChangImpact of combined lymphocyte and monocyte recovery on survival postmyeloablative allogeneic hematopoietic stem cell transplant for acuteleukemia. (Abstract #6561)M. Thoma, T. Huneke, L. DeCook, N. Johnson, R. Wiegand, M. R. Litzow,W. J. Hogan, L. F. Porrata, S. G. HoltanAn analysis of high ferritin levels before allogeneic hematopoietic celltransplantation (AlloHCT): A retrospective study to evaluate prognosticfactors in patients (pts) undergoing AlloHCT for myelodysplasia. (Abstract#6562)S. Hashmi, E. S. Rich, S. Basu, J. J. Maciejewski, S. Nathan, P. Venugopal,S. A. Gregory, H. C. Fung, J. M. ShammoSurvival after nonmyeloablative versus myeloablative allotransplantation forAML/MDS. (Abstract #6563)M. R. Khawaja, J. E. Schwartz, M. Yu, M. J. Robertson, G. H. Vance,S. Srivastava, L. L. Wood, R. Abonour, K. Cornetta, S. Farag, L. D. Cripe,R. P. Nelson Jr.Expression of topoisomerase (topo) II in adult acute myeloid leukemia (AML):Relationships to immunophenotype and treatment outcomes. (Abstract#6564)A. P. Michelson, K. J. Kopecky, E. R. Koegle, J. E. Anderson, J. E. Godwin,S. H. Petersdorf, A. F. List, C. L. Willman, F. R. Appelbaum, J. P. Radich,M. K. Ganapathi, R. N. Ganapathi, A. AdvaniAutologous stem cell transplantation (ASCT) as upfront or salvage therapyfor non-cutaneous T-cell lymphoma (TCL): The University of Texas M. D.Anderson Cancer Center (MDACC) experience. (Abstract #6565)A. Beitinjaneh, R. Saliba, G. Okoroji, A. M. Alousi, U. R. Popat, M. Korbling,P. Anderlini, M. Qazilbash, P. Kebriaei, C. Hosing, R. E. Champlin, I. F. KhouriAn evaluation of the risk/benefit ratio of low molecular weight heparin toreduce the high risk of venous thromboembolism in acute leukemia.(Abstract #6566)G. L. Simmons, B. E. Hillner, T. J. SmithTherapy-related acute promyelocytic leukemia (t-APL): Observations on APLpathogenesis. (Abstract #6567)M. A. Elliott, L. Letendre, A. Tefferi, W. J. Hogan, C. C. Hook, R. Pruthi,S. H. Kaufmann, A. D. Pardanani, K. Begna, A. Ashrani, A. P. Wolanskyj,A. Al-Kali, M. R. LitzowA phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) andgentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia(AML) and high-risk myelodysplastic syndrome (MDS). (Abstract #6568)H. Ghanem, H. Kantarjian, G. Garcia-Manero, F. Ravandi, S. Faderl, J. E. Cortes,A. Reyes, S. M. O’Brien, G. Borthakur, T. M. Kadia, J. A. Burger, M. Konopleva,E. JabbourImatinib mesylate as first-line therapy in patients with chronic myeloidleukemia in accelerated phase and blastic crisis: A retrospective analysis.(Abstract #6569)N. Thota, S. Gundeti, P. Coca, J. Srirambhatla, R. Parimkayala, V. Linga,S. Bheemnathi Hanuman, L. S. Maddali, R. DigumartiMONDAY381

Monday, June 6, 2011MONDAYBrd. 34G Long-term estimate of quality-adjusted life expectancy for nilotinib andimatinib as first-line treatment for newly diagnosed patients withPhiladelphia chromosome-positive (Ph) chronic myeloid leukemia in thechronic phase (CML-CP). (Abstract #6570)M. Botteman, J. Stephens, S. J. Snedecor, X. Ji, M. Hussein, J. CoombsBrd. 34H Interim PK analysis results of a phase IIa, open-label, randomized,pharmacokinetic comparative, cross-over studyof melphalan HCl forinjection (Propylene Glycol-Free) and alkeran for injection formyeloablativeconditioning in multiple myeloma patients undergoing autologoustransplantation. (Abstract #6571)O. S. Aljitawi, S. Ganguly, S. H. Abhyankar, D. Robinson, R. Marks, J. Pipkin,J. McGuirkBrd. 35A Cost-effectiveness of nilotinib versus imatinib as first-line treatment fornewly diagnosed patients with Philadelphia chromosome-positive (Ph)chronic myeloid leukemia in the chronic phase (CML-CP): Swedishperspective. (Abstract #6572)A. Ovanfors, J. Stephens, S. J. Snedecor, D. Patel, X. Ji, K. T. Carpiuc, J. Coombs,M. BottemanBrd. 35B Distinctions between adult T-cell leukemia-lymphoma (ATLL) secondary tohuman T-cell lymphotropic virus 1 (HTLV1) and peripheral T-cell lymphoma(TCL). (Abstract #6573)G. D. Ayalew, J. Yao, K. A. Killoran, K. Laveaux, C. A. Axiotis, A. S. BravermanBrd. 35C Phase II study of AZD2171 for the treatment of patients with acutemyelogenous leukemia. (Abstract #6574)M. Juckett, B. LaPlant, P. J. Flynn, A. Jumonville, A. Moreno-Aspitia, C. ErlichmanBrd. 35D Mediation of LA-4 lung epithelial cell injury by alloreactive donor T cells.(Abstract #6575)S. V. Radhakrishnan, T. Obermeier, G. Mueller, G. C. HildebrandtBrd. 35E The diagnostic and prognostic implications of nucleated red blood cells inmyelophthisis. (Abstract #6576)J. L. Schering, J. Munoz, E. Raybon, S. Hegab, A. S. Hanbali, P. KuriakoseBrd. 35F Vaginal bleeding in women with leukemia. (Abstract #6577)S. Ghazal, S. Barton, R. Boyajian, J. H. Antin, R. M. Stone, E. S. GinsburgBrd. 35G TLI-ATG for nonmyeloablative stem cell transplant: A single centerexperience. (Abstract #6578)D. A. Wong, A. S. Steinberg, C. Bresee, A. M. Lopez, S. Lim, M. LillBrd. 35H Subdural hematomas in patients with Philadelphia chromosome-positiveacute lymphoblastic leukemia receiving imatinib mesylate in conjunctionwith multiagent chemotherapy. (Abstract #6579)S. B. Patel, I. Gojo, M. Tidwell, Y. Ning, X. F. Zhao, E. A. Sausville, M. R. BaerBrd. 36A Effect of lenalidomide on antileukemia activity in vitro against adult T-cellleukemia (ATL) . (Abstract #6580)Y. Kitagawa, M. Matsuoka, S. MitaniBrd. 36B Relation of methylenetetrahydrofolate reductase C677T polymorphism tochronic myeloid leukemia in serbia. (Abstract #6581)R. N. Jankovic, K. Jakovljevic, M. Cavic, E. MalisicBrd. 36C Enhanced risk stratification in young and elderly patients treated withinduction chemotherapy as well as in frail patients with AML. (Abstract#6582)S. Wilop, T. H. Brummendorf, M. CrysandtBrd. 36D UCBT with ATG in adult patients. (Abstract #6583)W. M. Linkesch, D. Strunk, W. Zinke-Cerwenka, H. Sill, P. NeumeisterBrd. 36E Clinico-hematological characteristics and outcome assessment of chroniclymphocytic leukemia patients: A single institution study of 285 cases.(Abstract #6584)A. Gogia, A. Sharma, V. Raina, L. Kumar, R. Kumar, R. Gupta, S. Vishnubhatla382

Monday, June 6, 2011Brd. 36FBrd. 36GBrd. 36HBrd. 37ABrd. 37BBrd. 37CBrd. 37DBrd. 37EBrd. 37FBrd. 37GBrd. 37HBrd. 38ABrd. 38BEvaluation of the JAK2 V617F mutational status in coronary patients.(Abstract #6585)K. Gasser, A. Muendlein, N. Stark, T. Winder, P. Rein, C. H. Saely, K. Geiger,S. Geller-Rhomberg, B. L. Hartmann, B. Kohler, H. Drexel, A. LangTime from relapse after allogeneic stem cell transplantation (SCT) to donorleukocyte infusion (DLI) is longer, incidence of GVHD is higher, but survivalis similar for recipients of unrelated DLI compared to matched sibling DLI.(Abstract #6586)A. Kumar, N. V. Frey, P. Vassilev, S. Goldstein, E. O. Hexner, A. W. Loren,R. Reshef, S. M. Luger, D. L. Porter, E. A. StadtmauerPhase I/II study of sapacitabine and decitabine administered sequentially inelderly patients with newly diagnosed acute myeloid leukemia. (Abstract#6587)F. Ravandi, S. Faderl, J. E. Cortes, G. Garcia-Manero, E. Jabbour, P. A. Boone,T. M. Kadia, G. Borthakur, W. G. Wierda, J. H. Chiao, H. KantarjianComparison of cytarabine, mitoxantrone and CNDAC in vitro treatment ofAML bone marrow and peripheral blood cells. (Abstract #6588)S. Jagan, L. A. Paganessi, S. Gezer, A. Rizman, D. Rifai, M. C. Keller,M. L. Larson, P. Venugopal, S. Frame, K. W. Christopherson IIAdherence to treatment with second-line therapies, dasatinib and nilotinib, inpatients (pts) with chronic myeloid leukemia (CML). (Abstract #6589)M. Ulcickas Yood, S. A. Oliveria, I. Hirji, S. Phillips, M. J. Cziraky, C. C. DavisAltered mitochondrial metabolism as a target in acute myeloid leukemia.(Abstract #6590)T. S. Pardee, D. A. Levitan, D. D. HurdLACE: A conditioning regimen for lymphoma patients undergoingautologous transplant. (Abstract #6591)R. Thippeswamy, L. Mathew, B. Bhosale, N. Kumar, S. Kannan, A. Joshi,V. Rangarajan, N. KhattryThe role of minimal residual disease (MRD) by flow cytometry (FC) inpredicting outcome in similarly treated acute lymphoblastic leukemia (ALL)patients. (Abstract #6592)H. J. Lee, K. M. Wright, E. Kandeel, W. Tan, G. E. Wilding, L. Ford, S. N. Sait,A. W. Block, M. P. Barcos, P. L. McCarthy, C. E. Vigil, E. A. Griffiths,J. E. Thompson, E. S. Wang, P. K. Wallace, M. WetzlerDecitabine for the treatment of acute myeloid leukemia (AML): MemorialSloan-Kettering Cancer Center experience. (Abstract #6593)A. Ganetsky, N. G. Adel, M. G. Frattini, P. G. Maslak, M. L. Heaney,J. G. Jurcic, M. S. TallmanPrognostic factors of long-term survival in patients with acute myeloidleukemia after allogeneic or autologous stem cell transplantation. (Abstract#6594)L. Wang, C. Corona, X. Nie, L. Mejias, S. j. Hou, R. Mullaney, K. M. Ward,D. L. Topolsky, M. Styler, P. A. CrilleyPrevalence of venous thromboembolism (VTE) among patients (pts) withacute leukemia (AL) prior to treatment. (Abstract #6595)N. V. Luong, S. Faderl, H. Kantarjian, K. VuRelevance of PIG-A mutation in aplastic anemia and myelodysplasticsyndromes. (Abstract #6596)J. J. Pu, R. Hu, G. Mukhina, R. A. BrodskyRisk of progression to myelofibrosis and acute myeloid leukemia in patientswith essential thrombocythemia and polycythemia vera with priormalignancy. (Abstract #6597)M. A. Cherry, H. Pham, H. Kantarjian, J. E. Cortes, S. Pierce, L. Zhou,S. VerstovsekMONDAY383

Monday, June 6, 2011MONDAYBrd. 38CBrd. 38DBrd. 38EBrd. 38FBrd. 38GBrd. 38HBrd. 39ABrd. 39BBrd. 39CBrd. 39DBrd. 39EBrd. 39FRetrospective analysis of prognostic factors associated with response andoverall survival in patients with RAEB-t MDS treated with decitabine.(Abstract #6598)A. Malik, G. Garcia-Manero, M. Welch, H. Kantarjian, K. Stein, A. Teng, E. JabbourGenetic variation in vitamin D pathway and graft-versus-host disease riskafter blood and marrow transplantation. (Abstract #6599)K. Robien, L. G. Strayer, T. E. DeFor, B. Thyagarajan, D. Lazovich, S. A. Cooley,J. A. Ross, K. S. BakerRetrospective analysis of effects of dose modification andmyelosuppression on response to decitabine and overall survival in patientswith myelodysplastic syndromes. (Abstract #6600)M. Cornelison, G. Garcia-Manero, J. E. Cortes, F. Ravandi, H. Kantarjian, K. Stein,A. Teng, E. JabbourPharmacogenetic variants and outcomes after hematopoietic celltransplantation. (Abstract #6601)B. Thyagarajan, P. Jacobson, S. Jackson, S. Basu, D. J. Weisdorf, M. Gross,M. AroraChronic lymphocytic leukemia (CLL) patients at a VA medical center:Comorbidity and survival. (Abstract #6602)L. Soriano, S. Srinivas, M. Tufail, K. Kim, R. Paulin, V. T. Chang, B. Kasimis,M. L. GonzalezRole of topotecan, vinorelbine, thiotepa, and gemcitabine (TVTG)chemotheapy in relapsed/refractory adult acute leukemia: Asingle-institution retrospective analysis. (Abstract #6603)S. A. Srour, M. A. Cherry, E. Borders, H. Parekh, J. L. Holter, T. S. Herman,G. B. SelbyModel-based prediction of patient-specific residual disease levels forimatinib-treated chronic myeloid leukemia. (Abstract #6604)M. Loeffler, M. Horn, I. Glauche, M. C. Müller, A. Hochhaus, I. RoederAnalysis of patients (pts) with chronic-phase chronic myeloid leukemia(CML-CP) who develop pleural effusion on first-line dasatinib: Managementand outcomes. (Abstract #6605)P. Laneuville, M. Baccarani, J. E. Cortes, A. Hochhaus, H. Kantarjian, N. P. Shah,M. Bradley-Garelik, C. Zhu, K. PorkkaDisease management and treatment of chronic myeloid leukemia (CML):Experience from the patient (pt) perspective. (Abstract #6606)T. W. Victor, M. Talpaz, A. Buzyn, C. B. Lemoine, A. Moadel, E. Olavarria,S. Leighton, S. Gupta, I. Hirji, C. C. DavisValidation of a transplant-related mortality (TRM) risk score for pediatricpatients undergoing allogeneic haematopoietic stem cells transplantation.(Abstract #6607)P. Angelini, A. Gassas, I. Zaidman, J. Doyle, T. SchechterAnalysis of outcomes in relapsed/refractory acute promyelocytic leukemia(APL) patients (pts) treated with and without high-dose chemotherapy andhematopoietic stem cell transplantation (HCT). (Abstract #6608)N. Pemmaraju, F. Ravandi, G. Rondon, S. Giralt, J. Chen, S. Pierce,R. E. Champlin, M. De Lima, M. QazilbashRomiplostim for the treatment of amegakaryocytic thrombocytopeniasecondary to remission-inducing immunomodulation in a patient withrelapsing acute lymphoblastic leukemia after allogeneic hematopoietic stemcell transplantation. (Abstract #6609)L. Volodin, V. K. Bhanderi, J. Shahan, C. Leary, G. Jean, J. Comeau,J. Cotelingam, G. C. Hildebrandt384

Monday, June 6, 2011Brd. 39GBrd. 39HBrd. 40ABrd. 40BBrd. 40CBrd. 40DBrd. 40EBrd. 40FBrd. 40GBrd. 40HBrd. 41ASymptomatic burden in myelofibrosis (MF): Prospective internationalassessment in 128 MF patients. (Abstract #6610)R. M. Scherber, A. C. Dueck, P. Johansson, T. Barbui, G. Barosi, A. M. Vannucchi,F. Passamonti, B. I. Andreasson, M. L. Ferarri, A. Rambaldi, J. Samuelsson,G. Birgegard, A. Tefferi, N. Maldonado, F. Sackmann, P. Muxi,D. Hernandez-Maraver, J. Kiladjian, R. A. MesaLeukemia regression by targeting c-Kit activity with pazopanib. (Abstract#6611)A. Trujillo, C. S. McGee, E. Gars, R. Bosse, A. Meacham, E. Wise, S. Bais,C. R. CogleHealth-related quality of life (HRQoL) in newly diagnosed chronic phasechronic myelogenous leukemia (CP CML) patients (pts) treated withbosutinib (BOS) or imatinib (IM). (Abstract #6612)J. H. Lipton, P. C. Trask, D. Cella, L. Duvillie, C. Powell, M. V. Ramanan,Z. Maslyak, D. KimInvestigation of thrombopoietin (TPO) function in primary chroniclymphocytic leukemia cells. (Abstract #6613)R. D. Loberg, S. Wang, S. D. Patterson, I. McCafferyAssociation between chronic myeloid leukemia (CML) treatment responsesand patient satisfaction, functioning, and quality of life (QOL): Patient surveyresults. (Abstract #6614)S. Goldberg, V. K. Bollu, R. Morlock, A. Niyazov, A. Guo, E. JabbourOpen-label study evaluating change in chronic low-grade (LG) nonhematologic(heme) adverse events (AEs) in Philadelphia positive (Ph)CML-CP patients (pts) switched from imatinib (IM) to nilotinib (NL). (Abstract#6615)J. E. Cortes, C. B. Miller, J. H. Lipton, L. Busque, L. P. Akard, J. Pinilla-Ibarz,S. Ericson, M. J. MauroImpact of pleural effusion (PE) on treatment adherence, discontinuation,switching, and dose modification in patients with chronic myelogenousleukemia (CML). (Abstract #6616)E. Q. Wu, A. Guerin, V. K. Bollu, A. Guo, M. Cloutier, D. Ponce de Leon Barido,S. Ericson, A. Quintas-CardamaRetrospective analysis of effects of transfusion status on response todecitabine and survival in patients with myelodysplastic syndromes.(Abstract #6617)T. M. Kadia, G. Garcia-Manero, H. Kantarjian, N. Pemmaraju, K. Stein, A. Teng,J. E. CortesIntergroup study in elderly patients with AML to compare complete remissionrate and overall survival after intermediate dose or low dose AraC. (Abstract#6618)T. Lange, D. Niederwieser, V. Hoffmann, M. Pfirrmann, G. Maschmeyer,T. Fischer, M. Herold, H. G. Sayer, C. Junghanss, R. Krahl, H. Al-Ali, W. Pönisch,V. Vucinic, G. Doelken, M. C. Sauerland, A. Heinecke, D. Hoelzer,R. Hehlmann, W. E. Berdel, T. BuchnerArsenic trioxide followed by autologous stem cell transplant for patients withrelapsed APL. (Abstract #6619)D. D. Shepard, H. E. Kohrt, T. L. Rosenblat, J. G. Jurcic, J. H. Park, A. Goldman,J. S. Dalal, P. G. Maslak, A. A. Jakubowski, V. Klimek, E. Berman, S. Nand,S. E. Coutre, M. S. Tallman, H. P. ErbaHealth-related quality of life (HRQoL) of bosutinib (SKI-606) in imatinibresistant(IM-R) or imatinib-intolerant (IM-I) chronic phase chronic myeloidleukemia (CP CML). (Abstract #6620)P. C. Trask, D. Cella, N. Besson, V. Kelly, T. Masszi, D. KimMONDAY385

Monday, June 6, 2011MONDAYBrd. 41B Secondary malignancies in essential thrombocythemia and polycythemiavera: A retrospective analysis of 437 patients from a single institution.(Abstract #6621)S. Pierce, M. A. Cherry, H. Pham, H. Kantarjian, A. Al-Ameri, J. E. Cortes, L. Zhou,S. VerstovsekBrd. 41C Incidence of cytogenetic (CG) abnormalities in acute myeloid leukemia (AML)in African American (AA) population. (Abstract #6622)R. Khillan, A. S. Braverman, C. A. Axiotis, R. Latif, G. S. SidhuBrd. 41D Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts)with relapsed/refractory CLL. (Abstract #6623)J. M. Flynn, J. A. Jones, L. Andritsos, K. A. Blum, A. J. Johnson, J. Hessler,E. Wiley, N. A. Heerema, J. Poon, K. A. Small, Y. Jou, D. Zhang, P. Statkevich,M. R. Grever, R. Bannerji, J. C. ByrdBrd. 41E Modulation of nuclear factor-kb (NF-kb), IkB kinase (IKK), and inducible nitricoxide synthase (iNOS) via proinflammatory cytokines with adjuvantselenomethionine (Se-Met) in chronic myelogenous leukemia (CML) patientswith imatinib mesylate (IM) overexpression of bcr-abl fusion protein.(Abstract #6624)E. McPherson, K. Patel, P. Tassy, J. KleinfeldBrd. 41F Chronic myelomonocytic leukemia (CMML) associated with symptomaticpericardial effusion. (Abstract #6625)M. I. Ibrahim, P. G. Maslak, M. L. Heaney, M. S. George, R. J. Downey,M. S. TallmanBrd. 41G Cytomorphologic and clinical features of AML with translocation (8;16)mimicking APL. (Abstract #6626)S. Jhanwar, A. Diab, L. Zickl, G. A. Manji, J. Patel, O. I. Abdel-Wahab, J. G. Jurcic,P. G. Maslak, P. G. Steinherz, E. Paietta, J. Feldstein, R. L. Levine, M. S. TallmanBrd. 41H Chemotherapeutic drugs-induced apoptosis-related mRNAs in whole bloodex vivo as a new diagnostic markers for the prediction of clinical outcome ofAML. (Abstract #6627)N. Usui, K. Mitani, T. Maeda, T. Sakura, N. Dobashi, F. Yagasaki, K. Obata,M. Mitsubashi, S. MiyawakiBrd. 42A Influence of type of antecedent disorder on outcome of therapy-related AML.(Abstract #6628)S. R. Mohan, P. Elson, M. E. Kalaycio, R. V. Tiu, A. S. Advani, E. A. Copelan,J. P. Maciejewski, M. A. SekeresBrd. 42B A phase II study of chlorambucil plus rituximab followed by maintenanceversus observation in elderly patients with previously untreated chroniclymphocytic leukemia: Results of the induction phase. (Abstract #6629)F. R. Mauro, S. Ciolli, F. Di Raimondo, G. Del Poeta, F. Forconi, A. Cuneo,A. Cortellezzi, F. Nobile, M. Brugiatelli, M. Massaia, S. Molica, L. Trentin, R. Rizzi,L. Orsucci, M. Mura, A. Alietti, E. J. Runggaldier, E. Gamba, A. Guarini, R. FoaBrd. 42C Comparison of outcome in erythroleukemia patients treated with standardchemotherapy regimens or hypomethylating agents. (Abstract #6630)C. E. Vigil, W. Tan, G. E. Wilding, G. Garcia-Manero, E. S. Wang, M. Wetzler,A. F. ListBrd. 42D Phase I study of CAL-101, an isoform-selective inhibitor ofphosphatidylinositol 3-kinase P110d, in patients with previously treatedchronic lymphocytic leukemia. (Abstract #6631)S. E. Coutre, J. C. Byrd, R. R. Furman, J. R. Brown, D. M. Benson Jr.,N. D. Wagner-Johnston, I. W. Flinn, B. S. Kahl, S. E. Spurgeon, B. J. Lannutti,H. K. Hsu, R. Ulrich, S. Peterman, L. Holes, L. L. Miller, A. S. YuBrd. 42E Effects of eltrombopag on human cord blood hematopoietic stemcell/primitive progenitor cell expansion. (Abstract #6632)H. Sun, Y. Tsai, J. Liesveld, K. L. Dawson, C. L. Erickson-Miller, Y. Chen386

Monday, June 6, 20111:00 PM - 5:00 PMGENERAL POSTER SESSIONLymphoma and Plasma Cell DisordersLocation: Hall ATrack(s): Lymphoma and Plasma Cell DisordersBrd. 43A Six versus eight cycles of biweekly CHOP-14 with or without R in elderlypatients with aggressive CD20 B-cell lymphomas: Seven-year FU of theRICOVER-60 trial of the DSHNHL. (Abstract #8029)M. Pfreundschuh, M. Ziepert, S. Zeynalova, E. Lengfelder, H. Steinhauer,M. R. Clemens, C. Nickenig, A. D. Ho, L. H. Truemper, M. Hoffmann,R. H. Mertelsmann, B. Metzner, H. Mergenthaler, V. Poeschel, N. Schmitz,M. Loeffler, German Non-Hodgkin Lymphoma Study Group (DSHNHL)Brd. 43B High response rates with lenalidomide plus rituximab for untreated indolentB-cell non-Hodgkin lymphoma, including those meeting GELF criteria.(Abstract #8030)F. Samaniego, F. Hagemeister, P. Mclaughlin, L. W. Kwak, J. Romaguera,M. A. Fanale, S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, L. Lacerte,N. H. FowlerBrd. 43C Results from a pivotal phase II study of brentuximab vedotin (SGN-35) inpatients with relapsed or refractory Hodgkin lymphoma (HL). (Abstract#8031)R. W. Chen, A. K. Gopal, S. E. Smith, S. M. Ansell, J. D. Rosenblatt,K. J. Savage, J. M. Connors, A. Engert, E. K. Larsen, D. A. Kennedy, E. L. Sievers,A. YounesBrd. 43D Durable remissions with brentuximab vedotin (SGN-35): Updated results of aphase II study in patients with relapsed or refractory systemic anaplasticlarge cell lymphoma (sALCL). (Abstract #8032)B. Pro, R. Advani, P. Brice, N. Bartlett, J. D. Rosenblatt, T. Illidge, J. Matous,R. Ramchandren, M. A. Fanale, J. M. Connors, Y. Yang, E. L. Sievers,D. A. Kennedy, A. R. ShustovBrd. 43E Complete responses (CR/CRu) on a phase II study of romidepsin in relapsedor refractory peripheral T-cell lymphoma (R/R PTCL). (Abstract #8033)S. M. Horwitz, B. Coiffier, F. M. Foss, H. M. Prince, L. Sokol, M. Greenwood,D. Caballero, P. Borchmann, F. Morschhauser, M. Wilhelm, L. C. Pinter-Brown,S. Padmanabhan, A. R. Shustov, J. Nichols, J. Balser, S. Carroll, B. ProBrd. 43F The use of FDG-PET to guide consolidative radiotherapy in patients withadvanced-stage Hodgkin lymphoma with residual abnormalities on CT scanfollowing ABVD chemotherapy. (Abstract #8034)K. J. Savage, J. M. Connors, R. J. Klasa, P. Hoskins, T. N. Shenkier,R. D. Gascoyne, S. Bhimji, T. Pickles, F. Benard, D. Wilson, L. H. SehnBrd. 43G Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stageHodgkin lymphoma (HL): Analysis from the phase III randomized U.S.Intergroup Trial E2496. (Abstract #8035)A. M. Evens, F. Hong, L. I. Gordon, R. I. Fisher, N. Bartlett, J. M. Connors,H. Wagner, M. K. Gospodarowicz, B. D. Cheson, R. Advani, B. S. Kahl,R. T. Hoppe, S. J. HorningBrd. 43H Examination of the Follicular Lymphoma International Prognostic Index(FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohorttreated predominantly in community practices. (Abstract #8036)A. K. Nooka, N. J. DeJoubner, C. Nabhan, X. Zhou, M. Taylor, M. Byrtek,T. P. Miller, J. W. Friedberg, A. D. Zelenetz, B. K. Link, J. R. Cerhan, H. Dillon,D. Levy, J. Hirata, C. FlowersBrd. 44A Long-term survival among Hodgkin lymphoma (HL) patients withgastrointestinal (GI) cancers: A population-based study. (Abstract #8037)P. Youn, H. Li, M. T. Milano, M. Stovall, L. S. Constine, L. B. TravisMONDAY387

Monday, June 6, 2011MONDAYBrd. 44BBrd. 44CBrd. 44DBrd. 44EBrd. 44FBrd. 44GBrd. 44HBrd. 45BBrd. 45CBrd. 45DBrd. 45EAggressive craniofacial lymphoma in the prerituximab and rituximab era.(Abstract #8038)V. Poeschel, N. Murawski, B. Glass, S. Zeynalova, J. Fleckenstein, M. Ziepert,B. Kempf, M. Loeffler, N. Schmitz, M. Pfreundschuh, German Non-HodgkinLymphoma Study Group (DSHNHL)Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma(cHL). (Abstract #8039)Y. L. Kasamon, H. A. Jacene, L. J. Swinnen, L. Popplewell, B. K. Link,T. M. Habermann, J. M. Herman, R. J. Jones, R. F. AmbinderThe impact of high-intensity conditioning prior to allogeneic stem celltransplantation in patients with chemorefractory or relapsed T-celllymphoma. (Abstract #8040)B. Glass, J. Hasenkamp, W. Jung, C. Wilhelm, G. Held, M. Nickelsen,M. Pfreundschuh, N. Schmitz, L. H. Truemper, G. WulfPatients’ versus physicians’ roles in detecting recurrent Hodgkin lymphoma.(Abstract #8041)A. Bestawros, L. Foltz, N. Srour, J. M. ConnorsMulticenter analysis of more than 300 very elderly non-Hodgkin lymphoma(NHL) patients (pts): Impact of comorbidities and functional status onoutcome. (Abstract #8042)C. Nabhan, S. M. Smith, I. B. Helenowski, E. E. Ramsdale, R. Karmali,B. M. Parsons, J. Feliciano, B. Hanson, S. E. Smith, J. M. Mckoy, A. Larsen,A. Hantel, S. A. Gregory, A. M. EvensImpact of conditioning regimen on outcome of 2-year disease-free survivorsof autologous stem cell transplantation (ASCT) for Hodgkin lymphoma (HL).(Abstract #8043)B. M. William, F. R. Loberiza Jr., V. Whalen, P. J. Bierman, G. Bociek, J. Vose,J. O. ArmitagePET scans in HIV-related Hodgkin lymphoma (HIV-HL): Results of aretrospective study. (Abstract #8044)M. Hentrich, M. Berger, C. Hoffmann, J. Siehl, T. Wolf, M. Nickelsen, J. Rockstroh,D. Schuermann, A. Rieke, R. Schmidmaier, H. Knechten, M. Mueller,G. Fätkenheuer, R. Meyer, K. Arastéh, F. A. Mosthaf Sr., C. WyenBiomarker analysis of pivotal phase II study of oral panobinostat (PAN) inrelapsed/refractory Hodgkin lymphoma (HL) patients following autologousstem cell transplant (ASCT). (Abstract #8046)S. J. Harrison, A. K. Hsu, P. J. Neeson, A. Younes, A. Sureda, A. Engert, M. Li,P. Savage, R. Bugarini, C. Le Corre, D. E. Williams, J. D. Gallagher, A. Shen,D. RitchieActivity of anti-CD20-interferon- fusion protein against human B-celllymphomas. (Abstract #8047)G. Ngarmchamnanrith, R. E. Yamada, K. K. Steward, S. Khare, R. Sachdev,S. L. Morrison, J. TimmermanDiscriminatory power of the 111-indium scan (111-In) in the prediction ofaltered biodistribution of radio-immunoconjugate in the 90-yttriumibritumomab tiuxetan therapeutic regimen: Meta-analysis of five clinical trialsand 9 years of post-approval safety data. (Abstract #8048)J. W. Kylstra, T. E. Witzig, M. Huang, C. E. Emmanouilides, A. Hagenbeek,G. F. TidmarshSecond-line therapy in follicular lymphoma in the United States: Report ofNLCS observational study. (Abstract #8049)B. K. Link, T. P. Miller, M. Byrtek, J. R. Cerhan, A. D. Zelenetz, H. Dillon,C. Flowers, J. W. Friedberg388

Monday, June 6, 2011Brd. 45FBrd. 45GBrd. 45HBrd. 46ABrd. 46BBrd. 46CBrd. 46DBrd. 46EBrd. 46FBrd. 46GBrd. 46HThe association between the GOELAMS MCL-PET prognostic index andsurvival in patients treated with rituximab-hypercvad (R-HyCVAD) or highdosetherapy with autologous stem cell rescue (HDT/ASCT). (Abstract #8050)T. Feldman, A. R. Mato, T. Zielonka, S. D. Rowley, S. Goldberg, M. Donato,D. S. Siegel, K. Facchin, A. Campaiola, D. H. Vesole, C. Bejot, S. Stives, M. Curtin,M. Miller, H. Agress, D. Panush, P. Lizotte, P. Bhattacharyya, A. Pecora, A. GoyA new predictive model based on age, pretreatment LDH, and post-therapyPET-CT in patients with MCL treated with dose-intensive strategies. (Abstract#8051)A. R. Mato, T. Feldman, T. Zielonka, S. Goldberg, S. D. Rowley, M. Donato,D. S. Siegel, D. H. Vesole, A. Campaiola, K. Facchin, S. Stives, C. Bejot, M. Curtin,M. Miller, H. Agress, D. Panush, P. Lizotte, A. Pecora, P. Bhattacharyya, A. GoyVariation of hepatitis C virus genotype distribution between geographicallyrelated patients: A retrospective multicenter study. (Abstract #8052)H. A. Torres, M. Nevah-Rubin, B. J. Barnett, P. Mahale, D. P. Kontoyiannis,L. Mishra, M. Hassan, I. RaadPhase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) forpatients older than age 60 with untreated diffuse large B-cell lymphoma(DLBCL). (Abstract #8053)M. A. Rodriguez, J. Durand, A. B. Astrow, M. J. Bury, M. A. Fanale,F. B. Hagemeister Jr., X. Huang, P. McLaughlin, S. S. Neelapu, B. Pro,L. W. Kwak, L. Fayad, J. E. Romaguera, A. Younes, M. FischAllograft versus non-allograft post-transplant lymphoproliferative disorder,characterization of two distinct subtypes as defined by presentation,histology, and outcome: A case series of 165 patients. (Abstract #8054)D. E. Tsai, I. S. Hagemann, J. J. Morrissette, R. Daber, D. Xu, S. J. Schuster,R. D. Bloom, V. N. Ahya, M. Jessup, G. A. Makar, S. Chen, R. ReshefIdentification of prognostic tumor markers in HIV diffuse large B-celllymphoma (DLBCL). (Abstract #8055)C. Chao, M. Silverberg, D. I. Abrams, R. Haque, H. D. Zha, O. Martinez-Maza,M. McGuire, M. D. Chi, B. Castor, L. Xu, J. SaidEpigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease. (Abstract#8056)M. Cotto, F. Cabanillas, G. Garcia-Manero, H. Yang, M. Bruno, O. A. Pavia,E. Rivera, I. Liboy, M. Tirado-GomezPrognostic significance of absolute lymphocyte count in patients withearly-stage diffuse large B-cell lymphoma treated with RCHOP. (Abstract#8057)Y. Chae, Y. Lee, B. Kang, J. Moon, J. Kim, S. Sohn, D. Yang, J. Lee, T. ParkA phase II study of R-COMP14 in elderly patients with high-risk diffuse largeB-cell lymphoma (DLBCL) and moderate to high “life threat” impactcardiopathy. (Abstract #8058)G. Corazzelli, F. Frigeri, M. Arcamone, A. Lucania, G. Capobianco, M. Villa,F. Russo, S. Crisci, G. Marcacci, C. Becchimanzi, E. Morelli, F. Volzone,R. De Filippi, A. PintoQuality of life (QOL) as a predictor of survival in aggressive non-Hodgkinlymphoma (NHL). (Abstract #8059)C. A. Thompson, M. J. Maurer, C. Allmer, S. L. Slager, K. J. Yost, W. R. Macon,S. M. Ansell, D. J. Inwards, T. M. Habermann, B. K. Link, J. R. CerhanDifferences in regulatory T cells (Tregs) in responding and non-respondingpatients with indolent B-cell or mantle cell lymphoma during treatment withlenalidomide and rituximab dexamethasone. (Abstract #8060)N. Aqui, A. Gordon, Y. Xu, E. A. Chong, L. Leinbach, T. Ahmadi, S. Nasta,J. Svoboda, S. J. SchusterMONDAY389

Monday, June 6, 2011MONDAYBrd. 47ABrd. 47BBrd. 47CBrd. 47DBrd. 47EBrd. 47FBrd. 47GBrd. 47HBrd. 48ABrd. 48BBrd. 48CBrd. 48DCell cycle effects of CDK 4/6 inhibitor PD 0332991 in diffuse large B-celllymphoma cell lines in vitro. (Abstract #8061)H. A. Eradat, M. A. Eckardt, E. Dorfman, H. Hamidi, C. Ginther, R. S. Finn, G. Los,J. G. Christensen, S. De Vos, D. J. SlamonPiracy of COX-2/PGE2/EP receptor pathway by Kaposi’s sarcoma associatedherpes virus (KSHV): A potential Achilles’ heel of KSHV–related diseases.(Abstract #8062)A. G. Paul, N. Sharma-Walia, B. ChandranPreliminary evaluation of radioimmunotherapy with Tenarad, a I-131 labeledantibody fragment targeting the extra-domain A1 of tenascin-C, in patientswith refractory Hodgkin lymphoma. (Abstract #8063)L. Aloj, L. D’Ambrosio, M. Aurilio, R. Marreno, D. Neri, H. D. Menssen,L. Giovannoni, F. Di Gennaro, C. Caraco, M. Arcamone, F. Frigeri, A. Pinto,S. LastoriaAbbreviated 8-week chemotherapy (CT) plus involved node radiotherapy(INRT) for nonbulky stage I-II Hodgkin lymphoma: Preliminary results of theStanford G5 Study. (Abstract #8064)R. Advani, S. J. Horning, E. Jonathan, S. Daadi, J. Allen, S. A. Rosenberg,R. T. HoppeOutcomes following involved field radiotherapy (IFRT) with or withoutrituximab in patients (Pts) with limited-stage low-grade non-Hodgkinlymphoma (NHL) staged with CT versus PET. (Abstract #8065)J. N. Lukens, S. Nasta, E. Glatstein, J. P. PlastarasBendamustine and lenalidomide in relapsed/refractory lymphoidmalignancies. (Abstract #8066)B. D. Cheson, C. S. Ujjani, E. A. Gehan, S. M. Karim, T. Goswami, J. CrawfordEfficacy of pomalidomide plus low-dose dexamethasone in multiplemyeloma patients despite previous use of lenalidomide. (Abstract #8067)J. Mikhael, V. Rajkumar, V. Roy, S. R. Hayman, R. Fonseca, K. Detweiler Short,B. LaPlant, K. M. Laumann, A. Dispenzieri, M. LacyExtramedullary disease (EMD): A common terminal pathway in multiplemyeloma (MM) progression. (Abstract #8068)S. Z. Usmani, A. Mitchell, J. Szymonifka, J. D. Shaughnessy Jr., A. Hoering,Y. Alsayed, S. Waheed, B. Nair, J. Crowley, B. BarlogieSurvival outcomes of patients with multiple myeloma (MM) achievingstringent complete response (sCR) following upfront autologous stem celltransplantation (SCT). (Abstract #8069)P. Kapoor, S. Kumar, A. Dispenzieri, M. Lacy, D. Dingli, S. R. Hayman, F. Buadi,P. R. Greipp, R. A. Kyle, S. V. Rajkumar, M. A. GertzEfficacy and safety of bendamustine plus bortezomib in relapsed/refractorymultiple myeloma: A phase I/II trial. (Abstract #8070)J. R. Berenson, O. Yellin, A. Bessudo, R. Boccia, S. Noga, D. Gravenor,D. Patel-Donnelly, R. S. Siegel, T. Kewalramani, E. J. Gorak, R. Swift,D. Bensen-KennedyOutcomes of a late second autologous hematopoietic stem cell transplantcompared to nontransplantation salvage therapy in relapsed multiplemyeloma after upfront transplant. (Abstract #8071)J. M. Azar, S. Abdelqader, R. Abonour, A. Suvannasankha, R. Tabbey, S. FaragImpact of baseline characteristics on efficacy and safety after bortezomibbasedinduction and maintenance in newly diagnosed multiple myeloma(MM) patients ineligible for transplant in the phase IIIb UPFRONT study.(Abstract #8072)R. Niesvizky, I. W. Flinn, R. M. Rifkin, N. Gabrail, V. Charu, Y. Gaffar, R. Neuwirth,D. Corzo, J. Reeves390

Monday, June 6, 2011Brd. 48EBrd. 48FBrd. 48GBrd. 48HBrd. 49ABrd. 49BBrd. 49CBrd. 49DBrd. 49EBrd. 49FBrd. 49GAssociation of familial disease status with inferior treatment outcome inpatients with Waldenstrom’s macroglobulinemia. (Abstract #8073)Z. R. Hunter, C. Hanzis, L. Ioakimidis, C. Tripsas, R. J. Manning, C. J. Patterson,P. Sheehy, B. Turnbull, S. P. TreonEfficacy and improved toxicity profile of once a week bortezomib (BZ) withdexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients(pts) with older age and comorbidities: Preliminary results of an ongoingclinical study. (Abstract #8074^)N. C. Munshi, S. Lee, S. Kambhampati, A. Mohiuddin, M. G. Rose, C. Behler,A. Han, Y. A. Efebera, A. Houranieh, M. T. Brophy, A. Zimelman, R. H. Prabhala,T. Grady, C. E. Klein, P. Mehta, T. G. Hayes, G. D. Roodman, A. LichtensteinA phase lb study of oral panobinostat and IV bortezomib in relapsed orrelapsed and refractory multiple myeloma. (Abstract #8075)J. F. San-Miguel, P. G. Richardson, O. Sezer, A. Guenther, D. S. Siegel, J. Blade,R. LeBlanc, H. J. Sutherland, M. Mateos, M. Gramatzki, K. M. Hazell,B. Bengoudifa, P. M. Bourquelot, K. C. AndersonPhase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone inpatients with relapsed or refractory multiple myeloma. (Abstract #8076)S. Lonial, R. Vij, T. Facon, P. Moreau, X. Leleu, A. Mazumder, J. L. Kaufman,C. Westland, C. Tsao, A. K. Singhal, S. JagannathPrevalence of interleukin-6 receptor polymorphism in Castleman disease andassociation with increased soluble interleukin-6 receptor levels. (Abstract#8077)K. Stone, E. Woods, S. M. Szmania, O. Stephens, T. K. Garg, A. Moreno-Bost,B. Barlogie, J. D. Shaughnessy Jr., B. Hall, M. P. Reddy, F. Van RheeEffect of MOR202, a human CD38 antibody, in combination with lenalidomideand bortezomib, on bone lysis and tumor load in a physiologic model ofmyeloma. (Abstract #8078)J. Endell, C. Samuelsson, R. Boxhammer, S. Strauss, S. SteidlEvaluation of pretransplant variables predicting cardiomyopathy followinghigh-dose melphalan conditioning and autologous peripheral blood stem celltransplantation. (Abstract #8079)J. S. Bleeker, M. A. Gertz, P. A. Pellikka, F. Buadi, D. Dingli, A. Dispenzieri,S. R. Hayman, W. J. Hogan, S. Kumar, M. LacySingle-agent lenalidomide for newly diagnosed myeloma with on-demanddexamethasone: A phase II trial. (Abstract #8080)F. Buadi, M. Lacy, A. Dispenzieri, B. LaPlant, K. M. Laumann, G. S. Nowakowski,S. R. Hayman, K. Detweiler Short, D. Dingli, M. A. Gertz, P. R. Greipp, J. A. Lust,T. E. Witzig, S. R. Zeldenrust, S. J. Russell, V. Rajkumar, S. KumarThe impact of frontline risk-adapted strategy on the overall survival (OS) ofpatients with newly diagnosed multiple myeloma (MM): A population study inSingapore (SG). (Abstract #8081)D. C. Tan, K. H. Ong, L. P. Koh, S. S. Wong, M. T. Khin, L. H. Lee,Y. T. Goh, W. J. ChngA phase II study of pegylated liposomal doxorubicin, bortezomib,dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM). (Abstract #8082)O. Yellin, J. R. Berenson, T. Kazamel, C. Chen, A. Cartmel, T. B. Woliver,M. S. Flam, E. N. Bravin, Y. Nassir, R. A. Vescio, R. SwiftDefining the biological subgroup of multiple myeloma patients whichbenefits maximally from the overall survival (OS) benefit associated withtreatment with zoledronic acid (ZOL). (Abstract #8083)G. J. Morgan, F. Davies, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy,M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie,C. Rudin, G. Cook, G. H. Jackson, K. Boyd, J. A. Child, P. WuMONDAY391

Monday, June 6, 2011Brd. 49HBrd. 50ABrd. 50BAn evaluation of MIST 1 as an indicator of plasmacytic differentiation.(Abstract #8084)C. C. Yeung, J. Mills, J. FraterEffect of NF-kB2 mutation on pathway activitation in the pathogenesis ofB-cell lymphomas. (Abstract #8085)B. A. McCarthy, L. Yang, D. Liu, J. Ding, H. DingLong-term safety of lenalidomide (LEN) in relapsed/refractory multiplemyeloma (RRMM) patients (Pts): Analysis of pooled data. (Abstract #8086)B. G. Durie, G. Morgan, J. F. San-Miguel, R. Z. Orlowski, S. Lonial, R. Niesvizky,Z. Yu, K. C. AndersonMONDAY392

Monday, June 6, 20111:15 PM - 2:30 PMSPECIAL SESSIONASCO/Union for International Cancer Control (UICC) Joint Session: BreastCancer Health Disparities—Challenges and Opportunities from anInternational PerspectiveLocation: Hall B1CME credit: 1.25Track(s): Breast Cancer, International, Special SessionEduardo L. Cazap, MD—Co-ChairLatin American-Caribbean Society of Medical OncologyGeorge W. Sledge Jr., MD—Co-ChairIndiana University Simon Cancer CenterLarry Norton, MDMemorial Sloan-Kettering Cancer CenterDeveloping a Strategy for Independent Breast Cancer ResearchBenjamin O. Anderson, MDUniversity of WashingtonControversies in Screening for Breast CancerMary K. Gospodarowicz, MDPrincess Margaret Hospital and University of TorontoRole of Radiotherapy in Low-resource ScenariosGabriel N. Hortobagyi, MDUniversity of Texas M. D. Anderson Cancer CenterHow to Treat Advanced Breast Cancer with Limited ResourcesMONDAY393

Monday, June 6, 20111:15 PM - 2:30 PMEDUCATION SESSIONSChallenges in Treating Children, Adolescents, and Adults with Benign andMalignant Vascular TumorsLocation: S504CME credit: 1.25Track(s): Pediatric OncologyDenise Adams, MD—ChairCincinnati Children’s HospitalMultidisciplinary Strategies for the Treatment of Vascular Malformations and Tumors in ChildrenAnthony Montag, MDThe University of Chicago Medical CenterThe Pathology and Biology of Vascular Tumors in Children and Young AdultsSteven J. Fishman, MDChildren’s Hospital BostonThe Role of the Surgeon in the Diagnosis and Management of Vascular TumorsEvolving Therapy of Hodgkin LymphomaLocation: S406CME credit: 1.25Track(s): Lymphoma and Plasma Cell Disorders, General OncologyJoseph M. Connors, MD—ChairBritish Columbia Cancer Agency Center for Lymphoid CancerAdvanced-stage Hodgkin LymphomaAndreas Engert, MDUniversity Hospital of CologneLimited-stage Hodgkin LymphomaFrancisco J. Hernandez-Ilizaliturri, MDRoswell Park Cancer InstituteNew Therapies in Hodgkin LymphomaMONDAYHow to Advise the Patient with Early-stage Esophageal Carcinoma and HighgradeDysplasia Arising in Barrett’s Esophagus: Endoluminal Therapies toResectionLocation: Hall D2CME credit: 1.25Track(s): Gastrointestinal (Noncolorectal) CancerMartin S. Karpeh Jr., MD—ChairBeth Israel Medical CenterWhat Are the Surgical Options for High-grade Dysplasia and Carcinoma in Situ?Blair A. Jobe, MDUniversity of PittsburghWhat Are the Endoluminal Therapies for High-grade Dysplasia or Carcinoma in Situ?394

Myelodysplastic Disorders and Myeloproliferative Disorders: New TherapeuticDevelopmentsLocation: E354aCME credit: 1.25Track(s): Leukemia, Myelodysplasia, and TransplantationAlan F. List, MD—ChairH. Lee Moffitt Cancer Center & Research InstituteUpdate of Therapy for Myelodysplastic SyndromesPierre Fenaux, MD, PhDHopital AvicenneThe Biology and Prognostic Factors of Myelodysplastic SyndromesSrdan Verstovsek, MD, PhDUniversity of Texas M. D. Anderson Cancer CenterMyeloproliferative Disorders: JAK2 and BeyondOptimizing Data Collection for Clinical Trials to Support Clinically RelevantDecisions (eQuestions Session)Location: E353CME credit: 1.25Track(s): Clinical TrialsRichard L. Schilsky, MD—ChairThe University of ChicagoData Collection and Optimization in the Cooperative Group SettingJeffrey S. Abrams, MDNational Cancer InstituteChallenges in the Coordination of Clinical TrialsMonday, June 6, 2011Ann T. Farrell, MDU.S. Food and Drug AdministrationFDA Recommendations for Sponsors on Data Collection for Cancer Clinical TrialsPeter C. Adamson, MDChildren’s Hospital of PhiladelphiaData Collection Standards to Establish Safety and Efficacy in Pediatric Clinical TrialsMONDAY395

Monday, June 6, 20111:15 PM - 2:30 PMMEET THE PROFESSOR SESSIONSNon-oncogene Addiction to Stress: A Cancer Cell Fix Exploited for CancerTherapy (M23)—Ticketed SessionLocation: E451bCME credit: 1.25Track(s): Tumor Biology, Developmental TherapeuticsKapil N. Bhalla, MDUniversity of Kansas Cancer CenterOncogene and Non-oncogene Addiction in CancerSex and the Survivor (M16)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Patient and Survivor CareLeslie R. Schover, PhDUniversity of Texas M. D. Anderson Cancer CenterMONDAY396

Monday, June 6, 20111:15 PM - 2:45 PMCLINICAL SCIENCE SYMPOSIUMBRAF: From Biology to PatientsLocation: E354bCME credit: 1.5Track(s): Melanoma/Skin CancersKeith T. Flaherty, MD—Co-ChairMassachusetts General HospitalRichard Kefford, MD, PhD—Co-ChairWestmead Institute for Cancer ResearchDiscussion1:15 PM Levi A. Garraway, MD, PhDDana-Farber Cancer Institute1:30 PM Clinical characteristics and outcomes associated with BRAF and NRASmutations in metastatic melanoma. (Abstract #8500)J. A. Jakob, R. L. Bassett Jr., C. S. Ng, A. J. Lazar, G. C. Alvarado, M. L. Rohlfs,J. Richard, J. E. Gershenwald, P. Hwu, K. B. Kim, M. A. Davies1:45 PM Tumor genetic analyses of patients with metastatic melanoma treated withthe BRAF inhibitor GSK2118436 (GSK436). (Abstract #8501)K. L. Nathanson, A. Martin, R. Letrero, K. P. D’Andrea, S. O’Day, J. R. Infante,G. S. Falchook, M. Millward, C. M. Curtis Jr., B. Ma, R. C. Gagnon, P. F. Lebowitz,G. V. Long, R. F. Kefford2:00 PM Molecular analyses from a phase I trial of vemurafenib to study mechanismof action (MOA) and resistance in repeated biopsies from BRAFmutation–positive metastatic melanoma patients (pts). (Abstract #8502)G. A. McArthur, A. Ribas, P. B. Chapman, K. T. Flaherty, K. B. Kim, I. Puzanov,K. L. Nathanson, R. J. Lee, A. Koehler, O. Spleiss, G. Bollag, W. Wu, K. Trunzer,J. A. Sosman2:15 PM Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oralMEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oralBRAF inhibitor GSK2118436 (GSK436). (Abstract #CRA8503)J. R. Infante, G. S. Falchook, D. P. Lawrence, J. S. Weber, R. F. Kefford,J. C. Bendell, R. Kurzrock, G. Shapiro, R. R. Kudchadkar, G. V. Long,H. A. Burris III, K. B. Kim, A. Clements, S. Peng, B. Yi, A. J. Allred, D. Ouellet,K. Patel, P. F. Lebowitz, K. T. FlahertyDiscussion2:30 PM Reinhard Dummer, MD (Abstracts #8500–CRA8503)University Hospital of ZurichMONDAY397

Monday, June 6, 20111:15 PM - 2:45 PMCLINICAL SCIENCE SYMPOSIUMMolecular Biomarkers in Neuro-oncology: Ready for Clinical Practice?Location: S100bcCME credit: 1.5Track(s): Central Nervous System TumorsMONDAYMarkus Bredel, MD, PhD—Co-ChairUniversity of FreiburgRimas Vincas Lukas, MD—Co-ChairThe University of ChicagoDiscussion1:15 PM Martin J. Van Den Bent, MDDaniel den Hoed Cancer Center1:30 PM RTOG 0525: Molecular correlates from randomized phase III trial of newlydiagnosed glioblastoma. (Abstract #LBA2000)K. D. Aldape, M. Wang, E. P. Sulman, D. P. Cahill, M. Hegi, H. Colman, G. Jones,A. Chakravarti, M. P. Mehta, D. W. Andrews, L. Long, K. Diefes, L. Heathcock,R. Jenkins, C. J. Schultz, M. R. Gilbert1:45 PM Impact of MGMT promoter methylation in glioblastoma of the elderly.(Abstract #2001)M. Weller, B. Hentschel, J. Felsberg, G. Schackert, M. Simon, O. Schnell,M. Westphal, W. Wick, T. Pietsch, M. Loeffler, G. Reifenberger, German GliomaNetwork2:00 PM Predictive value of IDH1 mutation assessed by immunohistochemistry andDNA sequencing in WHO grade 3 oligodendrogliomas. (Abstract #2002)J. Frenel, C. Leux, D. Loussouarn, A. Le Loupp, F. Leclair, A. Von Deimling,M. Aumont, S. Martin, M. G. Denis, M. Campone2:15 PM Prediction of glioblastoma outcome using combined analysis of MGMTprotein expression and promoter methylation (Abstract #2003)A. Lai, S. Lalezari, A. P. Chou, A. Tran, O. E. Solis, J. A. Carrillo, W. Chen,P. S. Mischel, R. M. Green, P. L. Nghiemphu, L. M. Liau, H. Wang, R. M. Elashoff,T. F. Cloughesy, W. H. YongDiscussion2:30 PM Michael Prados, MD (Abstract #LBA2000–2003)University of California, San Francisco398

Monday, June 6, 20112:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONGastrointestinal (Noncolorectal) CancerDisplay Time: 2:00 PM - 6:00 PMDisplay Location: E450bDiscussion Time: 5:00 PM - 6:00 PMDiscussion Location: Hall D1CME credit: 1Track(s): Gastrointestinal (Noncolorectal) CancerAbby B. Siegel, MD, MS—Co-ChairColumbia UniversityGauri R. Varadhachary, MD—Co-ChairUniversity of Texas M. D. Anderson Cancer CenterDiscussion5:00 PM Alexandria T. Phan, MD (Abstracts #4008–4011)University of Texas M. D. Anderson Cancer CenterDiscussion5:15 PM Ian Chau, MD (Abstracts #4012–4019)The Royal Marsden HospitalDiscussion5:30 PM Eunice Lee Kwak, MD, PhD (Abstracts #4020–4027)Massachusetts General Hospital and Harvard Medical SchoolDiscussion5:45 PM Colin D. Weekes, MD, PhD (Abstracts #4028–LBA4032)University of Colorado Cancer CenterBrd. 1 Updated overall survival (OS) and progression-free survival (PFS) by blindedindependent central review (BICR) of sunitinib (SU) versus placebo (PBO) forpatients (Pts) with advanced unresectable pancreatic neuroendocrinetumors (NET). (Abstract #4008)E. Raymond, P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas,J. W. Valle, P. Metrakos, D. Smith, A. Vinik, J. Chen, D. Hoersch, D. E. Castellano,H. F. Kennecke, J. Picus, G. Van Hazel, D. Lu, S. Patyna, R. C. Chao,E. Van CutsemBrd. 2 Everolimus in patients with advanced pancreatic neuroendocrine tumors(pNET): Updated results of a randomized, double-blind, placebo-controlled,multicenter, phase III trial (RADIANT-3). (Abstract #4009)J. R. Strosberg, J. Lincy, R. E. Winkler, E. M. WolinBrd. 3 Everolimus in patients with advanced pancreatic neuroendocrine tumors(pNET): Impact of somatostatin analog use on progression-free survival inthe RADIANT-3 trial. (Abstract #4010)M. H. Shah, C. Lombard-Bohas, T. Ito, E. M. Wolin, E. Van Cutsem, C. Sachs,R. E. Winkler, J. Lincy, T. J. Hobday, J. C. YaoBrd. 4 Everolimus plus octreotide LAR versus placebo plus octreotide LAR inpatients with advanced neuroendocrine tumors (NET): Updated safety andefficacy results from RADIANT-2. (Abstract #4011)J. C. Yao, S. Ricci, R. E. Winkler, V. Jehl, M. E. PavelBrd. 5 HER2 expression/amplification: Frequency, clinicopathologic features, andprognosis in 713 patients with esophageal adenocarcinoma (EAC). (Abstract#4012)H. H. Yoon, Q. Shi, W. R. Sukov, A. E. Wiktor, M. Khan, C. A. Sattler, A. Grothey,T. Wu, R. B. Diasio, R. B. Jenkins, F. SinicropeMONDAY399

Monday, June 6, 2011MONDAYBrd. 6Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Impact of human epidermal growth factor receptor (EGFR) and ERBB2(HER2) expressions on survival in patients with stage II/III gastric cancer,enrolled in the ACTS-GC study. (Abstract #4013)M. Terashima, A. Ochiai, K. Kitada, W. Ichikawa, I. Kurahashi, S. Sakuramoto,T. Fukagawa, T. Sano, H. Imamura, M. SasakoPrognostic significance of human epidermal growth factor-2 (HER2) inadvanced gastric cancer: A U.S. and European international collaborativeanalysis. (Abstract #4014)M. A. Shah, Y. Y. Janjigian, C. Pauligk, D. Werner, D. P. Kelsen, E. Jaeger,H. Altmannsberger, E. Robinson, L. H. Tang, V. V. Barbashina, S. Al-BatranResults of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab inpatients with metastatic gastric and/or gastroesophagel junctionadenocarcinoma: Results of a randomized phase II study. (Abstract #4015)D. A. Richards, D. M. Kocs, A. I. Spira, A. D. McCollum, K. A. Boehm, F. Zhan,L. AsmarRandomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) inthe treatment for advanced gastric cancer (AGC): The START trial update.(Abstract #4016)M. Fujii, Y. H. Kim, T. Satoh, H. Hosaka, T. Kim, A. Tsuji, M. Inokuchi,A. Takagane, S. Oh, K. Tanabe, T. Okuno, K. Chin, T. Ura, J. I. Lee, Y. Kakudo,K. Yamaguchi, S. Iijima, M. Takeuchi, H. Kim, T. Nakajima, Japan Clinical CancerResearch Organization and Korean Cancer Study Group Inter-Group StudySAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trialto investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines(FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) withgastric cancer. (Abstract #4017)A. Tsuburaya, K. Yoshida, M. Kobayashi, S. Yoshino, Y. Miyashita, S. Morita,K. Oba, M. E. Buyse, J. S. Macdonald, J. SakamotoRandomized phase II study (GATE study) of docetaxel plus oxaliplatin with orwithout fluorouracil or capecitabine in metastatic or locally recurrent gastriccancer. (Abstract #4018)E. Van Cutsem, C. Boni, J. Tabernero, B. Massuti, D. A. Richards, H. Prenen,I. Steinberg, P. RougierA randomized, double-blind, multicenter, phase II, three-arm, placebo-controlstudy of apatinib as third-line treatment in patients with metastatic gastriccarcinoma. (Abstract #4019)J. Li, S. Qin, J. Xu, W. j. Guo, J. p. Xiong, Y. Bai, G. Sun, Y. Yang, L. Wang, N. Xu,Y. Cheng, W. Zhe-Hai, L. Zheng, M. TaoEvaluation of putative prognostic tissue biomarkers in pancreatic ductaladenocarcinoma. (Abstract #4020)J. M. Winter, L. H. Tang, D. S. Klimstra, M. F. Brennan, E. M. O’Reilly,W. R. Jarnagin, P. J. AllenMolecular prognostic markers in advanced gastric cancer: Correlative studyin the Japan Clinical Oncology Group trial JCOG9912. (Abstract #4021)Y. Yamada, J. Mizusawa, A. Takashima, K. Nakamura, Y. Tsuji, Y. Suzuki,K. Amagai, K. Yamaguchi, K. Konishi, T. Yoshino, T. Denda, W. Koizumi,S. Ohkawa, H. Kawai, H. Kojima, H. Nishizaki, T. Nishina, A. Tsuji, H. Fukuda,N. BokuGenome-wide interaction study of gemcitabine treatment and genotype onsurvival in pancreatic cancer. (Abstract #4022)R. R. McWilliams, W. R. Bamlet, M. Matsumoto, G. P. Kim, P. A. Burch,D. Grendahl, G. M. Petersen400

Monday, June 6, 2011Brd. 16Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25Association of excision repair cross-complementation group 1 (ERCC1) geneexpression (GE) with outcome in stage II-III esophageal adenocarcinoma(EA) patients treated with preoperative platinum-based chemoradiation(CRT) in a phase II cooperative group study (SWOG S0356). (Abstract #4023)P. O. Bohanes, B. H. Goldman, L. P. Leichman, C. D. Blanke, S. Iqbal,C. R. Thomas Jr., C. L. Corless, K. G. Billingsley, K. D. Danenberg, W. Zhang,J. K. Benedetti, P. J. Gold, H. LenzPrediction of gemcitabine benefit after curative-intent resection of pancreaticadenocarcinoma using HENT1 and dCK protein expression. (Abstract #4024)R. Maréchal, j. Bachet, J. R. Mackey, P. Demetter, K. Graham, A. Couvelard,M. Svrcek, A. Bardier, P. Hammel, A. Sauvanet, C. Louvet, F. Paye, P. Rougier,L. Hannoun, T. Andre, C. M. Dumontet, C. Cass, I. Salmon, J. Emile,J. Van LaethemComparing the classification precision and prognostic performance of anintrinsic gastric cancer signature with existing genomic signatures in sixindependent datasets. (Abstract #4025)I. B. Tan, H. Grabsch, H. Toh, J. Lee, A. Boussioutas, S. Y. Rha, J. A. Ajani, P. TanRandomized phase II study of gemcitabine (G) plus anti-IGF-1R antibodyMK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advancedpancreatic cancer. (Abstract #4026)M. M. Javle, G. R. Varadhachary, D. R. Fogelman, R. T. Shroff, M. J. Overman,L. Ukegbu, B. N. Bekele, S. P. Kar, R. A. Wolff, J. L. AbbruzzeseValidated biomarker signatures that predict pathologic response topreoperative chemoradiation therapy (CTRT) with high specificity anddesirable sensitivity levels in patients with esophageal cancer (EC). (Abstract#4027)J. A. Ajani, X. Wang, Y. Hayashi, D. Maru, J. Welsh, W. L. Hofstetter, J. H. Lee,M. S. Bhutani, A. Suzuki, D. A. Berry, J. IzzoBAYPAN study: A double-blind, phase III randomized trial of gemcitabineplus sorafenib versus gemcitabine plus placebo in patients with advancedpancreatic cancer. (Abstract #4028)A. Goncalves, F. Viret, E. François, L. Dahan, H. Perrier, R. Lamy, D. Re,R. Largillier, M. Gasmi, X. Tchiknavorian, O. Turrini, L. Moureau-Zabotto,J. Delpero, P. ViensA randomized phase II study of gemcitabine plus S-1 versus gemcitabinealone in patients with unresectable pancreatic cancer. (Abstract #4029)Y. Omuro, T. Ikari, H. Ishii, M. Ozaka, M. Suyama, Y. Matsumura, T. Itoi,N. Egawa, S. Yano, K. Hanada, Y. Kimura, T. Ukita, Y. Ishida, M. Tani, S. Ohoka,Y. Hirose, S. Hijioka, R. Watanabe, T. Ikeda, T. Nakajima,Japan Clinical Cancer Research OrganizationRandomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE)versus erlotinib-gemcitabine (GE) in patients with untreated, metastaticpancreatic adenocarcinoma. (Abstract #4030)G. P. Kim, N. R. Foster, M. Salim, P. J. Flynn, D. F. Moore, R. Zon, R. B. Mowat,M. Wiesenfeld, A. E. McCullough, S. R. AlbertsGlobal, multicenter, open-label, randomized phase II trial comparinggemcitabine (G) with G plus AGS-1C4D4 (A) in patients (pts) with metastaticpancreatic cancer (mPC). (Abstract #4031)B. M. Wolpin, E. M. O’Reilly, Y. Ko, L. S. Blaszkowsky, M. U. Rarick,C. S. Rocha Lima, P. S. Ritch, E. Chan, J. L. Spratlin, T. Macarulla, E. McWhirter,D. Pezet, M. Lichinitser, L. D. Roman, A. Hartford, L. Jackson, M. Vincent,L. M. Reyno, M. HidalgoPhase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinibin unresectable, metastatic biliary tract carcinoma. (Abstract #LBA4032)H. Y. Lim, J. Lee, H. M. Chang, J. S. Kim, H. J. Choi, M. A. Lee, J. S. Jang,H. C. Jeung, J. H. Kang, H. W. Lee, D. Shin, H. J. Jang, J. M. Sun, S. H. Park,J. O. Park, Y. Park, W. K. KangMONDAY401

Monday, June 6, 20112:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONHealth Services ResearchDisplay Time: 2:00 PM - 6:00 PMDisplay Location: S403Discussion Time: 5:00 PM - 6:00 PMDiscussion Location: S404CME credit: 1Track(s): Health Services ResearchMONDAYMichael J. Hassett, MD, MPH—Co-ChairDana-Farber Cancer InstituteScott Michael Gilbert, MD, MS—Co-ChairUniversity of FloridaDiscussion5:00 PM Scott David Ramsey, MD, PhD (Abstracts #6012–6016)Fred Hutchinson Cancer Research CenterDiscussion5:15 PM Jennifer J. Griggs, MD, MPH (Abstracts #6017–6023)University of MichiganDiscussion5:30 PM Lynne I. Wagner, PhD (Abstracts #6024–6028)Northwestern UniversityDiscussion5:45 PM Michael J. Hall, MD (Abstracts #6029–6036)Fox Chase Cancer CenterBrd. 1 Validation of specific chemotherapy drugs in Medicare data. (Abstract #6012)J. L. Lund, T. Sturmer, R. S. Sandler, H. K. Sanoff, L. C. Harlan, J. L. WarrenBrd. 2 Changes in cancer survival by ethnicity between 1992–1996 and 2002–2006:Are survival disparities increasing or decreasing? (Abstract #6013)D. Pulte, T. Redaniel, H. Brenner, M. JeffreysBrd. 3 High-cost imaging for managed care Medicare beneficiaries with cancer,2001–2006. (Abstract #6014)E. T. Loggers, P. A. Fishman, M. C. Hornbrook, C. C. Greenberg,M. C. O’Keeffe-Rosetti, A. Ramaprasan, N. Q. Vanneman, E. H. Wagner,J. C. Weeks, D. P. RitzwollerBrd. 4 Costs and trends in pancreatic cancer treatment: A population-basedanalysis. (Abstract #6015)C. B. O’Neill, C. L. Atoria, E. M. O’Reilly, J. LaFemina, E. B. ElkinBrd. 5 Costs of medical care after open or minimally-invasive prostate cancersurgery: A population-based analysis. (Abstract #6016)E. B. Elkin, W. T. Lowrance, B. Denton, J. N. Mirkin, J. A. EasthamBrd. 6 Different risk factors for mortality in younger and older women after breastconservingsurgery. (Abstract #6017)G. G. Kimmick, F. Camacho, W. Hwang, H. B. Mackley, J. H. Stewart IV,R. T. AndersonBrd. 7 Associations between county-level surgeon density and colorectal cancer(CRC) mortality. (Abstract #6018)J. S. Albarrak, M. Y. Ho, W. Y. CheungBrd. 8 Concordance with NCCN practice guidelines for local therapies as a measureof quality of care: Review of practice and identification of quality gaps.(Abstract #6019)V. Francescutti, N. L. Watroba, S. B. Edge402

Monday, June 6, 2011Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Physicians characteristics and variability of erythropoiesis-stimulating agentuse among Medicare patients with cancer. (Abstract #6020)J. D. Wright, A. I. Neugut, E. T. Wilde, D. Buono, J. Malin, W. Tsai, D. L. HershmanPatient access to breast reconstruction after mastectomy and long-termoutcomes. (Abstract #6021)M. Morrow, A. K. Alderman, S. T. Hawley, S. J. KatzTiming in adjuvant chemotherapy (CTX) initiation among women with breastcancer (BC) at National Comprehensive Cancer Network (NCCN) centers: Ananalysis from the NCCN Outcomes Database. (Abstract #6022)J. L. Vandergrift, J. C. Niland, R. L. Theriault, S. B. Edge, Y. Wong,L. S. Loftus, T. M. Breslin, C. Hudis, S. H. Javid, H. S. Rugo, S. M. Silver,E. M. Lepisto, J. C. WeeksThe association of obesity, smoking, and access to oncology services withcancer mortality in the United States. (Abstract #6023)A. J. Hayanga, S. B. Zeliadt, D. E. Wood, L. M. BackhusEarly palliative care, depression, and survival in metastatic NSCLC. (Abstract#6024)W. F. Pirl, J. A. Greer, E. R. Gallagher, V. A. Jackson, I. T. Lennes, J. S. TemelFertility concerns in young women with breast cancer: Results from aprospective cohort study. (Abstract #6025)K. J. Ruddy, S. Gelber, R. M. Tamimi, E. S. Ginsburg, L. Schapira, S. E. Come,M. E. Meyer, E. P. Winer, A. H. PartridgeDiscussions about end-of-life care planning between physicians and patientswith stage IV lung or colorectal cancer. (Abstract #6026)J. W. Mack, A. Cronin, N. Taback, H. Huskamp, N. L. Keating, J. L. Malin, C. Earle,J. C. WeeksPatient perspectives on a treatment plan and summary program incommunity oncology care. (Abstract #6027)V. S. Blinder, V. W. Norris, N. W. Peacock, J. J. Griggs, D. P. Harrington, A. Moore,R. L. Theriault, A. H. PartridgeEvaluation of an intervention to improve communication about phase I/IItrials. (Abstract #6028)L. Fallowfield, I. Solis-Trapala, C. I. Langridge, V. A. JenkinsPatients’ understanding of how genotype variation affects benefits oftamoxifen therapy for breast cancer. (Abstract #6029)N. T. Brewer, C. M. Walko, W. K. Chiu, L. G. Dressler, A. Yuen, P. Rubin,O. A. Olajide, S. G. Moore, R. E. Raab, D. R. Carrizosa, S. W. Corso, G. Schwartz,J. M. Peppercorn, H. L. McLeod, L. A. Carey, W. J. Irvin Jr.The balance between benefits and harms of molecular targeted agents.(Abstract #6030)S. Niraula, E. Amir, A. Ocana, B. Seruga, I. TannockAdjuvant hormone therapy use in early-stage breast cancer patients insuredby the New York State Medicaid program. (Abstract #6031)R. L. Yung, M. J. Hassett, K. Chen, F. C. Gesten, P. R. Roohan, F. P. Boscoe,A. H. Sinclair, M. J. Schymura, D. SchragPersistence with adjuvant hormonal therapy in older breast cancer survivors.(Abstract #6032)T. Hedin, C. Guo, A. NattingerAnthracycline adherence in older patients with breast cancer. (Abstract#6033)C. H. Barcenas, N. Zhang, H. Zhao, Z. Duan, G. N. Hortobagyi, S. H. GiordanoRacial disparities in chemotherapy for breast cancer: Are delays explainedby hospital quality and volume? (Abstract #6034)R. A. Freedman, Y. He, N. L. KeatingMONDAY403

Monday, June 6, 2011Brd. 24Brd. 25Preoperative breast MRI in early-stage breast cancer: A decision analysis.(Abstract #6035)P. Young, B. Kim, J. MalinAbandoning oral oncolytic prescriptions at the pharmacy: Patient and healthplan factors influencing adherence. (Abstract #6036)L. S. Schwartzberg, S. B. Streeter, N. Husain, M. JohnsrudMONDAY404

Monday, June 6, 20112:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONLung Cancer—Metastatic/Non-small CellDisplay Time: 2:00 PM - 6:00 PMDisplay Location: E450aDiscussion Time: 5:00 PM - 6:00 PMDiscussion Location: Hall D2CME credit: 1Track(s): Lung CancerShadia Ibrahim Jalal, MD—Co-ChairIndiana University Simon Cancer CenterRobert Charles Doebele, MD, PhD—Co-ChairUniversity of Colorado DenverDiscussion5:00 PM Kenneth John O’Byrne, MD (Abstracts #LBA7512–7518)St. James HospitalDiscussion5:15 PM Rebecca Suk Heist, MD (Abstracts #7519–7523)Massachusetts General Hospital Cancer CenterDiscussion5:30 PM Shirish M. Gadgeel, MD (Abstracts #7524–7529)Karmanos Cancer InstituteDiscussion5:45 PM Fred R. Hirsch, MD (Abstracts #7530–7536)University of Colorado DenverBrd. 1 An international, randomized, placebo-controlled, double-blind phase IIIstudy (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patientswith advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract#LBA7512)G. Scagliotti, I. Vynnychenko, Y. Ichinose, K. Park, K. Kubota, F. H. Blackhall,R. Pirker, R. Galiulin, T. E. Ciuleanu, O. Sydorenko, M. Dediu, Z. Papai-Szekely,N. Martinez Banaclocha, S. McCoy, B. Yao, Y. J. Hei, D. R. SpigelBrd. 2 A randomized phase II study of pemetrexed (PEM) with or without sorafenib(S) as second line therapy in advanced non-small cell lung cancer (NSCLC)of non-squamous histology: NCCTG N0626 study. (Abstract #7513)J. R. Molina, G. K. Dy, N. R. Foster, K. L. Allen Ziegler, A. Adjei, K. M. Rowland,M. Aubry, P. J. Flynn, S. J. Mandrekar, S. E. Schild, A. A. Adjei, North CentralCancer Treatment Group (NCCTG)Brd. 3 Initial phase II results with crizotinib in advanced ALK-positive non-small celllung cancer (NSCLC): PROFILE 1005. (Abstract #7514)L. Crinò, D. Kim, G. J. Riely, P. A. Janne, F. H. Blackhall, D. R. Camidge,V. Hirsh, T. Mok, B. J. Solomon, K. Park, S. M. Gadgeel, R. Martins, J. Han,T. M. De Pas, A. Bottomley, A. Polli, J. Petersen, V. R. Tassell, A. T. ShawBrd. 4 Comparative analyses of overall survival of anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer (NSCLC) patients whodid not receive ALK inhibitors. (Abstract #7515)D. Kim, J. Lee, H. S. Park, K. Kulig, T. M. Kim, S. Lee, Y. Jeon, D. H. Chung,D. S. Heo, W. Kim, Y. BangBrd. 5 Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel inpretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC).(Abstract #7516)G. J. Riely, S. N. Gettinger, R. G. Stoller, N. Y. Gabrail, G. K. Dy, G. J. Weiss,C. Tunkey, G. Skliris, S. Strychor, J. Dunbar, D. DeLucia, R. W. Ross, J. E. GrayMONDAY405

Monday, June 6, 2011MONDAYBrd. 6Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15The introduction of systematic genomic testing for patients with non-smallcell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). (Abstract#7517)T. M. Ortiz, V. A. Joshi, S. Heon, M. Butaney, L. Chen, D. M. Jackman,D. J. Kwiatkowski, N. I. Lindeman, P. A. Janne, B. E. JohnsonSNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinicalpractice. (Abstract #7518)L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, J. S. Temel, I. T. Lennes,E. Bast, B. A. Waltman, M. Lanuti, A. Muzikansky, M. Mino-Kenudson, A. J. Iafrate,D. R. Borger, D. Dias-Santagata, J. A. EngelmanFinal overall survival results of NEJ002, a phase III trial comparing gefitinib tocarboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment foradvanced non-small cell lung cancer (NSCLC) with EGFR mutations.(Abstract #7519)A. Inoue, K. Kobayashi, M. Maemondo, S. Sugawara, S. Oizumi, H. Isobe,A. Gemma, Y. Saijo, H. Yoshizawa, S. Morita, K. Hagiwara, T. Nukiwa,North-East Japan Study GroupUpdated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III,randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR ActMut) advanced non-small cell lung cancer (NSCLC). (Abstract #7520)C. Zhou, Y. Wu, G. Chen, J. Feng, X. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou,S. Ren, S. Lu, L. Zhang, On behalf of the OPTIMAL investigatorsIFCT-0504 trial: Mucinous (M) and non-mucinous (NM) cytological subtypesinteraction effect in first-line treatment of advanced bronchioloalveolarcarcinoma (BAC), by erlotinib (E) or carboplatin/paclitaxel (C/P). (Abstract#7521)J. Cadranel, R. Gervais, M. Wislez, P. Merle, D. Moro-Sibilot, V. Westeel,L. Bigay-Game, E. A. Quoix, S. Friard, F. Barlesi, M. Zaegel, L. Moreau, I. Monnet,J. Duhamel, G. Oliviero, P. J. Souquet, L. Thiberville, L. Baudrin, F. Morin,G. Zalcman, on behalf of the Intergroupe Francophone de CancérologieThoracique (IFCT)A randomized, double-blind phase III study of icotinib versus gefitinib inpatients with advanced non-small cell lung cancer (NSCLC) previouslytreated with chemotherapy (ICOGEN). (Abstract #7522)Y. Sun, Y. Shi, L. Zhang, X. Liu, C. Zhou, D. Wang, Q. Li, S. Zhang, S. Qin, C. Hu,Y. Zhang, J. Chen, Y. Song, J. Feng, Y. Cheng, H. Zhang, Y. Wu, N. Xu, J. ZhouAn evaluation of the possible interaction of gastric acid suppressivemedication and the EGFR tyrosine kinase inhibitor erlotinib. (Abstract #7523)J. F. Hilton, L. Seymour, A. Le Maitre, D. Tu, F. A. Shepherd, P. A. BradburyA phase II trial of afatinib (BIBW 2992) in patients (pts) with advancednon-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G)(Abstract #7524)N. Yamamoto, N. Katakami, S. Atagi, T. Hida, K. Goto, T. Horai, A. Inoue,Y. Ichinose, K. Kobayashi, K. Takeda, K. Kiura, H. Saka, T. Tamura, I. Okamoto,N. Nogami, R. Morinaga, K. Nishio, Y. Seki, R. M. Lorence, M. ShahidiActivity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLCpatients with acquired resistance to erlotinib or gefitinib. (Abstract #7525^)Y. Y. Janjigian, H. J. Groen, L. Horn, E. F. Smit, Y. Fu, F. Wang, M. Shahidi,L. J. Denis, W. Pao, V. A. MillerA randomized phase II study of pemetrexed versus pemetrexed plus erlotinibin second-line treatment for locally advanced or metastatic, non-squamousNSCLC. (Abstract #7526)J. Von Pawel, Z. Papai-Szekely, N. Vinolas, C. Sederholm, M. Klima, D. Desaiah,M. I. Leschinger, C. Dittrich406

Monday, June 6, 2011Brd. 16Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25Randomized, double-blind, phase II study of erlotinib in combination withplacebo or R1507, a monoclonal antibody to insulin-like growth factorreceptor-1 (IGF-1R), for advanced stage non-small cell lung cancer (NSCLC).(Abstract #7527)S. S. Ramalingam, D. R. Spigel, M. Steins, J. A. Engelman, C. Schneider,S. Novello, W. E. Eberhardt, L. Crino, P. A. Janne, L. Liu, C. M. Brownstein,M. ReckApricot-l: Results of a biomarker-based phase II randomized placebocontrolledstudy of apricoxib in combination with erlotinib in non-small celllung cancer (NSCLC) patients. (Abstract #7528)B. J. Gitlitz, E. D. Bernstein, G. P. Keogh, E. S. Santos, G. A. Otterson, G. Milne,M. Syto, S. L. ZaknoenExploratory biomarker analyses from OAM4558g: A placebo-controlledphase II study of erlotinib with or without MetMAb in patients with advancednon-small-cell lung cancer (NSCLC). (Abstract #7529)W. Yu, A. Pandita, E. Penuel, R. Raja, J. Zha, S. Mohan, R. D. Patel, R. Desai,L. Fu, A. Do, J. Mango, V. Parab, M. Lipkind, J. Huang, M. Lazarov,V. Ramakrishnan, L. C. Amler, A. C. Peterson, P. H. Patel, R. L. YauchUse of negative thyroid transcription factor (TTF-1) status to predict fornegative epidermal growth factor receptor (EGFR) mutations (Mts) statuswith a high negative predictive value (NPV) in patients (pts) withadenocarcinomas (AC) of the lung. (Abstract #7530)N. Somaiah, E. Garrett-Mayer, X. Huang, A. E. Wahlquist, K. Danenberg,G. R. SimonHepatocyte growth factor expression in EGFR mutant lung cancer withintrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanesecohort. (Abstract #7531)S. Yano, T. Yamada, S. Takeuchi, K. Tachibana, Y. Minami, M. Noguchi,F. R. HirschAn evaluation of phosphorylated EGFR expression in predicting outcome ofEGFR-TKI therapy for the advanced NSCLC patients with EGFR wild type.(Abstract #7532)F. Wang, J. Wang, H. Bai, J. Zhao, Z. Wang, M. Zhuo, T. An, J. Duan, L. Yang,M. Wu, Y. Wang, S. Wang, X. LiuMeta-analysis of the predictive and prognostic value of erlotinib-relatedbiomarkers in phase III, placebo-controlled trials in non-small cell lungcancer (NSCLC): Recommendations of the BioLOGUE advisors. (Abstract#7533)D. Soulieres, J. Wolf, F. A. Shepherd, F. Cappuzzo, P. A. Bunn, R. S. Herbst,F. R. Hirsch, K. M. Kerr, T. Mitsudomi, M. S. Tsao, C. Yang, F. C. Richardson,B. Klughammer, B. Wacker, D. Sternberg, A. M. DaviesComparison of high sensitive IHC, FISH, and RT-PCR direct sequencing fordetection of ALK translocation in lung cancer. (Abstract #7534)T. Mitsudomi, K. Tomizawa, Y. Horio, T. Hida, Y. YatabeAssociations between biomarkers and outcomes of first-line chemotherapyin advanced non-small cell lung cancer (NSCLC). (Abstract #7535)B. H. Grønberg, M. Lund-Iversen, E. H. Strøm, O. Brustugun, H. Scott,Norwegian Lung Cancer Study GroupDrug pathway-associated gene polymorphisms in patients with advancednon-small cell lung cancer receiving first-line platinum-gemcitabinecombination chemotherapy: A prospective multicenter observational study.(Abstract #7536)M. Joerger, S. A. Burgers, P. Baas, E. F. Smit, T. J. Haitjema, M. P. Bard,V. D. Doodeman, P. H. Smits, A. Vincent, A. Huitema, J. H. Beijnen,J. H. SchellensMONDAY407

Monday, June 6, 20113:00 PM - 4:15 PMSPECIAL SESSIONWhy Isn’t Cancer Research More Successful?Location: E354bCME credit: 1.25Track(s): Special SessionLaurence H. Baker, DO—ChairUniversity of MichiganYou Reap What You Sow: Research Goals (Incremental versus Large Gains) and PracticalBarriersLee M. Ellis, MDUniversity of Texas M. D. Anderson Cancer CenterChallenges in Translating Success from the Lab to the Clinic: A Perspective on Our CurrentInfrastructure and Suggestions on Ways to Improve ItAndrea Denicoff, RN, MSN, ANPNational Cancer InstituteScience of Patient Participation: Ethics, Decision-making Process, and Informed ConsentMONDAY408

Monday, June 6, 20113:00 PM - 4:15 PMEDUCATION SESSIONSFrom Minimalist Therapy to Bilateral Mastectomy: Controversies in LocoregionalManagement of Breast CancerLocation: Hall B1CME credit: 1.25Track(s): Breast CancerArmando E. Giuliano, MD—ChairJohn Wayne Cancer InstituteOverview and Evolution of Axillary Management: What to Do With Isolated Tumor Cells andWhen Do You Need to Dissect the Axilla?Julia R. White, MDRadiation Therapy Oncology Group and Medical College of WisconsinWhat Are the Clinical Data Regarding Partial Breast and Other Novel Radiation Techniques andSchedules?Monica Morrow, MDMemorial Sloan-Kettering Cancer CenterThe Bilateral Mastectomy EpidemicManaging Electronic Education (eQuestions Session)Location: E353CME credit: 1.25Track(s): Professional Development, Practice Management and Information TechnologyMichael Fisch, MD, MPH—ChairUniversity of Texas M. D. Anderson Cancer CenterMobile Applications for Professional and Patient EducationPeter Ravdin, MD, PhDUniversity of Texas M. D. Anderson Cancer CenterUsing ASCO and Non-ASCO Web-based ResourcesDavid L. Graham, MDCarle Clinic AssociatesProfessional and Social Networking Resources for Oncologists: Using Electronic Media toImprove Cancer CareRecent Advances in Non-small Cell Lung Cancer: Best of 2010 Basic andClinical Research in Lung CancerLocation: Hall D2CME credit: 1.25Track(s): Lung Cancer, General OncologyMONDAYLawrence H. Einhorn, MD—ChairIndiana University Simon Cancer CenterBest of 2010: In the Context of My Own Four Decades of ExperiencePasi A. Janne, MD, PhDDana-Farber Cancer InstituteBest of 2010: Basic Research in Lung CancerGregory Peter Kalemkerian, MDUniversity of Michigan Comprehensive Cancer CenterBest of 2010: Lung Cancer Clinical Research409

Monday, June 6, 2011Update on Quality Improvement Initiatives in OncologyLocation: S504CME credit: 1.25Track(s): Health Services Research, Practice Management and Information TechnologyMichael N. Neuss, MD—ChairOncology/Hematology Care, Inc.Quality Oncology Practice Initiative (QOPI) and QOPI CertificationAndrew Stewart, MACommission on Cancer, American College of SurgeonsAmerican College of Surgeons Electronic Quality Improvement Packets (e-QuIP)Steven M. Asch, MD, MPHVA Greater Los Angeles Healthcare SystemThe VA’s Cancer Quality Improvement ToolkitsMONDAY410

Monday, June 6, 20113:00 PM - 4:15 PMMEET THE PROFESSOR SESSIONUpdate on the Treatment of Adolescents and Young Adults with AcuteLymphocytic Leukemia (M17)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Pediatric Oncology, Leukemia, Myelodysplasia, and TransplantationStephen Hunger, MDUniversity of Colorado Denver Health Science CenterMONDAY411

Monday, June 6, 20113:00 PM - 6:00 PMORAL ABSTRACT SESSIONCancer Prevention/EpidemiologyLocation: S100bcCME credit: 3Track(s): Cancer Prevention/EpidemiologyMONDAYMichaela Jane Higgins, MD—Co-ChairMassachusetts General HospitalDean E. Brenner, MD—Co-ChairUniversity of Michigan Medical Center3:00 PM Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2mutation carriers: A combined analysis from the Kathleen CuninghamFoundation Consortium for Research into Familial Breast Cancer (kConFab),the International BRCA1 and BRCA2 Carrier Cohort Study (IBCCS), and theBreast Cancer Family Registry (BCFR). (Abstract #1500)K. Phillips, R. L. Milne, M. A. Rookus, D. Goldgar, M. Friedlander, S. McLachlan,S. S. Buys, A. C. Antoniou, K. E. Birch, M. Terry, D. Easton, P. Weideman,M. B. Daly, N. Andrieu, E. M. John, M. Hooning, I. L. Andrulis, T. Caldes,H. Olsson, J. L. Hopper3:15 PM Is hormone replacement therapy (HRT) following risk-reducing salpingooophorectomy(RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriersassociated with an increased risk of breast cancer? (Abstract #1501)S. M. Domchek, T. Friebel, S. L. Neuhausen, H. T. Lynch, C. F. Singer,R. A. Eeles, C. Isaacs, N. M. Tung, P. A. Ganz, F. J. Couch, J. N. Weitzel,O. I. Olopade, W. S. Rubinstein, G. E. Tomlinson, G. C. Pichert, M. B. Daly,E. T. Matloff, D. G. Evans, J. E. Garber, T. R. Rebbeck, PROSE Consortium3:30 PM Past use of hormone therapy and breast cancer risk. (Abstract #1502)W. Y. Chen, B. A. Rosner, S. E. Hankinson, Nurses’ Health Study Research GroupDiscussion3:45 PM Lynn C. Hartmann, MD (Abstracts #1500–1502)Mayo Clinic4:00 PM Metformin and breast cancer incidence in postmenopausal diabetic womenin the Women’s Health Initiative (WHI). (Abstract #1503)R. T. Chlebowski, A. McTiernan, A. K. Aragaki, T. Rohan, J. Wactawski-Wende,E. Ipp, D. Euhus, V. G. Kaklamani, M. Vitolins, R. B. Wallace, S. Liu,M. J. Gunter, L. Phillips, H. Strickler, B. Howard4:15 PM Incident cancers in people with dysglycemia and other cardiovascular riskfactors: Cohort study of the ORIGIN trial. (Abstract #1504)L. Bordeleau, G. Dagenais, N. Yakubovich, S. Yusuf, J. Probstfield, M. Riddle,L. Ryden, L. Xu, J. Bosch, H. Gerstein4:30 PM Cigarette smoking, fitness, and alcohol use as predictors of canceroutcomes among women in the National Surgical Adjuvant Breast and BowelProject (NSABP) Breast Cancer Prevention Trial (BCPT). (Abstract #1505)S. R. Land, N. Christian, D. L. Wickerham, J. P. Costantino, P. A. GanzDiscussion4:45 PM Pamela Jean Goodwin, MD (Abstracts #1503–1505)Mount Sinai Hospital5:00 PM DNA methyltransferase-3B (DNMT3B) in oral cancer (OC) development.(Abstract #1506)P. Saintigny, J. Jelinek, C. R. Pickering, W. Lang, M. J. Frederick, L. Zhang,H. Ren, V. Papadimitrakopoulou, J. Lee, E. S. Kim, Y. H. Fan, A. K. El-Naggar,W. K. Hong, J. Myers, J. J. Issa, S. M. Lippman, L. Mao5:15 PM Final results of a chemoprevention trial with enzastaurin in former smokers.(Abstract #1507)J. E. Gray, S. Altiok, M. Alexandrow, F. Walsh, J. Chen, D. Tai, G. Bepler412

Monday, June 6, 20115:30 PM Cervical cancer risk for 330,000 women undergoing concurrent HPV testingand cervical cytology in routine clinical practice. (Abstract #1508)H. A. Katki, W. K. Kinney, B. Fetterman, T. Lorey, N. E. Poitras, L. Cheung,F. Demuth, M. Schiffman, S. Wacholder, P. E. CastleDiscussion5:45 PM Eva Szabo, MD (Abstracts #1506–1507)National Cancer InstituteMONDAY413

Monday, June 6, 20113:00 PM - 6:00 PMORAL ABSTRACT SESSIONHead and Neck CancerLocation: S406CME credit: 3Track(s): Head and Neck CancerMONDAYEzra E. W. Cohen, MD—Co-ChairThe University of ChicagoDavid N. Hayes, MD, MPH—Co-ChairUniversity of North Carolina at Chapel Hill3:00 PM A randomized phase III trial (RTOG 0522) of concurrent accelerated radiationplus cisplatin with or without cetuximab for stage III-IV head and necksquamous cell carcinomas (HNC). (Abstract #5500)K. Ang, Q. Zhang, D. I. Rosenthal, P. Nguyen-Tan, E. J. Sherman, R. S. Weber,J. M. Galvin, D. L. Schwartz, A. K. El-Naggar, M. L. Gillison, R. Jordan, M. A. List,A. A. Konski, W. L. Thorstad, A. Trotti, J. J. Beitler, A. S. Garden, W. J. Spanos,S. Yom, R. S. Axelrod3:15 PM Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Resultsof the randomized phase II TREMPLIN study. (Abstract #5501)J. Lefebvre, Y. Pointreau, F. Rolland, M. Alfonsi, A. Baudoux, C. Sire,D. De Raucourt, E. Bardet, C. Tuchais, P. Garaud, G. CalaisDiscussion3:30 PM Ezra E. W. Cohen, MD (Abstracts #5500–5501)The University of Chicago3:45 PM A randomized phase II/III trial of a tumor vascular disrupting agentfosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) inanaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.(Abstract #5502)J. A. Sosa, R. Elisei, B. Jarzab, C. S. Bal, H. Koussis, A. W. Gramza,R. Ben-Yosef, B. J. Gitlitz, B. Haugen, S. M. Karandikar, F. R. Khuri, L. F. Licitra,S. C. Remick, S. Marur, C. Lu, F. G. Ondrey, S. Lu, J. Balkissoon4:00 PM A phase II trial of the multitargeted kinase inhibitor E7080 in advancedradioiodine (RAI)-refractory differentiated thyroid cancer (DTC). (Abstract#5503)S. I. Sherman, B. Jarzab, M. E. Cabanillas, L. F. Licitra, F. Pacini, R. Martins,B. Robinson, D. Ball, J. McCaffrey, M. H. Shah, D. Bodenner, R. Allison,K. Newbold, R. Elisei, J. P. O’Brien, M. SchlumbergerDiscussion4:15 PM Marcia S. Brose, MD, PhD (Abstracts #5502–5503)University of Pennsylvania4:30 PM Results of an Ontario Clinical Oncology Group (OCOG) prospective cohortstudy on the use of FDG PET/CT to predict the need for neck dissectionfollowing radiation therapy of head and neck cancer (HNC). (Abstract #5504)J. N. Waldron, R. W. Gilbert, L. Eapen, A. Hammond, D. I. Hodson, A. Hendler,B. Perez-Ordonez, C. Gu, J. A. Julian, D. H. Julian, M. N. LevineDiscussion4:45 PM Randal S. Weber, MD (Abstract #5504)University of Texas M. D. Anderson Cancer Center5:00 PM Prediction of clinical outcome in patients with primary laryngeal carcinomausing gene expression profiling. (Abstract #5505)E. Fountzilas, N. Angouridakis, I. Karasmanis, R. M. Wirtz, A. G. Eleftheraki,E. Veltrup, K. Markou, A. Nikolaou, P. Konstantinopoulos, V. Kotoula, D. Spentzos,G. Fountzilas414

Monday, June 6, 20115:15 PM Prognostic significance of plasma osteopontin in patients with locallyadvanced head and neck squamous cell carcinoma (HNSCC) treated withchemoradiation on TROG 02.02 phase III trial. (Abstract #5506)A. M. Lim, D. Rischin, H. Cao, R. Fisher, G. A. McArthur, L. J. Peters, R. J. Young,Q. LeDiscussion5:30 PM David N. Hayes, MD, MPH (Abstracts #5505–5506)University of North Carolina at Chapel HillMONDAY415

Monday, June 6, 20113:00 PM - 6:00 PMORAL ABSTRACT SESSIONSarcomaLocation: E354aCME credit: 3Track(s): SarcomaMONDAYAndrew J. Wagner, MD, PhD—Co-ChairDana-Farber Cancer InstituteBruce Brockstein, MD—Co-ChairNorthShore University Health System3:00 PM Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarkerand subset results of a phase II randomized discontinuation trial. (Abstract#10000)G. K. Schwartz, R. G. Maki, M. J. Ratain, S. D. Undevia, R. L. Jones,C. M. Rudin, L. L. Siu, B. Brockstein, D. Khayat, T. Gil, M. J. De Jonge,M. B. Sawyer, T. Evans, J. Medioni, P. J. O’Dwyer, C. Hartman, V. Poulart,I. B. Walters3:15 PM An evaluation of cediranib as a new agent for alveolar soft part sarcoma(ASPS). (Abstract #10001)S. Kummar, A. Strassberger, A. Monks, S. P. Ivy, I. B. Turkbey, P. L. Choyke,S. M. Steinberg, R. Simon, J. H. Doroshow, L. J. Helman, DevelopmentalTherapeutics Clinical Group, National Cancer Institute3:30 PM PALETTE: A randomized, double-blind, phase III trial of pazopanib versus(vs) placebo in patients (pts) with soft-tissue sarcoma (STS) whose diseasehas progressed during or following prior chemotherapy—An EORTC STBSGglobal network study (EORTC 62072). (Abstract #LBA10002)W. T. A. Van Der Graaf, J. Y. Blay, S. P. Chawla, D. W. Kim, B. Bui Nguyen,P. G. Casali, P. Schöffski, M. Aglietta, A. P. Staddon, Y. Beppu, A. Le Cesne,H. Gelderblom, I. R. Judson, N. Araki, M. Ouali, S. Marreaud, R. Hodge, M. Dewji,A. P. Dei Tos, and P. HohenbergerDiscussion3:45 PM Shreyaskumar Patel, MD (Abstracts #10000–LBA10002)University of Texas M. D. Anderson Cancer Center4:00 PM Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) inadvanced sarcoma. (Abstract #10003)S. Schuetze, L. Zhao, R. Chugh, M. Zalupski, D. Thomas, D. R. Lucas, L. H. Baker4:15 PM Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advancedor metastatic soft-tissue sarcoma and Ewing family of tumors. (Abstract#10004)P. Schoffski, D. Adkins, J. Blay, T. Gil, A. D. Elias, P. Rutkowski, G. K. Pennock,H. Youssoufian, N. J. Zojwalla, R. Willey, D. O. Grebennik4:30 PM Results of the phase III, placebo-controlled trial (SUCCEED) evaluating themTOR inhibitor ridaforolimus (R) as maintenance therapy in advancedsarcoma patients (pts) following clinical benefit from prior standardcytotoxic chemotherapy (CT). (Abstract #10005)S. P. Chawla, J. Blay, I. Ray-Coquard, A. Le Cesne, A. P. Staddon, M. M. Milhem,N. Penel, R. F. Riedel, B. Bui Nguyen, L. D. Cranmer, P. Reichardt, E. Bompas,Y. Song, R. Lee, J. E. Eid, J. Loewy, F. G. Haluska, P. F. Dodion, G. D. DemetriDiscussion4:45 PM Scott H. Okuno, MD (Abstracts #10003–10005)Mayo Clinic5:00 PM A phase II study of dasatinib for patients with imatinib-resistantgastrointestinal stromal tumor (GIST). (Abstract #10006)J. C. Trent, K. Wathen, M. von Mehren, B. L. Samuels, A. P. Staddon, E. Choy,J. E. Butrynski, R. Chugh, W. A. Chow, D. A. Rushing, C. A. Forscher, L. H. Baker,S. Schuetze, Sarcoma Alliance for Research through Collaboration416

Monday, June 6, 20115:15 PM A multicenter phase II study of regorafenib in patients (pts) with advancedgastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) andsunitinib (SU). (Abstract #10007)S. George, M. von Mehren, M. C. Heinrich, Q. Wang, C. L. Corless, J. E. Butrynski,J. A. Morgan, A. J. Wagner, E. Choy, W. D. Tap, J. Manola, J. T. Yap,A. D. Van Den Abbeele, S. Solomon, J. A. Fletcher, G. D. Demetri5:30 PM Neoadjuvant MDM2 antagonist RG7112 for well-differentiated anddedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD)biomarker study. (Abstract #10007b)I. Ray-Coquard, J. Y. Blay, A. Italiano, A. Le Cesne, N. Penel, J. Zhi, A.Beryozkina, F. Heil, R. Rueger, G. L. Nichols, and B. Bui NguyenDiscussion5:45 PM Jaap Verweij, MD, PhD (Abstracts #10006–1007b)Erasmus University Medical CenterMONDAY417

Monday, June 6, 20113:00 PM - 6:00 PMORAL ABSTRACT SESSIONTumor BiologyLocation: S100aCME credit: 3Track(s): Tumor BiologyMONDAYRobert Arthur Kratzke, MD—Co-ChairUniversity of MinnesotaKapil N. Bhalla, MD—Co-ChairUniversity of Kansas Cancer Center3:00 PM Comparative genomic analysis of primary versus metastasis in colorectalcarcinomas. (Abstract #10500)E. Vakiani, M. Janakiraman, R. Shen, Z. Zeng, A. Cercek, N. E. Kemeny,A. Heguy, P. Paty, T. A. Chan, L. Saltz, M. R. Weiser, D. B. Solit3:15 PM Exomic sequencing of pancreatic neuroendocrine tumors: Detection ofalterations in chromatin remodeling and mTOR pathway genes. (Abstract#10501)L. A. Diaz, Y. Jiao, C. Shi, B. H. Edil, R. de Wilde, D. S. Klimstra, A. Maitra,L. H. Tang, A. L. Blackford, V. Velculescu, B. Vogelstein, K. W. Kinzler,R. H. Hruban, N. Papadopoulos3:30 PM Tumor genomic profiling of FFPE samples by massively parallel sequencing.(Abstract #10502)N. Wagle, M. F. Berger, M. J. Davis, B. Blumenstiel, M. DeFelice, W. C. Hahn,M. Meyerson, S. B. Gabriel, L. E. MacConaill, L. A. GarrawayDiscussion3:45 PM A. John Iafrate, MD, PhD (Abstracts #10500–10502)Massachusetts General Hospital4:00 PM Effect of IGF1R protein expression on benefit to adjuvant trastuzumab inearly-stage HER2 breast cancer in NCCTG N9831 trial. (Abstract #10503)M. M. Reinholz, A. C. Dueck, B. Chen, X. Geiger, A. E. McCullough, R. B. Jenkins,W. L. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh,G. W. Sledge Jr., L. Harris, J. Gralow, E. A. Perez4:15 PM Effect of PTEN protein expression on benefit to adjuvant trastuzumab inearly-stage HER2 breast cancer in NCCTG adjuvant trial N9831. (Abstract#10504)E. A. Perez, A. C. Dueck, M. M. Reinholz, B. Chen, X. Geiger, R. B. Jenkins,W. L. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh,G. W. Sledge Jr., L. Harris, J. Gralow, A. E. McCullough4:30 PM Genomic patterns resembling BRCA-mutated breast cancers and benefit ofintensified carboplatin-based chemotherapy in HER2-negative breast cancer.(Abstract #10505)S. C. Linn, E. H. Lips, P. M. Nederlof, L. F. Wessels, J. Wesseling,M. van de Vijver, E. De Vries, H. van Tinteren, J. Jonkers, M. Hauptmann,S. Rodenhuis, M. A. VolleberghDiscussion4:45 PM Ana M. Gonzalez-Angulo, MD, MSc (Abstracts #10503–10505)University of Texas M. D. Anderson Cancer Center5:00 PM Detection of circulating miRNAs in serum from patients with breast cancerand their association with the presence of metastatic disease. (Abstract#10506)E. van Schooneveld, M. Wouters, I. Van der Auwera, D. Peeters, P. Huget,P. A. van Dam, P. B. Vermeulen, S. J. Van Laere, L. Y. Dirix, Translational CancerResearch Group Antwerp, GZA Hospitals Sint-Augustinus418

Monday, June 6, 20115:15 PM Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations inearly-phase protocols with PI3K/mTOR pathway inhibitors. (Abstract #10507)F. Janku, I. Garrido-Laguna, J. J. Wheler, D. S. Hong, A. Naing, G. S. Falchook,S. Fu, S. L. Moulder, R. Luthra, J. Lee, A. M. Tsimberidou, R. Kurzrock5:30 PM Prognostic and predictive blood-based biomarkers in patients with advancedpancreatic cancer: Results from CALGB 80303. (Abstract #10508)A. B. Nixon, H. Pang, M. Starr, D. Hollis, P. N. Friedman, M. M. Bertagnolli,H. L. Kindler, R. M. Goldberg, A. P. Venook, H. HurwitzDiscussion5:45 PM David Paul Carbone, MD, PhD (Abstracts #10506–10508)Vanderbilt-Ingram Cancer CenterMONDAY419

Monday, June 6, 20114:45 PM - 6:00 PMEDUCATION SESSIONSDeveloping and Implementing More Informative Phase II Oncology ClinicalTrialsLocation: Arie Crown TheaterCME credit: 1.25Track(s): Clinical Trials, Genitourinary Cancer, Lung CancerDavid B. Solit, MD—ChairMemorial Sloan-Kettering Cancer CenterHow Do We Improve Phase II Trial Designs to Better Ensure Success in Phase III?Catherine M. Tangen, PhDFred Hutchinson Cancer Research CenterThe Randomized Phase II Trial: Is it Useful in Predicting Results of Phase III Studies?Primo Lara, MDUniversity of California, DavisPitfalls in the Use of Progression-free Survival in Patients with Lung and Prostate CancerImplementing an Electronic Health Record (EHR) in Different Practice Settings:Strategies for Success (eQuestions Session)Location: E353CME credit: 1.25Track(s): Practice Management and Information Technology, Professional DevelopmentWilliam M. Jordan, DO—ChairThe Center for Cancer and Blood DisordersEHR Implementation: Community Practice PerspectiveNancy T. Sklarin, MDMemorial Sloan-Kettering Cancer CenterEHR Implementation: Academic Practice PerspectiveCarolyn P. Hartley, MDPhysician’s EHRThe Practice EHR Implementation TeamMONDAYTo Transplant or Not to Transplant? Current Controversies in Transplantationfor Pediatric Acute LeukemiasLocation: S504CME credit: 1.25Track(s): Pediatric Oncology, Leukemia, Myelodysplasia, and TransplantationMichael Pulsipher, MD—ChairUniversity of UtahChemotherapy versus Transplant for Pediatric Acute Lymphoblastic LeukemiaRichard Aplenc, MDThe Children’s Hospital of PhiladelphiaChemotherapy versus Transplant for Pediatric Acute Myeloblastic LeukemiaSaro Armenian, DO, MPHCity of HopeLong-term Outcome of Children with Leukemia after Treatment with Stem Cell Transplant420

Treating Genitourinary Malignancies (Prostate, Kidney, and UrothelialCancers): The Latest and GreatestLocation: Hall B1CME credit: 1.25Track(s): Genitourinary Cancer, Clinical Trials, General OncologyGary R. MacVicar, MD—ChairNorthwestern University Feinberg School of MedicineAdvances in Prostate Cancer TherapeuticsChristopher Sweeney, MBBSDana-Farber Cancer InstituteWhat’s New in Urothelial CancerElisabeth I. Heath, MDKarmanos Cancer InstituteRenal Cell Cancer UpdateMonday, June 6, 2011MONDAY421

Monday, June 6, 20114:45 PM - 6:00 PMMEET THE PROFESSOR SESSIONFinding the Best Job for You/Contract Negotiation (M18)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Professional Development, Practice Management and Information TechnologyDouglas W. Blayney, MDStanford UniversityMONDAY422

Tuesday, June 7, 20117:30 AM - 9:00 AMHIGHLIGHTS OF THE DAY SESSIONHighlights of the Day IIILocation: Hall D1CME credit: 1.5Track(s): Special Session, General OncologyRonald Levy, MD—ChairStanford University School of Medicine7:30 AMStephen K. L. Chia, MDBritish Columbia Cancer AgencyBreast Cancer—Triple-negative/Cytotoxics/Local Therapy and CancerPrevention/Epidemiology7:50 AMA. Oliver Sartor, MDTulane University School of MedicineGenitourinary (Prostate and Nonprostate) Cancer8:10 AMVassiliki Papadimitrakopoulou, MDUniversity of Texas M. D. Anderson Cancer CenterHead and Neck Cancer8:25 AMThomas J. Smith, MDMassey Cancer Center of Virginia Commonwealth UniversityPatient and Survivor Care8:40 AMJean-Yves Blay, MD, PhDCentre Léon BérardSarcomaTUESDAY423

Tuesday, June 7, 20118:00 AM - 9:15 AMEDUCATION SESSIONSHow the Human Genome Project Will Help Us in the ClinicLocation: S100aCME credit: 1.25Track(s): Tumor Biology, Cancer Genetics, Developmental TherapeuticsTodd Golub, MD—ChairDana-Farber Cancer InstituteGenomic Mutations Mediating Sensitivity and Resistance to Targeted TherapiesJordi Barretina, PhDBroad Institute of MIT and HarvardExploiting Genomic Mutations and Pathway Analysis for the Rationale Development of EffectiveTherapeuticsJoe W. Gray, PhDOregon Health and Science UniversityThe Future of Genomics in Directing Personalized Cancer TherapyTargeting Angiogenesis in Breast Cancer: Where Do We Stand in 2011?Location: E354aCME credit: 1.25Track(s): Breast Cancer, Tumor BiologyMaura N. Dickler, MD—ChairMemorial Sloan-Kettering Cancer CenterAntiangiogenic Therapy in Breast Cancer: The Current Status and ControversyRobert S. Kerbel, PhDSunnybrook Research InstituteAngiogenesis as a TargetDaniel J. Sargent, PhDMayo ClinicAppropriate Endpoints for Clinical Trials and Source of U.S. Food and DrugAdministration/Oncologic Drugs Advisory Committee ControversyTUESDAY424

Tuesday, June 7, 20118:00 AM - 9:15 AMMEET THE PROFESSOR SESSIONOrthopedic Oncology for the Rest of Us (M19)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): SarcomaR. Lor Randall, MDHuntsman Cancer Institute, University of UtahKristy Weber, MDThe Johns Hopkins University School of MedicineTUESDAY425

Tuesday, June 7, 20118:00 AM - 9:30 AMCLINICAL SCIENCE SYMPOSIUMImmune Correlates of Clinical OutcomesLocation: E354bCME credit: 1.5Track(s): Developmental TherapeuticsThomas Gajewski, MD, PhD—ChairThe University of Chicago8:00 AM Pharmacodynamic and predictive markers of ipilimumab on melanomapatients’ T cells. (Abstract #2503)J. S. Weber, B. Yu, M. Hall, D. Morelli, D. Yu, Y. Zhang, X. Zhao, A. Sarnaik,W. WangDiscussion8:15 AM Thomas Gajewski, MD, PhD (Abstract #2503)The University of Chicago8:30 AM Phase II cancer vaccination trial with multiple peptides derived from noveloncoantigens against advanced esophageal cancer. (Abstract #2504)K. Kono, H. Iinuma, Y. Akutsu, H. Tanaka, N. Hayashi, Y. Uchikado, T. Noguchi,H. Fujii, R. Fukushima, H. Matsubara, K. Hirakawa, H. Baba, S. Natsugoe,S. Kitano, K. Yoshida, T. Tsunoda, Y. NakamuraDiscussion8:45 AM Mary L. Disis, MD (Abstract #2504)University of Washington9:00 AM Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation withcolitis. (Abstract #2505)M. K. Callahan, A. Yang, S. Tandon, Y. Xu, S. K. Subudhi, R. Roman, A. I. Heine,E. Pogoriler, D. Kuk, K. Panageas, J. D. Yuan, J. P. Allison, J. D. WolchokDiscussion9:15 AM To be determinedTUESDAY426

Tuesday, June 7, 20118:00 AM - 11:00 AMORAL ABSTRACT SESSIONLung Cancer—Local-regional and Adjuvant Therapy/Small CellLocation: Arie Crown TheaterCME credit: 3Track(s): Lung CancerTom Stinchcombe, MD—Co-ChairUniversity of North Carolina at Chapel HillWilfried Ernst Erich Eberhardt, MD—Co-ChairUniversity Hospital–University Duisburg-Essen8:00 AM Randomized phase III trial of amrubicin versus topotecan (Topo) as secondlinetreatment for small cell lung cancer (SCLC). (Abstract #7000)R. Jotte, J. Von Pawel, D. R. Spigel, M. A. Socinski, M. O’Brien, E. H. Paschold,J. Mezger, M. Steins, L. Bosquée, J. A. Bubis, K. Nackaerts, J. Trigo Perez,P. R. Clingan, W. Schuette, P. Lorigan, M. Reck, M. Domine, F. A. Shepherd,R. McNally, M. F. Renschler8:15 AM A randomized phase II study of carboplatin (C) and etoposide (E) with orwithout pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small celllung cancer (ES-SCLC). (Abstract #7001)C. J. Langer, I. Albert, P. Kovacs, L. Blakely, G. Pajkos, P. Petrov, A. Somfay,A. Szczesna, P. Zatloukal, A. Kazarnowicz, M. M. Moezi, M. T. Schreeder,J. Schnyder, M. S. BergerDiscussion8:30 AM Bonnie S. Glisson, MD (Abstracts #7000–7001)University of Texas M. D. Anderson Cancer Center8:45 AM Randomized phase II trial on refinement of early-stage NSCLC adjuvantchemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin andvinorelbine (CVb): TREAT. (Abstract #7002)M. Kreuter, J. F. Vansteenkiste, J. R. Fischer, W. E. Eberhardt, H. Zabeck,J. Kollmeier, M. H. Serke, N. Frickhofen, M. Reck, W. Engel-Riedel, S. Neumann,M. Thomeer, C. Schumann, P. Deleyn, T. Graeter, G. Stamatis, I. Zuna,F. Griesinger, M. ThomasDiscussion9:00 AM Heather A. Wakelee, MD (Abstracts #7002)Stanford University School of Medicine9:15 AM Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031.(Abstract #7003)D. Harpole, K. V. Ballman, A. L. Oberg, G. Whiteley, R. Cerfolio, R. Keenan,D. R. Jones, T. A. D’Amico, J. Shrager, J. B. Putnam, American College ofSurgeons Oncology GroupDiscussion9:30 AM To be determined9:45 AM Evaluation of disease-free survival as surrogate endpoint for overall survivalusing two individual patient data meta-analyses of adjuvant chemotherapy inoperable non-small cell lung cancer. (Abstract #7004)S. Michiels, A. Mauguen, D. Fisher, S. Burdett, R. Paulus, S. J. Mandrekar,C. P. Belani, F. A. Shepherd, T. Eisen, H. Pang, L. Collette, C. Le Pechoux,J. Pignon, Surrogate Lung Project Collaborative Group10:00 AM Systematic evaluation of the impact of disease progression (DP) datedetermination on progression-free survival (PFS) in advanced lung cancer: Ajoint North Central Cancer Treatment Group (NCCTG) and SouthwestOncology Group (SWOG) investigation. (Abstract #7005)S. J. Mandrekar, Y. Qi, K. Allen-Ziegler, S. L. Hillman, M. W. Redman, S. E. Schild,D. R. Gandara, A. A. AdjeiTUESDAY427

Tuesday, June 7, 2011Discussion10:15 AM Suzanne Eleanor Dahlberg, PhD (Abstracts #7004–7005)Dana-Farber Cancer Institute10:30 AM A multicenter, randomized phase III maintenance study of thalidomide (armA) versus observation (arm B) in patients with malignant pleuralmesothelioma (MPM) after induction chemotherapy. (Abstract #7006)P. Baas, W. Buikhuisen, O. Dalesio, A. Vincent, N. Pavlakis, R. Van Klaveren,F. Schramel, F. Custers, H. Schouwink, S. A. BurgersDiscussion10:45 AM Rolf A. Stahel, MD (Abstract #7006)University Hospital ZurichTUESDAY428

Tuesday, June 7, 20118:00 AM - 12:30 PMPOSTER DISCUSSION SESSIONBreast Cancer—HER2/ERDisplay Time: 8:00 AM - 12:00 PMDisplay Location: E450aDiscussion Time: 11:30 AM - 12:30 PMDiscussion Location: Arie Crown TheaterCME credit: 1Track(s): Breast CancerHerve R. Bonnefoi, MD—Co-ChairInstitut Bergonie Cancer CenterAnne F. Schott, MD—Co-ChairUniversity of MichiganDiscussion11:30 AM Jennifer J. Griggs, MD, MPH (Abstracts #512–520)University of MichiganDiscussion11:45 AM Charles L. Loprinzi, MD (Abstracts #521–526)Mayo ClinicDiscussion12:00 PM Herve R. Bonnefoi, MD (Abstracts #527–532)Institut Bergonie Cancer CenterDiscussion12:15 PM Anne F. Schott, MD (Abstracts #533–536)University of MichiganBrd. 1 Randomized trial of a lifestyle intervention for women with early-stage breastcancer (BC) receiving adjuvant hormone therapy: Initial results. (Abstract#512)R. Segal, G. R. Pond, M. Vallis, M. Dion, K. I. Pritchard, J. A. Ligibel, M. N. Levine,P. J. GoodwinBrd. 2 Impact of a change of body mass index (BMI) on outcome following adjuvantendocrine therapy, chemotherapy, or trastuzumab for breast cancer.(Abstract #513)R. Yerushalmi, B. Dong, J. W. Chapman, P. E. Goss, M. N. Pollak, M. J. Burnell,V. H. Bramwell, M. N. Levine, K. I. Pritchard, T. J. Whelan, J. N. Ingle,W. Parulekar, L. E. Shepherd, K. A. GelmonBrd. 3 Effect of change of body mass index (BMI) during therapy on the efficacy ofendocrine therapy in premenopausal patients with breast cancer: Ananalysis of the ABCSG-12 trial. (Abstract #514)G. Pfeiler, R. Königsberg, B. Mlineritsch, H. Stoger, C. F. Singer, S. Poestlberger,G. G. Steger, M. Seifert, P. C. Dubsky, R. Jakesz, H. Samonigg, V. Bjelic-Radisic,R. Greil, C. Marth, C. Fesl, M. GnantBrd. 4 Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) inpostmenopausal women with breast cancer (BC) during letrozole (L)treatment. (Abstract #515)G. Lunardi, L. Del Mastro, C. Bighin, G. Bisagni, P. Driol, O. Garrone, S. Giraudi,P. Marroni, P. Piccioli, R. Ponzone, M. Porpiglia, M. Venturini, Gruppo ItalianoMammella (GIM)Brd. 5 Bone mineral density (BMD) in participants (pts) of trial BIG 1–98 comparingadjuvant letrozole (L) versus tamoxifen (T) or their sequence. (Abstract #516)A. De Censi, Z. Sun, B. J. Thurlimann, C. McIntosh, A. Guerrieri-Gonzaga,A. Monnier, C. Tondini, M. Campone, L. Mauriac, K. Zaman, A. Schoenberger,K. N. Price, R. D. Gelber, A. Goldhirsch, A. S. Coates, S. P. Aebi, BIG 1–98Collaborative and International Breast Cancer Study GroupsTUESDAY429

Tuesday, June 7, 2011TUESDAYBrd. 6Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16Bone effects of adjuvant tamoxifen (T), letrozole (L), or L zoledronic acid(Z) in early breast cancer (EBC): The phase III HOBOE study. (Abstract #517)F. Perrone, C. Gallo, S. Lastoria, F. Nuzzo, A. Gravina, G. Landi, E. Rossi,C. Pacilio, V. Labonia, F. Di Rella, M. De Laurentiis, M. Piccirillo, M. Di Maio,P. Giordano, G. Daniele, G. De Feo, R. Fiore, S. Signoriello, G. Esposito,A. de MatteisEffects of adjuvant exemestane versus anastrozole on bone mineral density:Two-year results of the NCIC CTG MA.27 bone companion study. (Abstract#518)D. L. Hershman, A. M. Cheung, J. W. Chapman, J. N. Ingle, F. Ahmed, H. Hu,J. Scher, S. Leeson, C. Elliott, A. Le Maitre, L. E. Shepherd, P. E. GossA population-based assessment of the risk of fragility fracture associatedwith the use of adjuvant hormone therapy for early breast cancer in olderwomen. (Abstract #519)K. Enright, M. E. Trudeau, N. Taback, M. K. KrzyzanowskaOverall survival with adjuvant zoledronic acid in patients withpremenopausal breast cancer with complete endocrine blockade: Long-termresults from ABCSG-12. (Abstract #520)M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, S. Poestlberger,P. C. Dubsky, R. Jakesz, C. F. Singer, H. Eidtmann, R. GreilIncidence and predictors of ovarian function recovery (OFR) in exemestanepatients with breast cancer (BC) with chemotherapy-induced amenorrhea(CIA) using two estradiol assays. (Abstract #521)A. Guerrero-Zotano, J. Gavila, E. Folkerd, B. Ortiz, T. Labrador, F. Martinez,A. Garcia, M. Climent, V. Guillem, M. Dowsett, A. RuizSymptoms of endocrine treatment and outcome: A retrospective analysis ofthe monotherapy arms of the BIG 1–98 trial. (Abstract #522)J. B. Huober, B. F. Cole, J. Wu, A. Giobbie-Hurder, M. Rabaglio, H. T. Mouridsen,L. Mauriac, J. F. Forbes, R. Paridaens, I. Lang, I. E. Smith, A. M. Wardley,K. N. Price, A. Goldhirsch, A. S. Coates, B. J. Thurlimann, BIG 1–98Collaborative and International Breast Cancer Study GroupsIncreased progression-free and overall survival in patients with breastcancer with menopausal symptoms or arthralgia/myalgia during adjuvanttreatment with exemestane or tamoxifen: Results of the German TEAM trial.(Abstract #523)D. G. Kieback, P. Hadji, T. Menschik, A. Hasenburg, J. Tams, M. ZillerSymptom experiences and nonadherent medication-taking behaviors ofbreast cancer patients taking adjuvant hormone therapy. (Abstract #524)R. A. Shelby, F. J. Keefe, S. N. Red, K. L. Blackwell, J. M. Peppercorn,P. K. Marcom, G. G. KimmickRelationship of treatment-emergent symptoms and recurrence-free survivalin the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. (Abstract #525)V. Stearns, J. W. Chapman, C. X. Ma, M. J. Ellis, J. N. Ingle, K. I. Pritchard,G. T. Budd, M. Rabaglio, G. W. Sledge Jr., A. Le Maitre, J. Kundapur,L. E. Shepherd, P. E. Goss24-month follow-up from the Patient’s Anastrozole Compliance to Therapy(PACT) program evaluating the influence of a standardized informationservice on compliance in postmenopausal women with early breast cancer.(Abstract #526)H. Lück, P. Hadji, N. Harbeck, C. Jackisch, M. Blettner, M. Glados, J. Terhaag,R. Hackenberg, T. Goehler, S. Zaun, A. Rexrodt von Fircks, R. KreienbergTBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts)with HER2 metastatic breast cancer (MBC). (Abstract #527)N. U. Lin, I. A. Mayer, J. S. Najita, T. J. Hobday, C. I. Falkson, E. C. Dees,M. F. Rimawi, R. Nanda, R. S. Gelman, K. Josephs, A. Richardson, L. Flores,A. D. Van Den Abbeele, J. T. Yap, C. L. Arteaga, A. C. Wolff, I. E. Krop,E. P. Winer, Translational Breast Cancer Research Consortium430

Tuesday, June 7, 2011Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25The role of EGFR amplification in trastuzumab resistance: A correlativeanalysis of TBCRC003. (Abstract #528)I. E. Krop, L. Flores, J. S. Najita, I. A. Mayer, T. J. Hobday, C. I. Falkson,C. L. Arteaga, A. C. Wolff, E. C. Dees, M. F. Rimawi, R. Nanda, K. Josephs,N. U. Lin, E. P. Winer, Translational Breast Cancer Research ConsortiumResponse to neoadjuvant trastuzumab and chemotherapy in ER and ER-HER2-positive breast cancers: Gene expression analysis. (Abstract #529)G. Bianchini, A. Prat, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov,W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti,F. J. Vazquez Mazon, J. Baselga, L. GianniValidation of p95 as predictive marker for trastuzumab-based therapy inprimary HER2-positive breast cancer: A translational investigation from theneoadjuvant GeparQuattro study. (Abstract #530)S. Loibl, J. Bruey, G. Von Minckwitz, J. B. Huober, M. F. Press, S. Darb-Esfahani,C. Solbach, C. Denkert, H. Tesch, F. Holms, T. N. Fehm, K. Mehta, M. UntchPrimary efficacy analysis of a phase II study of neoadjuvant bevacizumab(BEV), chemotherapy (CT), and trastuzumab (H) in HER2-positiveinflammatory breast cancer (IBC): BEVERLY2 study. (Abstract #531)P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov,F. Lerebours, H. H. Roche, M. Pavlyuk, T. D. Bachelot, E. Charafe-JauffretEfficacy of neoadjuvant therapy with trastuzumab concurrent withanthracycline- and nonanthracycline-based regimens for HER2-positivebreast cancer. (Abstract #532)S. Bayraktar, A. M. Gonzalez-Angulo, X. Lei, A. Buzdar, V. Valero, A. Melhem,H. M. Kuerer, G. N. Hortobagyi, A. A. Sahin, F. Meric-BernstamEtoricoxib and anastrozole in adjuvant early breast cancer: ETAN trial (phaseIII). (Abstract #533)M. S. Rosati, M. Di Seri, G. Baciarello, V. LO Russo, P. Grassi, L. Marchetti,S. Giovannoni, M. Basile, L. FratiFinal analysis of the NEOMET trial of neoadjuvant metformin: Examiningeffects on Ki67, gene expression, and pathway analysis in primary operablebreast cancer. (Abstract #534)A. M. Thompson, T. Iwamoto, L. Jordan, C. Purdie, S. E. Bray, L. Baker, G. Hardie,L. Pusztai, S. L. Moulder, J. A. Dewar, S. M. HadadUse of genomic grade index to improve tumor grading of invasive lobularbreast carcinoma. (Abstract #535)D. Fumagalli, O. Metzger, I. Veys, A. Catteau, S. Michiels, H. Sandy, R. Salgado,S. K. Singhal, K. V. Saini, C. Galant, N. Galland, F. Bertucci, H. P. Peyro Saint Paul,M. J. Piccart-Gebhart, C. Sotiriou, D. LarsimontA randomized controlled trial of primary tamoxifen versus mastectomy plusadjuvant tamoxifen in fit elderly women with breast carcinoma of highestrogen receptor content: Long-term results at 20 years of follow-up.(Abstract #536)S. J. Johnston, F. S. Kenny, B. M. Syed, J. F. Robertson, S. Pinder,L. Winterbottom, I. O. Ellis, R. W. Blamey, K. CheungTUESDAY431

Tuesday, June 7, 20118:00 AM - 12:30 PMPOSTER DISCUSSION SESSIONGenitourinary (Nonprostate) CancerDisplay Time: 8:00 AM - 12:00 PMDisplay Location: E450bDiscussion Time: 11:30 AM - 12:30 PMDiscussion Location: E354aCME credit: 1Track(s): Genitourinary CancerTUESDAYEmmanuel S. Antonarakis, MD—Co-ChairThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins UniversityScott E. Eggener, MD—Co-ChairThe University of ChicagoDiscussion11:30 AM Walter Michael Stadler, MD (Abstracts #4546–4552)The University of ChicagoDiscussion11:45 AM Thomas Powles, MD (Abstracts #4553–4560)St. Bartholomew’s HospitalDiscussion12:00 PM Christian K. Kollmannsberger, MD (Abstracts #4561–4565)British Columbia Cancer AgencyDiscussion12:15 PM Matt D. Galsky, MD (Abstracts #4566–4570)Tisch Cancer Institute, Mount Sinai Medical CenterBrd. 1 BEVLiN: Prospective study of the safety and efficacy of first-linebevacizumab (BEV) plus low-dose interferon-2a (IFN) in patients (pts) withmetastatic renal cell carcinoma (mRCC). (Abstract #4546)B. Melichar, S. Bracarda, V. Matveev, I. Rusakov, A. Kaprin, A. Zyryanov,R. Janciauskiene, E. Fernebro, G. H. Mickisch, M. E. Gore, A. Schulze, S. Jethwa,V. Sneller, P. Mulders, J. Bellmunt, on behalf of the BEVLiN InvestigatorsBrd. 2 Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC):Five-year (yr) overall survival (OS) data from a phase II trial. (Abstract #4547)R. J. Motzer, T. de La Motte Rouge, A. L. Harzstark, D. Michaelson, G. Liu,V. Gruenwald, A. Ingrosso, M. A. Tortorici, P. W. Bycott, S. Kim, B. I. RiniBrd. 3 Final phase II safety and efficacy results of study MC0452: Phase I/II trial ofCCI 779 and bevacizumab in advanced renal cell carcinoma. (Abstract #4548)J. R. Merchan, H. C. Pitot, R. Qin, G. Liu, T. R. Fitch, W. J. Maples, J. Picus,C. ErlichmanBrd. 4 Results from a phase I trial of tivozanib (AV-951) combined with temsirolimustherapy in patients (pts) with renal cell carcinoma (RCC). (Abstract #4549)F. F. Kabbinavar, S. Srinivas, R. J. Hauke, R. J. Amato, W. B. Esteves,M. M. Cotreau, A. L. Strahs, P. Bhargava, M. N. FishmanBrd. 5 Final analysis of the phase II randomized discontinuation trial (RDT) oftivozanib (AV-951) versus placebo in patients with renal cell carcinoma(RCC). (Abstract #4550)D. Nosov, P. Bhargava, W. B. Esteves, A. L. Strahs, O. N. Lipatov, O. O. Lyulko,A. O. Anischenko, R. T. Chacko, D. Doval, W. J. SlichenmyerBrd. 6 A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, inpatients with advanced or metastatic renal cell cancer (mRCC). (Abstract#4551)E. Angevin, V. Grünwald, A. Ravaud, D. E. Castellano, C. Lin, J. E. Gschwend,A. L. Harzstark, J. Chang, Y. Wang, M. M. Shi, B. J. Escudier432

Tuesday, June 7, 2011Brd. 7Brd. 8Brd. 9Brd. 10Brd. 11Brd. 12Brd. 13Brd. 14Brd. 15Brd. 16A noninterventional study of everolimus in metastatic renal cell cancer afteruse of one VEGFR-TKI: Results of a preplanned interim analysis of aprospective study. (Abstract #4552)L. Bergmann, U. Kube, M. Kindler, T. Koepke, G. Steiner, J. Janssen, S. Fries,P. Goebell, A. Jakob, T. Steiner, M. D. Staehler, F. Overkamp, M. Albrecht,C. DoehnCirculating baseline plasma cytokines and angiogenic factors (CAF) asmarkers of tumor burden and therapeutic response in a phase III study ofpazopanib for metastatic renal cell carcinoma (mRCC). (Abstract #4553)Y. Liu, H. T. Tran, Y. Lin, A. Martin, A. J. Zurita, C. N. Sternberg, R. G. Amado,L. N. Pandite, J. Heymach, VEG105192 TeamRisk factor migration and survival: Analysis from international dataset of3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinicaltrials. (Abstract #4554)S. Patil, J. Manola, P. Elson, W. Bro, S. Negrier, B. Escudier, R. M. Bukowski,R. J. MotzerThe association of clinical outcome to front-line VEGF-targeted therapy withclinical outcome to second-line VEGF-targeted therapy in metastatic renalcell carcinoma (mRCC) patients (Pts). (Abstract #4555)M. Y. Al-Marrawi, B. I. Rini, L. C. Harshman, G. A. Bjarnason, L. Wood,U. N. Vaishampayan, M. J. MacKenzie, J. J. Knox, N. Agarwal,C. K. Kollmannsberger, M. Tan, S. Y. Rha, F. Donskov, S. A. North, T. K. Choueiri,D. Y. Heng, International mRCC Database ConsortiumMolecular classification of sunitinib response in metastatic renal cellcarcinoma (mRCC) patients by gene expression profiling. (Abstract #4556)V. J. Thodima, A. M. Molina, X. Jia, J. Zhang, M. E. Georges, S. Patil, V. E. Reuter,R. J. Motzer, R. S. ChagantiHost-mediated changes in patients receiving antiangiogenic therapy forresected RCC. (Abstract #4557)R. S. Bhatt, J. Manola, A. J. Bullock, L. Zhang, N. B. Haas, M. Pins, M. B. Atkins,R. S. DiPaolaAssociation of germ-line SNPs with overall survival (OS) in pazopanibtreatedpatients (Pts) with advanced renal cell carcinoma (RCC). (Abstract#4558)C. Xu, N. Bing, H. A. Ball, C. N. Sternberg, I. D. Davis, Z. Xue, L. McCann, K. King,J. C. Whittaker, C. F. Spraggs, V. E. Mooser, L. N. PanditePolymorphisms as markers of sunitinib efficacy and toxicity in first-linetreatment of renal clear cell carcinoma: Final results of a multicentricprospective study by the Spanish Oncology Genitourinary Group. (Abstract#4559)J. Garcia-Donas, E. Esteban, L. J. Leandro-García, D. E. Castellano,A. Gonzalez del Alba, M. Climent, J. A. Arranz, E. Gallardo, J. Puente, J. Bellmunt,B. Mellado, E. Martínez, F. Moreno, A. Font, M. Robledo, C. Rodriguez de Antona,Spanish Oncology GenitoUrinary Group (SOGUG)External validation of the International Metastatic Renal Cell Carcinoma(mRCC) Database Consortium prognostic model and comparison to fourother models in the era of targeted therapy. (Abstract #4560)D. Y. Heng, W. Xie, L. C. Harshman, G. A. Bjarnason, U. N. Vaishampayan,J. Lebert, L. Wood, F. Donskov, M. Tan, S. Y. Rha, C. Wells, Y. Wang,C. K. Kollmannsberger, B. I. Rini, T. K. Choueiri, International mRCC DatabaseConsortiumAccelerated BEP for advanced germ cell tumors: An Australian multicenterphase I/II trial. (Abstract #4561)P. S. Grimison, D. B. Thomson, M. R. Stockler, M. D. Chatfield, M. Friedlander,V. Gebski, A. L. Boland, B. B. Houghton, H. Gurney, M. Rosenthal, N. Singhal,G. Kichenadasse, S. S. Wong, C. R. Lewis, P. A. Vasey, G. C. Toner,Australian and New Zealand Urogenital and Prostate Cancer Trials GroupTUESDAY433

Tuesday, June 7, 2011Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25Long-term survival with paclitaxel and gemcitabine for germ cell tumors afterprogression following high-dose chemotherapy with tandem transplants.(Abstract #4562)B. P. Mulherin, M. J. Brames, L. H. EinhornReproduction rates prior to diagnosis of testicular cancer: Does thetesticular dysgenesis syndrome exist? (Abstract #4563)M. Cvancarova, J. Oldenburg, M. Sprauten, H. Stensheim, S. D. FossaAssociation of single-nucleotide polymorphism (SNP) in the5-alpha-reductase gene (SRD5A2) with increased prevalence of metabolicsyndrome in chemotherapy-treated testicular cancer (TC) survivors.(Abstract #4564)H. Boer, C. Meijer, J. D. Dijck-Brouwer, I. P. Kema, J. D. Lefrandt, N. Zwart,H. M. Boezen, A. J. Smit, J. A. GietemaEvaluation of low-dose CT scans for surveillance in stage I testicular cancer.(Abstract #4565)P. W. Chung, M. O’Malley, M. A. Jewett, T. Panzarella, D. Hogg, M. J. Moore,P. Bedard, L. Anson-Cartwright, B. Tew-George, M. A. Haider,M. K. Gospodarowicz, P. R. WardePhase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients(pts) with advanced/metastatic urothelial carcinoma (UC). (Abstract #4566)A. V. Balar, M. I. Milowsky, A. B. Apolo, I. Ostrovnaya, A. Iasonos, A. Trout,A. M. Regazzi, I. R. Garcia-Grossman, D. J. Gallagher, D. F. BajorinClinical outcome of single agent volasertib (BI 6727) as second-linetreatment of patients (pts) with advanced or metastatic urothelial cancer(UC). (Abstract #4567)W. M. Stadler, D. J. Vaughn, G. Sonpavde, N. J. Vogelzang, S. T. Tagawa,D. P. Petrylak, P. J. Rosen, C. Lin, J. F. Mahoney, S. S. Modi, P. Lee,M. S. Ernstoff, W. Su, A. I. Spira, M. Ould Kaci, J. M. Watrous, T. Taube,R. Vinisko, C. Schloss, C. Zhao, M. A. CarducciIdentification of ALK gene alterations in urothelial carcinoma (UC). (Abstract#4568)J. Bellmunt, S. Selvarajah, S. Rodig, M. Salido, I. Costa, B. Bellosillo, L. Werner,C. Namgyal, F. A. Schutz, F. Pons, R. O’Brien, J. Barretina, S. Signoretti, M. Loda,J. Albanell, T. K. Choueiri, D. M. Berman, P. W. Kantoff, J. E. RosenbergIdentification of a novel urothelial carcinoma (UC) biomarker of lethality.(Abstract #4569)J. E. Rosenberg, L. Werner, S. Selvarajah, B. Weir, M. M. Regan, S. J. Jacobus,D. M. Berman, F. A. Schutz, R. O’Brien, T. K. Choueiri, J. Barretina, S. Signoretti,M. Loda, E. A. Guancial, E. Gallardo, F. G. Rojo, J. Lloreta, W. C. Hahn,P. W. Kantoff, J. BellmuntOptimization of the size variation threshold for imaging evaluation ofresponse in patients with platinum-refractory advanced transitional cellcarcinoma of the urothelium treated with vinflunine. (Abstract #4570)K. M. Krajewski, R. Fougeray, T. K. Choueiri, F. Pons, F. A. Schutz,J. E. Rosenberg, Y. Salhi, J. BellmuntTUESDAY434

Tuesday, June 7, 20119:30 AM - 12:30 PMORAL ABSTRACT SESSIONGastrointestinal (Noncolorectal) CancerLocation: Hall D1CME credit: 3Track(s): Gastrointestinal (Noncolorectal) CancerJennifer J. Knox, MD—Co-ChairPrincess Margaret HospitalAndrea Wang-Gillam, MD, PhD—Co-ChairWashington University School of Medicine9:30 AM Phase III trial of sunitinib (Su) versus sorafenib (So) in advancedhepatocellular carcinoma (HCC). (Abstract #4000)A. Cheng, Y. Kang, D. Lin, J. Park, M. Kudo, S. Qin, M. Omata,S. W. Pitman Lowenthal, S. Lanzalone, L. Yang, M. Lechuga, E. Raymond,SUN1170 HCC Study Group9:45 AM Global Investigation of Therapeutic Decisions in Hepatocellular Carcinomaand of its Treatment with Sorafenib (GIDEON) second interim analysis inmore than 1,500 patients: Clinical findings in patients with liver dysfunction.(Abstract #4001)J. A. Marrero, R. Lencioni, M. Kudo, S. Ye, K. Nakajima, F. Cihon, A. P. VenookDiscussion10:00 AM Bert H. O’Neil, MD (Abstracts #4000–4001)University of North Carolina at Chapel Hill10:15 AM Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of thephase III CLASSIC trial. (Abstract #LBA4002)Y. J. Bang, Y. W. Kim, H. K. Yang, H. C. Chung, Y. K. Park, K. W. Lee, K. H. Lee,Y. H. Kim, S. I. Noh, J. Ji, M. Johnston, F. Sirzen, and S. H. Noh10:30 AM Postoperative adjuvant chemoradiation for gastric or gastroesophagealjunction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional(CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) comparedwith bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.(Abstract #4003)C. S. Fuchs, J. E. Tepper, D. Niedzwiecki, D. Hollis, H. J. Mamon, R. Swanson,D. G. Haller, T. Dragovich, S. R. Alberts, G. A. Bjarnason, C. G. Willett,P. C. Enzinger, R. M. Goldberg, A. P. Venook, R. J. Mayer10:45 AM A multicenter, randomized phase III trial comparing second-linechemotherapy (SLC) plus best supportive care (BSC) with BSC alone forpretreated advanced gastric cancer (AGC). (Abstract #4004)S. Park, D. Lim, K. Park, S. Lee, S. Oh, H. Kwon, J. Kang, I. Hwang, J. Lee,J. Park, Y. Park, H. Lim, W. KangDiscussion11:00 AM Florian Lordick, MD (Abstracts #LBA4002–4004)Klinikum Rechts der Isar, Technische Universitaet Muenchen11:15 AM Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for analcarcinoma: Disease-free and overall survival with RT5FU-mitomycin versusRT5FU-cisplatin. (Abstract #4005)L. L. Gunderson, K. A. Winter, J. A. Ajani, J. E. Pedersen, A. B. Benson,C. R. Thomas Jr., R. J. Mayer, M. G. Haddock, T. A. Rich, C. G. WillettDiscussion11:30 AM Theodore S. Hong, MD (Abstract #4005)Massachusetts General HospitalTUESDAY435

Tuesday, June 7, 201111:45 AM Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label,randomized controlled phase III trial of adjuvant chemotherapy versusobservation in patients with adenocarcinoma of the ampulla of vater.(Abstract #LBA4006)J. P. Neoptolemos, M. J. Moore, T. F. Cox, J. W. Valle, D. H. Palmer, A. Mcdonald,R. Carter, N. C. Tebbutt, C. Dervenis, D. Smith, B. Glimelius, F. Y. Coxon,F. Lacaine, M. R. Middleton, P. Ghaneh, C. Bassi, C. Halloran, A. Olah,C. L. Rawcliffe, and M. W. Büchler12:00 PM Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versusgemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) inJapan and Taiwan: GEST study. (Abstract #4007)T. Ioka, M. Ikeda, S. Ohkawa, H. Yanagimoto, A. Fukutomi, K. Sugimori, H. Baba,K. Yamao, T. Shimamura, J. Chen, K. Mizumoto, J. Furuse, A. Funakoshi,T. Hatori, T. Yamaguchi, S. Egawa, A. Sato, Y. Ohashi, A. Cheng, T. OkusakaDiscussion12:15 PM Dan Laheru, MD (Abstracts #LBA4006–4007)The Johns Hopkins University School of MedicineTUESDAY436

Tuesday, June 7, 20119:45 AM - 11:00 AMEDUCATION SESSIONSBiomarkers for Vascular Endothelial Growth Factor (VEGF)-targeted AgentsLocation: S100aCME credit: 1.25Track(s): Tumor BiologyMichael L. Maitland, MD, PhD—ChairThe University of ChicagoHypertension Is a Biomarker for Vascular Endothelial Growth Factor (VEGF)-targetedTherapiesHerbert Hurwitz, MDDuke University Medical CenterHypertension Is Not a Biomarker for VEGF-targeted TherapiesBryan P. Schneider, MDIndiana University School of MedicineSingle-nucleotide Polymorphisms (SNPs) as Potential Predictive Biomarkers for VEGF-targetedAgentsEmile E. Voest, MD, PhDUniversity Medical Center UtrechtNovel Approaches to Identify Predictive Biomarkers for VEGF-targeted TherapiesEffective Time Management for the Busy OncologistLocation: E353CME credit: 1.25Track(s): Professional Development, General Oncology, Practice Management and InformationTechnologyTimothy Jerome Moynihan, MD—ChairMayo ClinicWhat Is Effective Time Management?Martha P. Mims, MD, PhDBaylor College of MedicineDeveloping a Healthy Balance of Work and Home-life DutiesDavid H. Johnson, MDUniversity of Texas Southwestern Medical CenterHow to Protect “Protected Time”: Prioritizing Competing ResponsibilitiesThe Changing Face of Castration-resistant Prostate Cancer: Standard Therapyand New TargetsLocation: E354aCME credit: 1.25Track(s): Genitourinary Cancer, Geriatric OncologyKim N. Chi, MD—ChairBritish Columbia Cancer AgencyEmerging Investigational Therapies in Castration-resistant Prostate CancerCharles G. Drake, MD, PhDSidney Kimmel Comprehensive Cancer Center at Johns Hopkins UniversityImmunotherapy in Castration-resistant Prostate CancerThomas W. Flaig, MDUniversity of Colorado DenverNew Standards in the Medical Management of Castration-resistant Prostate CancerTUESDAY437

Tuesday, June 7, 20119:45 AM - 11:00 AMMEET THE PROFESSOR SESSIONNon-melanoma Skin Cancer: Surgical Management of Aggressive Cases andMolecular Targeted Therapies (M24)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Head and Neck Cancer, Melanoma/Skin CancersRandal S. Weber, MDUniversity of Texas M. D. Anderson Cancer CenterSurgical Management of Aggressive Squamous Cell Carcinoma of the SkinDavid G. Pfister, MDMemorial Sloan-Kettering Cancer CenterRole of Molecularly Targeted Therapy in the Management of Non-melanoma Skin CancerTUESDAY438

Tuesday, June 7, 20119:45 AM - 11:15 AMCLINICAL SCIENCE SYMPOSIUMEmerging Issues in Comparative Effectiveness ResearchLocation: S100bcCME credit: 1.5Track(s): Health Services ResearchSharon Hermes Giordano, MD, MPH—ChairUniversity of Texas M. D. Anderson Cancer Center9:45 AM Development of a guideline for including patient-reported outcomes inpost-approval clinical trials of oncology drugs for comparative effectivenessresearch. (Abstract #6000)E. M. Basch, A. P. Abernethy, C. D. Mullins, M. R. Tiglao, S. R. Tunis10:15 AM The relationship between cost, quality, and outcomes among women withbreast cancer in SEER–Medicare. (Abstract #6001)M. J. Hassett, B. A. Neville, J. C. WeeksDiscussion10:30 AM Steven J. Katz, MD, MPH (Abstract #6001)University of Michigan Medical School10:45 AM Utilization and costs of nonevidence-based antineoplastic agents in patientswith metastatic colon cancer. (Abstract #6002)J. A. de Souza, B. N. Polite, S. Zhu, J. J. Dignam, N. J. Meropol, M. J. Ratain,L. N. Newcomer, G. C. AlexanderDiscussion11:00 AM Marcelo Blaya, MD (Abstract #6002)Tulane University Health Sciences CenterTUESDAY439

Tuesday, June 7, 201111:30 AM - 12:45 PMEDUCATION SESSIONSCancer Stem Cells as a Therapeutic Target: Fact or Fiction?Location: S100aCME credit: 1.25Track(s): Tumor Biology, Developmental TherapeuticsMax Wicha, MD—ChairUniversity of Michigan Cancer CenterTargeted Cancer Stem Cells: Is This Really the Answer?Michael Kahn, PhDUniversity of Southern CaliforniaTargeting Wnt-B-catenin Signaling in Cancer Stem CellsJoan Seoane, PhDVall d’Hebron University Hospital, Institut d’OncologiaTargeting Signaling Pathways That Mediate Cancer Stem Cell SurvivalThe Importance of Histology and Molecular Testing (EGFR and EML4-ALK) inthe Initial Evaluation of Advanced Non-small Cell Lung CancerLocation: E354bCME credit: 1.25Track(s): Lung CancerRenato Martins, MD, MPH—ChairSeattle Cancer Care AllianceEpidermal Growth Factor Receptor Testing: Who, What, When, and How?David N. Hayes, MD, MPHUniversity of North Carolina at Chapel HillThe Role of Histology in Managing Non-small Cell Lung CancerAlice Tsang Shaw, MD, PhDMassachusetts General Hospital Cancer CenterEML4-ALK Testing: Who, What, When, and How?TUESDAY440

Tuesday, June 7, 201111:30 AM - 12:45 PMMEET THE PROFESSOR SESSIONHow to Develop a Successful Career in Health Services Research(M25)—Ticketed SessionLocation: E451aCME credit: 1.25Track(s): Health Services Research, Professional DevelopmentJane C. Weeks, MD, MScDana-Farber Cancer InstituteTUESDAY441